<SEC-DOCUMENT>0000950123-15-010452.txt : 20160531
<SEC-HEADER>0000950123-15-010452.hdr.sgml : 20160531
<ACCEPTANCE-DATETIME>20151023161719
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-15-010452
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20151023
<PUBLIC-REL-DATE>20160531
DATE AS OF CHANGE:		20151104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01130
		FILM NUMBER:		151173082

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 693 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A Amendment No. 3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>As submitted confidentially with the Securities and Exchange Commission on October 23,
2015, as </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No. 3 to the confidential submission dated August 28, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Commission and all information herein remains strictly confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>FORM F-1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:19pt; font-family:Times New Roman" ALIGN="center"><B>AC IMMUNE SA </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of Registrant as specified in its Charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Not
Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s name into English) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Switzerland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Andrea Pfeifer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>EPFL Innovation Park </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Building B </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>1015
Lausanne </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Switzerland </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>+41 21 693 91 21 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>National Corporate Research, Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>10 East 40th Street, 10th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(800) 221-0102 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Richard D. Truesdell, Jr.<BR>Deanna L. Kirkpatrick<BR>Davis Polk &amp; Wardwell LLP<BR>450 Lexington
Avenue<BR>New York, NY 10017</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(212) 450-4000</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell S. Bloom<BR>Arthur R. McGivern</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP<BR>Exchange Place</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>53 State Street<BR>Boston, MA 02109</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) 570-1000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION
OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>aggregate<BR>offering&nbsp;price(1)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>registration&nbsp;fee(2)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common shares, nominal value CHF 0.02 per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become
effective on such date as the Commission, acting pursuant to such Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#de1a1e"><B>SUBJECT TO COMPLETION DATED &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </B></FONT></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g80t23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Shares </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is the
initial public offering of AC Immune SA. No public market has previously existed for our common shares. We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our common shares. We expect the initial public
offering price will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common share. We intend to apply to list our common
shares on the NASDAQ under the symbol &#147;ACIU.&#148; </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined under the federal
securities laws and, as such, will be subject to reduced public company reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company&#148; and &#147;&#151;Implications of Being a Foreign Private
Issuer.&#148; </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common shares involves a high degree of risk. See &#147;<A HREF="#rom16439_4">Risk Factors</A>&#148; beginning on page 12.
</B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Common&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for additional information regarding total underwriter compensation. </TD></TR></TABLE>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares to cover over-allotments. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delivery of the common shares is expected to be made on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Credit&nbsp;Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Leerink Partners</B></TD></TR>
</TABLE>  <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_3">Summary Historical and Other Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_5">Cautionary Statement Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_6">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_11">Exchange Rates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_12">Selected Financial and Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_13">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_14">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_15">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_16">Principal Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_17">Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_18">Description of Share Capital and Articles of Association</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_19">Comparison of Swiss Law and Delaware Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_20">Common Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_21">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_22">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_23">Expenses of the Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_24">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_25">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_26">Enforcement of Judgments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_27">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_28">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland and our registered office and domicile is located in Ecublens, Switzerland. Moreover, a number
of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service
of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United
States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon
the federal and state securities laws of the United States. See &#147;Enforcement of Judgments&#148; for additional information. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated or the context otherwise requires, all references in this prospectus to &#147;AC Immune,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;ours,&#148; &#147;us&#148; or similar terms refer to AC Immune SA.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own various trademark registrations and applications, and unregistered trademarks, including Morphomer&#153;, SupraAntigen&#153; and our
corporate logo. All other trade names, trademarks and service marks of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other companies appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We
do not intend to use or display other companies&#146; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements are presented in Swiss Francs and in accordance with IFRS as issued by the IASB. None of the financial statements
were prepared in accordance with generally accepted accounting principles in the United States. The terms &#147;dollar,&#148; &#147;USD&#148; or &#147;$&#148; refer to U.S. dollars and the term &#147;Swiss Franc&#148; and &#147;CHF&#148; refer to
the legal currency of Switzerland, unless otherwise indicated. Unless otherwise indicated, certain Swiss Franc amounts and certain U.S. dollar amounts have been translated into U.S. dollars and Swiss Francs, respectively, at a rate of USD 1.0274 to
CHF 1.00, the official exchange rate quoted as at September&nbsp;30, 2015 by the U.S. Federal Reserve Bank. Such Swiss Franc and U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars and Swiss Francs, respectively, that
could actually have been purchased upon exchange of the other currency at the dates indicated or any other date, and such translated amounts have been provided solely for the convenience of the reader. On October 20, 2015, the exchange rate as
reported by the U.S. Federal Reserve Bank was USD 1.0453 to CHF 1.00. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts
listed are due to rounding. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have not authorized anyone to provide any information other than that contained in this prospectus or in any free
writing prospectus prepared by or on behalf of us or to which we may have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters are making an offer to sell the common shares in any jurisdiction where the offer or sale is not permitted.
This offering is being made in the United States and elsewhere solely on the basis of the information contained in this prospectus. You should assume that the information appearing in this prospectus is accurate only as of the date on the front
cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of the common shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We are incorporated as a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland, and a majority
of our outstanding securities are owned by non-U.S. residents. Under the rules of the U.S. Securities and Exchange Commission, or SEC, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we
will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.<I>
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary may not contain all the information that may be
important to you, and we urge you to read this entire prospectus carefully, including the &#147;Risk Factors,&#148; &#147;Business&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
sections and our financial statements, including the notes thereto, included elsewhere in this prospectus, before deciding to invest in our common shares. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding.
Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and
alpha-synuclein. We believe that our large and diverse pipeline of seven therapeutic candidates, including three clinical-stage candidates, and three diagnostic candidates has the potential to drive a paradigm shift in the treatment of a broad
spectrum of neurodegenerative and other diseases related to protein misfolding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently an absence of reliable, early-stage
diagnosis and disease-modifying treatments for widely prevalent neurodegenerative and other diseases associated with protein misfolding. AD is the most common form of dementia, with an estimated worldwide patient population of 47&nbsp;million in
2015, which is expected to grow to 75&nbsp;million by 2030 and 132&nbsp;million by 2050 according to the World Alzheimer Report 2015. AD is typically diagnosed by neurologists and psychiatrists through a series of cognitive and functioning tests
once symptoms are clinically present, resulting in diagnosis at later stages of the disease after irreversible loss of neurons has already occurred. Currently approved AD treatments include medications that only treat the symptoms of the disease,
with limited clinical benefit. PD, the second most common neurodegenerative disease worldwide, affects an estimated 7 to 10&nbsp;million people. In PD, the use of symptomatic treatments, such as levodopa, is associated with the loss of control of
motor functions in approximately 50% of patients who have taken the drug for 5 years or longer. There remains a significant unmet medical need for reliable and accurate diagnostics to enable early diagnosis and disease-modifying treatments that slow
the progress of neurodegenerative diseases. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram below summarizes the status of our research and development programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g87t41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody
that we developed using our proprietary SupraAntigen<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> platform. Crenezumab is expected to enter Phase 3 clinical studies in early 2016 and we believe it has the potential to become a
best-in-class disease-modifying treatment for AD. Genentech, Inc., a wholly owned subsidiary of Roche, or Genentech, is advancing crenezumab for the treatment of AD under a collaboration agreement with us, pursuant to which it is responsible for the
clinical development of crenezumab, including the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Genentech met with the U.S. Food and Drug Administration, or FDA, in
October 2014 and again in September 2015 to discuss the Phase 3 study design. Under our collaboration agreement, we are eligible to receive payments from Genentech totaling up to approximately $340 million, as well as sales royalties. Crenezumab has
received Fast Track designation from the FDA. The Fast Track program is intended to expedite or facilitate the process for reviewing new drugs that are designed to treat a serious or life-threatening condition and demonstrate the potential to
address unmet medical needs, as further described under &#147;Business&#151;Government Regulation and Our Regulatory Department&#151;Product Approval Process.&#148; In 2012, crenezumab was independently selected by the National Institute of Health,
the Banner Alzheimer&#146;s Institute and Genentech for use in the first-ever AD prevention study, which serves as the cornerstone of the global Alzheimer&#146;s Prevention Initiative. While crenezumab did not meet its co-primary endpoints in its
Phase 2 studies, the data showed promising signals of activity in patients with a milder stage of the disease. </P>  <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved,
crenezumab has the potential to treat the underlying cause of the disease and intervene at an earlier stage of AD progression, prior to irreversible neuronal damage. We believe that crenezumab is ideally positioned to be at the forefront of
disease-modifying and preventive medicine. We believe key advantages of crenezumab include: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Unique mechanism of action:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Recognizes and binds to multiple forms of misfolded Abeta, a protein commonly associated with AD. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Helps to protect against neurotoxicity due to high affinity for the multiple forms of misfolded Abeta. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Promotes disaggregation of existing Abeta aggregates and disrupts their assembly to prevent amyloid plaque formation, which is associated with AD. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clears misfolded Abeta from the brain while limiting inflammation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Signal of activity in milder AD patients in Phase 2 studies:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the proof-of-concept Phase 2 studies of crenezumab, a positive trend in cognition was observed with a greater effect on cognition in patients with a milder stage of AD. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ABBY cognition study: although the study did not meet its co-primary endpoints, which were assessments using the ADAS-cog and CDR-Sum of boxes, the sample size was not expected to have adequate power to detect a modest
but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase&nbsp;2 studies in AD). Instead, consistent trends across different endpoints and dose dependency are
considered indicators of a response in this learning phase of development, with confirmation then sought in Phase&nbsp;3. The results showed trends favoring crenezumab in the milder patient population. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">BLAZE biomarker study: the high-dose crenezumab arm showed a consistent trend of reduced Abeta accumulation in the brain over time and a significant increase of Abeta in the cerebrospinal fluid, which suggests that
Abeta is being removed from the brain when patients are treated with crenezumab. </TD></TR></TABLE>   <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable safety profile allowing for potentially higher dosing:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Unique mechanism of action linked to the reduced ability to cause inflammation-related vasogenic edema, which is an accumulation of fluid in the brain that can lead to headaches, loss of coordination and disorientation.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical data showed a very low incidence of vasogenic edema. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1 study is ongoing to study crenezumab at higher doses to potentially increase the efficacy signal and to help define the optimal Phase 3 clinical study design. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through active
immunization, where the immune system is stimulated to make its own antibodies against pathological proteins: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-24 is our wholly-owned anti-Abeta vaccine candidate currently in a Phase 1/2a study. We expect to complete this study and announce top line results in the second half of 2016. ACI-24 is also being studied in
patients with Down syndrome, a population that is at high risk for AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-35 is an anti-tau vaccine candidate that we are developing under a collaboration agreement with Janssen Pharmaceuticals, Inc., a Johnson&nbsp;&amp; Johnson Company. We and Janssen are co-developing ACI-35 through
the ongoing Phase 1b clinical study, which we expect to be completed in the fourth quarter of 2016. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. We expect
Phase 2 clinical studies to begin in 2017. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical evidence suggests that early detection of neurodegenerative diseases is critical to
enhancing the effectiveness of both symptomatic and disease-modifying therapies. As such, we are using our Morphomer&#153; platform to develop complementary diagnostic products such as positron emission tomography, or PET, ligands, which are tracers
that can directly measure misfolded tau and alpha-synuclein in the brain, to enable early and reliable disease diagnoses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our tau PET imaging agent is currently in a First-in-Man study (a clinical study in which a medical procedure, previously developed and assessed through <I>in vitro</I> or animal testing or through mathematical
modelling, is tested on human subjects for the first time) and being developed under a collaboration agreement with Piramal Imaging. Piramal Imaging is expecting to advance this program into Phase 1 clinical development in 2016. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are also developing PET imaging diagnostics for diseases resulting from the misfolding of alpha-synuclein proteins, such as PD. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary Platform Technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. These
platforms are our engines for generating novel molecules that are designed to bind to their targets with high affinity and conformational specificity, meaning they are enabled to differentiate between misfolded proteins and normally-folded proteins.
All of our product candidates and our development programs have been derived from our proprietary platforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neurodegenerative diseases,
such as AD and PD, as well as other neuro-orphan diseases, such as progressive supranuclear palsy, amyotrophic lateral sclerosis, and Huntington&#146;s disease, are all associated with pathologies that involve misfolded proteins. Research has shown
that misfolded proteins are unable to carry out their normal functions and aggregate to form certain types of deposits that damage brain tissue. Our SupraAntigen and Morphomer platforms seek to produce conformationally specific molecules in order to
prevent or disrupt the formation of misfolded proteins. We believe that our proprietary platforms also have the potential to generate additional molecules for indications that relate to protein misfolding outside of neurodegenerative diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a
global leader in the treatment of neurodegenerative diseases by developing therapies and complementary diagnostics that target neurodegenerative diseases with significant unmet medical need using our proprietary SupraAntigen and Morphomer technology
platforms. Key elements of our strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Advance, in partnership or alone, our product candidates crenezumab, ACI-24 and ACI-35, and our diagnostic candidates through clinical development to regulatory approval and potential commercialization.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Expand into other neurodegenerative and neuro-orphan diseases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Accelerate the advancement of our diagnostic portfolio. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Leverage the duality of our therapeutic and diagnostic approaches to become the leader in personalized treatment of neurodegenerative diseases. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Strategically collaborate or selectively partner for the development and commercialization of product candidates. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to implement our business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk
Factors&#148; immediately following this prospectus summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The success of our and our collaboration partners&#146; clinical studies, and our and their ability to obtain regulatory approval and to commercialize crenezumab, ACI-24 for AD and ACI-35. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our direct reliance on our collaboration partners efforts to obtain regulatory and marketing approvals for and to manufacture, sell and market certain of our product candidates, including crenezumab, ACI-35 and our
anti-tau antibodies, in order to derive revenue from these product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab&#146;s not meeting its co-primary endpoints in its Phase 2 studies. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Morphomer and SupraAntigen proprietary technology platforms and their success in building additional product candidates for our pipeline. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The identification of serious adverse, undesirable or unacceptable side effects related to our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to maintain our current strategic relationships with our collaboration partners. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Failure to protect our, and not infringe on third parties&#146;, intellectual property rights throughout the world. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to raise capital when needed in order to continue our product development programs or commercialization efforts. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA&#146;s and applicable foreign regulatory authorities&#146; acceptance of data from studies we conduct in the future. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our foreign private issuer status, the loss of which would require us to comply with the domestic reporting regime of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and cause us to incur
significant legal, accounting and other expenses. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies incorporated in the United States. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company and Other Information </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
were incorporated as a Swiss limited liability company (<I>soci&eacute;t&eacute; &agrave; responsabilit&eacute; limit&eacute;e</I>) on February&nbsp;13, 2003 and transformed into a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under
the laws of Switzerland on August&nbsp;25, 2003. Our principal executive offices are located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland and our telephone number is +41 21 693 91 21. Our website is <I>www.acimmune.com</I>. Our
website and the information contained therein or connected thereto are not incorporated into this prospectus or the registration statement of which it forms a part. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to have only two years of audited financial statements in addition to any required interim financial statements and correspondingly reduced disclosure in the Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure in the registration statement of which this prospectus forms a part; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Section&nbsp;404 of the Sarbanes-Oxley Act of 2002; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from
the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would
cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.0 billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at
least $700 million of equity securities held by non-affiliates; (iii)&nbsp;the issuance, in any three-year period, by our company of more than $1.0 billion in non-convertible debt securities; and (iv)&nbsp;the last day of the fiscal year ending
after the fifth anniversary of this offering. We may choose to take advantage of some but not all of these reduced burdens. For example, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. However, given that we currently report and expect to continue to report under
International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or
revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Foreign
Private Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer.&#148; Accordingly, upon consummation of this offering, we will
report under the Exchange Act as a non-U.S. company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act we will
be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current
reports on Form 8-K, upon the occurrence of specified significant events. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although as a foreign private issuer we will not
be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act, we intend to report our results of operations voluntarily on a
quarterly basis. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign
private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our executive
officers or directors are U.S. citizens or residents, (ii)&nbsp;more than 50% of our assets are located in the United States or (iii)&nbsp;our business is administered principally in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company
and a foreign private issuer. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series E Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October
23, 2015, we completed a private placement of Series E preferred shares, each with a nominal value of CHF 5.00 per share (the &#147;Series E Private Placement&#148;). An aggregate of 12,453 Series E preferred shares were issued to certain
institutions and existing shareholders in the Series E Private Placement for an aggregate subscription amount of approximately $30.0 million. The Series E preferred shares have substantially the same terms as the Series A, B, C and D preferred
shares, will be accounted for as equity on our balance sheet and will automatically convert into common shares on a one-for-one basis upon the closing of this offering. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_2"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information presented in greater detail elsewhere in this prospectus. This summary is not complete and does not
contain all the information you should consider before investing in our common shares. You should carefully read this entire prospectus before investing in our common shares including &#147;Risk Factors&#148; and our financial statements. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common shares offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common shares to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Over-allotment option </P></TD>
<TD>We have granted the underwriters the option to purchase up to an additional&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares from us within 30 days of the date of this prospectus to cover
over-allotments, if any. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. We intend to use the net proceeds from this offering together with cash and cash equivalents on hand (including the net proceeds from the Series E Private Placement) to further the development of our
therapeutic product candidates under collaboration agreements (crenezumab, ACI-35 and anti-tau antibodies), advance our other clinical and pre-clinical programs, and for research and development of other indications and initiatives that are
complementary to our existing and planned research activities. See &#147;Use of Proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed NASDAQ symbol </P></TD>
<TD>&#147;ACIU.&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of our common shares to be outstanding after this offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding as at September&nbsp;30, 2015 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional common shares issuable upon the
automatic conversion of all of our preferred shares (including the preferred shares issued in the Series E Private Placement) on a one-for-one basis upon the closing of this offering, but excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our common shares reserved for future issuance under our new omnibus equity incentive plan that we intend to adopt in connection with this
offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our common shares issuable upon the exercise of options outstanding under our existing equity incentive plans at a weighted-average exercise
price of CHF 36.37&nbsp;per common share. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus reflects the
completion of a <FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;-for-one</FONT> stock split and assumes: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this
prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no issuance of any common shares reserved for future issuance under our new omnibus equity incentive plan or exercise of the options outstanding under our existing equity incentive plans, each as described in the
immediately preceding paragraph; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all of our preferred shares (including the preferred shares issued in the Series E Private Placement) into common shares on a one-for-one basis upon the closing of this offering and the filing and
effectiveness of our amended and restated articles of association and creation of authorized share capital of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares upon the closing of this offering; and
</TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the underwriters&#146; over-allotment option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional common shares. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_3"></A>SUMMARY HISTORICAL AND OTHER FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary historical financial information should be read in conjunction with &#147;Selected Financial and Other
Information,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements, including the notes thereto, included elsewhere in this prospectus. Our historical results are
not necessarily indicative of the results that may be expected in the future and results of interim periods are not necessarily indicative of results for the entire year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary income statement data and balance sheet data for and as at the years ended December&nbsp;31, 2014 and 2013 are derived from our
audited financial statements included elsewhere in this prospectus. The summary income statement data for the nine months ended September&nbsp;30, 2015 and 2014 and balance sheet data as at September 30, 2015 are derived from our unaudited condensed
interim financial statements included elsewhere in this prospectus. This unaudited financial data, in management&#146;s opinion, have been prepared on the same basis as the audited financial statements and related notes included elsewhere in this
prospectus, and include all adjustments, consisting only of normal recurring adjustments, that management considers necessary for a fair presentation of the financial information as of and for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain our books and records in, and our audited financial statements and unaudited condensed interim financial statements are prepared
and presented in accordance with IFRS in, CHF. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months<BR>Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in CHF thousands except for share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income Statement Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings / (loss) per share (basic)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings / (loss) per share (fully diluted)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings / (loss) per share basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings / (loss) per share fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma earnings / (loss) per share (basic)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma earnings / (loss) per share (fully diluted)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute pro forma earnings / (loss) per share basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute pro forma earnings / (loss) per share fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes preferred shares outstanding as of the dates indicated, and these preferred shares will be converted on a one-for-one basis upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma earnings&nbsp;/ (loss) per share basic and fully diluted data gives effect to the Series E Private Placement and the conversion of all the preferred shares issued in the Series E Private Placement into
common shares. The unaudited pro forma earnings / (loss) per share information presented is for informational purposes only and is not necessarily indicative of what our results would have been had the conversion of the preferred shares occurred at
the dates indicated or any other time, nor is the information indicative of our future performance. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at September&nbsp;30, 2015</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Further&nbsp;Adjusted(2)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">As adjusted to reflect (i) the conversion of all shares of our preferred stock outstanding as of September 30, 2015 into an aggregate of 136,248 common shares; (ii) the issuance and sale of preferred shares in the
Series&nbsp;E Private Placement and the conversion of all such shares into an aggregate of 12,453 common shares; and (iii) the filing and effectiveness of our amended and restated articles of incorporation. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">As further adjusted balance sheet data gives effect to our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares in this offering, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common share, which is the midpoint of the price range
set forth on the cover page of this prospectus, would increase (decrease) our as further adjusted cash and cash equivalents and as further adjusted total shareholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ), assuming that the number of common shares offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase (decrease) of
1,000,000 in the number of shares we are offering would increase (decrease) as further adjusted cash and cash equivalents and as further adjusted total shareholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;), assuming that the assumed initial public offering price remains the same and after
deducting the underwriting discount and estimated offering expenses payable by us. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the risks and uncertainties described below and the other information in this prospectus before making an
investment in our common shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common shares could decline and you could
lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See &#147;Cautionary Statement Regarding Forward-Looking Statements.&#148; Our actual results could differ materially
and adversely from those anticipated in these forward-looking statements as a result of certain factors. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on the success of crenezumab, and, to a lesser extent, ACI-24 for AD and ACI-35, all of which are in clinical
development. If our clinical studies are unsuccessful, we or our collaboration partner do not obtain regulatory approval or we are unable to commercialize crenezumab, ACI-24 for AD and ACI-35, or we experience significant delays in doing so, our
business, financial condition and results of operations will be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products
approved for sale and have invested a significant portion of our efforts and financial resources in the development of crenezumab, ACI-24 for AD and ACI-35, all of which are in clinical development. Our ability to generate product revenues, which we
do not expect will occur for at least the next several years, if ever, will depend heavily on successful clinical development, obtaining regulatory approval and eventual commercialization of these product candidates. We currently generate no
revenues from sales of any drugs, and we may never be able to develop or commercialize a marketable drug. The success of our current and future product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing clinical studies that demonstrate the efficacy and safety of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receiving marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales, marketing and distribution operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile following approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing effectively with other therapies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">qualifying for, obtaining, maintaining, enforcing and defending our intellectual property rights and claims and not infringing on third parties&#146; intellectual property rights. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our collaboration partner do not achieve one or more of these factors in a timely manner or at all, we could experience significant
delays or an inability to successfully commercialize our current or future product candidates, which would materially adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Results of early clinical studies may not be predictive of future study results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Positive or timely results from preclinical or early stage studies do not ensure positive or timely results in late stage clinical studies or
product approval by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or comparable foreign regulatory authorities. Products that show positive preclinical or early clinical results may not show sufficient
safety or efficacy in later stage clinical studies and therefore may fail to obtain regulatory approvals. For example, our collaboration partner Genentech may fail to achieve success in Phase 3 clinical studies of crenezumab. In addition,
preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical and clinical studies have nonetheless failed to obtain
marketing approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the product candidates. The FDA, the EMA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether regulatory
approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical studies of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other
regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different studies
of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other study protocols and the rate
of dropout among clinical study participants. In the case of our late stage clinical product candidates, results may differ in general on the basis of the larger number of clinical study sites and additional countries and languages involved in Phase
3 clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies are, or will be, based on patient reported outcomes, some of which are or will be captured daily by
study participants with electronic diaries. We have no assurance and cannot rely on past experience that the high frequency of questioning is not influencing the measured outcome. In addition, low compliance with daily reporting requirements may
impact the studies&#146; validity or statistical power. We cannot assure you that any Phase 2, Phase 3 or other clinical studies that either we or our collaboration partners may conduct will demonstrate consistent or adequate efficacy and safety to
obtain regulatory approval to market our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our collaboration partners are required to conduct additional
clinical studies or other testing of any of our current or future product candidates that we or our collaboration partners develop beyond the studies and testing that we or our collaboration partners contemplate, if we or our collaboration partners
are unable to successfully complete clinical studies of our product candidates or other testing, if the results of these studies or tests are unfavorable or are only modestly favorable or if there are safety concerns associated with our current or
future product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">remove the product from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
development costs will also increase if we experience delays in testing or marketing approvals and we may be required to obtain additional funds to complete clinical studies. We cannot assure you that our clinical studies will begin as planned or be
completed on schedule, if at all, or that we will not need to restructure our studies after they have begun. Significant clinical study delays also could shorten any periods during which we may have the exclusive right to commercialize our product
candidates or allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates, which may harm our business and results of operations. In addition,
some of the factors that cause, or lead to, clinical study delays may ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional competitors could enter the market with generic versions of our products, which may result in a material decline in sales of
affected products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a
pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generic copy of an approved innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application, or NDA, under section 505(b)(2) that references the FDA&#146;s
prior approval of the innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. Hatch-Waxman also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in
some circumstances, FDA filing and reviewing) of an ANDA or 505(b)(2) NDA. These include, subject to certain exceptions, the period during which an FDA-approved drug is subject to orphan drug exclusivity. In addition to the benefits of regulatory
exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#147;Approved Drug Products with Therapeutic
Equivalence Evaluations,&#148; known as the &#147;Orange Book.&#148; If there are patents listed in the Orange Book, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in the ANDA what is
known as a &#147;Paragraph IV certification,&#148; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days
of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, if crenezumab, ACI-24 and ACI-35 are approved, competitors could file ANDAs for generic versions of crenezumab, ACI-24 and
ACI-35, or 505(b)(2)&nbsp;NDAs that reference crenezumab, ACI-24 and ACI-35, respectively. If there are patents listed for crenezumab, ACI-24 and ACI-35 in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification
as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible for listing in the Orange Book, how
any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not
be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV
certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. Should sales decline, we may have to write off a portion or all of the intangible
assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Roche, the parent company of our collaboration partner Genentech, is evaluating gantenerumab, which is a product candidate in the same
indication as our lead product candidate crenezumab. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaboration partner Genentech is a subsidiary of Roche, which is
evaluating gantenerumab, a product candidate for the same indication as our lead product candidate crenezumab. Our collaboration agreement with Genentech for crenezumab provides Genentech with control over, and responsibility for, the clinical
development process, including obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. In addition, the collaboration agreement provides that Genentech may terminate the agreement at any time by providing
three months&#146; notice to us. As a result, Roche may choose to devote more time and resources to advancing gantenerumab instead of crenezumab, which could render crenezumab non-competitive and limit or make it more difficult for us to achieve or
maintain profitability with crenezumab. Should this occur, our business, financial condition and results of operations could be materially impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and
health insurers establish adequate coverage and reimbursement levels and pricing policies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful commercialization of our
product candidates will depend, in part, on the extent to which coverage and reimbursement for our products will be available from government and health administration authorities, private health insurers and other third-party payors. To manage
healthcare costs, many governments and third-party payors increasingly scrutinize the pricing of new technologies and require greater levels of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evidence of favorable clinical outcomes and cost-effectiveness before extending coverage. In light of such challenges to prices and increasing levels of evidence of the benefits and clinical
outcomes of new technologies, we cannot be sure that coverage will be available for any of our current or future product candidates that we commercialize and, if available, that the reimbursement rates will be adequate. If we are unable to obtain
adequate levels of coverage and reimbursement for our product candidates, their marketability will be negatively and materially impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third party payors may deny coverage and reimbursement status altogether of a given drug product, or cover the product but may also establish
prices at levels that are too low to enable us to realize an appropriate return on our investment in product development. Because the rules and regulations regarding coverage and reimbursement change frequently, in some cases at short notice, even
when there is favorable coverage and reimbursement, future changes may occur that adversely impact the favorable status. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that
presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unavailability
or inadequacy of third-party coverage and reimbursement could have a material adverse effect on the market acceptance of our product candidates and the future revenues we may expect to receive from those products. In addition, we are unable to
predict what additional legislation or regulation relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future, or what effect such legislation or regulation would have on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially
adversely affect our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA, the EMA or other regulatory
authority approves the marketing of any product candidates that we develop, physicians, healthcare providers, patients or the medical community may not accept or use them. Efforts to educate the medical community and third-party payors on the
benefits of our product candidates may require significant resources and may not be successful. If any of our current or future product candidates does not achieve an adequate level of acceptance, we may not generate significant product revenues or
any profits from operations. The degree of market acceptance of our product candidates that are approved for commercial sale will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how clinicians and potential patients perceive our novel products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and clinical profile of competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to provide acceptable evidence of safety and efficacy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient diagnostics and screening infrastructure in each market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third-party payors, both public and private; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other potential advantages over alternative treatment methods. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates fail
to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be
large enough to allow us to generate significant revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the potential market opportunity of our product candidates is difficult to precisely
estimate. Our estimates of the potential market opportunity are predicated on several key assumptions such as industry knowledge and publications, third-party research reports and other surveys. These assumptions involve the exercise of significant
judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions could not have been assessed by an independent source in every detail. If any of the assumptions proves to be inaccurate, then the actual
market for our product candidates could be smaller than our estimates of the potential market opportunity. If the actual market for our product candidates is smaller than we expect, or if any approved products fail to achieve an adequate level of
acceptance by physicians, health care payors and patients, our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical studies for our product candidates. If we are unable to enroll patients in our
clinical studies, our research and development efforts could be materially adversely affected. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful and timely
completion of clinical studies will require that we enroll a sufficient number of patient candidates. Studies may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. Patient enrollment depends
on many factors, including the size and nature of the patient population, eligibility criteria for the study, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical studies, the
availability of new drugs approved for the indication the clinical study is investigating, and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. In the
Phase 3 clinical studies of crenezumab, our collaboration partner Genentech will seek to enroll patients in the early stages of AD and it may be unable to successfully identify an adequate number of eligible patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific target population of patients and therapeutic time windows may make it difficult for us to enroll enough patients to complete our
clinical studies in a timely and cost-effective manner. Delays in the completion of any clinical study of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially
jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory
approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If serious adverse, undesirable or unacceptable side effects are identified during the
development of our product candidates or following approval, if any, we may need to abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative
consequences following marketing approval, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are associated with serious adverse, undesirable or
unacceptable side effects, we may need to abandon their development or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds
that initially showed promise in preclinical or early stage testing have later been found to cause side effects that restricted their use and prevented further development of the compound for larger indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech has not disclosed detailed information about serious adverse events associated with crenezumab either publicly or to us. However, at
the 2014 Alzheimer&#146;s Association International Conference, it was reported that in the combined Phase 2 study populations, serious adverse events occurred at similar rates in patients treated with crenezumab (16.5%) and in patients given a
placebo (11.9%). In addition, adverse events identified in the clinical studies of crenezumab initiated to date have included inflammation of the throat and nasal passages, urinary tract infections and upper respiratory infections. In addition, two
serious adverse events were observed in one patient during clinical studies of ACI-35, although we believe that these serious adverse events were not related to the treatment. The first event, pyelonephritis, was considered likely to have started
prior to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
study given the patient&#146;s tendency to contract urinary infections, including pyelonephritis. The second event, dizziness accompanied by confusion, was considered likely related to the
progression of the patient&#146;s underlying condition, since no abnormalities were noted during repeat MRIs and other examinations. A relationship between these serious adverse effects and ACI-35 cannot be ruled out, however. Non-drug related
serious adverse effects observed during clinical studies of ACI-24 were acute chest pain, death, colonic cancer, wound infections and pneumonia. Occurrence of serious procedure- or treatment-related side effects could impede clinical study
enrollment and receipt of marketing approval from the FDA, the EMA and comparable foreign regulatory authorities. Adverse events could also adversely affect physician or patient acceptance of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw approvals of such product and require us to take any approved products off the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered, conduct additional studies or change the labeling of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to limitations in how we promote the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of the product may decrease significantly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation and physician or patient acceptance of our products may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these
events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing
competing products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical and pharmaceutical industries are highly
competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and to market them
successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies, academic
institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. Many of our potential competitors, alone or with their strategic partners, have substantially greater
financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those
treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our
competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other
regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our key competitor product candidates are (i)&nbsp;aducanumab (Biogen),
solanezumab (Eli Lilly), gantenerumab (Roche) and bapineuzumab (Elan, Pfizer and Johnson&nbsp;&amp; Johnson) for crenezumab; (ii)&nbsp;CAD-106 (Novartis) for ACI-24; and (iii)&nbsp;AADVAC1 (Axon Neurosciences) for ACI-35, as described under
&#147;Business&#151;Competition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The highly competitive nature of and rapid technological changes in the biotechnology and
pharmaceutical industries could render our product candidates or our technology obsolete or non-competitive. Our competitors may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and commercialize products that are safer, more effective, less expensive, or more convenient or easier to administer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain quicker regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish superior intellectual property and proprietary positions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have access to more manufacturing capacity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">implement more effective approaches to sales and marketing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">form more advantageous strategic alliances. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these occur, our business,
financial condition and results of operations could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to
use and expand our Morphomer and SupraAntigen proprietary technology platforms to build additional product candidates for our pipeline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our Morphomer and SupraAntigen proprietary technology platforms to create unique drug
therapies for conformational diseases, such as AD, and progress these product candidates through clinical development. Although our research and development efforts to date have resulted in a pipeline of product candidates, we may not be able to
develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipelines, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being
shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to
commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect the price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to economic, political, regulatory and other risks associated with international operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. We and a number of our suppliers and collaborative and
clinical study relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals in non-U.S. countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in compliance with non-U.S. laws and regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. regulations and customs, tariffs and trade barriers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. currency exchange rates and currency controls; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political or economic environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative consequences from changes in tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties associated with staffing and managing international operations, including differing labor relations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future
viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began our operations in 2003. Our operations to date have been limited to financing and staffing our company,
developing our technology and developing crenezumab and our other product candidates. We have not yet demonstrated an ability successfully to complete a large-scale, pivotal clinical study, obtain marketing approval, manufacture a commercial scale
product or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully
developing and commercializing pharmaceutical products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Business interruptions could delay us in the process of developing our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss of our laboratory facilities through fire or other causes could have an adverse effect on our ability to
continue to conduct our business. We currently have insurance coverage to compensate us for such business interruptions; however, such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any
significant property or casualty loss to our facilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth and ability to compete depends on retaining our key
personnel and recruiting additional qualified personnel. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions of our key
management, scientific and technical personnel, many of whom have substantial experience with or been instrumental for us and our projects. Members of our key management include Dr.&nbsp;Andrea Pfeifer, our Chief Executive Officer; Dr.&nbsp;Andreas
Muhs, our Chief Scientific Officer; Dr.&nbsp;Wolfgang Barth, our Director of Development; George Pavey, our Chief Financial Officer; and Jean-Fabien Monin, our Chief Administrative Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of our key managers and senior scientists could delay our research and development activities. Laws and regulations on executive
compensation, including legislation in our home country, Switzerland, may restrict our ability to attract, motivate and retain the required level of qualified personnel. In Switzerland, new legislation affecting public companies has been passed
that, among other things, (i)&nbsp;imposes an annual binding shareholders&#146; &#147;say on pay&#148; vote with respect to the compensation of executive management, including executive officers and the board of directors; (ii)&nbsp;prohibits
severance, advances, transaction premiums and similar payments to executive officers and directors; and (iii)&nbsp;requires companies to specify various compensation-related matters in their articles of association, thus requiring them to be
approved by a shareholders&#146; vote. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled
scientific, technical and managerial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are
unsuccessful in the future, it may be difficult for us to implement business strategy, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development, and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience growth in the number of our employees and the scope of our operations.
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited
financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and
business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the
commercial stage; and our product liability insurance may not cover all damages from such claims. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to potential
product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently we have no products that have been approved for commercial sale; however, our
current and future use of product candidates in clinical studies, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers,
pharmaceutical companies or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for
commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical study process is designed to identify and assess potential side
effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical studies or after approval of the product candidate,
we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We purchase liability insurance in connection with the clinical studies that we undertake in amounts that we consider to be consistent with
industry norms. It is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates.
However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought
against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to obtain orphan drug designation for certain of our product candidates. Orphan drug designation may not
ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for such product candidates, we may be subject to earlier competition and our potential revenue will be reduced.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or
condition, defined as a patient population of fewer than 200,000 in the United States, or a patient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the
European Union, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically
debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or
serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no
satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical study costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may
not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or
biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to obtain orphan drug designation for any of our product candidates, and even if we do, we may not be the first to
obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug designation for a product, that exclusivity may not effectively
protect the product from competition because different drugs with different active moieties can be approved for the same condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug
any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Due to our limited resources and access to capital, we must prioritize
development of certain product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited resources and access to capital to fund our operations, we must
decide which product candidates to pursue and the amount of resources to allocate to each. As such, we are currently primarily focused on the development of ACI-24 and ACI-35 for the treatment of AD. Our decisions concerning the allocation of
research, collaboration, management and financial resources toward particular compounds, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities.
Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect
determinations regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for neurological disorders, our business, financial condition and results of operations could be materially
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our research and development activities could be affected or delayed as a result of possible restrictions on
animal testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws and regulations require us to test our product candidates on animals before initiating clinical
studies in humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and
regulation in these areas and by disrupting these activities through protests and other means. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems could face serious disruptions that could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to
the internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations
with our partners and delays in our research and development work. The loss of product development or clinical study data could result in delays in our regulatory approval efforts and significantly increase our costs. To the extent that any
disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of
our product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have never commercialized a product candidate before and may lack the necessary
expertise, personnel and resources to successfully commercialize our products on our own or together with suitable partners. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for our product candidates, we will have to develop our own sales, marketing and supply
organization or outsource these activities to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may affect our ability to commercialize our product candidates
on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our drug candidates and other unforeseen costs associated with
creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective
sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach
or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Relationships with Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain our current strategic relationships with Genentech, Janssen and Piramal, our business, commercialization prospects
and financial condition may be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have two partnerships with Genentech. In 2006, we granted
Genentech an exclusive, worldwide license for crenezumab. In 2012, we entered into a second partnership to commercialize our anti-tau antibodies for use as immunotherapies. We partner with Janssen to develop and commercialize therapeutic anti-tau
vaccines for the treatment of AD and potentially other tauopathies. We also have a diagnostic partnership with Piramal Imaging for a compound from our Morphomer chemical library that binds pathogenic tau for use as a positron emission tomography, or
PET, tracer. Genentech has the right to terminate its agreements with us at any time and for any reason upon providing us with a certain amount of notice. After a specified amount of time, Janssen and Piramal will also each have the right to
terminate their agreements with us for any reason upon providing us with a certain amount of notice. If Genentech, Janssen or Piramal terminate their respective agreements with us at any time, it could delay or prevent development of our product
candidates and materially harm our business, financial condition, commercialization prospects and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Good
relationships with Genentech, Janssen and Piramal are important for our business prospects. If our relationships with Genentech, Janssen or Piramal were to deteriorate substantially or Genentech, Janssen or Piramal were to challenge our use of their
intellectual property or our calculations of the payments we owe under our agreements, our business, financial condition, commercialization prospects and results of operations could be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, our collaboration agreement with Genentech for crenezumab provides Genentech with control
over, and responsibility for, the clinical development process, including obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Our other existing collaboration agreements provide our collaboration partners
with similar control over the clinical development process and future collaboration agreements may also relinquish development control to our partners. Genentech or our other current or future collaboration partners may separately pursue competing
products, therapeutic approaches or technologies to develop treatments for the diseases targeted by us or our collaborative efforts. Even if our partners continue their contributions to the collaborative agreements to which we are a party, they may
nevertheless determine not to actively pursue the development or commercialization of any resulting products. Our partners may also fail to perform their obligations under the collaboration agreements or may be slow in performing their obligations.
Any of these circumstances could result in a material adverse impact on our business, financial condition, commercialization prospectus or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to form additional strategic alliances in the future with respect to our product candidates, and if we do not realize the
benefits of such alliances, our business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund
expenses and may require expertise, such as sales and marketing expertise, which we do not currently possess. Therefore, in addition to our relationships with Genentech, Janssen and Piramal, we may decide to enter into strategic alliances, or create
joint ventures or collaborations with pharmaceutical or biopharmaceutical companies for the further development and potential commercialization of those and other of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document.
Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. We may
also be restricted under existing and future collaboration agreements from entering into strategic partnerships or collaboration agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on
acceptable terms, or at all, for any of our existing or future product candidates and programs because the potential partner may consider that our research and development pipeline is insufficiently developed to justify a collaborative effort, or
that our product candidates and programs do not have the requisite potential to demonstrate safety and efficacy in the target population. If we are unsuccessful in establishing and maintaining a collaboration with respect to a particular product
candidate, we may have to curtail the development of that product candidate, reduce the scope of or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our
sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense for which we have not budgeted. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and
generate product revenue. Even if we are successful in establishing a new strategic partnership or entering into a collaboration agreement, we cannot be certain that, following such a strategic transaction or license, we will be able to progress the
development and commercialization of the applicable product candidates as envisaged, or that we will achieve the revenues that would justify such transaction, and we could be subject to the following risks, each of which may materially harm our
business, commercialization prospects and financial condition: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to control the amount and timing of resources that the collaboration partner devotes to the product development program; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the collaboration partner may experience financial difficulties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to grant or otherwise relinquish important rights such as marketing, distribution and intellectual property rights; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaboration partner could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business combinations or significant changes in a collaboration partner&#146;s business strategy may adversely affect our willingness to complete our obligations under any arrangement. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third-party clinical research organizations, or CROs, to monitor and
manage data for our ongoing nonclinical and clinical programs, including the clinical studies of our product candidates. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory
responsibilities. We and our CROs and other vendors are required to comply with current good manufacturing practices, or cGMP, current good clinical practice, or cGCP, and Good Laboratory Practice, or GLP, which are regulations and guidelines
enforced by the FDA, the Competent Authorities of the Member States of the European Union and comparable foreign regulatory authorities for all of our product candidates in nonclinical and clinical development. Regulatory authorities enforce these
regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our nonclinical and
clinical studies may be deemed unreliable and the EMA, FDA, other regulatory authorities may require us to perform additional nonclinical and clinical studies before approving our marketing applications. We cannot assure you that upon inspection by
a given regulatory authority, such regulatory authority will determine that all of our clinical studies comply with cGCP regulations. In addition, our clinical studies must be conducted with products produced under cGMP regulations. Our failure to
comply with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our
relationships with these third-party CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us
under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical studies may be extended,
delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial
prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no
assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely on third-party suppliers and other third parties for production of our
product candidates and our dependence on these third parties may impair the advancement of our research and development programs and the development of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on and expect to continue to rely on third parties, for the manufacturing and supply of chemical compounds for the clinical
studies of our current and future product candidates. For the foreseeable future, we expect to continue to rely on such third parties for the manufacture of any of our product candidates on a clinical or commercial scale, if any of our product
candidates receives regulatory approval. Reliance on third-party providers may expose us to different risks than if we were to manufacture product candidates ourselves. The facilities used by our contract manufacturers to manufacture our product
candidates must be approved by the FDA or other regulatory authorities pursuant to inspections that will be conducted after we submit our NDA or comparable marketing application to the FDA or other regulatory authority. We do not have control over a
supplier&#146;s or manufacturer&#146;s compliance with these laws, regulations and applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. If our contract manufacturers cannot
successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition,
we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the
manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our
product candidates, if approved. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained
approvals could be revoked, which would adversely affect our business and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party providers may breach agreements they
have with us because of factors beyond our control. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. They may also terminate or
refuse to renew their agreements because of their own financial difficulties or business priorities, potentially at a time that is costly or otherwise inconvenient for us. If we were unable to find adequate replacement or another acceptable solution
in time, our clinical studies could be delayed or our commercial activities could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the fact that we are dependent
on our suppliers and other third parties for the manufacture, storage and distribution of our product candidates means that we are subject to the risk that our product candidates and, if approved, commercial products may have manufacturing defects
that we have limited ability to prevent or control. The sale of products containing such defects could result in recalls or regulatory enforcement action that could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Growth in the costs and expenses of components or raw materials may also adversely influence our business, financial condition and results of
operations. Supply sources could be interrupted from time to time and, if interrupted, we cannot be certain that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. Our current
and anticipated future dependence upon others for the manufacturing of our current and future product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely
and competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaboration arrangements with our strategic partners may make us an attractive target for potential
acquisitions under certain circumstances. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, due to the structure of our collaboration arrangements with
our strategic partners, our strategic partners may prefer to acquire us rather than paying the milestone payments or royalties under the collaboration arrangements, which may bring additional uncertainties to our business development and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospects. For example, under our collaboration arrangements with Genentech and Janssen, we may become entitled to substantial milestone payments and royalties. As a result, rather than paying
the milestone payments or royalties, Genentech or Janssen, or one of their affiliates including Roche or Johnson&nbsp;&amp; Johnson, may choose to acquire us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not have sufficient patent terms to effectively protect our products and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Although
various extensions or adjustments may be available, such as adjustments based on certain delays caused by the United States Patent and Trademark Office, or the USPTO, the life of a patent, and the protection it affords, is limited. Given the amount
of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. Even if patents covering our product candidates are obtained and
unchallenged, once the patent life has expired for a product, we may be open to competition from generic medications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While patent term
extensions under the Hatch-Waxman Act, in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity term for our products, we cannot provide any assurances that any such patent term
extension will be obtained and, if so, for how long. The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended.
However, we may not be granted any extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of
relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of
any such extension is less than we request, such result could have a material adverse effect on our business. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We and Genentech
are parties to interference proceedings with AbbVie that relate to crenezumab, and we may be involved in other proceedings or lawsuits to protect or enforce our patents or the patents of our licensors, any of which could be expensive, time
consuming, and unsuccessful, and may ultimately result in our loss of ownership of intellectual property. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may
infringe our patents or the patents of our licensors. To counter such infringement, we may be required to file claims against those competitors, which can be expensive and time-consuming. If we or one of our licensing or collaboration partners were
to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable, or that we infringe the
defendant&#146;s patents. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. In addition, third parties may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant
review<I>, inter partes </I>review, derivation proceedings and equivalent proceedings in foreign jurisdictions. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceedings or patent litigations could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates or otherwise provide
any competitive advantage. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing or collaboration partners were unaware during
prosecution. A court may also refuse to stop a third party from using the technology in question on the grounds that our patents do not cover that technology. An adverse result in any proceeding could put one or more of our patents at risk of being
invalidated or interpreted narrowly, which could have a material adverse effect on our business and financial condition. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could
require us or our collaboration partners to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be materially harmed if the prevailing party does not offer us or our collaboration
partners a license on commercially reasonable terms or at all. For example, we and Genentech are parties to an interference proceeding with AbbVie, Inc. before the USPTO. The interference involves two of our U.S. patents that relate to crenezumab
and a U.S. patent application owned by AbbVie. In addition, two opposition proceedings are pending before the European Patent Office involving us, Genentech and AbbVie. In one proceeding, we and Genentech filed an opposition against a European
patent issued to AbbVie. In the second proceeding, AbbVie filed an opposition against our issued European patent, which relates to crenezumab. See &#147;Business&#151;Legal Proceedings&#151;Patent Proceedings&#148; for additional information. If we
and Genentech are unsuccessful in any of these pending proceedings, we may lose our ownership of intellectual property or our patents may be narrowed or invalidated. There can be no assurance as to the outcome of the interference and opposition
proceedings, and any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our
management and other employees from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the funds necessary to continue our clinical studies, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. We may not be able to prevent, alone or with our licensors or collaboration partners, misappropriation
of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, decisions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our collaboration partners are unable to obtain and maintain effective patent rights for our technologies, product candidates
or any future product candidates, or if the scope of the patent rights obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully
commercialize our products and technology may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret
protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our collaboration partners&#146; ability to obtain and maintain patent
and other intellectual property protection in the United States and in other countries with respect to our proprietary technologies and product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sought to protect our proprietary position by filing patent applications in the United
States and abroad related to any of our novel technologies and products that are important to our business. This process is expensive, time consuming, and complex, and we may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost, in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our or our collaboration partners&#146; research and development output before it is too late to
obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license to or from third parties.
Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual
questions for which legal principles remain unsolved. As a result, the inventorship, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. The pending or future patent applications that we own or
in-license may fail to issue, fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries, or fail to effectively prevent others from commercializing competitive technologies and
product candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third-party intellectual property rights potentially relating to our technologies or product candidates.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions remain confidential for a period of time after filing, and some remain so until
issued. Therefore, we cannot be certain that we were the first to file any patent application related to our product candidates or technologies, or whether we were the first to make the inventions claimed in our owned patents or pending patent
applications, nor can we know whether those from whom we license patents were the first to make the inventions claimed or were the first to file. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or
scope, which may result in such patents being narrowed, found unenforceable or invalidated, which could allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability
to manufacture or commercialize products without infringing third party patent rights. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our
product candidates, prevent others from designing around our claims or provide us with a competitive advantage. Any of these outcomes could impair our ability to prevent competition from third parties, which may have a material adverse effect on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or our ownership of our patents or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patent policy and rule changes could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, thereby impairing our ability to protect our technologies and products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming the other requirements for patentability are met, in the United States prior to March&nbsp;15, 2013, the first to make the claimed
invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March&nbsp;15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on
September&nbsp;16, 2011, the United States has moved to a first-to-file system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to
the patent on an invention regardless of whether a third party was the first to invent the invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect
patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including
reexamination proceedings, <I>inter partes </I>review, and derivation proceedings. The effects of these changes on the operation of our business are currently unclear as, among other reasons, the USPTO must still implement various regulations.
However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the
development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners
in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and
regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain effective proprietary rights for our technologies, product candidates or any future product candidates, we
may not be able to compete effectively in our markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret
protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and
development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling
to protect trade secrets. Because we rely on our advisors, employees and third-party contractors and consultants to research and develop and to manufacture our product candidates, we must, at times, share our intellectual property with them. We seek
to protect our intellectual property and other proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors,
employees, contractors, consultants, collaboration partners, and other third parties. These agreements typically limit the rights of these third parties to use or disclose our confidential information, including our intellectual property and trade
secrets. These agreements also typically restrict the ability of third parties to publish data potentially relating to our intellectual property, although our agreements may contain certain limited publication rights. For example, any academic
institution that we may collaborate with in the future may expect to be granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time
period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. In the future, we may
also conduct joint research and development programs that may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require us to share intellectual property under the terms of our research and development or similar agreements. However, we cannot guarantee that we have entered into such agreements with each
party that may have or have had access to our trade secrets or other confidential information or proprietary technology and processes or that such agreements will not be breached or that our trade secrets or other confidential information will not
otherwise be disclosed. Despite the contractual provisions employed when working with these advisors, employees and third parties, the need to share intellectual property and other confidential information increases the risk that such confidential
information becomes known by our competitors, are inadvertently incorporated into the product development of others or are disclosed or used in violation of these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and
physical and electronic security of our information technology systems. Despite our efforts to protect our intellectual property, our competitors may discover our trade secrets through breach of our agreements with third parties, where we may not
have adequate remedies for any breach, independent development or publication of information by any of our collaboration partners. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient
recourse against third parties for misappropriating such trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Moreover, if any
of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us. A competitor&#146;s discovery of our
intellectual property would impair our competitive position and have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the
United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could
materially adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these
requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on a patent and patent
application are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and patent application. The USPTO and various foreign governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirement and we are also dependent on our licensors or
collaboration partners to take the necessary action to comply with these requirements with respect to certain of our intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in
accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly
legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The patent protection and patent prosecution for some of our product candidates is dependent on third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product
candidates, there may be times when the filing and prosecution activities for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents relating to our product candidates are controlled by our licensors or collaboration partners. If any of our future licensing partners fail to prosecute, maintain and enforce such patents
and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity
with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, and selling competing products. In addition, even where we
have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel
that took place prior to the date upon which we assumed control over patent prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with the obligations
in our intellectual property agreements, including those under which we license intellectual property and other rights to or from third parties, or otherwise experience disruptions to our business relationships with our licensees, our licensors and
partners, we could lose intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of
intellectual property license and co-ownership agreements that are important to our business and expect to enter into additional such agreements in the future. Under certain circumstances, the royalties payable to us under these agreements are
subject to certain reductions, which may have a materially adverse effect on our business, financial condition, results of operations and prospects. In addition, our existing agreements impose, and we expect that future agreements will impose,
various diligence, commercialization, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be required to make certain payments to the
licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues.
Disputes may arise regarding intellectual property subject to a licensing or co-ownership agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe or otherwise violate intellectual property of the licensor or partner that is not subject to the agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence, development and commercialization obligations under the agreement and what activities satisfy those obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors or partners and us and our licensors or collaborators; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property and
other rights that we have licensed or co-own prevent or impair our ability to maintain our current licensing or exclusivity arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain provisions in the agreements under which we currently license intellectual property or technology to and from third
parties may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology,
increase what we believe to be our financial or other obligations under the relevant agreement, or decrease the third party&#146;s financial or other obligations under the relevant agreement, any of which could have a material adverse effect on our
business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to our product
candidates through acquisitions and in-licenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our programs may in the future require the use of proprietary rights held by
third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and
efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as
necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual
property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that
perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development
under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we
may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to
pursue our applicable product candidate or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to successfully obtain a license to third-party intellectual
property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may expose us to substantial liability or prevent or delay our development and
commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends on our ability and the ability of our collaborators to develop,
manufacture, market and sell our product candidates and use our proprietary technology without infringing, misappropriating, or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and
pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding
intellectual property rights with respect to our product candidates and technology, including patent infringement lawsuits, interferences, oppositions, reexamination proceedings, <I>inter partes </I>review, derivation proceedings and post grant
review before the USPTO and corresponding foreign patent offices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent
applications, which are owned by third parties, exist in the fields in which we are developing product candidates. For example, we are aware of third party patents that may be construed to cover one or more of our product candidates. If these
patents are asserted against us or our collaboration partners and either we or our collaboration partners are found to infringe any of these patents, and are unsuccessful in demonstrating that such patents are invalid or unenforceable, then we and
our collaboration partners could be required to pay substantial monetary damages or cease further development or commercialization of one or more of our product candidates. There may also be other third-party patents or patent applications with
claims to materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of our product candidates and technology. Although we generally conduct a freedom to operate search and review with respect to our
product candidates, we cannot guarantee that our search and review is complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to
the commercialization of our product candidates or use of our technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In
addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third
parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these
third party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize our product candidates or technologies covered by the asserted third party patents. If we are found to infringe a
third party&#146;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be
able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to
us and it could require use to make substantial payments to the licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may also obtain injunctive or
other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would
be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful
infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Any of the foregoing could have a material and adverse
effect on our business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, claims that we have misappropriated the
confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions,
decisions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may have substantially greater resources and more mature and developed intellectual property portfolios than we do and
may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by
enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third
parties. The uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential
information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ and utilize the services of individuals who were previously employed or provided services to universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us,
we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our
employee&#146;s, consultant&#146;s or independent contractor&#146;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees
and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact,
conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties,
or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may
not be able to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as the laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States,
or from selling or importing products made using our inventions in and into the United States or other jurisdictions. In the ordinary course of prosecution and maintenance activities, we determine whether to seek patent protection outside the U.S.
and in which countries. This also applies to patents we have acquired or in-licensed from third parties. In some cases, we, or our predecessors in interest or licensors of patents within our portfolio, have sought patent protection in a limited
number of countries for patents covering our product candidates. Competitors may use our technologies in jurisdictions where we have not obtained or are unable to adequately enforce patent protection to develop their own products and further, may
export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights
may not be effective or sufficient to prevent them from competing, which would have a material adverse effect on our business and financial positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could
make it difficult for us to stop the infringement, misappropriation or other violations of our intellectual property and proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result
in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Our Financial Condition and Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company and have a history of operating
losses. We anticipate that we will continue to incur losses for the foreseeable future. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company. Since 2003, while we have received upfront and milestone payments from our collaboration partners and certain other revenue, we have also incurred significant operating losses. For example, we incurred net losses (defined
as net loss attributable to owners of the company) of CHF 11.2&nbsp;million for the year ended December&nbsp;31, 2013 and net losses of CHF 9.1 million for the nine months ended September 30, 2014.&nbsp;In addition, we had an accumulated deficit of
CHF 35.8 million as at September 30, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our losses have resulted principally from research and development expenses and from general
business and administrative expenses. We expect to continue to incur significant operating losses in the future as we continue our research and development efforts for our current and future product candidates and seek to obtain regulatory approval
and commercialization of such product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have financed our operations through private placements of preferred
securities, in addition to upfront and milestone payments from our collaboration partners and certain other revenue. We have no products approved for commercialization and have never generated any revenues from product sales. Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. It may be several years, if ever, before we or our collaboration partners complete pivotal clinical studies and have a product candidate approved for
commercialization and we begin to generate revenue or royalties from product sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>While we have generated revenues from upfront
and milestone payments related to our collaboration agreements, we have never generated any revenue from product sales and may never be profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have generated revenue from upfront and milestone payments related to our collaboration agreements, we have no products approved for
commercialization and have never generated any revenue product sales. Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of, and obtain the marketing approvals necessary to
commercialize, one or more of our product candidates. We do not anticipate generating revenue from product sales unless and until we or our collaboration partners obtain regulatory approval for, and commercialize, our product candidates. Our ability
to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing research and clinical development of our product candidates, including we or our collaboration partners, as the case may be, successfully completing a Phase 3 clinical study of crenezumab, a Phase 1/2a
clinical study of ACI-24 for AD and a Phase 1b clinical study of ACI-35; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining marketing approvals for our product candidates, including crenezumab, ACI-24 for AD or ACI-35, for which we complete clinical studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a sustainable and scalable manufacturing process for any approved product candidates and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate
(in amount and quality) products to support clinical development and the market demand for our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing product candidates for which we obtain marketing approval, either directly or with a collaborator or distributor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining market acceptance of our product candidates as viable treatment options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, assessing, acquiring and/or developing new product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negotiating favorable terms in any collaboration, licensing, or other similar arrangements into which we may enter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attracting, hiring and retaining qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if one or more of the product
candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Because of the numerous risks and uncertainties with pharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase beyond expectations if we are required by the FDA, the EMA, or other
regulatory agencies, domestic or foreign, to change our manufacturing processes, or to perform clinical, nonclinical, or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory approvals to market one or more of our product candidates, our revenue
will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement at any price, and whether we own the commercial
rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition,
physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Accordingly, we may not be profitable in the future from the sale of any approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to develop and commercialize any of our current or future product candidates and, even if we do, may not achieve
profitability in the future. Even if we do achieve profitability in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to be profitable in the future would decrease the value of our
company and could impair our ability to raise capital, expand our business or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we expect that we will need substantial additional funding before we can expect to become
profitable from sales of our products. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently advancing our product candidates through clinical development, either together with a collaboration partner (crenezumab and
ACI-35) or independently (ACI-24 for AD). We expect our research and development expenses to continue to increase in connection with our ongoing activities, particularly as we and/or our collaboration partners continue our ongoing studies and
initiate new studies of crenezumab, ACI-24 for AD and ACI-35 and initiate preclinical and clinical development of our other product candidates. As at September&nbsp;30, 2015, our cash and cash equivalents were CHF 53.7 million, or CHF 80.8 million
after giving effect to the Series E Private Placement. We currently believe that our existing capital resources, not including potential milestone payments and the proceeds we receive from this offering, but including the proceeds we received from
the Series E Private Placement, will be sufficient to meet our projected operating requirements for at least through the end of fiscal year &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove
to be wrong, and we could exhaust our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to: </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress, results and cost of our pre-clinical and clinical studies and other related activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing clinical supplies and establishing commercial supplies of our existing product candidates and any other products we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing, and outcomes of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any collaborative, licensing, and other arrangements that we may establish in the future, as well as our existing such arrangements, including any required milestone and royalty payments
thereunder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of competing technologies or other adverse market developments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential cost and timing of managing and protecting our portfolio of intellectual property. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that we will require additional capital to commercialize our product candidates. If we receive regulatory approval for our current
and future product candidates, and if we have not already licensed such product candidate to a collaboration partner and if we choose to commercialize such product candidate independently, we expect to incur significant commercialization expenses
related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We also expect to incur </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional costs associated with operating as a public company following this offering. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if
raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or
commercialization efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our shareholders, restrict our operations or require us
to relinquish rights to our intellectual property or future revenue streams. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate
substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and license and development agreements in connection with collaborations. We do not have any committed external
source of funds. In the event we need to seek additional funds, we may raise additional capital through the sale of equity, convertible debt or other securities. In such an event, your ownership interest will be diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds
through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to grant or otherwise relinquish valuable rights to our intellectual property or future revenue streams. If we are
unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer
to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use tax loss carryforwards in Switzerland may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2014, we reported tax loss carryforwards from financial years 2007 until 2014 for purposes of Swiss corporate income tax in
the aggregate amount of CHF 49.3 million that could be available to offset future taxable income. If not used, these tax losses will expire seven years after the year in which they were incurred. Due to our limited income, there is a high risk that
the tax loss carryforwards will expire partly or entirely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Exchange rate fluctuations or abandonment of the euro currency may
materially affect our results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our existing agreements, we receive a significant
amount of payments in USD, Swiss Francs and euro. As a result, changes and fluctuations in currency exchange rates between the Swiss Franc and other currencies, especially the USD and euro could have a materially adverse effect on our operating
results. Since our reporting currency is the Swiss Franc, financial line items are converted into Swiss Francs at the applicable exchange rates. We also expect that in the future, a significant portion of our revenues and expenses will be
denominated in Swiss Franc, USD and euro. Therefore, unfavorable developments in the value of the Swiss Franc as compared to the euro or any other currency could have a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Regulatory Environment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be
commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then
successfully commercialize one or more product candidates. We currently have one product candidate that has completed Phase 2 clinical studies. Enrollment in Phase 3 clinical studies of crenezumab initiated by our collaboration partner Genentech is
expected to begin in the first quarter of 2016, but may be delayed and no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurance is given that the studies will begin on that time frame. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, EMA
or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
cannot be certain that any of our product candidates will be successful in clinical studies or receive regulatory approval. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited
to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical or clinical studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&#146;s risk-benefit ratio for its proposed indication is acceptable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or other regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and
commercial supplies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally plan to seek regulatory approval to commercialize our product candidates in the United States, the European Union and in
additional foreign countries where we have commercial rights. To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry,
manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other
jurisdictions. Failure to obtain marketing authorization for our product candidates will result in our being unable to market and sell such products, which would materially adversely affect our business, financial conditional and results of
operation. If we fail to obtain approval in any jurisdiction, the geographic market for our product candidates could be limited. Similarly, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful
commercialization of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development involves a lengthy and expensive process with uncertain
timelines and uncertain outcomes. If clinical studies of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or
at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through
extensive preclinical and clinical studies that our products are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the
clinical study process. The results of preclinical and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. For example, the positive results generated to date in clinical studies for
our product candidates do not ensure that later clinical studies will demonstrate similar results. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through
preclinical studies and initial clinical studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. Our future clinical study results may not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies must be conducted in
accordance with FDA, EMA and comparable foreign regulatory authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and Institutional Review Boards, or IRBs, at the medical
institutions where the clinical studies are conducted. In addition, clinical studies must be conducted with supplies of our product candidates produced under cGMP and other requirements. We depend on medical institutions and CROs, to conduct our
clinical studies in compliance with cGCP standards. To the extent the CROs fail to enroll participants for our clinical studies, fail to conduct the study to cGCP standards or are delayed for a significant time in the execution of studies, including
achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, neither
we nor our collaboration partners have completed all clinical studies required for the approval of any of our product candidates. Crenezumab has completed Phase 2 clinical testing, ACI-24 for AD is in a combined Phase 1/2a clinical study, and ACI-35
is in Phase 1b clinical studies. The development of our other product candidates is less advanced and studies have not yet started. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
completion of clinical studies for our clinical product candidates may be delayed, suspended or terminated as a result of many factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the delay or refusal of regulators or IRBs to authorize us to commence a clinical study at a prospective study site or changes in regulatory requirements, policies and guidelines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays or failure to reach agreement on acceptable terms with prospective CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and
study sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in patient enrollment and variability in the number and types of patients available for clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results, which may require us to conduct additional preclinical or clinical studies or to abandon projects that we expected to be promising; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety or tolerability concerns, which could cause us to suspend or terminate a study if we find that the participants are being exposed to unacceptable health risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or safety concerns, among others;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lower than anticipated retention rates of patients and volunteers in clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a study;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays relating to adding new clinical study sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in maintaining contact with patients after treatment, resulting in incomplete data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in establishing the appropriate dosage levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the quality or stability of the product candidate falling below acceptable standards; </TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to produce or obtain sufficient quantities of the product candidate to complete clinical studies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exceeding budgeted costs due to difficulty in accurately predicting costs associated with clinical studies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delays in completing our clinical studies will increase our costs, slow our product candidate development and approval process and
jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the
commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain and maintain approval for our drug candidates from one jurisdiction, we may never obtain approval for our drug
candidates in other jurisdictions, which would limit our market opportunities and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our
approved drugs will be subject to U.S. and non-U.S. regulatory requirements governing clinical studies and regulatory approval, and we plan to seek regulatory approval to commercialize our drug candidates in the United States, the EEA, and other
countries. Clinical studies conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining
regulatory approval in one country may have a negative effect on the regulatory approval process in others. For example, approval in the United States by the FDA does not ensure approval by the regulatory authorities in other countries or
jurisdictions, and similarly approval by a non-U.S. regulatory authority, such as the EMA, does not ensure approval by regulatory authorities in other countries, including by the FDA. However, the failure to obtain approval in one jurisdiction may
have a negative impact on our ability to obtain approval elsewhere. Approval processes and regulatory requirements vary among countries and can involve additional drug testing and validation and additional administrative review periods. Even if a
drug is approved, the FDA or EMA, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming clinical studies or reporting as conditions
of approval. In many countries outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for a drug is also subject to
approval. Regulatory authorities in other countries also have their own requirements for approval of drug candidates with which we must comply prior to marketing in those countries. Obtaining non-U.S. regulatory approvals and compliance with such
non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our current and any future drugs, in certain countries. If we fail to comply with regulatory
requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our drug
candidates will be unrealized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations
and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if
we fail to comply with regulatory requirements or experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If marketing authorization
is obtained for any of our product candidates, the product will remain subject to continual regulatory review and therefore authorization could be subsequently withdrawn or restricted. Any regulatory approvals that we receive for our product
candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical
studies and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to ongoing regulatory obligations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and oversight by regulatory authorities, including with respect to the manufacturing processes, labeling, packing, distribution, adverse event reporting, storage, advertising and marketing
restrictions, and recordkeeping and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize such products. These requirements include submissions of safety and other
post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical studies that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occurs,
our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations. The
FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain
profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have conducted and may in the future conduct clinical studies for our drug candidates outside the United States,
and the FDA and applicable foreign regulatory authorities may not accept data from such studies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted and may in the
future choose to conduct one or more of our clinical studies outside the United States, including in Germany, Austria, Denmark, Sweden and Finland. The acceptance of study data from clinical studies conducted outside the United States or another
jurisdiction by the FDA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical studies are intended to serve as the basis for marketing approval in the United States, the FDA will
not approve the application on the basis of foreign data alone unless the following are true: the data are applicable to the United States population and United States medical practice; the studies were performed by clinical investigators of
recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other
appropriate means. Additionally, the FDA&#146;s clinical study requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar requirements. In addition, such foreign
studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable foreign regulatory authority will accept data from studies conducted outside of the
United States or the applicable jurisdiction. If the FDA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional studies, which would be costly and time-consuming and delay aspects of our
business plan, and which may result in our drugs or drug candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future legislation may increase the difficulty and cost for us to obtain
marketing approval of and commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and the
European Union, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system. These changes could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug
purchases by the elderly and introduced a new reimbursement methodology based on average sale prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any
therapeutic class. Cost-reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare
beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar
reduction in payments from private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More recently, in March 2010, President Obama signed into law the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Health Care Reform Law, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending,
enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Health Care Reform Law,
among other things, increased rebates a manufacturer must pay to the Medicaid program, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected, established a new Medicare Part D coverage gap discount program, in which manufacturers must provide 50% point-of-sale discounts on products covered under Part D and implemented payment system reforms including a
national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Further, the new law imposed a
significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were enacted, which may affect our business practices with health care practitioners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, other legislative changes have also been proposed and adopted in the United States since the Health Care Reform Law was enacted. On
August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of
2%&nbsp;per fiscal year, which went into effect on April&nbsp;1, 2013. On January&nbsp;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other things, further reduced Medicare payments to
several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in
additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, proposed new clinical study regulations will centralize clinical study approval, which eliminates redundancy, but in
some cases this may extend timelines for clinical study approvals due to potentially longer wait times. Proposals to require specific consents for use of data in research, among other measures, may increase the costs and timelines for our product
development efforts. Austerity measures in certain European nations may also affect the prices we are able to seek if our products are approved, as discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both in the United States and in the European Union, legislative and regulatory proposals have
been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We could
be subject to liabilities under environmental, health and safety laws or regulations, or fines, penalties or other sanctions, if we fail to comply with such laws or regulations or otherwise incur costs that could have a material adverse effect on
the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws, regulations, and permitting
requirements, including those governing laboratory procedures, decontamination activities and the handling, transportation, use, remediation, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of
hazardous and flammable materials, including chemicals and biological materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials or wastes either at our sites or at third party disposal sites. In the event of such contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations or
permitting requirements. Such laws, regulations and requirements are becoming increasingly more stringent and may impair our research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements also
may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and payors will be subject to
applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, if violated, could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm
and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and others play a primary role in the recommendation
and prescription of any products for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, primarily in the
United States, that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable healthcare laws and
regulations, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under U.S. government healthcare programs such as Medicare and Medicaid; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S.
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating
to healthcare matters; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transparency requirements under the Health Care Reform Law require manufacturers of drugs, devices, biologics and medical supplies to report to the U.S. Department of Health and Human Services information related to
payments and other transfers of value made by such manufacturers to physicians and teaching hospitals, and ownership and investment interests held by physicians or their immediate family members; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the U.S. federal
Anti-Kickback Statute, it is possible that some of our future business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the Health
Care Reform Law, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it.
Moreover, the Health Care Reform Law provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False
Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business with
are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our
business, prospects, operating results, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot ensure that our compliance controls, policies, and
procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare,
employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and
could adversely impact our ability to conduct business, operating results, and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud
or other misconduct. Misconduct by employees could include intentional failures to comply with FDA or EMA regulations, to provide accurate information to the FDA or the EMA or intentional failures to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. We will
adopt a code of conduct in connection with this offering, but it is not always possible to identify and deter employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions
could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business
activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving,
or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep
books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction
with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government
entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or SEC, and Department of Justice have increased their FCPA enforcement activities
with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of
complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of
business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and
could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and our Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common shares may be volatile and may fluctuate due to factors beyond our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share prices of publicly traded emerging biopharmaceutical and drug discovery and development companies have been highly volatile and are
likely to remain highly volatile in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">positive or negative results of testing and clinical studies by us, strategic partners, or competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates or entry into strategic relationships on terms that are not deemed to be favorable to us;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">technological innovations or commercial product introductions by us or competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in government regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning proprietary rights, including patents and litigation matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern relating to the commercial value or safety of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financing or other corporate transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publication of research reports or comments by securities or industry analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions in the pharmaceutical industry or in the economy as a whole; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other events and factors beyond our control. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general has recently experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market and industry factors may materially affect the market price of companies&#146; stock, including ours, regardless of
actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>There was no public market for our common shares prior to this offering, and an active market in our
common shares may not develop in which investors can resell our common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering there was no public market
for our common shares. We cannot predict the extent to which an active market for our common shares will develop or be sustained after this offering, or how the development of such a market might affect the market price for our common shares. The
initial public offering price of our common shares in this offering was agreed between us and the underwriters based on a number of factors, including market conditions in effect at the time of this offering, which may not be indicative of the price
at which our common shares will trade following completion of this offering. Investors may not be able to sell their common shares at or above the initial public offering price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our existing shareholders will continue to be able to exercise significant control over us, and your interests may conflict
with the interests of our existing shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of this offering, our existing shareholders are expected to
own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our common shares. Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in a position to determine the outcome of decisions taken at any such general
meeting. To the extent that the interests of these shareholders may differ from the interests of the company&#146;s other shareholders, the latter may be disadvantaged by any action that these shareholders may seek to pursue. Among other
consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of our
common shares. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future sales of a substantial number of our common shares, or the perception that such sales will occur, could
cause a decline in the market price of our common shares. Following the completion of this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding (assuming no exercise of the underwriters&#146;
over-allotment option) based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding as at September&nbsp;30, 2015 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional common shares issuable
upon the automatic conversion of all of our outstanding preferred shares into common shares. This includes the common shares in this offering, which may be resold in the public market immediately upon the closing of this offering without
restriction, unless purchased by our affiliates. Approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the common shares outstanding are expected to be held by affiliates (or &nbsp;&nbsp;&nbsp;&nbsp;% if existing investors, executives and directors purchase
all the shares they have indicated an interest in purchasing in this offering). All of these common shares will be subject to the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. If, after the end of such
lock-up agreements, these shareholders sell substantial amounts of common shares in the public market, or the market perceives that such sales may occur, the market price of our common shares and our ability to raise capital through an issue of
equity securities in the future could be adversely affected. We also entered into a registration rights agreement in connection with the Series E Private Placement with certain of our existing shareholders and certain investors in the Series E
Private Placement pursuant to which we agreed under certain circumstances to file a registration statement to register the resale of the common shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings
of such common shares. In addition, following the completion of this offering, we intend to cease any new grants under our existing equity incentive plans and to adopt a new omnibus equity incentive plan under which we would have the discretion to
grant a broad range of equity-based awards to eligible participants. We intend to register all common shares that we may issue under this equity compensation plan. Once we register these common shares, they can be freely sold in the public market
upon issuance, subject to volume limitations applicable to affiliates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. If a large number of our common shares or securities convertible into our common shares are sold
in the public market after they become eligible for sale, the sales could reduce the trading price of our common shares and impede our ability to raise future capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase common shares in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common shares is substantially higher than the as adjusted net tangible book value per common share.
Therefore, if you purchase common shares in this offering, you will pay a price per common share that substantially exceeds our as adjusted net tangible book value per common share after this offering. To the extent outstanding options are
exercised, you will incur further dilution. Based on the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common share, which is the midpoint of the price range set forth on the
cover page of this prospectus, you will experience immediate dilution of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per common share,
representing the difference between our as adjusted net tangible book value per common share after giving effect to this offering and the initial public offering price. In addition, purchasers of common shares in this offering will have contributed
approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate price paid by all purchasers of our common shares but will own only approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our common shares outstanding after this offering. See &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that
do not improve our results of operations or enhance the value of our common shares. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the
price of our common shares to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we
currently intend that any earnings will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing dividends. The proposal to pay future dividends to shareholders will in
addition effectively be at the discretion of our board of directors after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future
dividends is subject to certain limitation pursuant to Swiss law or by our articles of association. See &#147;Description of Share Capital and Articles of Association.&#148; Accordingly, investors cannot rely on dividend income from our common
shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are a Swiss corporation. The rights of our shareholders may be different from the rights of shareholders in companies governed by the
laws of U.S. jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Swiss corporation. Our corporate affairs are governed by our articles of association and by
the laws governing companies, including listed companies, incorporated in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and
directors of companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board of directors is required by Swiss law to consider the interests of our company, our shareholders, our employees and other stakeholders, in
all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder. Swiss corporate law limits
the ability of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an
action taken by our board of directors but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of our board of directors for breach of fiduciary duty would have to
be brought in Lausanne, Switzerland, or where the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders against us must be brought exclusively in Lausanne, Switzerland. See
&#147;Description of Share Capital and Articles of Association&#148; and &#147;Comparison of Delaware Law and Swiss Law.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The
shareholders&#146; resolution regarding the authorized share capital increase may be challenged. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering is based upon
and subject to a resolution regarding the authorized share capital increase that was approved by the shareholders at the shareholders&#146; meeting held on October 21, 2015. As with all share capital increases in Switzerland, the registration of the
capital increase in the commercial register of the Canton of Zurich may be blocked by a shareholder and, therefore, prevent or delay the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our common shares are issued under the laws of Switzerland, which may not protect investors in a similar fashion afforded by
incorporation in a U.S. state. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland. A further summary of applicable Swiss company law
is contained in this prospectus, see &#147;Description of Share Capital and Articles of Association&#148; and &#147;Comparison of Delaware Law and Swiss Law.&#148; However, there can be no assurance that Swiss law will not change in the future or
that it will serve to protect investors in a similar fashion afforded under corporate law principles in the U.S., which could adversely affect the rights of investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our status as a Swiss corporation may limit our flexibility with respect to certain aspects of capital management and may cause us to be
unable to make distributions without subjecting our shareholders to Swiss withholding tax. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss law allows our shareholders to
authorize share capital that can be issued by the board of directors without additional shareholder approval. This authorization is limited to 50% of the existing registered share capital and must be renewed by the shareholders every two years.
Additionally, subject to specified exceptions, Swiss law grants preemptive rights to existing shareholders to subscribe to any new issuance of shares. Swiss law also does not provide as much flexibility in the various terms that can attach to
different classes of shares as the laws of some other jurisdictions. Swiss law also reserves for approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example,
dividends must be approved by shareholders. These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided substantial benefits to our shareholders.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, a Swiss corporation may pay dividends only if the corporation has sufficient distributable profits from previous
fiscal years, or if the corporation has distributable reserves, each as evidenced by its audited statutory balance sheet. Freely distributable reserves are generally booked either as &#147;free reserves&#148; or as &#147;capital contributions&#148;
(<I>apports de capital</I>, contributions received from shareholders) in the &#147;reserve from capital contributions.&#148; Distributions may be made out of registered share capital&#151;the aggregate par value of a company&#146;s registered
shares&#151;only by way of a capital reduction. Upon completion of this offering, we expect the Company to have CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of qualifying capital contributions and CHF
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of registered share capital on its audited statutory balance sheet. We expect the aggregate of these amounts (less the minimum registered share capital of CHF 100,000) to
represent the amount available for future dividends or capital reductions on a Swiss withholding tax-free basis. We will not be able to pay dividends or make other distributions to shareholders on a Swiss withholding tax-free basis in excess of that
amount unless the Company increases its share capital or its reserves form capital contributions. We would also be able to pay dividends out of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributable profits or freely distributable reserves but such dividends would be subject to Swiss withholding taxes. There can be no assurance that we will have sufficient distributable
profits, free reserves, reserves from capital contributions or registered share capital to pay a dividend or effect a capital reduction, that our shareholders will approve dividends or capital reductions proposed by us or that we will be able to
meet the other legal requirements for dividend payments or distributions as a result of capital reductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, Swiss withholding
tax of 35% is due on dividends and similar distributions to our shareholders, regardless of the place of residency of the shareholder, unless the distribution is made to shareholders out of (i)&nbsp;a reduction of par value or (ii)&nbsp;assuming
certain conditions are met, qualifying capital contributions accumulated on or after January&nbsp;1, 1997. A U.S. holder that qualifies for benefits under the Convention between the United States of America and the Swiss Confederation for the
Avoidance of Double Taxation with Respect to Taxes on Income, which we refer to as the &#147;U.S.-Swiss Treaty,&#148; may apply for a refund of the tax withheld in excess of the 15% treaty rate (or in excess of the 5% reduced treaty rate for
qualifying corporate shareholders with at least 10% participation in our voting stock, or for a full refund in the case of qualified pension funds). There can be no assurance that we will have sufficient qualifying capital contributions to pay
dividends free from Swiss withholding tax, or that Swiss withholding rules will not be changed in the future. In addition, we cannot provide assurance that the current Swiss law with respect to distributions out of qualifying capital contributions
will not be changed or that a change in Swiss law will not adversely affect us or our shareholders, in particular as a result of distributions out of qualifying capital contributions becoming subject to additional corporate law or other
restrictions. There are currently motions pending in the Swiss Parliament that purport to limit the distribution of qualifying capital contributions. In addition, over the long term, the amount of par value available to us for par value reductions
or qualifying capital contributions available to us to pay out as distributions is limited. If we are unable to make a distribution through a reduction in par value or out of qualifying capital contributions, we may not be able to make distributions
without subjecting our shareholders to Swiss withholding taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under present Swiss tax laws, repurchases of shares for the purposes of
cancellation are treated as a partial liquidation subject to 35% Swiss withholding tax on the difference between the repurchase price and the par value except, since January&nbsp;1, 2011, to the extent attributable to qualifying capital
contributions (<I>apports de capital</I>) if any, and to the extent that, the repurchase of shares is out of retained earnings or other taxable reserves, the Swiss withholding becomes due. No partial liquidation treatment applies and no withholding
tax is triggered if the shares are not repurchased for cancellation but held by the Company as treasury shares. However, should Company not resell such treasury shares within six years, the withholding tax becomes due at the end of the six year
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our executive officers or
members of our board of directors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland and our registered office and domicile is
located in Ecublens, near Lausanne, Switzerland. Moreover, a number of our directors and executive officers and a number of directors of each of our subsidiaries are not residents of the United States, and all or a substantial portion of the assets
of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts,
including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original
actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely
upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on International Private Law. This statute provides that the application of provisions of non-Swiss law by the
courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Also, mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switzerland and the United States do not have a treaty providing for reciprocal recognition and enforcement of judgments in civil and
commercial matters. The recognition and enforcement of a judgment of the courts of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States in Switzerland is governed by the principles set forth in the Swiss Federal Act on Private International Law. This statute provides in principle that a judgment rendered by a
non-Swiss court may be enforced in Switzerland only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment of such non-Swiss court has become final and non-appealable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment does not contravene Swiss public policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in
Switzerland. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our status as a Swiss corporation means that our shareholders enjoy certain rights that may limit our
flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss law reserves for approval by
shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also
requires that our shareholders themselves resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize share capital that can be issued by our board of directors without additional shareholder
approval, Swiss law limits this authorization to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of up to two years and must be renewed by the shareholders from time to time
thereafter in order to be available for raising capital. Additionally, subject to specified exceptions, including exceptions explicitly described in our articles of association, Swiss law grants pre-emptive rights to existing shareholders to
subscribe for new issuances of shares. Swiss law also does not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the laws of some other jurisdictions. These Swiss law
requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided benefits to our shareholders. See &#147;Description of Share Capital and Articles of Association&#148;
and &#147;Comparison of Delaware Law and Swiss Law.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss law restricts our ability to pay dividends. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposal to pay future dividends to shareholders will effectively be at the discretion of our board of directors and shareholders after
taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future dividends is subject to certain limitation pursuant to Swiss law or by our
articles of association. See &#147;Description of Share Capital and Articles of Association.&#148; Accordingly, investors cannot rely on dividend income from our common shares and any returns on an investment in our common shares will likely depend
entirely upon any future appreciation in the price of our common shares. Dividends paid on our common shares are subject to Swiss federal withholding tax, except if paid out of reserves from capital contributions (&#147;<I>apports de
capital</I>&#148;). See &#147;Taxation&#151;Swiss Tax Considerations&#148; for a summary of certain Swiss tax consequences regarding dividends distributed to holders of the our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will be a foreign private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act
reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
consummation of this offering, we will report under the Exchange Act as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we are subject to Swiss laws and regulations with regard to such matters and intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange
Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;
(ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii)&nbsp;the rules under the
Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition,
foreign private issuers are not required to file their annual report on Form 20-F until four months after the end of each financial year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K
within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may
not have the same protections afforded to shareholders of companies that are not foreign private issuers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private
issuer and as permitted by the listing requirements of NASDAQ, we will rely on certain home country governance practices rather than the corporate governance requirements of NASDAQ. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be a foreign private issuer as of the effective date of this registration statement. As a result, in accordance with NASDAQ Listing
Rule 5615(a)(3), we will comply with home country governance requirements and certain exemptions thereunder rather than complying with certain of the corporate governance requirements of NASDAQ. Swiss law does not require that a majority of our
board of directors consist of independent directors. Our board of directors therefore may include fewer independent directors than would be required if we were subject to NASDAQ Listing Rule 5605(b)(1). In addition, we will not be subject to NASDAQ
Listing Rule 5605(b)(2), which requires that independent directors must regularly have scheduled meetings at which only independent directors are present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Swiss law also requires that we adopt a compensation committee, we will follow home country requirements with respect to such
committee and our compensation, nomination and governance committee will also be tasked with certain director nomination and governance responsibilities as described under &#147;Management&#151;Committees of the Board of Directors.&#148; As a
result, our practice will vary from the requirements of NASDAQ Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees, and from the independent director
oversight of director nominations requirements of NASDAQ Listing Rule 5605(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in accordance with Swiss law and generally
accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. Our practice thus varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an
issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. Our articles of association provide for an independent proxy holder elected by our shareholders,
who may represent our shareholders at a general meeting of shareholders, and we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders. However, Swiss law does not have a regulatory regime for
the solicitation of proxies and company solicitation of proxies is prohibited for public companies in Switzerland, thus our practice will vary from the requirement of NASDAQ Listing Rule 5620(b), which sets forth certain requirements regarding the
solicitation of proxies. In addition, we have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or
amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of NASDAQ Listing Rule 5635, which generally requires an issuer to
obtain shareholder approval for the issuance of securities in connection with such events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For an overview of our corporate governance principles, see &#147;Description of Share Capital
and Articles of Association.&#148; As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#146;s domestic reporting
regime and cause us to incur significant legal, accounting and other expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer and therefore we
are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as at June&nbsp;30, 2016 (the end of our second
fiscal quarter in the fiscal year after this offering), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of January&nbsp;1, 2017. In
order to maintain our current status as a foreign private issuer, either (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive
officers or directors may not be United States citizens or residents, (ii)&nbsp;more than 50 percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally outside the United States. If we
lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be
required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements
applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs
and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain
director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified
members of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced reporting
requirements applicable to &#147;emerging growth companies&#148; will make our common shares less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
an &#147;emerging growth company,&#148; as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an &#147;emerging growth company,&#148; we may take advantage of exemptions from various
reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act
of 2002, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an &#147;emerging growth company&#148; in our initial
registration statement we are required to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We could be an &#147;emerging
growth company&#148; for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common shares held by non-affiliates exceeds $700 million as of any June&nbsp;30 (the end of our
second fiscal quarter) before that time, in which case we would no longer be an &#147;emerging growth company&#148; as of the following December&nbsp;31 (our fiscal year end). We cannot predict if investors will find our common shares less
attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a result of being a public company we will incur additional costs and we may not manage
to comply with our internal control procedures and corporate governance structures. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur additional
legal, insurance, accounting and other expenses that we did not incur as a private company. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls and disclosure controls and procedures and bear
all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligation under the securities laws. However, if our efforts to comply with evolving laws, regulations and standards differ from the
activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us. This could have a material adverse impact on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>In connection with the audit of our financial statements as at and for the year ended December 31, 2014, we
and our independent registered public accounting firm have identified a material weakness in our internal control over financial reporting. If we fail to maintain an effective system of internal control over financial reporting, we may be unable to
accurately report our financial results or prevent fraud, and investor confidence in our company and the market price of our shares may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal
control over financial reporting. Further, our reporting obligations as a public company will continue to place a significant strain on our management, operational and financial resources and systems for the foreseeable future. In connection with
our preparation and the audit of our financial statements as at and for the year ended December 31, 2014, we and our independent registered public accounting firm have identified a material weakness as defined under the Exchange Act and by the U.S.
Public Company Accounting Oversight Board, or PCAOB, in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of the company&#146;s annual financial statements will not be prevented or detected on a timely basis. The material weakness identified relates specifically to the accounting for and disclosure of
non-routine and complex accounting transactions and the related internal controls and processes supporting these areas. In light of the material weakness that was identified, we believe it is possible that, had we performed a formal assessment of
our internal control over financial reporting or had our independent registered public accounting firm performed an audit of our internal control over financial reporting in accordance with PCAOB standards, additional control deficiencies may have
been identified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once public, we will be subject to reporting obligations under U.S. securities laws and the Sarbanes-Oxley Act of 2002.
Section 404 of the Sarbanes-Oxley Act will require that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form 20-F beginning with our annual report for the fiscal year
ending December 31, 2016. If we fail to remediate the material weakness identified above, our management may conclude that our internal control over financial reporting is not effective. This conclusion could adversely impact the market price of our
shares due to a loss of investor confidence in the reliability of our reporting processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have begun taking measures and plan to
continue to take measures to remediate this material weakness. However, the implementation of these measures may not fully address this material weakness in our internal control over financial reporting, and therefore we would not be able to
conclude that it has been fully remedied. Our failure to correct this material weakness or our failure to discover and address any other control deficiencies could result in inaccuracies in our financial statements and could also impair our ability
to comply with applicable financial reporting requirements and make related regulatory filings on a timely basis. As a result, our business, financial condition, results of operations and prospects, as well as the trading price of our shares, may be
materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If in the future we fail to maintain an effective system of internal control over financial
reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common
shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and,
together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting
obligations. As discussed above, in connection with the audits of our financial statements as and at the year ended December&nbsp;31, 2014, we have identified a material weakness in our internal control over financial reporting. In addition, any
testing by us conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting
that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also subject us to regulatory
scrutiny and sanctions, impair our ability to raise revenue and cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to disclose changes made in our internal controls and procedures and our management will be required to assess the
effectiveness of these controls annually. However, for as long as we are an &#147;emerging growth company&#148; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal
controls over financial reporting pursuant to Section&nbsp;404. We could be an &#147;emerging growth company&#148; for up to five years. An independent assessment of the effectiveness of our internal controls could detect problems that our
management&#146;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price
of our common shares and our trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common shares will depend in part on the
research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or too few securities or industry analysts commence
coverage of our company, the trading price for our common shares would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common shares or publish
inaccurate or unfavorable research about our business, the price of our common shares would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common shares could
decrease, which might cause the price of our common shares and trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Although we believe that we were not a
&#147;passive foreign investment company,&#148; or PFIC, for U.S. federal income tax purposes in 2014 and we do not expect to be a PFIC in the immediately foreseeable future, if we were a PFIC U.S. shareholders may be subject to adverse U.S. federal
income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a PFIC for any taxable year
in which, after the application of certain look-through rules with respect to subsidiaries, either (i)&nbsp;75% or more of our gross income consists of passive income or (ii)&nbsp;50% or more of the average quarterly value of our assets consists of
assets that produce, or are held for the production of, passive income. Passive income generally includes dividends, interest, certain non-active rents and royalties, and capital gains. Based on our business plan and certain estimates and
projections, including as to the relative values of our assets, we do not believe that we were a PFIC for our 2014 taxable year and do not expect to be a PFIC in the immediately foreseeable future. However, there can be no assurance that the IRS
will agree with our conclusion. In addition, whether we will be a PFIC in 2015 or any future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years is uncertain because, among other things, (i)&nbsp;we currently own, and will own after the completion of this offering, a substantial amount of passive assets, including cash, and
(ii)&nbsp;the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC for any
taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. investor holds common shares, we generally would continue to be
treated as a PFIC with respect to that U.S. investor for all succeeding years during which the U.S. investor holds common shares, even if we ceased to meet the threshold requirements for PFIC status. Such a U.S. investor may be subject to adverse
U.S. federal income tax consequences, including (i)&nbsp;the treatment of all or a portion of any gain on disposition as ordinary income, (ii)&nbsp;the application of a deferred interest charge on such gain and the receipt of certain dividends and
(iii)&nbsp;compliance with certain reporting requirements. We do not intend to provide the information that would enable investors to take a qualified electing fund (&#147;QEF&#148;) election that could mitigate the adverse U.S. federal income tax
consequences should we be classified as a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For further discussion, see &#147;Taxation&#151;Material U.S. Federal Income Tax
Considerations for U.S. Holders.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_5"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains statements that constitute forward-looking statements. All statements other than statements of historical facts
contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration
partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in
this prospectus can be identified by the use of forward-looking words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;estimate,&#148;
&#147;will&#148; and &#147;potential,&#148; among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements appear in a number of places in this prospectus and
include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#146;s beliefs and assumptions and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various factors, including, but not limited to, those identified under the
section entitled &#147;Risk Factors&#148; in this prospectus. These risks and uncertainties include factors relating to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The success of our and our collaboration partners&#146; clinical studies, and our and their ability to obtain regulatory approval and to commercialize crenezumab, ACI-24 for AD and ACI-35; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Morphomer and SupraAntigen proprietary technology platforms and their success in building additional product candidates for our pipeline; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The identification of serious adverse, undesirable or unacceptable side effects related to our product candidates; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to maintain our current strategic relationships with our collaboration partners; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Failure to protect our, and not infringe on third parties&#146;, intellectual property rights throughout the world; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to raise capital when needed in order to continue our product development programs or commercialization efforts; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA&#146;s and applicable foreign regulatory authorities&#146; acceptance of data from studies we conduct outside the United States in the future; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our foreign private issuer status, the loss of which would require us to comply with the Exchange Act&#146;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies incorporated in the United States; and </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The other risk factors discussed under &#147;Risk Factors.&#148; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements speak only as of the date of this prospectus and are subject to
a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and
elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these
forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law,
we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in this prospectus
are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains industry, market and competitive position data that are based on industry publications and studies conducted by third
parties as well as our own internal estimates and research. These industry publications and third-party studies generally state that the information that they contain has been obtained from sources believed to be reliable, although they do not
guarantee the accuracy or completeness of such information. While we believe that each of these publications, third-party studies and our internal research is reliable and that the definition of our market and industry is appropriate, you are
cautioned not to give undue weight to this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares in this offering will be
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (which is the midpoint of the price range set forth on the
cover page of this prospectus), after deducting the underwriting discount and estimated offering expenses payable by us. If the underwriters exercise their over-allotment option in full, we estimate that the net proceeds will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, after deducting the underwriting discount and estimated offering expenses payable by us. In addition, we received gross proceeds of approximately $30.0 million from the Series&nbsp;E
Private Placement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) our net proceeds by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover of
this prospectus, remains the same and after deducting the underwriting discount and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number
of shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discount and estimated offering expenses payable by us, by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price stays the same. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are undertaking this offering in order to access the public capital markets and to increase our liquidity. At September 30, 2015, we had cash and cash equivalents of CHF 53.7 million, which included a receivable related to milestone payments of CHF
14.0&nbsp;million received in July 2015 from Genentech in connection with our anti-tau antibody program and crenezumab, respectively. At September 30, 2015, after giving effect to the Series E Private Placement, we would have had cash and cash
equivalents of CHF 80.8 million. We intend to use the net proceeds of this offering over the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years, together with our existing cash and cash equivalents (including the net proceeds from the
Series E Private Placement), as follows:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our share of the costs for the further development of our therapeutic and diagnostics product candidates under collaboration
agreements (anti-tau antibodies and the tau PET tracers) in the next three years, of which approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million will be spent on therapeutic product candidates and of which approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million will be spent on diagnostic product candidates, and we expect these expenditures will take the tau PET tracers into Phase 3 and the anti-tau antibody program into Phase 2; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund our share of the costs for the further development of ACI-35, our tau vaccine under collaboration with Janssen, and we expect these
expenditures will take ACI-35 into Phase 2; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the further development of ACI-24 for AD through the remainder of the Phase 1/2a study and the Phase 2b study and for our ongoing Phase 1
study and a portion of the proposed Phase 2 study of ACI-24 for Down syndrome; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for funding our PD-focused programs, including further pre-clinical development, the completion of Phase 1 studies and commencement of Phase 2
studies for our alpha-synuclein diagnostic product candidate as well as further pre-clinical development and the commencement of a Phase 1 clinical study of Morphomer alpha-synuclein, our alpha-synuclein morphomer product candidate;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the further development of non-AD and non-PD programs, including our morphomer tau and glaucoma program for which we intend to commence a
Phase 1 study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for new research and development initiatives that are complementary to our existing and planned research initiatives (with the intent to
advance these new initiatives through the discovery phase); and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder for general corporate purposes. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, due to the uncertainties inherent in the product development process, it is
difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. The amount and timing of our actual expenditures will depend upon numerous factors, including the results of our
research and development efforts, the timing and success of our ongoing preclinical and clinical studies or preclinical and clinical studies we may commence in the future and the timing of regulatory submissions. As a result, our management will
have broad discretion over the use of the net proceeds from this offering, and investors will be relying on our judgment regarding the application of the net proceeds. In addition, we might decide to postpone or not pursue certain preclinical
activities or clinical studies if the net proceeds from this offering and our other sources of cash are less than expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the
use of the proceeds from this offering, we intend to invest the net proceeds in interest-bearing, investment-grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. and Swiss governments. We are likely to convert a
substantial amount of the proceeds into CHF shortly after the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any,
to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Under Swiss law, any dividend must be proposed by our board of directors and approved by our shareholders. In addition, our auditors
must confirm that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of incorporation. A Swiss corporation may pay dividends only if it has sufficient distributable profits brought forward from the
previous business years (&#147;<I>r&eacute;serves &agrave; libre disposition</I>&#148;) or if it has distributable reserves (&#147;<I>r&eacute;serves &agrave; libre disposition</I>&#148;), each as evidenced by its audited standalone statutory
balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association have been deducted. Distributable reserves are generally booked either as &#147;free reserves&#148;
(&#147;<I>r&eacute;serves libres</I>&#148;) or as &#147;reserve from capital contributions&#148; (&#147;<I>apports de capital</I>&#148;). Distributions out of issued share capital, which is the aggregate nominal value of a corporation&#146;s issued
shares, may be made only by way of a share capital reduction. See &#147;Description of Share Capital and Articles of Association.&#148;<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our total capitalization (defined as the sum of total debt and
shareholders&#146; equity) as at September&nbsp;30, 2015 derived from our unaudited interim financial statements prepared in accordance with IFRS: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as adjusted basis to reflect: </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the conversion of all shares of our preferred
stock outstanding as at September 30, 2015 into an aggregate of 136,248 common shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) our issuance and sale of preferred shares in
the Series E Private Placement and the conversion of all such shares into an aggregate of 12,453 common shares; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) the filing and
effectiveness of our amended and restated articles of incorporation; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as further adjusted basis to further reflect the receipt of the estimated net proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares in this offering at an
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (which is the midpoint of the range set forth on the cover page of this prospectus), after deducting the underwriting discount and estimated
expenses payable by us. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table in conjunction with our unaudited condensed interim financial
statements included in this prospectus as well as &#147;Use of Proceeds,&#148; &#147;Selected Financial and Other Information&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our
financial statements included elsewhere in this prospectus. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at September&nbsp;30, 2015</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Further<BR>Adjusted(1)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>(in CHF thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares nominal value CHF 5.00&nbsp;per share, 35,034 shares issued and outstanding;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, as adjusted; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, as further adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares nominal value CHF 5.00&nbsp;per share, 136,248 authorized preferred shares, 136,248 preferred shares issued and
outstanding; no shares authorized or issued and outstanding, as adjusted or as further adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) each of as further adjusted cash and cash
equivalents, additional paid-in capital, total capitalization and shareholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same, and after deducting the underwriting discount and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1,000,000 in the number of
shares offered by us would increase (decrease) as further adjusted cash and cash equivalents, additional paid-in capital, total shareholders&#146; equity and capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, after deducting the underwriting discount and estimated offering expenses payable by us </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of common shares in the table above excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our common shares reserved for future issuance under our new omnibus equity incentive plan that we intend to adopt in connection with this
offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our common shares issuable upon the exercise of options outstanding under our existing equity incentive plans as at September&nbsp;30, 2015 at
an exercise price of CHF 36.37&nbsp;per common share. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common shares, your interest will be diluted to the extent of the difference between the initial public offering price
per share and the as adjusted net tangible book value per share of our common shares immediately after this offering and our preferred shares that will automatically convert into our common shares on a one-for-one basis upon the completion of this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net tangible book value is determined by dividing our total tangible assets less our total liabilities by the number of our
common shares outstanding. Our historical net tangible book value as at September 30, 2015 was CHF 48.2 ($49.5) million, or CHF 1,374.45 ($1,412.15), per common share (on a fully diluted basis). Our as adjusted net tangible book value as at
September&nbsp;30, 2015, before giving effect to this offering was CHF 75.2&nbsp;($77.3) million, or CHF 409.58&nbsp;($420.61) per common share, based on the total number of our common shares outstanding as at September&nbsp;30, 2015, after giving
effect to the conversion of (i) all preferred stock outstanding as at September 30, 2015 into an aggregate of 136,248 common shares and (ii) all shares of our preferred stock issued in the Series E Private Placement into an aggregate of 12,453
common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors represents the difference between the amount per share paid by purchasers of common
shares in this offering and the as further adjusted net tangible book value per common share immediately after completion of this offering. After giving effect to our sale of common shares in this offering at an assumed initial public offering price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the underwriting discount and estimated expenses payable by us. Our as further
adjusted net tangible book value as at September&nbsp;30, 2015 would have been CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, or
CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share. This represents an immediate increase in as adjusted net tangible book value of
CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share to existing shareholders and an immediate dilution of CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(USD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share to investors participating in this offering, as illustrated in the following table: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;USD)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;CHF)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share at September&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,412.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,374.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share at September&nbsp;30, 2015, before giving effect to this offering but giving effect to
the automatic conversion of all outstanding preferred shares, including the preferred shares issued in the Series E Private Placement, into common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As further adjusted net tangible book value per share after giving effect to this offering </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share would increase (decrease) our as further adjusted net tangible book value by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per
share, and the dilution per share to investors in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share, assuming that the number of shares offered by
us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discount and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase
(decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) our as further adjusted net tangible book value by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per
share, and decrease the as adjusted dilution per share to investors in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share, assuming an initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share, after deducting the underwriting discount and estimated offering expenses payable by us. The as further
adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters&#146; over-allotment option is exercised in full, the as further adjusted net
tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share, the increase in as further adjusted net tangible book value per share
to existing shareholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share and the dilution to new investors purchasing shares in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table presents, on an as further adjusted basis described above, the difference between the existing shareholders and the purchasers of shares in this offering with respect to the number of shares purchased from us, the total consideration paid,
which includes net proceeds received from the issuance of common and preferred stock and cash received from the exercise of stock options. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration<BR>(USD)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration<BR>(CHF)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;per<BR>Share<BR>(USD)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;per<BR>Share<BR>(CHF)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share, would increase (decrease) the total consideration paid to us by new investors and total consideration paid to us by all
shareholders by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting the underwriting discount and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) the total consideration paid to us by
new investors and total consideration paid to us by all shareholders by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CHF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per share, after deducting the underwriting discount and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculations above are based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding as at
September&nbsp;30, 2015 after giving effect to the conversion of all outstanding shares of preferred stock (including the preferred shares issued in the Series E Private Placement) into common shares and exclude: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our common shares reserved for future issuance under our new omnibus equity incentive plan that we intend to adopt in connection with this
offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our common shares issuable upon the exercise of options outstanding under our existing equity incentive plans as at September&nbsp;30, 2015 at
an exercise price of CHF 36.37&nbsp;per common share. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options are exercised, new
options are issued under our stock-based compensation plans or we issue additional common shares in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_11"></A>EXCHANGE RATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the high, low, average and period-end exchange rates for the purchase of U.S.
dollars expressed in CHF per U.S. dollar. The average rate is calculated by using the average of the U.S. Federal Reserve Bank&#146;s reported exchange rates on each day during a monthly period and on the last day of each month during an annual
period. On October 20, 2015, the exchange rate as reported by the U.S. Federal Reserve Bank was CHF 0.9562 to $1.00. In this prospectus, translations from CHF to U.S. dollars were made at the rate of 0.9733 to $1.00, the official exchange rate
quoted as at September&nbsp;30, 2015 by the U.S. Federal Reserve Bank. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period-end</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;for<BR>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(CHF per U.S. dollar)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Years Ended December 31:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Months Ended:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 30, 2015 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2015 (through October 20, 2015)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_12"></A>SELECTED FINANCIAL AND OTHER INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our financial data as at the dates and for the periods indicated. The financial data for the years ended
December&nbsp;31, 2014 and 2013 have been derived from our audited financial statements, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or
IASB, and audited in accordance with the standards of the U.S. Public Company Accounting Oversight Board, and included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial data as at September 30, 2015 and for the nine months ended September 30, 2015 and 2014 have been derived from our unaudited
interim financial statements included elsewhere in this prospectus. The unaudited interim financial statements have been prepared on the same basis as our audited financial statements and include all normal recurring adjustments that we consider
necessary for a fair statement of our financial position and operating results as at the dates and for the periods presented. We maintain our books and records in, and our financial statements are prepared and presented in, Swiss Francs, our
presentation currency. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of the results that may be expected in the future. Our
interim financial results for the periods presented are not necessarily indicative of results for a full year or for any subsequent interim period. The following summary financial data should be read in conjunction with &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Comprehensive Income </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months</B><br><B>Ended</B><br><B>September 30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years<BR>Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in CHF thousands except for share and<BR>per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings / (loss) per share (basic)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings / (loss) per share (fully diluted)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings / (loss) per share basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings / (loss) per share fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes preferred shares outstanding as of the dates indicated, and these preferred shares will be converted on a one-for-one basis upon the closing of this offering. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;September&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_13"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion of our financial condition and results of operations should be read in conjunction with &#147;Selected Financial
and Other Information,&#148; and our financial statements included elsewhere in this prospectus. We present our financial statements in Swiss Francs and in accordance with International Financial Reporting Standards, or IFRS, as issued by the
International Accounting Standards Board, or IASB. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The statements in this discussion regarding industry outlook, our strategy, our
expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not
limited to, the risks and uncertainties described in &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in this prospectus. Our actual results may differ materially from those contained in or implied
by any forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel,
proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that we
developed using our proprietary SupraAntigen platform. Crenezumab is expected to enter Phase 3 clinical studies in early 2016 and we believe it has the potential to become a best-in-class disease-modifying treatment for Alzheimer&#146;s disease, or
AD. Genentech, Inc., a wholly owned subsidiary of Roche, or Genentech, is advancing crenezumab for the treatment of AD under a collaboration agreement with us, pursuant to which it is responsible for the clinical development of crenezumab, including
the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Genentech met with the FDA in October 2014 and again in September 2015 to discuss the Phase 3 study design. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through
active immunization, where the immune system is stimulated to make its own antibodies against pathological proteins: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-24 is our wholly-owned anti-Abeta vaccine candidate currently in a Phase 1/2a study. We expect to complete this study and announce top line results in the second half of 2016. ACI-24 is also being studied in
patients with Down syndrome, a population that is at high risk for AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-35 is an anti-tau vaccine candidate that we are developing under a collaboration agreement with Janssen. We and Janssen are co-developing ACI-35 through the ongoing Phase 1b clinical study, which we expect to be
completed in the fourth quarter of 2016. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. We expect Phase 2 clinical studies to begin in 2017. </TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also using our Morphomer platform to develop complementary diagnostic products such as positron emission tomography, or PET,
ligands, which are tracers that can directly measure misfolded tau and alpha-synuclein in the brain, to enable early and reliable disease diagnoses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific
small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. These platforms are our engines for generating novel molecules that are designed to bind to their targets with high affinity and conformational
specificity, meaning they are enabled to differentiate between misfolded proteins and normally-folded proteins. All of our product candidates and our development programs have been derived from our proprietary platforms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have primarily financed our operations through private placements of preferred
securities, in addition to upfront and milestone payments from our collaboration partners. We have no products approved for commercialization and have never generated any revenues from product sales. Biopharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of risk. It may be several years, if ever, before we or our collaboration partners complete pivotal clinical studies and have a product candidate approved for commercialization and we begin
to generate revenue and royalties from product sales. Since our inception, while we have received upfront and milestone payments from our collaboration partners and certain other revenue. We have also incurred significant operating losses. For
example, we incurred net losses of CHF 11.2&nbsp;million for the year ended December&nbsp;31, 2013 and net losses of CHF 9.1&nbsp;million for the nine months ended September&nbsp;30, 2014.&nbsp;In addition, we had an accumulated deficit of CHF
35.8&nbsp;million as at September&nbsp;30, 2015. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Collaborations and Licensing Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have entered into strategic collaboration agreements with a range of partners covering a number of our product
candidates. We entered into a strategic collaboration with Genentech in November 2006 (as amended in May 2015) regarding the development, manufacture and commercialization of crenezumab, and we refer to this agreement as the 2006 Genentech
agreement. In June 2012, we entered into an additional strategic collaboration agreement with Genentech regarding the development, manufacture and commercialization of our anti-tau antibodies, and we refer to this agreement as the 2012 Genentech
agreement. We expect to capitalize on Genentech&#146;s drug development and regulatory expertise and commercial capabilities to bring our partnered therapeutic products to market. In May 2014, we entered into a collaboration agreement with Piramal
Imaging, a leader in imaging agents, covering our tau PET Imaging tracer. In December 2014, we entered into a strategic collaboration agreement with Janssen regarding the development, manufacture and commercialization of ACI-35, an anti-tau vaccine.
We expect to capitalize on Janssen and Johnson&nbsp;&amp; Johnson&#146;s extensive regulatory expertise and experience in developing, manufacturing and, if approved, commercializing vaccines to bring ACI-35 to market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Crenezumab&#151;Collaboration with Genentech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2006 Genentech agreement, we may become entitled to receive upfront and milestone payments totaling up to approximately $340 million,
excluding royalties. We received an upfront payment of $25&nbsp;million in 2006 and are entitled to various milestone payments based on the achievement of specified development and commercialization milestones. To date, we have received payments
totaling $65 million from Genentech, including the $25 million upfront payment and milestone payments totaling $40 million for crenezumab entering into Phase 1, Phase 2 and Phase 3 clinical studies. Under the 2006 Genentech agreement, we are
entitled to various regulatory and marketing approval milestone payments. If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the U.S.
and Europe. These percentage rates range from the low double-digits to the mid-teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2006 Genentech agreement also provides for a
second indication for which we would be eligible to receive clinical milestone payments payable upon commencement of each of Phase 2 and 3 of clinical development as well as regulatory and marketing milestone payments similar to those applicable to
crenezumab. If this second indication receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes at the same rates applicable to crenezumab. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Tau Antibodies&#151;Collaboration with Genentech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2012 Genentech agreement, we are entitled to receive upfront and milestone payments in excess of CHF 400&nbsp;million, excluding
royalties. We received an upfront payment of CHF 17&nbsp;million in 2012 and are entitled to various milestone payments based on the achievement of specified clinical, regulatory and commercialization milestones. To date, we have received payments
totaling CHF 31&nbsp;million from Genentech. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to low double digits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2012 Genentech agreement also provides for a second indication for which we would be eligible
to receive clinical milestone payments payable upon commencement of each of Phase 2 and 3 of clinical development as well as regulatory and marketing milestone payments. If this second indication receives regulatory approval, we will be entitled to
receive royalties that are tied to annual sales volumes at the same rates applicable to the lead indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tau PET Imaging
Tracer&#151;Collaboration with Piramal Imaging </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our agreement with Piramal Imaging covering our anti-tau PET imaging agent,
we received an upfront payment of &#128;0.5&nbsp;million in May 2014 and are entitled to various clinical milestone payments totaling up to &#128;7&nbsp;million based on the achievement of specified development milestones. In addition, we are
entitled to further regulatory and sales-based milestones totaling &#128;150.0 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-35&#151;Collaboration with Janssen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the collaboration agreement with Janssen regarding the development of ACI-35, we may become entitled to receive upfront and milestone
payments totaling up to CHF 500&nbsp;million, plus royalties on sales at a percentage rate ranging from low double digits to mid-teens. To date, we have received an upfront payment of CHF 25.9 million. The total future payments that we would be
entitled to under the agreement for clinical milestones amounts to CHF 83.5 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, we were included in a research study focused on Huntington&#146;s disease as part of the 7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Framework Program of the European Union under the Marie Currie Actions program. This research study was coordinated by the University of T&uuml;bingen and ran over a 3 year period between September
2011 and September 2014. We recognized revenues from this grant on a straight-line basis over the study period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we were
awarded a grant from the Michael J. Fox Parkinson&#146;s Foundation for the further research and development of an alpha-synuclein diagnostic imaging agent. Under the terms of the grant, we retain all rights, results and intellectual property
relating to the program. The grant covers research and development work over a 1.5 year period. We recognize revenues from this grant on a straight line basis over the life of the grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our stage of development, we have not generated any revenue from product sales. Our revenue to date has been derived primarily from four
separate collaboration agreements on some of our product candidates in various stages of pre-clinical and clinical developments and a number of research grants we have secured. For collaborations established on programs in pre-clinical stage, we
recognize revenue from upfront payments under our collaboration agreements ratably over the term of our estimated period of performance under each agreement. For collaboration agreements on product candidates that are (i)&nbsp;in clinical
development, (ii)&nbsp;where the upfront payment reflects a payment for past investments we have made in the development of the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and
(iii)&nbsp;where there is no further performance commitment, we recognize the fair value of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements with product candidates in clinical development
but where the conditions described in clauses (ii)&nbsp;and (iii)&nbsp;above are not met, we recognize the upfront payments ratably over the term of our estimated period of performance under each agreement. For all of our collaboration agreements,
in addition to receiving upfront payments, we are entitled to milestone and other contingent payments upon achieving pre-defined objectives. Revenue from milestones, if they are non-refundable and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed substantive, are recognized upon successful accomplishment of the milestones. To the extent that non-substantive milestones are achieved and we have remaining performance obligations,
milestones are deferred and recognized as revenue over the estimated remaining period of performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues have experienced
significant fluctuations over the past three years as a result of securing new collaboration agreements, the timing of milestone achievement and the size of each milestone payment. We expect that any revenue we generate from our two collaboration
agreements with Genentech, our collaboration agreements with each of Janssen and Piramal Imaging, research and development grants, and any future collaboration partners will fluctuate from year to year as a result of the timing and amount of
milestones and other payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses comprise direct research costs, including the use of CROs, consultants and experts hired to assist on our
research and development activities, consumables used for research and development purposes, employment compensation for our research and development, intellectual property, regulatory affairs, quality control and manufacturing personnel, as well as
expenses related to regulatory affairs and quality control. Our research and development costs include the costs associated with our recurrent maintenance costs associated with our portfolio of intellectual property including patents. In addition,
research and development expenditures include the depreciation of fixed assets used in research and development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The largest component of
our total operating expenses has historically been, and will continue to be, our investment in research and development activities, including the clinical development of our product candidates. Historically, research and development expenses have
represented over 80% of our total annual operating costs. Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates, as well as development of new product
candidates from our SupraAntigen and Morphomer platforms as well as the development of product candidates pursuant to our collaboration agreements with Genentech, Janssen and Piramal Imaging. We recognize all research and development costs as they
are incurred. Clinical study costs, contract manufacturing and other development costs incurred by third parties are expensed as the contracted work is performed. At present, our research activities comprise five major areas: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AD therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Non-AD therapies that are not neuro-orphans therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Neuro-orphan disease therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Diagnostics; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">New discovery projects. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the limited financial resources of the Company, we have
historically allocated over 70% of our research and development budget to AD therapies. We expect our research and development expenses to increase substantially in the future and expect to fund a broader number of projects. Specifically, the
planned capital raising will impact our research strategy in four key ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">we expect to undertake later-stage research and development of our product candidates and, if approved, to take some of those product candidates into commercialization; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">we will allocate more funding to existing programs to advance the development of these programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">we will increase our research and development efforts on non-AD indications including neuro-orphans; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">we will initiate a number of new research initiatives that are complementary to our existing and planned research initiatives. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, research initiatives targeting AD will continue to be the primary focus of our
research efforts. However, other indications including PD, selected neuro-orphans and diagnostics are likely to consume an increasing share of the total research and development expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides a breakdown of our research and development costs, including direct research and development costs and employment
costs, by major development program for the periods covered by this &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section. With the exception of ACI-35, research costs that are subject to
collaboration agreements (for example, crenezumab for all periods, anti-tau antibodies for the years ended December&nbsp;31, 2013 and 2014 and the tau PET tracer for the year ended December&nbsp;31, 2014) typically have a limited amount research
expenses since our partners bear most or all of the research and development costs. We have shown below our research and development costs associated with advancing ACI-35, the tau vaccine candidate that is being developed jointly with Janssen,
since pursuant to our agreement we are required to provide significant research support for this program until the end of 2016. Our research and development costs for ACI-24 for AD and Down syndrome are expected to increase significantly in the
coming years as we fund Phase 2b and Phase 1 clinical studies for ACI-24 in AD and ACI-24 in Down syndrome, respectively. Research and development costs for our alpha-synuclein PET tracer diagnostics program and other new discovery areas are also
likely to rise substantially in the coming years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Detailed Research and Development Expenditures by Major Development Program </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months</B><br><B>Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Programs subject to collaboration agreements(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACI-35</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACI-24 (for AD and Down syndrome)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PD (therapeutics and diagnostics)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New discovery programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes research and development expenditures for crenezumab, anti-tau antibodies and tau PET imaging tracer. Does not include research and development expenditures for ACI-35. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses.
Personnel costs consist of salaries, cash bonuses, benefits and share-based compensation. Outside professional services consist of legal, accounting and audit services, IT and other consulting fees. Allocated expenses consist of rent expense related
to our office and research and development facility. We expect to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national
securities exchange on which our securities are then traded (including the NASDAQ on which we intend to list our common shares in connection with this offering), additional insurance expenses, investor relations activities and other administrative
and professional services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income and Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial expenses are bank fees associated with charges levied by banks on foreign payments and foreign exchange transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest received from banks on our cash balances. Other financial income relates principally to gains that we
have made historically on foreign currency transactions, which arise from the fact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that some of our collaboration agreements such as the collaboration agreements with Janssen and Piramal Imaging are in currencies other than Swiss Francs, and selected purchases, which we effect
in foreign currencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to corporate taxation in Switzerland. In 2005, the Canton of Vaud granted us a ten year tax holiday for all income and capital
taxes on a communal and cantonal level commencing in fiscal 2005 and valid through to 2014. In 2005, under a ruling created by the Swiss Federal Government to encourage the creation of new enterprises, we were granted a tax holiday of nine years
from inception. Both tax holidays expired on December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also entitled under Swiss laws to carry forward any losses
incurred for a period of seven years and can offset our losses carried forward against future taxes. As at December 31, 2014, we had tax loss carryforwards totaling CHF 49.3 million. There is no certainty that we will make sufficient profits to
avail ourselves of these tax loss carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporate tax rate in the Canton of Vaud where we are domiciled is currently 22.5%
The Canton does from time to time, amend the level of taxation levied on corporations and there is no certainty that the tax rate currently in effect will not change in the future. At present, there are discussions on lowering the corporate tax rate
in the Canton of Vaud to below 15% by 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Value Added Tax, or VAT, is charged on all qualifying goods and services by VAT-registered
businesses. An amount of 8.0% of the value of the goods or services is added to all sales invoices and is payable to the Swiss tax authorities. Similarly, VAT paid on purchase invoices is reclaimable from the Swiss tax authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the First
Nine Months Ended September&nbsp;30, 2015 and September&nbsp;30, 2014 </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our revenues during the first nine months ended September&nbsp;30, 2015 and 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research collaborations and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenues rose to CHF 38.8&nbsp;million for the nine months ended September&nbsp;30, 2015 from
CHF 4.2&nbsp;million for the nine months ended September&nbsp;30, 2014, an increase of CHF 34.5 million. The increase was principally due to revenues recognized in connection with a CHF 14.0&nbsp;million milestone payment from Genentech pursuant to
our collaboration agreement for the anti-tau antibody vaccine and the $25 million milestone payment from Genentech pursuant to our collaboration agreement for crenezumab. Income related to research collaborations declined to CHF 0.3&nbsp;million in
the nine months ended September&nbsp;30, 2015 from CHF 4.2 million in the nine months ended September&nbsp;30, 2014. The figure for 2014 includes a portion of the original upfront payment we received in connection with the anti-tau antibody
collaboration agreement, which we recognized over a three year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant revenue totaled CHF 0.2&nbsp;million for the first nine months of 2015, up CHF
0.1&nbsp;million from the same period in 2014. The amounts recognized in the nine months ended September 30, 2014 relate to a research grant we had with the University of T&uuml;bingen for Huntington&#146;s disease, which expired in 2014. The grant
income recorded in our income statement for the nine months ended September 30, 2015 relates to a grant we were awarded by the Michael J. Fox Foundation to conduct research on an alpha-synuclein PET imaging product, which commenced in February 2015
and is expected to run to July 2016. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses during the nine months ended September&nbsp;30, 2015 and 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of tangible fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses totaled CHF 11.3&nbsp;million for the nine months ended
September&nbsp;30, 2015, up CHF 0.3 million from the CHF 11.0 million of research and development expenses incurred in the nine months ended September&nbsp;30, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development operating expenses declined to CHF 6.6 million in the nine months ended September&nbsp;30, 2015, a decrease of
CHF 0.4&nbsp;million as compared to the nine months ended September&nbsp;30, 2014 due principally to a reduction in the amount of prepaid supplies. In the first nine months of 2015, salaries and related compensation costs amounted to CHF
4.6&nbsp;million, which represents a CHF 0.7&nbsp;million increase over the CHF 3.8&nbsp;million recorded in the first nine months of 2014. The increase is primarily due to the initial ramp up of joint research activity on ACI-35 with Janssen and
higher performance-related bonus payments to our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect a significant increase in research and development expenses in the
last quarter of 2015. This is due to the fact that we have agreed with Janssen, our partner for ACI-35, to increase the scale and scope of our clinical studies for ACI-35 product candidate. Beyond 2015, we would expect our research and development
expenses to continue to rise as we seek to increase the number of projects we are funding into later-stage research and development. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General
and Administrative Expenses </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses during the nine months
ended September&nbsp;30, 2015 and 2014: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses rose by CHF 1.2&nbsp;million to CHF 3.5&nbsp;million for
the nine months ended September&nbsp;30, 2015. The increase was driven principally by costs associated with us preparing for becoming a public company and seeking to raise capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first nine months of 2015, salaries and related compensation costs amounted to CHF 1.5 million, which represents a CHF 0.2 million
increase over the CHF 1.3 million recorded in the first nine months of 2014. The increase is primarily related to compensation related expenses in the finance function as we prepare for this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income and Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our financial income and expenses during the nine months ended September&nbsp;30, 2015 and 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial (expense) / income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total financial income rose to CHF 0.9 million for the nine month period ended September 30, 2015, an
increase of CHF 0.9 million as compared to the nine month period ended September 30, 2014. The increase was principally due to the positive impact of exchange rate movements of financial assets and payables owed by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2014 and 2013 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
summarizes our revenues during the years ended December&nbsp;31, 2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenues rose to CHF 30.3&nbsp;million for the year ended December&nbsp;31, 2014 from CHF
8.6&nbsp;million for the year ended December&nbsp;31, 2013, an increase of CHF 21.6 million. The increase was principally due to collaboration and license revenues rising to CHF 30.2 million for the year ended December 31, 2014 from CHF
8.5&nbsp;million for the year ended December&nbsp;31, 2013. In 2014, we recognized revenue from three collaboration and license agreements including a CHF 25.9&nbsp;million upfront payment from Janssen in connection with the collaboration agreement
on ACI-35 tau vaccine, CHF 3.9&nbsp;million related to the portion of the upfront fee associated with the Genentech collaboration agreement for our anti-tau antibody started in 2012, and CHF 0.6&nbsp;million related to the portion of the upfront
payment pursuant to our collaboration agreement with Piramal Imaging attributable to this period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses during the years ended December&nbsp;31, 2014 and 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of tangible fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses declined to CHF 16.1&nbsp;million for the year ended December&nbsp;31,
2014 from CHF 17.2&nbsp;million, a decrease of CHF 1.1&nbsp;million, as compared to the year ended December&nbsp;31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year
ended December&nbsp;31, 2014 our research and development operating costs decreased by CHF 1.3&nbsp;million to CHF 10.0&nbsp;million due principally to the transfer of costs within the collaboration with Genentech on the anti-tau antibodies program
in 2014 and the collaboration-related costs occurred in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our salaries and related costs related to our research and development
activities remained relatively stable, rising to CHF 5.8&nbsp;million in the year ended December&nbsp;31, 2014 from CHF 5.6&nbsp;million in the year ended December&nbsp;31, 2013, a CHF 0.2&nbsp;million increase. This increase is due to an average
increase in base compensation of 1% and a slight increase in stock based compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agreement with Janssen requires us to
significantly increase our research and development expenses related to the Phase 1b studies for ACI-35. Over a two year period, we have committed to spend over CHF 13.8&nbsp;million to support the on-going clinical development of ACI-35. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses during the years ended December&nbsp;31, 2014 and 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were CHF 3.4&nbsp;million for the year ended December&nbsp;31, 2014, an
increase of CHF 0.5&nbsp;million from CHF&nbsp;3.0 million for the year ended December&nbsp;31, 2013. The increase was primarily due to an increase in operating expenses associated with commencing initial preparations for becoming a public company
in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income and Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our financial income and expenses during the years ended December&nbsp;31, 2014 and 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense and bank fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gain / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial (expense) / income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial income declined to CHF 27&nbsp;thousand for the year ended December&nbsp;31, 2014 from CHF
0.3&nbsp;million in 2013, a decline of CHF 0.2&nbsp;million compared to the year ended December&nbsp;31, 2013. The decline was driven primarily by a reduction in gains related to foreign exchange and a decline in interest income driven by the
decrease in our cash balances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have been financed primarily from proceeds from the collaboration and license agreements we have with a number of partners,
including Genentech, Janssen and Piramal Imaging, research grants awarded to us and net proceeds from the issuance of preferred shares. At September 30, 2015 we had cash and cash equivalents of CHF 53.7 million. At September 30, 2015, after giving
effect to the Series E Private Placement, we would have had cash and cash equivalents of CHF 80.8 million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of
capital are, and we expect will continue to be, research and development expenses, compensation and related expenses, and other operating expenses including rent. Cash used to fund operating expenses is impacted by the timing of when we pay
expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We expect to incur substantial expenses in connection with a number of our product candidates in various stages of clinical development including
co-funding ACI-35 to the end of the ongoing Phase 1b clinical study, material increases in spending on ACI-24 in AD to fund a Phase 2b study, <FONT STYLE="white-space:nowrap">ACI-24</FONT> in Down syndrome and a number of research initiatives
focused on neurodegenerative orphan diseases other than AD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to fund our operating and capital funding needs through
proceeds received from collaboration and licensing agreements and through equity or other forms of financing. We may also consider entering into additional collaboration agreements and or selectively partnering for clinical development and
commercialization. The sale of additional equity would result in additional dilution to our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the First Nine Months Ended September&nbsp;30, 2015 and 2014 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash generated in operating activities was CHF 49.7 million for the nine months ended September 30, 2015 compared with net cash used in
operating activities of CHF 13.4 million for the nine months ended September 30, 2014. The significant increase in cash generated from operating activities in the first nine month of 2015 was due to (i)&nbsp;the Company generating a CHF 24.9 million
net income in the first nine months of 2015 driven by the anti-tau antibody and crenezumab&nbsp;milestone payments compared with a CHF 9.1 million loss during the same period in 2014, and (ii)&nbsp;receipt in January 2015 of the CHF 25.9 million
upfront payment associated with the collaboration with Janssen on ACI-35. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities rose to CHF 0.2 million for the nine months ended September 30, 2015 compared with cash used in investing
activities of CHF 0.1&nbsp;million in the first nine months of 2014. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was CHF 42 thousand for the nine months ended September 30, 2015, compared with CHF 9.8 million for
the nine months ended September 30, 2014. The 2014 figure contains the proceeds from a CHF 9.9&nbsp;million capital increase net of expenses associated with the issuance of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2014 and 2013 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net cash used in operating activities declined from CHF 19.8&nbsp;million for the year ended December&nbsp;31, 2013 to CHF
17.6&nbsp;million for the year ended December&nbsp;31, 2014, a decline of CHF 2.0 million. The decline is primarily related to three factors: (i)&nbsp;we generated net income of CHF 10.7&nbsp;million in the year ended December&nbsp;31, 2014 compared
with a CHF 11.2&nbsp;million net loss in the year ended December&nbsp;31, 2013, (ii)&nbsp;a significant increase in other current receivables from CHF 0.2 million at December&nbsp;31, 2013 to CHF 25.9 million at December&nbsp;31, 2014, and
(iii)&nbsp;a reduction in deferred revenue, which declined from CHF 8.5&nbsp;million to CHF 3.7&nbsp;million for the years ended December&nbsp;31, 2013 and 2014, respectively. The changes discussed in clauses (i)&nbsp;and (ii)&nbsp;above were
primarily due to the upfront fee associated with ACI-35 under the collaboration agreement that we signed with Janssen in December 2014, which fee was recognized as revenue in the year ended December&nbsp;31, 2014 but was not actually paid until
January 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was CHF 0.1&nbsp;million for the year ended December&nbsp;31, 2014, compared to CHF 0.2&nbsp;million for
the year ended December&nbsp;31, 2013. The decrease in net cash used was primarily the result of a deliberate policy in 2014 of reducing investments in fixed assets in the laboratory to a minimum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was CHF 9.8&nbsp;million for the year ended December&nbsp;31, 2014, compared with CHF
10.0&nbsp;million for the year ended December&nbsp;31, 2013. The decrease was primarily related to higher costs associated with the issuance of new shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Capital Requirements and Plan of Operations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate revenues from royalties based on product sales unless and until our partners obtain regulatory approval of and
commercialize our current or any future product candidates. As at September&nbsp;30, 2015, we had cash balances totaling CHF 53.7 million, a significant increase from the CHF 3.3 million we had as of December&nbsp;31, 2014. The significant increase
is due primarily to (i) receipt of the CHF 25.9 million upfront payment for ACI-35 under the Janssen agreement, and (ii) a total of CHF 38.3 million of cash proceeds from Genentech associated with the milestone payments for the antibodies program
and crenezumab collaboration. There can be no certainty as to the exact timing, or in fact whether any future milestone payments will ever be made given that these milestone payments are contingent on clear milestones being reached. Accordingly,
assuming we do not receive potential milestone payments and based upon our currently contemplated research and development strategy and expenditures and assuming our receipt of the net proceeds from this offering in the amount of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(based on the midpoint of the range set forth in the cover of this prospectus), we believe that our existing capital resources (including the proceeds we received from the Series&nbsp;E Private
Placement, as described below under &#147;&#151;Subsequent Event&#151;Series&nbsp;E Private Placement&#148;) will be sufficient to meet our projected operating requirements through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to generate losses for the foreseeable future,
and these losses could increase as we continue product development and if we successfully achieve regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all the risks pertinent to the
development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. Upon closing of this offering, we expect to incur additional costs associated with
operating a public company and we anticipate that we will need substantial additional funding in connection with our continuing operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need to raise additional capital to fund our operations and complete our ongoing and planned clinical studies, funding may not be
available to us on acceptable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including but not limited to
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The scope, rate of progress, results and cost of our pre-clinical and clinical studies and other related activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any other products we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The cost, timing and outcomes of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The costs and timing of establishing sales, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone and royalty payments thereunder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The emergence of competing technologies or other adverse market developments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The potential cost and timing of managing and protecting our portfolio of intellectual property. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing our financial statements as at and for the year ended December 31, 2014, a material weakness in our internal control over
financial reporting was identified, as defined in the SEC guidelines for public companies. The material weakness identified relates specifically to the accounting for and disclosure of non-routine and complex accounting transactions and the related
internal controls and processes supporting these areas. As a result, there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of implementing improvements and remedial measures in response to these assessments and recommendations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assembling a team from our finance department to be responsible for the preparation of financial statements under U.S. Securities laws, including hiring additional qualified personnel as necessary; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">organizing regular training sessions on IFRS for our finance department in the form of workshops, seminars and newsletters as well as requiring our finance personnel to participate in annual in-house or public IFRS
training courses; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">setting up an internal audit department to review our internal control processes, policies and procedures to ensure compliance with the Sarbanes-Oxley Act. </TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are implementing these measures, the implementation of these measures may not fully address this material weakness in our internal
control over financial reporting, and we therefore may not be able to conclude that it has been fully remedied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Significant Judgments and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically generated revenues from funds received under collaboration and license agreements as well as research grants. Revenues
from research activities made under collaboration arrangements are recognized when there is persuasive evidence that an arrangement exists, services have been rendered, the price is fixed or determinable and collectability is reasonably assured.
Since our inception, we have entered into strategic collaboration agreements with a range of partners covering a number of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For collaborations established on programs in pre-clinical stage, we recognize revenue from upfront payments under our collaboration
agreements ratably over the term of our estimated period of performance under each agreement. For collaboration agreements on product candidates that are (i)&nbsp;in clinical development, (ii)&nbsp;where the upfront payment reflects a payment for
past investments we have made in the development of the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and (iii)&nbsp;where there is no further performance commitment, we recognize the
fair value of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements with product candidates in clinical development but where the conditions described in clauses (ii)&nbsp;and (iii)&nbsp;are not
met, we recognize the upfront payments ratably over the term of our estimated period of performance under each agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record
amounts received prior to satisfying the above revenue recognition criteria as deferred revenue until all applicable revenue recognition criteria are met. Deferred revenue represents the portion of research or license payments received that have not
been earned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestones are considered substantive if all of the following conditions are met: (i)&nbsp;the milestone is non-refundable,
(ii)&nbsp;achievement of the milestone was not reasonably assured at the inception of the arrangement, (iii)&nbsp;substantive effort is involved to achieve the milestone and (iv)&nbsp;the amount of the milestone appears reasonable in relation to the
effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are priced at fair value. Such payments that are contingent upon achievement of a substantive milestone are recognized entirely as revenues in the period in which the milestone is achieved. To
the extent that <FONT STYLE="white-space:nowrap">non-substantive</FONT> milestones are achieved and we have remaining performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. If
there are no remaining performance obligations, we recognize the revenue in the period it is earned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grants provide funding for certain
types of expenditures in connection with research and development activities over a contractually-defined period. Revenue related to grants is recognized in the period during which the related costs are incurred and the related services are
rendered, provided that the applicable performance obligations under the grants have been met. We intend to continue to evaluate pursuing additional grant opportunities on a case-by-case basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accrued expenses for estimated costs of our research and development activities conducted by third party service providers, which
include amongst others the conduct of preclinical studies and clinical studies and contract manufacturing activities. We record accrued expenses for estimated costs of our research and development activities based upon the estimated amount of
services provided but not yet invoiced, and we include these costs in accrued liabilities on the balance sheets and within research and development expenses in the statement of operations and comprehensive income. These costs are a significant
component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed in accordance with agreements established with these third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the amount of work completed through discussions with our project leaders and external service providers as to the progress or
stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued
estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may
vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party
service providers. To date, there have been no material differences from our accrued expenses to actual expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in
exchange for the grant of options and shares is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting
conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are
expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, in the income statement, and a corresponding adjustment to equity over the remaining vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded share-based compensation expense related to options granted of CHF 0.2&nbsp;million and CHF 0.3&nbsp;million in each of the years
ended December&nbsp;31, 2013 and 2014, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Term </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected term represents the period that share-based awards are expected to be outstanding. We used the simplified method to determine the
expected term, which is calculated as the mid-point between the vesting date and the end of the contractual term of the options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we are not yet a public company and do not have any trading history for our common shares, the expected volatility was estimated based on
the average historical volatilities of common shares of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on similar geographic location, similar size,
and similar stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free
rate is based on long dated Swiss government zero coupon bond issues in effect at the time of the grant for periods corresponding with the expected term of the option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid
dividends on our common shares and have no plans to pay dividends on our common shares. Therefore, we used an expected dividend yield of zero percent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Black-Scholes assumptions, we estimate our forfeiture rate based on our actual forfeitures and continue to evaluate the
adequacy of the forfeiture rate based on the actual forfeiture experience, analysis of employee turnover behavior and other factors. The impact from any forfeiture rate adjustment would be recognized in full in the period of adjustment, and if the
actual number of future forfeitures differs from our estimates, we might be required to record adjustments to share-based compensation in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, for all periods prior to this offering, the fair value of the common shares underlying our share-based awards were estimated on
each grant date by our management and approved by our board of directors. In order to determine the fair value of our common shares underlying option grants, our board of directors considered, among other things, the breadth of our product candidate
portfolio, the stages of development of our various product candidates and major changes to stage of development, the progress and additions to our collaboration agreements, risks inherent in our activities, the lack of liquidity of our companies
securities and the valuations and sentiment toward biotech companies. Given the absence of a public trading market for our common shares, our board of directors exercised reasonable judgment and considered a number of objective and subjective
factors to determine the best estimate of the fair value of our common shares, including our stage of development, progress of our research and development efforts, the strength of our balance sheets and capital base, equity market conditions
affecting comparable public companies and the lack of liquidity marketability of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of 2015 Option Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we changed the character of our current option scheme. Historically, we have granted options at the outset of the award period with
the options vesting over a four year period. In line with IFRS accounting principles for option awards, we expensed the fair value of the awards on a straight line basis over the four year vesting period of the options. Starting in 2015, we changed
the nature of our option awards such that only one quarter of the total options awarded are issued at the end first year, with a further quarter of the options granted issued at the end of year two, three and four. This requires us to change the way
we account for our options. Specifically, rather than recognizing as an expense one quarter of the option value each year over four years, accounting rules require us to recognize that four separate options with four separate option periods were
issued. Consequently, in year one, we need to expense (i)&nbsp;the fair value of the awards issued in the first year, (ii)&nbsp;one half of the fair value of the awards to be issued in year two, (iii)&nbsp;one third of the value of the awards to be
issued in year three and (iv)&nbsp;one quarter of the fair value of the options issued to be in year four. The result in the change in the way we expense options means that we are recognizing a larger expense in years one and two (relative to the
traditional straight line expensing method) while recognizing a smaller expense in years three and four (relative to the traditional straight line expensing method). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Plan A Stock Option Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we amended the Plan A stock option plan that we developed in 2004. Two key amendments were made to the program: (i)&nbsp;the duration
of the stock option plan was increased by two years from 10.5 to 12.5 years and (ii)&nbsp;the strike price of the option was reduced from CHF 232.97 to CHF 36.37. The lengthening of the plan&#146;s term and lowering of the strike price was effected
to bring the plan in line with our other plans, and resulted in a material increase in the value of the options to the option holders and required us to recognize the impact of the transfer in value on our accounts in the first half of 2015. The
impact of the amendment of the Plan A stock option plan totaled CHF 0.4 million. There are no further expenses that we need to recognize in the future associated with this plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acceleration of Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The original
terms of our Stock Option Plan of 2005 (Plan C) contained a provision that would result in the automatic acceleration of all unvested options upon the consummation of an initial public offering.&nbsp;Pursuant to a board resolution on October 13,
2015 the Stock Option Plan of 2005 was amended and the automatic acceleration feature was removed.&nbsp;Instead, employees have the right, but not the obligation, to have their unvested options accelerated such that they vest immediately.&nbsp;A
total of 442 options could be accelerated upon completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to accelerate the
vesting of all outstanding unvested options granted to employees prior to July 2014, in the event of an initial public offering. Pursuant to a board decision on October&nbsp;13, 2015, if we are successful in completing this offering, the board will
accelerate a total of 517 options which were granted to directors and executive officers which were tied to the consummation of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been a tenant at our current location in the EPFL Innovation Park since shortly after our inception in 2003. We have entered into
long-term rental lease agreements with respect to these facilities. However, our lease agreements are structured such that we can exit these lease agreements without penalty provided we give the owner of our premises sufficient notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subsequent Event </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series E Private Placement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 23, 2015, we completed a private placement of Series E preferred shares, each with a nominal value of CHF 5.00 per
share (the &#147;Series E Private Placement&#148;). An aggregate of 12,453 Series E preferred shares were issued to certain institutions and existing shareholders in the Series E Private Placement for an aggregate subscription amount of
approximately $30.0 million. The Series E preferred shares have substantially the same terms as the Series A, B, C and D preferred shares, will be accounted for as equity on our balance sheet and will automatically convert into common shares on a
one-for-one basis upon the closing of this offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any material off-balance sheet arrangements or commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market risk arises from our exposure to fluctuation in interest rates and currency exchange rates. We are exposed to market risks in the
ordinary course of our business, which are principally limited to foreign currency exchange rate fluctuations and to a lesser degree, interest rate fluctuations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As at September&nbsp;30, 2015 we had cash and cash equivalents of CHF 53.7&nbsp;million (or
CHF 80.8 million after giving effect to the Series E Private Placement), which consisted exclusively of bank deposits. Such interest-earning instruments carry a degree of interest rate risk. However, historical fluctuations of interest income have
not been significant and have been principally impacted by the change in our cash balances as opposed to changes in interest rates received on the cash balances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in
interest rates during any of the periods presented would not have had a material impact on our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a number of
collaboration agreements where the upfront payments, milestone payments and future royalty payments are not denominated in Swiss Francs, our reporting currency. Furthermore, many of our research and development activities are subcontracted including
to parties outside of Switzerland and we purchase materials from suppliers outside of Switzerland. As a result, we are exposed to foreign exchange risk. Approximately 40% of our total costs are incurred in currencies other than the Swiss Franc. Due
to the size of some of the income received from collaboration agreements but also the high percentage of our costs indirectly being in foreign currencies, a hypothetical 10% change in exchange rates relative to the Swiss Franc could have a material
impact on our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_14"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding.
Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and
alpha-synuclein. We believe that our large and diverse pipeline of seven therapeutic candidates and three diagnostic candidates has the potential to drive a paradigm shift in the treatment of a broad spectrum of neurodegenerative and other diseases
related to protein misfolding. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta
antibody that we developed using our SupraAntigen&#153; platform. Crenezumab is expected to enter Phase 3 clinical studies in early 2016. Genentech, Inc., a wholly owned subsidiary of Roche, or Genentech, is advancing crenezumab under a
collaboration agreement with us for the treatment of AD, a progressive neurodegenerative disease that affected an estimated 9.0&nbsp;million people in the United States, the United Kingdom, Western Europe, Japan, China and India in 2013. Under this
collaboration agreement, Genentech is responsible for the clinical development of crenezumab, including the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Genentech
is the sponsor of an active Investigational New Drug Application (IND) for crenezumab in the treatment of AD. Genentech met with the FDA in October 2014 and again in September 2015 to discuss the Phase 3 study design. We believe our collaboration
with Genentech validates our technology and crenezumab&#146;s potential to become a best-in-class disease-modifying treatment for AD. We are eligible to receive up to $340 million in total payments from Genentech, as well as sales royalties.
Crenezumab has received Fast Track designation from the U.S. Food and Drug Administration, or FDA. The Fast Track program is intended to expedite or facilitate the process for reviewing new drugs that are designed to treat a serious or
life-threatening condition and demonstrate the potential to address unmet medical needs, as further described under &#147;&#151;Government Regulation and Our Regulatory Department&#151;Product Approval Process.&#148; In 2012, crenezumab was
independently selected by the National Institute of Health, or NIH, the Banner Alzheimer&#146;s Institute and Genentech for use in the first-ever AD prevention study, which serves as the cornerstone of the global Alzheimer&#146;s Prevention
Initiative. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, crenezumab has the potential to treat the underlying cause of the disease and intervene at an earlier stage
of AD progression, prior to irreversible neuronal damage. We believe that crenezumab is ideally positioned to be at the forefront of disease-modifying and preventive medicine. We believe the key advantages of crenezumab include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Unique mechanism of action:</I></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Recognizes and binds to multiple forms of misfolded Abeta, a protein commonly associated with AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Helps to protect against neurotoxicity due to high affinity for the multiple forms of misfolded Abeta. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Promotes disaggregation of existing Abeta aggregates and disrupts their assembly to prevent amyloid plaque formation, which is associated with AD. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clears misfolded Abeta from the brain while limiting inflammation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Signal of activity in milder AD patients in Phase 2 studies:</I></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">ABBY cognition study: although the study did not meet its co-primary endpoints, which were assessments under the ADAS-cog and CDR-Sum of boxes, the
sample size was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase&nbsp;2 studies
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
in AD). Instead, consistent trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of development, with confirmation then sought in
Phase 3. The results showed trends favoring crenezumab in the milder patient population. Notably, in an exploratory analysis, the high-dose crenezumab arm showed a non-significant slowing of cognition in the overall and mildly demented populations,
which was statistically significant (p=0.036) with a 35% slowing of the rate of cognitive decline measured by the ADAS-cog Scale over 73 weeks in patients with the non-pre-specified milder cognitive impairment (Mini-Mental State Examination score,
or MMSE, of 22-26). The MMSE is a widely used test of overall cognitive function, which assesses memory, orientation and ability to perform simple tasks. Scores range from 0 (worst) to 30 (best) with a score of 0-11 indicating severe dementia, a
score of 12-19 indicating moderate dementia and a score of 20-26 indicating mild dementia. Statistical significance is an indicator of the likelihood of an observed effect being due to the study drug rather than due to chance. The &#147;p&#148;
value is the probability of an event occurring by chance alone. When the p value is less than 5% (0.05) the results are considered to be statistically significant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">BLAZE biomarker study: the high-dose crenezumab arm showed a consistent trend of reduced Abeta accumulation in the brain over time and a significant increase in cerebrospinal fluid, or CSF, which suggests that Abeta is
being removed from the brain when patients are treated with crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Favorable safety profile allowing for potentially higher dosing:</I></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Unique mechanism of action linked to the reduced ability to cause inflammation-related vasogenic edema, an accumulation of fluid in the brain that can lead to headaches, loss of coordination and disorientation.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical data showed a very low incidence of vasogenic edema. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1 study is ongoing to study crenezumab at higher doses to potentially increase the efficacy signal and to help define the optimal Phase 3 clinical study design. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through active
immunization, where the immune system is stimulated to make its own antibodies against pathological proteins: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-24 is our wholly-owned anti-Abeta vaccine candidate that is T-cell independent, meaning it can generate an antibody response in the absence of T-cells. This product candidate is currently in a Phase 1/2a clinical
study to evaluate safety, tolerability, immunogenicity and biomarker endpoints in patients with mild to moderate AD in Europe. We expect to complete our Phase 1/2a clinical study of ACI-24 and announce top line results in the second half of 2016.
ACI-24 is also being studied in patients with Down syndrome, a population which is at high risk for AD, and we currently have an open Investigational New Drug Application, or IND, for ACI-24 in Down syndrome, which was approved by the FDA in January
2013 (IND 15342). A protocol amendment for the Phase 1b study of <FONT STYLE="white-space:nowrap">ACI-24</FONT> was submitted to the FDA in September 2015. Phase 1 and 2 studies are also currently ongoing in Finland, Sweden and Denmark.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-35 is an anti-tau vaccine candidate that is T-cell independent. We are developing ACI-35 under a collaboration agreement with Janssen, which we entered into in December 2014. A Phase 1b clinical study to evaluate
the safety, tolerability and immunogenicity of ACI-35 in patients with mild to moderate AD is ongoing in Finland and the United Kingdom. We and Janssen are co-developing <FONT STYLE="white-space:nowrap">ACI-35</FONT> through this ongoing Phase 1b
clinical study, which we expect to be completed in the fourth quarter of 2016. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. We expect Phase 2 clinical
studies to begin in 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical evidence suggests that early detection of neurodegenerative diseases is critical to
enhancing the effectiveness of both symptomatic and disease-modifying therapies. As such, we are using our Morphomer&#153; platform to develop complementary diagnostic product candidates such as positron emission tomography, or PET, ligands which
are tracers that can directly measure misfolded tau and alpha-synuclein in the brain, to enable early and reliable disease diagnoses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our tau PET imaging agent is currently in a First-in-Man study (a clinical study in which a medical procedure, previously developed and assessed through <I>in vitro</I> or animal testing or through mathematical
modelling, is tested on human subjects for the first time) and being developed under a collaboration agreement with Piramal Imaging. Piramal Imaging is expecting to advance this program into Phase 1 clinical development in 2016. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are also developing PET imaging diagnostics for diseases resulting from the misfolding of alpha-synuclein proteins, such as PD. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific
small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. These platforms are our engines for generating novel molecules that are designed to bind to their targets with high affinity and conformational
specificity, meaning they are enabled to differentiate between misfolded proteins and normally-folded proteins. All of our product candidates and our development programs have been derived from our proprietary platforms. Neurodegenerative diseases,
such as AD and PD as well as other neuro-orphan diseases, such as progressive supranuclear palsy, amyotrophic lateral sclerosis, or ALS, and Huntington&#146;s disease, are all associated with pathologies that involve misfolded proteins. Research has
shown that misfolded proteins are unable to carry out their normal functions and aggregate to form certain types of deposits such as Abeta plaques or tau tangles that damage brain tissue. Our SupraAntigen and Morphomer platforms seek to produce
conformationally specific molecules in order to prevent or disrupt the formation of misfolded proteins. We believe that our proprietary platforms also have the potential to generate additional molecules for indications that relate to protein
misfolding outside of neurodegenerative diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram below summarizes the status of our research and development programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g87t41.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neurodegenerative diseases and other diseases associated with protein misfolding are prevalent,
but there is currently an absence of reliable, early-stage diagnosis and disease-modifying treatments for these diseases. The growth in the number of people with neurodegenerative diseases has been significant as evidenced by the prevalence of
people affected by AD and PD, two of the most common neurodegenerative diseases. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AD is the most common form of dementia, which affects an estimated worldwide patient population of 47&nbsp;million in 2015, and is expected to grow to 75&nbsp;million by 2030 and 132&nbsp;million by 2050, according to
the World Alzheimer Report 2015. The estimated aggregate cost of prevention and treatments in the United States was $172 billion in 2010 and is estimated by Alzheimer&#146;s Disease International, or ADI, to grow to $408 billion in 2030 and $1,078
billion in 2050. ADI estimated that the cost of prevention and treatments in the United States could be reduced from over a trillion dollars to $631 billion in 2050 if the onset of AD could be delayed by five years in the patient population. In
addition, at autopsy, AD has been reported in 80% of people with Down syndrome over age 40 and 100% over age 60. Down syndrome affects approximately one in 1,000 live births worldwide. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">AD is typically diagnosed by neurologists and psychiatrists through a series of cognitive and functioning tests once symptoms are clinically
present, resulting in diagnosis at later stages of the disease after irreversible loss of neurons has already occurred. Currently approved AD treatments include medications that only treat the symptoms of the disease. The clinical benefit derived
from these symptomatic treatments is typically incomplete. Only between 40 and 70 percent of patients with AD benefit from taking symptomatic treatments and the symptoms improve for 6 to 12 months in most cases. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Therapeutic development for AD is increasingly focused on treating early stages of the disease to delay or prevent progression and to preserve
the maximum amount of cognitive function before irreversible neuronal damage occurs. Most clinical studies now target mild stages of the disease, increasing the need for accurate diagnosis that is independent of potentially subjective and otherwise
sub-optimal cognitive metrics. Diagnostics therefore have a crucial role in selecting more uniform and stage-specific clinical study subjects, tracking patient progress and results, managing patients receiving treatment and ultimately diagnosing the
disease at its earliest stage for immediate treatment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">PD, the second most common neurodegenerative disease worldwide, affects an estimated 7 to 10&nbsp;million people. In PD, the use of symptomatic treatments, such as levodopa, is associated with the loss of control of
motor functions in approximately 50% of patients who have taken the drug for 5 years or longer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There remains a significant
unmet medical need for reliable and accurate diagnostics to enable early diagnosis and disease-modifying treatments that slow the progress of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled an outstanding management team with relevant scientific, clinical and regulatory expertise. Our scientific founders,
Dr.&nbsp;Jean-Marie Lehn, Dr.&nbsp;Claude Nicolau, Dr.&nbsp;Roscoe Brady and Dr.&nbsp;Fred van Leuven, are regarded as pioneers in their respective scientific domains, including in the study of AD. Our co-founder and Chief Executive Officer,
Dr.&nbsp;Andrea Pfeifer, a pharmacologist with a Ph.D. in cancer research and former National Institute of Health researcher, has a 30 year track record in product innovation and implementation and was formerly head of Nestl&eacute; Global Research
and the co-founder of Nestl&eacute; Venture Fund. Our Chief Scientific Officer, Dr.&nbsp;Andreas Muhs, has more than 20 years of experience in various aspects of discovery research and drug development, including working on multiple drug development
programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a global leader in the treatment of neurodegenerative diseases by developing therapies and complementary diagnostics that
target neurodegenerative diseases with significant unmet medical need using our proprietary SupraAntigen and Morphomer technology platforms. Key elements of our strategy are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Advance our product candidates, in partnership or alone, through clinical development to regulatory approval and potential commercialization. </B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Crenezumab</I></B><I>.</I> Our collaboration partner, Genentech, will advance crenezumab into Phase 3 clinical studies and seek regulatory approval. We believe that crenezumab&#146;s efficacy, coupled with its
safety profile, has the potential to become a best-in-class disease-modifying treatment for AD. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-24</I></B><I>. </I>We will continue to advance ACI-24, both through completion of an ongoing Phase 1/2a clinical study to evaluate the safety, tolerability, immunogenicity and biomarker endpoints in patients
with mild to moderate AD and, if the Phase 1/2a results are favorable, through a Phase 2/3 clinical study in patients with Down syndrome. We expect top line results from our Phase 1/2a clinical study in the second half of 2016. Our Phase 1 clinical
study of ACI-24 in patients with Down syndrome is intended to assess safety and is expected to commence in the fourth quarter of 2015. We own the global rights to ACI-24 and we intend to continue to develop ACI-24 in-house as a therapeutic
candidate. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-35</I></B>. We will continue to advance ACI-35 through Phase 1b clinical studies in collaboration with Janssen. If the Phase 1b results are favorable, Janssen will advance ACI-35 through the additional
clinical development stages in collaboration with us. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Diagnostic candidates</I></B>. In addition to the above product candidates, we will continue to develop our complementary diagnostic product candidates and to advance these through clinical development, either
independently or with collaboration partners. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Expand into other neurodegenerative and neuro-orphan diseases.</B> We intend to leverage our proprietary technology platforms to develop product candidates that share the same disease targets as misfolded Abeta, tau
and alpha-synuclein proteins, which are the key features in the pathology of many neurodegenerative diseases. We plan to pursue selected neuro-orphan indications, such as PSP and Huntington&#146;s disease, as well as tau-related orphan diseases,
such as frontotemporal dementia and corticobasal degeneration. Pursuing neuro-orphan indications may enable us to obtain a streamlined regulatory approval pathway and favorable reimbursement treatment of any approved product. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Accelerate the advancement of our diagnostic portfolio.</B> We are also developing a complementary diagnostic portfolio. We currently have three diagnostics candidates in our pipeline that we developed using our
Morphomer and SupraAntigen platforms. Our tau PET imaging agent is currently undergoing First-in-Man studies and we intend to work with our partner, Piramal Imaging, to advance this product candidate through the clinical development process. We are
also developing PET imaging diagnostics for diseases resulting from the misfolding of alpha-synuclein proteins. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Leverage the duality of our therapeutic and diagnostic approaches to become the leader in personalized treatment of neurodegenerative diseases.</B>
Personalized medicine involves the development of diagnostics, therapies and treatment procedures best suited for an individual patient, taking into consideration the stage of the disease, as well as genetic and environmental factors. The biggest
limitation in neurodegenerative disease management is the lack of appropriate biomarkers and reliable diagnostics for early disease detection and the absence of approved disease-modifying therapies. We believe that the future treatment paradigm for
neurodegenerative diseases will likely involve early disease diagnosis and combination therapy, leveraging both symptomatic and disease-modifying treatments, with different disease-modifying treatments used at various points in the progression of
the disease. We believe that our multi-pronged approach to neurodegenerative disease </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
diagnosis and treatment may result in the generation of individualized treatment options for patients and improve clinical outcomes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Strategically collaborate or selectively partner for the development and commercialization of product candidates.</B> Historically, we have relied on collaboration agreements with leading pharmaceutical companies to
leverage their scientific, development, manufacturing and commercialization expertise and other resources in order to accelerate the development of our product candidates. To date, we have entered into collaboration agreements with leading global
pharmaceutical companies, including two collaborations with Genentech and one with Janssen, a Johnson&nbsp;&amp; Johnson company. We believe that these partnerships validate our core strategy of discovering safe and efficacious therapies using our
proprietary platforms and advancing them through the various stages of regulatory approval. In the future, for any approved products targeting large markets, we may selectively partner with leading companies that we believe can contribute
manufacturing and marketing expertise, geographic reach and other resources and know-how that can enhance the value of these approved products. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach to Treating Diseases Related to Protein Misfolding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Protein folding and unfolding are important ways of regulating the protein&#146;s biological activity and cellular location. Misfolding of
proteins occurs due to a breakdown of cellular quality control systems, and is a common feature of many neurodegenerative diseases. Research has shown that misfolded proteins are not only unable to carry out their normal functions, but also
aggregate to form deposits in the brain that eventually lead to neuronal damage and cell death. The progression of neurodegenerative diseases, such as AD and PD, is linked to the misfolded conformations of proteins, such as Abeta, tau and
alpha-synuclein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g47g88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above shows how, in today&#146;s understanding, misfolded proteins play a key role in the
pathology of neurodegenerative diseases. Typically, protein misfolding occurs during cellular stress, which can be triggered by many different causes, including oxidation and a lack of growth factors. A cascade of molecular events begins with the
misfolding of single proteins within a cell that then continue to aggregate to ultimately form plaques and tangles. These misfolded proteins are then exported and spread to healthy cells nearby, causing normal proteins to misfold in a process known
as seeding. This process eventually leads to cell death in various areas of the brain and is linked to a decline in cognitive function. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Challenges
in targeting misfolded proteins </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The central challenge in targeting misfolded proteins for therapeutic effect is a product&#146;s
ability to differentiate, or conformationally select, between a misfolded protein and a normally-folded protein. This ability to conformationally select for the misfolded protein prevents the therapeutic candidate from interfering with the function
of the normally-folded protein, thereby reducing the risk of side effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benefits of our approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key aspect of both our SupraAntigen and Morphomer technology platforms is conformational specificity, which we believe is central to the
development of effective therapeutics for neurodegenerative diseases. Our SupraAntigen platform targets misfolded proteins through antigens displayed on the surface of liposomes which mimic the targeted pathological form of the protein. In a
complementary approach, our Morphomer platform uses small molecular weight compounds to target the aggregation and seeding process, which prevents the misfolded proteins from aggregating inside the cell and the formation of new misfolded proteins in
healthy neighboring cells through a seeding mechanism. Small molecules derived from our Morphomer platform, which we refer to as Morphomers, also promote disaggregation of already formed pathological protein aggregates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g59n65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above shows how we believe our therapies aim to intervene in the key pathology steps involved
in neurodegenerative diseases: (1)&nbsp;prevent misfolding; (2)&nbsp;promote disaggregation; (3)&nbsp;inhibit spreading; and (4)&nbsp;prevent seeding in healthy cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment Paradigm for Neurodegenerative Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current diagnostic and treatment paradigms for neurodegenerative diseases are suboptimal. Diagnosis typically takes the form of observation of
cognitive, functional and behavioral impairment and other symptoms of the diseases, which are generally only apparent after irreversible neuronal damage has already occurred. These symptoms are treated with medicines capable of providing cognitive
benefit and functional improvement but fail to affect the progression of the disease. For AD, there are currently four approved therapies, all of which only provide modest efficacy in treating the symptoms of AD, while having significant side effect
risks, and fail to address the progression of the disease. Despite these shortcomings, marketed therapies, such as Eisai and Pfizer&#146;s Aricept, have achieved peak annual global sales of approximately $4&nbsp;billion prior to loss of exclusivity.
Similarly, in the treatment of PD, the current standard of care is intended only to alleviate physical symptoms. In both AD and PD, there are no approved disease-modifying treatments that slow or stop the course of disease progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Modifying the progression of the disease requires targeting the underlying biological processes that drive disease progression. Unfortunately,
these processes evolve over the course of many years prior to manifestation of symptoms and a high percentage of neurons may be lost prior to clinical manifestation. Many of the failed clinical studies for disease-modifying treatments targeted
patients with moderate stages of the disease, when irreversible neuronal damage and death had already occurred. This had led to the conclusion that early intervention is necessary to slow the disease progression and that disease-modifying therapies
should be studied </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in patients with milder stages of the disease. As a result of this, in recent years, there has been a movement towards early intervention in clinical development. Early intervention, however,
requires accurate disease detection prior to physical manifestation of symptoms, using new and sophisticated technologies that are superior to the subjective rating scales currently used to assess patients. Thus, new diagnostic technologies are
critical to the clinical development process of disease-modifying therapies and ultimately better disease management of patients with neurodegenerative diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opportunity for AC Immune in Neurodegenerative Diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to change the way that neurodegenerative diseases are treated by combining reliable diagnostic tools that facilitate intervening at
earlier stages of the disease with therapies that treat the underlying disease process, as shown in the diagram below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g82t66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our lead product candidate, crenezumab, is ideally positioned to be at the forefront of
disease-modifying and preventative medicine due to its demonstrated efficacy in milder AD subjects and favorable safety profile. Unlike the current standard of care, crenezumab seeks to modify the course of AD by intervening at an earlier stage of
the disease progression prior to irreversible neuronal damage. Beyond AD, we believe that we can leverage our proprietary platforms to generate additional molecules that treat the causes of other neurodegenerative and neuro-orphan diseases, such as
PSP, ALS and Huntington&#146;s disease. We believe that the future treatment paradigm for neurodegenerative diseases will involve different disease-modifying treatments used at various points in the progression of the disease. One such combination
may be passive immunization targeting Abeta, such as crenezumab together with anti-tau antibodies or immunotherapies and small molecules targeting Abeta or tau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we are a leader in discovering new PET imaging agents to improve the timing and accuracy of diagnoses in neurodegenerative
diseases. We have three diagnostic candidates in our pipeline that were developed through our Morphomer and SupraAntigen platforms and that target Abeta, tau and alpha-synuclein. We believe our tau-PET imaging program has received external
validation through our partnership with Piramal Imaging, a leader in imaging agents. We are also developing an Abeta and tau <I>in&nbsp;vitro</I> diagnostic agent for AD and an alpha-synuclein PET imaging agent for PD. We believe that our diagnostic
product candidate pipeline will complement our disease-modifying treatment product candidate pipeline, with the ultimate goal of reshaping the clinical course and treatment of neurodegenerative diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary Technology Platforms </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development program is based on our two unique proprietary technology platforms: our SupraAntigen platform, which is our
biological and immunological platform, and our Morphomer platform, which is our small molecule, chemical platform. These platforms are designed to generate antibodies and small molecules, respectively, which selectively bind to misfolded proteins
which are common in a broad range of neurodegenerative diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SupraAntigen platform generates humanized monoclonal antibodies and
vaccines for use as passive and active immunotherapies that are highly specific for pathological, or misfolded, forms of Abeta and tau typically found in AD and certain other neurodegenerative diseases. In addition to the high target specificity,
the generated antibodies clear the misfolded proteins from the brain without generating inflammation. This characteristic was clinically confirmed in the Phase 2 clinical studies of crenezumab, where a favorable safety profile was demonstrated.
Similarly, <FONT STYLE="white-space:nowrap">ACI-35</FONT> and <FONT STYLE="white-space:nowrap">ACI-24</FONT> have been well tolerated in their respective Phase&nbsp;1b and 1/2a clinical studies. Our diagnostic portfolio is also an important part of
our strategy, as PET and molecular diagnostics should enable earlier diagnosis of neurodegeneration than current approaches that are based on clinical symptoms, a result that we believe will result in better clinical outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research has shown that misfolded proteins are not only unable to carry out their normal functions but that they also aggregate to form
deposits commonly known as plaques and tangles that damage neuronal tissue and lead to cell death. Our SupraAntigen and Morphomer platforms seek to produce conformationally specific molecules, which are molecules that are able to differentiate
between misfolded proteins and normally-folded proteins, and target misfolded proteins with minimal side effects on normally-folded proteins. We believe that our platforms can also generate compounds in indications related to protein misfolding
outside of neurodegenerative disease, such as in glaucoma where aggregated Abeta peptides and tau proteins have been shown to cause damage to the optic nerve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platforms address two key issues in the development of drugs against diseases of protein misfolding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The body does not make antibodies against misfolded proteins because, although pathogenic, they are still recognized as &#147;self-proteins&#148; and do not trigger an immune response. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The difference between a normal protein and a pathological protein is only related to a conformational change in protein structure making drug specificity difficult to achieve. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g31v36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above shows the process by which conformationally-specific molecules break down the aggregation
of misfolded proteins. We expect that antibodies and Morphomers should prevent or disrupt the formation of insoluble plaques and stabilize soluble non-pathological proteins. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g81p33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SupraAntigen platform was created by our scientific founders Dr.&nbsp;Claude Nicolau in collaboration
with Dr.&nbsp;Fred Van Leuven. This technology generates conformation-sensitive antibodies and is used by us to create product candidates for both passive and active immunization. Passive immunization involves the application of therapeutic
antibodies, whereas active immunization stimulates the human body to make its own antibodies against pathological proteins, as shown in the diagram above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SupraAntigen Platform: Active Immunization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product approach is based on the ability of antigens attached to liposomes to elicit the immune system to produce antibodies against
self-proteins. The liposome is constructed of cholesterol, phospholipids and monophospholipid-A as an adjuvant. The liposome can accommodate antigens, or peptides, of different lengths that are chemically modified with palmitic acids to
&#147;anchor&#148; them in the liposomal membrane. The interaction between the charged liposome surface and the peptides force the peptide into the pathological conformation that mimics the targeted misfolded proteins. The diagram below shows the
vaccine construct which is used as a basis for ACI-24 and ACI-35 vaccine candidates. ACI-24 and ACI-35 are vaccine candidates developed using our SupraAntigen platform for active immunization. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g87q91.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SupraAntigen Platform: Passive Immunization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SupraAntigen platform can also be used to develop passive immunization product candidates. The antibodies are created by injecting the
SupraAntigen constructs in mice and by selecting the antibodies for their ability to break up aggregated fibers. The antibodies eliminate protein aggregates such as plaques and tangles by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changing the equilibrium from the insoluble pathological to the soluble fibers which are depleted by the antibodies. Both crenezumab and the anti-tau antibodies were derived from this platform.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Morphomer Platform </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Morphomer platform represents a highly promising technology to identify and develop therapeutic small molecules for the treatment of diseases resulting from misfolded proteins. This proprietary platform enables us to generate small molecules that
bind to their target and break up neurotoxic protein aggregates. As of September&nbsp;30, 2015, the Morphomer library consisted of more than 2,400 compounds. Our key platform assets have been validated for selective binding to Abeta, tau and
alpha-synuclein through <I>in vitro</I> efficacy studies and have a validated mechanism of action through reproducible <I>in vivo</I> efficacy for Abeta, tau and alpha-synuclein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g10t30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure above shows a Morphomer blocking amyloid growth. Only one end of aggregated amyloid fibers
grows, and these molecules are designed to inhibit that growing end as shown in the above diagram. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most molecules involved in
neurodegenerative diseases follow the same overall disease development and aggregation process, including Abeta in AD, alpha-synuclein in PD and huntingtin in Huntington&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key advantages of our Morphomer platform include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">High specificity for the targeted misfolded protein; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One Morphomer can inhibit multiple protein units in oligomers and fibers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Early inhibition of aggregation and seeding. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Morphomer platform was developed through a
collaboration of our scientific founders Dr. Jean-Marie Lehn, a recipient of the Nobel Prize in chemistry, and Dr. Claude Nicolau, a former Harvard University professor, and our board member Dr. Detlev Riesner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our AD Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Crenezumab </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crenezumab is a
humanized, conformation-specific monoclonal antibody that targets the misfolded version of Abeta and has a broad binding profile. Crenezumab was developed using our proprietary SupraAntigen platform. In 2006, we licensed crenezumab to Genentech and
a company with a long history of developing and commercializing innovative biologics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abeta is produced by the breakdown of a larger
protein called amyloid precursor protein, or APP. The Abeta fragment containing 42 amino acids, or Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, is believed to be associated with the highest toxicity of the Abeta fragments.
Misfolded Abeta subunits combine to form oligomers and fibrils that are found in amyloid plaques. Data resulting from preclinical and clinical studies show that crenezumab binds with high affinity to amino acids 12&#150;24 of Abeta<SUB
STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, as well as multiple forms of Abeta, including monomers, oligomers, and fibrils, which reduces Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB> induced cytotoxicity.
Furthermore, these data indicate that crenezumab enhances the uptake of neurotoxic Abeta oligomers by microglial cells, the resident immune cells of the brain, which normally respond to neuronal damage and remove the damaged cells for subsequent
disposal and clearance from the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A challenge with agents acting to remove Abeta is the potential to induce inflammation leading to
vasogenic edema, which is accumulation of fluid in the brain that can lead to headaches, loss of coordination and disorientation. The fluid can be seen clearly on MRI scans and is referred to as Amyloid Related Imaging Abnormality-Edema, or ARIA-E.
Crenezumab is engineered on an IgG4 backbone, which was selected because IgG4 antibodies are associated with a greatly reduced risk of causing inflammation. As a result, crenezumab&#146;s IgG4 structure activates microglial cells to clear Abeta
without producing inflammation and associated vasogenic edema, as demonstrated in the Phase 2 clinical studies. In contrast, ARIA-E and other inflammation-related side effects have been observed in other antibodies with an IgG1 backbone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We believe crenezumab may have the following important competitive advantages relative to other drugs targeting Abeta in
development<I>: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Unique mechanism of action:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab recognizes and binds to multiple forms of Abeta, including monomeric, oligomeric and fibrillar Abeta that are found in amyloid plaques. In contrast, certain other antibodies in development such as solanezumab
and aducanumab have only been shown in studies to recognize a subset of Abeta forms. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Due to its high affinity to the multiple forms of Abeta, crenezumab also protects against oligomer-induced neurotoxicity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Linked to its unique epitope, crenezumab has been shown to promote disaggregation of existing Abeta aggregates and disrupt their assembly to prevent amyloid plaque formation. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab has been designed with an IgG4 backbone to reduce effector function on microglia and to clear Abeta from the brain while limiting inflammation. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g17u43.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Signal of activity in milder AD patients (MMSE 22-26):</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the proof-of-concept Phase 2 studies of crenezumab, a positive trend in cognition was observed with a greater effect on cognition in patients with a milder stage of AD (MMSE 22-26). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the ABBY cognition study there was a statistically significant 35% reduction in the rate of cognitive decline in the non-pre-specified milder AD patient population (MMSE 22-26) for the high-dose arm.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the BLAZE biomarker study, the high-dose arm showed a consistent trend of reduced Abeta accumulation in the brain over time, as shown in two independent exploratory analyses of florbetapir-PET data. In addition, it
has been shown that crenezumab has the ability to enhance the removal of these proteins from the brain as evidenced by a significant increase in CSF Abeta, confirming target engagement by crenezumab. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable safety profile allowing for potentially higher dosing:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 data from ABBY and BLAZE studies suggested that there were no imbalances in overall rate of Adverse Events, or AEs, and overall rate of AEs was not dose-related, with only one case of asymptomatic ARIA-E (0.4%
in ABBY, 0.3% on active pooled) in crenezumab patients. AEs also included inflammation of the throat and nasal passages, urinary tract infections and upper respiratory infections. However, no patients in the studies experienced serious adverse
events that we believe were related to the administration of crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab is a member of the IgG4 isotype subclass of antibodies. This isotype was selected because IgG4 antibodies are associated with a greatly reduced ability to cause inflammation. By contrast, all other antibody
products currently in development that target Abeta are of the IgG1 isotype subclass, which is associated with a higher incidence of inflammation-related ARIA-E. Dose limiting toxicities are a major risk for failure of competing antibody products.
Potential safety at high doses is a key product feature of crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Due to its favorable safety profile, there is an ongoing Phase 1 study in which crenezumab is currently being studied at higher doses to potentially increase its efficacy signal. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth the relative incidence of ARIA-E of crenezumab and other competitive
product candidates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:32.00pt; font-size:8pt; font-family:Times New Roman"><B>Antibody</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stage of development</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Isotype</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ARIA-E (safety)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Crenezumab</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Genentech / AC Immune)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">Phase 3 (planned to commence in early 2016)</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">IgG4</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">&lt; 0.3% in Ph2</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Solanezumab</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Eli Lilly)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">Phase 3</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">IgG1</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">0.9% in Ph3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gantenerumab</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Roche)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">Phase 3</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">IgG1</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">~10% in Ph1 Multiple Ascending Doses</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Aducanumab</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Biogen)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Phase 3</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">IgG1</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">41% in Ph1b</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bapineuzumab</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Elan / Pfizer / J&amp;J)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Terminated after Phase&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>IgG1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>~10% in Ph3</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2 Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Study Design Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crenezumab has been studied in two Phase 2 clinical studies, the ABBY proof-of-concept study and the BLAZE biomarker study. These two studies
enrolled a total of 522 patients. The purpose of these studies was to investigate whether crenezumab could delay cognitive and functional decline and reduce the accumulation of brain amyloid in patients with mild to moderate AD. The sample size of
the studies was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent
trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of development, with confirmation then sought in Phase 3. Both studies had two active arms: a low dose arm receiving 300mg
subcutaneous injection, which is an injection administered beneath the skin, every two weeks and a higher dose arm receiving 15mg/kg intravenously every four weeks. The primary analysis was conducted at 73 weeks, after 68 weeks of treatment. Safety
and tolerability measures included repeated MRI scans to assess for the development of Amyloid Related Imaging Abnormalities, both vasogenic edema and hemorrhages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>ABBY Study Design </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ABBY study was a randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of crenezumab in patients with mild to moderate AD, with an MMSE score at screening of 18-26 points. 444 patients were enrolled
into the study including 13 patients who were included in a safety run-in cohort to support the use of the 15 mg/kg intravenous dose, which had not been tested in Phase 1. Since these patients received active medication after the second infusion and
were then no longer blinded, they were included in the safety, but not the primary efficacy, analysis. The remaining 431 patients were randomized separately to receive crenezumab, either subcutaneously at a dose of 300 mg every two weeks (low dose)
or intravenously at a dose of 15 mg/kg once every 4 weeks (high-dose), with a 2:1 active:placebo ratio in each dose group. In the subcutaneous injection dose arm, 122 patients received crenezumab and 62 patients received placebo. In the intravenous
dose arm, 163 patients received crenezumab and 84 patients received placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Co-primary endpoints were cognition assessed using the
Alzheimer Disease Assessment Scale-Cognitive Subscale, or ADAS-cog 12 scale, and global function assessed by the Clinical Dementia Rating-Sum of Boxes (CDR-Sum of boxes). Secondary endpoints such as the MMSE score and Digit Symbol Substitution Test,
or DSST, were also included in the study. ADAS-cog is a widely used scale in clinical studies that measures a patient&#146;s performance on tests of memory and other areas of cognition, especially orientation, praxis and language. Scores range from
0 (best) to 70 (worst). The ADAS-cog 12 score includes an additional item of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delayed recall, leading to a highest possible score of 80 points. On average, the score of patients with mild to moderate AD increases by 5 to 8 points per year. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CDR-Sum of boxes is an assessment of &#147;global&#148; (overall) function of the patient in daily life. The patient&#146;s performance in
the six domains of memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care are assessed through interviews with the patient and caregiver. Each domain is scored from 0 (best) to 3 (worst) based on the
level of impairment. The scores for the six domains are then summed up and the resulting score or &#147;sum of boxes&#148; ranges from 0 to 18, with a higher score indicating greater impairment. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DSST is a classic paper and pencil test used to assess a patient&#146;s processing speed in the so-called digit symbol substitution test
during which the patient is asked to insert a symbol in place of a digit according to a scheme as quickly as possible over a set period of time. The DSST measures the number of correct symbols the patient inserts within the allowed time, i.e. 90 or
120 seconds. A higher score demonstrates better performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABBY Study Disposition </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g08h09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>ABBY Study Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ABBY study, a positive trend in cognition was observed with a greater effect on cognition in patients with a milder stage of AD (MMSE
22-26), although the study did not meet its co-primary endpoints in mild-to-moderate AD (MMSE 18-26) patients. There was no significant change in cognition in patients who received low-dose subcutaneous crenezumab. Results of an exploratory analysis
of the high-dose intravenous arm demonstrated that patients with the mildest cognitive impairment at screening (MMSE 22-26) showed a statistically significant 35% slowing of the rate of cognitive decline over 73 weeks. The effect became greater over
time, as shown by the increasing separation of the crenezumab (solid line) and placebo (dashed line) curves in the diagram below. The milder group was not pre-specified, meaning the group of milder AD patients was not identified before commencing
the Phase 2 clinical studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABBY High Dose Arm: Change in ADAS-Cog 12 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g21g44.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g90m83.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">An exploratory subanalysis in a non-pre-specified subgroup of patients with milder symptoms <FONT
STYLE="white-space:nowrap">(MMSE&nbsp;22-26)</FONT> showed a 35.4% reduction in cognitive decline. The sample size of the study was not expected to have adequate power to detect a modest but clinically significant difference between active
medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of
development, with confirmation then sought in Phase&nbsp;3. In the pre-specified subgroup analysis in patients with mild AD (MMSE 20-26), treatment with high-dose intravenous crenezumab led to a 23.8% reduction in cognitive decline. In patients with
mild-to-moderate AD (MMSE 18-26) treated with high-dose intravenous crenezumab, there was a 16.8% reduction in cognitive decline. Effect sizes and p-values for exploratory analyses were not adjusted for multiplicity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABBY High Dose Arm: Change in DSST </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g82l25.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g62k44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ABBY high-dose arm result for DSST was significant in the milder patient sub-group (MMSE 22-26). The
mild and milder patients that were given crenezumab intravenously showed no further cognitive deterioration between 12 and 18 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ABBY study, patients in the high-dose crenezumab arm showed less decline on the measure of global function, CDR-Sum of boxes, as
compared to placebo. In mild-to-moderate AD (MMSE 18-26), a non-significant 3.1% reduction in global functional decline was observed. In the pre-specified subgroup analysis in patients with mild AD (MMSE 20-26), treatment with high-dose intravenous
crenezumab did not show reduction in global functional decline (1.0% reduction; p=0.96). An exploratory analysis in patients with milder symptoms (MMSE 22-26) showed a 19.6% reduction in global functional decline. Although the results were not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statistically significant, it should be noted that the sample size of the study was not expected to have adequate power to detect a modest but clinically significant difference between active
medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of
development, with confirmation then sought in Phase&nbsp;3. Trends favoring crenezumab were not observed in the activities of daily living scale (ADCS-ADL) although the study was significantly underpowered for this type of assessment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BLAZE Study Design </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
BLAZE study was a randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of crenezumab on brain amyloid burden as assessed by amyloid PET imaging and other biomarker endpoints in patients with mild to moderate AD.
The primary endpoint was to measure the change in brain amyloid load using florbetapir-PET. The terms brain amyloid burden and brain amyloid load refer to the total amount of amyloid deposited in the brain. Each of these typically increases over
time in an AD patient. Other endpoints included changes from baseline in other biomarkers (CSF, volumetric MRI), cognition (ADAS-cog12), global function (CDR-Sum of boxes), and activities of daily living (ADCS-ADL). Enrollment required
florbetapir-PET positive scans, or patients who were amyloid positive. Ninety-one patients were included in the study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BLAZE Study
Disposition </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g50q80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BLAZE Study Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary end point of change in brain amyloid load by florbetapir-PET was not met, but the study was not powered to detect statistically
significant results. When assessing the amyloid load, the amount of amyloid in a region of the brain is determined by comparing the amount of an amyloid tracer to that found in a region with little or no amyloid, such as the cerebellum or the white
matter, usually in the cortex. Recent studies have shown that the variability from scan to scan in the same patient over time is much higher when using the cerebellum than with the white matter, making the white matter a more powerful point of
comparison for use in longitudinal studies. The higher variability of the cerebellum may be due to difficulties in exact positioning between scans and higher background levels. Taking this into account, the exploratory analyses of the BLAZE amyloid
PET </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results using white matter reference region were conducted independently by two laboratories, the Banner Alzheimer&#146;s Institute and MNI Laboratories. The analyses produced analogous results
where a trend in the reduction of Abeta accumulation was observed in the high-dose arm. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g83h98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BLAZE biomarker study high-dose intravenous cohort showed a consistent trend of reduced Abeta
accumulation in the brain over time shown by two independent exploratory analyses of florbetapir-PET data. Using white matter rather than cerebellum as the key reference region in the brain is generally considered a more robust method of showing
treatment effects of AD therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the BLAZE study, patients also showed a statistically significant increase in CSF Abeta<SUB
STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, which we believe confirms target engagement by crenezumab. Similar results were observed in the ABBY study where CSF was assessed in 49 patients. These results suggest that Abeta is being
eliminated from the brain when treated with crenezumab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BLAZE High Dose Arm: Crenezumab Increases CSF Total Abeta Relative to Placebo
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g56h33.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>BLAZE Study Results: Effects on Cognition and Global Function </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A similar and consistent pattern of response was observed in the BLAZE study with slowing of loss of cognition compared to placebo observed at
the high-dose intravenous crenezumab arm, and having the most effect in patients with more mild MMSE scores. There was no significant cognitive change in patients who received low-dose subcutaneous crenezumab. Importantly, the sample size of the
study was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). BLAZE study results suggest
that Abeta is being eliminated from the brain as patients showed a statistically significant increase in CSF Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, which confirms target engagement by crenezumab. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BLAZE High Dose Arm: Change in ADAS-Cog 12 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g39g56.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BLAZE high-dose arm showed increasing separation over time of the curves of decline on ADAS-Cog 12
for placebo (dashed line) and intravenous crenezumab (solid line) in the mild subgroup of patients (MMSE 20-26). In a post-hoc analysis of a group of patients with mild AD (MMSE 20-26) treated with high-dose intravenous crenezumab, there was a 52.0%
reduction in cognitive decline (p=0.29). In patients with mild-to-moderate AD (MMSE 18-26) treated with high-dose intravenous crenezumab, there was a 10.3% reduction in cognitive decline (p=0.84). Importantly, the sample size of the study was not
expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Effect sizes and <FONT
STYLE="white-space:nowrap">p-values</FONT> were not adjusted for multiplicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the BLAZE study, patients in the high-dose crenezumab
arm showed less cognitive decline on the measure of global function, CDR-Sum of boxes, as compared to placebo. In mild-to-moderate AD (MMSE 18-26), a 7.4% reduction in global functional decline (p=0.84) was observed. In a post-hoc analysis in
patients with mild AD (MMSE 20-26), treatment with high-dose intravenous crenezumab resulted in a 41.5% reduction in global functional decline (p=0.44). Although the results were not statistically significant, the sample size of the study was not
expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Safety Data from ABBY and BLAZE Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crenezumab demonstrated favorable safety and tolerability in Phase 2 clinical studies even at high doses. Crenezumab&#146;s safety profile is
especially reflected in a low incidence of ARIA-E (0.3%) in Phase 2 clinical studies. ARIA-E was observed in only one patient who received high-dose intravenous crenezumab in the ABBY study. No case of ARIA-E was reported in the placebo arm or the
BLAZE study. Favorable pharmacokinetic properties coupled with a favorable safety and tolerability profile enables crenezumab to penetrate the brain more readily at therapeutically relevant doses. Since dose limiting toxicities are a potential
reason for the failure of other antibodies to demonstrate efficacy, crenuzamab&#146;s potential safety at high doses is a key distinguishing product feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no imbalance in the overall rate of AEs. AEs were observed in 91.3% of patients treated with crenezumab versus 90.3% of patients who
received placebo. AEs were generally mild-to-moderate and transient. AEs did not appear to be related to crenezumab exposure. Five deaths occurred during ABBY and BLAZE, all in patients who received crenezumab during the randomized
placebo-controlled period (1.4% of the crenezumab-treated population). The overall rate of deaths is consistent with the background rate of death in the elderly AD population. There was no consistent pattern for the cause of death and none were
considered by the investigators to be related to crenezumab. It was reported that 3.2% of crenezumab-treated patients developed pneumonia versus 0.6% in placebo-treated patients in ABBY and BLAZE, but the rate of pneumonia cases in
crenezumab-treated patients is consistent with the expected rate in the elderly population (2.5%&#150;4.4%) and no drug-related mechanism for pneumonia was identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech has not disclosed detailed information about serious adverse events associated with crenezumab either publicly or to us. However, at
the 2014 Alzheimer&#146;s Association International Conference, it was reported that in the combined Phase 2 study populations, serious adverse events occurred at similar rates in patients treated with crenezumab (16.5%) and in patients given a
placebo (11.9%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Phase 1 Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To explore safety at higher doses, crenezumab is currently being tested in a Phase 1 clinical study conducted in the United States. This
randomized, placebo-controlled, double-blind, four parallel-arm study will evaluate the safety and tolerability of two doses of intravenous crenezumab in approximately 24 patients with mild to moderate AD (MMSE 18-28) between the ages of 50 to 90.
An optional open-label extension stage will be offered to patients after completion of the double-blind stage of the study. The final data collection date for the primary outcome measure is planned for the fourth quarter of 2015. This study is
expected to be completed in July 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2 AD Prevention Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, crenezumab was independently selected from among twenty five product candidates for use in the first-ever AD prevention study. The
study, a $100 million collaboration between the NIH, Banner Alzheimer&#146;s Institute and Genentech, is the cornerstone of the global Alzheimer&#146;s Prevention Initiative. Crenezumab is being administered pre-symptomatically to 300 members of an
extended Colombian family, of which 200 members carry a mutation that causes early-onset AD. Family members usually develop symptoms before the age of 45. The five-year study has cognitive endpoints. An interim analysis is expected in 2017, but the
data and results of that analysis may not be made public given patient sensitivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Planned Phase 3 Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech has announced that it plans to enter Phase 3 clinical development of crenezumab in early 2016. The design and number of studies have
not yet been disclosed but will take into account results of the Phase 2 studies as well as the additional ongoing Phase 1 study of higher doses, which is expected to be completed in the fourth quarter of 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-24 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-24 is a vaccine candidate that is in a combined Phase 1/2a clinical study for AD. ACI-24 was developed utilizing our SupraAntigen platform,
and is designed to stimulate a patient&#146;s immune system to produce antibodies that specifically target the misfolded Abeta conformer to prevent plaque accumulation and to enhance plaque clearance. Pre-clinical data demonstrated significant
activity in plaque reduction and memory restoration. ACI-24 has a favorable safety profile, characterized by a lack of observed local inflammation and a mechanism of action independent of inflammatory T-cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1/2a Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered a Phase 1/2a study, a study or part of it must include as a primary goal the assessment of efficacy in a patient population,
assessed using either clinical endpoints or biomarkers. This is in contrast to a Phase&nbsp;1 study where the primary goal typically includes safety and pharmacokinetic or pharmacodynamic measures. The ACI-24 study is an adaptive design study where,
after completion of a first step assessment of safety and immunogenicity at different doses, the study may be expanded to assess the efficacy at the best dose in a Phase 2a-type design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1 part of the combined Phase 1/2a study is currently ongoing. The efficacy, tolerability and immunogenicity of ACI-24 are being
tested in mild to moderate AD patients with four different doses. It is a randomized, placebo controlled, double blind study. The different doses are tested via an ascending dose design in four consecutive cohorts with 12 patients each (9 on active,
3 on placebo treatment). ACI-24 is administered by subcutaneous injection with multiple injections per cohort. Each dose cohort is followed by a two-year treatment-free safety follow-up period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment of the first three cohorts has been completed. The treatment of the fourth cohort is ongoing. To date, ACI-24 has shown a
favorable safety profile and has been well tolerated. None of the observed serious adverse events were considered related to the administration of ACI-24. The Phase 2a study of the combined Phase 1/2a study will focus on safety, tolerability and
efficacy and will be conducted after all data of Phase 1 are available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pre-clinical Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre-clinical results showed that ACI-24 induced a rapid and significant anti-Abeta antibody response in a T-cell independent manner, which is
linked to a more favorable safety profile. The antibody response following treatment with ACI-24 reduced the Abeta brain burden and restored the memory capacity in double-transgenic AD mice. Anti-Abeta antibodies induced by ACI-24 preferentially
bind to both pathologically aggregated Abeta species such as oligomers and fibrils. Relative to other anti-Abeta vaccines currently or previously in clinical development ACI-24 has shown differentiation in pre-clinical studies on the basis of
mechanism of action, safety and efficacy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g57t30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the diagram above, immunization of an AD mouse model with ACI-24 led to a significant decrease
of insoluble, plaque-related (black bars) and soluble (grey bars) oligomeric Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1-40</SUB> and Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1-42</SUB>. This target engagement was
accompanied by the significant improvement of cognitive memory capacity in the novel object recognition test, or ORT. In contrast, immunization with ACI-01, the vaccine candidate which did not present the antigen in its pathological conformation,
did not result in any restoration of memory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-24 in Down Syndrome </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individuals with Down syndrome have an extra copy of chromosome 21 where the gene for APP resides. These individuals have a rate of AD that is
three to five times that of the general population and develop the disease at a much younger age. At autopsy, AD has been reported in 80% of people with Down syndrome over age 40 and 100% over age 60. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-24 is a vaccine candidate against the pathological form of Abeta in plaques of AD patients. It contains a palmitic-acid Abeta peptide
corresponding to amino acids 1-15 of the Abeta molecule anchored in liposomes and adopts the conformation of the pathological Abeta conformers found in plaques. ACI-24 has a novel mode of action whereby antibody production is induced through direct
B-cell (antibody producing cell) activation that is independent of T-helper cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND to study the disease-modifying properties of ACI-24 for the prevention of cognitive
decline with Down syndrome was filed and cleared by the FDA. ACI-24 is expected to enter Phase 1 clinical studies for Down syndrome at the end of 2015 after the authorization of the amended protocol. The study is supported by a substantial NIH grant
and other grants from the LuMind Research Down Syndrome Foundation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g11d65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above, based on unpublished work by AC Immune in collaboration with Dr.&nbsp;Mobley, shows in a
Down syndrome mouse model (Ts65Dn) a 20% significant improvement of the memory&nbsp;(left) and a 27% reduction of Abeta in the brain following vaccination with ACI-DS-01, the mouse equivalent of ACI-24 (right). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-35 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-35 is a vaccine
candidate directed against another key component of the pathology of AD: phosphorylated tau proteins, or p-tau, found in tau tangles. ACI-35 is designed to stimulate a patient&#146;s immune system to produce antibodies against the misfolded and
phosphorylated pathogenic conformers of tau protein that aggregate to create the neurofibrillary tangles that characterize AD. ACI-35 is the first vaccine candidate against phosphorylated pathological tau in clinical studies, and is currently in
Phase 1b clinical testing in patients with mild to moderate AD. In 2015, we entered into a partnership with Janssen Pharmaceuticals, a subsidiary of Johnson&nbsp;&amp; Johnson, for the clinical development of ACI-35 beyond Phase 1b. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dendrites and axons, or nerve endings, of the neurons contain an elaborate series of thin tubes, or microtubules, which serve to support
them and transport nutrients down to the nerve endings. Tau proteins are a key component of these microtubules, and, hence, are known as microtubule associated proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In AD, tau protein is misfolded, becomes hyperphosphorylated and aggregates into neurotoxic oligomers that ultimately form neurofibrillary
tangles within neurons. The degree of tau pathology correlates strongly with the degree of cognitive loss in AD. Approaches to reducing the level of abnormal tau proteins and slowing their build-up in the brain are considered important targets for
new AD therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed ACI-35 using our SupraAntigen technology. In pre-clinical testing, the vaccine candidate induced an
antibody response that was highly specific to misfolded and phosphorylated tau. This antibody response resulted in a reduction of phosphorylated misfolded tau and an improvement in cognitive clinical parameters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1b Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1b Study Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Safety, tolerability and immunogenicity of ACI-35 are being tested in an ongoing Phase 1b study in mild to moderate AD patients. It is a
randomized, placebo controlled double blind study, where ACI-35 is administered via subcutaneous injection. Different doses and dosing schedules are being investigated in an ascending dose design. Multiple injections of ACI-35 are administered per
cohort for active or placebo treatment in a three-to-one ratio. To date, ACI-35 has been generally safe and well tolerated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pre-clinical Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In research and pre-clinical studies, ACI-35 demonstrated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A high and specific anti-p-tau IgG antibody response in wild-type mice, tau transgenic mice and primates (cynomolgus and rhesus monkeys); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The induction of highly specific antibodies that are able to recognize p-tau over non-phosphorylated tau peptide and yield a 30-100 fold higher titer for p-tau over non-phosphorylated tau; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A favorable safety profile by showing that multiple doses in mice and monkeys induced strong antibody responses that were well tolerated and not associated with organ toxicity. The main adverse events were local
reactions observed at the injection site and were consistent with a normal granulomatous inflammatory reaction after subcutaneous injection of a foreign body; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No observable toxicity at the highest dose used in cynomolgus monkeys or mice; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No cross-reactivity to any human tissue with the antibodies induced in monkeys by ACI-35 immunization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-35 generated antibodies that are phosphor-specific for the full-length p-tau protein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g64u74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The left graph shows that the ACI-35 vaccination raised highly-specific antibodies against phosphorylated
tau protein in both transgenic and wild type mice. On the other hand, the right graph shows that a classical vaccine, composed of a p-tau peptide adsorbed to aluminum phosphate, raised antibody responses that do not discriminate between
phosphorylated tau and non-phosphorylated tau protein in both wild type and tau transgenic mice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pre-clinical and Discovery Stage Therapeutic Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using our SupraAntigen and Morphomer platforms, we have generated additional discovery and pre-clinical stage molecules targeting
neurodegenerative diseases, and diagnostics targeting both Abeta and tau. We currently have four therapeutic product candidates and two diagnostic product candidates in various stages of pre-clinical development. A number of our therapeutic product
candidates in pre-clinical development are focused on indications outside of AD and evidence our expansion strategy. Based on the data we have received to date, we believe that our technology platforms can be applied to misfolded proteins across a
broad range of indications. The table below lists our four pre-clinical product candidates, the platform from which each candidate stems and the lead indication being pursued: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:65.10pt; font-size:8pt; font-family:Times New Roman"><B>Product Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Partner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Platform</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Anti-tau antibody</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">tau</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Genentech</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SupraAntigen</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Morphomer tau</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">tau</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morphomer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Morphomer abeta</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Abeta</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Glaucoma</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morphomer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Morphomer alpha-synuclein</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">alpha-synuclein</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morphomer</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-tau antibody:</I></B> Our anti-tau monoclonal antibody program uses the SupraAntigen platform
to generate humanized monoclonal antibodies for use as passive immunotherapies that are highly specific for pathological forms of tau found in AD brains and other tauopathies. Results from studies conducted in pre-clinical development demonstrate a
significant reduction in pathological tau with reduced effector function, meaning decreased ability to affect the function of tau, as well as improvement of long-term spatial memory. A lead development candidate has been selected, and Genentech, our
collaboration partner for the anti-tau antibody program, announced that it intends to move this program into Phase 1 clinical studies in late 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-tau Morphomers:</I></B> Anti-tau Morphomers are small molecule compounds designed to inhibit tau aggregation with the aim of
interacting with the beta sheet conformation present in misfolded aggregated tau protein. Our anti-tau Morphomers show a significant inhibition of full length tau aggregation, size-reduction and solubilization of full length tau aggregates and
intracellular target engagement by reduction of cellular, aggregated and phosphorylated tau. Importantly, research data show that our compounds reduce cytotoxicity induced by tau. These data were further confirmed by the reduction of misfolded tau
in the brain and memory improvement in a tau disease mouse model. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Morphomer abeta:</I></B> Our Morphomer abeta product
candidate is a small molecule that inhibits and disrupts Abeta propagation and aggregation, and is currently being evaluated for the treatment of glaucoma, where its anti-Abeta properties represent a novel mechanism of action for that disease. In
pre-clinical testing, Morphomer abeta demonstrated a strong ability to protect the eyes of rats exposed to increased ocular pressure and chronic ocular hypertension which are clinical features of glaucoma. This molecule is expected to enter Phase 1
clinical studies in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Morphomer alpha-synuclein:</I></B> Our Morphomer alpha-synuclein product candidate is small molecule that
reduces the cytotoxicity of alpha-synuclein aggregates by a decrease in their beta sheet content. In pre-clinical studies, Morphomer alpha-synuclein significantly reduced <I>in vivo</I> the formation of alpha-synuclein pathological structures
accompanied by improvement of a neuronal marker relevant to PD. Ongoing activities are focused on increasing potency and pharmacokinetic properties and preparing compounds for pre-clinical development activities. In a mouse model of tauopathies, our
lead compounds show improvement of learning and memory deficit and reduce brain atrophy. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diagnostics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scientists increasingly believe that early detection of neurodegenerative diseases is critical to enhancing the effectiveness of both
symptomatic and disease-modifying therapies. As a result, therapeutic development for AD increasingly focuses on treating early stage disease to delay or prevent progression and to preserve the maximum
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of cognitive function before it is irreversibly lost. Most clinical studies now target mild stages of the disease increasing the need for accurate diagnosis that is independent of
potentially subjective cognitive metrics. At least one study estimates that as many as one-third of patients in previous AD studies did not in fact have AD. Accurate and early diagnosis of AD is thus a substantial unmet market need, and diagnostic
products will have a key role in generating a new treatment paradigm, including by selecting more uniform and stage-specific clinical study subjects, tracking patient progress and results, managing patients receiving treatment, and ultimately
diagnosing disease at its earliest stage for immediate treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing two diagnostic product candidates using our Morphomer
technology platform. These product candidates are PET ligands, that are tracers that can be used to target tau and alpha-synuclein aggregates. In May 2014, we established a licensing collaboration for our tau-PET imaging program with Piramal
Imaging. Our tau-PET imaging agent is currently in a First-in-Man clinical study. Piramal Imaging is expecting to advance this program into Phase 1 clinical development in 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PET tracers are designed to bind specifically to tau tangles and have demonstrated their ability to cross the blood-brain barrier. The
severity of cognitive impairment in AD patients is correlated with the presence of tau protein tangles, leading us to believe that an imaging agent for tau is equally important. Our tau-PET tracers are more selective for tau than Abeta when compared
to current published tau-PET agents in development and can be readily radiolabelled. While PET imaging has improved the diagnosis of AD by targeting Abeta, tau imaging will further enhance the diagnosis of early AD. To date, there are no approved
tau tracers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g15e00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagrams above show that our lead tau-PET imaging compound has high selectivity and can identify tau
aggregates as early as stage one of the six stages of the Braak scale, which is the pre-symptomatic stage (as indicated with arrows in the far left diagram), and have a favorable uptake in the brain (right diagram). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AD diagnostics are a major market opportunity that will be driven by the growth in the aging population and the testing and availability of
disease-modifying drugs. We believe a best-in-class tau tracer has the potential to achieve a substantial market share in this large and growing market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alongside our AD diagnostics activities, we have a program targeting PET imaging agents for alpha-synuclein, an important protein involved in
PD, and which progressively accumulates in structures in the PD brain. Scientists believe that the misfolding of alpha-synuclein is central to the neurodegenerative process of PD, as well as a number of other disorders, collectively called
synucleinopathies, such as Lewy Body Dementia and Multiple System Atrophy, making it a priority target for drug development. We have identified molecules from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our Morphomer library that stain selectively alpha-synuclein pathological structures in human PD brain sections. Ongoing work to optimize the potency, selectivity and pharmacokinetics of these
tracers is being funded by the Michael J. Fox Foundation for Parkinson&#146;s Research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently there are no imaging products in the
market that target alpha-synuclein. This provides us with a unique opportunity to become the market leader in alpha-synuclein PET imaging. We believe the ability to image alpha-synuclein deposits in the brain will enable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The diagnosis of PD at much earlier premotor stages than is now possible, thereby enabling early therapeutic intervention and corresponding better patient outcomes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The use of alpha-synuclein as a surrogate marker in clinical studies of novel therapeutic regimens designed to slow or halt progression of PD; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The diagnosis of sub-populations of PD and other synucleinopathies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These applications of
alpha-synuclein PET imaging agents have the potential to fundamentally change the approach of treating PD and other similar diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
PD market size is estimated to grow from $3.6 billion in 2012 to approximately $5.3 billion in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements and Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SupraAntigen and Morphomer platforms have generated large numbers of clinical assets that address diseases related to protein misfolding,
such as AD, PD and Down syndrome. Select key assets in the product pipeline have been licensed for upfront payments, milestones and royalties to help offset the cost of our research and internal product development. Discussions with other companies
are ongoing. We have signed a number of licensing agreements with leading pharmaceutical companies to assist and accelerate the development of our product pipeline, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Genentech signed in November 2006 (and amended in May 2015) for crenezumab for AD, under which we may become eligible to receive payments totaling up to approximately $340 million,
excluding royalties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Genentech signed in June 2012 for anti-tau antibodies for AD, under which we may become eligible to receive payments totaling up to $418 million, excluding royalties.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Janssen signed in December 2014 for therapeutic anti-tau vaccines for AD, and potentially other tauopathies, under which we may become eligible to receive payments totaling up to CHF
500&nbsp;million, excluding royalties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Piramal Imaging signed in May 2014 for small molecule tau ligands for use as PET tracers under which we may become eligible to receive payments totaling up to &#128;157&nbsp;million,
excluding royalties. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genentech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have two partnership agreements with Genentech, a company with a reputation for scientific excellence and a history of bringing innovative
protein therapeutics to market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Crenezumab Collaboration Agreement of 2006 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We signed our first agreement with Genentech in November 2006 and amended the agreement in May 2015. This is an exclusive, worldwide licensing
agreement for crenezumab, our humanized monoclonal antibody </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
targeting misfolded Abeta. The agreement provides for a second therapeutic product based on the same intellectual property and anti-Abeta antibody compound, as well as an anti-Abeta diagnostic
product. Genentech recently announced that it intends to commence Phase 3 clinical studies for crenezumab in 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement
with Genentech, we may become eligible to receive payments totaling up to approximately $340 million, excluding royalties. The agreement includes upfront and milestone payments. In addition, we will receive royalties on sales. The structure of the
collaboration agreement is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clinical milestone payments</I> are payable upon commencement of each of Phase 1 and 2 of clinical developments, and upon the earlier of Genentech&#146;s decision to authorize Phase 3 or the commencement of Phase 3
of clinical developments. In addition, for a second indication, clinical milestone payments would be payable upon commencement of Phase 2 of clinical developments and upon the earlier of Genentech&#146;s decision to authorize Phase 3 or the
commencement of Phase 3 of clinical developments. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Regulatory milestone payments</I> upon making regulatory filings in the U.S. and Europe, respectively, and milestone payments upon obtaining marketing approval in each of the U.S. and Europe. In addition, for a
second indication, additional regulatory and approval milestones would be payable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Royalties</I> on sales with different royalty rates applicable in the U.S. and Europe. Royalty levels are tied to annual sales volumes. We will receive royalties on sales of crenezumab with the percentage
rates ranging from low double-digits to the mid-teens. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have received total payments of $65 million which
comprise upfront and clinical milestone payments. We received a $25 million upfront payment at the time of signing of the collaboration agreement and have since then obtained three milestone payments totaling $40 million including the Phase 3
milestone payment we received in July 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Genentech bears all the costs of developing crenezumab
through the clinical phases. In addition, Genentech is responsible for the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs, sales and marketing costs. Intellectual property costs related to any
crenezumab-related intellectual property filed solely by us and any costs associated with filing, maintaining and protecting intellectual property filed jointly we share with Genentech. The agreement will terminate by its terms on the date on which
all obligations between the parties with respect to the payment of milestones or royalties for licensed products have passed or expired. However, Genentech may terminate the agreement at any time by providing three months&#146; notice to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-tau Antibody Collaboration Agreement of 2012 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2012, we entered into a second partnership with Genentech to commercialize our anti-tau antibodies for use as immunotherapeutics. The
value of this exclusive, worldwide alliance is potentially greater than CHF 400&nbsp;million and includes upfront and milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at percentage rates ranging from
the mid-single digits to high single digits. The agreement also provides for collaboration on two additional indications built on the same anti-tau antibody program, as well as a potential anti-tau diagnostic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have received payments totaling CHF 31&nbsp;million including a CHF 14&nbsp;million milestone payment associated with the recent
selection of the lead candidate to be taken forward into Phase 1 clinical studies. Genentech recently announced that it intends to commence Phase 1 clinical studies for this product candidate in 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of the collaboration agreement is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Preclinical and clinical milestone payments</I> upon selection of a lead candidate, commencement of each of Phase 1, 2 and 3 of clinical development. In addition, for a second indication, clinical milestone payments
would be payable upon commencement of each of Phase 2 and 3 of clinical development. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Regulatory milestones payments</I> upon making regulatory filings in the U.S., Europe, and Japan, respectively. In addition, for a second indication, similar regulatory milestones would be payable.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialization milestones</I> payable upon making a first commercial sale in each of the U.S., Europe and Japan. For a second indication, commercialization milestones exist for each of the U.S., Europe and Japan
which are triggered by the first commercial sale for the second indication in each of those jurisdictions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Royalties</I> on sales with royalty rates differing based on the source of the intellectual property underlying the commercial product. </TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Genentech bears all the costs of developing the anti-tau antibody compound through the clinical phases. In
addition, Genentech is responsible for the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs, sales and marketing costs. Intellectual property costs related to any anti-tau antibody-related
intellectual property filed solely by us and any costs associated with filing, maintaining and protecting intellectual property filed jointly we share with Genentech. The agreement will terminate by its terms on the date on which all obligations
between the parties with respect to the payment of milestones or royalties for licensed products have passed or expired. However, Genentech may terminate the agreement at any time by providing three months&#146; notice to us. </P>
<P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Janssen Pharmaceuticals </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
December of 2014, we entered into a partnership with Janssen Pharmaceuticals to develop and commercialize therapeutic anti-tau vaccines for the treatment of AD and potentially other tauopathies. The partnership includes a worldwide exclusive license
and research collaboration. We and Janssen will co-develop the lead therapeutic vaccine candidate, ACI-35, through Phase 1b completion. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and
commercialization of ACI-35. ACI-35 is an active therapeutic vaccine candidate stimulating the patient&#146;s immune system to produce a polyclonal antibody response against phosphorylated tau protein. The agreement also allows for the collaboration
to be expanded to include a second indication based on the same anti-tau vaccine program and intellectual property related to this program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received an upfront payment of about CHF 25.9&nbsp;million and are eligible to receive development, regulatory and commercialization
milestone payments potentially totaling up to CHF 500&nbsp;million for AD and a potential second indication outside of AD. Additionally, we will receive royalties on sales at a percentage rate ranging from the low double digits to mid-teens. We have
entered into a three-year joint research collaboration to further characterize and develop novel vaccine therapies for the treatment of tauopathies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of the collaboration agreement is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clinical milestone payments</I> upon completion of Phase 1b, commencement of each of Phase 2 and 3 of clinical development. For a second cohort, a milestone payment is payable to us upon commencement of Phase 2
clinical studies. In addition, for a second indication, clinical milestone payments would be payable upon commencement of Phase 3 clinical studies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Regulatory milestone payments</I> upon making regulatory filings in the U.S., Europe, and Japan, respectively. In addition, for a second
indication, similar regulatory milestones would be payable. Also, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
for a second indication, additional regulatory milestone payments are payable by Janssen to us upon receipt of each of the regulatory approvals in the U.S., Europe and Japan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialization milestones</I> payable upon making a first commercial sale in each of the U.S., Europe and Japan, and upon achieving certain commercial milestones. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Royalties</I> on sales with royalty rates differing based on the level of annual sales. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement will terminate by its terms on the date on which all royalty obligations have been paid thereunder. However, under the terms of
the agreement, Janssen may terminate the agreement at any time after completion of the Phase 1b clinical study by providing 90 days&#146; notice to us. </P>
<P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piramal Imaging </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, we
entered into our first diagnostic partnership with Piramal Imaging, one of the world leaders in imaging products. The agreement with Piramal is for a compound from the Morphomer chemical library that binds to pathogenic tau for use as a PET tracer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exclusive, worldwide licensing agreement with Piramal Imaging includes upfront and milestone payments totaling up to
&#128;157&nbsp;million, plus royalties on sales at percentage rates ranging from mid-single digits to low teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of the
collaboration agreement is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clinical milestone payments</I> upon the commencement of Phase 1, 2 and 3 for the lead indication. We would be entitled to further clinical milestone payments for the commencement of Phase 2 and 3 for a second
indication </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Regulatory approval and marketing approval milestones</I> upon filing and approval in each of the U.S. and Europe </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Sales milestones</I> tied to specific total sales amounts </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the tau tracer will
complement Piramal&#146;s already marketed Abeta tracer product Neuraceq and could be commercially available within five years. The agreement will terminate by its terms on the date of expiration of the last-to-expire royalty term, where each
royalty term under the agreement expires on a product-by-product basis and country-by-country basis on the later of (i) ten years after the first commercial sale of the relevant product in such country and (ii) the date on which the patent covering
the sale of such product in such country is no longer valid or enforceable. However, Piramal Imaging may terminate the agreement at any time after the first eighteen months from the effective date of this agreement by providing three months&#146;
notice to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>National Institutes of Health/Banner Alzheimer&#146;s Institute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, the NIH and Banner Alzheimer&#146;s Institute selected crenezumab for the first ever AD prevention study before onset of symptoms in
highest-risk individuals. This landmark study is being performed on a family clan in Colombia with Paisa mutation leading to Abeta accumulation and early onset AD. The $100 million multi-year study is being funded with grants from the NIH, Banner
Alzheimer&#146;s Institute and our partner, Genentech. Interim results from this study are expected to be available in 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael J. Fox
Foundation for Parkinson&#146;s Research </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we were awarded an important grant from the Michael J. Fox Foundation for
Parkinson&#146;s Research. The grant is funding the development of a diagnostic imaging agent capable of detecting PD at an early stage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The project focuses on alpha-synuclein PET tracers. We have identified molecules from our Morphomer library that stain selectively alpha-synuclein pathological structures in human PD brain
sections. We are optimizing the potency, selectivity and pharmacokinetics of these tracers and expect to select a lead candidate in the first quarter of 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nestl&#233; Institute of Health Sciences SA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, we entered into a research collaboration agreement with the Nestl&#233; Institute of Health Sciences SA, or NIHS, a
fundamental research institute of the global nutrition, health and wellness company Nestl&#233;, to develop a novel, minimally invasive tau diagnostic assay for the early diagnosis of AD. Under the terms of the agreement, we will provide expertise
in the biology and pathology of tau as well as commit our laboratory capabilities to support the collaborative research program. NIHS will apply its proprietary multiplexed antibody technology platform to the research program with the goal of
identifying and validating a highly sensitive diagnostic assay for the detection of tau in human cerebrospinal fluid and blood plasma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceuticals industry is highly competitive across all therapeutic fields. In the field of neurodegenerative diseases, there
are many public and private companies or institutions that are actively engaged in the discovery and development of therapeutic and diagnostic products. Some of these products may have a similar target to our product candidates or address similar
markets. The industry is still in its infancy in terms of defining the pathology of neurodegenerative diseases. As disease understanding progresses, the number of novel product candidates may well increase and broaden the therapeutic and diagnostic
options in our product markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there are no approved disease-modifying products for AD or any other neurodegenerative
disease. Current approved therapies seek to treat the symptoms of AD, such as cognitive decline, but do not slow or stop the progression of the disease. In addition, commonly, there is off-label prescription of antidepressant and antipsychotic
agents for more advanced AD patients who may suffer from agitation, aggressive behaviors, psychosis and depression. No new drugs have been approved for the treatment of AD since 2003. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect there to be several classes of disease-modifying agents that will enter the AD market. One such class is monoclonal antibodies that
target Abeta plaques, the same target as for our candidate product crenezumab. Another target for monoclonal antibodies is tau protein aggregates. Therapeutic vaccines are a second class of disease-modifying therapies, and include our candidate
products ACI-24, that targets Abeta plaque, and ACI-35, that targets aggregated tau protein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability of novel diagnostic agents
to visualize the disease development in AD patients is critical for successful clinical development of disease-modifying products in AD. At the forefront of this new diagnostic effort are PET agents for in-life imaging of disease, and in particular,
tau-targeting PET agents which we believe will allow precise assessment of disease AD patients. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Crenezumab:</I></B> If crenezumab is approved, it would compete with other monoclonal antibody products that target Abeta plaques and act as disease-modifying agents. Currently, no product has been approved that
is a disease-modifying agent targeting Abeta plaques; however, a number of such product candidates are in clinical development. These include solanezumab, gantenerumab and aducanumab, each of which is in Phase 3 clinical study and which are being
advanced by Eli Lilly, Roche and Biogen, respectively. Biogen has a second product candidate known as BAN2401, which is currently in Phase 2 clinical study. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B><I>ACI-24 in AD:</I></B> ACI-24, if approved, would compete with other approved anti-Abeta-targeting therapeutic vaccines. Several potential
competing product candidates have not continued through the regulatory approval process, including ACC-001 (Janssen / Pfizer) and AN-1792 (Elan / Janssen), both of which were discontinued after completing Phase 2 studies. Other potential competing
product </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
candidates for ACI-24 include Affitope-AD-02 (AFFiRiS AG / GlaxoSmithKline) and CAD-106 (Novartis International AG), each of which has completed a Phase 2 study. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-24 in Down syndrome:</I></B> ACI-24 is the first disease-modifying vaccine candidate addressing AD in Down syndrome, with a potential preventive and therapeutic application. While there are symptomatic
treatments of Down syndrome in clinical development, to our knowledge there are no other disease-modifying treatments for AD in Down syndrome. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-35:</I></B> ACI-35, if approved, would compete with other approved tau-targeting therapeutic vaccines. This includes AADVAC1, an anti-tau vaccine product candidate currently being advanced in the regulatory
approval process by Axon Neurosciences. AADVAC1 entered Phase 1 clinical studies in May 2013. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Anti-tau Antibodies:</I></B> To our knowledge, there are no competing products currently in clinical development for AD. However, the anti-tau monoclonal antibodies BMS-986168 (Bristol-Myers Squibb Company) and
ABBV-812E (AbbVie) are currently in Phase 1 clinical development in the orphan indication PSP, a tau protein-based neurodegenerative disease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Anti-tau Morphomers:</I></B> A potential competitor to our anti-tau Morphomers is LMTX. LMTX is a methylene blue derivative that is being advanced by TauRx Therapeutics and is intended to target tau protein
aggregation. LMTX entered Phase 3 clinical study in September 2012. No clinical data read-out has been made available. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Diagnostics</I></B><B><I>:</I></B> Currently, there are no approved tau PET imaging products. However, should our tau PET imaging agent be approved, it would compete with other approved tau-PET agents. These
include (i)&nbsp;18F-AV-1451 (previously T807), which is being advanced by Eli Lilly subsidiary, Avid Radiopharmaceuticals, and is currently in Phase 2 clinical studies that began in December 2013, (ii)&nbsp;THK-5117, is being advanced by GE
Healthcare under license from the Tohoku University School of Medicine and is currently in Phase 1/2 studies, (iii)&nbsp;PBB3, a product candidate in Phase 1 studies and being advanced by the National Institute of Radiological Services and
(iv)&nbsp;Roche is evaluating internal tau PET imaging ligands in Phase 1 clinical studies in AD patients. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our
competitors have significantly greater financial, technical and human resources than we have available. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller
number of our competitors. Our commercial opportunity and our success will be based in part on our ability to identify, develop and manage a portfolio of product candidates that are safer and more effective than competing products. However, this
opportunity could be eroded or even eliminated if our competitors develop and/or market products that are novel and have superior safety and efficacy profiles, that may be brought to the market more rapidly due to greater available resources, or
that are less costly than our current or future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy to date has been to focus on identifying partnerships for our early stage product candidates as both a way to secure non-dilutive
capital to fund our other research and development programs but also as a way to accelerate the development of these partnered products by leveraging our partners&#146; extensive knowledge in clinical studies, drug development, manufacturing and
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With greater financial resources at our disposal but also given the significant knowledge acquired by our scientists
and scientific leadership, we intend to retain selected promising product candidates in-house for a longer period of time and fund their development from our own resources. This will allow us to generate greater value from these product candidates,
allowing us to demand more significant terms from a prospective partner. For example, our current plan is to retain full control of our two Abeta vaccine programs focused on AD and Down syndrome, meaning that we would fund the planned Phase 2 and
Phase 2/3 studies, respectively, from our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial resources. In the field of diagnostics, the parallel development of therapeutic compounds and companion diagnostics is of growing importance to the pharmaceutical industry. The
development timeframe of a PET diagnostic agent is significantly shorter than for a therapeutic product providing the prospect for potential diagnostic product revenues to be realized quicker than potential therapeutic product revenues. Our
Morphomer platform is particularly well suited to generate molecules for use in the development of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our
current stage of product development, we currently do not have a commercialization infrastructure. If any of our diagnostic product candidates is granted marketing approval, we intend to focus our initial commercial efforts in the United States and
select European markets, which we believe represent the largest market opportunities for us. In those markets, we expect our commercial operations to include our own specialty sales force that will target neurologists and gerontologists, both in
hospitals and in private practice. In other markets, we expect to seek partnerships that would maximize our products&#146; commercial potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect the proprietary technology that we believe is important to our business, including seeking and maintaining U.S. and foreign patents intended to cover our products and compositions, their methods of use and processes for their manufacture, as
well as our proprietary technology platforms, diagnostic candidates, and any other inventions that are commercially important to the development of our business. We also rely on trade secrets and know-how to protect aspects of our business that are
not amenable to, or that we do not consider appropriate for, patent protection. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will significantly depend on our ability
to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce patents, preserve the confidentiality of our trade secrets and operate our
business without infringing any patents and other intellectual property or proprietary rights of third parties. See the section titled &#147;Risk Factors&#151; Risks Related to Intellectual Property&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October 19, 2015, we owned or co-owned approximately 16 issued U.S. patents and 117 issued patents in other jurisdictions, as well as 22
pending U.S. patent applications and 378 pending foreign patent applications. As of October 19, 2015, we licensed approximately eight issued U.S. patents and 15 pending U.S. patent applications, as well as 73 issued patents in other jurisdictions
and 285 pending foreign patent applications </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolios for our three most advanced product candidates as of October 19, 2015
are summarized below. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Crenezumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for crenezumab includes composition of matter claims (including for the humanized crenezumab monoclonal antibody, of a
fragment thereof, a polynucleotide encoding the antibody or fragment thereof, a cell line used to produce the crenezumab antibody as well as pharmaceutical compositions comprising crenezumab), claims directed to treating certain indications using
crenezumab including AD, and claims directed to a method of manufacturing crenezumab. Our patent portfolio includes three patent families that are directed to a humanized IgG4 antibody, methods of using such humanized IgG4 antibody for ocular
indications, and the murine antibody equivalent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for crenezumab consists of approximately 28 issued patents and 72
pending patent applications in 35 countries. With respect to the patent family directed to a humanized IgG4 antibody, we own approximately three issued U.S. patents and one pending U.S. patent applications. The PCT patent filing date for such
humanized IgG4 antibody patent family is July&nbsp;13, 2007. The issued patents from this patent family, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are expected to expire in 2027, excluding any additional
term for patent term adjustments or patent term extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-24 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for ACI-24 includes composition of matter claims (including claims directed to the ACI-24 antigenic construct) claims
directed to treating certain indications using ACI-24 including AD, and claims directed to using ACI-24 to induce an immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
patent portfolio for ACI-24 consists of approximately 19 issued patents and 15 pending patent applications in 31 countries. With respect to the U.S., we own two issued U.S. patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents in this patent portfolio claim the benefit of a PCT application with a filing date of December&nbsp;8, 2006. The issued patents in
this patent portfolio, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are expected to expire in 2026, excluding any additional term for patent term adjustments or patent term extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-35 </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio
for ACI-35 includes composition of matter claims (including claims directed to the ACI-35 antigenic peptide and a pharmaceutical composition comprising such an antigenic peptide), claims directed to treating certain indications using ACI-35
including AD, and claims directed to using ACI-35 to induce an immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for ACI-35 consists of approximately
seven issued patents and 23 pending patent applications in 28 countries. With respect to the U.S., we own one issued U.S. patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
patents in this patent portfolio claim the benefit of a PCT application with a filing date of April&nbsp;1, 2010. The issued patents in this patent portfolio, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are
expected to expire in 2030, excluding any additional term for patent term adjustments or patent term extensions. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
manufacturing and supply of the clinical study materials are currently done in collaboration with our collaboration partners (<I>e.g.</I>, Genentech in the case of crenezumab and anti-tau antibodies and Piramal Imaging in the case of tau PET
imaging) or contract manufacturing organizations (<I>e.g.</I>, for ACI-35 and ACI-24) for the supply of raw materials, drug substances and drug products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an established standard operating procedure to properly select the contract manufacturing organization to which the manufacturing
tasks will be assigned. In the assessment, we consider the availability of the technical skills necessary to support the project, the business and commercial aspects related to the collaboration and the compliance of our providers with local and
international regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Partners and Contract Manufacturing Organizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech, a leading biotech company with extensive experience in developing, producing and distributing products worldwide from pre-clinical
to commercial stages of development, manufactures and supplies clinical study materials for crenezumab and anti-tau antibodies. Tau-PET imaging compounds are produced in collaboration with Piramal, a well-established Indian company with a strong
chemical background supported by an India based contract manufacturing organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-24 and ACI-35 are produced by Bachem AG, an
experienced company based in Switzerland. Drug products for the advancement of ACI-24 are manufactured by Polymun, a company based in Austria with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant experience in developing and producing Liposomal formulations, while drug products for the advancement of ACI-35 are produced by Northern Lipids, a company based in Canada with a
strong and long experience in the field of liposomal formulation and production. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance with Governing Rules and Quality Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our collaboration partners and contract manufacturing organizations to manufacture our product candidates
are systematically audited by local authorities and occasionally inspected by competent authorities where the clinical studies are ongoing. The facilities where the commercial productions are performed must be approved by the FDA or other relevant
regulatory authorities pursuant to inspections that are conducted after we submit our NDA or comparable marketing applications. We perform periodic quality audits of the manufacturing facilities and contract manufacturing organizations to monitor
their compliance with the regional laws, regulations and applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. The scope of our audits also involves monitoring the ability of our
providers to maintain adequate quality controls and quality assurance systems including personnel qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After manufacturing, our
products are submitted to extensive characterization and quality control testing plans performed by using properly developed analytical methods that are qualified or validated; this ensures the accuracy of the results generated and provides evidence
of the quality of our products. In addition, our products are submitted to detailed and standardized stability programs aimed at demonstrating the stability during the storage period; this, while it guarantees the safety of the products, supports
the definition of a suitable supply chain that may encompass the distribution of the products in different continents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual framework
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established, with each contract manufacturing organization supplying drug substances or drug products, quality agreements
and master service agreements. Quality agreements define the quality standards required to develop, produce and supply the product. Quality agreements also define the responsibilities related to the collaboration with regards to the quality related
aspects. Master service agreements define the framework under which the quality agreements operate. Any failure to achieve and maintain compliance with the laws, regulations and standards, suspension of the manufacturing of our product candidates or
revoke of cGMP permissions which would adversely affect our business and reputation are defined in the master service agreements and quality agreements. The risk that any third-party providers may breach the agreements they have with us because of
factors beyond our control and the possibility they may also terminate or refuse to renew their agreements because of their own financial difficulties or business priorities, potentially at a time that is costly or otherwise inconvenient for us is
managed by us with constant investments toward maintaining reserve stocks and in-depth process know-how. The latter is supported by continuous in-house process development and production activities of small-scale/research grade materials that may
offer the chance to rapidly identify alternative contract manufacturers to which the manufacturing process could be transferred providing continuity for the clinical study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interaction with collaboration partners and contract manufacturing organizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, our partnership with contract manufacturing organizations is managed through an efficient project management platform in which teams
are formed with the representatives of each key function from both parties. Meetings occur either by telephone conferences aimed at updating short term actions or face-to-face when mid-long term development plans are discussed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Our Regulatory Department </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our regulatory department has a strong culture of regulatory compliance, operating under three guiding principles, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide constructive regulatory input for development products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ensure smooth regulatory approvals by anticipating hurdles. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Build confidence with regulators by continuous communication. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our regulatory department has
conducted four pre-IND meetings with the FDA (ACI-24 for AD and Down&#146;s syndrome, ACI-91 and tau Imaging) and three Scientific Advice meetings, which are the European equivalent of pre-IND meetings (with German BfArM, Swedish Medical Products
Agency and the European Medicines Agency). Since 2008, our regulatory department has filed a total of six clinical study applications in the EU (Germany, Austria, Denmark, Sweden and two in Finland) and one IND in the US. Given the seriousness of AD
and public pressure for new therapeutics, we consider regulatory agencies to be important stakeholders in our clinical studies. We are committed to working closely with world regulatory authorities to adhere to and achieve the highest levels of
safety in the most timely and efficient manner. The transparency we have achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA, are intended to facilitate expeditious execution through the
regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our regulatory department contains a quality assurance, or QA, function. As every quality issue ultimately
requires regulatory involvement and input, this approach is intended to lead to rapid resolution of issues and ensure full compliance to satisfy both the reviewers and the inspectors at the government health authorities. The mission of our QA
function is to establish, maintain and manage the corporate quality management system. Our regulatory department is charged with keeping our entire organization directly or indirectly involved in the clinical study application process in a state of
&#147;inspection readiness.&#148; To that end, we ensure that the study master file is complete and regularly updated. Our regulatory department is also tasked with generating our annual quality plan. The personnel tasked with QA have issued a set
of approximately 30 standard operating procedures and continuously train the relevant staff. Our QA personnel conduct regular audits, including in-person audits of the contract manufacturers, contract research organizations and laboratories
conducting primary end-point analysis. Other supervision by our QA function involves their service procedures standard operating procedures and periodic communication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Product Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical studies, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing,
among other things, of our product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. The U.S. Food and Drug Administration, or FDA, under the Federal Food, Drug, and Cosmetic Act, or
FDCA, regulates pharmaceutical products in the United States. The steps required before a drug may be approved for marketing in the United States generally include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the completion of pre-clinical laboratory tests and animal tests conducted under Good Laboratory Practice, or GLP, regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the submission to the FDA of an Investigational New Drug, or IND, application for human clinical testing, which must become effective before human clinical studies commence; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining a positive opinion from the Ethics Committee (Europe) / Institutional Review Board (United States) to commence study on human subjects; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of adequate and well-controlled human clinical studies to establish the safety and efficacy of the product candidate for each proposed indication and conducted in accordance with current Good Clinical
Practice, or cGCP, requirements; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the submission to the FDA of a New Drug Application, or NDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the NDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA Pre-Approval Inspection (PAI) of the manufacturing facilities at which the product is made to assess compliance with current Good Manufacturing Practice, or cGMP, requirements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s review and approval of an NDA prior to any commercial marketing or sale of the drug in the United States; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">having a parallel scientific advice from the European Medicines Agency or Health-Technology-Assessment body where the payors are involved at the outset (Phase 2), which is intended to facilitate the design of clinical
studies to primarily target populations with a high chance of obtaining reimbursement and accelerate the process of time-to-reimbursement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including fast track, priority review, accelerated approval, and breakthrough therapy designation, that are
intended to increase agency interactions, expedite or facilitate the process for reviewing drug candidates, and/or provide for initial approval on the basis of surrogate endpoints. We believe that one or more of our product candidates may qualify
for some of these expedited development and review programs. Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fast Track program is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new
drugs are eligible for Fast Track designation if they are designed to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of
the product and the specific indication for which it is being studied. The sponsor of a new drug may request the FDA to designate the drug as a Fast Track product at any time during the clinical development of the product. AD, for example, meets
both pre-requisites&#151;it is life-threatening and constitutes an unmet medical need. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is
submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees
upon submission of the first section of the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a Fast Track
program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective
therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an
application for a new drug designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug candidates studied for their safety and effectiveness in treating serious or
life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing
that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA
may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. Failure to conduct required post-approval trials, or the inability to confirm a clinical benefit during
post-marketing trials, may allow the FDA to withdraw the drug from the market on an expedited basis. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact
the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act of 2012 also amended the FDCA to
require FDA to expedite the development and review of a breakthrough therapy. A drug can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence
indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug be designated as a breakthrough therapy at any time during the clinical development
of the product. If so designated, FDA shall act to expedite the development and review of the product&#146;s marketing application, including by meeting with the sponsor throughout the product&#146;s development, providing timely advice to the
sponsor to ensure that the development program to gather nonclinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead
for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as
practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of
any approval is uncertain. Given this paradigm, AD has been given a Life Threatening Disease status by the FDA and therefore AD therapies are eligible for the expanded access program for investigational drugs and other pathways like Breakthrough
Therapy, Accelerated Approval and Priority Review. Also, a single well-designed, well-conducted pivotal clinical study could be sufficient to trigger market approval pending a successful PAI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre-clinical studies include laboratory evaluations of the product candidate, as well as animal studies to assess the potential safety and
efficacy of the product candidate. The results of the pre-clinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of the IND, which must become effective before clinical studies may be
commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the studies as outlined in the IND prior to that time. In this case, the IND sponsor and the
FDA must resolve any outstanding concerns before clinical studies can proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies involve the administration of the product
candidates to healthy volunteers or patients with the disease to be treated under the supervision of a qualified principal investigator. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Further, each clinical study must be
reviewed and approved by an independent institutional review board, or IRB, either centrally or individually at each institution at which the clinical study will be conducted. The IRB will consider, among other things, ethical factors, the safety of
human subjects and the possible liability of the institution. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. The FDA, the IRB or the clinical study sponsor may suspend
or terminate clinical studies at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Additionally, some clinical studies are overseen by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the
study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive climate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies are typically conducted in three sequential phases prior to approval, but the
phases may overlap. These phases generally include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase 1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phase 1 clinical studies represent the initial introduction of a product candidate into human subjects, frequently healthy volunteers. In Phase 1, the product candidate is usually tested for safety, including adverse effects, dosage
tolerance, absorption, distribution, metabolism, excretion and pharmacodynamics.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phase 2 clinical studies usually involve studies in a limited patient population to (1) evaluate the efficacy of the product candidate for specific indications, (2) determine dosage tolerance and optimal dosage and (3) identify
possible adverse effects and safety risks.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase 2 studies, the clinical study program will be expanded to Phase 3 clinical studies to further demonstrate clinical
efficacy, optimal dosage and safety within an expanded patient population at geographically dispersed clinical study sites.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 4 clinical studies are conducted after approval to gain additional experience from the treatment of
patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA in the form of post-market requirements or commitments.
Failure to promptly conduct any required Phase 4 clinical studies could result in withdrawal of approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of pre-clinical
studies and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information on the manufacture, composition and quality of the product, are submitted to the FDA in the form of an NDA
requesting approval to market the product. The NDA must be accompanied by a significant user fee payment. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for
approval and require additional pre-clinical, clinical or other studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that it generally takes 10 to 15 years, or possibly
longer, to discover, develop and bring to market a new pharmaceutical product in the United States. Several years may be needed to complete each phase, including discovery, preclinical, Phase 1, 2 or 3, or marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and
effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Recently, the Food and Drug
Administration Safety and Innovation Act, or FDASIA, which was signed into law on July&nbsp;9, 2012, amended the FDCA. FDASIA requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a
new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-phase 2 meeting or as may be agreed between the sponsor and FDA.
The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such
detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. FDA and the sponsor must reach agreement on the
PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of preparing and submitting an NDA is substantial. Under federal law, NDAs are subject to substantial application user
fees and the sponsor of an approved NDA is also subject to annual product and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establishment user fees. Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis.
According to the FDA&#146;s fee schedule, effective through September&nbsp;30, 2015, the user fee for each NDA application requiring clinical data is $2,335,200. PDUFA also imposes an annual product fee for drugs ($110,370), and an annual
establishment fee ($569,200) on facilities used to manufacture prescription drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.
Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the NDA submission has been submitted, the FDA has 60 days after submission of the NDA to conduct an initial review to determine whether
it is sufficient to accept for filing. Under the Prescription Drug User Fee Act, or PDUFA, the FDA sets a goal date by which it plans to complete its review. This is typically 12 months from the date of submission of the NDA application. The review
process is often extended by FDA requests for additional information or clarification. Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing
facility complies with cGMPs and may also inspect clinical study sites for integrity of data supporting safety and efficacy. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to
risk, benefit and interpretation of clinical study data. The FDA is not bound by the recommendations of an advisory committee, but generally follows such recommendations in making its decisions. The FDA may delay approval of an NDA if applicable
regulatory criteria are not satisfied and/or the FDA requires additional testing or information. The FDA may require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its API will be produced,
it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle
of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical study(ies), and/or other significant, expensive and
time-consuming requirements related to clinical studies, pre-clinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could
also approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market
studies or clinical studies. Such post-market testing may include Phase 4 clinical studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Special Protocol Assessment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and an IND sponsor may agree in writing on the design and size of clinical studies intended to form the primary basis of a claim of
effectiveness in an NDA. This process is known as a special protocol assessment, or SPA. Upon a specific request for a SPA by an IND sponsor, the FDA will evaluate the protocol. If a SPA agreement is reached, however, it is not a guarantee of
product approval by the FDA or approval of any permissible claims about the product. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of
the SPA agreement. In particular, the SPA agreement is not binding on the FDA if previously unrecognized public health concerns later come to light, other new scientific concerns regarding product safety or efficacy arise, the IND sponsor fails to
comply with the protocol agreed upon, or the relevant data, assumptions, or information provided by the IND sponsor when requesting a SPA agreement change, are found to be false statements or misstatements, or are found to omit relevant facts. A SPA
agreement may not be changed by the sponsor or the FDA after the study </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
begins except with the written agreement of the sponsor and the FDA, or if the FDA determines that a substantial scientific issue essential to determining the safety or effectiveness of the drug
was identified after the testing began. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is a disease or condition that affects fewer than 200,000 individuals in the US, or if it affects more than 200,000 individuals in the US there is no reasonable expectation that the cost of developing and making a drug product available in the
US for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting an NDA. After the FDA grants orphan product designation, the identity of the therapeutic agent and
its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax
advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the
orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug or biological product as defined by the FDA or if our drug candidate is
determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be
entitled to orphan product exclusivity. Orphan drug status in the European Union has similar but not identical benefits in that jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Clinical Trial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials (other than Phase 1 trials) of FDA-regulated products, including drugs, are required to register and disclose
certain clinical trial information. Information related to the product, comparator, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is made public as part of the registration.
Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of certain trials may be delayed until the new product or new indication being studied has been approved. However, there are
evolving rules and increasing requirements for publication of trial-related information, and it is possible that data and other information from trials involving drugs that never garner approval could in the future be required to be disclosed. In
addition, publication policies of major medical journals mandate certain registration and disclosures as a pre-condition for potential publication, even when this is not presently mandated as a matter of law. Competitors may use this publicly
available information to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new
application fees for supplemental applications with clinical data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution
of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the
manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on post-approval clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of FDA approval of the use of our drug candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term to be extended up to five years as compensation for patent
term effectively lost due to the FDA&#146;s pre-market approval requirements. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration
period is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any
time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension. Extensions are not granted as a matter of right and the extension must be applied for prior to expiration
of the patent and within a 60 day period from the date the product is first approved for commercial marketing. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or
restoration. Where a product contains multiple active ingredients, if any one active ingredient has not been previously approved, it can form the basis of an extension of patent term provided the patent claims that ingredient or the combination.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may apply for patent term restoration for some of our presently owned patents
to add patent life beyond their current expiration date, depending on the expected length of clinical studies and other factors involved in the submission of the relevant NDA; however, there can be no assurance that any such extension will be
granted to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The
specific scope varies, but fundamentally the FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity never previously approved by the
FDA either alone or in combination. For a new chemical entity that was issued orphan drug designation, the FDCA provides marketing exclusivity for the &#147;same drug&#148; and &#145;&#145;same indication&#146;&#146; for a period of seven years. A
drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the compound responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval.
However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing
NDA if new clinical investigations, other than bioavailability trials, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages, or
strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and
three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical trials and adequate and
well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Non-U.S. Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical studies, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product,
we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical studies or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above
with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods, as
described in greater detail below. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not
ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>European Union Drug Review Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA (which is comprised of the 28 Member States of the European Union plus Norway, Iceland and
Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations: the Community MA, which is issued by the European Commission through the Centralized
Procedure based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, a body of the EMA, and which is valid throughout the entire territory of the EEA; and the National MA, which is issued by the competent authorities of the
Member States of the EEA and only authorizes marketing in that Member State&#146;s national territory and not the EEA as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Centralized Procedure is compulsory for human medicines for the treatment of human
immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS), cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases; for veterinary medicines for use as growth or yield enhancers;
for medicines derived from biotechnology processes, such as genetic engineering; for advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines; and for officially designated &#145;orphan medicines&#146;
(medicines used for rare human diseases). The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical
innovation or for products which are in the interest of public health in the European Union. The National MA is for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for
marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be
approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of
which is selected by the applicant as the Reference Member State, or RMS. If the RMS proposes to authorize the product, and the other Member States do not raise objections, the product is granted a national MA in all the Member States where the
authorization was sought. Before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety
and efficacy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulation in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product development, the regulatory approval process, and safety monitoring of medicinal products and their manufacturers in the European Union
proceed in much the same manner as they do in the United States. Therefore, many of the issues discussed above apply similarly in the context of the European Union. In addition, drugs are subject to the extensive price and reimbursement regulations
of the various European Union Member States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case in the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant
regulatory controls. The Clinical Trials Directive 2001/20/EC, as amended (and which will be replaced from May 2016 or later by Regulation (EU) No 536/2014) provides a system for the approval of clinical studies in the European Union via
implementation through national legislation of the Member States. Under this system, approval must be obtained from the competent national authorities of the European Union Member States in which the clinical trial is to be conducted. Furthermore, a
clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application, which must be supported by an investigational medicinal product dossier with supporting information prescribed by
the Clinical Trials Directive and corresponding national laws of the Member States and further detailed in applicable guidance documents. A clinical trial may only be undertaken if provision has been made for insurance or indemnity to cover the
liability of the investigator or sponsor. In certain countries, the sponsor of a clinical trial has a strict (faultless) liability for any (direct or indirect) damage suffered by trial subjects. The sponsor of a clinical trial, or its legal
representative, must be based in the European Economic Area. European regulators and ethics committees also require the submission of adverse event reports during a study and a copy of the final study report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing approvals under the European Union regulatory system may be obtained through a centralized or decentralized procedure. The
centralized procedure results in the grant of a single marketing authorization that is valid for all (currently 28) European Union Member States and three EFTA members (Norway, Iceland, Liechtenstein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Regulation (EC) No.&nbsp;726/2004, as amended, the centralized procedure is mandatory
for drugs developed by means of specified biotechnological processes, advanced therapy medicinal products, drugs for human use containing a new active substance for which the therapeutic indication is the treatment of specified diseases, including
but not limited to acquired immune deficiency syndrome, neurodegenerative disorders, auto-immune diseases and other immune dysfunctions, as well as drugs designated as orphan drugs. The CHMP also has the discretion to permit other products to use
the centralized procedure if it considers them sufficiently innovative or they contain a new active substance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the marketing
authorization application, or MAA, the applicant has to properly and sufficiently demonstrate the quality, safety and efficacy of the drug. Under the centralized approval procedure, the CHMP, possibly in conjunction with other committees, is
responsible for drawing up the opinion of the EMA on any matter concerning the admissibility of the files submitted in accordance with the centralized procedure, such as an opinion on the granting, variation, suspension or revocation of a marketing
authorization, and pharmacovigilance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CHMP and other committees are also responsible for providing guidelines and have published
numerous guidelines that may apply to our product candidates. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of drug products and may include, among other things,
the pre-clinical studies required in specific cases; and the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse
reactions. Although these guidelines are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum timeframe for the evaluation of an MAA by the CHMP under the centralized procedure is 210 days after receipt of a valid
application. This period will be suspended until such time as the supplementary information requested by the CHMP, has been provided by the applicant. Likewise, this time-limit will be suspended for the time allowed for the applicant to prepare oral
or written explanations. When an application is submitted for a marketing authorization in respect of a drug which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the
applicant may request an accelerated assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time-limit for the centralized procedure
if it considers that it is no longer appropriate to conduct an accelerated assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the CHMP concludes that the quality, safety and
efficacy of the product are sufficiently proven, it adopts a positive opinion. This is sent to the European Commission which drafts a decision. After consulting with the Member States, the European Commission adopts a decision and grants a marketing
authorization, which is valid for the whole of the European Economic Area, or EEA. The marketing authorization may be subject to certain conditions, which may include, without limitation, the performance of post-authorization safety and/or efficacy
studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">European Union legislation also provides for a system of regulatory data and market exclusivity. According to Article 14(11) of
Regulation (EC) No.&nbsp;726/2004, as amended, and Article 10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved on the basis of a complete independent data package benefit from eight years
of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic (abbreviated) application. During the
additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity.
The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which,
during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
innovator is able to gain the period of data exclusivity, another company nevertheless could also market another version of the drug if such company obtained marketing authorization based on an
MAA with a complete independent data package of pharmaceutical test, pre-clinical tests and clinical studies. However, products designated as orphan medicinal products enjoy, upon receiving marketing authorization, a period of 10 years of orphan
market exclusivity. See also &#147;&#151;Orphan Drug Regulation&#148; below. Depending upon the timing and duration of the EU marketing authorization process, products may be eligible for up to five years&#146; supplementary protection
certification, or SPC, pursuant to Regulation (EC) No.&nbsp;469/2009. Such SPCs extend the rights under the basic patent for the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional rules apply to medicinal products for pediatric use under Regulation (EC) No.&nbsp;1901/2006. Potential incentives include a
six-month extension of any supplementary protection certificate granted pursuant to Regulation (EC) No.&nbsp;469/2009, but not in cases in which the relevant product is designated as orphan medicinal products pursuant to Regulation (EC)
No.&nbsp;141/2000, as amended. Instead, medicinal products designated as orphan medicinal product may enjoy an extension of the ten-year market exclusivity period granted under Regulation (EC) No.&nbsp;141/2000 to twelve years subject to the
conditions applicable to orphan drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan Drug Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, Regulation (EC) No.&nbsp;141/2000, as amended, states that a drug will be designated as an orphan drug if its sponsor
can establish: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the Community when the application is
made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in
the European Union would generate sufficient return to justify the necessary investment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, that the drug will be of significant
benefit to those affected by that condition. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No.&nbsp;847/2000 sets out further provisions for
implementation of the criteria for designation of a drug as an orphan drug. An application for the designation of a drug as an orphan drug must be submitted at any stage of development of the drug before filing of a marketing authorization
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a European Union-wide community marketing authorization in respect of an orphan drug is granted or if all the European
Union Member States have granted marketing authorizations in accordance with the procedures for mutual recognition, the European Union and the Member States will not, for a period of 10 years, accept another application for a marketing
authorization, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication, in respect of a similar drug. This period may however be reduced to six years if, at the
end of the fifth year, it is established, with respect to the drug concerned, that the criteria for orphan drug designation are no longer met, in other words, when it is shown on the basis of available evidence that the product is sufficiently
profitable not to justify maintenance of market exclusivity. Notwithstanding the foregoing, a marketing authorization may be granted, for the same therapeutic indication, to a similar drug if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder of the marketing authorization for the original orphan drug has given its consent to the second applicant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder of the marketing authorization for the original orphan drug is unable to supply sufficient quantities of the drug; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the second applicant can establish in the application that the second drug, although similar to the orphan drug already authorized, is safer, more effective or otherwise clinically superior. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other incentives available to orphan drugs in the European Union include financial incentives
such as a reduction of fees or fee waivers and protocol assistance. Orphan drug designation does not shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Manufacturing and Manufacturers&#146; License </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Directive 2003/94/EC, as transposed into the national laws of the Member States, the manufacturing of investigational medicinal
products and approved drugs is subject to a separate manufacturer&#146;s license and must be conducted in strict compliance with cGMP requirements, which mandate the methods, facilities, and controls used in manufacturing, processing, and packing of
drugs to assure their safety and identity. Manufacturers must have at least one qualified person permanently and continuously at their disposal. The qualified person is ultimately responsible for certifying that each batch of finished product
released onto the market has been manufactured in accordance with cGMP and the specifications set out in the marketing authorization or investigational medicinal product dossier. cGMP requirements are enforced through mandatory registration of
facilities and inspections of those facilities. Failure to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost revenues, and subject the applicant to potential legal or regulatory action,
including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Wholesale Distribution and License </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Directive 2001/83/EC, the wholesale distribution of medicinal products is subject to the possession of an authorization to engage
in activity as a wholesaler in medicinal products. Possession of a manufacturing authorization includes authorization to distribute by wholesale the medicinal products covered by that authorization. The distribution of medicinal products must comply
with the principles and guidelines of good distribution practices, or GDP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Advertising </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, the promotion of prescription medicines is subject to intense regulation and control, including EU and national
legislation as well as self-regulatory codes (industry codes). Advertising legislation inter alia includes a prohibition on direct-to-consumer advertising. All prescription medicines advertising must be consistent with the product&#146;s approved
summary of products characteristics, and must be factual, accurate, balanced and not misleading. Advertising of prescription medicines pre-approval or off-label is not allowed. Some jurisdictions require that all promotional materials for
prescription medicines be subjected to either prior internal or regulatory review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Regulatory Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A marketing authorization holder, or MAH, for a medicinal product is legally obliged to fulfill a number of obligations by virtue of its status
as an MAH. The MAH can delegate the performance of related tasks to third parties, such as distributors or marketing partners, provided that this delegation is appropriately documented and the MAH maintains legal responsibility and liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of an MAH include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Manufacturing and batch release</I>&#151;MAHs should guarantee that all manufacturing operations comply with relevant laws and regulations, applicable good manufacturing practices, with the product specifications and
manufacturing conditions set out in the marketing authorization and that each batch of product is subject to appropriate release formalities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Availability and continuous supply</I>&#151;Pursuant to Directive 2001/83/EC, as transposed into the national laws of the Member States, the MAH
for a medicinal product and the distributors of the said medicinal product actually placed on the market in a Member State shall, within the limits of their </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
responsibilities, ensure appropriate and continued supplies of that medicinal product to pharmacies and persons authorized to supply medicinal products so that the needs of patients in the Member
State in question are covered. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Pharmacovigilance</I>&#151;MAHs are obliged to establish and maintain a pharmacovigilance system, including a qualified person responsible for oversight, submit safety reports to the regulators and comply with the
good pharmacovigilance practice guidelines adopted by the EMA. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advertising and promotion</I>&#151;MAHs remain responsible for all advertising and promotion of its products, including promotional activities by other companies or individuals on their behalf and in some cases must
conduct internal or regulatory pre-approval of promotional materials. Regulation in this area also covers interactions with healthcare practitioners and/or patient groups, and in some jurisdictions legal or self-regulatory obligations to disclose
such interactions exist. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Medical affairs/scientific service</I>&#151;MAHs are required to disseminate scientific and medical information on its medicinal products to healthcare professionals, regulators and patients. Legal representation and
distributor issues. MAHs are responsible for regulatory actions or inactions of their distributors and agents. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Preparation, filing and maintenance of the application and subsequent marketing authorization</I>&#151; MAHs must maintain appropriate records, comply with the marketing authorization&#146;s terms and conditions,
fulfill reporting obligations to regulators, submit renewal applications and pay all appropriate fees to the authorities. We may hold any future marketing authorizations granted for our product candidates in our own name, or appoint an affiliate or
a collaboration partner to hold marketing authorizations on our behalf. Any failure by an MAH to comply with these obligations may result in regulatory action against an MAH and ultimately threaten our ability to commercialize our products.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Price and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, the pricing and reimbursement mechanisms by private and public health insurers vary largely by country and even within
countries. The public systems reimbursement for standard drugs is determined by guidelines established by the legislator or responsible national authority. The approach taken varies by Member State. Some jurisdictions operate positive and negative
list systems under which products may only be marketed once a reimbursement price has been agreed. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits and may limit or restrict
reimbursement. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products and some of EU countries require
the completion of studies that compare the cost-effectiveness of a particular product candidate to currently available therapies in order to obtain reimbursement or pricing approval. Special pricing and reimbursement rules may apply to orphan drugs.
Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for reimbursement may come
with cost, use and often volume restrictions, which again can vary by country. In addition, results based rules of reimbursement may apply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws restrict certain business practices
in the biopharmaceutical industry. These laws include, but are not limited to, anti-kickback, false claims, data privacy and security, and transparency statutes and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration, directly or indirectly, to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare
programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply
to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities
from prosecution, the exceptions and safe harbors are drawn narrowly, and our practices may not in all cases meet all of the criteria for a statutory exception or safe harbor protection. Practices that involve remuneration that may be alleged to be
intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe
harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts
have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Patient Protection and
Affordable Care Act as amended by the Health Care and Education Reconciliation Act, or collectively, PPACA, amended the intent requirement under the Anti-Kickback Statute and criminal healthcare fraud statutes (discussed below) such that a person or
entity no longer needs to have actual knowledge of the statute or the specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below). Further, the civil monetary penalties statute imposes penalties against any person or entity
that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal false claims laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a
false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a
modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been
prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to
be submitted because of the companies&#146; marketing of the product for unapproved, and thus non-covered, uses. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created new federal criminal statutes that prohibit
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits, items or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our
business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually
identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates&#151;independent contractors or agents of covered entities that receive or obtain protected
health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition,
state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the PPACA also included the federal Physician Payments Sunshine Act, which requires
that certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report information related to certain
payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain
ownership and investment interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many states have similar healthcare
statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Certain states require the posting of information relating to clinical studies,
pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual medical or health professionals and track and report gifts and other payments made to physicians and other
healthcare providers. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or
administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion of products from reimbursement under government programs, contractual damages, reputational harm, administrative burdens, diminished profits and future
earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products will be sold in a foreign country, we may
be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting
of payments or transfers of value to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Coverage, Pricing and Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both domestic and foreign markets, our sales of any approved products will depend in part on the availability of coverage and adequate
reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. Patients who are prescribed treatments for their conditions and providers performing
the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products, if approved, unless coverage is provided and reimbursement is adequate to cover a
significant portion of the cost of our products. Sales of our products will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by third-party payors. These third-party payors
are increasingly focused on containing healthcare costs by challenging the price and examining the cost-effectiveness of medical products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, significant uncertainty exists as to the coverage and reimbursement status of newly approved healthcare product candidates. The
market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#146; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement.
The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict
patient access to a branded drug when a less costly generic equivalent or other alternative is available. Because each third-party payor individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a
time-consuming, costly and sometimes unpredictable process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval would be obtained, and we may
need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. This process could delay the market acceptance of any product and could have a negative effect on our future revenues and operating
results. We cannot be certain that our product candidates will be considered cost-effective. Because coverage and reimbursement determinations are made on a payor-by-payor basis, obtaining acceptable coverage and reimbursement from one payor does
not guarantee the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company will obtain similar acceptable coverage or reimbursement from another payor. If we are unable to obtain coverage of, and adequate reimbursement and payment levels for, our product
candidates from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our
products and impact our profitability, results of operations, financial condition and future success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in many foreign
countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of
foreign products that compete with our own products, which could negatively impact our profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory
changes to the healthcare system that could affect our future results of operations as we begin to directly commercialize our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, there have been and continue to be a number of initiatives at the U.S. federal and state level that seek to reduce healthcare
costs. Initiatives to reduce the federal deficit and to reform healthcare delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative
benefits, controls on healthcare spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing groups, price controls on pharmaceuticals and other
fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit or eliminate our spending on development projects and affect our ultimate profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, PPACA was signed into law. PPACA has the potential to substantially change the way healthcare is financed by both governmental
and private insurers. PPACA, among other things, established an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents; revised the methodology by which rebates owed by
manufacturers for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to
utilization of certain injectable outpatient drugs, as well as prescriptions of individuals enrolled in Medicaid managed care organizations; required manufacturers to offer 50% point-of-sale discounts on negotiated prices of applicable brand drugs
to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and implemented payment system reforms including a national pilot program on payment
bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, there may continue to be additional proposals relating to the reform of the United States healthcare system, some of which
could further limit the prices we are able to charge for our products candidates, or the amounts of reimbursement available for our product candidates. If future legislation were to impose direct governmental price controls and access restrictions,
it could have a significant adverse impact on our business. Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. Some states have implemented, and other states are considering, price
controls or patient access </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constraints under the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. Due to the
volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy actions, which may include cost containment and healthcare reform measures. Such policy
actions could have a material adverse impact on our profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the recently enacted federal Drug Supply Chain Security Act
imposes new obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new federal legislation, manufacturers will be required to provide certain information
regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. Further, under this new legislation, manufacturers
will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or
which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Physician Payment Sunshine Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Physician Payment Sunshine Act requires most pharmaceutical manufacturers to report annually to the Secretary of HHS any and all financial
arrangements, payments, or other transfers of value made by that entity to physicians and teaching hospitals. The payment information is made publicly available in a searchable format on a CMS website. Over the next several years, we will need to
dedicate significant resources to establish and maintain systems and processes in order to comply with these regulations. Failure to comply with the reporting requirements can result in significant civil monetary penalties. Similar laws have been
enacted or are under consideration in foreign jurisdictions, including France which has adopted the Loi Bertrand, or French Sunshine Act, which became effective in 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental, Health and Safety Laws and Regulations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations and permitting requirements, including those governing
laboratory procedures, decontamination activities and the handling, transportation, use, remediation, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, and the
risk of injury, contamination or noncompliance with environmental, health and safety requirements cannot be eliminated. Although compliance with such laws and regulations and permitting requirements has not had a material effect on our capital
expenditures, earnings or competitive position, environmental, health and safety laws and regulations and permitting requirements have tended to become increasingly stringent and, to the extent legal or regulatory changes occur in the future, they
could result in, among other things, increased costs to us or the impairment of our research, development or production efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2015, we employed 55 employees, 10 of whom were part-time employees. 29 of our employees hold Ph.D. degrees and 15
hold M.Sc. degrees. Our 55 employees are from over 20 countries. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations
to be good. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
lease approximately 10,700 square feet of space at the Innovation Park of the EPFL (&Eacute;cole Polytechnique F&eacute;d&eacute;rale Lausanne), Switzerland. This property serves as our corporate headquarters, our research facility and laboratories.
We believe that using the EPFL facilities instead of building our own infrastructure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
helps us to maximize the value of our research and development capital and make efficient use of our funds as we continue to build and develop our pipeline. We believe that our existing facility
is sufficient to meet our current needs and that suitable additional space is available as and when needed in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we
may become involved in legal proceedings that arise in the ordinary course of business. During the period covered by the financial statements contained herein, we have not been a party to or paid any damages in connection with litigation that has
had a material adverse effect on our financial position. No assurance can be given that future litigation will not have a material adverse effect on our financial position. When appropriate in management&#146;s estimation, we may record reserves in
our financial statements for pending litigation and other claims. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 13, 2014, the USPTO declared an interference involving us, Genentech and AbbVie. Our U.S. Patent Nos. 7,772,375 and 7,892,544,
which relate to crenezumab, and AbbVie&#146;s U.S. Patent Appl. No. 13/188,034 are implicated in this interference. On September 24, 2015, the interference proceeded to the priority phase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 15, 2014, AbbVie filed an opposition in the European Patent Office against our EP2361638 patent, which relates to crenezumab. On
that same day, we and Genentech filed an opposition in the European Patent Office against AbbVie&#146;s EP1976877 patent. Oral argument in both proceedings currently is scheduled for March 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance as to the outcome of the interference and opposition proceedings, but if we and Genentech are unsuccessful in any of
these pending proceedings they could result in a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information on the risks associated with these proceedings, see the section titled &#147;Risk Factors&#151; Risks Related to
Intellectual Property&#151;We and Genentech are parties to interference proceedings that relate to crenzumab, and we may be involved in other proceedings or lawsuits to protect or enforce our patents or the patents of our licensors, any of which
could be expensive, time consuming, and unsuccessful, and may ultimately result in our loss of intellectual property.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_15"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers, Other Key Employees and Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about our executive officers, other key employees, directors and director nominees, including their
ages, as of October&nbsp;21, 2015. The term of each of our directors is one year and, accordingly, will expire one year from the date of our 2015 annual shareholder meeting held on April&nbsp;14, 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:13.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:48.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Initial&nbsp;Year&nbsp;of<BR>Appointment</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrea Pfeifer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director Nominee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andreas Muhs, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Pavey, CFA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fabien Monin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Administrative Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Key Employees</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Barth, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director of Development</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David A. Lowe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Deputy Chief Scientific Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin Velasco</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hans-Beat G&uuml;rtler</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Detlev Riesner, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mathias Hothum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Friedrich von Bohlen und Halbach</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Director Nominee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Bollmann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director Nominee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current business addresses for our executive officers, other key employees, directors and
director nominee is AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Andrea Pfeifer, Ph.D., Co-Founder, Chief Executive Officer</B><B> and Director Nominee:</B> Dr.&nbsp;Pfeifer co-founded AC Immune in April
2003, and has agreed to serve as a director on our board effective upon completion of this offering. Prior to founding us, Dr.&nbsp;Pfeifer was head of Nestl&eacute;&#146;s Global Research in Lausanne, Switzerland. While at Nestl&eacute;, she led
the scientific development of the first Functional Food, LC1, and one of the first Cosmoceutical products in a joint venture with L&#146;Oreal, Inn&eacute;ov Fermet&eacute;. She also co-founded the Nestl&eacute; Venture Capital Fund, a Life Sciences
corporate venture fund. She serves as chairwoman of Investment Fund BioMedInvest, Basel and AB2 Bio, Lausanne and is a member of the Supervisory Board of Symrise AG, Holzminden. Dr.&nbsp;Pfeifer is a member of the CEOi Initiative on Alzheimer&#146;s
Disease. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Pfeifer holds a Ph.D. in Toxicology, Cancer Research from the University of W&uuml;rzburg, Germany. She continued
with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, Maryland. Dr.&nbsp;Pfeifer is a registered toxicologist and pharmacist. She received her habilitation from the
University of Lausanne, Switzerland and is also an honorary professor at the Ecole Polytechnique F&eacute;d&eacute;rale de Lausanne (EPFL). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Andreas Muhs, Ph.D., Chief Scientific Officer</B><B>:</B> Dr.&nbsp;Muhs has served as our Chief Scientific Officer since 2005. Prior to
joining AC Immune in 2005, he was responsible for the development of the cardiac stem cell-based program to treat myocardial infarction, including worldwide pre-clinical program collaborations and technology transfers at ViaCell Inc., Cambridge, MA.
Prior to ViaCell Inc., he was the Director of Pharmacology and Histology at Cardion AG where he developed research projects with translation into clinical applications in the fields of heart and circulation, angiogenesis and immunology and based on
gene-, protein- and stem cell therapies. Dr.&nbsp;Muhs holds a Ph.D. in Biology from the University D&uuml;sseldorf, Germany, where he worked on regulation of endothelial barrier functions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>George Pavey, CFA, Chief Financial Officer</B><B>:</B> Mr.&nbsp;Pavey has served as our Chief
Financial Officer since July 2015. Before joining AC Immune in 2015, Mr.&nbsp;Pavey was an independent financial advisor to a broad range of private and public companies from June 2013 to July 2015. Between 1991 and 2012, Mr.&nbsp;Pavey was an
investment banker at various financial institutions including Credit Suisse, UBS and HSBC. His most recent role at Credit Suisse was that of Co-Head of the Global Markets Solutions Group for Asia-Pacific at Credit Suisse where he was responsible for
Credit Suisse&#146;s equity and debt capital markets businesses and structured products business across Asia-Pacific. He has a degree in Bachelor of Arts from the Richard Ivey School of Business, Canada. He is also a Chartered Financial Analyst.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jean-Fabien Monin, Chief Administrative Officer</B><B>:</B> Mr.&nbsp;Monin was nominated Chief Administrative Officer in July 2015
following his role as our Chief Financial Officer from March 2009 to July 2015. Prior to AC Immune, he held several positions during his tenure of 14 years at bioM&eacute;rieux, a leading international <I>in vitro</I> diagnostics group, culminating
in his nomination as Chief Financial Officer. His last position was CFO of bioM&eacute;rieux Central Europe based in Vienna, Austria from December 2006 to March 2009. Mr.&nbsp;Monin holds a Masters in Finance and International Business from the
University of Paris-Dauphine, France. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Key Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Wolfgang Barth, Ph.D., Director of Development</B><B>:</B> Dr.&nbsp;Barth has served as our Director of Development since June 2010. Prior
to joining AC Immune, he was the Head of Development at TRIN-Pharma. Previous to TRIN-Pharma, Dr.&nbsp;Barth was at Bayer Healthcare, where he was the responsible project leader of numerous preclinical and clinical development projects. The most
important project was the development of the PDE5 inhibitor Levitra which he led from the start of preclinical development until market launch. Wolfgang Barth holds a Ph.D. in Chemistry from the University of Marburg and received a NATO stipend for
a postdoctoral staff position at the Ohio State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>David A. Lowe, Ph.D., Deputy Chief Scientific Officer</B><B>:</B>
Dr.&nbsp;Lowe has served as our Deputy Chief Scientific Officer since January 2014 and leads our Parkinson&#146;s Disease Therapeutics and Imaging programs. Previously, Dr.&nbsp;Lowe was the Chief Scientific Officer at PsychoGenics Inc., Chief
Scientific Officer at Memory Pharmaceuticals (acquired by Roche), Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group in Boston, president, CEO and director of Envivo Pharmaceuticals (now Forum Pharmaceuticals), Vice
President and therapeutic area head at Roche Bioscience in Palo Alto, Vice President and global therapeutic area head at Bayer AG, and head of CNS Biology and deputy head of CNS Research at Sandoz Ltd (now Novartis). Dr.&nbsp;Lowe is also an adjunct
professor of Neuroscience at the Icahn School of Medicine in New York City. He received his Ph.D. in Neurobiology from the University of Leeds, UK. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Martin
Velasco, Chairman and Director</B><B>:</B> Mr.&nbsp;Velasco has served on our board of directors since December 2003.&nbsp;Martin Velasco is an entrepreneur and Business Angel with extensive experience in the IT, medical and biotech areas.&nbsp;He
serves on the board of directors or advisory board of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive technology (ART) company and World Economic Forum Technology
Pioneer 2008, as Founder and Chairman of Sumerian, an Analytics company transforming Big Data into business focused IT intelligence, as Chairman of the Supervisory Board of Cocomore, a digital communications agency&nbsp;and IT services firm, as
Board Member of Aridhia, a Health Informatics company, and as Board Member of Aleva Neurotherapeutics, a Deep Brain Stimulation (DBS) company. Martin is also the Founder and Chairman of Infantia Foundation, a philanthropic organization aiding
children in the developing world. He is a member of the Board of BlueOrchard, the leading private microfinance investment advisory company, member of the Strategic Advisory Board of the EPFL, Vice President of the Board of the Foundation
EPFL<B>+</B> and Vice Chairman of the European Tech Tour Association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Hans-Beat G&uuml;rtler, Director: </B>Mr.&nbsp;G&uuml;rtler has served on our board of
directors since August 2003. Mr.&nbsp;G&uuml;rtler brings extensive management, marketing and finance experience from more than 30 years in Ciba-Geigy and Novartis&#146; agricultural and animal health businesses, both in Switzerland and abroad.
Until 2002, he was CEO of Novartis&#146; Animal Health business. Mr.&nbsp;G&uuml;rtler also has extensive experience in Mergers and Acquisitions and serves as Board Member in various companies, among them publicly traded Basilea Pharmaceutica
(Switzerland) and Implenia (Switzerland). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Detlev H. Riesner, Ph.D., Director: </B>Prof. Riesner has served on our board since
2004. He held the Chair of Biophysics at the Heinrich-Heine-University in D&#252;sseldorf, Germany from 1980 to 2007. He has also held the positions of Dean of the Science Faculty and Vice-President of Research. In 2007 he became member of the
university&#146;s Board of Trustees. He worked as a research fellow at Princeton University and held a guest professorship at the department of Neurology at the University of California, San Francisco. Prof. Riesner is a co-founder of Qiagen N.V.,
Netherlands, was a member and from 1999 to 2014 chairman of the Supervisory Board. He was also a member of the supervisory boards of NewLab Bioquality AG, Erkrath, Direvo AG, K&#246;ln, and Alantos AG, Heidelberg. Prof. Riesner was a member of the
scientific advisory boards of the Friedrich-L&#246;ffler-Institut, Isle of Riems, and PrioNet and APRI, both Canada. He received the Max-Planck Forschungspreis for International Co-operation and the Bundesverdienstkreuz 1. Klasse from the
Bundespresident of Germany. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mathias Hothum, Ph.D., Director:</B> Dr.&nbsp;Hothum has served on our board of directors since April
2013. He is managing director of Dievini, a life science investment fund. He holds a Ph.D. in Economics from the University of Magdeburg, Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Friedrich von Bohlen und Halbach, Ph.D., Director: </B>Dr.&nbsp;von Bohlen<B></B> has served on our board since October 2015. He is
co-founder and managing director of dievini Hopp BioTech holding GmbH &amp; Co. KG. He brings extensive industry experience from Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG, founded LION bioscience AG in 1997 (now SYGNIS Pharma AG) and
served as the company&#146;s CEO. Dr. von Bohlen is a board member of various companies of the dievini portfolio and Chairman of Apogenix AG, CureVac AG and Molecular Health GmbH. He holds a PhD in Neurobiology from the Swiss Federal Institute of
Technology in Zurich, Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Director Nominee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Peter Bollmann, Ph.D., Director Nominee:</B> Dr. Bollmann will join our board in December 2015. He has extensive management and finance
experience in Switzerland and abroad as CEO, CFO and member of the board. His broad industry experience embraces biotechnology and medical technology including Cytos Biotechnology and Prionics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors After This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is composed of five members and will be expanded to a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; members
upon completion of this offering. Each director is elected for a one-year term. The current members of our board of directors were appointed at a shareholders&#146; meeting held on April&nbsp;14, 2015 to serve until their successors are duly elected
and qualified. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be a foreign private issuer. As a result, in accordance with the NASDAQ stock exchange listing requirements,
we will rely on home country governance requirements and certain exemptions thereunder rather than relying on the stock exchange corporate governance requirements. For an overview of our corporate governance principles, see &#147;Description of
Share Capital and Articles of Association.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, under the listing requirements and rules of NASDAQ, we are not required to have independent directors on our board
of directors, except to the extent that our audit and finance committee is required to consistent of independent requirements, subject to certain phase-in schedules. However, our board of directors has determined that, under current listing
requirements and rules of NASDAQ (which we are not subject to) and taking account any applicable committee independence standards,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are &#147;independent
directors.&#148; In making such determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances our board of directors deemed relevant in determining the
director&#146;s independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors will establish two separate committees prior to the consummation of this offering: an audit and finance committee and a compensation, nomination and governance committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Audit and Finance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit and finance committee, which is expected to consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, will assist our board of directors in overseeing our accounting and financial reporting processes
and the audits of our financial statements. In addition, the audit and finance committee will be directly responsible for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve as Chairman of the committee. The audit and finance committee will consist exclusively of members of our supervisory board who are financially literate, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is considered an &#147;audit committee financial expert&#148; as defined by the
SEC. Our board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; satisfies the &#147;independence&#148; requirements set forth in Rule 10A-3 under the Exchange Act and that upon the
consummation of this offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will satisfy such &#147;independence&#148; requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit and finance committee will be governed by a charter that complies with NASDAQ rules. Upon the completion of this offering, the audit
and finance committee has the responsibility to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and assess the qualifications, independence, performance and effectiveness of the independent auditor; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review the scope of the prospective audit by the independent auditor, the estimated fees, and any other matters pertaining to the audit; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approve any audit and non-audit services proposed to be provided by the independent auditor to ensure independent auditor independence; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and assess the independent auditor&#146;s report, management letters and take notice of all comments of the independent auditor on accounting procedures and systems of control, and review the independent
auditor&#146;s reports with management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be responsible for the resolution of disagreements between the management and the independent auditor; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and evaluate the lead audit partner of the independent audit team and confirm and evaluate their rotation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review, discuss with the chief financial officer and the independent auditor and approve (i)&nbsp;the annual and quarterly financial statements, (ii)&nbsp;reports intended for publication and (iii)&nbsp;any other
financial statements intended for publication to consider significant financial reporting issues and judgments made in connection with the preparation of our financial statements, including any significant changes in our selection or application of
accounting principles; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review with the management, personnel responsible for the design and implementation of the internal audit function and the independent auditor in separate meetings any analysis or other written communication prepared by
the management and/or the independent auditor setting forth significant financial reporting issues and judgments made in connection with the preparation of the financial statements, including critical accounting policies, the effect of regulatory
and accounting initiatives, as well as off-balance sheet transactions and structures on our financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and approve our quarterly financial statements for the first three quarters of each calendar year and the corresponding financial results releases; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review in cooperation with the independent auditor and the management whether the accounting principles applied are appropriate in view of our size and complexity; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">periodically review our policies and procedures for risk management and assess the effectiveness thereof including discussing with management our major financial risk exposures and the steps that have been taken to
monitor and control such exposures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discuss with management and external advisors any legal matters that may have a material impact on our financial statements and any material reports or inquiries from regulatory or governmental agencies which could
materially impact our contingent liabilities and risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review our disclosure controls and procedures and internal control over financial reporting which shall include significant deficiencies and material weaknesses in the design or operation of internal controls over
financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish procedures for the receipt, retention and treatment of complaints received regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submission by employees of
concerns regarding questionable accounting or auditing matters; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommend to the board whether to approve and ratify any related person transaction in accordance with our related person transaction policy. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit and finance committee will meet as often as it determines is appropriate to carry out its responsibilities, but in any event will
meet at least four times per year. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation, Nomination and Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation, nomination and governance committee, which is expected to consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, will assist our board of
directors in overseeing our cash compensation and equity award recommendations for our executive officers along with the rationale for such recommendations, as well as summary information regarding the aggregate compensation provided to our
executive officers. Swiss law requires that we adopt a compensation committee, so in accordance with NASDAQ Listing Rule 5615(a)(3), we will follow home country requirements with respect to the compensation, nomination and governance committee. As a
result, our practice will vary from the requirements of NASDAQ Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees, and from the independent director
oversight of director nominations requirements of NASDAQ Listing Rule 5605(e). We will be subject to the Swiss Ordinance Against Executive Compensation (&#147;Say on Pay&#148; Rule). This means that the compensation of our board of directors and
Executive Officers must be presented by the board of directors to our shareholders and our shareholders must vote on the proposed compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this committee will also be responsible for director and board committee nominations as well as reviewing and amending, if
required, our corporate governance framework and guidelines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct, that is applicable to all of our
employees, executive officers and directors. Following the completion of this offering, the Code of Conduct will be available on our website www.acimmune.com. The audit and finance committee of our board of directors will be responsible for
overseeing the Code of Conduct and will be required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be
disclosed on our website. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2014, the aggregate compensation accrued or paid to the members of our board of directors and our
executive officers for services in all capacities was CHF 1,637,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2014, the total payment made
to directors and executive officers under performance incentive plans was CHF 511,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount set aside or accrued by us to provide
pension, retirement or similar benefits to members of our board of directors or executive officers amounted to a total of CHF 96,000 in the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the
completion of this offering, we intend to cease issuing new grants under our existing equity incentive plans, which we refer to as the Prior Plans, and to adopt a new omnibus equity incentive plan under which we would have the discretion to grant a
broad range of equity-based awards to eligible participants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Prior Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2003, we have had four separate Prior Plans: Plan A, which was established in 2003/2004 and amended in June 2015; Plan
B, which was established in 2005; Plan C1, which was established in 2006; and Plan C2, which was also established in 2006 but which is intended specifically for members of our board of directors to purchase our common shares. Due to a change in the
taxation of options in 2013, we introduced a new Equity Incentive Plan in 2013. As at September&nbsp;30, 2015, there were 1,822 and 13,691 common shares underlying outstanding unvested options and vested options granted pursuant to our Prior Plans,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The original terms of our Stock Option Plan of 2005 (Plan C) contained a provision that would result in the automatic
acceleration of all unvested options upon the consummation of an initial public offering.&nbsp;Pursuant to a board resolution on October 13, 2015 the Stock Option Plan of 2005 was amended and the automatic acceleration feature was
removed.&nbsp;Instead, employees have the right, but not the obligation, to have their unvested options accelerated such that they vest immediately.&nbsp;A total of 442 options could be accelerated in the event this offering is completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, pursuant to a board resolution on October 13, 2015 all options which were granted to directors and executive officers in
connection with this offering will be accelerated upon consummation of this offering. This will result in the acceleration of a total of 517 unvested options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Under each of the Prior Plans, an option, which can only be granted with the approval of our board of directors,
is evidenced by an option agreement signed by the participant to indicate his or her acceptance of the option subject to the terms and conditions of the applicable Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Under Plans A, B and C1, options were granted to our directors, employees, advisors and agents. Under Plan C2, options
were granted only to selected members of our board of directors. Under the Equity Incentive Plan 2013, options were granted to our director, employees, advisors and agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Option Exercise Price</I>. With the exception of Plan A, the exercise price of all options
issued under the Prior Plans is CHF 36.37. The original exercise price for options issued under Plan A was CHF 232.965. However, this exercise price was amended in June 2015 with the approval of our board of directors to be CHF 36.37. As a result,
as at September&nbsp;30, 2015, all options outstanding under our Prior Plans have an exercise price of CHF 36.37. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Vesting
Period</I>. The vesting periods of options issued under our Prior Plans vary. The options granted under Plan A vested immediately but were subject to a four year lockup period. The options granted under Plan B vested over a four year period with 25%
of these options vested after one year of service and thereafter, 6.25% of the options granted vesting each quarter. Under Plan C1, the vesting period for options was four years with 25% of the options vesting each year. Under Plan C2, options were
immediately exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our board of directors has the authority to amend each of the Prior Plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
the beginning of the last fiscal year ended December 31, 2014, we granted our executive officers, in the aggregate, the right to acquire 500 shares at a price of CHF 2,000 per share for a period of two months after the commencement of employment
with us. At our sole discretion, we are permitted to repurchase such shares over a one year period as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">500 shares prior to October 15, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">375 shares prior to January 15, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">250 shares prior to April 15, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">125 shares prior to July 15, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price at which we are allowed to acquire the
shares, at our sole discretion, is the original purchase price of CHF 2,000 per share, plus 0.25% per month starting on July 15, 2016. Our right to repurchase the shares will lapse on the first day of trading of our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, since the beginning of the last fiscal year ended December 31, 2014, we have granted our executive officers, in the aggregate,
the right to acquire 787 shares at a price of CHF 36.37 per share. Contingent upon continued employment and approval of our Board of Directors, such options will vest as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">180 shares which became purchasable on July 1, 2015, on a monthly basis over a 24-month period but become fully exerciseable upon completion of the offering at a price of CHF 36.37 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">394 shares which will become purchasable on July 1, 2016, on a monthly basis over a 48-month period; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">213 shares which will become purchasable starting on July 1, 2017, on a monthly basis over a 48-month period. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_16"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information relating to the beneficial ownership of our common shares as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, as if the conversion of our preferred shares into common shares on a one-for-one basis had occurred, by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our executive officers, directors and director nominee; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all executive officers, directors and director nominee as a group. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of
this offering, all of our outstanding preferred shares will automatically be converted into common shares on a one-for-one basis and we will have only one class of shares issued and outstanding. All holders of our common shares will have the same
voting rights upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of common shares beneficially owned by each entity, person, executive
officer or director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which
the individual has sole or shared voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable
community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of outstanding common shares is computed on the basis of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, based on the
midpoint of the price range stated on the front cover of this prospectus. Common shares that a person has the right to acquire within 60 days of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not
deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all executive officers and directors as a group. Unless otherwise indicated below, the address for each
beneficial owner is AC Immune, EPFL Innovation Park, Building B, Lausanne. As at September 30, 2015, a total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our common shares were held by a total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. record holders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of common shares
beneficially owned before this offering is computed on the basis of common shares issued and outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. The
percentage of common shares beneficially owned after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares that will be issued and outstanding upon the completion of this offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Before&nbsp;This&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>After&nbsp;This&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent of Shares<BR>Beneficially Owned<BR>Assuming&nbsp;Full&nbsp;Exercise<BR>of Underwriters&#146;&nbsp;Over-<BR>Allotment&nbsp;Option</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:42.20pt; font-size:8pt; font-family:Times New Roman"><B>Shareholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>5% Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">dievini Hopp BioTech holding GmbH&nbsp;&amp; Co KG</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Varuma AG</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Executive Officers, Directors and Director Nominee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Andrea Pfeifer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Andreas Muhs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">George Pavey</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jean-Fabien Monin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Martin Velasco</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mathias Hothum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hans-Beat G&uuml;rtler</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Detlev Riesner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Friedrich von Bohlen und Halbach</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Peter Bollmann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">All executive officers, directors and director nominee as a group (10&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1% of the total issued and outstanding common shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_17"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of related party transactions we have entered into since January&nbsp;1, 2012 with any of our executive
officers, directors and holders of more than 10% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons, other than the compensation arrangements we describe under &#147;Management.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2013 Series D Preferred Shares Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we agreed to the terms of our Series D preferred share financing with certain of our existing shareholders, including dievini
Hopp BioTech holding GmbH&nbsp;&amp; Co GK, Varuma AG, Dr.&nbsp;Riesner and Dr.&nbsp;Andrea Pfeifer. These shareholders agreed to subscribe to a CHF 20&nbsp;million capital increase with an understanding that the capital increase would be executed
via two separate tranches on the same terms. Subsequently, we offered our shareholders the option to subscribe for 16,490 Preferred Series D Shares for CHF 1,212.90 each (in two tranches), and all shares were subscribed by current shareholders. On
December&nbsp;10, 2013, we entered into agreement with our shareholders and investors pursuant to which we agreed to issue 8,245 Series D preferred shares in exchange for a contribution of CHF 10&nbsp;million as a first tranche and an additional
8,245 Series D preferred shares in exchange for a contribution of CHF 10 million. The 8,245 Series D shares of the first tranche were issued on January&nbsp;7, 2014 for CHF 10&nbsp;million and the 8,245 Series D shares of the second tranche were
issued on July&nbsp;7, 2014 for CHF 10 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of our Series D preferred shares purchased by
our executive officers, directors and certain related parties and their affiliates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D&nbsp;Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D&nbsp;Preferred&nbsp;Shares&nbsp;Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">dievini Hopp BioTech GmbH &amp; Co KG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Varuma AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Andrea Pfeifer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Riesner(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Riesner acquired a total of 232 preferred shares as part of the Series D financing with 8 preferred shares being acquired by Dr.&nbsp;Riesner directly, 16 shares being acquired by Dr.&nbsp;Riesner&#146;s wife,
Hannelore Riesner, and 208 shares being acquired by Riesner Verwaltungs GmbH / Peter Esser. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all of our then-existing shareholders entered into a shareholders agreement in November 2013, which replaced a prior shareholders
agreement entered into in November 2008. The agreement entered into in November 2013 provided our shareholders with certain board nomination rights, preemptive rights, certain rights of first refusal and tag-along rights. The agreement was replaced
by a shareholders agreement entered into in October 2015 in connection with the Series E Private Placement. However, the October 2015 agreement will terminate in connection with this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
entered into a registration rights agreement in connection with the Series E Private Placement with certain of our existing shareholders and certain investors in the Series E Private Placement pursuant to which we granted them certain demand and
piggyback registration rights for the resale of the common shares held by them, as described below. The shareholders party to the registration rights agreement hold an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our common shares, representing approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the voting power of our common shares outstanding upon completion of this offering (assuming no
exercise of the underwriters&#146; over-allotment option). The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration rights described below will expire on the earlier to occur of (i)&nbsp;the fifth anniversary of the completion of the offering contemplated by this prospectus and (ii)&nbsp;the date
on which there are no remaining registrable securities held by the parties to the registration rights agreement. The registration rights agreement provides that we must pay certain registration expenses in connection with any demand, piggyback or
shelf registration. The registration rights agreement contains customary indemnification and contribution provisions. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Demand
Registration Rights </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the registration rights agreement, at any time after the date that is six months
after completion of the offering contemplated by this prospectus, or the trigger date, a shareholder or group of shareholders holding at least 10% of our outstanding common shares may request that we effect a registration under the Securities Act of
all or any portion of such requesting shareholders&#146; registrable securities. At least 10 business days prior to the anticipated filing date of the registration statement relating to such demand registration, we must give all other shareholders
party to the registration rights agreement notice of such requested registration. Within five business days of such notice, any of the other shareholders party to the registration rights agreement may request that we also effect the registration of
the registrable securities held by them. We will not be required to effect a registration of all such registrable securities unless the aggregate proceeds expected to be received from the sale of such registrable securities equals or exceeds
$10&nbsp;million or such lesser amount that constitutes all of the requesting shareholders&#146; registrable securities (<I>provided</I> that such lesser amount is at least $5&nbsp;million). In no event will we be required to effect more than two
demand registrations or underwritten take downs referred to under &#147;&#151;Shelf Registration Rights&#148; below. Depending on certain conditions, we may postpone a demand registration on two occasions during any period of twelve consecutive
months for up to 90 days. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the registration rights agreement, at any time after the trigger date, if we propose to register any of our
securities, whether or not for sale for our own account, we must give notice to the shareholders party to the registration rights agreement, and they will be entitled to certain piggyback registration rights allowing them to each their shares in the
registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, the holders of these shares are entitled to notice of the registration and to request that
we include their shares in the registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Shelf Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the registration rights agreement, at any time after the first anniversary of the completion of the offering
contemplated by this prospectus, if we are eligible to use a shelf registration statement, then a shareholder or group of shareholders holding at least 10% of our outstanding common shares may request that we effect a shelf registration on similar
terms as the demand registrations described above, except that offerings will be conducted as underwritten takedowns. We will only be required to effect one public offering from such shelf registration statement within any six month period, each of
which shall be deemed to constitute a demand registration for purposes of the number of demand registrations we are required to effect as described under &#147;&#151;Demand Registration Rights&#148; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to the consummation of this offering, we intend to adopt a new related person transaction policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification agreements with our executive officers and directors. The indemnification agreements and our Articles
of Association require us to indemnify our executive officers and directors to the fullest extent permitted by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to enter into employment agreements with certain of our executive officers in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_18"></A>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Swiss stock
corporation (<I>soci&eacute;t&eacute; anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute; &agrave; responsabilit&eacute; limit&eacute;e</I>) on February&nbsp;13, 2003
with our registered office and domicile in Basel, Switzerland. We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August&nbsp;25, 2003. Our domicile and registered office is in Ecublens,
Canton of Vaud, near Lausanne, Switzerland. Our head office is currently located at EPFL Innovation Park, Building B, Lausanne, Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share
Capital </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our share capital is divided into common shares and five categories of preferred
shares. Conditional upon the closing of this offering, all of our preferred shares will be converted into common shares on a one-for-one basis, effective upon the registration of the revised articles of association with the commercial register of
the Canton of Vaud, Switzerland. See &#147;&#151;Articles of Association.&#148; Upon the closing of this offering, giving effect to (i)&nbsp;the issuance of the common shares to be sold in this offering, (ii)&nbsp;the conversion of our preferred
shares into common shares on a one-for-one basis and (iii)&nbsp;our planned stock split, our issued fully paid-in share capital will consist of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; divided into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares with a nominal value of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each and no preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of Association </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
closing of this offering, we intend to adopt amended and restated articles of association which will become effective upon the closing of this offering and the registration of the revised articles of association with the commercial register of the
Canton of Vaud, Switzerland. When we refer to our articles of association in this prospectus, we refer to our amended and restated articles of association as they will be in force upon the closing of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Capital Increase, Authorized and Conditional Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, we may increase our share capital (capital-actions) with a resolution of the general meeting of shareholders (ordinary capital
increase) that must be carried out by the board of directors within three months of the general meeting in order to become effective. Under our articles of association, in the case of subscription and increase against payment of contributions in
cash, a resolution passed by an simple majority of the shares represented at the general meeting of shareholders regardless of abstentions or empty or invalid votes is required. In the case of subscription and increase against contributions in kind
or to fund acquisitions in kind, when shareholders&#146; statutory pre-emptive rights are withdrawn or where transformation of reserves into share capital is involved, a resolution passed by two-thirds of the shares represented at a general meeting
of shareholders and the absolute majority of the nominal amount of the shares represented is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, under the Swiss Code
of Obligations, or the CO, our shareholders, by a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal amount of the shares represented, may empower our board of
directors to issue shares of a specific aggregate nominal amount up to a maximum of &nbsp;&nbsp;&nbsp;&nbsp;% of the share capital in the form of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditional capital (<I>capital conditionnel</I>) for the purpose of issuing shares in connection with, among other things, (i)&nbsp;option and conversion rights granted in connection with warrants and convertible bonds
of the Company or one of our subsidiaries or (ii)&nbsp;grants of rights to employees, members of our board of directors or consultants or our subsidiaries or other persons providing services to the Company or a subsidiary to subscribe for new shares
(conversion or option rights); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorized capital (<I>capital-actions autoris&eacute;</I>) to be utilized by the board of directors within a period determined by the shareholders but not exceeding two years from the date of the shareholder approval.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pre-Emptive Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the CO, shareholders have pre-emptive rights (<I>droits de souscription</I>) to subscribe for new issuances of shares. With respect
to conditional capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have advance subscription rights (<I>droit de souscrire pr&eacute;alablement</I>) for the subscription of
conversion rights, convertible bonds or similar debt instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A resolution passed at a general meeting of shareholders by two-thirds
of the shares represented and the absolute majority of the nominal value of the shares represented may authorize our board of directors to withdraw or limit pre-emptive rights or advance subscription rights in certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If pre-emptive rights are granted, but not exercised, the board of directors may allocate the pre-emptive rights as it elects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our authorized share capital, the board of directors is authorized by our articles of association to withdraw or to limit the
pre-emptive rights of shareholders, and to allocate them to third parties or to us, in the event that the newly issued shares are used for the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the issue price of the new registered shares is determined by reference to the market price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for the acquisition of an enterprise, part(s) of an enterprise or participations, or for the financing or refinancing of any of such transactions, or in the event of share placement for the financing or re-financing of
such transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for purposes of broadening the shareholder constituency of the Company in certain financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing or registration
of new registered shares on domestic or foreign stock exchanges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for purposes of granting an over-allotment option of up to 20% of the total number of registered shares in a placement or sale of registered shares to the respective initial purchaser(s) or underwriter(s);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for raising of capital (including private placements) in a fast and flexible manner which probably could not be reached without the exclusion of the statutory pre-emptive right of the existing shareholders;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to the other
shareholders a takeover offer recommended by the board of directors, or for the defense of an actual, threatened or potential takeover bid, in relation to which the board of directors, upon consultation with an independent financial adviser retained
by it, has not recommended to the share-holders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for other valid grounds in the sense of Article 652b para. 2 of the CO. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our Authorized
Share Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, our board of directors is authorized at any time until December&nbsp;31, 2015 to
increase our share capital by a maximum aggregate amount of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; through the issuance of not more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares, which would have to be fully paid-in, with a nominal value of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in partial amounts are permitted. The board of directors has the power to determine the type of contributions, the issue price and
the date on which the dividend entitlement starts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is also authorized to withdraw or limit pre-emptive rights as
described above. This authorization is exclusively linked to the particular available authorized share capital set out in the respective article. If the period to increase the share capital lapses without having been used by the board of directors,
the authorization to withdraw or to limit the pre-emptive rights lapses simultaneously with such capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares to be sold in this offering will be issued out of our authorized share capital.
Accordingly, upon the consummation of this offering, our authorized but unissued share capital will decrease by the amount of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or by a larger amount, to the extent that any
over-allotment shares will be issued). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our Conditional Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital for Warrants and Convertible Bonds </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share capital may be increased by a maximum aggregate amount of CHF
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; through the issuance of not more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares, which would have to be fully paid-in, with a
nominal value of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each, by the exercise of option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries.
Shareholders will not have pre-emptive rights in such circumstances. The holders of convertible bonds are entitled to the new shares upon the occurrence of the applicable conversion feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When issuing convertible bonds, the board of directors is authorized to withdraw or to limit the advance right of shareholders to subscribe to
the convertible bond issuance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for the purpose of financing or refinancing the acquisition of enterprises, divisions thereof, or of participations or of newly planned investments of the Company; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the issuance occurs in domestic or international capital markets including private placements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the advance subscription rights are withdrawn, (i)&nbsp;the convertible bonds are to be issued at market conditions;
(ii)&nbsp;the term to exercise the option or conversion rights may not exceed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years as of the date of the convertible bond issue and twenty years for conversion rights; and
(iii)&nbsp;the exercise price for the new shares must at least correspond to the market conditions at the time of the convertible bond issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital for Equity Incentive Plans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share capital may, to the exclusion of the pre-emptive rights of shareholders, be increased by a maximum aggregate amount of CHF
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; through the issuance of not more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares, which would have to be fully paid-in, with a
nominal value of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each, by the exercise of option or conversion rights that have been granted to employees, members of the board of directors or consultants of the Company
or of one of our subsidiaries or other persons providing services to the Company or a subsidiary through one or more equity incentive plans created by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Uncertificated Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares are uncertificated securities (<I>droits-valeurs</I>, within the meaning of art. 973c of the CO) and, when administered by a
financial intermediary (<I>d&eacute;positaire,</I> within the meaning of the Federal Act on Intermediated Securities, &#147;FISA&#148;), qualify as intermediated securities (<I>titres interm&eacute;di&eacute;s</I>, within the meaning of the FISA).
In accordance with art. 973c of the CO, we will maintain a non-public register of uncertificated securities (<I>registre des droits-valeurs</I>). We may at any time convert uncertificated securities into share certificates (including global
certificates), one kind of certificate into another, or share certificates (including global certificates) into uncertificated securities. Following entry in the share register, a shareholder may at any time request from us a written confirmation in
respect of the shares. Shareholders are not entitled, however, to request the printing and delivery of certificates. We may print and deliver certificates for shares at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General Meeting of Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Ordinary/Extraordinary Meetings, Powers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders is our supreme corporate body. Under Swiss law, ordinary and extraordinary general meetings of shareholders
may be held. Under Swiss law, an ordinary general meeting of shareholders must be held annually within six months after the end of a corporation&#146;s financial year. In our case, this means on or before June&nbsp;30. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following powers are vested exclusively in the general meeting of shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adopting and amending the articles of association, including change of a company&#146;s purpose or domicile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee, the auditors and the independent proxy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving the annual report, the annual statutory financial statements and (to the extent required) the financial statements, and deciding on the allocation of profits as shown on the balance sheet, in particular with
regard to dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving the compensation (basis, bonus and equity) of members of the board of directors and executive management, which under Swiss law is not necessarily limited to the executive officers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discharging the members of the board of directors and executive management from liability with respect to their tenure in the previous financial year; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dissolving a company with or without liquidation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deciding matters reserved to the general meeting of shareholders by law or the articles of association or presented to it by the board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An extraordinary general meeting of shareholders may be called by a resolution of the board of directors or, under certain circumstances, by a
company&#146;s auditor, liquidator or the representatives of convertible bond holders, if any. In addition, the board of directors is required to convene an extraordinary general meeting of shareholders if shareholders representing at least 10% of
the share capital request such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board of directors must convene an extraordinary general meeting of shareholders
and propose financial restructuring measures if, based on a company&#146;s stand-alone annual statutory balance sheet, half of the share capital and reserves are not covered by its assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Quorum Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholder resolutions and elections (including elections of members of the board of directors) require the affirmative vote of the simple
majority of shares represented at the general meeting of shareholders regardless of abstentions or empty or invalid votes, unless otherwise stipulated by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A resolution of the general meeting of the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute
majority of the nominal value of the shares represented is required for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amending a company&#146;s corporate purpose; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creating or cancelling shares with preference rights or amending rights attached to such shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancelling or amending the transfer restrictions of shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creating authorized or conditional share capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the share capital out of equity, against contributions in-kind or for the purpose of acquiring specific assets and granting specific benefits; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting or suppressing shareholder&#146;s pre-emptive rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changing a company&#146;s domicile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">alleviating or withdrawing of restrictions upon the transfer of registered shares and the removal of the voting cap of 15%; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">removing the indemnification provision for the board of directors and executive management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">converting registered shares into bearer shares and vice versa; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dissolving or liquidating a company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The same voting requirements apply to resolutions regarding transactions among corporations based
on Switzerland&#146;s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets, or the Merger Act (including a merger, demerger or conversion of a corporation) see &#147;&#151;Compulsory Acquisitions; Appraisal Rights.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements
generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such
quorum may not be less than one-third of the outstanding voting stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Notice </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General meetings of shareholders must be convened by the board of directors at least 20 days before the date of the meeting. The general
meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed by ordinary mail or e-mail. The notice of a general
meeting of shareholders must state the items on the agenda, the proposals to be acted upon and, in case of elections, the names of the nominated candidates. Except in the limited circumstances listed below, a resolution may not be passed at a
general meeting without proper notice. This limitation does not apply to proposals to convene an extraordinary general meeting of shareholders or to initiate a special investigation. No previous notification is required for proposals concerning
items included in the agenda or for debates that do not result in a vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the owners or representatives of our shares may, if no
objection is raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders (a universal meeting). This universal meeting of shareholders may discuss and pass binding
resolutions on all matters within the purview of the ordinary general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Agenda Requests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Swiss law, one or more shareholders, whose combined shareholdings represent the lower of (i)&nbsp;one tenth of the share capital or
(ii)&nbsp;an aggregate nominal value of at least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting of shareholders. To be timely, the shareholder&#146;s request must be received by us generally at
least 120 calendar days in advance of the meeting. The request must be made in writing and contain, for each of the agenda items, the following information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a brief description of the business desired to be brought before the ordinary general meeting of shareholders and the reasons for conducting such business at the ordinary general meeting of shareholders;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name and address, as they appear in the share register, of the shareholder proposing such business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other information required under the applicable laws and stock exchange rules. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if the shareholder intends to solicit proxies from the shareholders of a company, such shareholder shall notify the company of this intent in accordance with Securities and Exchange Commission Rule 14a-4 and/or Rule 14a-8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business report, the compensation report and the auditor&#146;s report must be made available for inspection by the shareholders at our
registered office no later than 20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our shares entitles a holder to one vote, regardless of its nominal value. The shares are not divisible. The right to vote and the
other rights of share ownership may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off date determined by the board of directors. Those entitled to vote in the general
meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third person with written authorization to act as proxy or the shareholder&#146;s
legal representative. The chairman has the power to decide whether to recognize a power of attorney. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our articles contain provisions that
prevent investors from acquiring voting rights exceeding 15% of the outstanding share capital. Specifically, no individual or legal entity may, directly or indirectly, control voting rights with respect to 15% or more of the registered share capital
recorded in the Commercial Register. In the event that a shareholder should exceed the 15% ownership threshold, the registered shares exceeding the limit of 15% shall be entered in our share registered as shares without voting rights. The board of
directors may in special cases approve exceptions to the above regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Other Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may propose to shareholders that a dividend or other distribution be paid but cannot itself authorize the distribution.
Dividend payments require a resolution passed by a simple majority of the shares represented at a general meeting of shareholders regardless of abstentions or employ or invalid votes. In addition, our auditors must confirm that the dividend proposal
of our board of directors conforms to Swiss statutory law and our articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, we may pay dividends only if
we have sufficient distributable profits brought forward from the previous business years (<I>report des b&eacute;n&eacute;fices</I>), or if we have distributable reserves (<I>r&eacute;serves &agrave; libre disposition</I>), each as evidenced by our
audited stand-alone statutory balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association have been deducted. We are not permitted to pay interim dividends out of profit of
the current business year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributable reserves are generally booked either as &#147;free reserves&#148; (<I>r&eacute;serves
libres</I>) or as &#147;reserve from capital contributions&#148; (<I>apports de capital</I>). Under the CO, if our general reserves (<I>r&eacute;serve g&eacute;n&eacute;rale</I>) amount to less than 20% of our share capital recorded in the
commercial register (i.e., 20% of the aggregate nominal value of our issued capital), then at least 5% of our annual profit must be retained as general reserves. The CO permits us to accrue additional general reserves. Further, a purchase of our own
shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which are not
distributable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions out of issued share capital (i.e. the aggregate nominal value of our issued shares) are not allowed and may
be made only by way of a share capital reduction. Such a capital reduction requires a resolution passed by an simple majority of the shares represented at a general meeting of shareholders regardless of abstentions or empty or invalid votes. The
resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that claims of our creditors remain fully covered despite the reduction in the share capital recorded in the commercial register. The share
capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of
shareholders of the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two months of the
third publication, satisfaction of or security for their claims. The reduction of the share capital may be implemented only after expiration of this time limit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors determines the date on which the dividend entitlement starts. Dividends
are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends in quarterly or other installments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the taxation of dividends, see &#147;Taxation&#151;Swiss Tax Considerations&#151;Taxation of Common Shares&#151;Swiss
Federal Withholding Tax on Dividends and Distributions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares in uncertificated form (<I>droits-valeurs</I>) may only be transferred by way of assignment. Shares that constitute intermediated
securities (<I>titres interm&eacute;di&eacute;s) </I>may only be transferred when a credit of the relevant intermediated securities to the acquirer&#146;s securities account is made in accordance with the relevant provisions of the FISA. Article 5
of our articles of association provides that in the case of securities held with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of a security interest or usufructary right in such
intermediated securities and the appurtenant rights associated therewith requires the cooperation of the intermediary in order for such transfer, grant of a security interest or usufructary right to be valid against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Voting rights may be exercised only after a shareholder has been entered in our share register (<I>registre des actions</I>) with his or her
name and address (in the case of legal entities, the registered office) as a shareholder with voting rights. Our articles contain provisions that prevent investors from acquiring voting rights exceeding 15% of the outstanding share capital.
Specifically, no individual or legal entity may, directly or indirectly, control voting rights with respect to 15% or more of the registered share capital recorded in the Commercial Register. In the event that a shareholder should exceed the 15%
ownership threshold, the registered shares exceeding the limit of 15% shall be entered in our share registered as shares without voting rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Inspection of Books and Records </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CO, a shareholder has a right to inspect our share register with respect to his own shares and otherwise to the extent necessary to
exercise his shareholder rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected with the express authorization of the general meeting of shareholders or by resolution of the board of
directors and subject to the safeguarding of our business secrets. See &#147;Comparison of Swiss Law and Delaware Law&#151;Inspection of Books and Records.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Special Investigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the shareholders&#146; inspection rights as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting of shareholders that specific facts be examined by a special commissioner in a
special investigation. If the general meeting of shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders, request a court sitting in Lausanne, Switzerland, our registered
office, to appoint a special commissioner. If the general meeting of shareholders rejects the request, one or more shareholders representing at least 10 percent of the share capital or holders of shares in an aggregate nominal value of at least CHF
2,000,000 may request that the court appoint a special commissioner. The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors or our executive management infringed the
law or our articles of association and thereby caused damages to the Company or the shareholders. The costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compulsory Acquisitions; Appraisal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Business combinations and other transactions that are governed by the Swiss Merger Act (i.e. mergers, demergers, transformations and certain
asset transfers) are binding on all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal value of the shares represented.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a transaction under the Swiss Merger Act receives all of the necessary consents, there are no
appraisal rights and all shareholders are compelled to participate in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss corporations may be acquired by an acquirer
through the direct acquisition of the share capital of the Swiss corporation. The Swiss Merger Act provides for the possibility of a so-called &#147;cash-out&#148; or &#147;squeeze-out&#148; merger if the acquirer controls 90% of the outstanding
shares. In these limited circumstances, minority shareholders of the corporation being acquired may be compensated in a form other than through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of
the acquiring corporation or of another corporation). For business combinations effected in the form of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved
or compensation payments in the transaction are unreasonable, a shareholder may request the competent court to determine a reasonable amount of compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under Swiss law, the sale of &#147;all or substantially all of our assets&#148; by us may require the approval of two-thirds of
the number of shares represented at a general meeting shareholders and the absolute majority of the nominal value of the shares represented. Whether a shareholder resolution is required depends on the particular transaction, including whether the
following test is satisfied: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a core part of our business is sold without which it is economically impracticable or unreasonable to continue to operate the remaining business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our assets, after the divestment, are not invested in accordance with our statutory business purpose; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proceeds of the divestment are not earmarked for reinvestment in accordance with our business purpose but, instead, are intended for distribution to our shareholders or for financial investments unrelated to our
business. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder of a Swiss corporation participating in certain major corporate transactions may, under certain
circumstances, be entitled to appraisal rights. As a result, such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder receives the fair value of the shares held
by the shareholder. Following a statutory merger or demerger, pursuant to the Swiss Merger Act, shareholders can file an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an adequate
compensation payment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our articles of association provide that the board of directors shall consist of at least three and not more than nine members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the board of directors and the chairman are elected annually by the general meeting of shareholders for a period until the
completion of the subsequent ordinary general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Powers </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of
directors has the following non-delegable and inalienable powers and duties: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ultimate direction of the business of the Company and issuing of the relevant directives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">laying down the organization of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">formulating accounting procedures, financial controls and financial planning; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for the Company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to law, our articles of association, and regulations and directives of the Company;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuing the annual report and the compensation report, and preparing for the general meeting of shareholders and carrying out its resolutions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">informing the court in case of over-indebtedness. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors may, while retaining
such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, managing directors, committees or to third parties who need be neither members of the board
of directors nor shareholders. Pursuant to Swiss law and Article 25 of our articles of association, details of the delegation and other procedural rules such as quorum requirements must be set in the organizational rules issued by the board of
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification of Executive Management and Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Swiss law, Article 29 of our articles of association provides for indemnification of the existing and former members of the board of
directors, executive management and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and permits us to advance the expenses of defending any act, suit or
proceeding to our directors and executive management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under general principles of Swiss employment law, an employer may be
required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the employer. See &#147;Comparison of Swiss Law and
Delaware&nbsp;Law&#151;Indemnification of directors and executive management and limitation of liability.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered or will
enter into indemnification agreements with each of the members of our board of directors and executive management. See &#147;Related Party Transactions&#151;Indemnification Agreements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conflict of Interest, Management Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss law does not have a general provision regarding conflicts of interest. However, the CO contains a provision that requires our directors
and executive management to safeguard the Company&#146;s interests and imposes a duty of loyalty and duty of care on our directors and executive management. This rule is generally understood to disqualify directors and executive management from
participation in decisions that directly affect them. Our directors and executive officers are personally liable to us for any breach of these provisions. In addition, Swiss law contains provisions under which directors and all persons engaged in
the Company&#146;s management are liable to the Company, each shareholder and the Company&#146;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss law contains a provision under which payments
made to any of the Company&#146;s shareholders or directors or any person associated with any such shareholder or director, other than payments made at arm&#146;s length, must be repaid to the Company if such shareholder or director acted in bad
faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our board of directors will adopt a Code of Business Conduct and Ethics that will cover a broad
range of matters, including the handling of conflicts of interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Principles of the Compensation of the Board of Directors and the
Executive Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Swiss law, beginning at our first annual meeting as a public company in 2016 our shareholders
must annually approve the compensation of the board of directors and the persons whom the board of directors has, fully or partially, entrusted with the management of the Company. The board of directors must issue, on an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
annual basis, a written compensation report that must be reviewed together with a report on our business by our auditor. The compensation report must disclose all compensation, loans and other
forms of indebtedness granted by the Company, directly or indirectly, to current or former members of the board of directors and executive management to the extent related to their former role within the Company or not on customary market terms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure concerning compensation, loans and other forms of indebtedness must include the aggregate amount for the board of
directors and the executive management, as well as the particular amount for each member of the board of directors and executive officer, specifying the name and function of each person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain forms of compensation are prohibited for members of our board of directors and executive management, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">severance payments provided for either contractually or in the articles of association (compensation due until the termination of a contractual relationship does not qualify as severance payment); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incentive fees for the acquisition or transfer of corporations, or parts thereof, by the Company or by companies being, directly or indirectly, controlled by the us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equity securities and conversion and option rights awards not provided for in the articles of association. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation to members of the board of directors and executive management for activities in entities that are, directly or indirectly,
controlled by the Company is prohibited if the compensation (i)&nbsp;would have been prohibited if it was paid directly by the Company, (ii)&nbsp;is not provided for in the articles of association or (iii)&nbsp;has not been approved by the general
meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in 2016, the general meeting of shareholders will annually vote on the proposals of the board of
directors with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maximum aggregate amount of compensation of the board of directors for the subsequent term of office; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maximum aggregate amount of compensation of the executive management for the subsequent financial year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors may submit for approval at the general meeting of shareholders deviating or additional proposals relating to the same
or different periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that, at the general meeting of shareholders, the shareholders do not approve a proposal of the board
of directors, the board of directors must form a new proposal for the maximum aggregate compensation and the particular compensation for each individual, taking into account all relevant factors, and submit the new proposal for approval by the same
general meeting of shareholders, at a subsequent extraordinary general meeting or the next ordinary general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to fixed compensation, members of the board of directors and executive management may be paid variable compensation, depending on the achievement of certain performance criteria. The performance criteria may include individual targets,
targets of the Company or parts thereof and targets in relation to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient of the variable compensation. The board of
directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria and the respective target values. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation may be paid or granted in the form of cash, shares, financial instruments, in kind,
or in the form of other types of benefits. The board of directors or, where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Borrowing Powers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Swiss law nor our articles of association restrict in any way our power to borrow and raise funds. The decision to borrow funds is made
by or under the direction of our board of directors, and no approval by the shareholders is required in relation to any such borrowing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Repurchases of Shares and Purchases of Own Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CO limits our right to purchase and hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that
(i)&nbsp;we have freely distributable reserves in the amount of the purchase price; and (ii)&nbsp;the aggregate nominal value of all shares held by us does not exceed 10 percent of our share capital. Pursuant to Swiss law, where shares are acquired
in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20 percent. We currently do not have any transfer restriction in our articles of association. If we own shares that exceed the threshold
of 10 percent of our share capital, the excess must be sold or cancelled by means of a capital reduction within two years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares held by
us or our subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and pre-emptive rights in the case of share capital increases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, selective share repurchases are only permitted under certain circumstances. Within these limitations, as is customary for
Swiss corporations, we may purchase and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out variances in the market price of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Notification and Disclosure of Substantial Share Interests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure obligations generally applicable to shareholders of Swiss corporations under the Swiss Act on Stock Exchanges and Securities
Trading do not apply to us since our shares are not listed on a Swiss exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to art. 663c of the CO, Swiss corporations whose
shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in the notes to their balance sheet, where this information is known or ought to be known. Significant shareholders are defined as
shareholders and groups of shareholders linked through voting rights who hold more than five percent of all voting rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common shares on the NASDAQ under the symbol &#147;ACIU.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Depository Trust Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initial
settlement of the common shares issued in this offering will take place on the consummation date of this offering through The Depository Trust Company, or DTC, in accordance with its customary settlement procedures for equity securities. Each person
owning common shares held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share register will initially be kept by Computershare Trust Company, N.A., which acts as transfer agent and registrar. The share register
reflects only record owners of our shares. Swiss law does not recognize fractional share interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_19"></A>COMPARISON OF SWISS LAW AND DELAWARE LAW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Swiss laws applicable to Swiss corporations and their shareholders differ from laws applicable to U.S. corporations and their
shareholders. The following table summarizes significant differences in shareholder rights between the provisions of the Swiss Code of Obligations (<I>Code des Obligations Suisse</I>) and the Swiss Ordinance against excessive compensation in listed
stock corporations applicable to our Company, as implemented by the Company in its Articles of Association, and the Delaware General Corporation Law applicable to companies incorporated in Delaware and their shareholders. Please note that this is
only a general summary of certain provisions applicable to companies in Delaware. Certain Delaware companies may be permitted to exclude certain of the provisions summarized below in their charter documents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Mergers and similar arrangements</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a
majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such
shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation
Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such
merger, dissenting shareholders of the subsidiary would have appraisal rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the
respective general meeting of shareholders as well as the absolute majority of the nominal value of shares represented at such shareholders&#146; meeting. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant
to the Swiss Merger Act (<I>Loi sur la fusion</I>) can file a lawsuit against the surviving company. If the consideration is deemed &#147;inadequate,&#148; such shareholder may, in addition to the consideration (be it in shares or in cash) receive
an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the
transferring legal entity, who are entitled to vote, shall approve the merger agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholders&#146; suits</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In
such actions, the court has discretion to permit the winning party to recover attorneys&#146; fees incurred in connection with such action.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A
shareholder is entitled to bring suit against directors for breach of their duties and claim the payment of the company&#146;s losses or damages both to the corporation and to the individual shareholder and creditors. Likewise, an appraisal lawsuit
won by a shareholder will may indirectly compensate all shareholders. In addition, to the extent that US laws and regulations provide a basis for liability and US courts have jurisdiction, a class action may be available.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, the winning party is generally entitled to recover or to partially
recover attorneys&#146;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">fees incurred in connection with such action, <I>provided</I>, <I>however</I>, that the court has broad discretion to permit the shareholder whose claim has been dismissed to recover attorneys&#146; fees incurred to the extent he or
she acted in good faith.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholder vote on board and management compensation</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Swiss Ordinance against excessive compensation in listed stock corporations (<I>Ordonnance contre les r&eacute;mun&eacute;rations abusives dans les soci&eacute;t&eacute;s anonymes cot&eacute;es en bourse</I>), the
general meeting of shareholders has the non-transferable right, amongst others, to vote on the fixed and on the variable compensation of the members of the board of directors, of the executive management and of the advisory boards.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Annual vote on board renewal</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless directors are elected by written consent in lieu of an annual meeting, directors are elected in an annual meeting of stockholders on a
date and at a time designated by or in the manner provided in the bylaws. Re-election is possible.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Classified boards are permitted.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The general meeting of shareholders elects annually (i.e. term of office until the end of the following general meeting of shareholders) the members of the board of directors and the members of the compensation committee
individually for a term of office of one year. Re-election is possible.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Indemnification of directors and executive management and limitation of liability</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law provides that a certificate of incorporation may contain a provision eliminating or limiting the
personal liability of directors (but not other controlling persons) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate of incorporation may eliminate or limit the liability of
a director for:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any breach of a director&#146;s duty of loyalty to the corporation or
its shareholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;statutory liability for unlawful payment of dividends or unlawful
stock purchase or redemption; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any transaction from which the director derived an improper personal
benefit.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive management in relation to potential personal liability is not effective to the extent the director or member of the executive
management intentionally or negligently violated his or her corporate duties towards the corporation (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification). Furthermore, the general meeting of
shareholders may discharge the directors and members of the executive management from liability from actions taken during the past financial year. Such discharge is effective only, however, for disclosed facts and only as against the company and
those shareholders who approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the
shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding, other than an
action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably believed to be in,
or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless ordered by a court, any foregoing indemnification is subject to a determination
that the director or officer has met the applicable standard of conduct:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by a majority vote of the directors who are not parties to the
proceeding, even though less than a quorum;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by a committee of directors designated by a majority vote of the
eligible directors, even though less than a quorum;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by independent legal counsel in a written opinion if there are no
eligible directors, or if the eligible directors so direct; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the shareholders.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Moreover, a Delaware corporation may not indemnify a director or officer in connection
with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the
case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporate law, including shareholders of the corporation.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The articles of association of a Swiss corporation may also set forth that the corporation shall indemnify and hold harmless, to the extent permitted by the
law, the directors and executive managers out of assets of the corporation against threatened, pending or completed actions.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Also, a corporation may enter into and pay for directors&#146; and officers&#146; liability insurance which may cover negligent acts as well.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Directors&#146; fiduciary duties</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the duty of care; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the duty of loyalty.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The duty of care requires that a director act in good faith, with the care that an
ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors of a Swiss corporation manages the business of the corporation, unless responsibility for such management has not been
delegated to the executive management (for example by organizational rules and comparable bylaws). However, there are several non-transferable duties of the board of directors:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the overall management of the corporation and the issuing of all
necessary directives;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">disclose to shareholders, all material information reasonably available regarding a significant transaction.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The duty of loyalty requires that a director act in a manner he or she reasonably
believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and
its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in
good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Should such evidence be presented concerning a transaction by a director, a director must
prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determination of the corporation&#146;s
organization;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the organization of the accounting, financial control and financial
planning systems as required for management of the corporation;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the appointment and dismissal of persons entrusted with managing and
representing the corporation;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;overall supervision of the persons entrusted with managing the
corporation, in particular with regard to compliance with the law, articles of association, operational regulations and directives;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compilation of the annual report, preparation for the general meeting,
the compensation report and implementation of its resolutions; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notification of the court in the event that the company is
overindebted.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the board of directors must perform their duties with
all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal circumstances.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The burden of proof for a violation of these duties is with the corporation or with the shareholder bringing a suit against the director.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholder action by written consent</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consents. The articles of association must allow for (independent) proxies to be present at a
general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholder proposals</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the
board of directors or any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">At any general meeting of shareholders any shareholder may put proposals to the meeting if the proposal is part of an agenda item. No resolution may be made on proposals relating to the agenda items that were not duly notified.
Unless the articles of</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">association provide for a lower threshold or for additional shareholders&#146; rights:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shareholders together representing at least 10% of the share capital
may demand that a general meeting of shareholders be called for specific agenda items and specific proposals; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shareholders together representing at shares with a nominal value of
at least CHF 1.0 million may demand that an agenda item including a specific proposal be put on the agenda for a regularly scheduled general meeting of shareholders, provided such request is made with appropriate notice.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder can propose candidates for election as directors without prior written
notice.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, any shareholder is entitled, at a general meeting of
shareholders and without advance notice, to (i) request information from the Board on the affairs of the company (note, however, that the right to obtain such information is limited), (ii) request information from the auditors on the methods and
results of their audit, (iii) request to convene an extraordinary general meeting or (iv) to carry out a special audit and to appoint an auditor at the request of a shareholder.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Cumulative voting</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#146;s certificate of incorporation provides for it.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates. An annual individual
election of (i) all members of the board of directors, (ii) the chairman of the board of directors, (iii) the members of the compensation committee, (iv) the election of the independent proxy for a term of office of one year (i.e. until the
following annual general meeting) as well as the vote on the compensation for the members of the board of directors and the executive committee as well as for the members of the advisory board, if applicable, is mandatory for listed companies.
Re-election is permitted.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Removal of directors</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a simple majority of the shares represented at a general meeting of shareholders concerned.
The</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">articles of association may require the approval by a qualified majority of the shares represented at a meeting for the removal of a director.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Transactions with interested shareholders</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an &#147;interested shareholder&#148; for three years following the date that such person becomes an
interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation&#146;s outstanding voting stock within the past three years.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No such rule applies to a Swiss corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Dissolution; Winding up</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is
initiated by the board of directors may it be approved by a simple majority of the corporation&#146;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in
connection with dissolutions initiated by the board.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A dissolution of a Swiss corporation requires the approval by two-thirds of the shares represented as well as the absolute majority of the nominal value of the share capital represented at a general meeting of shareholders passing a
resolution on such dissolution. The articles of association may increase the voting thresholds required for such a resolution.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Variation of rights of shares</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general shareholder meeting of a Swiss corporation may resolve that preference shares be issued or that existing shares be converted into
preference shares with a resolution passed by a simple majority of the shares represented at the general meeting of shareholders. Where a company has issued preference shares, further preference shares conferring preferential rights over the
existing preference shares may be issued only with the consent of both a special meeting of the adversely affected holders of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in the articles of
association.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shares with preferential voting rights are not regarded a special class
for these purposes.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Amendment of governing documents</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation&#146;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The articles of association of a Swiss corporation may be amended with a resolution passed by a simple majority of the shares represented at such meeting, unless otherwise provided in the articles of association. There are a number
of resolutions, such</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as an amendment of the stated purpose of the corporation, the introduction of authorized and conditional capital and the introduction of shares with preferential voting rights that require the approval by two-thirds of the votes and
an absolute majority of the nominal value of the shares represented at a shareholders&#146; meeting. The articles of association may increase the voting thresholds.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Inspection of Books and Records</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of
shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The information may be refused where providing it would jeopardize the
corporation&#146;s trade secrets or other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise such shareholders&#146; rights, subject to the interests of the corporation. The
right to inspect the share register is limited to the right to inspect that shareholder&#146;s own entry in the share register.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Payment of dividends</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors may approve a dividend without shareholder approval. Subject to any restrictions contained in its certificate of
incorporation, the board may declare and pay dividends upon the shares of its capital stock either:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;out of its surplus, or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in case there is no such surplus, out of its net profits for the
fiscal year in which the dividend is declared and/or the preceding fiscal year.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stockholder approval is required to authorize capital stock in excess of that provided in the charter. Directors may issue authorized shares without
stockholder approval.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend payments are subject to the approval of the general meeting of shareholders. The board of directors may propose to shareholders that
a dividend shall be paid but cannot itself authorize the distribution.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Payments out
of the Company&#146;s share capital (in other words, the aggregate nominal value of the Company&#146;s registered share capital) in the form of dividends are not allowed; however, payments out of share capital may be made by way of a capital
reduction only. Dividends may be paid only from the profits brought forward from the previous business years or if the Company has distributable reserves, each as will be presented on the Company&#146;s audited annual stand-alone balance sheet. The
dividend may be determined only after the allocations to reserves required by the law and the articles of association have been deducted.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Creation and issuance of new shares</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&#146;s certificate of incorporation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">All creation of shares require a shareholders&#146; resolution. An authorized or contingent capital increase requires at least two-thirds of the voting rights represented at the general meeting of shareholders and an absolute
majority of the nominal</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">value of shares represented. Authorized shares can be, once created by shareholder resolution, issued by the board of directors (subject to fulfillment of the authorization). Conditional shares are created and issued through the
exercise of options and conversion rights related to debt instruments issued by the board of directors or such rights issued to employees.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_20"></A>COMMON SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there was no public market for our common shares. Future sales of substantial amounts of our common shares in the
public market could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of common shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on
resale as described below, there may be sales of substantial amounts of our common shares in the public market after such restrictions lapse. This may adversely affect the prevailing market price and our ability to raise equity capital in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common
shares outstanding assuming no exercise of the underwriters&#146; over-allotment option. Of these shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares if the underwriters exercise their option in full to purchase additional common shares, sold in this offering will be freely transferable without restriction or
registration under the Securities Act, except for any common shares purchased by one of our existing &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The remaining
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares outstanding are &#147;restricted shares&#148; as defined in Rule 144. Restricted shares may be sold in the public market only if registered or if they qualify for
an exemption from registration under Rules 144 or 701 of the Securities Act. After the expiration of the contractual 180-day lock-up period described below, these common shares may be sold in the public market only if registered or pursuant to an
exemption under Rules 144 or 701, which are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, of the options to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 and assuming no
outstanding options are exercised and no exercise of the underwriters&#146; option to purchase additional shares, options exercisable for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares will be vested and
eligible for sale 180 days after the date of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has beneficially owned our common shares that are restricted shares for at least six months would be entitled to sell
such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, the sale and (ii)&nbsp;we are subject to, and in compliance with certain of, the
Exchange Act periodic reporting requirements for at least 90 days before the sale. If such person has beneficially owned such common shares for at least one year, then the requirement in clause (ii)&nbsp;will not apply to the sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned our common shares that are restricted shares for at least six months but who are our affiliates at the
time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of
either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of our common shares then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares immediately after this offering, assuming no
exercise of the underwriters&#146; over-allotment option; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common shares on the NASDAQ during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, in each case, that we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90
days before the sale. Such sales must also comply with the manner of sale and notice provisions of Rule 144.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who purchases shares from us in connection with
a compensatory share or option plan or other written agreement before the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective date of this offering is entitled to resell such shares 90 days after the effective date of this offering in reliance on Rule 144, without having to comply with the holding period
requirements or other restrictions contained in Rule 701. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has indicated that Rule 701 will apply to typical share options granted
by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities issued in reliance on Rule 701
are restricted securities and, subject to the contractual restrictions described below, beginning 90 days after the date of this prospectus, may be sold by persons other than &#147;affiliates,&#148; as defined in Rule 144, subject only to the manner
of sale provisions of Rule 144 and by &#147;affiliates&#148; under Rule 144 without compliance with the one-year minimum holding period requirement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options to Purchase Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
intend to file one or more registration statements on Form&nbsp;S-8 under the Securities Act to register all common shares issued or issuable pursuant to the exercise of outstanding options and reserved for issuance under our new omnibus equity
incentive plan. We expect to file the registration statements, which will become effective immediately upon filing, shortly after the date of this prospectus. Shares covered by these registration statements will then be eligible for sale in the
public markets, subject to vesting restrictions and any applicable holding periods, any applicable lock-up agreements described below and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation S provides
generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into
a registration rights agreement in connection with the Series E Private Placement with certain of our existing shareholders and certain investors in the Series E Private Placement pursuant to which we agreed under certain circumstances to file a
registration statement to register the resale of the shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings of such shares. Registration of these shares under the Securities Act would result in these
shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Related Party Transactions&#151;Registration Rights
Agreement.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-up Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors, executive officers and the holders of all of our capital stock have agreed, subject to limited exceptions, not to offer,
pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or
enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 180 days after the date of this prospectus without the prior
written consent of Credit Suisse Securities (USA) LLC. See &#147;Underwriting.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_21"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary does not purport to address all tax consequences of this offering, the acquisition, the ownership and sale or other
disposition of our common shares (such shares for the purposes of this &#147;Taxation&#148; section, &#147;Shares&#148;) and does not take into account the specific circumstances of any particular investor. This summary is based on the tax laws,
regulations and regulatory practices of Switzerland and the U.S. as in effect on the date hereof, which are subject to change (or subject to changes in interpretation), possibly with retroactive effect. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Current and prospective shareholders are advised to consult their own tax advisers in light of their particular circumstances as to the
Swiss or U.S. tax laws, regulations and regulatory practices that could be relevant for them in connection with this offering, the acquiring, owning and selling or otherwise disposing of Shares and receiving dividends and similar cash or in-kind
distributions on Shares (including dividends on liquidation proceeds and stock dividends) or distributions on Shares based upon a capital reduction (remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions) or
reserves paid out of capital contributions (apports de capital) and the consequences thereof under the tax laws, regulations and regulatory practices of Switzerland or the United States. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Swiss Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss
federal, cantonal and communal individual income tax and corporate income tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Non-Resident Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders who are not resident in Switzerland for tax purposes, and who, during the relevant taxation year, have not engaged in a trade or
business carried on through a permanent establishment or fixed place of business situated in Switzerland for tax purposes (all such shareholders for purposes of this section, &#147;Non-Resident Shareholders&#148;), will not be subject to any Swiss
federal, cantonal and communal income tax on dividends and similar cash or in-kind distributions on Shares (including dividends on liquidation proceeds and stock dividends) (such dividends for the purposes of this, &#147;Dividends&#148;),
distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital</I>) on Shares, or capital gains
realized on the sale or other disposition of Shares (see, however, &#147;&#151;S<I>wiss Federal Withholding Tax&#148;</I> below for a summary of Swiss federal withholding tax on Dividends, and &#147;&#151;<I>Foreign final withholding tax&#148;</I>
below for a summary on final withholding taxes in respect of Shares held in Swiss accounts by Non-Resident Shareholders). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Resident
Private Shareholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss resident individuals who hold their Shares as private assets are required to include Dividends, but not
distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>Apports de capital</I>), in their personal income tax
return and are subject to Swiss federal, cantonal and communal income tax on any net taxable income for the relevant taxation period, including the Dividends, but not the distributions based upon a capital reduction (<I>remboursements li&eacute;s
&agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital)</I>. Capital gains resulting from the sale or other disposition of Shares are not subject to Swiss federal,
cantonal and communal income tax, and conversely, capital losses are not tax-deductible for Resident Private Shareholders (the shareholders referred to in this paragraph for the purposes of this section, &#147;Resident Private Shareholders&#148;).
See &#147;&#151;<I>Domestic Commercial Shareholders</I>&#148; below for a summary of the taxation treatment applicable to Swiss resident individuals, who, for income tax purposes, are classified as &#147;professional securities dealers&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Domestic Commercial Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate and individual shareholders who are resident in Switzerland for tax purposes, and corporate and individual shareholders who are not
resident in Switzerland, and who, in each case, hold their Shares as part of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trade or business carried on in Switzerland, in the case of corporate and individual shareholders not resident in Switzerland, through a permanent establishment or fixed place of business
situated, for tax purposes, in Switzerland, are required to recognize Dividends, distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of
capital contributions (<I>apports de capital</I>) received on Shares and capital gains or losses realized on the sale or other disposition of Shares in their income statement for the relevant taxation period and are subject to Swiss federal,
cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings for such taxation period. The same taxation treatment also applies to Swiss-resident private individuals who, for income tax purposes, are
classified as &#147;professional securities dealers&#148; for reasons of, <I>inter alia</I>, frequent dealing, or leveraged investments, in shares and other securities (the shareholders referred to in this paragraph for purposes of this section,
&#147;Domestic Commercial Shareholders&#148;). Domestic Commercial Shareholders who are corporate taxpayers may be eligible for dividend relief (<I>r&eacute;duction pour participations</I>) in respect of Dividends and distributions based upon a
capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital</I>) if the Shares held by them as part of a Swiss business
have an aggregate market value of at least CHF&nbsp;1 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Swiss cantonal and communal private wealth tax and capital
tax</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Non-Resident Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-Resident Shareholders are not subject to Swiss cantonal and communal private wealth tax or capital tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Resident Private Shareholders and Domestic Commercial Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Resident Private Shareholders and Domestic Commercial Shareholders who are individuals are required to report their Shares as part of private
wealth or their Swiss business assets, as the case may be, and will be subject to Swiss cantonal and communal private wealth tax on any net taxable wealth (including Shares), in the case of Domestic Commercial Shareholders to the extent the
aggregate taxable wealth is allocable to Switzerland. Domestic Commercial Shareholders who are corporate taxpayers are subject to Swiss cantonal and communal capital tax on taxable capital to the extent the aggregate taxable capital is allocable to
Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Federal Withholding Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends that the Company pays on the Shares are subject to Swiss Federal withholding tax <I>(imp&ocirc;t anticip&eacute;)</I> at a rate of
35% on the gross amount of the Dividend. The Company is required to withhold the Swiss federal withholding tax from the Dividend and remit it to the Swiss Federal Tax Administration. Distributions based upon a capital reduction (<I>remboursements
li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital</I>) are not subject to Swiss federal withholding tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Swiss federal withholding tax on a Dividend will be refundable in full to a Resident Private Shareholder and to a Domestic Commercial
Shareholder, who, in each case, <I>inter alia, </I>as a condition to a refund, duly reports the Dividend in his individual income tax return as income or recognizes the Dividend in his income statement as earnings, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Non-Resident Shareholder may be entitled to a partial refund of the Swiss federal withholding tax on a Dividend if the country of his or her
residence for tax purposes has entered into a bilateral treaty for the avoidance of double taxation with Switzerland and the conditions of such treaty are met. Such shareholders should be aware that the procedures for claiming treaty benefits (and
the time required for obtaining a refund) might differ from country to country. For example, a shareholder who is a resident of the U.S. for the purposes of the bilateral tax treaty between the U.S. and Switzerland is eligible for a partial refund
of the amount of the withholding tax in excess of the 15% treaty rate, provided such shareholder: (i)&nbsp;qualifies for benefits under this treaty and qualifies as beneficial owner of the Dividends; (ii)&nbsp;holds, directly or indirectly, less
than 10% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
voting stock of the Company; (iii)&nbsp;does not qualify as a pension scheme or retirement arrangement for the purpose of the bilateral treaty; and (iv)&nbsp;does not conduct business through a
permanent establishment or fixed base in Switzerland to which the Shares are attributable. Such an eligible U.S. shareholder may apply for a refund of the amount of the withholding tax in excess of the 15% treaty rate. The applicable refund request
form may be filed with the Swiss Federal Tax Administration following receipt of the Dividend and the relevant deduction certificate, however no later than 31&nbsp;December of the third year following the calendar year in which the Dividend was
payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Federal Stamp Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will be subject to and pay to the Swiss Federal Tax Administration a 1% Swiss federal issuance stamp tax (<I>taxe sur les
&eacute;missions</I>) on the consideration received by it for the issuance of the Shares less certain costs incurred in connection with the issuance. The issuance of the Shares to the initial shareholders at the offering price is not subject to
Swiss federal securities turnover tax (<I>droit de timbre de n&eacute;gociation</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any subsequent dealings in the Shares, where a bank
or another securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act, acts as an intermediary, or is a party, to the transaction, are, subject to certain exemptions provided for in the Swiss Federal Stamp Tax Act, subject to
Swiss securities turnover tax at an aggregate tax rate of up to 0.15% of the consideration paid for such Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Final
Withholding Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2013, treaties on final withholding taxes of Switzerland with the United Kingdom and Austria
entered into force (each, a &#147;Contracting State&#148;). The treaties require a Swiss paying agent, as defined in the treaties, to levy a flat-rate final withholding tax (<I>imp&ocirc;t lib&eacute;ratoire</I>) at rates specified in the treaties
on certain capital gains and income items (interest, dividends, other income items, all as defined in the treaties), deriving from assets, including the Shares, held in accounts or deposits with a Swiss paying agent by (i)&nbsp;an individual
resident in a Contracting State or, (ii)&nbsp;if certain requirements are met, by a domiciliary company (<I>soci&eacute;t&eacute; de domicile</I>), an insurance company in connection with a so-called insurance wrapper (<I>contrat d&#146;assurance
vie utilis&eacute; comme enveloppe</I>) or other individuals if the beneficial owner is an individual resident in a Contracting State. The flat-rate tax withheld substitutes the ordinary income tax on the respective capital gains and income items in
the Contracting State where the individual is tax resident. In order to avoid the withholding of the flat-rate tax by the Swiss paying agent, such individuals may opt for a disclosure of the respective capital gains and income items to the tax
authorities of the Contracting State where they are tax residents. If Swiss federal withholding tax of 35% has been withheld on dividends, the Swiss paying agent will&#151;to the extent provided in the applicable bilateral treaty for the avoidance
of double taxation between Switzerland and the Contracting State&#151;in its own name and on behalf of the relevant shareholder file with the Swiss tax authorities a request for the partial refund of the Swiss federal withholding tax. The Swiss
federal withholding tax, which is not refundable according to the bilateral tax treaty (residual tax), is credited against the flat-rate final withholding tax. Switzerland may conclude similar treaties with other European countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of Davis Polk&nbsp;&amp; Wardwell LLP, the following is a description of the material U.S. federal income tax consequences to
U.S. Holders, as defined below, of owning and disposing our common shares. It does not describe all tax considerations that may be relevant to a particular person&#146;s decision to acquire common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to a U.S. Holder that holds common shares as capital assets for U.S. federal income tax purposes. In addition, it
does not describe all of the U.S. federal income tax consequences that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including alternative minimum tax consequences, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the potential application of the provisions of the Code known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers or traders in securities who use a mark-to-market method of tax accounting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the common shares;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. Holder whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entities classified as partnerships for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt entities, including an &#147;individual retirement account&#148; or &#147;Roth IRA&#148;; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own or are deemed to own ten percent or more of our voting shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding common shares in connection with a trade or business conducted outside of the United States. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax
treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal
income tax consequences of owning and disposing of the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, administrative
pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland and the United States (the &#147;Treaty&#148;) all as of the date hereof, any of which is subject to change or
differing interpretations, possibly with retroactive effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax
purposes, is a beneficial owner of common shares, who is eligible for the benefits of the Treaty and who is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a citizen or individual resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing
of common shares in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above under &#147;Dividend Policy,&#148; we do not currently expect to make distributions on our common shares. In the event that
we do make distributions of cash or other property, subject to the passive foreign investment company rules described below, distributions paid on common shares, other than certain pro rata distributions of common shares, will generally be treated
as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax
principles, we expect that distributions generally will be reported to U.S. Holders as dividends. For so long as our common shares are listed on NASDAQ or we are eligible for benefits under the Treaty, dividends paid to certain non-corporate U.S.
Holders will be eligible for taxation as &#147;qualified dividend income&#148; and therefore, subject to applicable limitations, will be taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holder.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. Holders should consult their tax advisers regarding the availability of the reduced tax rate on dividends in their particular circumstances. The amount of a dividend will include any amounts
withheld by us in respect of Swiss income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations
under the Code. Dividends will be included in a U.S. Holder&#146;s income on the date of the U.S. Holder&#146;s receipt of the dividend. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated by reference to the
exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should
not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, Swiss income taxes
withheld from dividends on common shares at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S.
Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Swiss income
tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Disposition of Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the passive foreign investment company rules described below, gain or loss realized on the sale or other disposition of common
shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#146;s tax basis in
the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses
is subject to various limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain &#147;look-through&#148; rules with respect
to subsidiaries, either (i)&nbsp;75% or more of our gross income consists of &#147;passive income,&#148; or (ii)&nbsp;50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of,
&#147;passive income.&#148; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly
or indirectly own at least 25%, by value, of the shares of such corporation. Passive income generally includes interest, dividends, rents, certain non-active royalties and capital gains. Based on our business plan and certain estimates and
projections, including as to the relative values of our assets, we do not believe that we were a PFIC for our 2014 taxable year and do not expect to be a PFIC in the immediately foreseeable future. However, there can be no assurance that the IRS
will agree with our conclusion. In addition, whether we will be a PFIC in 2015 or any future years is uncertain because, among other things, (i)&nbsp;we currently own, and will own after the completion of this offering, a substantial amount of
passive assets, including cash, and (ii)&nbsp;the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time. Accordingly, there can be no assurance
that we will not be a PFIC for any taxable year. If we are a PFIC for any year during which a U.S. Holder holds common shares, we generally would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which
the U.S. Holder holds common shares, even if we ceased to meet the threshold requirements for PFIC status. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were a PFIC for any
taxable year during which a U.S. Holder held common shares (assuming such U.S. Holder has not made a timely mark-to-market election, as described below), gain recognized by a U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder on a sale or other disposition (including certain pledges) of the common shares would be allocated ratably over the U.S. Holder&#146;s holding period for the common shares. The amounts
allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for
individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any distribution received by a U.S. Holder on its common shares
exceeds 125% of the average of the annual distributions on the common shares received during the preceding three years or the U.S. Holder&#146;s holding period, whichever is shorter, that distribution would be subject to taxation in the same manner
as gain, described immediately above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market
election with respect to its common shares, provided that the common shares are &#147;marketable.&#148; Common shares will be marketable if they are &#147;regularly traded&#148; on a &#147;qualified exchange&#148; or other market within the meaning
of applicable Treasury regulations. If a U.S. Holder makes the mark-to-market election, it generally will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over their adjusted tax
basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as
a result of the mark-to-market election). If a U.S. Holder makes the election, the holder&#146;s tax basis in the common shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale or other disposition
of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to avoid the application of the foregoing rules, a United States person that owns stock in a PFIC for U.S. federal
income tax purposes may make a &#147;qualified electing fund&#148; election (a &#147;QEF Election&#148;) with respect to such PFIC if the PFIC provides the information necessary for such election to be made. If a United States person makes a QEF
Election with respect to a PFIC, the United States person will be currently taxable on its pro rata share of the PFIC&#146;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that
the entity is classified as a PFIC and will not be required to include such amounts in income when actually distributed by the PFIC. We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we were a PFIC or, with respect to particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid a
dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns common shares during any year in which we are a PFIC, the holder generally must file annual reports containing such
information as the U.S. Treasury may require on IRS Form 8621 (or any successor form) with respect to us, generally with the holder&#146;s federal income tax return for that year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisers concerning our potential PFIC status and the potential application of the PFIC rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries
generally are subject to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct
taxpayer identification number and certifies that it is not subject to backup withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit
against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Information With Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals (and, under proposed regulations, certain entities) may be required to report information relating to
an interest in our common shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding the effect, if
any, of this legislation on their ownership and disposition of the common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_22"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions contained in an underwriting agreement dated the date of pricing of this offering, we have
agreed to sell to the underwriters named below the following number of common shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the underwriters are obligated to purchase all the common shares
in this offering if any are purchased, other than those shares covered by the over-allotment option described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to
the underwriters a 30-day over-allotment option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional common shares from us at the initial public offering price less the underwriting discounts and
commissions. The option may be exercised only to cover any over-allotments of common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters proposed to offer the
common shares initially at the public offering price on the cover page of this prospectus and to selling group members at that price less a selling concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The
underwriters and selling group members may allow a discount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share on sales to other broker/dealers. After the initial public offering the underwriters may change the initial public offering
price and concession and discount to broker/dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the compensation and estimated expenses we will pay:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions payable by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the expenses paid or payable by us in connection with this offering, other than the underwriting
discounts and commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters
have informed us that they do not expect sales to accounts over which they have discretionary authority to exceed 5% of the common shares being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that we will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, or file with the
Securities and Exchange Commission a registration statement under the Securities Act of 1933, the Securities Act, relating to, any common shares or securities convertible into or exchangeable or exercisable for any common shares, or publicly
disclose the intention to make any offer, sale, pledge, disposition or filing, without the prior written consent of Credit Suisse Securities (USA) LLC for a period of 180 days after the date of this prospectus, except issuances pursuant to the
exercise of employee stock options outstanding on the date hereof or pursuant to our dividend reinvestment plan and in certain other limited circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers and directors and all of our shareholders have agreed that they will not offer, sell, contract to sell, pledge or otherwise
dispose of, directly or indirectly, any common shares or securities convertible into or exchangeable or exercisable for any common shares, enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement
that transfers, in whole or in part, any of the economic consequences of ownership of the common shares, whether any such aforementioned transaction is to be settled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by delivery of the common shares or such other securities, in cash or otherwise, or publicly disclose the intention to make any such offer, sale, pledge or disposition, or to enter into any such
transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of Credit Suisse Securities (USA) LLC. In addition, each such person has agreed that, without the prior written consent of Credit Suisse Securities (USA)
LLC, it will not, during the 180-day lock-up period, make any demand for or exercise any right with respect to, the registration of any common shares or any security convertible into or exercisable or exchangeable for the common shares. Any common
shares received upon exercise of options granted to each such person will also be subject to the lock-up agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However,
notwithstanding the immediately preceding paragraph, the restrictions described in the lock-up agreement will not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions relating to common shares or other securities acquired by such person in this offering or in open market transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) the exercise of stock options or other similar awards granted pursuant to our equity incentive plans or the vesting or settlement of awards granted pursuant to our equity incentive plans (including the delivery and
receipt of common shares, other awards or any securities convertible into or exercisable or exchangeable for common shares in connection with such vesting or settlement); <I>provided</I> that, in the case of this clause (i), the foregoing
restrictions shall apply to any of such person&#146;s common shares issued upon such exercise, vesting or settlement; or (ii) the transfer of common shares or any securities convertible into or exercisable or exchangeable for common shares from such
person to us (or the purchase and cancellation of same by us) upon a vesting event of our securities or upon the exercise of options to purchase common shares by such person, in each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis,
or to cover income or withholding and other tax obligations of such person in connection with such vesting or exercise in 2015 and 2016 of options for our common shares, whether by means of a &#147;net settlement&#148; or otherwise;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of common shares or any security convertible into or exercisable or exchangeable for common shares: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift or gifts, including as a result of the operation of law or estate or intestate succession, or pursuant to a will or other testamentary document; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such is a natural person, to a member of the immediate family of such person (for purposes of the lock-up agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage, domestic partnership
or adoption no more remote than first cousin, and shall include any former spouse); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a natural person, to any trust or other like entity for the direct or indirect benefit of such person or the immediate family of such person; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a natural person, by operation of law or by order of a court of competent jurisdiction pursuant to a qualified domestic order or in connection with a divorce settlement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a natural person, to a corporation, partnership, limited liability company or other entity of which such person and the immediate family of such person are the direct or indirect legal and beneficial
owners of all the outstanding equity securities or similar interests of such corporation, partnership, limited liability company or other entity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a corporation, partnership, limited liability company or other entity, to any trust or other like entity for the direct or indirect benefit of such person or any affiliate, wholly-owned subsidiary,
limited partner, member or stockholder of such person; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a corporation, partnership, limited liability company or other entity, to any affiliate thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a corporation, partnership, limited liability company or other entity, to any investment fund or other entity controlled or managed by such person; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a distribution to any affiliate, wholly-owned subsidiary, limited partner, member or stockholder of such person; </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that in the case of any transfer or distribution pursuant to the sub-bullets above of this third bullet, each donee,
distributee or transferee agrees to be bound in writing by the terms of the lock-up agreement prior to such transfer, such transfer shall not involve a disposition for value and no filing by any party (donor, donee, transferor or transferee) under
the Exchange Act shall be required or shall be voluntarily made in connection with such transfer; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the establishment or modification of any contract, instruction or trading plan intended to comply with Rule 10b5-1 under the Exchange Act for the transfer of common shares; <I>provided</I> that (i) such plan does not
provide for the transfer of Securities during the 180-day lock-up period, (ii) the establishment of such plan shall not be voluntarily publicly announced or filed under the Exchange Act and (iii) to the extent a public announcement or filing under
the Exchange Act, if any, is required by or on behalf of the undersigned or us regarding the establishment or modification of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be
made under such plan during the 180-day lock-up period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer of common shares or any security convertible into or exercisable or exchangeable for common shares to us, pursuant to agreements or rights in existence on the date of this prospectus under which we have the
option to repurchase such shares or a right of first refusal with respect to transfers of such shares or in connection with the termination of such person&#146;s employment with us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer of common shares or any security convertible into or exercisable or exchangeable for common shares that occurs by any order or settlement resulting from any legal proceeding; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer of common shares or any security convertible into or exercisable or exchangeable for common shares pursuant to a bona fide third-party tender offer, merger, amalgamation, consolidation or other similar
transaction made to all holders of the common shares involving a change of control of us; <I>provided</I> that in the event that the tender offer, merger, amalgamation, consolidation or other such transaction is not completed, the common shares
owned by such person shall remain subject to the restrictions contained in the lock-up agreement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of any right with respect to, or the taking of any other action in preparation for, a registration by us of common shares or any securities convertible into or exercisable or exchangeable for common shares;
<I>provided</I> that no transfer of such person&#146;s common shares proposed to be registered pursuant to the exercise of such rights under this bullet shall occur, and no registration statement shall be filed, during the 180-day lock-up period.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against liabilities under the Securities Act, or contribute to payments that
the underwriters may be required to make in that respect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common shares on the NASDAQ under the symbol &#147;ACIU.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering
transactions, penalty bids and passive market making in accordance with Regulation M under the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which
creates a syndicate short position. The short position may </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that
they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either
exercising their over-allotment option and/or purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Syndicate covering transactions involve purchases of the common shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to
close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option. If the
underwriters sell more shares than could be covered by the over-allotment option, a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in this offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the common shares originally sold by the syndicate member are purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In passive market making, a market maker in the common shares who is an underwriter or prospective underwriter may, subject to limitations, make bids for or purchases of our common shares until the time, if any, at
which a stabilizing bid is made. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of
raising or maintaining the market price of our common shares or preventing or retarding a decline in the market price of the common shares. As a result the price of our common shares may be higher than the price that might otherwise exist in the
open market. These transactions may be effected on the NASDAQ and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format will be made available on the web sites maintained by the underwriters, or selling group members, if any,
participating in this offering. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area that has implemented the Prospectus Directive, each a Relevant Member State, the
underwriters represent and agree that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, or the Relevant Implementation Date, they have not made and will not make an offer of our
common shares to the public in that Relevant Member State prior to the publication of a prospectus in relation to our common shares that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in
another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that they may, with effect from and including the Relevant Implementation Date, make an
offer of our common shares to the public in that Relevant Member State at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive) subject to obtaining the prior consent of the manager for any such offer; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of our common shares shall require the publication by the issuer or the underwriters of a prospectus
pursuant to Article 3 of the Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any of our common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an
investor to decide to purchase or subscribe our common shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Member State and the expression Prospectus Directive means Directive
2003/71/EC and (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each Relevant Member State) includes any relevant implementing measure in each Relevant Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity within the meaning of section 21 of the Financial
Services and Markets Act 2000, or FSMA, in connection with the sale or issue of the common shares in circumstances in which section 21 of FSMA does not apply to the underwriters; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have complied with, and will comply with all applicable provisions of FSMA with respect to anything done by them in relation to the common shares in, from or otherwise involving the United Kingdom. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is directed solely at persons who (i)&nbsp;are outside the United Kingdom, (ii)&nbsp;have professional experience in matters
relating to investments or (iii)&nbsp;are persons falling within Article 49(2)(a) to (d)&nbsp;of The Financial Services and Markets Act (Financial Promotion) Order 2005 (all such persons together being referred to as Relevant Persons). This
prospectus must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this prospectus relates is available only to relevant persons and will be engaged in with Relevant Persons only.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the shares or this offering may be publicly distributed or
otherwise made publicly available in Switzerland. Neither this document nor any other offering or marketing material relating to this offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In
particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on
Collective Investment Schemes, or the CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the
DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the
information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their
own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice
to Prospective Investors in Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has
been lodged with the Australian Securities and Investments Commission, or the ASIC, in relation to this offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act
2001, the Corporations Act, and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons, the Exempt Investors, who are &#147;sophisticated investors&#148; (within
the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations
Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares applied
for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under this offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian on-sale restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the
investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the
information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the common shares has
been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong
(except if permitted to do so under the securities laws of Hong Kong). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948,
as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in
compliance with all applicable laws, regulations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148;
shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors
in Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be circulated or distributed, nor may the Non-CIS Securities be offered or sold, or be made
the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore,
the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in
accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the Non-CIS Securities are subscribed or purchased
under Section&nbsp;275 of the SFA by a relevant person which is: (a)&nbsp;a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital
of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that
corporation or that trust has acquired the Non-CIS Securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of the issuer or its affiliates. If the underwriters or their affiliates
have a lending relationship with us, the underwriters or its affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, the underwriters and their affiliates would hedge such exposure by
entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common shares offered hereby. Any such credit
default swaps or short positions could adversely affect future trading prices of the common shares offered hereby. The underwriters and certain of their affiliates may also communicate independent investment recommendations, market color or trading
ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_23"></A>EXPENSES OF THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our expenses in connection with this offering, other than underwriting discounts and commissions, will be as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:31.55pt; font-size:8pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> *</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All amounts in the table are estimates except the U.S.
Securities and Exchange Commission registration fee, the NASDAQ listing fee and the FINRA filing fee. The Company will pay all of the expenses of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common shares and certain other matters of Swiss law will be passed upon for us by Vischer AG. Certain matters of U.S.
federal and New York State law will be passed upon for us by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York, and for the underwriters by Goodwin Procter LLP, Boston, Massachusetts. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of AC Immune SA for the years ended December&nbsp;31, 2014 and 2013 and for each of the years in the two-year period
ended December&nbsp;31, 2014, have been included herein in reliance upon the report of Ernst&nbsp;&amp; Young AG, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting
and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_26"></A>ENFORCEMENT OF JUDGMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland and our registered office and domicile is located in Ecublens, Switzerland. Moreover, a number
of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service
of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United
States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon
the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss
Federal Act on International Private Law. This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result would be incompatible with Swiss public policy. Also, mandatory
provisions of Swiss law may be applicable regardless of any other law that would otherwise apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switzerland and the United States do
not have a treaty providing for reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set
forth in the Swiss Federal Act on Private International Law. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment of such non-Swiss court has become final and non-appealable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment does not contravene Swiss public policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in
Switzerland. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_27"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the U.S. Securities and Exchange Commission, the SEC, a registration statement (including amendments and exhibits to the
registration statement) on Form F-1 under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the
registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we
refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may review a copy of the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials
at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet website
that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to the informational requirements of the Exchange Act. Accordingly, we will be
required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. Those reports may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt
under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
are registered under the Exchange Act, although we intend to report our results of operations voluntarily on a quarterly basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom16439_28"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_1">Balance Sheets as at September&nbsp;30, 2015 and December&nbsp;31, 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_2">Income Statements and Statements of Comprehensive Income for the Nine Months Ended September&nbsp;
30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_3">Statements of Changes in Equity for the Nine Months Ended September&nbsp;30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_4">Statements of Cash Flows for the Nine Months Ended September&nbsp;30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_5">Notes to the Interim Condensed Financial Statements for the Nine Months Ended September&nbsp;30, 2015 and
2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_7">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_8">Balance Sheets as at December&nbsp;31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_9">Income Statements and Statements of Comprehensive Income for the fiscal years ended December&nbsp;
31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_10">Statements of Changes in Equity for the fiscal years ended December&nbsp;31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_11">Statements of Cash Flows for the fiscal years ended December&nbsp;31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_12">Notes to the Financial Statements for the fiscal years ended December&nbsp;31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_1"></A>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;September&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment&nbsp;&amp; Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>653</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,486</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,139</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDERS&#146; EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net employee defined benefit liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,410</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables&nbsp;&amp; other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,685</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,987</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity and liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,139</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_2"></A>Income Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands except for share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,775</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research&nbsp;&amp; development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income / (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,940</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Finance result, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>924</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (EPS):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic, income/(loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted, income/(loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Other Comprehensive Income </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income not to be reclassified to income or loss in subsequent periods (net of tax)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Re-measurement gains / (losses) on defined benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income / (loss), net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,156</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,135</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_3"></A>Statements of Changes in Equity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(70,092</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total Comprehensive income / (loss)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,135</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,135</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- preferred Series D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(80,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total Comprehensive income / (loss)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#150;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>24,156</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>24,156</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>856</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(35,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_4"></A>Statements of Cash Flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile income/(loss) for the period to net cash flows:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in pensions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferral of unearned revenue (current)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,652</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences-gain, on payables / receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows from / (used in) operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,659</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,454</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(239</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred Series D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs of issue of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost on issue of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from employee loan repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,462</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at September&nbsp;30</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,462</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_5"></A>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(CHF thousands, except share and per share amounts) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Corporate information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AC Immune SA (the &#147;Company&#148;) is a clinical stage biopharmaceutical
company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are
generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein. We believe that
our large and diverse pipeline of seven therapeutic candidates, including three clinical-stage candidates, and three diagnostic candidates has the potential to drive a paradigm shift in the treatment of a broad spectrum of neurodegenerative and
other diseases related to protein misfolding. Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that we developed using our proprietary SupraAntigen platform. Crenezumab is expected to enter
Phase 3 clinical studies in early 2016 and we believe it has the potential to become a best-in-class disease-modifying treatment for AD. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and
Morphomer (conformation-specific small molecules) to discover, design and develop medicines and diagnostics to target misfolded proteins. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim
condensed financial statements of AC Immune SA for the nine months period ended September&nbsp;30, 2015 were authorized for issue in accordance with a resolution of the Board of Directors on October&nbsp;20, 2015. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation and changes to the Company&#146;s accounting policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going concern </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the two milestone payments
received in 2015 pursuant to its collaboration agreements with Genentech. Specifically, in July the Company received a CHF 14&nbsp;million milestone payment for reaching the ED-GO decision for its anti-tau antibody program and in August the Company
received a $25&nbsp;million (CHF&nbsp;24.3&nbsp;million) milestone payment associated with the decision by Roche/Genentech to move crenezumab into Phase&nbsp;3 studies. These two milestones have increased the Company&#146;s cash position to CHF
53.7&nbsp;million as at September&nbsp;30, 2015. Furthermore, in October 2015, the Company completed an approximately $30.0 million Private Placement of preferred shares Series E which have resulted in a pro forma cash balance as of September 30,
2015 of CHF&nbsp;80.8&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company has financed its cash requirements primarily from share issuances and the revenues from
collaboration agreements. The Company is a development-stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&#146;s business are various risks and uncertainties, including the substantial
uncertainty as to whether current projects will succeed. The Company&#146;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent position and protection, (ii)&nbsp;enter into collaborations with partners in
the biotech and pharmaceutical industry, (iii)&nbsp;successfully move its product candidates through clinical development, (iv)&nbsp;attract and retain key personnel, and (v)&nbsp;acquire capital to support its operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of compliance </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed
financial statements for the nine months ended September&nbsp;30, 2015 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information required in the annual financial
statements, and should be read in conjunction with the Company&#146;s annual financial statements as of December&nbsp;31, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been
prepared under the historical cost convention. </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical judgments and accounting estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#146;s interim condensed financial statements in conformity with IAS 34 requires management to make judgments, assumptions and
estimates that affect the amounts reported in the condensed interim financial statements and accompanying notes and the related application of accounting policies as it relates to the reported amounts of assets, liabilities, income and expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i)&nbsp;revenue recognition on collaboration and licensing
agreements, (ii)&nbsp;clinical development accruals, (iii)&nbsp;pensions, (iv)&nbsp;income taxes and (v)&nbsp;share-based compensation. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing
basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income
taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has tax losses which will expire after the tax holiday period. These tax losses represent potential value to the Company to the
extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant judgment is required in
determining the classification of the Preferred Shares issued by the Company as either equity or liabilities. The Preferred shareholders receive certain preference rights that represent a significant proportion of the net assets of the Company in
the case of liquidation or certain exit events, the occurrence of which are outside the control of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting policies, new Standards,
interpretations and amendments adopted by the Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies adopted in the preparation of the interim condensed financial statements
are consistent with those followed in the preparation of the Company&#146;s annual financial statements for the year ended December&nbsp;31, 2014, except for the adoption of new standards and interpretations effective as of January&nbsp;1, 2015. The
Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nature and the effect of
these changes are immaterial to the Company&#146;s interim condensed financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenues </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research collaborations and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestones</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Licensing and collaboration agreements </B></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Research Collaboration and License Revenue </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tau-PET imaging agent in AD&#151;Collaboration agreement
of 2014 with Piramal Imaging </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd. entered into an exclusive
worldwide license agreement for the research, development and commercialization of AC Immune&#146;s tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of AD and potential tau-related disorders.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront payment of EUR 500&nbsp;thousand received from this collaboration is deferred over a period of 12 months which is the Joint Research
Collaboration period. As such, the remaining CHF 205&nbsp;thousand in deferred revenue at December&nbsp;31, 2014, was recognized until May 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Milestones </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-tau antibody in AD&#151;Collaboration agreement of 2012 with Genentech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2012, the Company has entered into an exclusive global license agreement and research collaboration with Genentech, Inc. for the development of
anti-tau antibodies for the potential treatment and diagnosis of AD and other human diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of this agreement, Genentech has made an
upfront payment to AC Immune, with the potential of over CHF 400&nbsp;million in payments upon successful completion of non-clinical, clinical and regulatory milestones for Alzheimer&#146;s and additional applications. Upon commercialization of a
product, Genentech will pay AC Immune royalties on net sales of AC Immune&#146;s antibodies in the field of Alzheimer&#146;s or other human applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront payment received from the collaboration with Genentech is deferred over a period of two years, ending June 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2015, the Company recognized as revenue a milestone payment of CHF 14&nbsp;million as there is no further performance obligation. This milestone was
due upon the ED-GO decision by Genentech on the anti-tau Antibody&#146;s Product in AD. At the same time, Genentech announced that it intends to move the anti-tau Antibody program into phase&nbsp;1 clinical studies in late 2016. On July&nbsp;3,
2015, the Company received the proceeds related to this milestone payment of CHF 14&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-Abeta antibody in AD &#151; Collaboration
agreement of 2006 with Genentech </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>In November 2006, AC Immune signed an exclusive, worldwide licensing agreement for crenezumab, our<I>
</I>humanized monoclonal antibody targeting misfolded Abeta. Genentech recently announced it intends to<I> </I>commence Phase&nbsp;3 clinical studies for crenezumab in 2016. If crenezumab receives regulatory approval,<I> </I>we will be entitled to
receive royalties that are tied to annual sales volumes with different royalty rates<I> </I>applicable in the U.S. and Europe. These percentage rates range from the low double digits to the mid-teens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement with Genentech, we may become eligible to receive payments totaling in excess of $340&nbsp;million, excluding royalties. On July&nbsp;29,
2015 we received the proceeds from milestone payment of $25&nbsp;million (CHF 24.3&nbsp;million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of our accounting policies and the fact that
there are no further performance requirements from AC Immune, we have recognized the Phase&nbsp;3 payment as revenue in our Q3 2015 financials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income tax </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was granted by the Canton de Vaud, Switzerland, a 10-year tax holiday for
all income and capital taxes on a communal and cantonal level, commencing in the fiscal year 2005 and valid through to December&nbsp;31, 2014. It has also been granted a 9-year tax holiday for direct Swiss Federal tax commencing in the fiscal year
2006 through to December&nbsp;31, 2014. Therefore, the Company has not recognized any deferred tax asset relating to tax loss carry-forward expiring by the end of 2014 since they will expire within the tax holiday period and also because of a
forecasted effective tax rate of nil. The Company has also not recognized any deferred tax asset relating to tax loss carry-forward expiring after the tax holiday since the criteria for recognition are not met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax expense recognized for the nine month period to September&nbsp;30, 2015, is based on the best estimate of the weighted average annual income
tax rate expected for the full financial year to December&nbsp;31, 2015. The estimate of the weighted average annual income tax rate 2015 takes into consideration the utilization of previously unrecognized tax losses, as the Company has made taxable
profits for the nine month period to September&nbsp;30, 2015 and expects also to make taxable profits for the full financial year to December&nbsp;31, 2015, due to contract revenue earned in 2015. In accordance with IAS 34, no deferred tax assets
have been recognised at the date of the interim balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The major components of income tax expense in the interim condensed statement of income or
loss are: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accounting income / (loss) before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,864</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax expense calculated at the statutory rate of 22.5% (2014: 0%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Swiss tax holiday</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax rate benefit / (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related-party transactions </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key management including the Board of Directors (five persons) and the
Executive Officers (four persons) compensation is: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2015, one of the Board members resigned reducing the number of Board members to four as at
September&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2015, we expanded our Executive Team by one person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term employee benefits comprise salaries, bonus payments, social security and expenses allowances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">180 options were granted to Executive Officers of the Company for the nine months ended September 30, 2015 compared to 250 options for the nine months ended
September 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No options were granted to Directors of the Company for the nine months ended September 2015 compared to 205 options that were granted
for the nine months ended September 30, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share-based compensation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has created conditional share capital for the potential issuance
of common shares under the stock option plan for employees, board members and persons in comparable positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors administers the
stock option plans. The granting to employees, Executive Officers and members of the Board of Directors is, according to the stock option plan regulations, under the discretion of the Plan Administrator, who is elected by the Board of Directors. All
plans are equity-settled plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Update on Plan A: SOP 2003/2004 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this plan a total of 1,451 options on common shares were granted and vested in 2004. The exercise price was set at CHF 232.97, the lock-up period was
four years and the duration is 10.5 years from the date of grant, which was December&nbsp;31, 2004. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2015 the Board of Directors has
decided to modify the conditions of exercise of these options and amend the above mentioned Notice as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reduction of the Exercise Price (Strike
Price): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-Exercise Price (Strike Price): &nbsp;&nbsp;&nbsp;&nbsp;CHF 36.37 (instead of CHF 232.97) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extension of the Expiration Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-Expiration Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;June&nbsp;30, 2017 (instead of June&nbsp;30, 2015) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net impact of the change in the Plan A options was an increase in share-based compensation costs for the nine month period ended September&nbsp;30, 2015
of CHF 336 thousand. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Movements in the number of options outstanding are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan A </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Strike&nbsp;price<BR>in CHF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Strike&nbsp;price<BR>in CHF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>- of which exercisable</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,451</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,451</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding as at September&nbsp;30</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,451</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36.37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,451</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>232.97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>- of which exercisable</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,451</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,451</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average remaining life of options in circulation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.8&nbsp;years</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.8&nbsp;year</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited interim condensed financial statements </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial instruments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts of financial assets and financial
liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial assets</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Receivables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,861</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,241</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial liabilities</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above contains assets and liabilities held at amortization cost. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Post balance sheet events </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 23, 2015, AC Immune completed a private placement of Series E
preferred shares, each with a nominal value of CHF 5.00 per share (the &#147;Series E Private Placement&#148;). An aggregate of 12,453 Series E preferred shares were issued at a price of $2,409.06 per preferred share to certain institutions and
existing shareholders in the Series E Private Placement for an aggregate subscription amount of approximately $30.0&nbsp;million. The Series E preferred shares have substantially the same terms as the Series A, B, C and D preferred shares and will
be as accounted for as equity on AC Immune&#146;s balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin16439_7"></A>Report of Independent Registered Public Accounting Firm </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Shareholders of AC Immune SA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying balance sheets of AC Immune SA at December 31, 2014 and 2013, and the related income statements, statements of comprehensive income, statements of changes in equity and statements of cash flows for each of the two years
in the period ended December 31, 2014. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AC Immune SA
at December 31, 2014 and 2013, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2014, in conformity with International Financial Reporting Standards as issued by the International
Accounting Standards Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young AG </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst
&amp; Young AG </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Geneva, Switzerland </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 25, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_8"></A>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment&nbsp;&amp; Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDERS&#146; EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net employee defined benefit liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,410</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables&nbsp;&amp; other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,820</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity and liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_9"></A>Income Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years<BR>Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands except for share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,637</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research&nbsp;&amp; development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(20,135</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income / (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,498</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Finance result, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (loss) before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,243</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,243</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (EPS):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic, income/(loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted, income/(loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings/(loss) per share&nbsp;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings/(loss) per share fully&nbsp;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Comprehensive Income </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income / (loss) for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,243</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income not to be reclassified to income or loss in subsequent periods (net of tax)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Re-measurement gains/(losses) on defined benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income / (loss), net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,426</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,739</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_10"></A>Statements of Changes in Equity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(59,608</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,532</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the period in 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total comprehensive income / (loss)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,739</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(10,739</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- preferred Series D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(70,092</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(70,092</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Profit for the period in 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total comprehensive income / (loss)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>9,426</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>9,426</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- preferred Series D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_11"></A>Statements of Cash Flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net income / (loss) for the period to net cash flows:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in pensions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferral of unearned revenue (current)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,641</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,865</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(131</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(249</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred Series D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs of issue of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost on issue of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from employee loan repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,801</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,008</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction cost due on closure of Series D round financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_12"></A>Notes to the Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>General information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AC Immune SA (the &#147;Company&#148;) is a clinical stage biopharmaceutical
company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are
generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein. We believe that
our large and diverse pipeline of seven therapeutic candidates, including three clinical-stage candidates, and three diagnostic candidates has the potential to drive a paradigm shift in the treatment of a broad spectrum of neurodegenerative and
other diseases related to protein misfolding. Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that we developed using our proprietary SupraAntigen platform. Crenezumab is expected to enter
Phase&nbsp;3 clinical studies in early 2016 and we believe it has the potential to become a best-in-class disease-modifying treatment for AD. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and
Morphomer (conformation-specific small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
was initially incorporated as a limited liability company on February&nbsp;13, 2003 in Basel and effective August&nbsp;25, 2003 was transitioned into a stock company. The Company&#146;s corporate headquarters are located at EPFL Innovation Park
Building B, Ecublens/Lausanne, Vaud, Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies adopted in the preparation of these financial statements are set out
below. These policies have been consistently applied to all the years presented, unless otherwise stated. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the Company&#146;s cash position
of CHF 3.3&nbsp;million as at December&nbsp;31, 2014, the non-refundable upfront fee payment of CHF 25.9&nbsp;million associated with the licensing agreement the Company entered into with Janssen Pharmaceuticals on December&nbsp;24, 2014 (funds
received on February&nbsp;6, 2015) and also in the light of current financial plans and financial commitments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have considered the two
milestone payments we received in 2015 pursuant to our collaboration agreements with Genentech including a CHF 14&nbsp;million milestone payment for reaching the ED-GO decision for our anti-tau antibody program and a $25 million (CHF 24.3 million)
milestone payment associated with the decision by Roche/Genentech to move crenezumab into Phase 3 studies. These two milestones have increased our cash balance as at mid-August 2015 to over CHF 57.6 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company has financed its cash requirements primarily from share issuances and revenues from collaboration agreements. The Company is a
development-stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&#146;s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will
succeed. The Company&#146;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent position and protection, (ii)&nbsp;enter into collaborations with partners in the biotech and pharmaceutical industry,
(iii)&nbsp;successfully move its product candidates through clinical development, (iv)&nbsp;attract and retain key personnel, and (v)&nbsp;acquire capital to support its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of
compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the
International Accounting Standards Board (IASB). These financial statements have been approved for issue by the Board of Directors on August&nbsp;25, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been
prepared under the historical cost convention. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functional currency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of the Company are presented in Swiss Francs (CHF), which is also the functional currency of the Company. All financial information
presented in Swiss francs (except for share capital and earnings per share data) has been rounded to the nearest thousand CHF (CHF thousands), unless otherwise indicated. The Company also has transactions denominated in U.S. Dollars ($)&nbsp;and
Euros (EUR) that are translated to CHF at the date of transaction or as of the balance sheet date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of significant accounting policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies adopted in the preparation
of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current vs. non-current classification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within twelve months after the reporting period to be current and all other amounts to be
non-current. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign currency transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign
currency transactions are translated into the functional currency Swiss Francs (CHF) using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates
of exchange prevailing at reporting date. Any gains or losses from these translations are included in the income statement in the period in which they arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue includes license fees,
milestone payments as well as revenue from research agreements associated with collaborations with third parties and grants from public institutions and foundations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Upfront fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from non-refundable, upfront
license fees and performance milestones where the Company has continuing involvement is recognized over the estimated performance or agreement period, depending on the terms of the agreement. The recognition of revenue is prospectively changed for
subsequent changes in the development or agreement period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For collaboration agreements on product candidates that are (i)&nbsp;in clinical development,
(ii)&nbsp;where the upfront payment reflects a payment for past investments the Company has made in the development of the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate, access to the product candidate, the associated intellectual property and our knowledge, and, (iii)&nbsp;where there is no further performance commitment, pursuant to guidelines on
revenue recognition as contained in IAS 18, the Company recognizes the fair value of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements (i)&nbsp;in clinical development but where conditions
(ii)&nbsp;and (iii)&nbsp;are not met, the Company recognizes revenue from upfront payments under our collaboration agreements pro-rata over the term of the estimated period of performance under each agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For collaboration agreements, in addition to receiving upfront payments, the Company is also entitled to milestone and other contingent payments upon
achieving pre-defined objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestone payments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from milestones, if they are non-refundable and deemed substantive, are recognized upon successful accomplishment of the milestones. To the extent that
non-substantive milestones are achieved and the Company has remaining performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grants provide funding for certain types
of expenditures in connection with research and development activities over a contractually-defined period. Revenue related to grants is recognized in the period during which the related costs are incurred and the related services are rendered,
provided that the applicable performance obligations under the grants have been met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development expenditure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the stage of development of the Company&#146;s products, all research expenditure is recognized as expense when incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For external research contracts the &#147;stage of completion&#148; method is used to estimate the amount of accrued expense related to the research projects
for its clinical studies. The Company estimates its accrued expenses as of the balance sheet date in the financial statement based on facts and circumstances known at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when
incurred as long as the research and development project concerned does not meet the criteria for capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upfront payments relating to
in-licensing agreements are recognized over an appropriate, project-specific duration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property, plant and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures
that are directly attributable to the acquisition of the items. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IT equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laboratory&nbsp;equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leaseholds&nbsp;improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets&#146; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where
an asset&#146;s carrying amount is greater than its estimated recoverable amount, it is written down immediately to its recoverable amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Profits and
losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the income statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intangible
assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenditure to acquire patents, trademarks and licenses is capitalized and amortized using the straight-line method over their useful lives of
five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses at the balance sheet date are charged against the income statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial assets&nbsp;&amp; liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s financial assets and liabilities are only comprised of receivables, cash and cash equivalents and trade payables. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receivables </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receivables are non-derivative financial assets with fixed payments that are not quoted in an active market. They arise when the Company provides money, goods
or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities greater than 12 months after the balance sheet date. These are classified as long-term assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receivables are measured at amortized cost. Amortized cost is the amount at which the receivable is measured at initial recognition minus principal
repayments, plus or minus the cumulative amortization using the effective interest method of any difference between that initial amount and the maturity amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at
the bank comprise the cash on hand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trade payables </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses at each period whether there is objective evidence that those financial assets are
impaired. Impairment losses are recognized in the income statement<B>.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary (Common) Shares as well as Series A, B, C and D Preferred Shares are classified as equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses directly attributable to the issue of new shares are shown in equity as a deduction, net of tax, from the proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AC Immune has four classes (Class A, B, C and D) of Preferred Shares outstanding. The Preferred Shares are a class of shares that AC Immune SA issued in
connection with four separate capital increases and convey voting rights and certain other rights to their holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Shares own
79.7% of the total amount of shares outstanding (assuming conversion of the Preferred Shares into Common Shares on a one-for-one basis), have been the primary source of equity financing for the Company over the past 12 years and the Company&#146;s
Board of Directors consists predominantly of holders of Preferred Shares. The Preferred Shares do not have mandatory redemption features and the redemption of the Preferred Shares is within the control of the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Shareholders&#146; Agreement allows for the conversion of Preferred Shares into Common Shares under certain circumstances, all of which are at the
discretion of the Board or our Shareholders. The Preferred Shares have to be converted into Common Shares in the event of a change of control or an initial public offering or some other form of liquidity event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting rights associated with Preferred Shares are the same as for Common Shares-each Preferred Share entitles the holder to one vote. No dividends have
been paid on the Preferred Shares and the holders of Preferred Shares are not entitled to any dividends unless dividends are paid on the Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Shares have a liquidation preference wherein, in the event of a change of control or a liquidation of the Company, the holders of Preferred
Shares are entitled to receive, prior and in preference to the holders of Common Shares, the amount corresponding to the price paid for each Preferred Share. Thereafter, all holders of Preferred Shares will participate with the holders of Common
Shares on an as-if-converted basis in any remaining proceeds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-employment benefits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates the
mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated
contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net pension liability is the
present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected unit credit
method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&#146; projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to
maturity approximating the terms of the related liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share-based compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of options
and shares is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting
conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It
recognizes the impact of the revision of original estimates, if any, in the income statement, and a corresponding adjustment to equity over the remaining vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted under the Company&#146;s stock option plans A, B and C are valued using the Black-Scholes model (see Note 16). This valuation model as
well as parameters such as expected volatility and expected term of the stock options was partially based on management&#146;s estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds
received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions are recognized when the Company
has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current income tax assets and liabilities for
the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the
country where the Company operates and generates taxable income. Taxation is provided for in accordance with the fiscal regulations of the respective country in which the Company operates. Deferred tax is provided using the liability method on
temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is
settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It
is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the balance sheet date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary
differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss
carryforwards, historically, due to the fact that the Company had limited certainty on key milestones, it has not recognized any deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnings/Loss per share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents basic earnings/loss per share for each period in the financial statements. The earnings/loss per share is calculated by dividing the
earnings/loss of the period by the weighted average number of shares (common and preferred) outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options were
vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from basic and dilutive earnings per share calculation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical judgments and accounting estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i)&nbsp;revenue recognition on collaboration and licensing
agreements, (ii)&nbsp;clinical development accruals, (iii)&nbsp;pensions, (iv)&nbsp;income taxes and (v)&nbsp;stock-based compensation. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing
basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income
taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As disclosed in Note 14, the Company has tax losses which will expire after the tax holiday period. These tax losses represent potential value
to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant judgment is required in
determining the classification of the Preferred Shares issued by the Company as either equity or liabilities. The Preferred shareholders receive certain preference rights that represent a significant proportion of the net assets of the Company in
the case of liquidation or certain exit events, the occurrence of which are outside the control of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting
misfolded proteins which are present in a broad range of neurodegenerative diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, management considers that there is only one operating
segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Standards, amendments and interpretations effective in current reporting period but without impact on the Company financial statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards, amendments and interpretation currently are mandatory for accounting periods beginning on or after January&nbsp;1, 2014 but
did not have any effect on the Company financial statements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRS 10, IFRS 12 and IAS 27 <I>Investment Entities</I> (Amendments) </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IAS 19 <I>Employee Benefits entitled Defined Benefit Plans: Employee Contributions</I>&#151;<I>Amendments to IAS 19</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IAS 32 <I>Offsetting Financial Assets and Financial Liabilities&#151;Amendments to IAS 32</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IAS 36 <I>Recoverable Amount Disclosures for Non-Financial Assets&#151;Amendments to IAS 36</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IAS 39 <I>Novation of Derivatives and Continuation of Hedge Accounting&#151;Amendments to IAS 39</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">IFRIC 21 <I>Levies</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual improvements (Dec 2013) </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as several other amendments from the annual improvement project of
IFRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Standards, amendments and interpretations to existing standards not yet effective </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain new standards, amendments and interpretations to existing standards have been published and are mandatory for accounting periods beginning on or after
July&nbsp;1, 2014 or later periods but which the Company has not adopted early: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:160.90pt; font-size:8pt; font-family:Times New Roman"><B>Recently released Standards/ Interpretations&#151;<BR>check which ones are applicable for
disclosure</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Issued</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effective date (mostly annual periods<BR>beginning on or after)
Early adoption<BR>is&nbsp;often&nbsp;permitted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Planned&nbsp;application<BR>by AC Immune</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFRS 9 Financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nov&nbsp;2009&nbsp;to July&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Effective Jan 1, 2018 with early adoption allowed Early application of the own credit risk improvements, prior to any other changes in the accounting for financial instruments, is permitted by IFRS 9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan&nbsp;1,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accounting for Acquisitions of Interests in Joint Operations (Amendments to IFRS 11)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">An entity shall apply those amendments prospectively in annual periods beginning on or after January&nbsp;1, 2016.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non&nbsp;applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Clarification of Acceptable Methods of Depreciation and Amortization (Amendments to IAS 16 and IAS 38)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An entity shall apply those amendments prospectively for annual periods beginning on or after January&nbsp;1, 2016. Earlier application
is</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">permitted.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan&nbsp;1,&nbsp;2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IFRS 15 Revenue from Contracts with Customers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual periods beginning on or after January&nbsp;1, 2017. Earlier application permitted.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Note: IASB has proposed 1 year deferral</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan&nbsp;1,&nbsp;2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agriculture: Bearer Plants (Amendments to IAS 16 and IAS 41)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">An entity shall apply those amendments for annual periods beginning on or after January 1, 2016. Earlier application is permitted.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:160.90pt; font-size:8pt; font-family:Times New Roman"><B>Recently released Standards/ Interpretations&#151;<BR>check which ones are applicable for
disclosure</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Issued</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effective date (mostly annual periods<BR>beginning on or after)
Early adoption<BR>is&nbsp;often&nbsp;permitted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Planned&nbsp;application<BR>by AC Immune</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Method in Separate Financial Statements (Amendments to IAS 27)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Aug&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with earlier application being permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to IFRS 10 and IAS 28)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sept&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with earlier application being permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Improvements 2012-2014 Cycle</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sept&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with earlier application being permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan&nbsp;1,&nbsp;2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disclosure Initiative (Amendments to&nbsp;IAS&nbsp;1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dec&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with early application permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan&nbsp;1,&nbsp;2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investment Entities: Applying the Consolidation Exception (Amendments to IFRS 10, IFRS 12 and IAS 28)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dec&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with early application permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not yet evaluated the impact of these revised standards and amendments on its financial statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property, plant and equipment and intangible assets </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Laboratory<BR>Equipment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IT<BR>Equipment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Building<BR>and&nbsp;Furniture</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Historical cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,571</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>136</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,815</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>172</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated depreciation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>74</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>92</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>418</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>544</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial assets </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposit (restricted cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Prepaid expenses and accrued income </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prepaid expenses relate mainly to research contracts with down-payments at contract signature and their related activities
will start or continue in 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other current receivables </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss VAT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maturity of these assets is less than three months. The Company considers the counterparty risk as low and the carrying
amount of these receivables is considered to correspond to the fair value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cash and cash equivalents </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By Currency</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EUR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the balance sheet date, Company funds were held in CHF, EUR and USD bank accounts. Assets in EUR and USD were translated
into CHF at a rate of 1.21463 and 0.99879, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share capital </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, the issued share capital amounting to CHF 853,900 is
comprised of 170,780 shares. The table below summarizes the capital structure: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares with a nominal value of CHF 5 each</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series A with a nominal value of CHF 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series B with a nominal value of CHF 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series C with a nominal value of CHF 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series D with a nominal value of CHF 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">853,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common and Preferred Shares have a nominal value of CHF 5 and are fully paid in. In a liquidation or winding up event
(including trade sale), Preferred A, B, C and D Shares are senior to common shares in such a way that Preferred shareholders get in advance, prior and in preference to the holders of common shares, the amount corresponding to the price paid for each
Preferred Share. The remaining funds shall be distributed pro-rata to all shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Increase of Conditional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extraordinary General Assembly held on November&nbsp;28, 2013, approved an increase of the conditional capital of 2,910 registered Common Shares with a par
value of CHF 5.- These shares are reserved for the Company&#146;s stock option plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of Preferred Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2013, the Company successfully completed a financing round of CHF 20 million. The share price of the round was CHF 1,212.90 for each of
the 16,490 Series D Preferred Shares (8,245 issued immediately in December 2013 and 8,245 as authorized capital subscribed in May 2014). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Trade payables and accrued liabilities </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An accrual of CHF 947&nbsp;thousand and CHF 568&nbsp;thousand was recognized for performance-related remuneration relating to
2014 and 2013, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current portion of deferred income </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd. entered into an exclusive worldwide license agreement for the research,
development and commercialization of AC Immune&#146;s tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of AD and potential tau-related disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront payment of EUR 500&nbsp;thousand (CHF 616 thousand) received in May 2014 from this collaboration is deferred over a period of 12 months. As of
December&nbsp;31, 2014, the remaining CHF 205&nbsp;thousand is recorded as a current liability in deferred income. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenues </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration agreement of 2006 with Genentech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2006, AC Immune signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal antibody targeting misfolded Abeta.
Genentech recently announced it intends to commence Phase&nbsp;3 clinical studies for crenezumab in 2016. If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different
royalty rates applicable in the U.S. and Europe. These percentage rates range from the low double digits to the mid-teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement with
Genentech, we may become eligible to receive payments totaling up to approximately $340 million, excluding royalties. As at August&nbsp;25, 2015 we have received total payments of $65 million (CHF 70.1 million): $40 million (CHF 45.8 million) were
received in three milestone payments prior to 2013 and $25 million (CHF 24.3 million) were received in the subsequent period in July 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
recognize the Phase&nbsp;3 payment in our third quarter financials since there is no further performance requirement on our side. The agreement provides for a second therapeutic product based on the same intellectual property and anti-Abeta antibody
compound as well as an anti-Abeta diagnostic product. Genentech may terminate the agreement at any time by providing three months&#146; notice to us. In such event all costs incurred are still refundable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration agreement of 2012 with Genentech </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June
2012, we entered into a second partnership with Genentech to commercialize our anti-tau antibodies for use as immunotherapeutics. The value of this exclusive, worldwide alliance is potentially greater than CHF 400&nbsp;million and includes upfront
and milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to high single digits. The agreement also provides for collaboration on two additional
indications built on the same anti-tau antibody program as well as a potential anti-tau diagnostic product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date we have received payments totaling CHF 31&nbsp;million including a subsequent CHF 14&nbsp;million
milestone payment received in the second quarter of 2015 associated with the recent selection of the lead candidate to be taken forward into Phase&nbsp;1 clinical studies. Genentech also announced it intends to commence Phase&nbsp;1 clinical studies
for this product candidate in 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genentech may terminate the agreement at any time by providing three months&#146; notice to us. In such event all
costs incurred are still refundable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration agreement of 2014 with Janssen Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December of 2014, we entered into a partnership with Janssen Pharmaceuticals, a Johnson&nbsp;&amp; Johnson company, to develop and commercialize therapeutic
anti-tau vaccines for the treatment of AD and potentially other tauopathies. The partnership includes a worldwide exclusive license and research collaboration. We and Janssen will co-develop the lead therapeutic vaccine, ACI-35, through Phase 1b
completion. From Phase&nbsp;2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. ACI-35 is an active therapeutic vaccine stimulating the patient&#146;s immune system to produce
a polyclonal antibody response against phosphorylated tau protein. The agreement also allows for the collaboration to be expanded to a second indication based on the same anti-tau vaccine program and intellectual property related to this program.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received an upfront payment of CHF 25.9&nbsp;million which we recognized in 2014 and are eligible to receive development, regulatory and
commercialization milestone payments for AD and a potential second indication outside of AD. Additionally, we will receive royalties on sales at a percentage rate ranging from the low double digits to mid-teens. The two companies have entered into a
three-year joint research collaboration to further characterize and develop novel vaccine therapies for the treatment of tauopathies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of this
agreement, AC Immune has committed to spending CHF 13.8&nbsp;million in research and development to the end of Phase&nbsp;1b which is currently anticipated at the end of 2016. Under the terms of the agreement, Janssen may terminate the agreement at
any time after completion of the Phase&nbsp;1b clinical study by providing 90 days&#146; notice to us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The recognition of the upfront payment from
Janssen was recorded at the time of receipt as the Company determined that the license granted to Janssen was a separate, non-contingent deliverable under the agreement. The Company determined the license had stand-alone value based on
Janssen&#146;s ability to create value from the license without our R&amp;D support services due their extensive experience in vaccine development and production which would allow them to complete the phase 1b clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration agreement of 2014 with Piramal Imaging </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
May 2014, we entered into our first diagnostic partnership with Piramal Imaging, one of the world leaders in imaging products. The agreement with Piramal is for a compound from the Morphomer chemical library that binds pathogenic tau aggregates for
use as a PET tracer. The exclusive, worldwide licensing agreement with Piramal Imaging includes upfront and sales milestone payments totaling up to EUR 157&nbsp;million, plus royalties on sales at a percentage rate ranging from mid-single digits to
low double digits. We received an upfront payment of EUR 500&nbsp;thousand and are entitled to further clinical milestones totaling EUR 7&nbsp;million should the compound make it through to Phase 3 clinical studies and are further entitled to
regulatory, commercialization and sales based milestones totaling EUR 150 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piramal may terminate the agreement at any time after the first
eighteen months from the effective date of this agreement by providing three months&#146; notice to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both 2013 and 2014, we recognized revenue associated with a research grant given to us by a European Institution in October of 2011 and which had a 3-year
duration. We recognized the revenues on a straight line basis over the period of the grant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Expenses by category </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of tangible fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related-party transactions </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key management including the Board of Directors (five individuals) and the
Executive Management (three individuals) compensation is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term employee benefits comprise of salaries, bonus payments, social security and expenses allowances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 and zero options were granted in 2014 and 2013, respectively, to the Executive Management of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">205 and zero options were granted in 2014 and 2013, respectively, to the Directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income taxes </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income tax recognized in profit or loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax expense for the year can be reconciled to the accounting profit as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accounting income / (loss) before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,243</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax expense calculated at the statutory rate of 22.5% (2013: 0%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Swiss tax holiday</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,420</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax rate benefit / (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax rate used for the 2014 and 2013 reconciliations above is the corporate tax rate of 22.5% payable by corporate entities
in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was granted by the Canton de Vaud, Switzerland, a
10-year tax holiday for all income and capital taxes on a communal and cantonal level, commencing in the fiscal year 2005 and valid through to December&nbsp;31, 2014. It has also been granted a 9-year tax holiday for direct Swiss Federal tax
commencing in the fiscal year 2006 through to December&nbsp;31, 2014. Therefore, the Company has not recognized any deferred tax asset relating to tax loss carry-forward expiring by the end of 2014 since they will expire within the tax holiday
period and also because of a forecasted effective tax rate of nil. It has also not recognized any deferred tax asset relating to tax loss carry-forward expiring after the tax holiday since the criteria for recognition are not met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no income tax recognized directly in equity or in comprehensive income. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unrecognized deductible temporary differences, unused tax losses and unused tax credits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are
attributable to the following:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Tax Losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Deductible temporary differences related to the retirement benefit plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,663</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,699</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deductible temporary differences related to the retirement benefit plan do not expire. Tax losses expiry
dates are shown in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax losses split by expiry date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax losses available for future offset against taxable profits have decreased by CHF 10.5&nbsp;million, representing the
amount of tax losses that would have been used as an offset if the negotiated tax holiday had not enabled the Company to pay no taxes during 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with prior years, the Company has not recorded any deferred tax assets in relation to the past tax losses available for offset against future
profits as the recognition criteria have not been met at the last annual balance sheet date. The criteria are not expected to be met at the next annual balance sheet date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Retirement benefit plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apart from the social security plans fixed by the law, the Company maintains
one independent pension plan covering all of its employees including its executive officers. In addition to retirement benefits, the plan provides death or long-term disability benefits to its employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benefits under the plan are principally based on contributions, computed as a percentage of salary, adjusted for the age of the employee and shared
approximately 46% and 54% by employee and employer, respectively. For accounting purposes under IFRS, the plan is treated as a defined benefit plan. Liabilities and assets are calculated annually by an independent actuary. In accordance with IAS 19,
plan assets have been estimated at their fair market value and liabilities have been calculated according to the &#147;Projected Unit Credit&#148; method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This plan is governed by the Swiss employment laws, which require final salary payments to be adjusted for the consumer price index once in payment during
retirement. The defined benefit pension plan requires contributions to be made to a separately administered fund. The fund has the legal form of a foundation and it is governed by the Board of Trustees, which consists of an equal number of
employer&#146;s and employee&#146;s representatives. The Board of Trustees is responsible for the administration of the plan assets and for the definition of the investment strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each year, the Board of Trustees reviews the level of funding in the pension plan as required by Swiss employment legislation. Such a review includes the
asset-liability matching strategy and investment risk management policy. The Board of Trustees decides its contribution based on the results of this annual review. Generally, it aims to have a portfolio mix of a combined 40% in equity and property
and 60% in debt instruments. Swiss employment practice recommends the Company to clear any plan deficit (based on a valuation performed in accordance with Swiss Employment Law) over a period of no more than 5 years after the period in which the
deficit arises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio
that respects the requirements of the Swiss BVG. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main
risks are investment risk, interest risk, disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized these risks, since they are shared between a much greater number of
participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pension plan is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the
different affiliated companies. The Company has no direct influence on the investment strategy of the foundation board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the pension liability is
adjusted to consumer price index, the pension plan is exposed to Swiss inflation, interest rate risks and changes in the life expectancy for pensioners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the status of the defined benefit pension plan and the amount that should be recognized in the balance sheet: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to IAS 19, the following amounts have been recorded as net pension cost in the income statement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net pension cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A. Change in defined benefit obligation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in demographic assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in financial assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other actuarial gains / (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees&#146; contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Defined benefit obligation as of December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B. Change in fair value of plan assets </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees&#146; contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employer&#146;s contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gain / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of plan assets as of December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employer&#146;s contribution to the pension plan for the financial year 2015 are estimated to be CHF&nbsp;401 thousand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C. Change in net defined benefit liability </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net defined benefit liabilities as of January 1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net pension cost through Income Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Re-measurement through OCI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employer&#146;s contribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net defined benefit liabilities as of 31&nbsp;December</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The major categories of plan assets held by the separately administrated fund, of which the Company&#146;s pension plan assets
form a part, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Real estate and mortgages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alternative investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the plan assets above is the cash surrender value of the insurance with AXA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investment strategy defined by the Board of trustees follows a conservative profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plan assets are primarily held within instruments with quoted market prices in an active market, with the exception of the real estate and mortgages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the year
2014 and 2013 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate of future increase in compensations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate of future increase in current pensions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mortality and disability rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BVG&nbsp;2010G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BVG&nbsp;2010G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and
Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quantitative sensitivity analysis for significant assumption as at December&nbsp;31, 2014 is as shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Discount rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Future salary increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Future pension cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Assumptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">+0.5%&nbsp;increase</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">-0.5%&nbsp;decrease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">+0.5%&nbsp;increase</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">-0.5%&nbsp;decrease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">+0.5%&nbsp;increase</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">-0.5%&nbsp;decrease</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on the net defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sensitivity analyses above have been determined based on a method that extrapolates the impact on net defined benefit
obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share-based compensation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following share-based compensation plans outstanding: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.95pt; font-size:8pt; font-family:Times New Roman">PLAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>instruments&nbsp;awarded</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Vesting conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Contractual<BR>life&nbsp;of&nbsp;options</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option plan A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years&#146; service from grant date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8&nbsp;1/2&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option plan B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years&#146; service from grant date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6 1/2 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option plan C1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years&#146; service from grant date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number and weighted average exercise prices (in CHF) of options under the share option programs for Plans A, B and C1 are
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Term&nbsp;(Y)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Term (Y)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exerciseable at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The range of exercise prices for outstanding options was CHF 36.37 to CHF 232.97 as of December&nbsp;31, 2014 and 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair values of the options granted in 2014 and 2013 are CHF 192.61 and CHF 171.53, respectively. These fair values have been determined using the
Black-Scholes model and an exercise price of CHF 36.37 (2013: CHF 36.37), a spot price of CHF 225.67 (2013: CHF 203.80), a risk-free interest rate of 0.232% (2013: 0.453%) and a volatility of 50% (2013: 50%) with an expected duration of 6 years
(2013: 6 years). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price is set by the Board of Directors. The volatility is based on the historical trend of an
appropriate sample of companies operating in the biotech and pharmaceutical industry. The risk-free interest rate is based on the CHF swap rate for the expected life of the option. The weighted average fair value of exercised common share options in
2014 is CHF 225.67 (2013: CHF 203.80). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expense charged against the income statement for the financial year 2014 amounts to CHF 211 thousand (2013:
CHF 256 thousand). The expense assumes a departure rate based on the fact that some beneficiaries will not be able to exercise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and contingencies </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Between one and five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has research contracts with several external service providers. As of December&nbsp;31, 2014, external research
projects for CHF 3.1&nbsp;million were committed for 2015. Rental contract for laboratory and offices space at the EPFL Innovation Park in Ecublens/Lausanne can be cancelled within a 6 month notice period. As of December&nbsp;31, 2014, rental
contracts for CHF 169&nbsp;thousand were committed for 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income / (loss) per share </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years<BR>Ended&nbsp;December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands except for share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) attributable to owners of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (EPS):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic, income / (loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fully diluted, income / (loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings / (loss) per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings / (loss) per share, fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December 31, 2014 and 2013 basic and diluted loss per share is based on the weighted average
number of shares issued and outstanding. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Sensitivity analysis </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign currency </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company undertakes certain transactions denominated in foreign currencies. Hence, exposure to exchange rate fluctuations arises. Exchange rate exposures
are managed by matching its cash holdings to the currency structure of its expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, if the CHF had strengthened/weakened by 10% against the EUR and the USD with
all other variables held constant, the net loss for the period would have been lower/higher by CHF 25&nbsp;thousand (2013: CHF 22 thousand), mainly as a result of foreign exchange gains/losses on transaction of EUR/USD denominated assets and
liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest rates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not
materially exposed to any interest rates fluctuations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial instruments and risk management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities expose it to the following
financial risks: market risk (currency risk), credit risk and liquidity risk. The Company&#146;s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the
Company&#146;s financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts of financial assets and financial liabilities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial assets</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loans and receivables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial liabilities</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,584</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,243</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign exchange risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to foreign exchange risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and
SEK. The currency exposure is not hedged. However, the Company has the policy of matching its cash holdings to the currency structure of its expenses, which means that the Company holds predominately CHF, EUR and USD (see also Notes 8 and 19). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of the cash and cash
equivalents is held within one bank. However, the credit risk on liquid funds is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies. The maximum amount of credit risk is the
carrying amount of the financial assets. Trade and other receivables are fully performing, not past due and not impaired (see Note 7). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inherent in the Company&#146;s business are various risks and uncertainties, including its limited operating history and the high uncertainty that new
therapeutic concepts will succeed. AC Immune&#146;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent position and protection, (ii)&nbsp;enter into collaborations with partners in the biotech and
pharmaceutical industry, (iii)&nbsp;acquire and keep key personnel employed, and (iv)&nbsp;acquire additional capital to support its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s approach of managing liquidity is to ensure sufficient cash to meet its liabilities when
due. Therefore, management closely monitors the cash position on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 24 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the current cash position and the upfront fee subsequently received on February&nbsp;6, 2015 from Janssen for the anti-p-tau vaccine program in AD
(ACI-35), the Company is well financed until the end of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below shows the maturities of the liquidity relevant financial liabilities as of
December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;3<BR>months</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Between&nbsp;3<BR>months&nbsp;and<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;3<BR>months</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Between&nbsp;3<BR>months&nbsp;and<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Capital risk management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objectives when managing capital are to safeguard the
Company&#146;s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against AD. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Segment and geographic reporting </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has one Segment. The Company currently focuses all of its
resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins that are present in a broad range of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, management considers that there is only one operating segment under the requirements of IFRS 8, Operating Segments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s geographic information is worldwide. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Post balance sheet events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront payment received from Janssen for the anti-p-tau vaccine program
in AD (ACI-35) was recognized at signature on December&nbsp;24, 2014 and the further co-development cost for Phase 1b and related manufacturing cost will be equally shared between both partners. The milestone payment amounting to CHF
25.9&nbsp;million has been booked on February&nbsp;6, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2015, we received a CHF 14&nbsp;million milestone payment related to our anti-tau
antibody program which we have partnered with Roche/Genentech. Genentech also announced that it intends to move the lead compound into Phase 1 clinical studies in 2016. In July 2015, Roche/Genentech announced that they intend to commence Phase 3
clinical studies for crenezumab in early 2016. The decision to move crenezumab into Phase 3 clinical studies triggered a $25 million (CHF 24.3 million) milestone payment which AC Immune received in August 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus), all dealers
effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with
respect to their unsold allotments or subscriptions. </P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common
Shares </B></P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g58k30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:130pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:130pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Indemnification of Directors and Officers </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, a corporation may indemnify
its directors or officers against losses and expenses (except for such losses and expenses arising from willful misconduct or negligence, although legal scholars advocate that at least gross negligence be required), including attorney&#146;s fees,
judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action, suit or proceeding by reason of having been the representative of, or serving at the request of, the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Swiss law, Article 29 of our articles of association provides for indemnification of the existing and former members of our board
of directors, executive management, and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and permits us to advance the expenses of defending any act, suit or
proceeding to members of our board of directors and executive management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under general principles of Swiss employment law,
an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification agreements with each of the members of our board of directors and executive officers in the form to be
filed as an exhibit to this Registration Statement upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the underwriting agreement that we enter into in
connection with the sale of the common shares being registered hereby, a form of which will be filed as Exhibit 1.1 to this Registration Statement, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers
and persons who control us within the meaning of the Securities Act of 1933, as amended, the Securities Act, against certain liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Company, the Company has been advised that, in the opinion of the U.S. Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Recent Sales of Unregistered Securities </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth information regarding
all unregistered securities sold during the last three fiscal years. Within the last three years, the registrant has issued and sold the following securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. On December 10, 2013, the registrant issued 8,245 shares of preferred stock for aggregate consideration of CHF&nbsp;10.0
million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. On June 25, 2014, the registrant issued 8,245 shares of preferred stock for aggregate consideration of
CHF&nbsp;10.0 million. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. From September 30, 2012 through September 30, 2015, the registrant issued options to
purchase 2,174 shares of its common stock to its employees with an exercise price of CHF&nbsp;36.37 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. From
September 30, 2012 through September 30, 2015, a total of 587 options were exercised by the registrant&#146;s employees at an exercise price of CHF&nbsp;36.37 for aggregate consideration of CHF&nbsp;21,349. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. On October 21, 2015, the registrant issued 12,453 shares of preferred stock for an aggregate subscription amount of
approximately $30.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sales and issuances of restricted securities in the transactions described in the paragraphs
above were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
were no underwritten offerings employed in connection with any of the transactions set forth above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits and Financial Statement Schedules </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exhibits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the Exhibit Index beginning on page II-5 of this registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financial Statement Schedules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Undertakings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting
agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed
in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of
the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under
the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Lausanne, Switzerland on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">AC IMMUNE SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrea Pfeifer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby
constitutes and appoints Andrea Pfeifer and George Pavey and each of them, individually, as his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of
substitution and resubstitution, for him and in his name, place and stead in any and all capacities, in connection with this registration statement, including to sign in the name and on behalf of the undersigned, this registration statement and any
and all amendments thereto, including <FONT STYLE="white-space:nowrap">post-effective</FONT> amendments and registrations filed pursuant to Rule 462 under the U.S. Securities Act of 1933, and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and
about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute, may lawfully do or cause to be done by virtue hereof. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following
persons on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 in the capacities indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Chief Executive Officer<BR>(principal executive officer)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Andrea Pfeifer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Chief Financial Officer<BR>(principal financial officer and principal accounting officer)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">George Pavey</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Chief Administrative Officer<BR>(principal operating officer)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Jean-Fabien Monin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Chairman and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Martin Velasco</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Hans-Beat G&uuml;rtler</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Detlev Riesner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Matthias Hothum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Friedrich von Bohlen und Halbach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Authorized Representative in the United States</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Colleen A. DeVries</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SVP of National Corporate Research, Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are filed as part of this registration statement: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Articles of Association**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Vischer AG, Swiss counsel of AC Immune SA, as to the validity of the common shares*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Vischer AG, Swiss counsel of AC Immune SA, as to Swiss tax matters**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Davis Polk &amp; Wardwell LLP as to U.S. tax matters**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research Collaboration and License Agreement between AC Immune SA Corporation and Genentech, Inc. dated November 6, 2006**#</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to the Research Collaboration and License Agreement between AC Immune SA Corporation and Genentech, Inc. dated May&nbsp;7, 2015**#</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research Collaboration and License Agreement between AC Immune SA Corporation and Genentech, Inc. dated June 15, 2012**#</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License and Collaboration Agreement between Piramal Imaging Ltd., Piramal Imaging SA and AC Immune SA, dated May 9, 2014**#</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License, Development and Commercialization Agreement between Janssen Pharmaceuticals, Inc. and AC Immune SA, dated December 24, 2014**#</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AC Immune SA 2013 Equity Incentive Plan*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shareholders&#146; Agreement dated October 23, 2015*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subscription Agreement among certain investors and AC Immune SA, dated October&nbsp;16, 2015*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst &amp; Young AG*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Vischer AG, Swiss counsel of AC Immune SA (included in Exhibit 5.1)*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Vischer AG, Swiss counsel of AC Immune SA (included in Exhibit 8.1)**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Davis Polk &amp; Wardwell LLP (included in Exhibit 8.2)**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Powers of attorney (included on signature page to the registration statement)*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Peter Bollmann, as director nominee*</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Previously submitted. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from the registration statement and submitted separately to the United States Securities and Exchange Commission.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g16439g08h09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g08h09.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X7;;:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,34M,#DM,S!4,3,Z,C8Z,S K,#@Z,# \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-2TP.2TS
M,%0Q,SHR-CHS,"LP.#HP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,34M,#DM,S!4,3,Z,C8Z,S K,#@Z,# \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,38X/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G07%!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T98
M67$W)B-X03M&6%EQ-T9867$W1EA9<6@W=$5D-V1854UP:TY6659(.3(O:FER
M1B]/<BMD<E-A>5AY;F]L:F9W=DAC=&936$%4;$A):4$R-F]J4S)W)B-X03MB
M;3%19FDK6E@W5TMP3F58=C5U<&$R>E<O;')41W5(:W9H8W%05&-):V-S67-3
M=DLV:'(V<49Z2G8X3DLP<CA$2V]69%$O3SAA<F51)B-X03MV-58P9S9B05IJ
M85A336AE-$522FE54G1C<C9:;4%O0WAO<$\O5$974V522#@V6&QV8TXU>3!7
M>3 R9%9H34-7<6]Y;#)5*W-/46UU)B-X03M+9T5,46M,,4DK2VY*;%=55TM)
M:T)61D-Q2DIA2T)11#DT,DMQ*TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5F)*
M2$A)=D=2438K1$%%9FII<6XY4W,O=T1F168X07=#+S!X5D)A-5HR:39,<41,
M0D=#)B-X03M,85EG:%9Q1#9:.7-69&]D;F%.;W5N<S!%6DIT;U-35E=P4'!J
M,GA61R]5<E O9D5F+T%,+U1&6%-F=59I:6=662MB1E(X4'=J6FY0)B-X03MW
M9W(T67%G3E<Q=3 P9%E',4\O9W1)-VAZ2$9,3$<V>#AL4G!$>69N>%%C54IQ
M>$%X5E)I.# V1DYB1S9H,3=46DQ94W)B;61*63)1)B-X03M43WA222M1;'!Z
M6FAX0SE38U91-V5E=DM3>"MQ,VUF4GA&>#5C>F-1:&50:E@Q<55X5DY9-W@U
M.5!7+W1,<3-U8E=33#$T2F]L-7AY)B-X03M)5C5+>4]S:$)6:#!)>%9(67$W
M1EA9<7!36$U34T=-.&DT05EH561T:5-"=6]0:&ER6#%U3"M75"]K5DHO=T$P
M-'$W-C-&+TQ*+WE+)B-X03MK+S5P>%8S,75,*U=4+VM62B]Z5&EQ<$A):VMA
M>4EA;S1$2V%%8D561WAX5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I)B-X03MR<U9D:7)S5E%/=F8X8U!59BM986(O:S)C5E%M:5=6>61&<T-.
M475&0G1O4T9#=U5(-W-B8GA%-'%J9G%&,2\Q8V)J+T%)1S,O=T-Q)B-X03M7
M2W%$,D8P;6\R53=A:%!,1VI32S%U-&A#35=J3D=00TY4.%!(8F9V:7)T9#AT
M-DYR,75T=G%S1%A%0V-Q4FE75TY4>E5Q95%J6D]7)B-X03MX,C5D1%%J8T$T
M<3AW,3-Y1G)T<G)K;6TV1C54<S=Z>7)0.$%5,FUE-'4U=S5B5&\T;'1A:')X
M9&M5=6Q04S-61D161DU+<2]L1#AQ)B-X03M,3%A,45AN-6<K5F)7,3%I>619
M-T5W,V1Z35=I249W-W9)8FUD;6(V,4Y..7!Q+U!Q47(P-6)',7-.1TYL85(K
M;&$R,$)I:&IQ5S1O)B-X03MQ54%Q>$HK+T958FER<U9D:7%'8552,VMH6EA)
M84Y+1E5D:%5-.60Q0CAC5EDU-6@X=5A'<F$W<"MP4C9L3F)1,E5T=$XY5DYV
M3RLY)B-X03MU,'!F,&U6-#%J85I:=41K;S%62%$W5599=&$O;#=R3GES2W0U
M.#%3-D9T8E,V9&9P1W1Z=VMK6C586C)6<'!/36EI64PX6$EG2TU+)B-X03MV
M43E)5#9H<'-&;DQ08UAK:TLX5&-Y>'EL,S-*2$EK361H='5C0V]Y>D)&;D%#
M0T-),'%#2T5(:4]O3TMQ,DMU>%8R2W5X5C)+=7A6)B-X03LR2W5X5E)U-W!B
M84%Y;$=K*TI%5D5P>4Q33T551&M62%9U-7A64BMV,U@O5G5U4"M#="\K<75+
M=2MV,U@O5G5U4"M#="]W1'%R:7)V)B-X03MR.3$O,6)R:B]G<F8O<7)I<G9R
M.3$O,6)R:B]G<F8X039Q-'$W-B]D9CE7-C0O-$LS+S9Q-'$W-B]D9CE7-C0O
M-$LS+T%/<75+=2MV)B-X03LS6"]6=750*T-T+RMQ=4MO6%9*-S8U,'DW=#1T
M3W5056UH:VI3<E<T2$IK24@K-V9F1E9,5$PS57)B5&)3,FLP83=-:T5-8V(P
M97I))B-X03MQ:6A45"]34&)&550K;&(O05 V<S$U+W=D;B\R55EQ=&LQ0SAK
M041A3F4W1V]):W1&25!466DT0GA65"MT6% O049A3E$O-E-,9CA!)B-X03LW
M2W-69#EA=68K<E)Q2"]34F(O.6Q72W4K=%A0+U9O,40O<$ET+SA!<W%X5G!R
M:31:4W)A4'%"56EH0FYT>4-$+W="2%=+<2\V5G8O)B-X03M!4'%Z6&XO0C)F
M.$$R55EQ,V(V=%!02#9I86)C9T)N46=T8C%$4G-5668S,VEU2W%V,2LV+W=#
M<F1C9CA&8B\Y5F-69#EF=78K<F1C)B-X03MF.$9B+W=$5EA&6&98-W(O04MT
M,7@O=U9V+S%6>%9R4V]P56IN95-%=TY.3SAN<'-53%5A;$-E0EEB,#AC5E)U
M2W5X5C)+=7A6,DMU)B-X03MX5C)+=DY.52].-61*=$ER=E55:'0W958P:5=1
M<DMW1'EF6D1&95A%934R=S!H0U<O=T-E,FHS06M+,T9P1W-30U-6-2]59U96
M3$)+)B-X03M-,'9!0F=Z0494=4MI;S-'2U55=C5Y5T1+>G)D86-Y<$8Y661H
M3W!!:')X.5%N;CEI=3-,<&I314QD+VY*<%5X:G1N=DQ"4WIM5E=%)B-X03MO
M2U9S,VIL:U5V>31";$)5;&$Q<'8R>%968C@W=$E49U=V9$Y#>5)M5DI06%AG
M63%C4FQU6%!J5&UE4%AR:6Q64#5Y5T%A5E1D861Y)B-X03MH-6E9975T53E+
M;G%C=FHR-&-H>7(P>'!#*T@X,V)A961)25IR0U=E4C-J:FE364TW4$5!,&EQ
M;V5P2TMA<T\R3DMY6'EZ-6]U=%=V)B-X03M*8F5A1DEW:V9Q0FMR,EE#;350
M:FEL:VU"6%EQ-T9867$W1EA9<3=&6%EQ>'9Z3C5O=71*=DER94=&2D$X9G%&
M;G(S66EM>$AH:%9I)B-X03MA+VY66G9Q;S!P1$$Y*UAL:3E&5FU)1'=2<DI)
M1V-$9W9&6D8V;G)T,3)X<%9H+U!(4E)(-F<Q1%1'6&-$:&-)>$I!<5%O5GE3
M9"MG)B-X03LS>%9F0BMD96UZ,EEV26)I>6MG3G4Q-3A,:W8V0VUJ4T=/=DU"
M4T]*,C)/,UA&5D,Q+T]J4EE%94YD43 Q;#5035A.=V]8.3E*23E/)B-X03M8
M4&IT>&)V,GA1:4I0>G$P<4U6:W9T35%%16=T8V].;&)I,U8K>F)(,WA692]W
M0V-L9VEU-S-7;DMK635335HQ055F1'5X-3=F,VDO)B-X03LX15!(1VQ2:69M
M5F1Y,GDS345.=DY#-D-32U)'6FQD4TMQ>7-#45%2,$].3&(P1$%L,DMU>%8R
M2W5X5C)+=7A6,DMV0TY2,%13.5AS)B-X03LT24Y2:#EE1TUP2W-:9#%5<V\R
M-4)#=DEE>E9'4U%W3%AB>CAU9$HQ4S<P1R]W0DAU2D9E3D9L94IP6$1O9U,U
M9&U,4TLS=VII>DUP)B-X03M,3G@S-D%%2E$X5C$U1&4O.'=3+V]R5DAI5&QA
M-G!A2#!X17-T>D]T46ER2W-V3V%A2F9I<E190W%R5$985#,O04]7='9D,V5K
M>C9*)B-X03ME0F]P-W=Z;VMJ;44Q8C S:V1M;E)65U$R-FQE9$%P06)B-U=+
M=&%N9&9L:&%%>#-/:39I+W="8G-5=7!'1'IT5S)K2#%G0FEB:6\U)B-X03M3
M03AV1C9K+WI9<6A(.'EF;%5M<'I4<&]D,S9H3C%*8UA82U-/55-G2DE39V56
M9#(S;U%W6E-/9W)81E=A951V3"]L1V$R=&1:,'I4)B-X03M$6G9$8S-J5S8K
M<$ME16I/8F%69W!B:%(Q:$<Q2T1T:6@V="M8,R](5W50*TU"+S1M=4I532MW
M2F1I<G-69&ER<U9D:7)S5F1I<D%F)B-X03MZ0B\T-C%V+T%-64(O=T%48D-%
M1C5B-71K.'4K6'I(-6EV3$M396-80EET13AL43<R,W!02G<U96U4-D5016-H
M5#-&4V-664YE+SA!)B-X03M+<C4U-TM)861Q;'9B43)K:V=G:5!'1V5"67IQ
M2'!3;'!'9'9H64]T0TXR1E1T.$ML2%!*-4PP-C4K=%(V5F9,66963'92-W$Q
M:VQ2)B-X03M%:FEJ;FDY5VY.*U(O9C-F07-:;%5!365G<FEQ=EDO.'$Q,5-#
M-V$R,%,X6DQE2S0Y9$]5:V)&3DYG:FA+.&985G58<#-)4D%D.7I7)B-X03MN
M6$95<G0Y8R]*+S8S8GEX84AE2F-7:&EL=&Y+>41D6%-"4U%*:EAG>4M$>4A7
M=E5N9%AD1F%F3BM81W)2-F)91%$U,&$X=#1N94PV)B-X03MX2G=I:6MU4F$K
M;GEJ;$Q.4V11+T5Q0B]U=S!A=4MV54E,3S-S=$]3>G1K.4\R=&]21D1(56YI
M:4QX5599:S=!9#A+2'0R4E,W1EA9)B-X03MQ-T9867$W1EA9<3=&5THR=FM$
M4TAT65=.>&,Q6D9*;S!F8T0O:79$84M83"M81VA,23AQ>3-!:VM!1'5$14=9
M3%AJ52MN=E-U,DYR)B-X03M3,F8X=&9,.#9Q<S=Z>7%J<DEG9C!7061$5E=&
M63EI<#-">'1.368Q;68X04Q$4G)Q-'1D4S$V5T,T=$IB84,U:BLR635B=T]9
M16)H)B-X03M#,WA/26U.3W=&5%%%67)3839(-6,X;C8W669P1%-.4VYV3$PQ
M2DE24$=Y8U,X3&U.=T-9:%5";$\T,E!B8D<P56U(+T%#<C-2+SA!)B-X03ML
M;W5F*T-J+T%/<65.<E-Y3#AU3D-I5&A&3&-2<%5T>%5X0599;&U.0D@S2G%C
M8E133S!F>3-:85)Q2$\S;&QK37-4<7=L2VM#:DED)B-X03MU2W)G5E!-5F1I
M<G-69&ER<U9D:7)S5F1I<5(V>#5B<W18,41N8U-Y>&U+2D954D911%9N3R]*
M5WA607EF;'AO56]54U,S1&A71'%')B-X03M-4F]Y;6]95FHV:G1H=$9,+W=$
M;%AU:B]!4$Q28R\X04)2+SE5.&)7:W Q9GET-4DX<C958GDK=7)I># U2%!*
M;V]W>7%Z,60R2U%W)B-X03MS45!T3S=5;TYY5&IA541:3BM81B]Q>6%66F%T
M9#-6-#EZ3EI+65E:2&@K<U<X66QM:4YW='5947E)=TIQ+S0T<E1*4"M69390
M+WDP)B-X03M84#A!=U5F+T%&5'AT1DQ*4'DT,$M1;UI*8FAZ1S-/37-9:GA9
M06IK2W@W2&9',7!B9&513DE3,6U96$9Z5E59:7)2.6=F.$%I=D<Q)B-X03MP
M;&U"3'-69&ER<U9D:7)S5F1I<40Q3C4Q:FA71U9O5VQM4D=K44M7-&UT86-W
M=R]$1E9A>"\S:70K+S=T3B\Y:4U65G-6950R,S5N)B-X03MF;61B23A6.35(
M=6(R-V1N93-A1T]E,&E724IB;$9C9V%G0U=-,'1'-4)V9S-J53%O<6LK<6%P
M<65V-C-D:2\O04,R:W9P<FTT:F=7)B-X03LT;&LQ3S!#,CEU:DI(-C!H<WI%
M4B]P8WEV-E1&5U5S1'E507-64E=G*V4Y8CAV,3!B4G9Y,'9,2WAK939U955-
M5C5(0D9)-&%B-# K)B-X03MQ3T],8DM"0WHK0V]0:%1!<C!4>68U9S$O5G)6
M1')':E!P8R\Q94M6:7AB:7IU5U8Q-'5Q<VA"4W9%:VMF2VA:5FM72W!B<7)Z
M4C-&)B-X03MR2D9+,%I$2VI+07!$3$I00VI!.&=4,&)T5$95>7A6,DMU>%8R
M2W5X5C)+=7A6,DMP8G!4>E-81C%*3$LP:$Q-:7%1;T-R2%!-:6=C)B-X03M1
M1#!8=EA&57EX5FAN-6HK6G9/5V=X,D9X-6(P6CE::DQ-*V]W4G=V32]P2DI%
M=D9'4U-->'-Y>5!29VMP<5!S16-I1E=&95EV3UAM)B-X03MB>DYP1VU7,G$O
M;#EF<EHS3&TX;F=%,G!X4U)',U)Z1W-J5VQT1DMJ:5I/5D-'*T5+>7%Z<V]#
M<6IO=7,S;6DK851C,D@U6%A';6UA)B-X03M6,$XS0V)T,5E88E)P23173S)A
M1TYU3F]H879W,5 X065,5FEX5FM8;&HX,%!/*W)Z>71E95)R,U1,9%)%<5)4
M:31%=DIM:T1T>64S)B-X03MJ46HT5F]".'EW<4)I<C!Z07%J9F8W>%A(8CDR
M*R\X07-4:7%J<&IZ=$A-<S!R5$Y&339,23153GA&2U8T0E(K1TMO>D9867$W
M1EA9)B-X03MQ-T9867%G.50O-#E0*UEI4"M/2W%Q5TU#27%+6D%Q9T)2-G-M
M=T@K>7A6=C9P1B].2B]Y3FLO-7%X5C,Q4TPK850O:V)*+WI6:7)V)B-X03MQ
M:U@X,&XO23)4+VUR1EAF5DEV-7!0.$%K8DHO>E9I<G9Q:U@X,&XO04-.:R]W
M0V%S5F0Y56DO;6LO-4=Y9CA!3E=+;U15<F%*24DU)B-X03M">4Q#93)51FYD
M=&IC>&LO84HX35942$9867$W1EA9<3=&6%EQ-T9867%L,FTR,%1W4U-(:T=-
M.7EP2W4V-T,U:TDK>5(T-'%I+W%K)B-X03M8.#!N+TDR5"]M<D989E9)=C5P
M4"M2<VXO3E=+=2MQ4F9Z4V8X:EI0*V%S5F0Y56DO;6LO-4=Y9C@Q67$W-G!&
M+TY*+WE.:R\U<7A6)B-X03LS,5-,*V%4+T%*1WEF.#%9<3 Y:D$V36I'47%W
M25EE<DIU1"]!3$Q&5DQ44"M0=B]!2FE*4#19<6I-5F1I<G-6545V;TA26%53
M1E=!)B-X03M+;C!P3G=F.6II<F8Q=4PK5U0O:U9*+WI4:7)V<F-8.'-N+TEQ
M5"]M;D951G%D>$DS,50P24I*94YZ1S!V=T]V1TU6-5!U=3E01$95)B-X03MB
M.6)I+VQK+S5&4V8X,#1Q-S8S1B],2B]Y2VLO-7!X5C,Q=4PK5U0O04I&4V8X
M,#1Q=6EU27!86D8U0FM!3$)L6F1M<E0W44@X<'A6)B-X03M9=#=!>6AL16A6
M:%5%4E-B9R\W2$97+W)C6#AS;B])<50O;6Y&6&97-'8U6E K4E5N+TY/2V],
M5G)I4C=A3F)E0U-6+W)&=7I,=V1A)B-X03M)<WE--V)R*WEO<E1&56(Y8FDO
M;&LO-4939CA!3D]+=2MT>&9Y>68X:7!0*V%C5F0Y8FDO;&LO-4939C@P-'%U
M:G59;F9G3U%A:%E")B-X03MK6F1H44@W44AJ:7)P3&U*2#1(:U=O1TE61V)9
M,4$K>40T67%T*W1X9GEY9CAI<% K86-69#EB:2]L:R\U1E-F.# T<3<V,T8O
M3$HO)B-X03MY2VLO-7!X5D)A5&-32F)33&-14U)0.$%73&AL6&<W5E)P;EI'
M,E@Y<%17;4MO,S8S1B],2B]Y2VLO-7!X5C,Q=4PK5U0O:U9*+WI4)B-X03MI
M<E18<T-Q5UE30E9&4U1&2G-"+W-C5EAY,T555'%J8VEZ9VQ1<7,R>3!R.6M(
M*UE9<70K='AF>7EF.$%)<50O04IP>%8S,75,*U=4)B-X03LO:U9*+W=!,#1Q
M-S8S1B],2B]Y2VLO-7!X5D)A6F-33#EB.65#4TQL8WE.1CA$='EJ3D],-TQT
M6'=X5D<O5S1V-5I0*U)5;B]!1%1I)B-X03MR=G)C6#AS;B])<50O;6Y&5VYV
M;T52;EE30E9"3$@P<$YG4#EJ:7%N83-#2F%W;WE30FQ247<Y2U1Q05 X;D96
M6#8S1B],2B]Y2VLO)B-X03LU<'A6:F9N5%%T5#$K1S!J,'I83'I1,G0R;6%5
M=U%Z:U1E<$,P4T(O5&5"-DEZ0GA2=6\X845+<U8Q;CAV+TYL-W$P.3)03RMO
M-EIA)B-X03M44V]L=F%12F5S1U%79V=03#DY1T5:<$]4+T%003$U8F=Q=71F
M>3(X,U$S3%-V-3<Q3U=->FU666UH=F%):%E%4DI7-4Y65419=4=.)B-X03MA
M5G%V3DA#=E10<F-8.'-N+TEQ5"]M;D989E<T=C5:4"M256XO3D]+<EE81#-5
M<FA70SA)=T-Y<W4T3#$K,$(T-'%S=&)H23=A2TXQ)B-X03MK1$EI<7<Y3U$W
M9U504F-65F9R8U@X<VXO27%4+VUN1E=",G9K9E@T:D]*4$YE;U-2>3)K,7%N
M-W4K-6\X='9&0W,S2G)L>'I2-#)K)B-X03LK1E%A=#A*53%*2W!03BM76&UI
M2TA52R]M1'$X9C%W3$A::W@S<DQA=DLT5FEL8FMU+TE/>6](8C13468R4F=6
M6'4O>3$X,S-415 U)B-X03LX,5-+3#9Z3&-G47<S:V)K4W)W151-='HY:$%&
M2W%O54)Q;6TY0594<GE(-5,Q,WDS3DTK<2M:-R]W07=*2D=54F)M1S5(16U4
M;GDO)B-X03ME4WIR.$DK1F5+<65V270X4$5+>E V,T8O3$HO>4MK+S5P>%9A
M<FE7-E)L5F=Q;S19<W),=7A7;C)G4$1&6$TT:75N6FQ9<7E)1DMQ)B-X03MZ
M8G%7<CEK2'AX5F0Y8FDO;&LO-4939C@P-'$T,V-63VMG.2]3:R\U<'A6-7)$
M*U@O;D]#,G0W5F9/;#EC4DDP26MK:VEV5FQ666YU)B-X03M*5UI8.60S:UIZ
M8TEV1U)I2TET95-J:&A63&XO04-S.#0S3F@V55 U:C9S2E)+83-):'9Q.%DU
M6D,P5D9U:S)Q+T5T.7(T4E)Q8EE&)B-X03M:>C5(,%A5=DPR;%1797%A>F0V
M.6-35'1-;#-C43-!6D5+<6]J2'%V8TYT>'(Y<6TO45EQ>4PV,T8O3$HO=T%I
M<% X06UN1E9+-G5%)B-X03MK='!9,%=1<S9-<6HP-4)U4E%D5GA69DTT4S9I
M8W%X6&A)0U96;3-*4VXR469$1E8S,75,*U=4+T%*1E-F.# T<7AV>FIO1B]R
M>E=*)B-X03MS9&)V9$=7,65T=VQV1DU6=45-<U5H4G=#9W!X:5I/*WI(=%5&
M5FI-;C5:834K:G)A>G1F3BMO,D@Q87IE,%$R:U8U1D=R35IY<G!%)B-X03M,
M9W%!9W5&041C;2M"84]+0VEQ16TO3$QZ6&--4'%N-6AA=$9&1F(O049:-&I&
M9793-$-%3D](*W-R2GDY53@K3$UW<#A05$-Q-"]L)B-X03M8-716>3!8;B]6
M>GEK4U(T-55V,U$X56U6:RM'-FI:5F-Z2U-&669:1DMB14)8<'1L24QE>F=G
M;&MM=4I)63!J931E2BM5:DMO0F1Q)B-X03M,4W)D5&ER9#%C23ER36EP25=:
M1T-J,'!/<$(O>6-66'!D=39+-C(X:%9G1U4Q:C9(9CA!;GA69#E9;"\U6G!0
M=FHO-7)X5C,Q:5@O)B-X03M!2EIP4'9J+T%/83A645=P4'%%:'10<3EK,&Y#
M-&IA8FY*1VY'358U34XR-4@R,BME2V\S-GA,+T%-<S!N,W@O.#$T<3<V>$PO
M=T%S)B-X03LP;C-X+W=$3F5+=2MS4R\X<S!N,W@O.$%.94MR;W K8G-H:F%.
M;$%9:'504G%G9EI,9GDT<7-3-F0Q1'!B>4UJ0497<DAU1#!/-UEQ)B-X03LS
M.5EL+W=#5V%4-S0O=T1M=D989E=*9BM7850W-"\X06UV1E5&<7HV:$IB4G)A
M,E13=4QI,UIW.&MA04EK>74W03%A<$%8<&EQ3BMS)B-X03M3+SA!3$Y*.3AF
M.$%Z6&ER=G)%=B],3DHY.&8O0418:7)V<D5V+TQ.2CDX9B].94MT>'IL<$]$
M4G1'>$):43-%,4%O1#EK=#1J1EA3)B-X03M4;%I/0WAT27=!6F=V155"<4(Y
M;W(T2$97=G)%=B],3DHY.&8O3F5+=2MS4R]W1$Q.2CDX9B].94MU*W-3+SA!
M3$Y*.3AF.$%Z6&EQ)B-X03M#,&PY46IT<$9U<DIO;DYX8TUG4U-.=U5E6FY2
M:6%R46M.,'A61R]72F8X06QM:RLK4#A!-7)X5C,Q:5@O;&UK*RM0+T%*<GA6
M<#=P)B-X03LP574Y=DEQ2T-787-E=TA5-TYI<2M79F<V;TDR:UIG5T%8:C!7
M9U R:78X04YI<3,V>$PO04US,&XS>"\X,31Q-S9X3"]W07,P;C-X)B-X03LO
M=T1.94MU*W-3+SAS,&XS>"\X04YE2V],5%@Q0TTS9C%I>6%0;F-33D1W:VIF
M;$=A8U=/-CA4-V(O4$958CE9;"\U6G!0=FHO=T-A)B-X03LX5F0Y66PO-5IP
M4'9J+S5R>%9A.3(V27IT8GE"5D)::E=0;TXO=T-F1E=!95I96B\X5BM8-5<X
M,C-E;'=O3$9K,$LR=' U175!3&=))B-X03LS<5-23G@T>D9X1R].4T9&1'0Q
M=W%X:2]':WDV-G0S9"MB-RM(54QD1VIK94,Q,6%61E(O565/84]:1U-&26HV
M5%-Y,%5X55)68C1&)B-X03M03E9:<E=O5W%E6$Y,5R\O041';G-:>70T,$XW
M0D1Q3$=A2TYR8W4W<$A,1DER0F9I55-L<4-4-$MG5DMR2$)Q3VUW<$E9=GI3
M,6PW)B-X03M3.&=K87AN*W)A>$I+5V5.;T1X36HK:T5$<4A74FUR>2MY>4-P
M6E9(>%AE9W@S84M0>E4Q1S-J94MY4WIT-4QB55E947-C,$U4<VA-)B-X03MI
M22]R3VY&>E=I8VTV3%A&6'-0-64S1VXS4&QI,W5D3C%E-C%Z5#5I5W1D4G92
M24IN5%E$:UI64FTS1S4T:F5U=S991EI*:7%I;BLY)B-X03MK=CA!>&IJ+T%/
M2E!I<GIF>G9.0TYE,$\R;3AZ6&UG0S1T64DT1FE%,S%E860W<4E*2%='94PY
M.4E+9TMY3CA)2G)W5U)72W!:939H)B-X03MP<C9V93)T>#5V=C0W,S8W8T=3
M>F=H,6U25$5'=3!I:&=.=DI#2S%01FI&,5I%4F9I-'-654LK;S)H,$<S:75F
M>DAL:TXQ<45K5VYA)B-X03MJ2$AE;')G1S!H9%5:3&%71FAX1S5+=C9:-45R
M>&M+.$974#-S,79'175R6#AZ.5I/;E17:&U76F)85EIN.5)R9%!J5W)E:T59
M=WEY)B-X03M(;5%%64UO<'AE:7$R1396<$55:5@S-75A;$9X;#5Q<VQP9G=H
M5W1R;%)/865R.&9.>5DS3S9L:3-H44MV6E!Y-FMS<#E%:W5R2%=B)B-X03MZ
M5S=/-&YK84LV=C!M4C%)3DA24%A62#1+.5%U,4%T0G5A<U%R2V-655@O,W-I
M+S1X>68X4U1&56LX-7A03#5F,7!%,4MF4T-B24@Y)B-X03M*,G-B>E17-$)C
M;5))-'9J66=$.6YF1EAN-U=/;G=A9%!:<#5V=6],3U<T=7!*2G)/3%5)2EEP
M2'5R0G%C65A,,$EC<3AH9%)756Q6)B-X03M!-55+<59H9#(V,V1U,$AN*S9K
M:4YJ03$P8FE+*VIQ:&I)1B]',#=34F9V1E5X;&%C3UER6#%68FUQ>#(O;G-R
M,%A&=%DO;61Q86%J)B-X03MA>$UF<4-7*W12:TY.=U=0,59-<W1W07-K9G K
M>%I64#=X=55I<4=L=DY)939U;S(O3F970DUR=WA15&EX,4%R1U$T36EX<TA,
M1E@Y)B-X03M)8VY*-%50531Q>G)Y4F5A1F-E845I<W905V]A>F11>5A-<395
M5G4R:2MR>7E,2G=L.5EY.'925S=H4EA,8D1L=%5F07$Y6'=+;S-V)B-X03LK
M.&,O+T=.+RM);D953G%X06AM2DUI:C9R8V9&0V%3:EID-'I59D8T8CEC5F53
M5U=T5W)A6DIR.&9N83EL='AB3'IS2'0Y441G3F)7)B-X03LW33AI;SDP-C=2
M='EL:51I<D\Q4&E"<5923VM4-F1F>G=7.7 U=C%/>3%D9%)347<S-C9G5EI,
M3S1L4V5(:3EW64=I;FMD;W<S3FMO)B-X03MQ<%%U=7ER1W)V5W1),4XT,&DO
M33=5<DLV93!68FU',G1D66M:6&ET5FAK:U4X-&Q#:&](:S5'245L<6LQ3E-Q
M9W)Q.# W5DI.4E-()B-X03LX>F17=')%>65P8G=F5717=4,Q<VMF>%)Y2DDV
M>71X;V5:555++T573&-Q2W S;TYJ83-/=%%A1D@K865R,RMR>'HS354Y<TER
M-4I*)B-X03M*24=T-4="<DE55DDQ54-O*T9L6G%(-U=+=F1,84HT8F%+2C5$
M33AA2VI3=#EP>6]O5U!U975"5G0W+W9(4#A!.%DS+T%/26Y&541*)B-X03M:
M;SER65A59&IB,VPW0C9):65E:4Y(1S=)2FY35&A)=TMP5F=O*S!24V\V:%8U
M9TY(+TUJ5$QA2F1,.&UA5F4S1GI*3611=7(Q3%%4)B-X03MS:'5K.49836,T
M1$),8W-Q:7 R4DYL*W=#<49S3D@O36QV.$%22F9);FQU6%,W85%,06=71UE!
M6$4P4S-I2C9L>3-O<6MA1491<$AW)B-X03MQ04M+1GA69DYO4#5I=S)I,T9H
M*UA8;&A.5$9N8C%*:'0V974S<71C4D%I5D-%1&E-<4]63GHX5&165EI0-4PX
M<F%L4'%E<%,K8E!+)B-X03MU:E=C5G5S165I4&%7='-125),3$MY8W5C,&YW
M3T5F;VDQ,T%R5V=6;D=M,D=K86)$*VHY370W97IH:$%B-G!B26M3;T=Q1E!P
M;T%")B-X03M8:G1T,GA61C1Q;W O=EI,+W=!630O.$%I5#1Q;$XY;U=L,S%R
M6C-5,FHR5W S<4QB>'$Y,FMF2DEF5E(S2WE.2$MF,V10559E-T%B)B-X03MJ
M<497039T;S-N83)H3GAO+VMJ4C=Q*W5R;E5B:3=K=6]B67EL:DMQ,G-J8W)Z
M-&UL9VUN0B]E-T-I+T%0:$MQ1G1.2R]-35-T05!*)B-X03M8;#5R94]A2S=N
M4D5I;%9B-E-D66)L;S0R=5%)1RMP2#%A9V)N>$PP=W%P4V%.*UI9:'-*8F8X
M04QN>7=T,'1L3#E:-5(R-3E/671*)B-X03MB:3-J26M7:5!A4GA!.5)1.%1T
M<T%R279+4&QB5G(K-UHO3UAL4%),840V;6XQ94LS=$Q:>$9-.'IV4$5836MZ
M144X6DMH47!*+VU")B-X03LU2W,W,'I49$<P>4YR2%,W5S-S67=42S%R8E)P
M171:0V%U55%,.7!G9#9B-'%J35956"\S<VDO-'AY9CA35$960S=S8DLO839S
M-S8S)B-X03MJ=7)394=.2G)E9$9K:F13>B]#>4U#<D0U-'%X2%AT03%3-3@P
M,FMK6&PV>G5.2G0T-VM%>4,R;&ED=E)H:V=L94]4,&Y365A&=6E*)B-X03MX
M1&II=&5A.4U+<TYJ<W9Z5V%S>#AI*UA%,4MY:'1"85%W;4I(54])9E=2*T9W
M2WA!*W)W4G9H-4E$.%A&4U955&(K6"]0669864IV)B-X03MY.3AT3F)W,C O
M-D5L1G9B24QM9$@Y2S-35U Q<$]+3F)Y3U-#5C8X86EU0E9'-C!,.'I:,&Y:
M+TEN;'A:6'-A>75L=&%Y=DQC*W$V)B-X03LK:W)3,T-Q;T5B0U%C=WEN8T5I
M=7A6-G!:*U=F2V5N,TU2<SE+<TQ3-4-%46U',VAJ:T-*-EE02&EO3D8Y3U!P
M+TMV9TU#<'1I<6IE)B-X03LO=T,X8R\X07AJ9B]!26EC5E=834U-.#9W>DES
M<TUS37%34G5!>7-R1D%664A99VIQ35996'(S;%=23&DQ='1,.&]A5$YP:3-,
M975H)B-X03M724LP361Q9VAK84@O4C!Q<W%#3E594T%"1EEC9'5+<D-H6B]M
M,6)2=S,P9FM(>35:,S%L26HR45%W=T5Y>D-->4)8:G514&EN9'IX)B-X03MB
M<5%P,UE"<TMO<&9,9FYS4EA33BM86&QI4GAB5"MI,S%A,6I74V-W=W9'<%@Q
M<%!G96%38TU#=W)18G(Q6E91,5!2=GI74V%7,3!Z)B-X03MY1#5A:C O,%IK
M:6M30S%D>$<S-W8P07(S15-694QU5C1(;U(R>%8V=EDK5%!*.6A*2$Q9-D9P
M.7!*0WI013A&<D)'>4TO2&UY;%5&)B-X03M#,T)A,#8P2&AG5D]-5E5B,R]E
M3V8O:D<O=T1X131Q9W)L95=K5V<Y2S5L+V57:#0R:VYP4T-K<UHU33-/2W-A
M.5I6<CA38VA2<3!+)B-X03MR>4QZ=D)Z:3$O4DDO2RMP6#0Q4TM2-S5B5V52
M2F925%8W:5I(:CE/>FPK1U%L,V]A:V=H44=(2G=667!$-4Y15T-7<VYK-U=%
M:E5-)B-X03LW<3-.:39-9U=.2%EA6$\O=TER531%3G9)0T)Z4TXQ5DLU+TQ#
M=W11:W-F;%!Z27I2=U<Y>D=5=6=X6C5/33=1<W-D:3E(4U-2;R]S)B-X03LY
M="M+.&U#<5!B4G1F=3E8,2ME4'EL<552,3):8D5#-%)U2' O6&A+.&IT.5-:
M1U)V435!>E)K2VI%1FXO9&]Y<C$W.'5V25=L*U<T)B-X03MP.5-S6DPV3U17
M:U,U=3='*V5/47A33SAK-5AK26MK-4DQ=WEN:S,T,4]"5UHT<6]P+W9:3"]X
M:FHO-&LK2V]+-5AL<$9O4%-U6F8S)B-X03ML;V5.<$HV56=P3$=E5$YZ:7)'
M=E=682]%;DE5871#<3A7.#)A4$1F,S!K4"M'.5=U6G9-2U@Y:F1W5SEX3$%9
M-U=,5FMV1W555U-X)B-X03M"2'%Y4S=C*TML84Q6<3AG5EER4#5(:$5S8S,K
M1$YB85)W.3 P<V9Q:C T-#-F,&]&-3962DEE9G!+=W)2>'DS-&1-5E)';V9L
M.6(R)B-X03MT;6)U1'EH-6EK3W0R,W$S,&-6>E$R.&XQ-'5S06E3=UIH+V-Q
M+TQH.$MM:$%R6$9883%A*UDY5#AW87)R2V533EAI=714=#4W3#!*)B-X03M9
M-5=26&QH97E78FUT;GA+*VI(>31Y0G9T9F%!;T=697=F;%8K6$=K*U8W2#E+
M5W$S<T8Y<3!34S,Q;F5Y4GEM1U)L0F%.5T5-1$%+)B-X03LR,U%6.$]L07)0
M<U956"\S<VDO-'AY9CA35$982B]V6DPO>&IJ+S1K*TMS03@X-E!A4S9I*W$S
M3VYA:E!&6E)A;VMS;C%H4D%9-3E,)B-X03M4;C992S-$4GA0-EA!53E0.3=5
M;%=Q2W%V1EIV245%9&I#,&9K>EAP1G%);"M*-VE123-Q9D=J4V%75U9:0W8W
M86UI+V%74&MV27%M)B-X03M*+TPV,S%30RMA-#AO95E%;'19:W59-$5U5VI3
M4V%73T<S:U-0,610:%5Y3$=3,TE!,5I4-#1Q=75,1%=6,6I28BMZ.&MA-# R
M;'E')B-X03M0;&-E<$ER4C(X:W1Y<%ER6G=0>6%A6%DX;5-N4E-46$9762]K
M>#5093(Q3S$Q2S0P9E4Y2G593$%7>7I86E5),V]Y.#-8,$I,3S--)B-X03M8
M<6975'AO,6%":'13<DMV83A#<4XW+W9(4#A!.%DS+T%/26Y&6% O04PR4F8X
M6350*TI*:7)#9E!0<DMR0TQ2=%(Q1U$S<S!I2VLP)B-X03MO1E)P8G@X-V1O
M-#=S47A%3UDV2#!V,W172$MV>$MV269-2#58<F(K9'9Q3VXK5W1D=7)7,V$Q
M95!64')%8U9M-U!%;TM*2$994TI#)B-X03MQ1U-J;%)T>$Y&1WA"5FUU;2]M
M4#5T,$Q4;TY/,&XX=4Y4=4Y045108D-T>$=Y2WI034EZ1SEL2'=#,4-+=E%D
M0E5!35%Q87@O;3<U)B-X03MT+U%M;V%L9&51-RMY97EK4E)"8U!-;V5.;S-D
M<$]9=%<T<6A12U=P>$).5UI6,WA69G$O-7(K84E&2S9B-4]U-S914C)X;$U2
M;FPY)B-X03M#4S1S:F1K4W!(8FUV0FES9$5A<%!8:E9!-G(P=4]26DDQ:U5%
M2W="05I3<F(K2W-!4CE/2W%D-R]V2% O=T%9,R\T:6-646,X:V-E)B-X03MK
M,FI09D149UAT5D9W5$5/4F%604EF,V]:9C,U4'!B9D8X6'<O1E1&6&QF;C8U
M<S0P;E K4&13,'-03&-X;&)A,W9P5VE9,VQW:$LK)B-X03ML2DAV17I'3D%A
M.&MJ2E)44E-H5E4X;#).:C5K,49B:GEV-31U<FE,4V1/1VXV:D%T=&928W S
M:FYJ:&UC>GI)9V1/9DPP*TI+;&$Q)B-X03M7;V]Q:C4O>6@X-7E&,5@X=W14
M:6E94T)1:'5E86QL0V\S23-:<5%2>6%O;U-F:$-#9T%637)$.'4O3CEP-6LP
M-B]K.#58=#EP,7)$)B-X03M!=#%A,T)D4SAT=6]5='AJ9%EM131R>CE21W Q
M*TIZ>E96-D1I<G-6554O,W-L+S1X>"\X4V9&54A02DA(<$YO>C-W,#1&-U92
M8T5X)B-X03M$:U=L44-(.39'6#DK5#97,WAF1CA0>%5X5C5B-2LQ1%1P3%<R
M:5AZ-7%/:$TY-7%1.5-/>C%*,EEI66QO:C944D9"8FQW:6-V:$DK)B-X03MY
M4$%Q9TY+=69,*VI*65A-=C5G6&MY>$I7-TLR96]'4UE2>E-Y97)+<&55;TI"
M97AQ<&M5<2]X37135DUA<59F<%11-VI1-#1O=GI7)B-X03LQ4T]09T%,.%=M
M<6<W27IQ=V0U3U)K9&0V3WI"<5!X5558,#%5,&)8.4MN,6IY-W%L=CA!;4YF
M='!6<75M=S-533%T9GAX6$)4;$5*)B-X03ME87)(1WAV2F%"=E<U1%IZ5G5&
M1E9E-EE&9&EQ:2\X079:1B]X:FLO-&MM2W54+V5Y6"]J2$@O>$HX5EE8-7,Y
M0U165F1V3G-T9VQU)B-X03M.440R:T%K67A-9$Y5.$<K<E!'=C=H5#EA0WIO
M-VMS3T)557A6-7%T.35:=#E+:#%4569Z4'9B:3%N43).=F1T86%I4DAC5S@V
M>GEY)B-X03M585=1;U0V:U-69EDP-FYB:5921W%A=&]N,2LQ:% U;C9J85A&
M;&%Q;#%#;')Q:%=7<DU5;6I(<45-<$5M>DXV:DUV13AZ,7A653AP)B-X03LV
M8G%M<C-5,7)P9C5H835E4S9H8DPY5'9P8E<U:G,T>D1)5VLO9#-&=THK5&-#
M3W%N+TM+;FE66')F:W91.5@P8E$P<SE8,4HY579I)B-X03LW4U-4=3!J:%,Q
M4&=6-6UE46=%13=N=CA)5F%+07%E-'%O,W8K.&,O+T=.+RM);D984#A!-S)2
M9CA9-5 K2DII<D0O3V9P>4DW9C1Q)B-X03MK,#%)3'566F915C5(9U V3V%4
M-G5F<7)X8V5+2V)N.2M(3S1#,'%U2W9/;TIV3#AM<S,Q=F5F;4YE>GI8,6IC
M5VM&=F17=7!243)Z)B-X03MU<E-E<7IY4W%I>40T955:6F%S3T-H9FA64W)D
M+W%U:WA75VY7;'@K6D]Q5W0S6F]9<#5Z639S:&QF,4HU>5-P979Q8U5A24Q)
M>B]9)B-X03M:44]12$)61#9B<G5H-E9,3&-49FUT<60U3#E8:50V=3%L<44X
M26QA67EP2S!41V%8:5)#55E+-FYS5T%B:598<'8U4UA553-L5F]F)B-X03LP
M-B]M0S=S-VPW92]U<%)C0F\W:$91>5%N-C-78C1E5E1Y-VMG0E)2449:<FEQ
M:F4O=T,X8R\X07AJ9B]!26EC5F%T159R2S-$04U/)B-X03M%6F]26&-!14@V
M1&EQ1'903$AL<3E93F5A5%I83$%S43 Q=D9)45AK17IF854O86Q26% K54%E
M=4MQ=6PV1&]E:VE9859P,7)P-'5')B-X03LU>B]665DT9E5B8SAN.4U,>5!X
M2')I<4]X5C)+=7A6,DMQ2V8W,E,O.%DT+RM*4&EQ2')C:E1,6#9V0DAC4V8V
M4'EJ;&8P,4-C,#5U)B-X03M$>&LK2TY+=6]P=5)3;S9H5C5P-6IK0TPY5V<P
M>GEI,6A:='%6>F4R.2\X059X>$,S;VET5U)F531).'-V.39Z,$AQ0V@T='1H
M5FIL)B-X03LS-6XQ>E9.54YL1C5F.&]8;6ER8U1R64=6-T=75FQ%>7<R=SE#
M4S=I2T\V9E91>#0Q0DMJ:%AI;U9282M79GI*=7)Q,35E4E!,=&M:)B-X03MB
M84-'-W5'=#=E4DEU42]F3$5N,7%25DMS>#,Y2G%G0W9,<&ER,&9Y+W=#461(
M<S='2TA63DXP=3AU8EII='1C4E=&=D-&:35I5E%Q)B-X03M+;$4O93%E:3E$
M,THS=TMY<D9867%O=B]!3#)29CA9-5 K2DII<FLO,W-L+S1X>"\X4V9&5TTK
M65 X5WDV,6)W5VUG-F9E84]W=E1C)B-X03LS3GA)<G98-FMQ,C5+344T97)+
M-W=V45-F04\S3%I69S$W<#,U<39J1D%.5#AK-D1Q3'1C6$5Q;3ET-U9V47!#
M4%-K22MT>4%U-T-.)B-X03M+2U1267E#-7%R67$Y26LX:"M32FYE4V9Y.7!K
M<W-P-5133EI7-4QS5S5K=%9#5#AF>&(Y.%9497IS<DMY9U<S<S=E3S)T,7%6
M:&A2)B-X03M9,$)*<6%+;T$S3TMQ,DMU>%92=F8Y-#4O=T1J1R\X07A%-'$U
M+SA!97E,+T%)>'EF.%-41E=*960Y4S%E,45-34]N86)..5IU<%DT)B-X03M&
M=G!)5U=:4EES43%*<$Q5<$E8-5)C545N-W5P4$5(6E8U>DXU=78W44Y.<#%J
M-4EU=DY%<SAX=7!R964R:$5K5#)F3S-L5G!:;W!:)B-X03M/8VII3C(U539G
M8F9%0W%+;3!4>C5D<DIA=RM19DQS,F=8,%5R=DQB=S)Y;&=&84\Q36)*95(K
M<BLT86=B.3-7=$MO=2M+<VPX="M2)B-X03MD6G5,=$QZ6'1',$MY:#1W>%1A
M9&)71G51-D-.,V8T+S-Z9D$X;VI!-3!0171103!+<C!$5&1*,')3-%AG,'EY
M9W-96DA-<GA7,%-1)B-X03MQ>FM!1GEQ0E%7255B-$925TMQ3C<O=DA0+WAJ
M9B]I2GA66D%T-T9"2$@V8UHT2T9R-FIB,$90-4U66#@W>B]F568X07E-8B]!
M2F]X)B-X03M6,T\X+W=".5(O.$%)>'8K84U69'IV4#DY4B\X:D<O-6]X5C-/
M."\S,4@O>4UB+VUJ1EAC-WHO9E5F.$%Y36(O04IO>%8S3S@O=T(Y)B-X03M2
M+SA!27AV*V%-5F1#:R]R>5-3<7$X;%)60W-7*WE72C9Q=C@R2V]75W=-.7!&
M83-6<D)C4E%T1$EQ>4U34%5T,U=32C9&1'5R;T=()B-X03MG4FEQ4V%J*UAF
M;&Y5<$QI5S@P=$I(=6MA3V1L=3=P2W$Q>CEC86Y!<GA*;BM):V(P*T@W3S)+
M<59R*U=(;$,Q,4<P,4=$4F]K=3=")B-X03M1=&Y*.6%U4TEW2B]R4'=O4U4O
M=F0K;G0P,GA6;%A/."]W0CE2+SA!27AV*V%-5F1Z=E Y.5(O.&I'+S5O>%8S
M3S@O,S%(+WE-8B]M)B-X03MJ1EAC-WHO9E5F.$%Y36(O04IO>%9Y2D\P-GE3
M2W%H5EI11EET6&M64&16+VQX5GIP3W,W4U)Q<D)L5E-'67)4:5=06E<O;7A6
M,T\X)B-X03LO=T(Y4B\X04EX=BMA359D>G90.3E2+SAJ1R\U;WA6,T\X+S,Q
M2"]Y36(O;6I&6&,W>B]F568X07E-8B]!2F]X5C-/."]W0CE2+SA!)B-X03M)
M>'8K84U69'IV4#DY4B\X:D<O-6]X5EI-=#5,1$I&-F-A.#%+,3E2:E-O<"]*
M:7$K6DHO6&IK:597-'$V<T=9<CEO<5(P5G8U8U93)B-X03M05F9*96<V<F-*
M8S,K:U<P,#943F,X+U5D4S!Z=T,R6C,T<79/<TMH4&ER<T(T67%K;'@K5%!K
M0S5D6DQN46MM:U-26G<X;#EE=7AK)B-X03M294%C:W-3>'!U83E7*TDO16$T
M<7I:4')A27%,1$=&54%!96\S468W1$97*V0U+W9Q4#A!-4=.+WI2:7)U9#4O
M=G%0+T%*1TXO=T$P)B-X03M9<3=N968W-FHO-4=.+WI2:7%Y9&(R5T-34# T
M>'I5<E@Q1S)Q2V9Y67$X>6PO2B]Z>$IB,VM9+TUF5D9L=6](9VEK06Y!:%IR
M,4QO)B-X03M3;T)D03AH1W)1.69S;G-0:$MQ:&,O:W0U-6Y3,E4O;4QF2V)9
M>G9(2C9D,#!N<3-&=4QC=GIA*UIH=W!Z569S<WHP;W)!0E9Q>"]*)B-X03MF
M.'<T1$UB:CAZ.51U>$Q%,&%Q.&1W9U(R9FM*055V03%6,S1I=$]G4$I+;U95
M5F$O;$0U,V<P:E4W0G9Z1C%/86$K9VIG='(R45A")B-X03ML=#)J=2]R0FQ5
M+U<V.&UJ+V1(:58K2#(R>%9:6B]K-S4U9S!U.',U9GI(,4]E935T+U%H=E-,
M9U-24#EB:'5055@O4WE.:VAA255O)B-X03LQ2D=Q>%AI9U952E!Y3S@Q97)Q
M1%<O-6@V=&)P95AS5GI%16MU*V-516%U:E%&+W)N-WAN57AJ,5=(3#1",7)I
M<7(O>7!R>C$Y85-9)B-X03LO;5AQ>GAO6$IG8U1"6#5W<DAX8W@S35HT.&Q,
M9D1X27(X2E9V:GA61C98*U90;F%Z=3=Y830O34Q58C%,:4LY:6AJ;%-596TQ
M,T=%)B-X03MH9F$U-%9T,DA*94MR,3(T-'%P5"]L1#4P:W5,9590>D,Q2TI)
M031E,U@V,%DU96-A;T))5W9$2E%%9&Y$53-$0U1L2WEQ-D0X;G9-)B-X03LP
M5W),9FYZ-7%J0C=+-W,W=$MZ0G!8=5!R46=M-6970W%',D8P;G!G2G-9=U)X
M<G-Q9V@K4VYN=U%#3"]!2E=H<D)P1U4U:U,X=59*)B-X03M1<E8K<S$R.59A
M-S<X9794:7%I3F8O2C=Z,7%D,38Q<BM:1W%A96A73EI)-&QM*TEP0D1%4T]&
M,4=Q.&YH85$X5C9U=WA64F(X;'90)B-X03M%;'I,2DPK6D]R1T8T-5931TTS
M569'4C13:V-V25AN-TUL2E-O;W!.5D%65'A#<E58-4UE9C!J5E@O3795<%=%
M;VQD;5<W2'%,4C9X)B-X03MV>'9H>%4K<"]U;W!S4$5+>7%Q*W)F:S4U,'99
M-5!Q+S5J87):>G9&67=P26AU3TMI,'1H1&-.=U<V46-R<59&;5IU;TY253AM
M2E91)B-X03MQ9FLU*UI0-E1M;&(X>7131FYW5#!+97%73&TV861W.%IM0T%+
M9U9!451516EG56-75F)I+TI8.'=K,'DU=$<O3D166'5*-7)A4DQS)B-X03MP
M3GEJ:F=J;6IE3E(Y8E Y-EI666UV5D)7<#-#;$5A6"M54&Y05'9-2S-O.#=8
M,3-95%=V<%AC56MT>6XK:W!:3&%R3UDO5VM%<E-3)B-X03MQ2FU*9$-V14PX
M45EK2T98>6HK56YN<E)0359H<6UP9FU,<4]T5V1M6$UU;51P37-5=V5%>$M(
M-5A59U!%,&)D5'5013%X5D)W+VML)B-X03LU,6DP95-Y6#AX=%0K=514=%!.
M<4E&>4I4>5-.1EAA.'(X0WAC5C5-4E)M<4LX0VEQ.69Y5S@X9EA8;F8X>3E8
M94(W6F]V<35.=W1,)B-X03MG,GAI5V--=#!T07-X.5AG0E$O6DHW-'%R-F8K
M5%!M4T)L:W9F4$=O86I-3%I)6&5C5'176DY1:'9F5U-T,#-P:&\W6EE#:45B
M9D97)B-X03MP3TMT95=F>68X.#90<3%P93-8-6MA<G%D=F(S359X3EI806Q:
M2EDT=S1E1FI*8WDO0R]-5C(W9$-A14MO4%1F>5DX+VU/=V95+WI#)B-X03LQ
M0EAI94M454QE,6TQ16E92W%R3$8V,&PW54LS1FE'4TY$5FEA54-Q<7%-,&XX
M;F9/1F@U63%Z4C(O34156G)R5EI)2DQ4575->5-7)B-X03M::6UE86(P>#EA
M2B]F.#90>%IF<'A62%AV-5IE8S=J-C)&.#E8<UEU9$IT9$Y10DHQ.4\V=#)H
M6C<Y5$9D>$53>2MK.5%T4'0O15=&)B-X03M1>7%T<FXU965B-WI31S O5"].
M;'I:>3-&-&LX=#1R,U!/1T9D3TYQ631A>G9+=RMS051"5VQ'+S)M6FA6;%5K
M:"]*3'IE;#%B6%(O)B-X03M-5%96;6AT:W0U,FE.>41/.&-R=4I*9E=U-38O
M0DE6-#E!9#%P,'A68DPK5#,U:7EQ,70O>7-/*VEI5WIT-$5V,&$X*W-04$A)
M>E-U)B-X03LX4G4O4U5-;D)E4TAK861J>DUQ<71.*U1V;G0W4W=G5#AX=%)$
M5VI&<FU6:&1C<F]&26Q#4VU/.6I+9T=*=G-&5%)T>GIQ-TMO:3,O)B-X03M!
M0W0X.7)P5W4V6$PU-794*VMK<V8P9G%A=&-M93)K='!(831)5G)G<W9R<G<U
M8TI60DYA2W%H5GA65SAN9FQ2-6\X=C8Q<&PY8RMD)B-X03LW-U4W3WE355AM
M;GEI8U(S8W-X;5EY>3@W;5IE46%C9G-F<T1V=FEQ8B]L;C5H,6978DLW:S%+
M4V0S:DU8<"]764DT2"M.4U-Y*VM!)B-X03MR>'0Q4G8R;&\S4FAH5DMV>D4Q
M6'IV86%P24Y%=3E6:'1L=#%D6710,%=$555,<6LU86MK:S!:3$TS1#1E,T5$
M.6\T1EEF92MC+WI2)B-X03MI,#8R6EID971:9VMO04]H47E35'9-4CE854LW
M5D5K354V37EG;FLX8VEN-%)Y=W%J.4PQ-SAZ575R63-D-S5G=59A6F)E8TXU
M9G1O)B-X03M5;UDT,41K:5A:4%5K3&PK3S%'2#=)<7%Z3WHO041,;6UT<%I:
M4$MN;4)'=#--57%T64979#%)0F5&4R]X4FUT43%C0W%W+TUI<F]O)B-X03LX
M<BM94&IC4C%.:%%$;$I*2'E*3"]:2&\X:68U5U4Y.%97<BM:4RMM<S!V;&Y8
M66)D-&QM.5-3>31C1EHQ4FA+0S0T1D]82G$O<V=N)B-X03MT=7%H;"].:$<P
M<CE):GEJ-6U)255P8D144UHR1$YX2D-#42]:,DHS-DAA=3E&5E169GI4=#E-
M<V)Q.7503%=V;3-S,6YE6GA:2T)W)B-X03MT-5)'>D%V2VDP64AM=2LV0W5+
M;VEX+TU8-C-Q6G-5.'1A-'$Q0D8X,6U"86Q'6&MR0U5U03%2+TM$=FEQ0V<O
M3G%#4S1T27!F2W9M)B-X03M+>D8P-GAI5S8P.'A)<GE396MI;'5:2$ES46%6
M*WIV:7%*,%0X>EET4S%A,S!Y9GDU<FUL5%A25EE*<C9Z.4M&:3!44S U.#)0
M=TML)B-X03M(,BM%-UEQ>E!&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ=VXX<TQ06$Q3>G9O.593.55U)B-X03LX
M57-F,396<%-7;%0Q2E-H9C1L2$YV<TAD9&<S>&-S2E9#*V9V3#-M8E5D5SE8
M4W!.85=)>%%+5' K<5%71G5V>%-P2E-.-#583'%K)B-X03MV<59P4FEQ:6\T
M-$99-7!U:69M6EHS040V9')5<3(X.7I"1$PK;G)54E!B=&-X;4-:;U=J8V-K
M:&ME9R\T<F]2.%E!2W1R-5HO34<U)B-X03MS-U%Z5S-M2S!N36%03D9&-6IT
M;3133&1X+T%Z*VPX9DM'4U(R249+2G<W9S1Q=&HP6#AX,V=&:DQO,G1*8E)K
M1F)K95EB57EY97%V)B-X03LQ;5@Q9C-61S1Z>$Q#3G9S<V%F1%=Q<3-5=$0O
M041+=6)Q,W5L,'IZ0D=895<W;&=T+TUL<DA(2$Q"2DTP3G5Y;4MJ4EA!.4]V
M1W9%)B-X03M':"MZ=7%O,E=K9FUF2&]H,'-A9'(X9"MB1U=72S1V3F9H=4A-
M=G)G4$,Q>$9%<4Q*-F)G>$]4,#=F0V-65DQV42]Z1VE:-61/<V9-)B-X03M5
M,7I:4$9)='10<C!0<%A+1SAO>6-M4E8S=')D5W%(*T@Q0T-#,U966&HX<V5D
M-WI5-WAI=FU7,G0T<$I$1$PK;F]64U9P:DIZ55).)B-X03M#0W%1;&=)*WA&
M0T-A5GA62W)J4V9Z570U.4YE5W<X>'I4;4M33U0P9&1H340S4#%D-#$Y5D9I
M8TEJ9E9K:T):=T9E52]&=&ER269,)B-X03LQ="M:+VQI>&MN6%-.5#AY,S P
M4E-7,S%$5S=6:T5K52]W04QX8S1X-F9Q<$UZ9F%.1E%+9#991EI83G(O;GHV
M=F-M2'EO<&Y355(R)B-X03MY4'%%05=20W-:37!)53A1<D\T-#EF9R]Y:&EQ
M2&PX>F9M3W0P:V-F:W-004I1<VLO=T-K-V)E3&Q%3V%O4418:DI),40O=G-J
M.7!4)B-X03MI<7HO04)4*UII;4]V:V181'E7=V9J<6QS4%1J;51L3S(V+T59
M2"M'9RLS*WII<5DK53EF.#)A;&0S.71R+VQW-DHY5DMM,FU7-5,V)B-X03MI
M;5)M6E)X9%94-'%*>4\R=UE6,WA6:VU+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W8X02\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C
M=6UE;G1)1#YX;7 N9&ED.C4X0C(Y-39",C,V-T4U,3$Y1C$P1#A%.#$Y1D,R
M0S9&/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.C4X0C(Y-39",C,V-T4U,3$Y1C$P1#A%.#$Y1D,R0S9&
M/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/G5U:60Z8S8Y-6-B.#(M868Q82TT9# X+6$T.&8M-F4Y,C4Q
M.64X.&(T/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#
M;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HU-T(R.34V0C(S-C=%-3$Q.48Q,$0X13@Q.49#,D,V1CPO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HU-T(R.34V0C(S-C=%-3$Q.48Q,$0X13@Q.49#,D,V1CPO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.F,V.35C8C@R+6%F,6$M-&0P."UA-#AF+39E.3(U,3EE
M.#AB-#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N
M0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @
M(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#I#0CDT0D4V-T)&-$%%-3$Q.$)&0S@V.$4R1C<T-$)%-SPO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q
M-2TP."TR-%0Q-SHR,CHT-"TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-3A",CDU-D(R
M,S8W134Q,3E&,3!$.$4X,3E&0S)#-D8\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,34M,#DM,S!4,3,Z,C8Z
M,S K,#@Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @
M(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/E18.30\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^2F]N97,L
M(%-A;75E;"!3+B H5DQ202D\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R
M87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIP9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O
M,2XS+R(^"B @(" @(" @(#QP9&9X.D-O;7!A;GD^0W)E9&ET(%-U:7-S93PO
M<&1F>#I#;VUP86YY/@H@(" @(" @(" \<&1F>#I?061(;V-2979I97=#>6-L
M94E$/C0U,S(P.# V-#PO<&1F>#I?061(;V-2979I97=#>6-L94E$/@H@(" @
M(" @(" \<&1F>#I?16UA:6Q3=6)J96-T/D=R87!H:6-S/"]P9&9X.E]%;6%I
M;%-U8FIE8W0^"B @(" @(" @(#QP9&9X.E]!=71H;W)%;6%I;#YC:')I<W1I
M;F$N:'5 8W)E9&ET+7-U:7-S92YC;VT\+W!D9G@Z7T%U=&AO<D5M86EL/@H@
M(" @(" @(" \<&1F>#I?075T:&]R16UA:6Q$:7-P;&%Y3F%M93Y(=2P@0VAR
M:7-T:6YA("A63%)!*3PO<&1F>#I?075T:&]R16UA:6Q$:7-P;&%Y3F%M93X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X
M;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @
M("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\
M+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXX
M+C4P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^,3$N,# P
M,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y);F-H97,\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4
M+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A;6EL>3Y!<FEA;"!-5#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP
M92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^,# Q+C P,SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&
M;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I
M;&5.86UE/F%R:6%B7U]?+E!&0CL@87)I86)?7U\N4$9-/"]S=$9N=#IF;VYT
M1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O
M;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!
M<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF
M;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I
M;F<^5F5R<VEO;B S+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M05))04Q?,RY45$8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @
M/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C
M:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \
M+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U
M<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.D5X=&5N<VES1F]N=%-E;G-E/2)H='1P.B\O=W=W+F5X=&5N<VES+F-O
M;2]M971A+T9O;G1396YS92\B/@H@(" @(" @(" \17AT96YS:7-&;VYT4V5N
M<V4Z<VQU9SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@
M+2!45#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B @(" @(" @(" @
M(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^07)I86P\+T5X=&5N
M<VES1F]N=%-E;G-E.D9A;6EL>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N
M<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XP/"]%>'1E;G-I<T9O;G13
M96YS93I/=71L:6YE1FEL95-I>F4^"B @(" @(" @(" @(" @(" @(#Q%>'1E
M;G-I<T9O;G1396YS93I&;W5N9')Y/DUO;F]T>7!E(%1Y<&]G<F%P:'D\+T5X
M=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I697)S:6]N/C4N,3 \+T5X=&5N<VES1F]N=%-E
M;G-E.E9E<G-I;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93I+97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R
M;FEN9T-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XR-3DP.30U.#4P/"]%>'1E
M;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@(" @(" @
M(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^,C4Y,#DT
M-3@U,#PO17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @(" @(" @
M(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93Y!<FEA
M;$U4/"]%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@+2!45#PO17AT96YS
M:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B @(" @(" @(" @(" @(" @(#Q%>'1E
M;G-I<T9O;G1396YS93I&86UI;'D^07)I86P\+T5X=&5N<VES1F]N=%-E;G-E
M.D9A;6EL>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E
M.D]U=&QI;F5&:6QE4VEZ93XP/"]%>'1E;G-I<T9O;G1396YS93I/=71L:6YE
M1FEL95-I>F4^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS
M93I&;W5N9')Y/DUO;F]T>7!E(%1Y<&]G<F%P:'D\+T5X=&5N<VES1F]N=%-E
M;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93I697)S:6]N/C4N,#@\+T5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^
M"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I+97)N:6YG
M0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E
M;G-E7S$N,E]#:&5C:W-U;3XQ-3DX-S Q-#4Q/"]%>'1E;G-I<T9O;G1396YS
M93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^,34Y.#<P,30U,3PO17AT96YS
M:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E
M;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93Y!<FEA;"U";VQD350\+T5X
M=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \
M+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &* EX# 1$
M A$! Q$!_\0 '@ !  ,  P$! 0$           8'" 0%"0,! @K_Q !.$  !
M! ("  $'!PD$!@H#  ,% P0&!P " 0@5"1,4%U:7UQ$2%C=7=]88(39459:V
MM]49=K74(B,T-76T)"4F,3A3DY6XTC)!83-1<?_$ !<! 0$! 0
M       ! @/_Q  U$0 " 0$' P0" @(" @,! 0$  1$A C%!46&1T1)Q@:&Q
MP? 3X2(R _%"4F*2<H*RHC/2_]H # ,!  (1 Q$ /P#_ '\8 P!@# & , 8
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MWT31013U_-HFEIKIKQ^;77CC*[_"]D17>7[LM#(48 P!@# & , 8 P!@# &
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MP_S;F^5W^%[(BN\OW98V0HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M,;X=S7DF'<*_2>7 HMRMZ7Q:;[YGH7!KT[S?HV_I'HWHWST//>?3J2;B'O\
MHC;2F5M^RQO#+;]M:Y]U\F^+V2F3W7!:YK9\CPRV_;6N?=?)OB]BF3W7 KFM
MGR/#+;]M:Y]U\F^+V*9/=<"N:V?(\,MOVUKGW7R;XO8ID]UP*YK9\CPRV_;6
MN?=?)OB]BF3W7 KFMGR=Q!XX^BT?\*)DVA@@L<EIYZ08"U@S)1S*Y8;E*J+4
M:X*FUVR#/<SRR3\Z4=J+:M^%]M].5?-)G7T]% 5/7U<DNR%& , 8 P!@# &
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MOEA8Z/X3+(R%& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M3U^7GY--->/E_-F31SL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M>8-_E<?CU]/V/R:>OZ']HH#^R61?O,&_RN/QZ^G['Y-/7]&O:-N%C=\)WF3
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MV4KHEO&7MZP9UL#RD=,1RL9O/(<!L*8%HM$Z]G(J,$H!.H9O*X79LA1C,9G
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M'-V_%2B=?OWT@S;MNW%+IO<NN=IU<13(UWE,'KAY/?ZHIM][!7^!J^SE;O\
M'RSK8N\_"-X9@V, 8 P!@# & , 8 P!@# & , 8 P!@# & , \=>_?U[!?NE
MBW\8V-G6Q=Y^$<K=_CY9BG-F#/!7KVR(V9;]GM)Q+(X;MNHXM4ZB\95;"RD0
M2BCR8O1\JC1C9-RHD?T<3!99#TMJNS05'-=MT'":BZ6TB_51[\FNJEE0OXVG
M:KC/31Z?Q]3K:-Z[/*I.6;.)?9L@MJR[7:PL3*)D;" (UIX!7@<D&B(QD!CK
M=%@BLV3-&'I4DHHLY+D""BV_#9%)!LF2AMYQZ"U:5J$K*LI3"4NKO<NOZ*1#
M>3ZB :"#X*G8<C6:C^H%C]0M'^XD9JX4CUC'&!M[,=DM5?-\&AJK#1!L/XY]
M!634VV5WUVXXXR=/_P">G]F_RN6X5?\ )9_R>;,T[5,RV7TVOC>SR,)K05)6
M%,RJR.L4ZDL@4G=8+P@T_IS2!-9)*)!&2,>:6K'S2@B$MVK*)10A( !X\W%2
M%X?#--7(#6-.:72G?2F:ORIZFU_DLQU6HZE9_P BNM3_ "ZH2<M1-IN75*D.
M\TM-?)V5I9<7J*.3^2E#BM4QR]FJ!9J,;#7A*>7R2'R(U9[+;EV\6 2B-RUH
MXD\<V0<OM4"3OYSA9;S&N^]Z4XG"=WB87^5V7:Z5'4[--+-%9U35&9KO'J'V
M3DM@S&,P[F3DX9;)GK$=LBP59C5;6'322TX^A*4AF\TA9*/H61$BO :'I>9C
M5<DY %E!Q$,:>$ 39!]'EY#G2DNF'B<+O]&[-NPK*F)LK_(DHM2E:3A)S#J[
M[2HF^YZ'WAUP#7?)8;)2DE)@EH= [R@C=JP9M7*3UK>,.'PXH_6W<;Z[IN 3
M8?H]8))\<INEU-DW'.J?''.::GU]:'&S:Z<,;+_]7)1DS\G_ !281=:-J6+)
M!O//5JI.L30BW$"EU6K&G9PE/8_--FZ^_*+@B^+MVZ!(1MSHRW9:*)H.$E%/
M.Z3II?@EM4TO\C33A4MVK>/_ "236RHR1G^EZ4D@U]1@C;4FT/\ 8"65S-I5
M*V ,.QUT.5_'(&!79KQY%3PTK%IAM!^%9-&7*B3)T..$PJ:FC3S:F6*.M7>^
MWQIW"_R0[-%%A6DE_P#)VG?FNJCT3*X=^35KXA1<PI)S/#8]"472^NME)XA&
M8Q"'41*2"*C(1+(Q%@4;;,@0J*FXBE((ZD.;-DO01,AW06V(JL-'#B=*B-9^
M,(P+^5]2M0J6>B'+F'*;F]S7P2F8^3XJ^2W0WMH8]#@V+G6K-)##R%65A.='
M"5/M6PR*-8C))O'#A: LW00>("GT0>JBKUF*9.!S@042U(:WI4SVRP[D_(^G
MIK-8:M-?VOE)I/SYE4.X8=%(,DUKX:5EATP'@T\[,35R.49LVG$B1[.!IV"E
M %VX;J>>8M0C&>/]1CQKSRY7V:-^5^-.=]^>$7:3ZWC\C4TOLV+/;HZ8WZ5/
MD@"GDY 9^&FX98EV3^>-&M$J==*M>N@</!NZUKK@J ,ME-N HMNE+Y1JZB44
M;.SQ?1MZ8,#[-?0FZ[]V\VG32)PA:791-4:_+=%E+^77:ANMK>BJX6&9W9OH
M:I*QML*32YGLUE-Q2:KI5+R<KJBL3<6(.JOBSV(CP[N!/Q"XCD"^&ND%N/"W
M0>3#2(YD^:2CE;9]R\=-]:N,*4T_9/R0[,685F8BTTZN;^96AI[KM20KKM4,
M5J(*?,R4=&.3*J)0URDFMSN<.$CZ[(>P;?\ 1 X$:N34'@ K7G=$4(;,V?GW
M*B2CE:I0H,6K75:=JZ?N^;Q=2[,ID]A^A'U(D?O!D7^'@<Y6[_'RSK8N\_"-
MLY@V, 8 P!@# & , 8 P!@# & , 8 P!@# /([R@GUJPO[OM?XC,9UL7>?A'
M*W?X^680S9@8!B'L9:9R(WQ1P!!8[K%(Y6G8[L#* H)ZY8.9VYJ6*1X-'(<I
MNUVUV(LO2; ?GEA*_"S-P7$QURX;+\---,C<>$WM_LZ6;*=FT\>JQ96G4VY_
M_F*9LRI"?*"7\4KD_94BJV%. 4<KZH[[+*@Q<N%J-*=EDIY'60(:,S)]T_.2
M&&Q/?>6@9^S;MH?)$ T@9:1]!PRUUVRK3BJR=SJL?]FW_CLS";GJM6(I_9+^
M-;JNC56LS]EGE#;H70CCRNJ^A+@586W8:?UJ;-A9B99R"EZ4,B8Q'WKIN$/#
M=F)F?$52DE=2E9TC'8="5 A1R$->E[JXZG[QC,.(OOQ>@7^*S66_X]%FTE']
MK4SAA$1#;<Y$Z(=O.T$G6O0Y6%<54C'J,IJH;<)Q&6\RLO/I&M955^LHC"Q#
MZ.FV,?3)@=&!<<D3Y;.D"2ZHU%HP6VX665=3<Q$))UF:J<"=%A=,VG_*U:LR
MH246H5IS@[\(-%T?V'D?8J&7G8M?-XTU@(<R4B]"R-ZU)K[REV A(YR=D\E3
M2?\ *#H"A8+Y\ 9-@^K)QLTCQ'A5=9=9)732<RUXORY,6K/0[*<S$VEE5PEK
M$.N9YR17O]V3K/KO23R2 H;;UCW72;*8T^2W0/-GDPG@BQ1K.Q(S,MFI71IR
M_#5K(64O;\ FX9OHNP(-DFNH]%%%/,M)8RE%\Z^F)V?^*Q:MVTGTV;-J+5U%
M%([VE%^4WFB@W>JSK3YK9.IP=7 QE^V[<$7IJ>V3Q)MXEK75)Q(:\.'3S029
M%O#<FETRUD@B*CQ) *R2$!%R#CE\H@MKM>IN[%N'A"^N%0P_\2LS,S8LV7;2
MB4[3<):)0V]<"VA_;F9&.DS#M>PA@'0D"=*/I_'$W!,L#6A\(M!Q";3DD-)M
MU&+MPQXC 603>'O7B3I+9BDR1?H/>-E%=D_QG[?7T)T+\G1+A_U>,VK,V4_+
M29FV&^4SG,K<SK9&K0KAO7\4[ WN19,N3'#POUMA,"CLDHZ3#7NSU=JA(;//
MREJ)?N=VSP>U9@9 Y:"4=]4?-SJTNE^,'Y-/_$DE6]V+.%+;;ZD]+,3A>JG'
M:^40O5E '3H_6,1<3*0RKKS'X(>$1Z:-HFV3OA$ZZWV/0EW(7DS-[1EO']N
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MP_0CZD2/W@R+_#P.<K=_CY9UL7>?A&V<P;& , 8 P!@# & , 8 P!@# & ,
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MJ&:[:;:[:^M@M^?7GC;C\T&K[_\ ?'R\9RMW^/EG6Q=Y^$;RS!L8 P!@# &
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M)J7Q9^,=3741HUYBP^[ZF[54U=_26_ZM739K2^JK187&T/)+3*XD?*^6T7[
MTEVDCG8/L7TMCLXOLI:L*CL<CD.G7K<FY1HK'QK6PI([CO7X+$H]$:*IQWPF
ML?/%H;R\D4< KE'CW*2W'0H=EI6G$8T5]+\7WH?ZYL'$8 P!@# & , KF$?I
M-</WC#/Y25;E=R[?+(KWW^$6-D*, 8 P!@# & , 8 P!@# & , 8 P!@# &
M, KD9];<W^[FK?XFN'+@N[]D3%]E[LL;(48 P!@# & , _R&Q.P>@=J^4WB\
M8ZLHT?54?Z6=A+ON&02#Z?#7O;/OEW'G$;E;*25/3?TND)&PCM6)&R1+B32
MX57B\T-HL(M A*$<&:F4AV?7TUE]22NI9LIT;BY^+JS-"(=$9):MA^6;7D'<
M7JQV2;VSV]Z+W[&[P@EOUY$%ZEA4"*W/ ](I%0,<(34P@]ZPQ"O(@+J8N>,
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M_3/2D%-7J"2;=QKNEKQKFT_ZJ%7-5_LS#7]G+49/_P 4;ZS!L8 P!@# & ,
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M9M)8?*#4/DW+5ZM'QQAN^&2<&:&JO4_F<.%6JCEHX<-5D7"HLNZ7A2=BZ=@
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M(BZ"_ EUJ[065T?:+(;ZN_G\\K<;9M?\4TJI][V8?_)INC7:Y&^<P;& , 8
MP!@# & , 8 P!@# & , 8 P#/7:CZCI5_P 9KS^940RJ_P /V9FW_5^/=$_8
M_6W*?NY@7\361C!=W[(N+[+W98V0HP!@# /,3L?TEL>]KM['6#&[8GU0<S;J
MAUYJFL3D%LR8Q(26L"M[&[:RV4";5C4*+ BYV!N1]K0(2Y7'F!,FU"'IHE"Y
M!&) FB:0&U:25E1,6FVH3HU9S[/Y,X:]/>Q9B_:4LQM1U>U(PK.9]8'H1.$R
M2N2+>#TU":CA\*LRJD9P?#'[<77 2E2<AP$$K%U4]-R>KM!LID/CEDGI5&S
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MMU"+ES)5VSA95!BTYU&9GWW+6P!@# & 8S[ ?4!WL_NS.O\ XYP3-*^QX_\
MTS+NM^?_ ,HV9F30P!@# & , 8 P!@# & , 8 P!@# & , 8!GGM!]5HW[[.
ML/\ \EZDRJ_P_9D=WE>Z+ &?6W-_NYJW^)KAQ@N[]D,7V7NRQLA1@# & >5?
M9+HQ9=XV7VNG$;LN:5TYL2DJ/AU9MH[:4VB<'FY^O75POY3#;FC4'+!##Z R
MI&6@XD;)"28Z6-HR?D2T2,"3#9!UP-*U$+5NY8Q=K3L9]DW3?LI,.P,4M493
M<&JW2/RR)/!RT7D=:;Z :?4ZF[5(2J]6;/0IVWGY2,6(2>CU8%"BM7T YAXM
MM-FPF43\H7X?BRH:F;_+F9P5V+FU/B.<)\GM/:^0KS0-4D EM9!ZQZ.NKYH%
MJ: ,@_8ZT:DBW;N+W8]E2!]-*)2^6_2&U>OMH;2JQ'/"=I$J<"!I*>2V$#7C
M4.I1K-J'DGTQ[-:30AL>Z 7Z%A_$;5J. ?2,M$6H*C)>UL=D^_(4EJ':B_K;
M+S.&OR(UJ>=;OH+9%;N&QRN6G$IGANNF<!L5F)AR TLT"5?/?_R4)5ORQSF\
M[29^2_DYV$6 X:UQ6SBTY1UW\HZ.;REZ29*&'?9"VKR#3GIC8+\\NW4=[R:I
MXFO+&D%G:ZBIBE6Y9X#A[H2S?K([ K6KOL]H2<[TI<\29SWJ#:<EM8)K/NK<
M!N.M15^W#>CF9M#U5ZVB7\;N E+ZGK/21SG5C(H;605+9*=SD/%"?+J;%-Q$
M&?;LX?Q.@\S?>"31PX=%%<$I=*3@I]XBK@OD\.R[%U9:[S8D7DI767K6+(2E
M@5 !B';$&4[1UE;ZU?R-.$TRPMPZWL*GHA,JO>G+SG;OBE4IR5@4';3>OI ;
M,,A>I4RPO;LT:SP;FE\)NM#</5'J$C!U[E/R2K@M(@K%GMQI1ZF8J8"D0XRI
MK:@U""EQ[U>(\MP\<D+(_5!)= /%WCZ.QE$\:$ 79(?L(+I"-S2^ZO:>>YMR
M#5H&@968%AJRZZTK<1A/31Q\O/ <!#H@&B8".M%-E%%7#1IR.)&MG+K;=VJ2
MD)/YZG+?1JDB,ECX P!@# ,:7E]379_^^H7^'JES=F^SV?O:,6KK7=>UDV7F
M#8P!@# & , 8 P!@# & , 8 P!@# & 9Z[4?4=*O^,UY_,J(95?X?LS-O^K\
M>Z)V8%3-A,WDHBPN,&T"L8!@';0_)RL959*@BLC(IN&Z@Z'RS1\F\TD/*>^B
MG##9KLSXVUY=<.>>&ZD0^;XU61:S*BY8Q=.CS/[\4MWV'KCWIR;X.XIF]ER*
MY+=\#Q2W?8>N/>G)O@[BF;V7(KDMWP/%+=]AZX]Z<F^#N*9O9<BN2W? \4MW
MV'KCWIR;X.XIF]ER*Y+=\#Q2W?8>N/>G)O@[BF;V7(KDMWP/%+=]AZX]Z<F^
M#N*9O9<BN2W? \4MWV'KCWIR;X.XIF]ER*Y+=\#Q2W?8>N/>G)O@[BF;V7(K
MDMWP/%+=]AZX]Z<F^#N*9O9<BN2W? \4MWV'KCWIR;X.XIF]ER*Y+=\#Q2W?
M8>N/>G)O@[BF;V7(KDMWP/%+=]AZX]Z<F^#N*9O9<BN2W? \4MWV'KCWIR;X
M.XIF]ER*Y+=\#Q2W?8>N/>G)O@[BF;V7(KDMWP/%+=]AZX]Z<F^#N*9O9<BN
M2W? \4MWV'KCWIR;X.XIF]ER*Y+=\#Q2W?8>N/>G)O@[BF;V7(KDMWP4+V #
M2 =U@[>%9*W#LB,LKVQSVH\&5>FV3!LUI\5%DD>2;\''5W*ZVT;4>J?(*031
MU=Z-]=U^4MEMZK[,81[SKF1W6IQGVC3(V#F30P!@# & , 8 P!@# & , 8 P
M!@# & , 8!GGM!]5HW[[.L/_ ,EZDRJ_P_9D=WE>Z)R5%S<=-RTGBXF*FV9N
M*Q4"X0/2HO&7+)S&B\T(<K(\#X7+$GJ#U*5IZ<<[J,E&ZC+?_07U7UV34B'-
M[PF^-5D*S*BY8Q=.CS/MXI;OL/7'O3DWP=Q3-[+D5R6[X'BEN^P]<>].3?!W
M%,WLN17);O@>*6[[#UQ[TY-\'<4S>RY%<EN^!XI;OL/7'O3DWP=Q3-[+D5R6
M[X'BEN^P]<>].3?!W%,WLN17);O@>*6[[#UQ[TY-\'<4S>RY%<EN^!XI;OL/
M7'O3DWP=Q3-[+D5R6[X'BEN^P]<>].3?!W%,WLN17);O@>*6[[#UQ[TY-\'<
M4S>RY%<EN^!XI;OL/7'O3DWP=Q3-[+D5R6[X'BEN^P]<>].3?!W%,WLN17);
MO@>*6[[#UQ[TY-\'<4S>RY%<EN^!XI;OL/7'O3DWP=Q3-[+D5R6[X'BEN^P]
M<>].3?!W%,WLN17);O@>*6[[#UQ[TY-\'<4S>RY%<EN^!XI;OL/7'O3DWP=Q
M3-[+D5R6[X'BEN^P]<>].3?!W%,WLN17);O@HB]0IP9U]O$C(D1+0G*"PP_N
M/"DGAAB/2TW@P!%OH4?!P+AXHIJ"],4WY$M-4MG7HVO"W"'I*VK/]EI/R_DS
M:_J]8^%\&OLP;& , 8 P!@# & , 8 P!@# & , 8 P#/7:CZCI5_QFO/YE1#
M*K_#]F9M_P!7X]T:%R&A@# & , 8 P!@# & , 8 P!@# & , 8!GGMO_ .%K
ML7]R=F_P>7RJ]=U[D=S[/V-#9"C & , 8 P!@# & , 8 P!@# & , 8 P!@&
M>>T'U6C?OLZP_P#R7J3*K_#]F1W>5[HT-D*, 8 P!@# & , 8 P!@# & , 8
M P!@# ,]=K/_  _61_PX3_$8;-6/[+S[,S;_ *OQ[HT+F30P!@# & , 8 P!
M@# & , 8 P!@# & 9Z[4?4=*O^,UY_,J(95?X?LS-O\ J_'NC0N0T, 8 P!@
M# & , 8 P!@# & , 8 P!@# ,\]M_P#PM=B_N3LW^#R^57KNO<CN?9^QH;(4
M8 P!@# & , 8 P!@# & , 8 P!@# & , SSV@^JT;]]G6'_Y+U)E5_A^S([O
M*]T:&R%& , 8 P!@# & , 8 P!@# & , 8 P!@&>NUG_ (?K(_X<)_B,-FK'
M]EY]F9M_U?CW1H7,FA@# & , 8 P!@# & , 8 P!@# & , R!WKL$/6G6Z4R
M4\P//16DDKIJZW "E"Z['C>?QQTFZ>-T5-%$VBBK30>FKIPISL1?#VWS/^D?
M/TU94OP_:#-O^K\&LQ[OQ!@Q?^BO&/IK-L[]"((\-W[/TE'1;T5\AKNIJ@\;
M_/\ -.4>%%.$UM-].-]N-?G<Y-',P!@# & , 8 P!@# & , 8 P!@# & , R
MAWFEK"%=1.P9DFS+/&:]82D!OP'8[$7#5Q*!J\<8/7+?131308V(%&FY1YIP
MIP/8^??KZ<-6RZB=L_V7?VJ2U_5]O>AI.,'F\JC<?D[1D3'-9$%&'&K TSY'
M&&;8LR1?-VQ4?MNINP((I+Z:/&2F_*K5QJH@K\BB>W'$*JU.\P!@# & , 8
MP!@# & , 8 P!@# & , 8!CCO/9 >L:3#GCHN2$V"MW=>M=N(R%6..F_(6ZX
M++UN7#1LIJOIJ\8QIX.';:Z;\.SSP2)U^:X)-^>=65+\/V@S:<+RO>?@V&BI
MRJBDKLDHALJGHILBM\SA9'G?7C;E)7A/=1/A1/GGYF_FU%-/G<<_-WWU^3;G
M)H^F , 8 P!@# & , 8 P!@# & , 8 P!@&1>]4[$USU?L>2'&1IV+UXC@]R
MH#&[E%F/)"3B$&[QX@FIHHFQ]*Y0:*.-.%/-KNVW&^G">^ZB>K']EY]C-O\
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M_KD]][%J?C+$O39<"%KN^3*O;Z/_ $$K4&7B$HLH 2<SD:-7>,+:M#591BL
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MW?LEDD=TW2&RD+ VLJNM9<Q@&T^A6L\)L_$1L)VE0+B7$!_+-P1X?,8WR_\
M&7;/D>T=/O24&2B/H;9PZ^?YA%3?4(QP.'+K;JJOUN&\]LVOH0XV]'^:A+IG
M'(VMMZ7JYW:_(D9),M^?2=&;O=O\FO\ KM6KG9/YW""O.H1-QU36]Z/>F-8\
MRN6J79_<>H6T!M;#B+@QL*1";R98GJ,2,;O=AZ4;34D"CWA#EMH$TW*[*<,-
M=G' L/)DD:6+7S\.A(6,[AKT ZC;V9-CC23A'(=Q#QOF^",K0)HOMV2L;8>=
M2]-.IK["VOG4_/ND_GZ_*(3+ & , X.Q,;H20#;D&.AARQ=$VPG9VWU).!K%
MPS:/2"#'E3ATJQ9NB#!LZ=II;-V[A\S154T4<HZ[@<GA='991MJLELX22275
M0X4TY631<;K)H+*)<<_/T26W;.-$E-M>-%-VZVNG.W*6_&H'UP"IY5>%90H[
MI&Y#(':);DD!$N4AT9ED@:"G\F>C1X9$^5CX,H)CNKAV; )N'!YZ.;#=)'&E
MR:S-O(PBK\6']T^_8+ CL@#2R/@Y3'7Z12/R4.-/@R:&JNB) 089HD!KU+1=
M-);1-TS<(KZ:+))JZZ[\:J)Z;\;:\"'<8 P!@&+>]7U21W[QA'\,R_-V+_'R
MC%N[S\,N^(IRE7K]&$H,X!LYLI3@5.'NY.W>O(TUE.\*;:Q]Q(6@U9L1= T"
MW+14LW'N&[U=AJX2:K)+[)[ZY=[[OW-6;EV1X[Q_IS?T2'6*RM6NK$EZ&G;Y
M2](M)>M-D5&1F\LF1_HS!J<DMO2@7V"C@:/%64DL#>;,'C!LI$'0:=FB9-2)
MK5 U;K[PZ-IW7=,5G.ZFG?4W;R)LIG+O)YH]@-(^1*-ZYG<5L]*/LV^L(_*G
M*TI'4&[\6/1028LX\YB@WLE'@/.S=!APA)601+35<LR:K"?]HS])Y@H0YUKD
MS7K$51,=>I,_NSL43MN8V<=I_3KNZM.C9%:45* (Y%XTTMS96KB0*-5;H"ZS
MD2P<HNLP (\R!%1;QB13@2$UHZ*Y.8<=JU=</9'12[JY<D1=5K9,0B+IY8,?
MBE*S2W(PSW;3:LF5@<EZ'ALR#57&7QF*3&>LH0/JE6]=&<WL%Z0;3>H:4TB"
MR^LIFL<,!*]]'%7VQBE(;G T+5_-Z269]J#8ED!@ME&^L76@26'(+)D81$^[
MVM?V\7L1'93E0LB60C\1E'6@<^)<*E$7\:$ 6G*SWECOQR#BG=^;-(]GN9F?
MU]VFW" 4AM>]Z$(2E7MBM"\7<]KXLO;J_9M]"ZE;5S/F\IXNU)PTID.6&VT*
M+Q9_9QJOGTZ-")1ZGT:^0;%M'WY^\%IG9F5_QI&*N[8>3@'>M_>@W&Y<;/3^
M]UK2(0#M\IQS!NQ4CB$*7L=C'X$KU9VBD5%SP''@ 5Q-&\R+C6W D6W=-'.X
M"U.%XCRQCV@39P2BEZEZ\>Q#3,1[17OQ<PZ'B[P/;(77V"BD_?S6U@CVF9'#
M(Y801O 8-6$ )6"X:QB4Q>1B]'VIM*%1=5N"CLV'$)*0&26%#7X2E%W_ !N5
M<&V_KP/BWZ_=ZI0^1<W'Q<$W;QBZ:>L&81P)+EHP$E9R(]M85*-)559=UV]E
M#1M'HI3C:9%D(G&ZZZ_ 7X9]&4BD2*VE%QPH&$K"+FO1K*]YRXS.^J"B?*"G
MEXE'[MG%X-1I.454GV!=QVP"]?MS91EO9"]F2"KIN'[7V3+@<+**K1]#<;5\
M2Z]AU !B'J1ZOH_*8_(!T6!NSA&,>E_\5-,Y+DH&@>S4HEUC#+JDMT14"%.\
MRB!62?F:;^8Z2621WL/6,H:0X4YN:\8R&(!859H*2!+#A0*G( Y(-(<T9]?@
M[X#*1^@C:I$:K;1/#-]S?-/T4+IYZ1<CI$3D&KB$P:OV6Y05&A;Q,#!3MCR9
M@X)\1(-'09 X\,6C(^'Y1F #\O6;84H20('N#)\T(W.F--8X+VP08 P!@%<S
M?])J>^\8G_*2TLJN?;Y1'>N_PRQLA2L*J]+XIBM^6&K?9]Q6$/\ 0M7>RNC3
M9W]%!WHVKK='7=;1ORM\SA;9+3=75/YW*>NVW'''-=[[OW(KEV7L>#E:]..S
M<3C];^EU_=8AC!&W4,3*"XU3JT^N.#NJ4K'ME'38#KF!?%3M.3:J87*+3@00
M-(.P@6>6Z<@TVL8L^E$]F4:@96%PZMJMV.>+5])FF$*4M9WS$Z_FE7U-Y+B#
M6* :QL/5THB4#L2.H/$B@F-F&O6.UZ\JEK*7R14^)>ZZ3=Y%8SQJW.'A&]KF
MXAM'BA/A 04P9QM1CRG]T(7(:EM6MZ[D5G1#JH-L+LE;79Z7'D%!XZI"B/7R
MMPC6SJNIZ=L8U)+#KV/2GF(T&X1;,X %F8W@K:5QS@T2> F<CF)) *.DPDM:
MXM7/'T6.,-DW3,U7\8ILCU_@UH(\Q2L8DM+899[R"2'5NQ@3#K?#6T9)@(B6
M':2.R#HJD:REQV,1VR5*I-CJ'+5Z/' ]+>?$R 3,SGSS2DUG U-1#VUI+?4A
ME$N##HO,G'4"@AET#627.T=&W2I*+8/ 0:39L8/(,C4>CQLL2E -"1&7HT%+
M((@X.FQZ@$LX!W>7':GWP91BU?=KD([5R$]@W=8N&8A8HGV8% NTD=;3>P;N
M2KJ=LCLSIXH.NB.%X=4O%@+@W9..1BPZ]AQ=<E!%@M01F,0^Q.#(4P:TIAM?
MXSEW'71?K7WFD(@&1N2PKZ6GK]=Z%GRD$[(2&%Q1<2.Z,UTB,=1P)!)M%0H7
MTKN8'DA;@['@H"4D';HFT,JZU*97!N0E8>*8SQX\E.S2'=Q[XCO:ZO PR])%
M8C=A.ZHL#8];,:3HM]'Y=Y+*&Z>J*.5^M8:,;93PEVKL.+2W24M8*-Y:>D2)
MZI9^D-W=1=\-?Q479JCG^^?_ ,>_:;I59'7WO5/3MNMYYS;\TC&ML$IRI%HK
M+EHG'YE"(?W1J:S*8'5?(%NWOH4=E\9Z_1@RQ&MXK3M$<+EVQ=K9,DDTUWB4
MK*B2J1EZ]-<,]620+2?E"9%+)",G,TNEB"D-EBF]E.(K-7T'%F86[[>UP:U(
MU=-FG:N9&(>*$]9&5C!EVE35-UZ-*1Z1-VI],S:@D.L,";-(CS6L.^D.N<^$
M7-3]$=ER%]6*C8!NX!=? YE,)M6]BS::*21X"(<SB5QB,Q^+1PK=UO1>0-W]
M&SV6M8Y.PU?41O$TFT)3L^NK,G[(N0:B-J/$-+_2Q2Q?<W!3W7D53Q%FZ93"
M22]$3"MH@(<RMK&])%LH6F!N:3$_(S,6"1EG*CDK+O1#LB:*A-I$[*#BQXX=
M/&905><"-S]VVJ:&P08 P!@%<V3_ +'$?O&@W^.M\$=Z[_#+&P4B-@?H'-O[
MHR3_  9[@%27Y!9E:'4RZ:TKDD@'L*Q.NUC06"%W3I5BV%3*6UJ9 1<DX>H<
M<KLT&)L@Q<JND>.56Z:6RJ?'S].,"RXZ7E#/+$_UYN,U35\PUUUNMA\VM./R
M.#U[+N1/1T5V.A*INBZ_@TC"'VH5$552]23IW'W-7:2,::0L.%QH-HPC:X>O
M=H))X6-RI5>_]H=6\:SZ?._)*,D6M^]-D[.&AE0#BD>P4/-!V'I)2&<=B2H.
MD2,?9"=#/*KAUMM5$8[.C@+XMSLY4C+B0LGBFZI97509P<9KO%?UY@Q%+.IE
ME,*5J.6M*DM/3L5)@=X6]/&],G.N"36$=GKDC\+7BL?G *V6+R)RR$UDQ$H4
MO%Y+') N.CD(@XX.=!RV,REX2"L_U]W+*JI44OFY3EOJR<6YURNZ%3=M;%61
MQ[+9@.90*PIR+<,A,GK]]:)V4;HFT*T@WC->G90$AQ3266Z5#3Z<;KA)>^IT
M[7A%NC#34-=A*B,)\^:.N%%G.9<\:;7M(UN^1"L]0\,LZ1U37 J,\<NV[Z*@
MNYZ'7\@A)GZ#YVB\9% H!F_H"/O"V[=ZP7WBCQ@YT6="R#5(*4QOVG_9FJ:U
M[VP="C*5;0/N\"C2E>6DSJ<+)NU48)S^,=EWL7J1&NK L,XYN<D]+4V-.L)T
MEK$)5-;4@_!M&:%R56NXG):Z'(A3%K##"LX7^%W.1*^NO=1\+FTJ:3:_E+%>
M0CRB\I#CPG8N1A8=S<(?LA&7_D^V(:))V&SC(N*N:<=3+;2)*,V\*+AUT ]Z
MCWY,5&6 U]X$K3_CAA'\L,_.1!A,/[,7B5-DHJ-O [%Q?<>Y$K%)V/:P@W6<
MG TGY5Z NJO;5#""E@O]H?ZI:CJJQF;W8=#X&H\$!'(@CI.2Q:$/-1:+*Y85
MK9>,8MK$CL/Z]]_#@F!/KG4M:8R:"V7UTG4N';2MR" $;;CY^<CY_8<$?[]O
M9\J2KD6C(F)TW#(_%J/@9>&?1_B-TZE,0A>*APFS6$KG$WUIE?Y?<GM 47WS
M+D:B"WG,[[9Q+:>U60OG5"Q"L%?/2\>H3M3O8Y@#- ':^XIDZA$HNI_UX:E(
M[7R=25Z[X9!'<+JB.ADY]H@^_?OH&[.&L8TE1@JQ-:]RSNL77CLU)VDJ#W[+
M+OA>P)N+XC-G&YLB^M$P3FL LZ#VJR"-7=R]@H["#P%=Y7<H:V57SJ$US(S:
M:^E<T/5C-B2\2$;4RDNV"JM%.*SS;/0FH:2%U&L659'7AWTJ-P:$"-G0:,@.
M1D,K]L;5 BUQ\.#QV,KO]#<NESY8F*CH%)4<0$BU!RBX90J3$;^7O]U+MP08
M P!@%<S?])J>^\8G_*2TLJN?;Y1'>N_PRQLA2N:>^J2K?NYA'\,C,KO?=^Y%
M<NR]CS!DM)6=1L:M(#2W5MU.GDP[@2J85W*&ZM83=[44*F?76$0Z<7PUCUL6
MC$=9[/I$9TGT1;CI-)VY8V=E1J53=P0CZI!E*8;E.)>&M:W43PKX@Y%)]<)_
M45]5<YJ:MKUA$(:O:P'3)[;<HZ]32"I4-">F,8J0/&6ZP'5Y;("V0L^AL,$%
M1PHS(12\B8SN6M9H0KR9;A% ;483YG^T]O;L2J1U9*+;#]GZ==QM Q); [I1
MP?:IIUL*;D ?6N3Q"JG#Z0QAR37:OVZ!ZA(YS2XL[$MN2H>=+2 @-YV-10TJ
MV#+1>LOYKVSQN"3]38Q;%VV-I.JY# :;"=:M*/JG:-M8V&<[DKC&3.+WM(!B
M8M-1T*(@ZT'5I7D%(OA[5Q&Q1"PQX/E8/+";?<)A:S+\7>LF?ZIA-S4;:<E(
M3.'-7772R&]BRJWIO9K:/$CD;K+Q'M)84FVEQ0(<CD:!N2<_,Q*TR,2%UDL/
MWV[.67$V6C:.4Z+Y @X:U_UA?=2_#4EK:&]@>>I'1$*9!7B>XCD&@#?LA"ZG
ML7U9WH_T0Z_FQ@%J[F2\_K0MRY V@I%59VS$3L.1)F&Z;PCL3B;22C'H4FU=
MC%)5_9X&?Y?6/E!BH4LRCNO8H#;3U]/=)3.%K]AA"MGM.$ZB?#:OB%? V$M#
M1P5>$:LI6!.I)8(RH($N5)P^V#+V0*12:Q,2>%FSI%,-5+<WJ)I.1\+VK?M!
M0]>7W8$:F_8[Z.!0W:T>)<O^Q,CF9$57:XVOC%'+QC6P)^>U9R]&4IS9&.38
MLFM-AC=\J$E1]*'(A1C,)3:HK[.%^?Q3R=1/*-[RDI46F=8![?C$*;N)0 A8
M^?62A.KXCU&GI]TL,S6#KRI'L-'IJ^-RN0U]V"F(#9KV#%2D963IE%P\WB<H
M6BL68 G9Q]**?Y1AVP^3IM^O?>T4_+R]EZY'DIFE8T%%Y3+>9<[;R)2L*W[3
M]M)07K+F+".Y#"1-IV$JNU*&<-)&POM2<&X:!M)KZWB%GR.3!YP+-FZE[=V+
M5G2Z4\,;BQ&=#]WW=:3TS+9QV.7G+6.TF$KAF(L)Z/Y:QGUORN1V$R/UI$^V
M,=XD,B'5TVKF,3:2;=CN+=*!!!CZ!VV1E$BER$N&96E[]H58SEQ$:&KJ-ZRS
MTU!:VE5PRNPH1.6T@B-HRNO-CD3GK<E9$/BT;KP.1L(Y+6-C\RK72(5Y S8M
MDD=(22$3G8[($;/ETK0CTP"A/RI]:79[8*J-H5E"$*VKV&P)N^4*ZQ..C JQ
M55#AHH6>-&VFC\KLSU6<:,>2;[TA]Z"BNHW9<./16^WF$4\&63K & , Q;WJ
M^J2._>,(_AF7YNQ?X^48MW>?AFD*C^JFL?N]A?\ #8W,N]]W[FE<NR]CSHDU
M^]JU:+NJ3*2JM85=4%[-.*,@T/B$2=SJ'RN23GFM(S4%?['Y4YC9CAFG-+$&
MZ3:S5(XPV3!-CLMXA (4P\$9PW"E9.S.6;>>"N]35,[G]J1>1]?Z7%FX<6M"
M7P.RYK,YH; N@T.+ZTY"8Z-)KM@K8@3=QEI);;L:NR+AJB0+NQ,$;RP>/>;E
M^!YEJ)F^WW9/R8V*WYVD?4G/YS K@B,GTXLZ!5GUOL7BEVC %V.F=EI1.&,V
MX86XESC5K302W#[GEA< I-]H3K47))(Q9RX#&!\\FPL*<;FW54B7O&&>Q+9U
MV$[-TC;+6&VPZ%;024DX&%CU@A(,T-[OA0QQ20B82Z&UO C$[M-^2F<SE\KJ
MY8$?BZR$8LFQ:#;15.41CZ9FG(0FJ7_[QB+J[Z&AX_VA HG^PY$H4;26L*\H
M>HNVT-E<6'\J*$*3M6,6AHW8I-^=D=S9G0U0<]DP]YSPTY=@Y=&1.Z6KD:X=
MNA(=-6UY4<HR:1[]7/%K&D+*;TP00:( (9)(;55=D6%E2B3M9#0%[VYRQW.B
MQ34HN5=.J[#BU@T;BQHLT/C2HR+HSL6_#$C8O2L'G+=,E\_Z+GKGOBZM1R.'
M0FIF!\E'Q;61W5HVM8((9UW'"=IR*K1:H+::1V(F)!)U%XC)Y85@M@ J<E,>
MC@CT,PP;3 Q'8J9$C7M2]Q/U[4(R%\HB8D:]+"0] /=Y%V: 5[/.O[![9H5L
M,.US9D3L"7!#MC%VT;?JUZ>"#8,V=2V,BAD]1;,)..WB9^9EAIP(.%Z;ZT5_
M?3/TU@IU]Y3^3L$"UEFJQ3%5((C >:"@(HPT)6$9X:=)NU/9Z=0^3*O$$H\,
MV8&Z#VC\</Q]^[U>J-V*SYLF/-/N!HO3ZRMK21HI7OMS'C-RQ&PJ=)Q::TC7
M'8*RI2)%S<1)Q#L7158]:+:U'BC^@D1YTA)XQV<C#!?E<8@U 26+R=DFX/!N
M0T@*"1=#OCUE5VU^"!N?*> M#\D9#J'M(M&D)L>J*$RUN(E+0-)+A V&$J+Z
M-R&1$X.RKJ(1,W9A=W&0<T:6%+'/R "SV01:/<JAVI4.FZJNEZ*)[NGV\TIU
MAN"X+35LU"S8.!CBL-N&V(&XV R=N:91_6&*P5.+AFSCPL8[EC:1LCTB-HRE
M<?&W;1F+'LS,8&E"2C(<)3/+#[<:VP08 P!@%<S?])J>^\8G_*2TLJN?;Y1'
M>N_PRQLA2M:CWU2I^L5=MD]-4ZUA>^VZN_":6FND7&[<[*;\_FT3UXX^7??G
M\VNO'///_=E=[[OW(KEV7L>4EA=_[/Z]";VA]MS.JW=EMH34YNAI?)A VNJR
MD9NSX[<Q<].1[]C/92(,]?XLE4I%W D3LM V_,38PE7YMBR>RNM95*,_?O\
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M#AS.H]RR(L1[JQ+W@$E.$V#I)WI$8?)A37=N\,M7[(1*DNY-+>?A,P(=[/\
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MH7(A#$6.D\.0Y=@Y&P:,&QT._00;Z:A+S?W]G<3!OU:M&QCE-R?6*R2P3D.
MJ&130@^;D6H&L)8X?QX2F<!O6F\<.QN1S!Z2:AAY 9(MFI-T[5;K"]-N4P4J
MNWDDL4@]+Q S9#+@Q#R+VV&R3LS%B;N,<L$*[@D5'UNTAP>-:\:IZ5S%1P<B
MD_'JMW0UL>/2U9ULWX**L6XD_?62NX[UMZ/JZ+Q&-UU2))Q(F9$DJ*9+!3)L
MJT'+!HTZ+I*<OWAI?Z..(1'0# L@MRK%%X:!%BG0M2-C4&0LM8O[7]DHC/7'
MJ<60B$DB5:U6;:P9ZYWC9T,B---4BS"9$IPNZ*$6[EVA)3(JR")F<I/I*L7)
M";"(EI@W7:RIZ])JA+S^_4MC^ZVIKJ;#4!4EJR'U"*:@7ZDS!'XPH#7;@]HM
M&9?7*;P*4;NG"0F/0V)SR<0X6*'KMHW#Q,JD0@6Q%I%'J*H-O%OR=4GU^Z:M
M=#[-.OZ701C 2*1"4,./ DVL=#!X.[KF'B3K'TOAN'Y1KPDM#A>S]%L\=1?E
MF(U57'LF"+<)>;^OGU.HD57=)>P$\DL'D,/J&SIVI%F-MR@8JR:&')>&W$P;
M5TA)"#UM\K&11Z:L:,!AB#'TLBP7XKN%/RK!-4=$GO(52G"[;_?KJ6*[ZI]<
M'Y6:&WM+P!V4L)N:;RUTX ME>2/$E/"Y9)5VR._'+<,_DLN! IA(R8-(:1/3
M &%E99T\D @<2;!+S>Y+Z[I*IZE210K:!Q^&IHHG$>. K79OLK])I"O+9(X=
M*;*;J/7\@E#EU(39)WLN0*F73HB^=+NW*ZJ@EY:6 , 8 P"N9O\ I-3WWC$_
MY26EE5S[?*([UW^&6-D*5K4B*3BGJR0723707K6%HK(K::J)+)*1<;HHDJGO
MQMHHFIIMSIOIOQSKOKSSKMQSQSSQE=[[OW(KEV7L5@WZ:=66D=VBK.C8"R"\
MEAIM!%B)Y9/1[X*")18+J',-5DC(4>%B9DU$0X<0_9!Q41-&8L/8MP!8@.<P
MU+S>_GWJ0;L7QU[A'J%BTNCTO04 K2QC65>TU4$WL91_ V=<OJZGT,>0BK(?
M)'@ZL$X9,QP]TGZ&)#"CB4&7;.-7HX8S6!37W;C&<7H<YSU,Z5PF,!X01JVK
M8K&BQT0E&095YP(34/M A:,C!L5\0*H.VKQ>,GSD96# 54."L<,%(^^9NQ+Y
MTR4"7F_O[@[^5-^K!RP(_0IUO#59P\K4FC&HH)75&.(A!ZIF5/O4QX-W'G++
M2M2H2936GC<4;B'4=DSL@-C)J.<K\PEDZ#!6KU4]W.]S)) *\INM9:=TCY6,
M-RTXC41KV.1'A^";(A*OHH,2CP&LX> ;[)*+16#EC<\-/6^R#UR,-3.0M'CA
M$>B/'L O]]\?8K>/=<NBO&GT2CM<4&^UE.CYJE'&O$9,;&VL<B4SKQT.9"U'
M;S=T-BD%L&9PA 4S1V81:*GGD=9MAHK1NS01P)>O^Z^MY)@76CJ5(&P54!6E
M7R5*!28TJU(L^&<C=M)6J:#'I A)2_IC]Z?*<R./QHT5'RUV44U-QV.$G+?5
M^"$+,PEY_?OR<N!TEU/$/E9%74(J))ZJ=XD*92-\ W?H16!DRCCCPA5HX72"
ML(:;F!IWX((]"#1XU*2KSD>T(G':KH&WC]^T]#JW=!=.3!(QP[@5,OB;..Z"
MS[;GD'NJVC<S86**;:&6.COYB3.2"[ELT<P>/D.-B+"P)&S9+J-RZR>X2[Z_
M?](ZV40/I9=4T:P231VH[$FDRCSBWFXSE!D9<2>*CQ@^H7\CW(L-E&1>/NPB
M3&"%!B[UP./!V6PQ^.(,!SC5N%;_ !\_LG.W4WK3N4/&%J/KAR\D\=)10_J[
MC3!VP)@C0 ;%#C1P(<IJB>%SL7#"(V>))LDR9L"*&B"KQVP8MFZ02\R4U[0U
M/U0XU>5W7X"*/?.29=5\,16]/>NYGQ#/I:0)/G"Z[LH4DFU>0I0T5(K.B1%:
M.CUG3I1;57=422W, 8 P!@&+>]7U21W[QA'\,R_-V+_'RC%N[S\,TA4?U4UC
M]WL+_AL;F7>^[]S2N79>Q'NP5#UWV<IJ?4-;+(P0KJRP^@.4LP$C-Q,NNP2(
M,RB6K*01YZ/+,-M7K!KNKPW=:I.T-56+Y)TP<NFJT-)PTU@45VQZY3ZZJB0H
M^O"$ 80,G!C<((?3YQ.E9'"3NK4$VK.WX?) !)4M()'5:@\L2UAD@<B]9N8?
M!2;FQ(NM'G&I\$TG+^/*\YX9/"JN\/3&T^T#D2VBDS@HT6C4DG@*SZ4C$1\D
M%28H>C<@:RK0X!AI23'A#Y2-,6[F%"I974?&F6["8$T)WL,'QAL+9:6=_P!]
M_P#5Y62WDZI^I)B1MF;IL*7AD3[![U%9;&/G5K$D5K61VIJ'MK4TYN3YK8>F
M08UQ.*K0#2H2-/%UIXW,24PW>1IO+'D8%!*UPGLDTX[K0Z1'R7LB#SZ+FA\[
M 2,8F/I4K)Y5*"$O'2]K/:K;&GTM,"049]#8G4[@FYT_.#"[Z71YA'C\]LO8
MQ%;)"2YU'M0ZO%]T8^,%2-%=!]%?)BR0:\ID;7TCK6KQD*H6L*?ETVAH1WK)
M=UX' K!B!4H!@1\,>ANLA)/)^4+P^U(@6J"R(4N_-:&WMB,WS<>S#JOQK*WG
M_:QTBMFT;T%E$ H7LE4)J6QZ%%;UI 518^25D1F)?>,-P-:R^OA]C-$3RL:'
MBS/',MU?!XR%"(/XX,CP./E+)G3<<#=@ FJ>3G#O'V_*^:T%^3,ERT/>,%97
M":ZD4DG0T3-480]FLF'2#KO(ZL'TU=]=:%S.L8U%&;#B;(64C;L%$0VL++5_
M5;$J3G"40X*N@ZJY^$JWITUUX.OV\EN>=3J4/B<B@1:(D+A/6,@Z,J2TJ8E,
M6G'<ZI^TLCKJ10WS+&&"08B.UZYKGC5VXL!K,UV\/-MF%:,0I "5#J]HPI":
M7>^=-34]"=0"M'7N<LQ@O7[B+2 ;>HWPP6*<B#48:6/V+E-Y1<>!T1'[#E1N
MB4U-,),T](%I(%VK<@.3(Z$G?H@C<J.WLE\>K-\8(, 8 P!@# *YF_Z34]]X
MQ/\ E):657/M\HCO7?X98V0I7-/?5)5OW<PC^&1F5WON_<BN79>Q^7!5,.O2
MJ[#IJPFQ)Y!;1AT@@LN:!S16.%'$?DHUP**(L3@1TR*C'*C1RKJFZ9NDE-.>
M?DV^>GSNGO"IPYR\^YE^]^NEJ$Z;I_KWU[+Q,)3,0"#8+9$6GDSGXV23RJHI
M%&48C-<Z64'%RV7M11I%OKI8AK59M,Y*+:<#&\I8<&CCEP-)J6W?HEYI1=L%
MD5UW<Z9V5VC@4-A$2+57"QK:D+FJ61BG0G5!I'R=IQV"!@QV'GVD*)RU:&0W
M6+F69&L 92K49^W)QQX;EP_2',@[X++C.].FGVCK&658$O)PS&1'B*1HY5+1
MFUY[12.-6Z.#&'=Y<S[L/* =D0TH4>NV" ])MUYG\> <0AQL:-*2$!"Z[T4&
MQ-2)J,S *U&MTK"G-<KW>==OY-";;6%7<]?SF)28LY&TT8M\F_>S>/Z,+7@G
M8JPNS=DSZN00!7AR3;V+/;,,I1<$5E\0XK;<!%R;]_8HAGM"]0ZJ-85A4=ZA
M5OHM]#D@_)JR2%[]6$X&2J6+/*@A-!QFRIF)!NTRLG(U)/?IQ+RW,&/@)9 )
MB2G'+@BE#)ILQK*UJAE[]S8;.P9HMP'BP$)O\QYI??3RGDBR.FW0R4=;XM/(
MN?F0GT@[1=?4(,FD+,S%>4F&L ;3MLA9A9 WL/!Q<X[5F>Y4/%!S"4OXP8WD
M+EU:,L:'&; $%ISNW=%^'C,HV$^2[L:*U>4!!+)AU<6H-$TU#()8D.6FQ[@8
M @L*M6G[!E6XPPL$%@R\OJ:[IRVA40&AR?T%EHJ&$9-8UGCX_'FL8%ZJUK?1
MQBT_-5>[\C\EGDI'Y:0V@-!&X"TKZ4/+*(1-8LXF3HN.#6'"!,":582AK#1C
M&=H=#0+!$,.*$SDO8%(K&H(!UKP$8BP^8MPZKKY498.9SG;',UC7/3A]6/:G
M:]8]S72$.=/>Q".L58A5@Q.,![ICO4WP]6->A#MQ>KUC+NN<H<&V''AC5XRL
MU\50?;$FQ!B7:_<."32*S3TZN5L;]P9& , 8 P!@%<V3_L<1^\:#?XZWP1WK
MO\,L;!2(V!^@<V_NC)/\&>X!VT>_W #_ .#C/^20P17+LO8J3LCUTJ_M?3<K
MH>Y6!TG74T5CRQYC&Y7(X286WB\F#RT1Z-(XH2$FV6J9H&/573;/4]':":C5
MQJH@MOIR-)M.5?X?N5'V[H"S>P,8'5W$S< %0YV@R<;&I-K+$9S5-A1XV,*P
MBZ:[>@W"K*6R.&:(D%AL'EW@P-[(= 1HG(G(]@3CAH$TG+^Z%4=S>F]G]DY^
M$.Q:5P +'&,3A@K3@X.\/D@*0PVU&UDK%/&0\1)2F7AY @-"B!D9XG4% 0@X
M-4FKP58CAZF"'BIQGXU4>([;%.B_)S6<'17= I)2L9G%;U>.B])VD,C)UU+Y
M794'O$9>,$M"\^.6XQ1WL?(L7L<M$ %+F71]K+;'*-I)RC/%0 (.KO6]781"
MO\90J."*R/R4!K4V9'Q*=@7\6+1:*-64JF1.9:3:,'HAUS7HM1LT"1SAF//-
MYP:V(6-))(2EK31$I8=KL"D%FG$MV>I"]5WM2+YQF,HT5:$HL;R9$@DDB=#Z
MVDE;4M##5-&JQ*R"%Q]TO(1RICK=8-$</X_ S8TC'8U+!Q:<\RT;;55S&GY,
MI'$"%=R:-RMN:*R5ZC[QD3JI6KGYGZJX/""UZ_Z*R<7UJ[84H8D<8@)SLQ$3
M,/0(P G,96*B7#JH656,I"Y4/<P_0DZ539I*+B0$<AV[.*,0</7D!]T'0E:@
MDU3OCQC/V_,K(-Y-63*C&RS^3PV%$Y/:ZVUN XX^F,W$3;K/*(A4D<MNFG1F
M1(QA%8I:CJCJ^U?G!D)B@\)#V6L5V&GRK5U,C8O5YRP_E+:;6DON='&_)=2%
MF>?\262P22 &]BQR2ZDCBTOD1FQH^EW@J+MS(6\XB[U)C#A)50=63N+.>7*=
MC*2>5R)_+F)JN@Q&1PX\+U>/C^+L]W?C<:FZP]0C'7:X[+G23F O8Q84>FHE
MNV"BW0@[%=7G<+M5V)B 88CJP\/7CWT-[+-(H903=CN!9>MQ/ MD3%$TMP@C
M<J,MKDOCUWWM@R, 8 P!@# *YF_Z34]]XQ/^4EI95<^WRB.]=_AEC9"E<T]]
M4E6_=S"/X9&97>^[]R*Y=E['47U1]?\ 9.G;!HFU&9=_7MG1YQ&96S!2 Q%B
MRXMPJBOMHR/ 'C$JP4\\W1VVY;N>$G*7"C1XDY8N'+9:&DVFFKU<9?[6=.]K
MJAL%A</BM(&6,/JJQ:CCI:[ LFE4LJOF:C((-CEKUG+DG!0SQ-(!M!VQ+<>Y
M4"R&7%> 9-G;$"?@'#H\*G%7-Z=,=//ID\()W?Z3VIV:"@HU$9W#FX]K1-C5
M*[.3EEHC+F<DEW,0683K:2AX>9E1YDJK%$=S$'$2FN CD[P*EAM>8> C8TD"
M:5=</.??_5Y G?DZYP]F9\YH9J 2XCT9[1NJJLM@!-K6@4M:Z>UE.=NZDF=G
M_P#1631PQI>P:D'#B(]D=.*3Q'90PVWAJ))W&FX=5(KA/A.R]T](U.J'>3)D
MX2RX!+4YS'90V:)4#(9Y)) _F(F1Z6344SD=E3Z21\#&]FS4XC=-A2J2RUVW
M(RZ,CHA()C.'IH%:,?E#V'<!U4BZ^Z,>(5U\*Z).(.\F')8UMUW%P&05C72%
M94'1U/3B=1$*[3D3]U5 *:"SY</!9 $D4*=G)"YFYI_";/CSNI+2K@L4,ERI
M^R6SH< $AU7SC-/W1TCL]+RT>N7064513-^U:;EX&*DK?H>(T$,E5:$IB2>@
MVT,@\_AS&RVK<^J!%1\PKS.^'X6(AA"Y",-X^.$%[3G[1 !M%P=J6G?#G!8S
M]9507R8TST@;\3K,H56LL+R:+Q\TZ@;R;GV1*C7]6$*.NB,I$2W,8X"'9O7Y
MU4I"M <89<0645]4*1V26"TAK1\B'5W?>+YE=]<:O,X[_P EH:(3>;N')^ /
M8::M&<S\>Z+;RQ^6,1JRNS==WV7JXU"D46$.%1.+1Z'*5TQX>/I\SE(X+7SE
M '7R<:7:O@ZJ:Q'HU,W^V.9JBD^GQ2F.PA.UQ:M?*Q0TUO\ 8<AQPEP',Q=C
M:5PC+9CC6/:MQ^XU1JF[5DB,G9^>%(ZD7^A1AR_4?/\ 302:1V]%!OG!!@#
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M*,(E%GTH-&W1R4EG6@Y)X62CPV+@PLQTA?/Z&"[OS<>?4V[Y=L-I5/*F;U6
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M>?RR?N"P(0'C&WTYE%HS:32I5APA$-=GVC:/!X^$:)C^ E[/A?'<J:,>3JH
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MM!%C<Q/1AC8#TD+G1J0V.]KTL(&FH[GV94U3P[JS-;E=&'I)((O37<*.20L
M1"W0#3)7^_DM5&(19X,!4\2KF9]\;PL+L \MF,,9TP^D1R;=?92(?1M<Q%)@
M28(EXLRK9>$6(*E!%B4^K]W\?;R2M+M?^J2CL_W*._HB#>4\5LH3K94LY QI
M&-)E>#4Q(CIC$DI]1T5E/7/@8?B<.F$=D1B(]HESX7N P8#S@[>.$HL@"DY
M496\ 5I6[/VE]<O^/]7GA0CO;"5=XZ]K_L80XTL9DU@V][70O=4$,1F-UFQK
M0)Y+"; 1(V&A2M@R&?!N6O<QEI+ 4.?B#:D?,CV$J*FGC18:6*QSA]H_D**7
M8**_]L:1<;]ZGAK-$)6YS,!ML@8$]G@9>HH]>DV;6!: T,E74-:398E(D9A/
M77  E9"$I> !A.5$%F:FQ5<&B-A#V(CFU,N*>L45_9&N<$& , 8 P"N9O^DU
M/?>,3_E):657/M\HCO7?X98V0I7-/?5)5OW<PC^&1F5WON_<BN79>Q^7!%9Q
M.:KL.&UG9+FG;"E$./@H7:K.-"IDZKR2DQKAH'EZ$4.*MQ$A4!/54B&HA^X;
M-WW*/F-W+?Y_"VD*KU*E8JZ=#,'9GKS*K/ZCQVL9*\>WI;$&2IXMI)E]&D'U
MGMD04O&=#%B%(D,+#H<W7>*H&YFRC3WE^!C9WP]^ 0T, @+YJ+-7@G-+XE.$
M1#NC7%\26SJBG%,!I6^816K+-BD^>P:2!8M-58E,NRW1:23N(0DP4. '(N:S
M.D*SNEK%C(XD'<CB@Y/5A*(M(G<>+)BJ,?M'\P9F'P7O$C9M5$D6/8-Y6>MC
MMF(2&2RT5D2<9I<G?1OQ<A8]B1N_4UR$S!4T^T*K#K:KZ_3<FA;*&Q.&32L+
MR9S*1D@I6[]Q@HI75;0B2"NNUTA^F7DXH9'X-8@JUNM<N@NLG"E+'?.G\4DX
M&C[>J?B6GR#>QG",TJ\99\EC1Y:/(&9 U4J)PL+8P_<(FYAV@2IM9/35/*^,
M<\2WNNL"OM]#KOCMABKY"Q64]?*TC#03<UKMY383WL2N"M<?V D<,ED;G\H?
M1*(&T2-4-([Q&Y'%XF/D8F0%JVC46%[<D3 .,(O>&%(P[F&G76KN6)Z^DZ.C
ML0NS8_K2ZM=@VKFWA).BM*1?=">8:8JTA%S5CNV[JSE^TK@OHQD+F-N96S(N
M@SUE836E&2H!@-2IFE\W.9ZK[O\ KA=I-2TPM.]RH:3E0L+'+@&>(3^6R:AG
M$%LB.@:[A\VE?=:]9U8\LOV.H3D0WF<)EE&2&H7XD0> S_AN&&SH/&0<9LH@
M.\8&97P^W2E2E(<]Z85)355?>4N:6X-"RF7$TJW:E#D992Z92 =)1249ZS0D
MU$:FFDJCT<E065GC/;NQ;!&VA8S%D:8NU(C4&\9D3N*DBS/5X#Z8^XN?1*/,
MI'[V0.=YH.#NOC9*;/$AYHC;.EPUL_!1.J(W6,<Z32$"?#B )^RSEA!'"788
M$G)DHBFTD2O+DL.E.I=PCZ;NS!13PH_^W:+C6/2EG:NHR;EY>SN$37AUC6#^
MOQ-]3AE8%D;R;F#M^;6/IFFDMFVS&%G#Z@K@ "V-MAS0Z/EY**@ \++QSAT(
MXT\*%I][&X\$& , 8 P"N;)_V.(_>-!O\=;X([UW^&6-@I$; _0.;?W1DG^#
M/< [:/?[@!_\'&?\DA@BN79>Q4G9&O+<M6FY7!:+O=]UIL\RK'MXY<PV!1NS
M7D33&28.6-))PJ6N&H(OQ(@+$G&5-W;A+<<F8V*-N=W+-))0:4)U4K*J]C)/
M=R%2FPI5!:_&]<)A8D2F</(QVX;XA8^LBTSB]?ZRF.%G-40%A-I_#%XT>L4D
M)2+';%8)NMH,* L'<;&E9FXCY:$BJ,^U]^=SN^Z\?M#6MY$>Q\<L*$1RQRM1
M*0>M8I<>E13)G";.D<.%26Z3!*.08ZWEL-DPI\,EYRJY/)E8](8^;*P%E*P<
M<)/C+W0*]!-=,8S*GM]\F-I%2_E!)BU-1"4#[IE FP*7N" *A9#:+, -BL0D
MM27.(KAI)9=#;U5A$OL%F2(U=';"3(TVM/W]E;O)L [#D*O1)!&0LV=+T_5:
M3G%;L$S3/8ZG[Y/U[U/DU$Q*TQEFUI2-S18 DZL5)I(Z\G<SZ^)AH6YL-203
MYY'I<3:2@$B!\>E"UCCA<L?,"I;AX%=F">PBBLNCC.M5=3*<C[RJF[GL_IQW
MXJKZ,78B"LN%3:/];X#;MJ.3=PJ>(T<!8$A).?<V1)CB,;D=O)R#0:(FUB/M
MU&+LVQ>^C5L5!!40E39NI>TJ7Y0L"H+%I+MR>>D(:(CUSE=&MORQ69$93:HR
M04I*>OP&]XF>ZU!ZSC!ZP23H38D1K<-%=YC(>(I&I&5)1:UU9_()42E4)>GQ
M94.ZZBBLM.:PJ3A6]9'4P2A>YPX$+K;?6]J]/.Y- Q$!G4(M $+J&L*++%G_
M *_D)K#AT[02.6ZY;$IP3@\A5ADG.L#,@IUU#I($;12<; Q6U+='XK.#NNNE
M3=)9O7V,^4],S98Q:YH3!-#<2*VQRE,7+6=U]$K<=FA5,C*62B$"G$4.FJ_9
MU!!R5W*:I2(:,1MRU69CTA\Z"D0^HR^G#MW5\W7S3L0#LI*>[<'@MI>F,KE%
ML(,4['R8K:T'E,( QP[&IBE&EZ8$ULF5GY&1LWXUP_," 8^2"DF,)*#MDCA3
M<>X'%"84;49V5'O.%:'H[U4$V.)C=EZ39E8P>)/+8)O:2CMORW><VE'ZKVA4
M#;.&4TD[F438L06?6HUL^01E$]+SQP7!#44$D5QZK'@(+$?^XIQA!J3!!@#
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M:0-O7LV%.P[$ZKXTMV*<]@:RY%A)''G<*3<[P+19K+*PB9,+*UPC&H>)/-)
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M</(.5FQ]B3;5])P<'<CM=8Z1GBSB!M!8FYWW>%+[>I (1Y1DK+G$->N^N<D
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MR6*QR9#FPB4AF)T8SD$3E35D11X7;H2."2H--X>93TYYX^:^CLNCP20"UO\
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MWE]/RZ$GU @Y&!EN# 1\<Y&$'#X2YW'NEQZ*K4$X3\8)YYD4%=.1L:$]FX3
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M4.?[#BLA/"=49WKS$M^YZ%J];JI(QIU'CD98D^2',ZV>%%T&RQM'2U7)E]:
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M([UW^&6-@I$; _0.;?W1DG^#/< [:/?[@!_\'&?\DA@BN79>QW&"C & , 8
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M=B&_4/TVD?9:NI+ZRMI\1:.RLJF4<;5TJ)3@6C5TR*K/4B*I=9HDP$Z5%_\
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MCC7=]P*Y<.(TZ!+^5M1@X67;Q=H9AA7E ^\T;J&+[5B[JT2'A-3]79N7%V=
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MGSENH[6'.TH;2P-58(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M4&M'1!=BI,+"D3^734PT:O7;I 7M))26+2(DQ%:,AJAHJ3):,]'9!XJL!.,
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M9!%EU7V[S1@S#.I37+)]48R%FHIL_FKH*?(QJ+J1M6&RZ2PZ2M%=9"]#6*Q
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MD=O&95*GD)CY'1H6WW)2@=H<7)"DQ^@_DFEN,'QF0FB;ERR19#HX%)25ZY0
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1 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g16439g10t30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g10t30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1KZ4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'"9
M"D         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -/    !@             #X@  !3\    - $D ;@!F &\ 9P!R
M &$ < !H &D 8P @ $$    !                          $
M    !3\   /B                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   /B     %)G:'1L;VYG   %/P    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #X@    !2
M9VAT;&]N9P  !3\    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!0       0    %.$))
M300,     !%M     0   *    !V   !X   W4   !%1 !@  ?_8_^T #$%D
M;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !V * # 2(  A$! Q$!_]T
M!  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$!
M 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2
M,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D23
M5&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A
M<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C
M%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W
M1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U1K6L:&, :UHAK1H !V"=)))2DDDD
ME*23$P/'R0W/N'%4^$.$?VI_[[O24RM=LK+^S=3\!]+_ **ESJ%3/5*:GNJS
M!]GL;J!JYKF_O5/VC?\ U-N]9K>NV,Q&TM9MM:-@M)!:&\->6_OM9^:DIV]V
M]Y:#[&?2/B[]W^RB*AG=/RKZJ68.:_!=2=Q>UK;-\B/TK;?I_P"D_P",03TW
MK1!'[7>)@ MHJD- U^DUWZ5W[_\ -_\  )*=5)1K#FL:U[M[P '.B)/=VU22
M4I))))2DDDDE*22224I))))3_]#U5))))2DTB=LZ\QWA.N?ZQTXY'4GY#NE-
MSV-IK:VS[0:WN<'7.]/[,8I].G_2O]_J7_H_STE.^7-$R1ISKQIN3KE+.CTF
MOTW]#OO!#1:XY0#G;ME3_P##,;98UKK/5^A7^B]EG\TM['NR\NC]/2<$EQ!:
M7ASRW0-<PU_0]7_MS_KG\VE-7JY=F 48M+KGTNFRQH&UL"'5M>[;O?\ OL8J
M#+V/P_L3,=SL@Z0!W!]SW?G[FKI&,96P,8 UK1#6C0 *IA^FRVXFOTW9%CG-
M?I#P-!!'\EN_8[_C/](DIK8%77**Q66U&MNC66N.X#]UKZ@_VJX']3[U4?\
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M[66?I?=]--;T;*?:;&]4RJI>]VQI9M#7G=Z0:^MWMK_,_P )_P""*_C?S0^
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M>TR>[1!^DW\Y&IRL;(W>A:RW88=L<'0?/:JIZ167FSUG^H='/].B3R?^X_\
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MYJS]-_A%T*K8'3L3I])IQ&N:QSB]VY[["7$!L[[G66?F_O*RDI__UO3Z=P8
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      $N34T *@    @
M!P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !
M  (   $Q  (    >    <@$R  (    4    D(=I  0    !    I    -
M*(6B   G$  HA:(  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q-3HP.#HR-2 Q.3HS,SHP.0   Z !  ,    !__\  * "  0    !   %
M/Z #  0    !   #X@         & 0,  P    $ !@   1H !0    $   $>
M 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 3!-30 J    "  ' 1(  P    $      1H !0    $   !B 1L !0    $
M  !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !
M  $   "D    T    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$U.C X.C(U(#$Y.C,S.C Y   #H $  P    '__P
MH ( !     $   4_H , !     $   /B          8! P #     0 &   !
M&@ %     0   1X!&P %     0   28!*  #     0 "   " 0 $     0
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M 0$! 0$! 0$! 0$! ?_  !$( 6<!Y@,!$0 "$0$#$0'_Q  >  $  @(" P$
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MG6 P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P(YC*H":?V6P][>QF"B$Q"'>_4 E^9CHUW2]=OJ
M!M3!%)PM:UK6SCC![[1#%@2-@,!@,"'Y/VV#*]5\2/O16/A0N]CC!ZRW0U1V
M*6"!C%V; ,AQ 7IZE2;?K&QZ;&Q0 Q')#>Z$OA#H.M!#K00AUH(0AUK6@ZUK
MLUK6M>K6M:]6M:]6M8'G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M  ZT$(=:UH.M:UK79K J9S8XO&<P*024X7-@5^)+=/'"W=R$R.;E(3 4!?\
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M$ 0=ZV'>]8'U8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MYN9/+/-Y14>9&YA3#*VO4*E/B'IV\H\_OGB#XPS/#T '=!H(1Y%?":BUV?\
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M$U2+4;D[(YAT-4%[;64-O6!4CF9\%[#\?6OZO2G GIN^$^8?$*N/K#:F!GN
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MR.*V/.*N *C%<6=FM\9#=2V7@TD<F980O;SQ  ]Z H"2J3%&"*4!-*-T'8#
M" +8=A;O 8# 8# 8# IMU!(^_2GAU=[!&&1WD;ZY,3$4W,C"VK'AW7FES*-J
M#"T3:WDJ%BH99!)IPP$$F" 248:+6@ %O0:,#*3N;='G-WN26;MQ\TA!I!Z!
M2KRW8]%;UW-)?-/C;%^+8>YV_BWKMP-G_$GI[THUT96,BD<;G+/.I7 XT\S9
MM=7ER;%*&1N32G4.Z4QG5I"%#482L-.+$A.+":FWKPAAT(.]8%V:*XSU=QU%
M-1ULE>DVY^YMKM(?.[P:ZZ,5M2=4F2;2:-++\E+"4L/[X ][OBV'>]_@ZP+
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MIZS-^8>/'%7C5R)GT&F-@S.(<C"Y3R<9)<HCE2-U&--!S)U7.D"?(5(/=%=
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M?)1S!3&]PY18>HEJUO0H%HG1$0HL9:9<=#8@XZ(3+N3[;1"3;#'3. _#\V"
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MD)5.G4DY8.:YE- _RQD7[<HVM6*(Z]&DHC6<]Y:EY\==G^/F-CZXA>OTM?\
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MU&F*8PZ4L;ZRKV62Q63-:5ZC[^T+B641*QL>&E:D<$"LK>RU"504< 6PCUO
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M2#ON;,VR5J*?DC8N4A2X&X3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@,_!&+ ^ETIZ"/3;MH=&U0L;1NT]>3DIB]4 !RNR4\A2RL)@R3"CM$JR).[
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M@3JUA$< 3D@"-.H(2* "6)]"(5*MATF3'!V9VE*%.Q!T02/03#MB#HL(NW6
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MA^/K7]7I3@3TW?"A,/B%6_UAM3 SW 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8&M_JO\ ["N=_&RL?K\P_P _7@:,Y[\ @NW_ /"R_P#$Z[/[V!PU+&KB:1>S
MFQ,6M<B6-S-;T9QO@$JEQ:0T:1,:?V;\$H\\)91AW9OPP"V/LWW>S K!5L<K
M]V8),XR&0JB'+Q%3JD,,&8B/5K5G8<)881HS6TR@W?=#X/:+: LDEL+[A"(H
MHL.P=T9))9;M3=C-+^F6JJQ9ID6;7TC<-C )2^..W$R<LK6 P =JFE$80P/B
MA87WB-222R!-H\Y66M3-P7SYIV9,:=XP6U94 <BFB815G:%;(Y'H$+H4E/5R
MAB;#QC0.:=4A4]Y&N4EZ"H3F@"(>C AT, 1:#40+GYRAU4ILJ].VWSV%NTHT
MJU#(AL&C=E[%WO)MLOD_9WNSU>%V?BUKLP*%\<)&[S%PG,M?U(5C[*'][D+T
MK 00E J=GI<K<7%0!*E+*3)@G+%)Q@2$Y19).A:+*+  .@Z#"*^_9 23_K?_
M (MX"T)'."N0J5) 9I)*[<T;9MF4/T9D+M%GM4!\2D*CRRW-E6MSF!ETE" D
M0BE04SJXA6)#=; RJB%(6SXC<B;IHWEA7L1F=E6%;$3G*Y'!GQG>)?*)J;LJ
M7.+>U-CLVH'9S="O.4>?S6EU$J0D!7F1XJ1MI.C!N(>P.TE@,!@,"C5V=/7C
MUR)MZS[:N% _3,-O\15?"^;UVY*64=?+JL66$OLO;VE2:8O21#/DDB7[$UR!
M/)@I6H*-O6MS4F>493IH*T1'HUT;#['JBURKKO>43JOH!2M:3606,S<9;.=K
MYC/'I:Z&509:3S87'*3/C1(F9D=38F^2VFW2J)+-&!(W"ESF\/B$E[T'%LG1
M,XWM+LSI5MP\E9)4<.A?+BN*RX^/DLK4-55; >:[6]MMW1:)*&:IV>RUJ,X3
M^M51!=-+#EKQ$PE(VMN<O,:?;68'"LO0]HU >OD;]R7Y;S>TDS1Q/05S<4GD
M-%AG%-N7"ITERR@I%7K=':#8*].=&-KFCU&Y*FG<'FS).&E2M52II=) \/CV
MY!GDTZ/]1V%.JQMN;<@>1$SN>"0E76LLMFP&WC%:,FN.OE%K.MQ)(G.F>T>-
MDS@4:;V"4OSZW1E33,.JMS8H@\+HDC7:9AEIRPY^/])JG(M?D!NECNSD8BBM
M6<G;/Y>5YQR#(*OW1$4NNZ8E-XM:3R@1ZJ8-FGL\I.L*42<F/.-G+6J+R-U<
MSH@G86UY>VQQ#:?@,!@,!@:Q.I-U.H'TUHY#Y=85<K9S'7]GFLF>%+=;M%U\
M\M[% A1L3TBA\-L^P8O-;9FZM#(3'5GAE<QY[./;6!]4NCFSZ(2!6A%AW6'A
M:2_G&JEO'.W4]6,O+:$\,GKD7Y_K?<+;[>LNEH_=D&+W#1R@JQE+,L8Y D;7
M]S3QT:./K%+</1[GI4K); J8]];FT'A_8;&C7'1\K;C?+NG3S2YHU*Z6<IA;
MU)[W-IEZIYKHI9&2X-/G59"TTW%.56G>"R]G2OYY4M@IB%T+5[=D*,+9QGJO
M)V:81>#V/1MBN$(:^0T#X(V5RMCRF -E6?JWGN-L0'J$L=9K9LIMDNO?=$=R
M*\+GFV)6T()BK"U:VO942B3;"4*+ZE1=P]/^=]0]TXSW!#*OCM>3.TH3 $3C
M#; M:U(9"&I>J7N$:CD0=U*5L4NKNTNK4PMLA<6Y>H2I2GQS3M*!2#0 I8V]
M;IJLUGX@6E!66%0BIK!Y8VU2_(0Q38-:7JI::]K+B%:/(Y7((N\TM.WP47?$
MRR*-*5R89TPM,P2Z;GYN%$/)U;0^*@E-OZV</0-,9?+2XJ7G3C78-8TSR,K9
M5+W^JW8$HXLVY=U9T@ON9QW#)C) P]=5[E;]>RZPZ\D8DCXW0^0DN#>M<3T+
MLF;@E#B#U>*AYHW&P4S5E96 G>G%TY+G/SF\'M!:")U[0;C4J.(6>Z%DF#4&
MQKD$BNN#OE4@(#XZYF.=%R@6RFTT0PVW8# 8%2.9GP7L/Q]:_J]*<">F[X4)
MA\0JW^L-JX&>X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# UO]5_\ 85SOXVUC
M]?F'W_VM?G_]V!HTGOP";_M67_B=?O\ \_Q?BP/BH3X(E>O_  %1_P"IO[,"
M_/ ;I\<7+^X_([&L^&/SS*%<_GZ4]0@GTWCZ+:=%)% BB@-S"^MZ0D(QF&FG
M[)* (XXXTT8MF#$+ WG5]7\/JN&1VO8 Q)(W#XJW%M;&S(]G&%I4P!#,&,U0
MI-/6+EJM08<M<7)<H4N#DO4*5Z]2H6*#CAA5#J1?L)+\^+\>^O$7P.OR/?90
M9_\ :</[6_\ D=_M_P"#W_XMX$<\1_ZU//\ UA__ ,SL_O8'#5]^R DG_6__
M !"P)YCW&C]5%RV8:[(FFZ_4*8/(G-1(BF <A.V4P[2+$A):$M]CHO*"3E*D
M*508X&$D$K7 L20[ROO%AN7XD=-*'\9K*66U)+#67!-D[48U0]>Z18,;3Q'R
M\LY,].:9+N227RMY7-YNVE,N"8A\W-:EV3%DG"=3S0!.=S\B[^K6<*(O7G +
MD9R&C9+<W+"K)K6SN&<6BZM6L*$8K:26F[.3]53L"QI'K1"P]3$2&X\P6A-R
MY<5H1F@BC]63RV_<D>9?\N/38_TYL"H/*CJE\\:+?./J"$=&7EC-?=6M;<$D
M+&NLGB]('@#(..NCH:\1Y;0=[7F3&SV<]&2K<7>U&J'UWYNT<E73IB7G(QFA
MN^CCFO>H^QO#K'G6(N;HTMSBXQ5\4L:QZC:Y8D*4*F)V5QEWD$<4N32>8-"M
M4,+Z\LYR@@PQM<UR01*DP.9P.L#UPI!R;NFZXA5?%6G[CM5UX'4Z+GDN<ZLD
M5;L#1%>3J>9HS.+Y<]1V)8]<*II%TD&K3D$&3PJOPSZ9+DD\CAR2$+S1HM&A
M3UHYO7"/G)RVN[BQ;]G-DQY'\BND[**9X@J:6;9+"^3-:V]Q9XUM]YI9)-'R
MN7B50M72M;OK_+7YQ@D[K\%;NL>4N%C(WY&\(D*,([GG+KJE<G.*O4TC]D6V
M[0=SBW&7D!*9=2U>HT2&\Z%F\$O-"UPV&Q)C;N)4.=(;6\KJ-OE+)-")U==W
M61-&PYMLNLIS$V1:J*2A="&]1SDB?U->,5'5C?=SVQQP=;,JVD;")L^KJ+C\
M4FT(E7#X^RX_>$=4P&C&>=JQSRPRVU<CM<ZS:QKEWD!SW7$)H-4WLRI_1AVM
M,!@4ALSD_P D(3.Y'%8=TW>4-QQEF6%)VBS(1;/!5@BLM3C1IE U[,T6ARW@
M,]0IR3SCD RI+#V)8)0D.-*2F(QIE)X8)^K)Y;?N2/,O^7'IL?Z<V!5"X^J#
MSJKGD?Q8J%AZ-G+!]BEY"M J<.2JR.,#P^0Y%#%-9EH96@?:DO2UZQ8&1N!,
M'(M_27;,*B(?E*AB)A$C=%*&1(TH;Q"AB,*+,&480(98!B)-V5LTD0@ZWLHS
M9)AQ.S"][V >RC32MBUO99@P]@MAKIYT\">$?*92UV/RT4NT7TW5O,N/*J4M
MMZ3&CFR1UU=;JP%N-92Y?')9%VZ3M3Y,&B,N+)'G@:HI?)$B)")(Y)%RMI6A
MR+=P0X:'RI[BZ<)KO-VODI4W.241HRR%2^2(K@A==LU05S-GZ/EK]K445<XG
M79+<6SJT*>-R)Q:7A6$H]4%;W A"/=(;IV1^R&QK:B)RHE4,AV@16IW?D?94
MG::]I9VO.!W(GA</JZ13)V2PZEU=L5"UD)V9H:4+ N0E2"%F*%3-L#4@"=I+
MTZ>')-UNW*.2L$A:G%%/P\AY%&G"W9^U\>R;NCT9VPAY&O=.GRHBJ"+19HLD
M+ ;.U3"5Y,<W)Y4I!Z4(PR  2O5G%KCO&>(47XHUZD6.O&@=7"A$8*:9_(5"
MUQKV1IE"Q,M8[,CCVCDVC5:9UVX,DNC\@2NB?Q$CDSNA)I292$*_P?I+\+X.
MNCCUZ(SJ<2ABN%VO1TF-J6G.K-E<]L!WI5\X[FGV*]3-X=U$N8DE/2%PAR"-
M+]:9$Z405NT1CF8J6*0QY%TMNGY3U<VG%)&TOY<%N"G2>(IJRX[]L:6 @=%3
M!Y"@CG'VF7ZRIJZF5A%%$K=FT,6C\05(79?)2(J2%4Y*V.-$( G;C9T]^*W$
MJP'ZSZ.KXZ+S.24M1] .;JI?GAXT*L^/<53PRNFM.F<51Z=,O!'V]G22-Y*!
MIQDPV%D4.YZ@YM('H+K8# 8%2.9GP7L/Q]:_J]*<">F[X4)A\0JW^L-J8&>X
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# UO\ 5?\ V%<[^-E8_P '^SYAP-&D
M^^ 07]JR_P#$Z_G]F!N*H7IQU)JE8,I],K#[\P@L9?U^M*H[H*93(6%"Y*B4
MG^Q_M"02<K, 1H[9IFB]!T88,6MBV%Z^.E!1?C56B:L(@[/KTS)GQ^?@KI$8
M@-<A*I O&O5%"$VH6]-X!)@^X1K2?1F@:_I@QB]>!.V!1_J1?L)+\^+\?^O$
M7P.OR9V>X$?_ &G#_'X._P!_^?[6!'?$C^M3S_XYWO>]_P ?U^][W\7OX%A>
M)?$ZP[_M.U9E#G>)-S7"'EJ:74B0KG5*M/4NZ=<K2B0EM[*Y$F$@+1&:.&<>
MG&$8@: 6,.]BT&TWCQP<M:IN433=<B?H*LBR"%R>/&H6AR?#WP2UZ*1EI3"T
MZN/HD6TP-D#V<,2\)@=;#W"C-[WK0;6,!@,!@,!@:M>6?5DH3B7R'2<9)%%)
MG-;'*X\V3R;E:EED-1PN(P6LZX;EZ\XZ2R>W+*KU !T?]MJPML3-NUZ5 E(-
M>)$M9F5,L<$P9W5/5"XBV;>UD<:EUD1^M;I@5QMM*-$$L.40YJ>[.DSO4L$N
M!L6URD02%S,>6MS8YP)I90J]-SF_OD4EQ#$WN21G,6##/=]1K@=J.V=+OU7%
M!BB]+N+ UVH_EV/'3&J#*)3,M5Y'5#ZM+6"(3M+S.]&P] ^@&8R'R-*N: N'
MEJ!:20'/0OGCPUL2S(Y3,*Y)U)(;7EK<D<XW7R*6H RIW*71 BP4B)*T*!$J
MMOIT"4IYP&-& !(=0\\F3":PLI@%VPMI@,!@,!@,#01UI:%Y,\WY%1_#:E*,
M3V'6Q<"OJ_K7F4_G4SI&JVR<H8"Y4CQT9VRWF&H[=;G.SH7/K:=^03#7 V1.
M>I74W&GUQ=65$4E4J U63B;\XGV+<B^2\EXC]0=CY%7#P6Z<-.,Q%/P?E76$
MB:N4<%F?+.'VY+I8Z4$TH+,<:>KQQ4#M:51^+IW0V41)^KA(0W"'.(RM$'-S
M_C?R[*:+ N6@;%ZGLRL^DNC9"DE779+X-R,K"[+_ .7M=<LK\EB^*3Z)V1#6
MRRIB!0J7*5K!0,I2.34[U3*HDH5LDE9"H<^A"6YF5U9)+RPYG:D,OY%L;*9'
M^622OZU9*4Y*RFE+$H5;Q<=2:(9*^F+(G5<8HA:)=AJ&-[3*FD*3D*X68WR6
M&OXE\6>&MJ"&&P.INIG(%E=KG>>=1BOD+1:_1DJ8$6C#G:T6BK13%D\3:XBW
M/20*(VI9#VDP4>E)[Q[H,P<DA^Z4LAH721$JB$W&\N*D,'L+_5EPPWCW#B;
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MEQ2>LK\EC],X%87,L\YHA\E55JV<:$4/C\8 $<6E#\FL:RJD<%0I@<RU:R6
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MTIC<OL:4M1<$0<D5<?D\9V8PKI.SO^QN3R A$#L $;\?>GOSO?:LIB V\'F
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<S<D1-S6@-4DDGJ?#3F."\Q.DVZN+AM"BVG#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g16439g11d65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g11d65.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4E!:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,34M,#@M,C14,3<Z,S4Z,#(M,#<Z,# \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-2TP."TR
M-%0Q-SHS-3HP,BTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,34M,#@M,C14,3<Z,S4Z,#(M,#<Z,# \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3 X/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06)!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'%K9FY$4G13,6)43&5$
M5')T)B-X03MR3S9G=C='-CE26%I!67)E-FIK;5(K4#)W66QA:6Y9=%-U,DMS
M1SAS9FPO*UE.:')%1C-D-FQ(2$%V;VU.0F-Z,U%T:D9A>5$S3D5K)B-X03M7
M351#.6YD6C(U16-A94Y-2W91=DQ.+V18*V=73C5D1E=U6F]G,'))3TML=6A)
M5W!P.2M"57IX5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W5X5C)+=7A6
M,DMS1#$S.'A.4C K=SAW4$A:5S1V=$HQ3DQ#,F=M=4526DE'9W1:,G5(6GI'
M0CA.,E!H<C%+:714:7%1,E@U,S-.)B-X03MZ<6M.;6UM>'9&3%-66D9A45-&
M5&9#>$YR-E1+1T8U=C8O<$AF:'0W-%9E;C94<6QT<6QK=#5B0C%I3'EX1EI5
M84XQ94-2;UI&6E=O)B-X03M24C!)=TMI.%9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&EQ,E9Y:V)U0E5Q0U%+9U9O4$4W1$98;&9L5#@V-VY7.59J<S5T
M35=+)B-X03M)3VE34$-:2G!*4DQ"3D]7=%DP471+='5B9C U94DV:T5E0DMS
M-3AI>4Q*-5(P=#%"0W1#0T%Y;%0Q4%9704DK;D%65#-&6%EQ-T98)B-X03M9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%O>5=D<$I-2G!)23-L5E=J16I+
M0W=2>7!D86YS>&I7=GE(:&EQ+W="1T=V3# Q-6-U)B-X03MD84-V2VY(;#@V
M8E9X5DM02U X07AY<"\K,FIQ;B]D4G5-5E1R1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T98:R]K5S5G,7(X=V12)B-X03MU24Y!=')3>'-$3$=D8FE%<C-%
M.3-(24$V=F0O0DE2>&8T;W!G4$%6;V-+=E=-0W!(<'9M,WED9C-&=$)P,F\R
M<S@X+TU7<5)-<$HR)B-X03M,='AP+TU%3$0K64-O<4)I<F9K<B]L1F1.+S1W
M:CE:>$MP,VER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER1W!V>D0X
M<W=E)B-X03M91C!'5U-D3'@W9U=34VTS;2MR;31-85-E:THK4' X=4UQ9"MP
M<&ER2F-69&EQ4RM59CA!:FQ4+T%08E(Q5"]U;S-'2W!H9#-L>D$T)B-X03M7
M2W=N=6=2579#,$%!4&=F5FQJ4#19<6@Y33%M5%5%9VQ45')M1S-N6&US.')7
M+T5#;&9I5DIN8TAT5&IS975+<&QI<G-69&ER<U9D)B-X03MI<G-69&ER<U9D
M:7)Y,WDU<5=K,T@U<F%J;U-79D)D3SEA949V6'5M:$5I*VXY:3%E6G)33FPY
M52]&1W!9.3%J-#=L6'%,<4=5<5-1)B-X03M'0D9184AF=TEW2W=,479Y8C!(
M4TQT8FE++W9P4E=->7A'4DEW>&=J;&EG26%&66YJ2TQC>4U41W<U3S-)-S1Q
M>4AY3$=S9FQ(4S!5)B-X03MK<7-)04Q-5U!5.5=9:VXV8U-Q931Q-T95<SAY
M-G!F859O='IF,D=N>6%R9'=G96IP.%)+>5-S>D)1<6M+.4]U-4EO0G5A1$95
M8EI4)B-X03MY6$9N0E!*15E:2EDP9#17<E9'6E%3<#5"5'0P,T%X5E=X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6-#-(66$Q1BMD57I72G,W>4%Z26)U)B-X03M+
M-5<R;FU3,S1++TM/-FQL83A7849P5U!P2W9"54M5-C%W<3EK=TLW1E5J.')3
M>%)A3F-34W5S8UDQ3%4V=7A#9U8Q2V-$8RLK2W!N)B-X03LK:SE.+W=#5W5(
M+VM9=CA!6$95=C!#*W-O=$IG:FQU26MC8S9Q>G%#2W5X-D4T<6UK3C-A>FQH
M0DUK<%-H64EW86QA,')1.399<7$T)B-X03MQ-T9867$W1EA9<3=&6%EQ-T98
M;$AK>C8V4'IH,3E8;%=33D5M:FMU6D1::31N54=!>$EY4GA25'%S2DQQ<D8S
M1$$Y1G=Q.5A)2D)!)B-X03M.1#)/0EAM,FPK679Z1E188F$P=5E'=DQ7-%HS
M9T5L<6)F;D-'=6M0<51+0VM,2CE79V8T:'8V,T=H<&A6;&YK674S;$A3>DEO
M4GI#)B-X03M/4V<X<4=P-S=90W%D>7A25%)01DMI>5)/0W)X=4%Y<T1S45%D
M:4U644@K1W9,;B]!1F%R4"]P2&DO-7!X5C,K1W9,;B]6<7,O=T1P)B-X03M(
M:2\U<'A65&TP2'ET0V]A8E1R1TI384)N:&A55CA+:UEQ;#@W85AP,'(S5VTV
M9G!.255,2DU*:V=M*WEE44%30B]L.7)#<4\P-UA()B-X03MU06ML,&)+0T8P
M1'%9-W8Q2'%A14%Q,%512"]"64944TMA1UI/8U1R26Y4:VA$1#=X:7$O1EA9
M<3=&6%EQ-T9867$X<3AV83$U6C%N)B-X03LX,$QQ,B]2>5)A>$),8U102DAD
M,VYQ4G1B;%E!.&E&63=35#%54F1O;F5L04<V1VA63G1C.#(K84Q'4%<W6FPY
M3SAI,4E2-EI*1&%4)B-X03M80B]2<3(Y;S=Z<D5O67EL2F)V,#)),D)R,E4T
M<7@W5%!0.$$K86LK;U<P9#-O<VM+4V-'=4E26GEJ:&1M.$5,-F-*1TE4:4Q1
M*W5,)B-X03MG;FA8=E1B1E=C*U=:6&PX=&U2-&YG9#E7=D=A1U%O6%%N5C5F
M:%EO>G!597I%649:4&ER<U91,&8O2%-N+S1W=R\X045P8U923TMU)B-X03MX
M5C)+=7A6,DMU>%8R2W5X5C5P-6(Q37(K62MQ8619,G-5<5%/>51T2F8S0S-A
M27A"85%78W-T>DA*2'HV4%=-*T,W659E;$\V;W!D)B-X03MY1E914WI%,$%!
M-FMN07)%9$,O3F)Y6')K.$U7;EA4>4-D=4MZ3D=Y>$%S<VI2.#-/>2MO24I/
M3F4V37!O=W!I<6%E4U-'.'%A65%A)B-X03MG=VEH2'I/2E9(,U=S-E)A4RMJ
M9#,Q=F)Y,$(Y3U=616%H-D=J14A&6%=U<S909'EI1S%V<F4T;4E*16-5<4\Q
M0C%.1DI/2V]Z1E5.)B-X03MD+S,Y;"]X;5 O2FU41E54:7)S5E$Q<"]F,W8O
M04)M2"]*;5!&5D16.5A';DI'>&DY6#%#4E%(:E-N,$A&5TTV<'%T=F5X6$I2
M8G$S)B-X03MU6F\R5T]72SAU159(2SA665)O>4IT,39B-%5);3 Q*WIT2$QX
M45A$1FA1:6$W;6U&3W5Y>6QW4&YI;&MU;EAG=F)/3S5#8T)*6#1A)B-X03LQ
M<%)I=EAB=W=+:4U69&ER>DQY+S5O.'9Z+VTY<75M85IO54U6,7AK:'9T8VEM
M8FQ*2D-Q3S1E,U=0,'@X5'%0534Q8G!V43A3<C R)B-X03MG<EAV9U8R2W-C
M,$@O:FA3+W=$8EAV9BLV=DQI<DDX5F1I<4=J+S0V52\X07AH:"\T;$QI<7)C
M6$U&=$5:6C-#4F<P3$AX3TMS8CAX)B-X03LO=T-'3#=43E%F,&)A92]L='!6
M:6MA2E=K3"MM46Q(2S%R5VQ..$MO-C!M.'!78W!L=$DW5S-L231M4TM*56%H
M,W!65D)P=&EQ83)T)B-X03LS8EA56FMT,T5I03A34EAR4W9F-31&5F-69&ER
M<U9D:7)Y>GEP=VLO3V)Z02]P;4U2<$UQ9C=Z54Q(-G5(8FU*1G4R-6-2.$UK
M6E)A)B-X03MF05(S2W95;E)856\T1$MW25I32V=G.5%29U9I*VYF;&HU33 K
M-U<W=#=%;5E"42]Q>7EY<DE);VUG:#E62D=:6E!2:&1O-"M1*T94)B-X03MT
M:7%287 U-70O25@U55=/=719;3AI9T552719,T50.38U5V]B:7<R*U=&43@V
M+S9(1S W+W%6-78K:WAF*W%70DY)8E10.$%N3')4)B-X03MR3%1B4WHO=WI.
M2CE7:&IH-2]7,4A,,#%#,7 V4G!7;4LP.5HO2U0X,5E0>D8P=2MV-&1/8E1H
M67IR05DS;$5X67-N3W11<55X47I+)B-X03LW+W8W3"]J368K5$UM2V]N1EA9
M<6AR5"LO=F8K37<O-4UX-'%K+VY(*S5T=CE:=C%$0T99=FEH,DMS,SAU9CA!
M2$=T+SEN+WEC8D%L)B-X03M-<U9D:7)Y<E%R>E=0*U8R-FU:-VTY:C V.&EE
M3S P*S0Y5T]/;')'9TTX84]"1WE/-TU">$A,-%%A,$\U5C9R9U8R2W-C,$@O
M:FA3)B-X03LO=T1B6'9F*S9V3&ER23A69&EQ1VHO-#95+SA!>&AH+S1L3&EQ
M0S@P9CAC;'8Y9&8Q-'%W>D-H,DMS=3AO+SA!2$YK+S1Z3B]X1F-3)B-X03ML
M3SA#<%9D-C5086IL2G!6,EDO55-*6%9R56=T231J4VXW*W4W34]O>%9(5VQZ
M3D]J3DQA>3)H0F]&;4U22CEX-E1Y1#<X5E8X5F52)B-X03LK4DYE=F12+T](
M>D9&3&58;G!2=W9X,#1Z2F,R,%I2;S!R>F=K;6A4<%956E5C5DYA-S16971U
M1TM-1DY'24Y$-$A!<GER>7(K6%AN)B-X03LS4TY5='!:3E-J3G1">$U$5%1Y
M,TQX8TE::VTY5D%T=71X.6%L;&IF8W%55D9'-T-U1E=09FY12D(O>FIV8FE6
M9S!N<5=N2FQ"544K)B-X03MQ96=*86XS-'%(>6)G6D]X5CE69C@T9F8X;W)R
M,R]-8VXO2FM9;TPS83<O=C=,+VI-9CA!:WI*:6A%-'$W1E5.868S.3<O>&U(
M+TIM)B-X03M01E5N.#0O,TYT+W).*V]947)&.%5/>%9M+VQZ+VIJ5R]W1',O
M=T1K-#)"2UI9<3=&5TXV4C5#,%12+TUT-S5G,#%P;TQN56=2<45")B-X03M:
M6DDU5TQC9S5-:71+<%5K,$-U0C)P44-I<DI-5F1I<DA.0B\T-%5V+V)8=F8K
M-G9,:7)).%9D:7%':B]!3T]L4"]X:&@O-&Q,:7%#)B-X03LX,&8X8VQV.61F
M,31Q=WI#:#)+<W4X;R\X8S)4+VI-,R]%5GA+6&DO+T]4=C5G96-V2RMS84A"
M-68Q5V)4;W)M,VUE9$EU4'A-<G%!)B-X03M4>4(V1$%K4$5:=GIS+TY76D%K
M=FU/-F11>4]!9E0K,4=W9%0Y;G-Y9S1R4R]W1#58;BMB6"]5>EA8+TI0+VUN
M1F%F66XU5C9R<4=R)B-X03MF;#,U9C%,55HR=6(V-G,P:W5*,W!Y9'I7<$Y!
M0FEH4$Q044Y#<W)P-W5Z,#8Q=')Q44508U%W>'AY34=.5W$V<4=.5#%X5D=S
M=U93)B-X03MX<E%#<&]#5'0W1&9&6&U0;"\X04]76%9T8E=Z8E-P3%<S.5IO
M>D<V5$<X84YH8W-J>#(T:C5S63%T05IL05!(,49(56)L5TPO;E)))B-X03MS
M;B]/3SEU-F=H5VMT0T%Y;%0O96YQ<D%%9E1I;V9*=4)K-T98,58O>F@Y+WEI
M=79F.'AY9CAM4FEG=F1R=CA!=C=,+T%)>D@O:WI*)B-X03MI:$4T<3=&54YA
M9C,Y-R]X;4@O2FU01E5N.#0O,TYT+W).*V]947)&.%5/>%9M+VQZ+VIJ5R\X
M07,O.$%K-#)"2UI9<3=&6%EQ>'(X)B-X03MW9%0X=V%B-69.>&]10G905U)7
M67A35#A9.7DQ16E35G%S445"-&M#=2M+<TUJ.#EF;55D949T*VEP5%IE<E0O
M04AJ;$(Y8U@S;VUX)B-X03LY4G5+52MP9C92.5DR4W9E;3)&5UDK5UI8;#AT
M;5(T;F=D.5=V1V%'46]846Y6-69H66]Z<%5E>D591EI0:7)S5E$P9B](4VXO
M=T--)B-X03M-4#A!>$M81E5&-6\O=T-/4S,K=78V.%996FA1-T976&559BM/
M8DHO>&UB+T%):75*4RMD=BMC=R]W1&IV*UA0*UE79B]K-'5"2690)B-X03M7
M2UA9<2LY9GE7+SAL5C59+W=#64=0.$%J:7A:<&ER:5%"53=!67%K;&@U=3AO
M-FAD,CA.;'%.=%!D6$A-5S9)=TQM9TQ-0C-(2E5,)B-X03M$*UE#;W%":7)Y
M8C@W4#A!,6YU1"]J3&$O=T1*,#161#5+=TUN67$K<78X06Y$-R]!2E)86'8X
M06U/5"]!2DUJ1D)E-UAF.$%F,E@O)B-X03M!0FU0+TIM5$9#2GA6,DMO83 O
M=C<S+VI-4#A!:WI(:7%4*V-F-VTR+W="6G8Q1$-&679I:#)+<S,X=68X8V$S
M+W=";B]W06Y'=TI4)B-X03M,1EA9<3=&6%EQ-T973V%$+W=!8TM8+W1R,W8O
M04A6-6-66DAI<G-643!F+T%",' O=T1J1$0O>$M81E5&-6\O-#5,9C8V+W)X
M5FAM)B-X03M&1'-66F0U4B]W0T]B2B]X;6(O:4LT;$PU,B\U>D0O-#<O;'HO
M;49N+W=#5&DT16@X.5EP9&ER-S$O2F(O=T%L5C59+S5G62\T-'-7)B-X03MA
M67$T:6])<E-V8UEQ=V)49GEL,&%Y,5(Y4F)53#9E86515%AA;5)):$I*1VMY
M475':%=*-'EG=7!74'!L951N:V0X5F0U<B]!0RLX)B-X03MM3#52=F\W-U0W
M,U9.3G-,95,V6%-4<48K-&M.=6AK5D52<'E/4DEO=G9I<GEE8GEX*U-';CAO
M<G9Y,5HV;$UQ4U-#9E-T5'5N:&-,)B-X03M$-GEO;G%Z25=F<7)C86AF:$IP
M>6]$4S)G:'!V-4M*8S-S52]K3FM7,'5:3%IM3W!Z<48Y0T=",TUJ4$UQ:7-K
M>%)$6#1I0C-/3DQB)B-X03LQ:CAT4$I8:VME6#5B=E).3W5T1V=U3#(Y:64S
M=#E1,4-,;#E4=35B4DAC0V-F17E19VMD=6U"56TQ;GI(<$YV-6MV=$A72R]3
M1S%K)B-X03MH:'-T5W5T53%E1S!--4MP8VPU+U8Y4&I#2C%7:4]7-4)G,T55
M3T960U!Z4'!K,$8S1W-T>DAC,BMO45=+,S=A<G):,'AO<&)A,VUA)B-X03MB
M-C1:231Q.')J-%4U8VEV>&)J9D964%-03T]M,V5S3EHS3G1Q46E.=4I)571.
M5S%I-VUA47=X4U9+=U-Y1T])=$Q14U1+:3AA3EAE)B-X03MM2W!P-4TQ1S(Q
M=2MS64=H=6QT-S5,<#-V-V)7=%-L:F53,U="9TDV>F9%07,O0FU**S!T3594
M-WIF;S)J-EIA5V-X='13,4EZ6&-6)B-X03MS3&1.4W9Z2E-7=%1'2'566&QT
M,TEX5C5X1"M96#5F>'=R.64P9E99-58K<6E:;SE4=D-G835I.59G2S-03#12
M<TLY5%AE9W)I<7!A)B-X03LK8G9+-C9L9E<Y.7!&,F)7>$UF<E17,G)8>E!'
M<E%V3WIV1S T86Y#2C9!8FUN=FEH-G(U9CAV85!C-E)P.2]#=7!7:3-%361Y
M;')*)B-X03MQ5BM42#9I:51G-BMU5DI(3&-D34-75%EQ-T9867$W1E9S<V%Y
M>%!%>%E+-FQ72TUY3E%I;7I+47EN,T)R:7)(2G9*;6<R9&A/,%$Q)B-X03M*
M;S0O57540D9Q5V\X;FM,1UII;T9X.7!P0U0X.%990D@U=C!#,FET;798=7)X
M<G=,26<P>EAD4VTY25 V4RML24I*,$Q3;S V;'=N)B-X03M23U1K2T)U5E%S
M9FXO4E P;V)+9E1T5FER0D9-0BMN<C=M9VMN*W(X<&$S0599,60T*U0Q;W%K
M:SE-5EIP-4MT3D<X>#97*W%P*VMR)B-X03MD6DI/16%T<75O<R]P:$9K5&UF
M<D)&9C-N63!X5FIN;DQ89$<P<GI$2F]J5VUO,TYQ2319,C%#8E5T5D9R1F5Z
M=7!62G!F5DU3<$9B)B-X03M%,T5N>&-G9W%"5&9&549,9BM7-'1/=G!'9VMM
M=6)E4TM+0S=T=%(Q:6)4,C54:4M34U<U5U%2=W%!86IM=W%A:%,Q2S1O43%L
M<G9L)B-X03MT=DU&;G Q,5EZ=F)4;#1N;G-.4S%A.6MK9$=N55-W47=34U1.
M131G1$LS<#A+2#=E,4U5<'0U33%3>#%78E1)67)+-W1R8E5:,E=3)B-X03M3
M3%=.4DEI2C Y3#%9;5@Q:"LK5&PV8V\O6DLK.4%Q<B]M:C5..&IO9$UN,511
M3&YZ1DY)8FE/35,S,35,2D=S5G9*8TAJ-G1W;S0X)B-X03MO>'DS-EEQ.#)D
M9GE%42MG+VMI6DQS,TES;$IU<FHP>DMZ:4E%56XU8V954&@Y;F9Q475+,G9S
M3DTO2C,V<F1897!E4D-L<D$X>4(W)B-X03M7-W9*5TIG=5AG<#9F<3AZ>4-"
M=&AJ4S(Y-#!V>4HU9G-D3W1R4S!3*W-B84=.5FIS-'13=C%3254K=V]79FIT
M-UE&6DII<G-69&EQ)B-X03ML9%)Z>5%L64IV46M.2U-C43E0;T]+<U!V+TU&
M<'!U<'EA9&5A:3%U='-0,W0R,6MN,6%->7AT3GAA46)+6%)'4'8P-C153&8X
M52M7)B-X03LR:F54+T9&:W=O5VLO8WA&<4MQ>4YY6#=7=UI39'9X>%-R=C5Q
M,&5+4S!I8GI68DDY*VE45VE'3TU&,6UK36%.,3(U3T-.*S109V-6)B-X03M1
M53-N<GEZ.5A,1'I28GIG;%4Y0T\S4C-B,6E12THQ24IR53E02$96,'9N4'ES
M8F-E=#5P=%!18W@P5U,S44$X-'I):#1S3G@V86-Q)B-X03LY;#,V67%M3VHV
M=EEA=F544396-6ET-W$X:&EJ:VU32T=)>4Q&24%Y8W4Y2T5B9'$W-'%Y1W=T
M2G)E37).34IM0E!":$=S9D5(8VEI)B-X03LK2C-W2VE306%61F%B:D9633(Q
M=6$Q:5$Q<%@T4BMY2T0W<U958GI3=$]V8E=E,75R84]7,W56-%1X;%)2,7!3
M:E4V-T=M2V]O04M!)B-X03M!2T%B041P5$9867$W1EA9<3=&6%EQ<VY35C17
M5T=4,'!#4&AK-&AQ9E%C5EEJ-6<Q;4Q13&DS:'8W.7@V,%9X971,1EI)-E%W
M5S5J)B-X03M7-75*;4(K0D4K<W)Y8G=*=W%H+SA8*U9I.'EN>EI98S!8:DM$
M2$15;WE024)U9FE6:VAD:%199U8V67%I13@Q-DXY471R-5!.3G8Y)B-X03M5
M=EIV<3ET27-+9DA+441X04<O,E-$,#9%94EX5E1L.#-A07)S:VYM<3$U8T)+
M45E9>GE$35EH5"M9<U9+9T1C,$]+;U=W.#EE5F(O)B-X03M!13)'-&DX>C)W
M=')I1EI&:&MT:U5I4# K659O>C!O=&1V.$%*86XR5%)61V%:-6TP1%5,,C)T
M3D\X,%=C,3=+1VIT;UDT;W95;W$X)B-X03LK2VI9:C10:4$W:F-B67%Y:7AS
M-VE!3THU,75+='E3:U-X.%=.95(K2'%7<F=61D9686Q11%1P6#55>%9:.5AT
M+W=$9E-D95@R4CEQ)B-X03ML2R]/9WA64G4Y3# V-VA-1GIB4GEW;#!L84UQ
M2T8T,D1Q4T(Q;WEG-S1Q:7-69&ER<U9D:7)S5EEL-70X=2M663%U.64Q84\V
M:U9X)B-X03M(1DY$0DY-1EHS+S!A2FQH4C%8,4(V,49B<4]V6$-R0TY0=E!Y
M2W4U;TQY,W,U5W5M15%7.&1,;C%3.'--:W-1:VM:<2MP3F(X-60Y)B-X03MY
M=34S>%9$95ET6"]!0U8Q4RMJ,$LT:W5R8E5X0V10=%=#5%-E;D1E;'95:U5%
M<VXK-VE/8D19:TAF:CA+<5HV=$PK5#ER<FHR5C%A)B-X03M88TXO8GI.06IW
M:3554U-&-6)J-G-J>'-/4WEY234T9EI9<4LY0FEQ5V%J<78U2E=E;U=55C=A
M6&E24U)(-G!--75U0TXY5T5%:7AX)B-X03LX<3$Y0S10<D5$-U$S<3%-5F5G
M*U)F3"]!2E=J:%AZ3G!&:SER8V%X0D=:9E5K95%H04)284UZ2U!S:7101$%R
M3$U69&ER<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I<G-64U!Z3#57,$Q71VEV
M3E975FA:47IX37-C<W-A=F)Z;4XU-%I6:EI22D<O,61/4W1S85EQ.#!S8FXX
M:DQI)B-X03LW=$%U;3-*=DDO4VMT9E=J=65C8T-Y4D-*,4I9.%E95$)%9S,K
M1E13;$=B0W$W5E!-,S5*=S(Q='!L,G0P:U9R2F)A;F%28V)G:'!X)B-X03M$
M0VM&2TXX5$)"2'-D9V5T2S=Q<78Q2#AO.4MH,%A3-6\W<5=:;TQ054Q/+W0Q
M;FDT+U=(=5=G=4%94VYP35,P-S=#;T$S.3%51DQQ)B-X03MN-4MA3%I72WA7
M3C=(8E=N<%<X,&1B<%1!<G)C4&%E=4=B-&UF.3A)83$K,F5M2W-Q.&@K5U!Y
M-3%#*U!M:E$Y3F5'-71P231O8G%6)B-X03LU951G5TU+>'-56FI4:D1*>#1N
M;V%N<F=6-DAI<G-69&ER<U9D:7)S5F1I<G-69&EQ1C%0.4<O5D0K:W93*W%C
M-'$K=G@Y4&XV:2ML)B-X03M8;'18,4]02#-X5FE39CA!2VTO.3$O;U-N,5 Y
M;C9V5#9N-DLP<%0Y:C!E3E X;G S>%9B868X04MM4')%4#%8.4-E=C9T<CE8
M-&5H)B-X03M8,65"*W$X2V0K2#)+6592,G)F.'%X.65F.4LO;W(Q*V)F5U!R
M2&\X+U4Y3V9N6&QV>3E0,7$Y-F-S0V]#5"]L4S,Q;5!N*V<O<DA')B-X03LS
M.4]V,69L>#1*.5@K:C K4$@O2CES5EIH<&8V3B]2,78K:E!3+U(O06969E$T
M*VQW-V-/3S%-5E)72W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W):
M9E,Y2B]6-"ML>%!Q8S9C94Y.-C$R<%1&5TEJ+VQ62'%7;% P4C9N<7=F578W
M:79Q+T8Y6#1E+W="<FIH5DQO+SA!)B-X03ML4EA#5# O,$1W.4DX*U Q96YP
M.&@T9C584VTY96U+<#EE+SAQ*RMS42]84#!B.5DY0S,K<C@O4C5F5C949E9U
M2"]&9%!7-%4R*S%4)B-X03M!<51N+VQ3=C%A,'(K9R]Q+T,T*W O-WHX95!&
M+W)(1"]9.#8K,69F0W)*+TQN*T=V<4(O=S<Y5BMO.&QR.5,T96QY.4I/4#DS
M=%@P)B-X03LK2#!5=TMM;4MU>%8R2W5X5C)+=B\Y:ST\+WAM<$=);6<Z:6UA
M9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C%#-CA!1C Y0C4T044U,3%!,$)%1CDP
M.38Y-$,W0C9%/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.C%#-CA!1C Y0C4T044U,3%!,$)%1CDP.38Y
M-$,W0C9%/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z8S8Y-6-B.#(M868Q82TT9# X+6$T.&8M
M-F4Y,C4Q.64X.&(T/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD
M:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A
M;F-E240^=75I9#HQ-S<V,&(R-"TP964Q+30U960M.&)B9"UE-V4X8S8R,V%E
M83<\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z,3DV.$%&,#E"-31!134Q,4$P0D5&.3 Y-CDT0S="
M-D4\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^=75I9#IC-CDU8V(X,BUA9C%A+31D,#@M830X9BTV
M93DR-3$Y93@X8C0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z,3DV.$%&,#E"-31!134Q,4$P0D5&.3 Y-CDT0S="-D4\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,34M,#@M,C14,3<Z,S0Z,#,M,#<Z,# \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C%#
M-CA!1C Y0C4T044U,3%!,$)%1CDP.38Y-$,W0C9%/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$U+3 X+3(T
M5#$W.C,U.C R+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I
M<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @
M(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CY46#$P,3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y*;VYE<RP@4V%M=65L(%,N("A63%)!*3PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@
M4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.G!D9G@](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F>"\Q+C,O(CX*(" @(" @(" @/'!D9G@Z0V]M<&%N>3Y#<F5D:70@
M4W5I<W-E/"]P9&9X.D-O;7!A;GD^"B @(" @(" @(#QP9&9X.E]!9$AO8U)E
M=FEE=T-Y8VQE240^-#4S,C X,#8T/"]P9&9X.E]!9$AO8U)E=FEE=T-Y8VQE
M240^"B @(" @(" @(#QP9&9X.E]%;6%I;%-U8FIE8W0^1W)A<&AI8W,\+W!D
M9G@Z7T5M86EL4W5B:F5C=#X*(" @(" @(" @/'!D9G@Z7T%U=&AO<D5M86EL
M/F-H<FES=&EN82YH=4!C<F5D:70M<W5I<W-E+F-O;3PO<&1F>#I?075T:&]R
M16UA:6P^"B @(" @(" @(#QP9&9X.E]!=71H;W)%;6%I;$1I<W!L87E.86UE
M/DAU+"!#:')I<W1I;F$@*%9,4D$I/"]P9&9X.E]!=71H;W)%;6%I;$1I<W!L
M87E.86UE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @
M(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @
M(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.
M4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E
M4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=$1I;3IW/C<R,"XP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I
M;3IH/C4T,"XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU
M;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X
M4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @
M(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.
M86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T
M1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y
M<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B U+C$P/"]S=$9N=#IV
M97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S
M:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86PN='1F/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \
M>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @
M(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E
M9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T
M<#HO+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(CX*(" @(" @
M(" @/$5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(" @(" @(#QR9&8Z
M0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E
M.D9O;G1+:6YD/D]P96Y4>7!E("T@5%0\+T5X=&5N<VES1F]N=%-E;G-E.D9O
M;G1+:6YD/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z
M1F%M:6QY/D%R:6%L/"]%>'1E;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I
M>F4^,#PO17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @
M(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-;VYO
M='EP92!4>7!O9W)A<&AY/"]%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/@H@
M(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXU
M+C$P/"]%>'1E;G-I<T9O;G1396YS93I697)S:6]N/@H@(" @(" @(" @(" @
M(" @(" \17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/C \+T5X
M=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3X*(" @(" @(" @(" @
M(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS
M=6T^,C4Y,#DT-3@U,#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N
M,E]#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E
M;G-E.D-H96-K<W5M/C(U.3 Y-#4X-3 \+T5X=&5N<VES1F]N=%-E;G-E.D-H
M96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z
M4&]S=%-C<FEP=$YA;64^07)I86Q-5#PO17AT96YS:7-&;VYT4V5N<V4Z4&]S
M=%-C<FEP=$YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO17AT96YS:7-&;VYT4V5N<V4Z
M<VQU9SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_  !$( -\"%0,!$0 "$0$#$0'_Q  ?  $  @(" P$!
M            !P@&"00% PH+ 0+_Q !@$  ! P4   (""@D,#0H%!0 %! 8'
M  $" P@)$1(5$Q06&"$W.7BWN H7,3A9=7>4V"(V05%887F'E;2UMAD:(R0U
M5G1VD9FRL]57<8&6EZ'2U-;7*"E(4IA4DJBQT__$ !@! 0$! 0$
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MW%E/W?%R[D%#/EB7M_!I1=]:.8*&OTUXW_5&RVA@4 H!0"@% * 4 H!0"@%
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MW<O3$4&M1DJ'J]6H5J*$K=INS3R6IO4;IJ',4 H!0"@% * 4 H!0"@% * 4
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M='4G*TJH>"BRO.&E"C*#?\ 4FE@$(K<@I$"<2H0-4G@@TMF?'AS6]'IVE!2
M[L&!=AI$/79;TB4ML#B<R.C3@LR&(,MUTNH<SMZ 4 H".9A^*24OR<O?^K).
MA5BMZZE7O# ^37\/OYE'+?T(LBA:^W5XJNK.*VX.B28IVZQ*RDP6^_"#>E1@
M-T"J<B;,CL#@O>YPL<N)&VW;;X(T&1DR6*9)M&.&K)>26JLL;[E.W/():2AO
M#U9*GO+^5/\ D&CK^0]?_CH27K?-CWE_*G_(-'7\AZ__ !T$O6^;.O$\,<?
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MD>"U:WHT;SI>PUGLK6/0C!S<'9NQQ%U.A!N+.,Z;<1$J77"/'=:SGS+D4(*
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M10<38&?7)@/O<(5NJ?ANC0N@XWDV\^#:ZU4G<)D'KN7&#%8Z]E-Q8<3%OO\
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M,GVX:K9;<L+4)33I5*E9^TGKI_VX'R?^Y-Z'_E^-O^-4.OR'WER8_MP/D_\
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MX??S*.6_H19%"U]NKQ5=629"/QR]D_EM8'U7X$H1X+=ZLLW0@H!0"@*Q=?\
MQ)_QP\S?66B.A5CP?1EG:$% 4*[ _7"S?Q,1_GVJNM&''T1RKQX>K*>5LP*
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M$1JH.E&.V)&BIV*.L/5KD!MIIN6T8L3)F1<#3 7^[B<X.MI.;>3?HET35O\
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MKWA@?)K^'W\RCEOZ$610M?;J\575DF0C\<O9/Y;6!]5^!*$>"W>K+-T(* 4
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M;-!+[P,_ ^&[%[D"B'(W.W/$<<C=<(L>< 'PWB&3P5"FPI9)J7BRX<H-=NU
M3%DT*C0M0$$>_>E6)-VE0FW;-.S#/(33?=H_@O8[:_AA,?*WE?L'Q+O^CO\
MZ(QO_IQ==K_]]!IONT?Q1%VWPH>6E3L4--5U+W$L?F\1F\%3<4=\37M=VX I
M)[!V;HWA?=A8MF'W&+;1^1O-+=%L)6V);J<E5LL*LO6^9)6.A1OT5B> !X37
M)[P2KEK5Z>[<<R(4><#6)JVYWS-Q=*.<[4+JV^Z6X04"GGOU)#S:/#UX0^'4
MYZR 8NB6#2"=,M3;]."7K?-B4OR4<:%ZG?6\'#G.UK6^WOWU?]^_<W0WG?\
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M#M* 4 H!0"@% * 4 H"KO3'+B+IL>W11*<^D(;' TCI0+T?/\H_:WT/-$Z]
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M>&65K6H6E2TM;2YL@;1U#.,)RW'$>=C-."VLRIC%29FQYBB207:J;[<=42,
MS++H;,E@)%:3<VA!BZ+FH^'>'>8EPE4.BS),C#H@7[9&$5(L)RZ9M%GM<9;8
M,Y:OB"<LNQ4,0Z'D\6VN/$HO1-I#(<+S5&2YU()I>2*/(M=C71R#'S:4GV(\
M'R4$-1&^1FI0U1YTV '&RHM0>#8+A-%_;6_7CLQ.02\0'D44UG:]%$O)=S<8
MC_GR,':N&M-]F-H1Z<P,-WR;.0Y4/%-A82R1,=E,<\7S/Z$FUO']F0(6V"AH
MPZVL@,"Z+PC%)Y8.(YRMIG\)]4POT$<=;9C<N[,G"S@C2=90(^(OD^*RBUDO
MW:X$[)?S90R<T&BH=S#=2EJ.5($=[8UE0*M4$7I[+L=NO#'8(TUCU3Z&$+.[
M^:T!Y]@5#D?5[1WKES$ZY$T)S6N8A$I J$P0F)KLQ_H8_4LU_O1@:6\X-!EF
MLDV><VXFWW"&%"R)=OG$(\(?35-\+8WE'/D?N+F&*=HK0[I'49J#K:BQVA$S
M28LB2&K,A9P<1II0]F)1L!IN942)28XVX>$LD$BT[SKB5B5N(T<HQTY94"I;
MRYM+#''5*DZ+#O[F;<V0#C2'I')+W&]7K':*.@\"SL9FE([XU2IB$B"S<("H
MY62R U,@8N&%'$5,L]$'2#SC:4ZB"C!U-GUL&B_7%1?;@0]!7B?P)(<>Q&:D
M(LN9[YDN(5L\%!#>84INME,2']+GDAO:)-?<B"V8M:$?,7'.,S6LHXWZ<;J
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M39NI2^8.1[2_/ ]".6NAPK\MTA6L$=23 XV]C792C%01="1R#52M0VKHG)H
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M5M_.0G:,3,UO-L0_9JO)SO$MI*02CRR<HZ'F8<@NE>82O/'BWY0N2C8]0R*
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$!0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g16439g15e00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g15e00.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1@&4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&K2
M5@         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -)    !@             "0@  !4D    * $< <@!A '  :  @
M #@ 7P!V #(    !                          $             !4D
M  )"                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  )"     %)G:'1L;VYG   %20    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M,M.;4P#^<=D4.;(!]A;75ZGNVU_I-N_WV?F?SF]&J4:I*< XW67M@MRF!M)
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M))*?JCW>2?W>2^5DDE/U3[O))?*R22G_V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      $N
M34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4    !
M:@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0    !
M    I    -  (+W"   G$  @O<(  "<0061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q-3HP.#HR-2 Q.3HS.3HT-@   Z !  ,    !__\  * "
M  0    !   %2: #  0    !   "0@         & 0,  P    $ !@   1H
M!0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !     $   $N
M @( !     $              $@    !    2     $X0DE- _T       @
M         /_A 3!-30 J    "  ' 1(  P    $      1H !0    $   !B
M 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0
M  "0AVD !     $   "D    T    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C X.C(U(#$Y.C,Y.C0V   #H $
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M>9(\/2:I9;A+IM57JD55H*4L$B1FB9,BSL[&):NW16R)U4B*+BD"29E4RG,
MG* A*D(J5='?)MHU^X4BV[AW)IH,W*IXYHT,!'3I\5-(QFC=L<Q2.%G )IHF
M,!5#E$0Y" T#0-!\_G_X?^O_ #QH/O\ S_S_ .N@:!H&@C(^.D)9ZVC8IB\D
MI%ZL5!FPCVJ[UZ[7/Z%1;-6Q%%UUC\<%323.<>/0HZ"#T#03AG7K!(Q,S/Q\
M',/X*NC'A8)IG&/7,3!#+N#M(H)F10149Q@R;I-1M'@]60\ZX3.BV[BA3% )
M/H&@:"9PT),V.48P=>B).>FY-<K:-AX9@ZE)20<F 3%;L8]BDN[=KB!1$J2"
M*B@@41 O #P$ L@LV65;N$E4'#=4Z*Z"Z9DED5DC"FJDLD<I3IJIG*8JB9RE
M,0Y1*8 $!#0=>@]0G@>?]6S*/_;A)_\ D*B:#=)H&@\2^_[_ *YVXS_M*E_Z
M)KH,5W-=L#.&C+$[@IAK7YMR]:0TZYC'J,-+.XTR19%K&2:J)63]PP,LB5Z@
MT754:&53!<A!4* A-Y7'M^@TIM>;H]PAT*TK$(6-:4K4S'I0"U@;E=P",VH[
M9(DBE9MH<KJ(3?&;GDFYBK,@62$#"%,-&CM^[:L6+9P]>O7"+1FS:(J.73MT
MY4*BW;-FZ)3K+N%UCD2111(=554Y2$*8Q@ 0[Y6(E8&3?0TY&R$-,Q;I9C)Q
M4JS<QTE'O6YQ3<-'[!VFBZ:.D% ,19NX2352. E.0I@$-! :"+CHY_+OV,3$
ML7DG*2;IM'QL;'MEGC^0?/%B-VC)DS;$4<NGCI=1-!LV;I'666.1)(ACF*40
M^R,=(1#][%2K%Y&2D8\<Q\E&R#99D_CW[-8[=VQ?,W)$W#1VU<)J(.6RZ::R
M"R9TE2%.4Q0"#T$W"O3XP VH(.8&KDEB5\UD]F/1@2SQV9Y D*:8!#V<66.P
M34?%C1< \,T(=R"/9*)]!*- T#01@1T@,>:6!B\&**\+'&DP:K^SRR!T#N2,
M3/.CRP/#MDU'!6HJ=\R!#J@04RF, 1D#7I^U2S2!K$',6.<?BJ5C"P,:]F)9
MZ9!!5TN#2.CT7#QR*+9%9PJ"*)Q30255/PFF8P!)_P#T_P#IH&@:!H&@:!H&
M@:"<+5Z?;0C*S.(.80KDD^=1D=8%HQZE"/Y)B1-5['LI4Z)6#IZS2624=-$'
M"B[=-5,ZJ9"G*(A!JQT@BR:2:S%XE&OUG;=C(*M5DV3QPP!N+Y!H[.0$'"S(
M';47:2*ASMP<M^\4G>3Z@@] T#0- _Y_Y_Y#0-!&-HV0>H/G+-@\=MHQN1W)
M.&S5=="/:G72:D<OE4B'3:-SN5T&Y%ES)IF7622 PJ*$*(3B3IMOA'4@QF:K
M9(A[$Q[*6E6DG!R;!U&1<D#48Z2D&[IJDJRCWY7S$63QR5-NZ!XU%!0X.$>L
M*;T#09J;/_\ WA__ "E_^3:#"O0;EMA$OD1EMTL\3&8VRY=J!*9HC7[ZR;5L
M@.:YGRE61K7D6Y/=#66H-R6*B/8WZNR1F'R<&,F14KT@G,W79!?L^W;%[&];
MG+A?!=;D,DQF=\?5B<.OAQ;*=ECZ;9Z)'V9X$GCS%EGH<?"6V0F%EZC,WUF#
MMM&S$"L=.*1>RT@*02''V(L(WN!POBE]%V*+PR[WY;@4(NJ71N^@K(*$-A]"
M8K='L#5=TUE6[UU/1\?67+0[UM*/04\J1TB^=%6*%-?H%8!L>2(!9OA*=1R5
M"8/SS=(S&5@PY=<(8_S3>Z.O'&QW$0-)FK=9924<L6KJ=+8HV"GP3GC0#%TN
MV*F[=). EVWE2Z14[N,0D]HE,Q?;+3LAL]EBJ 2G6I8;ZXBWZ4<59E3)"8<2
MD;%V]PL9I-5*/2;JNUHB/.3MN176>!!GQ!C'(\]B' 3VHU^/O6</#SQO8,86
M60%RD[@,W0$E>+&U0;NWCHPQ<?;&$8]A9=L0.ST(-4DFP*"8#A4U;POMK<7_
M ')0M<H4%99';!2L+XSB&D?C2<RZ>WV91_+,<OY-?XWKULJLM;9(D\@C  [+
M,"V@&:R4@=FH<J72&!]NHF(R[[(JD5?&%^-BQ[DJEMGF(I]DXI%V.@_2AW%E
MI[1E:IMB\C_,R"L@VKS:3L3=TZCUH]L27*LND\T&TB,Q32\;;H-H&0J9C[&U
M?A;+F&ZXZ<L7N)\@8@O,>]]E^TV";JE6V<D(>8<U%(#,&N1ZRLI&R$D^% @/
MFZC(R04[MNVR0V1["M)9IP!BZ,A\K9=R]#O&33'F4WEUCF-<AE&B#91Z@]:5
M+!K-I)>7F8J1EY%><N3F4YCXTY/++E"U.)<4XH?T?;-(73'T1<6:&TO=_>9>
M%G%9(S:4G:)=I T&NKV'S==@X:HM_+$7C5&*Z8'.J4Y7 %5 .FFX]Q;<(7#&
M66.,ZI1Y3*.S?>#,VJOTLDM%5<]BQ>K,05?G6$>M*O%VKH[=,BKQ,7BJ#E5-
M,5R*B4PG".:8SP5(*8\Q I@S'Q#W'PWVF<9J_)-I=&[I9)9T.2FF$]&/TI<D
M>R$'T2HYDTR18GF%GABR"R[1!-KH*IHNWC''?JU49[:*M;<1'V72.6R[@'L=
M/O7\ME)]1Y*1=KN+.$G[FUS,9HZD8RI/DA?1"K-&90(DBT-H,#-H>.Z]/XQW
M%Y#8XPB\XY=QQ%47]#_%DPQE9YBI%62=<QMMNBE.@GC*4MAJVU39()LDCJMF
M)Y('[A$PIHG3#8/#$K6WQINK>4+'=/I]KDMEN+\K7RA.49AV?&F2++86+2R8
M\2.::2F8F \NXC;(-9<O0?1CUXS1%R1LU(UT&'&P.9DRXTWLP\-0:_?YUQ@4
MLNPBY*N2%EEIA1O;(5FM"@QCW23Q_$JE>C)NV+=/O'?L6+H7!2(&34#(N_;7
M:=6MGF4)*W8LQW#7>@8EPC=*]9*)5<C NE(V><BR3#^7RW97;>OY!?SL++>8
MFZ]5X^1@:DN<6Q)+ZA'"4(//.U>I5&4\0RW,L/,X/&]7QWB.4P?/EA'+6MM'
MTZO3AEGU%DE2E9OCK)JR9)-6/7=$;&=@FY%,[E(I@I'PZ]O=<R%4(FQWS&&-
M[G4+?FM"@.Y26J&1+]> 8,ZVB[F(IO[G'4=4,6PK<LLSEB7ZQ2B#PZJ3U!%E
M(G:Q;1R%U,0[;\=,)#;S7*YMP@LTUK(NX#,E7S;<YYC8YI_C6,Q_D=S 5> -
M*1LFUCZF@UK+9"Q/4YMNH%M*HHP5*NDX!( YXMV]8Z&1P&QK.VNL9A@,J;F<
MU5G-UE?L+!)#BR"HN3UX:IU]H\BI-M&TR.9U1)&R+MY=!1.UMP-%* Y;O44
M"WECQO@J IV%*O(8UQ]$I9GWAYHQ5<,AOX]4)ZI8UKF7F<.@C6WPOD6,0Y8Q
M3LK%M*NVKP\;'H'(W!(55%@"\MHVW;7IG-N)\>6+$EDI'.X6P4YL];XCNN(\
M?W"E151GY*'H,G<)R[6=G>+%(66+KR#*X0SB$?6*+G'I4FY#>7,@%#,]O*>1
M:#@N3GMIN,L0Y3MV\>:I[RISC*ZT:O6?'E:QY)V &<HCYR2LK")45BG[ $8)
M+IL$E"$D&K1968<'<!D'1,9T3%VXC9/:ZSC"F0EIRO6]T5=M?D<9W/',:NXI
M<*V>U>4KU!N<HK8*]*KLW;J)+(23=L_L$!(K+JQ3,7C4K0+%4'!>!C8,HENR
M%@Z=D)/)A,VO\NL<=X(O=MLF.K' 3<FQ85ROS$9=(Y+"Z6/VR#*2) SU;FU9
MQJ+@KY55 HE(%.2NW?&=@V=N)>JXHK].MD#MRC,ERLQD.@71&0F9",58/)V^
M4W<!6+/+8_E#V JKAA7\83C-C(@=VB1Y'L4H\X"&)>UNHURP[:MU\G-1:,@\
MB+AM.9QZJRCD"H-;#EI_'3*!D$UDV[A-\R#RZA722O07D413.(F$,F=S6/,)
MNZIO_A*KA2A4%SMCO6'0Q]8ZJA,-9]RG=;BA6K0RGUW4N]:/HUP1PX7C6*#-
MFUC !L1!'K1[@A3^R;#.%Y[;V\R5:\?.\IVMYG9M0K-!1F*K5F*9BJ$6L,I-
M!G$0=2N-2>4M]9GKJ13;Y!=$ER,G,<W9-VA3"KUAD+MFVEXJL\<W;3.):M+8
MNR/;-PB%5FIRD9,F,QH5RH+S4+74[C:D'<?2<)RM;EHHC1M'.7$A/69TNV2+
M$ NLZ?-0H+"+6BT3)'AEU^L8OHL;9,F0,3>+OD(T4Z/=7\@RL]LC&:#1^9\#
M./341CU22JB<>=W(I';MU%TTFB93!3,!B_"=EQ?.;JYBG5%2.P) 9_H.3JJZ
M23*UNV8QGTD<(RTI&F4*:2/,H7ILM*.0#H%>KD*8JAB&*(:9Q]>>>/7_ &
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M&BRM5D9HUARY>UI)K.2;=.O/7JA57KN#(BZ(6)<NU2D4<KL ;JKJ%*=4YS
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MCBFDF4H0I;/9"0B=:)89PE<2D2S"4 66?EA$Y8I!3+*)Q0. 8DD2IB)"O2H
MY @B4%>GTT'*PVFSVUZ22M=CGK-(IH$:IO[#+R$T]3;)F,9-N1U).'*Y$"&.
M<Q$2J F4QS"4H"8>0[&-NMD9"2%:C;/8H^N2Q^Y*P#&:DFD))J "8 I(12#E
M-B]/PDD'4Y04-PDF'/P"\!P+;+2G7U*F2RV E55= ]5K))F1+7U'O)!\XI#
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M##_0- T#0- _Y_Y_W_\ T_\ N#0- T#0- T#_G_G_P!= T#0- T#0- T#0-
MT#0- T#0- T#0- _Y_Y]/]W_ #\8- T#09J;/_\ WA__ "E_^3:"\?O0^]W[
MAJE^<2J?3] ]Z'WN_<-4OSAU3Z?H'O0^]W[AJE^<2J?3] ]Z'WN_<-4OSB53
MZ?H'O0^]W[AJE^<2J?3] ]Z'WN_<-4OSB53Z?H'O0^][[AJE^<.J?3] ]Z'W
MN_<-4OSB53Z?H'O0V]W[AJE^<.J?S>?T#WH?>[]PU2_.)5/I^@>]#[W?N&J7
MYQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@
M>]#[W?N&J7YQ*I]/T#WH?>]]PU2_.'5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]P
MU2_.'5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]
M/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YPZI]/T#WH?>[]PU2_.)5/I^@>]#[W
M?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PM2_.)
M5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH
M?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH?>]]PU2_.'5/I^@>]#[W?N&J7
MYQ*I]/T#WH?>[]PU2_.)5/I^@WD>&!MKROM?PO>J7EZ(C8>>G<GO;1'-XR;C
MIU%2(7JE5BDUCN8U99%)47L4\(*!S J!"$4$O2H41#93H&@\RV[3PR]VN6MR
M68\DTJH5I]5+E=)":@G;N[UR/<N&#A- J2BS)T\3<-CB)#<I+$*<./4/708[
M^]#[W?N&J7YQ*I]/T#WH?>]]PU2_.'5/I^@>]#[WON&J7YQ*I]/T#WH?>[]P
MU2_.)5/I^@>]#;W?N&J7YQ*I]/T#WH?>]]PU2_.)5/I^@>]#[W?N&J7YQ*I]
M/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YPZI]/T#WH;>[]PU2_.)5/I^@>]#[W
M?N&J7YPZI]/T#WH?>[]PU2_.'5/I^@>]#[W?N&J7YQ*I]/T#WH?>]]PU2_.'
M5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH
M?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7
MYQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@
M>]#[W?N&J7YQ*I]/T#WH?>[]PU2_.)5/I^@>]#[W?N&J7YPZI]/T#WH?>]]P
MU2_.)5/I^@>]#[W?N&J7YPZI]/T#WH?>]]PU2_.)5/I^@>]#[WON&J7YPZI]
M/T#WH?>[]PU2_.'5/I^@>]#[W?N&J7YQ*I]/T#WH;>[]PU2_.)5/I^@>]#[W
M?N&J7YQ*I]/T&2VW?PTMV.._=A[J*C6VOMCW/^1\O=JZ\[GL_P!M^9Z_+O#]
MOI\\WZ>OCKZC=//2;@/2WH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H.M4>$E!#T$$SB A]KX(Z#ZG]C)]X7^8-!
MST%..;?5F=GC:4ZL$2A;IB)D9Z,KBCU LR]A(A9JVDI9%AU^8&/9N'K5!5V)
M 1!94$RG,<IP*%+FS'BTL! VD+U7E*Y9W;QE S2+XJ\=)JQSU6.D54'*(*)@
MQCGB"B$A)J"G',3 0SITD11,QPN7H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&
M@:!H&@:!H&@Z%Q$ 2X$0Y72 >!XY 3>H?[A^V&@[] T#0- T'SD.>.0Y_8Y]
M?_IH/N@:!H&@<Z!H'.@:!H&@:!H&@<_:^WH/G(#\0AH/N@:!H&@:!H&@:!H&
M@:!H&@:!H&@:!H&@:!H&@:#K6^Q*_@S_ #1T'U/[&G]X7YH:#GH+.Y"Q*3(5
MDA9=Y8WD3%QU3O%0?QL4V.UE7[&^,6C"2<-+(@_0=Q#QDDQ;'C5FS54[94SI
M0#"=9,R 6A2VHD]DA55[[)#46+.^UZ,9>R(H\FK4,JSBEDR!$/7B2+-DW7=/
M2Q<;77,=&I! QL0=4Q)!Q+JDCPREL!SIQH=M11(3R4&@8Z*ATE.TXFX]NL0%
M$S%4*"B*BB9A*8!$IS!SZZ")]DM/VS[\JRGTS0/9+3]L^_*LI],T#V2T_;/O
MRK*?3-!"OXUNDQ>*IJ/R*)M7"A#A*2?)3D1.8I@_38^I3  AZ#ZA\6@[TXMJ
M9-,1.^$1(41'VI*>HB4!'_\ S-!S]DM/VS[\JRGTS0/9+3]L^_*LI],T#V2T
M_;/ORK*?3-! QD<W6C8]951^=15BT44.,K*<G.=!,QS#^FP]3&$1'T#X_BT$
M=[):?MGWY5E/IF@>R6G[9]^593Z9H'LEI^V??E64^F:""CXYNLW$ZBC\Y@=/
MT^1E)/GH2?.4DR^CP/0B9"E#[?!0YY'UT$;[):?MGWY5E/IF@>R6G[9]^593
MZ9H'LEI^V??E64^F:""9QJ!S/>XH_$"/5")\RDH'2F"2(@4/TV'IU&,(#Z_'
M\>@C?9+3]L^_*LI],T#V2T_;/ORK*?3- ]DM/VS[\JRGTS003>-0,ZD"'4?B
M1-5 $@&4E."E,U1.8"_IOU 3B81^/U$=!&^R6G[9]^593Z9H'LII^V??E24^
MF:![):?MGWY5E/IF@ZF:16\D\03.X%+R,>J!%G3ER!5%'$D0YB"Y55$@G*DF
M!@*( /07D.0T$>X^)'\81^?H(C0- T#0-!Y;LM7RM8Y\5;=0@>P%;6"<'&5A
M)'L)$63DZ;7&M3B"I2'0<ICH)]:;HR <]TG2!P$!] V#8ZRSDM&;7J]XO+!Y
M#SC@KBM/I)W[G14CS-BJI-$EU#I&DE^]PD1%(QS"@!0$.GUT&1TUDD(I2$*W
M>V,).Z,W#((!%D[?+J/HH#<K@[2 [-JAV2 JVZ# HJ4Q0-Z\AH)%6&5D?Y"<
M.9*8<K,6C9JLU;N"JE<L5!*"B2+]YR""R)EA-]2 XKIJ<E5*!  =!;_)93I.
M9YHLO.RT=,*AV$#OEUXUFX<*=ML^8&.<2MT1=E424;EZ2]).2AP.@Y62NV!Z
MRADY$7B36.90DT6:3D7;)K+-$U.RLR71*<JZC6/!/K*CP*0',)^ ZM!<UF]G
M8^Q)10P9#+S;=-"H6PC\QHINR:(E67<^0=G!T26;=?#A4A  4C)] CH-;WBF
M^);A[8-@!ODG.I^_:YR7=5ZC8WK"\<E>LL3<6F115>,!P82,Z_$D60<REF?I
MJ,85)RB0Q'<F^C(Q^&2VS#>GC+>/MPQQG[;]<6EUI$\\+$/FBI3C<:=.L6R2
MJU0N<4V6<*5ZS1!URE?L3**,EFZC>2CW3Z+?,'SD,EYP[J08RC"2+TJVE-!6
M7="\,8S8C-8BC9)BV.?])E,!!,HL($7.8H&)R4!Y"+3DZQ,F0F6#Q\_G&[:0
MCH]P@N+?SYX\A$1*_0(8"/@3]4BNC=11ZN2F$0T""BSOVQ4)B5?QTL@R<$2B
MW[UUVTT)!4!(BP3Z^'"B!N!(54!$GQD^"'H$UE9I\BS5H(H/9,$B-C2<]+I>
MRF[4[8Y!24*[;B55<Z90!,BH")3 /2<WKQH.E"-FAKLJFU*7VJ073=L=^L5Y
M&H Y-Y@)0Z@F-T)HL 54(D;I 3%*!OCT&-B:&28J51N5I<0LC%Q)CM_9[F3$
MDE*195@+&2"AV9Q8MBN41 S1%4Q>ML((F#UXT%S-I\[,V#<%>GP,(9K7#8X5
MX5C"JH",N-KBNEN#8P F4B+0%2KG)Z"N4O3\ 0T&RS0-!2[L !TN(  ")_40
M#X_0/C_9T$(=)-02"HFF<4C]Q,3D*84U  2@HF)@$2' IC%ZB\&X,(<\"("'
M/0- T#0- T#0- T#0-!U H<5S)"D<" F4X+\AVSF$1 R8>O4!B^@CR' @/H/
MIH.W0-!5Q/K"_>E_F#0<M T#0-!UK?8E?P9_FCH/J?V-/[POS0T'/0- T$AL
MA@+&%,80*4LM7C&,80 "@%@C!$1$?0  /41'T -!TPESI]F=/F5<M=;L#V,,
M)9)I"3L7*NH\P*&1$KYNP=+JM# J4R0@N1,04*8@_" 0T%2:!H(*3_6Z0_$G
M?] I^QZZ")1^Q)?@R?-#0=F@:!H)=$?K3%_O<R_JR6@F.@:!H)=%_J0WX[)_
M^)N]!,= T#0- T#0- T#0- T$M3_ %X>_O;&?UJ6T$4X^)'\81^?H(C0- T#
M0-!Y,,T1./I7QE=U*,^*;>>1H=!?-GKIF@*9D$*91O\ -[91P  HLY/VR&63
MY.1,QBE'X(Z#9#D&JLY=GCAB5CTOJP+*9KTX=LUFV99.53(D1D8%NX"$0"1R
MMO,?JE!T @0   $ N?5IW(YT+B,M&Q25JCB,EHQK'O7HI1[ANH"#-1L4.2HH
M.3%*9P5+A0_4)#@)/B#(-LQ<K41B_P#/PC^V-9-C+6@0=N&T442&!9RS1$G
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M&-,EP>"8B1Q+X@^W_:X3<C;L;&R#+.(ZAT''=_F,H7B/=V9]-1T; S3!CD"
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M)F+I. R*Z59'D'*:9ECAL$W?VW-V--R:66Y KJL2$O+^Z:&2CY5PY:*NFR@
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M-F"J-XF<8+." FHI[/>,WBZ29AY 3HIJJ&3*J "4ICE#GUZ?4-!-P]  .>>
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MWL8S:LV%5.95VR;GE)(TR/L^/B%"%[KES)J+])TT&R!55  HE^M#H$ T%P<
M/ZM,RJ"*EA(:-FC ,2\A9#A[+V)\V,DD-473/UN!Z3]XR* B/0 G4 3<CH-G
MNQV%CFF8+V2"7EI&-IU$]QTE*S(];Y6?=V2.EW3=513ZJ)B @H)@ >@1+R(=
M7&@VG:!H*&G9F'APE7\O*QL4RBF+J7E'DD^:L6L;$LDCK/)1^X=*I(LXYJBB
MJLY>N#IMD4DE%%5"E3,(!^7I_E"GC173Q1L]Q6RC9ZXL=AVLTB^LJ]7X^GM7
M[R7W29B+(C#1ED0BF*9I"6J+&27]G8NKH(*'E7*ZEO>-SOG\&S@0],?A%_Y/
MKM6V/[.W%FW]T7&V0=Q.7@IEUR-(7<6#J+P>-5EF-RI>/*!/E617C9RN3C%C
M*W:RP$@C[HY]H$41P_J\.R.^##OQ=BXOO<#'R4;[%I[%Q<+$.-VD3Y5TTLK9
MKV6KM\T<MNM))%PLB9<4Q6 J9U#(E(4>D #47LDW*N=M.8V#NQ+RSBD2G7#6
M*%(Y7*Q[#M0"><6CQZDW':$2J]($ X\!P</CT'HKNLB_;.3W#'BTE6(FP%8O
M*Y.0,@[C'B9GC/S2<@UCB+ *WGDRD2D.^F90J)>V0I1^,+=VFN7V7QL_D,E1
M59N6/YV8:Q\I#S$(F]<><D"]XTF19PU2>Q,C*K"F<%NI+I.L $5-\,-!JCS'
M5,S;9HJ1ON&YB0989M!"Q5QI#!VY/%0SMZ;NN(R0*BJ4ZK5P*11:O>KKZ/J)
MQ*8# (4!A'Q!,Q1MBC(:TVR#9P0.DO)SDG" L[KR '(4PHO6 H2"@),R^50*
MLLJ4 Z?0!$PB&=VY/</$2]5M>7,>V^5AYD[-LQ:SE=<R,+.RC)VF0R3V-DW3
MI1<SA)=/IG08@D0PG*(@8O Z#57AS=[N6K>9*M;HG.V0(Z9=3D4U=2#^U2BK
M-RT!T0B:$HV7<':N&I ,(="Z1B%$>0 OQZ#]!?8]F?(&5Z_:6F19=M+S%<)
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MKR98/V8 W1;NF:J*+-HF0&Z8;PM!!27ZW2'XDZ_H%-!$H_8DOP9/FAH.S0-
MT$NB/UIB_P![F7]62T$QT#0-!+HO]2&_'9/_ ,3=Z"8Z!H&@ES#Z^0_?%7^A
M;Z"8Z!H&@ES3]6ROX=M_4D-!,= T#02U/]=WG[VQG]:EM!%./B1_&$?GZ"(T
M#0- T#0:EK%"NQWHYH?BL9F5>!KJL:Z3!([A19M6X@'+5)%0!,HFLB0Y!%/U
M(<>H!Y+H)1N$++LZL6=N4C76%?6K@'B(MTS2550[2HBR4(Z<D43]JKN."*F]
M#]LPD(;0:Y9?'"LM L"&33=N96'DW#MPU,;SKI!X0YVK=%41\P=-(Y@ 2$.
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M0X#0>@70-!2K@W4Y<< 8.%CE^%]O@?C+_P#"/VM!"I',H!A,F=+@YB@!^.3
M4> .' C\$WQASP/'VM!\772;(JN%U"I(()G664-Z%323*)SG,/[4I0$1_P!@
M:"6DE64C"&EXQ5M)L7#%9TT4!0 :/$@2.8H"J<.DJ*G2)3G,'!2]0B' :#QQ
M;L=Y>W#'&:+K"U6D+364U;0\\W6*HV)*P%>LS=4Z:1X5VH'2H5XJIYAT+1MP
M1WU@GT!R.@QJP3B?(%MMU@W';BV$TPNI_/%P]5Y$HH3+AX_16[$VFF;DZ?LP
MG0=JJ*)DR' !$ #I'0;3<*QJR-5KDY)S[F8;UFPR,N"36!3DW3MV\9 Y9M55
MVS<BS5['+"9H^5$2^9("JJ@$/QH-G6+[R-U@))LFV&/)'2;:=G%DUD4VLPU>
M)+2QV$PV4^KQL<NFGVVZ0&3<- ,D0R8\F'070=5.D7<64O(0JSITBLY.#::D
MSRL2DC,I"X.HFX0430,V39J%049\="9$$@ !Z0$P6!S!BNO25+N#20IT2^K<
MTC&QD#&U^/2<SQ/.O$B++,114<((%3413<M':XE%-$%$BF+R8-!;:J[9*A)O
MZFE8:K*13FCG<L7DH[1;JOI4I!,A$HRCM%N5LF:%^ <H+&474 Q 54$?B#/S
M;K7&M=L]F8Q96;R*BXIC7TIM)L1O(O7D:H91T25(F!2$4Y< +<"\E.F'44P\
MCH,O= T'P>>!X]1X].?V?M:#K1+TD 1232.;X2A4^GCK'X^3% .L?_B'U'05
MF3ZPOWI?Y@T'+0- T#0=:WV)7\&?YHZ#ZG]C3^\+\T-!"EDHXSX\85^R-))I
M@LI'E=("^(D(%,"IV@*=\J8E.0P',F!>#E'G@P<A&Z!H+6YM<>4Q-?7?/'E:
M^[<<_L=DR:G/Q#^U_8'_ '#H-,./<)7UEM0J.5R&4=LU*[6U21\198 [5K6X
M9-E!JL9&.G*1#O@>.Y)H+Q-Q'6=^H5NLHU.*/83<+ACAX8>0:=MNWG;M<5/X
MK+T\QDVDE+J6]RQDIM**C:;+J/G$E9:W#1LE(R'MIS8U A[X#H"R+(6"BD.T
M//JF;!Z=6+LC]FU?)).D$W;=)P1%\T<,'B1%B H5-TR=IHNFC@H& %6[A)-9
M$X"10A3E$ #A)?K=(?B3K^@4T$2C]B2_!D^:&@[- T#02Z(_6F+_ 'N9?U9+
M03'0- T$NB_U(;\=D_\ Q-WH)CH&@:"71_U\C^^*O] WT$QT#0-!+FGZME?P
M[;^I(:"8Z!H&@EJ?Z\/?WMC/ZU+:"*<?$C^,(_/T$1H&@:!H&@U0S,O$1>_'
M(JLD5T]24K4$U41$IS((J#!QBB2+;@P=I8W(+*J@ =PAA1 >H?0+A9485O(.
M-KS$FC'H,6#$YCNNEN ]AN)G)/*'?E430Z'/P3B0"GX 2%$#Z#4-,0J2P,!C
M'#ADBR)YA)P+MTHB^<(@!$FQ4FZI3H-2<<N3D$J8B(\<ASH)$HE,S#PKV28O
MFL&T4>&69("#AT=X@T(8#M ^P.%2*<N"$(7NJMQ*F8PG 1$*C;R!I")<&;,%
MF[A)H8IG"J A$29 *(%0=ID$O9%4IN@4"@!R. 4Y'UT&'.38VR0-ZKUPK,,2
M54@7T>WE(R),8(L8YXH(S$.<#=0GY;B7R[1,>L!,<5>0XT&8,&+)W$1C5%TB
M$D^2=R!4@54-&-P3(54C)L].(^163ZRHK(''K442$">@< $6P=L9UQ&@?V<:
M;9R#3W1R\HW'LOD(T5//D9*B';.=N0S<$E# (*CSU=7 #H)>BA:6"KQ=Z[.M
M[?GCL",&P Z%*+<J<L"H&,!TVQ'12@+HYP%("% >D.-!44@J>,LJ<-UM6J)T
M4BOD6#M!YWQ.0#/$VQT2@'=;]!3-N !(YNL"%#UT$$V=1+60!UV7#!-3S8D?
MJE+[6FV90$IE% 6 YT'+;U%-,IBF,4HB3XN-!%RHQS=5>=75=N6/L1D6+>QJ
MPJOY%-0P(JA)@83(@<BA@(<"E*N4 Y.81#02#S+MND\033%%K&F(NY>)'56<
MM3D$%TD&[9,X'< +<IC* CP45.!,(F#G09#;6V%@C7]CRM&/F#&AN07"3;O(
METO-33YPIY5)LM")G,^6;J]?49TF8I4 Y.;T+H,QD6L>SEFCEPBUC47*9G[P
M(E1=1H@"B!DP$\<_.LD*B"!A5,FB0JG<#J,8>.=*NA4FSYVS:9ORO Q[KSC)
M6LM)EF^6;'3D9-O[59-@>22Q.EL<Y!5!)HF!.XFW'CGCJ#0;*- T%OG[I\VF
M4VA&YY!!VZ=*.70&31"+0$I1:D%,"AY@AC@=,Q@'NE^"8P& WH$QT'$Q2G*8
MARE.0Y1*8A@ Q3%,' E,4>0$HAZ" @("'H.@@U8]H>/6C$TDVS-9JLT!)NDF
M1-%%9,Z9@22Z>T % XB4HEZ.?C 0YT'DKW-;187;!GJW6>-955>4N2DE/5Z\
M$;LY&R(Q[N3$R[D63@H,&4NS<+&:%%HQ4 Z2G>*4QR#R%OZM(3$HLI-#((6J
M<2DXPL=<WTBZ:*QZ(<M31;1L*9V[9^5)547!SH-T3&33350X$#:"^&#LY6#%
MU8LE70IR;ANO#SCI)9@==9!N=RD\11>F=HIMSMQ6<B#B46<H.T7:154A%,O5
MU!E=A>Y5F9J:=LN;&JUBW3#YG"2IXN4F%$;/&QA :@NE#D(VAAE$D  IE735
MPV*JD3K.)2ET&8<>:?J#F#IU(J;:5@4RLS4N2-(R[MA!E620ZW5G,"B2ZQU2
MJ.BJ-$7/9/\ 45E3%((I$"MFRSE6]-:L\>1]=1ET5CE3@BNH\I7,4JH\3CFY
M&I_,$3%;AR^D!62*L"X-6PE*0QM!4V29R7@H=LT,N66>.@:N%T4EUH>&70(J
MJG(NUGPMU'J3HK,1679JKN 4-VS$.'(F*%:;?EU'+Y28CH ]>C+-'C)/6+YN
M]4=@YX3%)9J\7<&,FB<PJ&<$=)G\R<Y%6ADB =/098Z!H&@M_9X_([FVT-[4
M[#7HRG1[V3'(<+*Q"[Z5L$>NS D82!DDG"18ETQ>E[RIU4ETW"1S)F+Z%X"]
MQ/K2_>A_,&@Y:!H&@:#K6^Q*_@S_ #1T'U/[&3CX^@O'/WH:#6MB S1GOBR6
MW=(L$9J8A925?+H1$&H@YDQ8UR/E&T+:'N)8.Z/F#%["OF@LE,B2<<@9DK_F
M_H!NDT#.?+LS9J_C"^35+;N75MCJO+N:VBTC!F5AF2M% CSA&E QG2:+DR:R
MY2HNS)H)J*E82 I@Q<!B ;-.:WM'J;-@69)D=E&7=S96S*EJRI'EO0G3H8EJ
M,LX-66C9"LWR%;R4BK:2P='DW\,TBK$ZC,>^WF\,F&2^Y)<6N LNN0 !,VH-
MB<<"(E#E%@JIZF IQ /@_'TFX_8T%D,"XI3E=G>-:;83M+5"V'%-4GVP343
M2[B%7LE:;SKL(R*6J3I@[<M7<L\"*.]:/GB(&2("RRA>LX:\H>-D\29'EK2>
M*D(R/L*%HVS6DDS'#6UNU9*M(9+Q,]<Q:,2P:(HQ\A19"L1AFS5,B:]W39)I
MIG6.0 WL]R5^1Q_Y3<_X3H(.14E/9[_EFP /)NN1"2<"(!V#\B #%  B'V@$
M0 ?V0T$0DI*=I+])Q_';)_\ R3C]J'VO9/\ ]_\ OT'9W)7Y''_E-S_A.@=R
M5^1Q_P"4W/\ A.@=R5^1Q_Y3<_X3H)?$J2?LJ,Z6; 2^SV72(R3@!$OED^!$
M/90\#QQZ<B'^W03#N2OR*/\ RFY_PG0.Y*?(X_\ *3C_  G0.Y*_(H_\IN?\
M)T$OC%)/RINEFP$/.27J:2< //M%WU>@11O0#<@ \^H<"( (\ $P[DK\BC_R
MFY_PG0.Y*_(H_P#*;G_"= [DK\BC_P IN?\ "=!+V"DGU2'#-@/^<%>KF2<!
MP;LH>@?YJ'D../7T_P!P:"8=R5^1Q_Y3<_X3H'<E?D<?^4W/^$Z!W)7Y%'_E
M-S_A.@E[524\Y)\,V CWFW4 R3@  ?)H<<#[*'GTX$1$"\#R' \<B$P[DK\C
MC_RFY_PG0.Y*?(X_\I./\)_Y_8T#N2OR./\ RFY_PG00[0S@TJ^%RDBD?V?&
M=)4'"C@HE\S+>HF4;-A*///H!3!QZ\_:T$P<?$C^,(_/T$1H&@:!H&@T9SXO
MWGB29G5F9*(3A(5O3?8K21;O"I^94I-?6-U'043*Z7!P=10$_B(EP(\B \AE
ME-.B2>.KTSE(UHLL8C]2*A((K@/, J"A'($6$_U9(Y.IZ=$3"* F$>?30:FU
MD!.Y\Q&%DG\8X@7#1%B0@(,FSAF[.#D#JG 3)NBE(9$YNKI6('!>3>HA3S1)
MTMTH>=6;I)/"MH9%J90JJRYT@5.DD<PB55-0QC-U%^!. E$@'* :":%DVBS(
M\$CV4DV,B1-=L\:N>\Y=',(NRI*I& B:;83=2"ZP&*9<3>@\<:"DCPC0"SD:
M2):KD,1R1,SMTH5^SGR)]SSBZR1RI+&61,D1OR4/K0#T]=!VXZ;3$M$M0=QK
M:/5@T19LX]=1-N#R01754$[I$1,)772?K;KG$4W'/'!NG0751C644B6,.FX,
M870RP(BLVZ2*'*87<:"YB=*W=/T]2!1$3?!Z?B'D*7,QD(F++8'DE*1;TKQP
MNA")&2<B":PBFW57,!3 DZ:E,84$A "B)@ "C\0AQ*VKGG6DBF$B_4B&*7M,
M[Q4C>1=.3& 1?."=)/*J$,K\$HAT"0!X#UT'?)P3^/[\N1="2BCKJ* 4"^;7
M2,N<AB$0 !$S<#\A]5-P0 *("  .@Z"N8MJO(,#RA4&"[('$@Q5:G[Y%G)B=
M0)* '0"1P,)P*@ "4"\_[=!KGW$;GK1AS<[0L1X[J#BUUNQ'@VKV59JJ.',^
M$F*2+M%HH83E:C&(KJ 7T,H8Z(F4,!>1$-R>':Q9,/-6$Y7(&2LC>^2KXRU=
M0E14?1"++X+=9ZZ=BHU:(R*0F.X2(4@I&'D../0,MT(RQRK E@=LEZ\*K@KE
MPR4:'77*@H7L##-77J@LR6(<4U712@*AC"8A@#@=.:^,"K]G,&F&7\B3ZTUR
M^;U4:^6N&$G4U8FGV3U-R0A2@<J3042L"]PQA'N<\Z#9/H&@I9V4H.W!@ .3
M'^$(?;Z0X]?]WJ&@Z- T#0:=O%+PUC]:ALLDV"V,8&7"R1+6'2GG#:/@VB2;
M=R1V1-P MS<+**I.3@[7.@1=),X$$X\Z#2K'T>ZM6)[6NU(\CBR57>,%X5LQ
M=0DH1I(-E16.BBMVE/.IMC$</ *;N(++&Z>1ZM!=6"M=MC0LL1&&JYD9HKIR
MX;G2*$E'B]<(KH0#Q\1!L+)%$XG51:HH/VZHGZ#G53.)=!D'BZPR[M!C:(HL
M187D=.NX*;[$2M&$CFID"G]I,E%XMRV*Y,ND!$V[]$6JYA4!8A1. :#84QH^
M3%I%!E'O5(^L-*ZYEI>TLUO..W4JX5$[%&)B%% ;@X(W*"Z@F2[20N1*W1*V
M*DF6;Z\?0O)0:_(R 0+M^19238)O?)V%8K?VJN;N*$:'FV9SG13<$/P11FBJ
M5/LE(?@3G$I:+HQ]>\PI)H/1DWCM]T(HOI%BPDV;%H5D5$Z+)B@J19HP,J!G
M &=G4<]:ARJ"<!#0<SV*#Q"\@7=ELYH6MOC&CDC/T>MHJW JHHG<*G77<,2H
MG*0".E%.V<IBI]@ISF. =>.]TM(R;FBU8@K"1WHUV )/-+,@X36C9M%-P@VD
M!8]')10:KND6X*=8G.NDZ*8A2IE,8,G=!Q$!'IX,)># (\<?" .?@CR'Q#]O
MC@?3T'06^K^3JQ9;S=,>1II+W1T).+5GR.8QXV8E3F$A69&8OUDBM7P'(4>O
MRRB@I#\%0"CQR%\2?6%^]+_,&@Y:!H&@:#K6^Q*_@S_-'0"#PD0?7T3*/H B
M/H4/B /41_8 /4?M:# /#+VV3FZ*^63W.Y;BZ-*M[(>*)?*78:[&QZ@HU1-9
MTQ?VK$,$\38S[QDL>/KC'(;L6AV"SYS&.4%6YF@; -!Q*0A1.8I"E,H8#J&*
M4 %0P$*F!CB <F,!"$( FY$"$*7G@H  8O[V_+?]$+<F+L4@1+AJ^F RW3T$
M7+7WAFJ@";T*HFZ!$Z)P^$18J9R"!RE$ J?:PJP/MLP,C'=DJ;#$..8QRW13
M[/DI&/J$.UDF*R E(9NZ:/4UT'2!R%427(H0Y0, AH-;'B)8-SE9<59Q3P4]
MM#:01M&-\NSSVR@W!&PL<:-;)*O8VA316!AC[#'S)Z8^BFW#+VFC".8Y.0 %
M'J3P-FVVN?GK5MYP;9K39VEULMAQ+CZ:G[:Q;@T:V.8DZM%O9&82:@BW['GG
M2RJZB0MFHD5.<IFK4P"W3"[\E^MTA^).OZ!301*/V)+\&3YH:"V&1\Y85PXY
MJS++F7L8XN>7F6) TIKD.^5:EN;=-G402)$5E"QRD:I.21E739,&485RY[CA
M G;ZEDP,%TP$! ! >0'U 0]0$!^(0'0-!+HC]:8O][F7]62T%-6+)6.JBZ.R
MM=]IM9>IK55!1G/V>%B'2:]ZL(5&DI*-Y!ZW6(I;[4/N:K!#$ T]/\Q$6#J0
M 6^@J&&G82QLSR-?F(N=CTW\I%G?0\@TDV9).#DG4--1QG3)5= KZ(EV+V*D
MV@G!=A),W3%TFDY;JI$"9F,4A3'.8I"$*)CG,(%*4I0Y,8QAX I2@ B(B(
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M_M$>.1T$/H&@:" E7";6,D7*O';08NU3]1#*!TD04$0%,@@93GCCH*(&-]:
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M]KU$!YT$Q<?$C^,(_/T$1H&@:!H&@\Q>\:J.+#OMS1Y)XU9+NU:+$N'2ZB3
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M&5W%21+ND6UHO&*J"Z$Z9610.FY77.H$^E=E&T"<@'=5F=L>"I6M/ZQ%TM[
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M9DIN-0AQCDV2$5(,TF_E73-^1T'M']JQWRQ'^$/_  T%B[[$L+=;):'L5/\
M=)CVPXMLE,L#IZXKB\$Y),N$G:\>^BW,RG.+MUFS0[14[>(6 '#IL8A@2*NX
M;AK4V-[D\MP>YG,.US-%3E:W7X!&7KN$<BY""70G[K'X]EGR%-KK^==II1%]
MF7N.'I9U"6AE$)*1A:P\E'A))PJ^D2!MDQY<I"PPCY_9%H%!ZWLUJ@TB0H/B
MMC-JU89&NE<* ^465[SQ:+6>=!3="*3A)ORH=(ZR@5W[5COEB/\ "'_AH'M6
M.^6(_P (?^&@E\3*1Y8J,*+M$!+'LP$!-Z@(-DP$!]/M#H)A[5COEB/\(?\
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M1,Y1$IB'(8#%, B!BB @/ Z")^J^5^H F*WE_J(*B8J0J]OZF"AB%,<J8GX
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MZ#ZG]C3^\+\T-!ST$'(.Q8,7;T&KQ\+5NJN#*/2*N^=BD03@W:(F.D11PL(
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MB54%/KRGY,0W/Q@8@B)1 ?ME$.!^V&@^!&LR@!2I=)0   I3' H 'Q   (
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MA?\ N.\7/M;QK3+#(9&QW%VW*4UN(F:M"Q&'&TL>%HN"[<-,21=R5]SWBRB
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; O/2!C!\(B13!P( /H(?[?305[H&@:!H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g16439g17u43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g17u43.jpg
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M 0$! 0$!_\  $0@ \0'< P$1  (1 0,1 ?_$ !X  0 ! P4!
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MFTDB.\162HTA<BD[J;U)LUCKN<07NUAHT T T T T T T T T T T T T T
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MVOL<HV9^:=_*J8UR?'X.W>59K$?!N]U<MV;P6519'C6.&KK\&Z.9X=.#MF$
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M(<HL8]>A@WD!]$>MLZJHEU4UL[&E%]=Z>?DW9&IN7-V%()<:DH: : : : :
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M0#0#0&-_PP?7]^4W_&'@_P#\$K;5/[;/'N2ONM<.QD@U)0T T T T T T T
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M?J<='OC#KT):F.*YJ^];N)9"@\$6/TMK65LG/LKN]LJI+@L7$7RI6(W?>O\
M#*/![:O?E&V4W!!+CDNJQBE?(HV4@PV,A;8]R6SD6DB1JMO2N?&;G/FXS8UI
M6F]1>CW;SPIT$3&MY#TD9]YEV;P]PH.!PIES?PL3P>-GV$0<![$3%9.0R,2
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M0><D?X5/M_SWCZ/8%;^T7ZBW=Q]&78OX>J)WZY'4: : : : : : : : : :
M: : : : : : : : : QC;!Q;>=XW/E586/V(Z>_F1O"G%H[8P&R0U=O(V$O0
MUMB6,YKFR!PIKPR2 <US2M$HU:J.XU3^VSQ[DXV^'8JLGAZW_MTK)EOD=<IJ
MN+=0ZV#=[@Y)G5A5+:EV2/;'9EE[0ALYD7(+? \SN@U10I%H16E;!@=F/))
MI]VE@NB_[>Z,V7CW;_;/9\RG\/Q/Q,Y+:99#DSL\974\W$DOP7NXFYV##W"E
MQLCWA3)/F?D,W'HTS 5DQ)^VEN:)MV.RPQ:JCBX_ R(WM*T''.*7<$G%U]:X
MWXX&)6M:9MJ=U*>5*M-L-XH#U\R1.WBM9>5-I9,:)/K]Q,RI:,]Q"VIVJJZ&
M:^A@1XU6$/\ TJ4.X-_:(E:GM.MNPMLX\N)8S*2,FSET6;GI0V+4W]7?$=ZZ
MUW%1X[LWXBB9"9<RW*L3XZ;=&)D%E[#W%R^!(ML3C1]UB.CP(P8H#XN&26^V
MWAR\9IK2+CY1XY(>*O!*KW6^4Y*P6&*6G/$)6L7CF]?Q='!EU_#OAF[>$T62
M5NZ]^S(I$B\!*H9LC+<BS*Y\G[+B L/:EM=BA0T:6Q"4T$-#1XU6*$CS_-RG
M*9T1AM.[C1)<(-LIJ_W+32_#=G1L[R3)JY-O*%MEF]QDS[Z'+LI>19I46V>X
M'DT2@S*"3#XL2.'%ZW%[1:,JV^4.9;S(?D'4(%FR2;M*,;HW4:SQ,=EZ7N<V
MFYR-D':CQ90XN-@+NCC[UI<IL+:98IE>8V]Y.II"8:U(<T-E1UN-9-*D#@YH
MJ54RLQO'ZV1:5'L5*@;9)8B;-:9=/$(MPJU4\?0M]CE+XMN[A)+&)G(8TC<*
MC2?$EY\&6ZCQZ&;8-N26]U,(K95_!M@4^\PPXS8@C0( [J9,J)4V8W& V.O9
MK==EOIU7+>8MJE]^;TJ^3IKN*VG[4>*+'*9DJ)NA.RHD#;"C@6E?$RJW6[O,
MW"$)<QCUBVE.&%&@7U@LT]-EX)E;E&-0B1X572F%#'73,FSEC?IA=VN>8:M8
M/"[7'WSP1X8]G_%-FV/@6\S -#!G4-@ F.6.XN8QKYQFYL7(Z.%=6%/36,*.
M0-9%KZMV1UB-O?9DF1 M($I@WUZILK"=8TX/AR$6GC&E<Y7+@\"L6;*^(R&6
M5$I]SJ:EJRDR L5:N[N((8<&WGY%-'1AQR/B3:UL_P!IVM;DAL]\\MX,L$^+
M-J9%7*+:$R;-*97WX>E(NQ-BUG@]%7AQF_#4E)M[29%CF+1J;*+E]_:0[7)N
MQ:%F2[&02ADY/<2\4C39\\09LVPK<6/35MA*DH8QYL201\N<KO.'QW^<>I2N
M\X=#!S\IQ]<[8S\CB_WWR37;X-SWKO9.=N_AZLQS>,G_ '_;W\>0?T+M=?T+
M_P!=K1!=O<7ZO4W\0%_5':VS>MWI8!X/A5_DJ+_5'?HM3A8WON"/FQGU@LQ_
M&3/T::/[GN?^(/;\8_V\X%^-P?HBZK![K?<$C<[_ ) R_B?_ -#6*Y_Q?^-@
M'T&>!_ZGOAG_ "*[??W=@Z\CO>]]SNKEN78E-K#1H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H#$#0_QQ?_ (VL_P!:/KT'G)(>%3TS_/4^]0UW[1?J+=W'T9=B
M_AZHG=KD=1H!H!H!H!H!H!H".N9>)S;O",GW!Q6VC9"6=MOA1<UN9<2% 6KF
MAA,HI5QC]1-EV<1LG):*IRO$KRUKY#8@05&354H<LW5)9&V'35QYR)=I*;Z?
MCW14SO$%LXUD9?GU5N-+;:=J&T-@E@(U1*E0)<.? ?#;+J; EC"E5M=7VP8,
MRVL0N@589DK@2[LO+QC:LYG:PG?#;;/UQ6/07KDL\RQB%EM)3V-?/K[ U7-K
M8UMV7N-'\A[4C5\L$R76 G'EBAD9/:,E>04LF--;IB0K2=S+M:PH: : : :
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M%C;S-ZG<KQ!^(?/J*/81:?+MU,UOJV-;"C L@1+&[E2 BG!B2YT4<EC'HTK
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M"CF$"5Y4X9'9(Y']HHW\=+D5>WPFE,M*JO<8V3G;3;HG=[D=,@\,F[&5[_\
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MJYB"5L6+YPTB1.C*A!S7RI/>3I,YJTG]-K3U)M*;2JZSPA8$T=06- - - -
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M*C:]R*UKG(Y45$XT56EF'1-Y'1QK*ZK* &="4T6?#[;;2FGM&&UJRE1_;;*
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MUP[DO[K/'L23U)0T T T T T T T T T T T T T T T T T T T!A1H-P\
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M(]HE[?I\;@KF!^#U_&>P/\(]K5&SY[9\#3VI7_"3S8N3?O4Y5.E>M1HA>4^
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MC,TSKR3A8;KKQKP>&*KCA#ON. <9@P0Z9I7#ATD@=O$DN[?6^6XLHSP&7MM
MX43O]\PV-&YP9T1CNT)O5)V<<;MU(ZKE&JA&$TO7.;]_&MYO609_FY[TZ#Y
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M$7J5.>4YYT$&_M#[G=[;.[T]'<Z&]SHYYZ.OCJZ>?7IYXY]>.= ;$C1T8P:
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MM-GJ5[BK,1J2%(YSU)U*JJGV-CW-2X]0&$0!J.G*$W4I0EK(1!%ZWPB.[@W
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A^?QO>_B\7ZPS7/XF''T+L7\/5$JM<SJ- - - - - ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g16439g21g44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g21g44.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1CR4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&3U
MXV         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -#    !@             !Z@  !"8    ' $< <@!A '  :  @
M #(    !                          $             !"8   'J
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   'J
M %)G:'1L;VYG   $)@    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !Z@    !29VAT;&]N9P  !"8
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!0       0    *.$))300,      ]R
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M^R5?O6_]NV?^E$XQ:AWL_P"W+/\ R:,DDIJTXI-8.07-LUW!EUI;SIRYOYJ
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M2FN_'(>QU4F#[]SW_1/TMFKO<C-8UI)$DG0DDGCXJ222G__9.$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M$P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X
M0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0    $   !B
M 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0
M  "0AVD !     $   "D    T  9EB@  "<0 !F6*   )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C X.C(U(#$V.C$U.C T   #H $
M P    '__P  H ( !     $   0FH , !     $   'J          8! P #
M     0 &   !&@ %     0   1X!&P %     0   28!*  #     0 "   "
M 0 $     0   2X" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!,$U- "H    (  <!$@ #     0     !
M&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@
M '(!,@ "    %    )"':0 $     0   *0   #0   #P     $   /
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,C4@,38Z
M,34Z,#0   .@ 0 #     ?__  "@ @ $     0  !":@ P $     0   >H
M        !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H
M  ,    !  (   (!  0    !   !+@("  0    !              /
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M  (1 0,1 ?_$ !X  0 " @(# 0             '" 8) 04#! H"_\0 <Q
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MP'\G\O\ +\_:]O@/Z/'_ +_V?V/]_ ?Y?Z/]F.!SP' <#CY_[_GGV^!S\_\
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M%33TF^208>+&-\K>3G&>!T,0[T4O"3O39PHJ</@()UKDM&72@.$/61:.[RI
M:BL\!;D4$&YE4<X8(N,Y8*J)+M]%TDEO/*)>,(UD-E]1ZRZ==B:!J.VIG9<O
MM"90*5"B9ZN2T.&JL 4K#/< V^JRY#R7@00/=+DBQ)0:B8=N4M!C%/"?F<!7
M+KP\2D5)]L:>:?JI5,8-"I_%&FF<;+F5*;EF91)P[5#QX4<.=86]D,@T31\I
M7S,><9QIMKY6=0F6MNPM+-H[UAKF?E2N8"RIJ[ZEOM)B')K.@C6=V3*IO$R
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M_;[7 YX#@<9_E\7CX'/ <#CY_P GM?Q_Q?\ AP.> X''CQ];Q^W_ "^WP.>
MX'<'I"=E!'8M(BQ T3V:L&/LXBY5=N-60IB@-&--5%MMLZ-6 ]HV9,V^GB2;
M-D$D$M-4T]<8#IO'_'_-_-\__'V^!S\_'_KQ]?\ R\!P' X_G^?S_P!W >/^
M/^/YY^?['\X<_/\ T<#ZL_ K?K0SGW:IG_5J#?/V_P#9P/F<N_\ PT6_]U"?
M_6_^U9;@1?\ /^G@. X#&?'[? ?/^7@.!Q_I^O\ /Z_\G\?M^+@<_/\ U?S>
MUP' ?// <!P' <#M@)XU%S ^01PJ_"'!3C5T.*C'*K-\R<:Z[:X5;N4=M5$]
MLZ;[Z;>3MXM]-]]-L9TVVUR'59VSOG.VV?'MMG.V<Y^OG.<^/.<_SYX'' <!
MP'\_[? X^O\ T_[/YO;^?M\#G@. X#@<?L^+^?\ U?L?^'M^/VN ]K_5\_G[
M?M?Q<#N%I"<<@V$97+/U(\+(/RPX+NY4R-9DRJ+) B00:>/S.KQX@.8H.'&-
M<J[HM44_+QKIC' ZCY^W^QP' ?/Y_P W <!\\_/^C@/Y_G\_X^!^?K?/&?%[
M7C^OGV_V_P!O^;' _7 LETW_ %VO6;[O%4_UW"?/^;@?59]30Z-^]^C_ .4D
M\^5? ?4S^C7O?H_^4D\^5? ?4S^C7O?H_P"U_P#2.>?*O@/J:'1KWO\ '_RD
MGGRKX#ZFAT;][]'_ ,I)Y\J^ ^IH=&_>_1_\I)Y\J^ ^IH=&O>_Q_P#*2>?*
MO@/J:'1KWO\ '_RDGGRKX#ZF?T:][_'_ ,I)Y\J^ ^IH=&O>_P ?_*2>?*O@
M/J:'1OWOT?\ RDGGRKX#ZFAT;][]'_RDGGRKX#ZFAT;][]'_ ,I)Y\J^ ^IH
M=&_>_1_\I)Y\J^ ^IH=&O>_Q_P#*2>?*O@/J:'1KWO\ '_RDGGRKX#ZF?T:Q
M_P#%^C_Y23SY5\!]30Z->]_C_P"4D\^5? ?4T.C?O?H_^4D\^5? ?4T.C7O?
MX_\ E)//E7P'U-#HU[W^/_E)//E7P'U-#HW[WZ/_ )23SY5\!]30Z-^]^C_Y
M23SY5\!]30Z-^]^C_P"4D\^5? ?4T.C?O?H_^4D\^5? ?4T.C7O?H_\ E'//
ME7P'U-#HU[W^/_E)//E7P'U-#HW[WZ/_ )23SY5\!]30Z->]_C_Y23SY5\!]
M30Z->]_C_P"4D\^5? ?4T.C?O?H_^4D\^5? ?4T.C?O?H_\ E)//E7P'U-#H
MU[WZ/_E'//E7P'U-#HW[WZ/_ )23SY5\!]30Z-^]^C_Y23SY5\!]30Z->]^C
M_P"4<\^5? ?4T.C?O?H_^4D\^5? LQ45*U?0T66A-21)I#(NX,.SRPAD\*OD
M=R[YNR:.WN5C#\B[QNLW'LTMD]7&$=<(:YT3UVVWSL%>3'@YNED@+E3QBB +
MTN;)/BY1[O(9PGN[(DG2KQ\ZW31E"2.FSARLJKMHDFFGKG?.J>FFF,:X#K?J
M:'1OWOT?_*2>?*O@/J:'1OWOT?\ RDGGRKX#ZF?T:][_ !_\I)Y\J^ ^IG]&
MO>_1_P#*.>?*O@/J:'1OWOT?_*2>?*O@/J:'1KWO\?\ RDGGRKX#ZF?T:][_
M !_\I)Y\J^ ^IH=&O>_Q_P#*2>?*O@/J:'1KWOT?_*.>?*O@/J:'1OWOT?\
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M]'_RDGGRKX#ZFAT;][]'_P I)Y\J^ ^IH=&_>_1_\I)Y\J^ ^IG]&O>_Q_\
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MNN*U#^ER672O:E?L=ZR^KXO"&&:W>W;N1ZI^B_6_SF7.H_;U!],>SL)9>?\
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M#Y@XP@IX\>=1\A3R=?*\6 [KU7!_P13\>(?I7 >JP/\ @BGX\0_2N ]5@?\
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MOZT:ZZ=>J3TUQXM=*OA6NN,YSG.-=0#'&,9SG.<Y\6,?7SG.?V\YX$X<!P'
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MK:;RQ6+)+:K:I8'J)1.42G+Q33.F^5],IQI1GA+7*><;N]%?+\E+.FX9AP'
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MJ:>R6JNR2JR6=%=PLEP' <!P,8FV\R3ALLWKIO&G=@:QLWM!VLR?$QD0<2[
MUSF.(RDB%&F##&/*%_8FIET*%$B* [+A1DQ<N-4T=PTA]3.E/?4)O: SN#$>
ML)F:]G(?*XEV9[K4[V_O$]VA5&FPY=(/&:.BDGZ75U%*HK.)DWZ;> UO'[!&
M@H*SSL?WVETNU?%#(2'UW\$V7ZR=SJ4NJ#]G;^EM#4OU/E= Q^N;)LT(8),W
M3R7P-U$X6SCX"H8V ^@V*B\:=D5V.DA8G4)N&ASAN@Y%MW_ [?N!X-R7]FF?
M8<F,4IR.&G8ZM0W6.&/6I76L\,8W9$!NVX'=TLA,4;K-BW9":0@%75AO (N:
M*L:RA$4>:JGGI$Y&<!;+H+URFO6.B"4,L7-?LII-KBNJ[#\0J-<L[J2M7MS6
M.>G^U:UB\.QZ(EG\-ANAG04P*/HE%5C#G1Z7]6@6C[46U"Z_ @^._KCK<^XW
M0/\ 7+L9P)PX#@.!J%\-G*IM&.F6B5==@3G7B92BT8U$@!Z.N>S(0K,RYF.S
M#43!VLTZB5S:E[0A7)9%A,T2L5AS]J<7AJ4&.J)!I8]\H,M\$SV7C%_]?C(G
MZ/NMX6K!II*BEE-%15\,5ZU:V#-YH6AT!&&.R=;51;<^B,.;B3<!CUB2*&#-
MSSN$'!JC<>_ OPXT-IO I%:WA".N%03T]5DA4N,Y8D6DU61J0Q:#]=+YERK#
M-P2B/Q.('6QT37:D3D$>5)2-IJX>Q>0''"[EJ0CP9F7F#?2-K!G]F3^)*6EU
MA#[E-VA=_.CDH0$$1I464T"/*&NA%%R]'$F+5X.6PMXT' X@BU),W&FZ#MH@
MJGOIJ%@O64'[HH_>J_V?)6O\D/64'[HH_>J_V?%8]B>X>LH/W11^]5_L^6M/
MY,_@>LH/W11^]5_L^/>0>LH/W11^]5_L^*^TD/64'[HH_>J_V?)7OXD/64'[
MHH_>J_V?*'K*#]T4?O5?[/CWD'K*#]T4?O5?[/BOM)#UE!^Z*/WJO]GR5CKX
MG >LH/W11^]5_L^*Q'\F?P/64'[HH_>J_P!GQ6.OB<#JG#F&.73DAOLQ3*.Q
MJPA4PU149FL#5\XWW:(F6J:)-NEA771=/#=TGE%PFDX2SHLDFIJKW\3@8%EN
M4B$/8 JYFR)<B.*^R<.;<(R>8N'P9===5R&6DNKK60:K-]%4TQ9<EN?=(IMM
M$GZ1#*NR^BL=?$X&3;6:*2EB$57#235%R+R11EZ0U%S#=ETO+]D"E239ZL0'
M$D===%$]"XD>T>ZK::#GCQ9-RD@KW\3^<QVH2Q(+)6>2,=E80ZPPNNUV>AWR
M))KJY;*92<MMUV>5D]'#=37*:Z&VV%4M\9U4TUS[7+6G\F?P=OZR@_=%'[U7
M^SY*]_$_G,="O84>1DXR,9<>4L3 G#VCS'E>QT4@9"/#U6RFN=/.Y6<;R%%5
M+;77*>NC9;&^<;;)XS?>0[[UE!^Z*/WJO]GR5CKXG >LH/W11^]5_L^*]_$X
M%;)_2T/*R5Y9M2S9S2-PO%$5RLPB;#1S'Y]['T\VDQMR K>QX]8C7S.,-FYA
M_JSFP-OY2<9EH355QJNKW\2.IC?:?,0+,H/V9"CZMDKMSJ/ V0(</BM$6"XW
MWUT:ZA9D\;-W,'D+W"B6-H38S<*\V?;JL(J;FR#?)16BG,O\&I3=Y]Q>V'8'
ML$[<GZ_O&$]=H3%(Y7=U7G6;^1QBMHU,1EBP6]H[7)B"1JQZSDQ,P"=L(-+2
M,^BY1-J_6)A!BRFR3Z5CE\^)P-KXA]#@ D8!!8%A@@0>R$!Q MEJP&"A0ULD
MS'C1S%J@DV9,6+1%%JT:-TDT&[=)-%'31/377"O?Q.!5+L?TZZH=K#H64V\&
MDV92&C):"*R>M[6MNEI')ZV/O6I(]54^.4_,(03L.J31)DU(E*TFSH]"GC]+
MV8L$V<;JJ;VOM)$M)5122&HX>BR62A@JGG%#-*FTD$HUI#Z&#GT:CZ#<TGZ1
M^A6]>MA8IM'&$B>1)>1CXFJ0BC(JA'2A$:ZE>_B<" Z7Z&=**'VF.85!GYM.
M:UYO3C]K;%D6I>#$%2N^RN^:2@;&X9;.&E=4UC*WZFK8*C'X1C5%IKZ$SJR:
M815[^)P//471?IQ2[\Z2CT;D\Q<&X$4J=#2[[>N7L(TB52'/8V#=2URPO&;6
M RK6KS.C 6@6@,$0C\7)M@X9L^&+H"1Z;97OXG [7K]TSZG=995M-*L%2]22
M-8JI7\3?V/<5SW-BL:X5=CWRM9TXUMV;39I3]<*N0X/=:#5LA&(RMH  I*C=
MT@HS1K:^TD3AUHVUWZ]4IOKGRM=ZPA6VN?V]=@#'.,_SXSX^!-_ <!P' ^3-
M+N"_IKPJ-DF[@\( 9&]>6/8H^&(BB;?PB9$(P>P@'<PPE0V]8DNN/TEL(C$<
M83R)/IK:L8N-PVU%T6(M RCJ]D1DR$#ZS.!%US7+7U 5S(;8M,D:#0.*)M%Y
M"7!0N;3YX,:O'K=AH^6CM>QV4R;<<V7<I*$B* =5B(986)%7#(<V<ND@AFL.
MX=.WNPNA.%-K2&#JCPX8R.16!2]J5O&'[9> 1*>:% !V;1,*Q?M_0<W%;X%N
M5&$GW31=%T@"D97$'B@9SUYDH+% T;C))OX_H/5G^^9__<L)^SC3Q9_FX$P^
MLP'W30_H4_E_>_VN ]9@/NFA[7U_:4_L^ ]9@/NFA_0I_9\#CUG ^Z;?^A3^
MSX'/K,!]TT/VOK*?V? X]9P/NFW_ *%/[/@<^LP'W20_H5_L^ ]9@/NDA_0I
M_9\#CUG ^Z;?^A3^SX'/K,!]TT/Z%/[/@/68#[I(?T*_V? X]9P/NFW_ *%/
MS.!Z[@W&'.JF%WK7;*K=9ILIC"NBWL9SC&%DM'">FJR>JGDZ[;>:4TSY6FF^
M,XVTUVP$<88[Q&(M(_5\R;H.1Y;V:EM93V7V#HN+7755=@_2Y$]B0LT$]5==
M1"^S\BD)2019I,%&?DI)!DF;-%)RQ.++AI%HW6%9(HS%-DS<0U1PGG.'(A1\
MV(K%1Q-'7R%--2X8>R>Z*ZZC7SU=)TDW#N!%A0>0,M"0&5!#8Y3=5+1^(?HD
MF>RJ&^R2Z6'+/99'*J*NNR:R?E^6DIKG3?77;&<<#HK"L #'8-+3V-V97(:/
ME".!JV^Z23W9HT56U;[J[-UL)X4VTQKY>4E/)S^J\C;./%P(#5I*/$856#D5
M8!ZI+CK^O8M$FD\@!)3+??(<8WU=@I7%GB:D0L6);%O9CGT1)Q+G**KA9^$>
MA2BNI!,/58=FI'5+K /L^#&" N'";45V KIN4*5&33WQG5#>>B5\.I5399;R
M-U72IU,Y7+;QZ)ZV1AVX;CLA:P?-HD68M"8J0#"8T@W1=L"(]QJ]8OFCC3"B
M#IF\;>=;N6RZ>VJB*Z"FZ2NFVN^F^VN<9X'M^LP'W20_H5_L^!3GL-X0KKSU
MKL.&5),4K7F-H6'"I38$+@--T]8%NRD_&82:CH25/6XJ#!"R[;0*K)QKQZL1
MPS9ILL*Y]E9=[LVCL,4(^$TZ^+0:K[,K>'=DK\@-MQA>4QF44%UOM>T& Y!H
M05$O@DS1"Q[4C")>-)-W; I$9.R&2 6\9O&A!@V<M5DM ABR^\]HW+..ME%=
M4VKWK[/;X'WI8$HFW;.@YZV.5Q5G7[,!#G'0ZC2L@K8U(#4UFUKP(/'WQ24!
MPC8!ZQEM<OWB#!KN%B^BO:@]V$IN1O;:TBXFX*=NRZ>N%K[1!$BUAQ^<4=/B
M\'>S2(,2:[XH+C4\&L!<S$!R3UX^#-CNHIP[=[L_9*H0E5/>&\YWX1"QNMTX
MIEC3U'Q[KB6L^LWDH.@C-J6:8$6\E7BLT(-8F<.QV$04VU277A<<)/W$S>,%
M4S,N911ZKI&VH1-]--WFIZY>I&_8.6];20WMM=1RKR/4B!0D\G:5)Q?>)327
ML)Z'NI.R#XFV&]=LXL$1MARK7$3C:&)0MN#)^>0#($@KOU;\+)<=O]LJ?K*0
M69UWD+FVKD[+5I:/3V)P.8![MZ@Q.C_7I('8DQMA[,2T>L'0D2B<7"R%CM"8
M@T>OK('N84N49!2&40W>1 @R(]B[>49.-'&FE.T!KOMIY7BUVS,>QF?%GRL8
MS];@3YP' <#4]X8"3L8O0E-JH.PT9GICL]7(.I;2DG8_'56-T[83R+V LWGQ
M^WMJYN!(<,4C362PM0*\JJ=C3R\O0'D@Z#3=0L.#L?!8];H?5-:R^YT#\*F5
MJ7HZ:M+.F=:=GR7;6OY$M"9K9\F;DP]L$:JIC8@>/S2V+(FT[:HP$4U'S&7%
M@XK",=$@QP\-J' BNQZ/J.WB$&,657L9F!JLI:#G5>G"P_3<[#95'38F1BRL
M>-(91*#-M3 (.[?LVSO0>8U'MVIAH_9ZY;Y#I[0_P@];ONM2;_V!71P)LX#@
M. X#@. X#@. X#@. X#@.!A9J! 2H0X%'^SX=F0/D"I$S!'JD1D"A=NJS52*
M;%0^&ZSAYM[ :MW>'V';8DP3R,)MWHU59HH'Y7;3QB9BC<0[CQ6)(,MV,M6D
M.2"$P561;9U9F1;P8AD*\77733U)CG0P:EOE=5VT?(82T8*A7>7]B*[CO;FN
M*=?O5/60M )0-7<Z*-,,!)J5$XJ8BP8AYQQHZP\.L8B6W:Y1;JHI*JB45U$U
M"K7&0M]P' <#J3H$)* Y*/24.+D  RT68%PAI@U*"2;%QKY"[,@.>I+M'C5;
M7/DJ(.$E$]\>UMKG@5/VJ.V:#UR]ZX%=9M7;;&N5.M]CR!RFR$,M=\[JI4S9
M;_0H6AV4$O&F+@<MP:@6-=6HH(]KT8EE?4)=JF^H%;CDR"$[EXS8$5U;^NM6
M3<=F.V)#E'.=M4=RP)59=%\*<*:*)CY3&WQV(&O(RJ$/D4,ZJY":> X#@. X
M$(]:OUOE*_<QA?\ W"RX$W<!P' <#Y2]*4@/=+N1=5+2:5UE'NN&W:SL7&S?
M7LCX3 D-N1"REQ\LB-LVE ^I##K(8W2=VV//3C&L:=]DU0(V$V-*I4'#1:7:
MLDA(?5GC&-<8UQCQ8QC&,8Q^QC'M8Q_-C@<;:Z[Z[:;ZZ[:;:YUVUVQC;7;7
M;'BVUVUSX\9USC.<9QG'BSCVL\"'8'252T;&I\*J" 1NN!$T.&)Y(PT28:B
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M=\Q^#"?$W Y]&._=\O\ @@GQ-P./1COW?,?@PG^CT-XN!SZ,=^[Y?\&$^)N
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M'0EE# ^K3@0I?]A2.LJZ5DD8;BM2"\EB$=<2&0C2)J+P05)I(-!E;"E0825
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M)"V3886-1N/&Y*(BQM<;*R4<%O#[((N(2R\X%V?5H%[FM_\ .?G\!ZM L?\
MP:W_ ,Y^?[7 >K0+W-;_ .<_/X#U:!>YK?\ SGY_ >K0+W-;_P"<_/X#U:!>
MYK?_ #GY_ >K0+W-;_YS\_@<>K('W,;_ /\ ?^?\_K\#GU:!>YK?_.?R_N^
M]6@7N:W_ ,Y^?P'JT"]S6_\ G/S^ ]6@7N:W_P Y^?\ [N ]6@7N:W_SGY_
M>K0+W-;_ .<S_P#]\#CU9!>YJ']*GY_ >K0+W-;_ ,WG,?Z-^!SZM O<UO\
MYS\_@/5H%[FM_P#.?Z?+\? X]60/M?\ %C?VO_XGY_ >K0+W-0_I4_/_ ,O
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M3Z?^^DZ^_"_ OC[@/IT^G_OI.OOPOP+X^X#Z=/I_[Z3K[\+\"^/N ^G3Z?\
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M_/ D8(:2,A#_ $>@KG@=G&/";^#&/UUB>.BP\64:'X9"S%7I]8KK+W*G-IQ
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M,C3EB#YT]7B>Q9RZR?2U(+.E2&SM=7.^%5]]5-\;!GTE6ZLS0PRD4Q5H"62
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MM(W\9<!]%RJ?MG5[^6D;^,N!%DC$=/9B:>2.7"^M4ID)'V/Z0/2-E5YPT_\
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M'\_^S@/I":(_<2?\:CGR8X''TA%$?N91^-1SY+\!](11'[F4?C4<^3'S\?\
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MEU;ZP"PAQUPSL\::<5Y!@B4^D&99/:4=1@ 7M"9.H/(P".P^!(/- VM<!P'
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M:E*3.\ADN3PR-CV)%:0&E<85(F7+A#=P3<+9V7R\56U7WW5UWWV"=N X#@.
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M>1V94Q(>KL-H:T[U#>E&FR\0[%U\8#X>Q)T5)M%2<382((+78*2MRH_#ZA>
MX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
9X#@. X#@. X#@. X#@. X#@. X#@.!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g16439g31v36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g31v36.jpg
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M&B(C05>7UQ@D,3)",U$E-$-2<39A8G.A_\0 & $! 0$! 0
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M03++$QHQB7.CC4FW"[S?D1'SKW?R"Q47I5Z[0$N_C*+R"S!JMT*![";I/(F
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M-Q"QPWG.!^A^5&=]+?DV'55"<JM@>FV&W7AG]G4LF1/52M7$3/J-L/KA K8
MFBK6*CL'0LV4.<+IGB&WE38$EI R//2_?;,](=$Y^(FC1I:]4X81,O!XX> 0
MLP2%-+2+#N7H P-BR9S3\YXYN!.T':BMNK)[A2]0DO[CO?0!F. , 8 P!@#
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MZR_3':Z[L;H-MS*A<-(V8X1SWEC(?@WF,;R7U/Q]*Z%V@K2NTP+L.Z/?I]M
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M+$:F,;L]L,.PE2(SDMJ(XS'D2Y2FOO*&-MN7N\E!8;!@P!@# & , 8 P!@#
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MS-2I(X'&EM!12MQHBG!P^*I \>C:83'%W>AU1.F , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , K;ZHF?1S&*)5OZ46"Y5B&M>O\ N3^B2G;J
MUI'_ /:_56F'/G_]%US_ !^651^2Y^C)J_%F->2AOTA>@'7D_*3+ML$"PI.O
MDE0@)6A!2+]6O_)[1:T'M+<UOZ=L_CMZ3I32E+VO\N"_8H_'C_1;?(*& , 8
M P!@# & , 8 P!@# & , 8 P!@# & 819N9<WNA&&7N//J1;"P^$^-@%+-4P
M)XC!'27D2),"'-*0)4F-"D2&VWWXK+J&'7FT.N-J6E*M 4']:<\YO1"5'FUR
MJQ*; _:O3BYF+S_<BDM$_P!"?H#L=R9%JLH&Q/E1F9L]$)<K2]M_ER$Z<1IU
M6]]*&VW+Y=]W(KPE)2WHF8IYFX5 N!.1$MQ6W34U.BA6S4I-YMCZ"%O/24-Q
MBL3\PBY%DZAHK5DW)BRAS4#:38]?Z<O:6T0E3:A3>+]LRE)RXMEEZ<B3^\\$
MJ=)J8TH.M-T?GS+A6(P^"1D59P2ZX.G_ +HE(F)C52*36E0RO3VX_P",1CK3
M+7&<=6MA#S:U-3;2;]-!52DFTO744#S:5N-6:MT>[0P#UCFSYFQTNHOFDQFX
M#^P,529+-J"*=3+AB(\[>ML(VTN4ME*G$-I6HZVFTH\PJ$TFY\CMI_E/H##;
MK$6W4JS,R$[2ZW/$&Z>VE&]_S:=9;EWU$U._^NU*W$UK?\OM;_ZX^IN\_P!#
M8W^7[+BT"L/4RFUZKR)VB+P8>B(N2VTIB-K?W''=11\92W%1!4!+FH F'MQ?
MX@R-$C:5O36LYLZ(S# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# (9[ES8KTVICAH*? A&@-BC6,:@JN2R*(/-"S 1^ 0E0XTV7"9<@G);[,M
MB#.4S,CQ=KB/,[<3FIPTS&I4'9\8H4_FW/A58,3() WJ<=,&)8Y+_P"&J:>.
M$"Z84=Z4AJ3-CA8<R(!BD'XT%R?%%L2]CAOWM0(QN7(2A)$IYAHP!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M>#4_Y.%Y?OH>N_!Q& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!@W3NCT_CO.
M+[UGH)=D!1.:4ZR7RX&I&]?:%UJJ")9PU-VG:D_<4P/A/K;93OZWW-(9;UMQ
M:=;!7LL6>5_^&^HMO]-=V]__ !<>IB7H1OT9T\_S3EC4OYK6+JKAZ)>;N-'/
M.I^J4#"-,\JHH2<QOZ-*I)N XZZ['>2V.WBN%30O\5+X]SU/6S@XC & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MRPE*M+E-SI5:(F@\,E- 29K+;3,N0'DR71STIIIIN0Y&4ZAM"5Z3K2&99@#
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MIUM>OJ0XVXC:D+0K6];2I*MI5K?SUO>L ^N , 8 P!@# & , 8 P!@# & ,
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MFVT6P8%AP"DV+;#XMF:[, "ILD7^AZ&'@@EU)*6C;)B4ZB/ (5%FYPW6Y/\
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M8B;95'*RE?-$2+.@QF);VVXD66].?CQ7:J\*JE3BEC&7(Q5IXVY_T7XSD6,
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M;2GZ$HIU-KE80E'R^7TI2$&P4Z3\OY?3K7R^7\OE@DD# & , 8 P!@# & ,
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M9N1VQ3>$-1P<VWO?QF<MDV"1@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & =6@
M(%;B$8#8@6W!+N372T) ^(F(3=))V@BX1C):TS-<GH5M$U<E#JI2=[2_M>M[
MU@'G*^ D2(V/J7Q%MV&?-/;Y/W&+QWEGZS*?*?T:<B%&KQ(&<LY_^<X_^S><
M#GQ\!Z!1ZY^FUF&]"B.1Q;:XS*D#I7^-&]2][G%ZO>>DG!S& , 8 P!@# &
L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g16439g39g56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g39g56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1H&4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&62
MAR         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -#    !@             "'   !$4    ' $< <@!A '  : !?
M #8    !                          $             !$4   (<
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (<
M %)G:'1L;VYG   $10    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "'     !29VAT;&]N9P  !$4
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!0       0    &.$))300,     !"%
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T  :55X  "<0 !I57@  )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C X.C(U(#$V.C R.C P
M   #H $  P    '__P  H ( !     $   1%H , !     $   (<
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M 0 "   " 0 $     0   2X" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!,$U- "H    (  <!$@ #
M 0     !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M    '@   '(!,@ "    %    )"':0 $     0   *0   #0   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z
M,C4@,38Z,#(Z,#    .@ 0 #     ?__  "@ @ $     0  !$6@ P $
M 0   AP         !@$#  ,    !  8   $:  4    !   !'@$;  4    !
M   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M ?_$ !\  0 " @,! 0$!           '" 8) 00% PH""__$ '00  $$ @(
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MV==L9QG@?QP.,_J_5_N?Z/%P.>!Q^?C_ -/ YX#@.!O$\!G_ %:;J_>O&?\
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MX#\_S_N\!]3]S' <!P' <#>)X#/^K1=7[UXS_K6PX'Z9. X'^?(2_P",7_\
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M551\^FIYI3=/R=LA*O <!P' P:SY:O *UL.=MF21)S"H-+):W'+K;MT'Z\;
M$#*3)9=/111%)THRU046T3WW3T4SOKIMMKC7(:R*:\*:,L8%U_,2BII9&"LT
MIF\IO?==1..SFW;3J6Q:2TI!1U"8M758Q:3S:RALQ&7"RFD&)1Z-N"DLKPA#
MY:($*LI#G5N&>VIWDF\@H><W?U<AHZ.A::V(G+B>^$"IWNGTR%C(.,C1$ZZ,
M04=-NM&LRGSY%1FF@MH!C3L7ILI[!](^F%F8YP%Q^M\LN*>415<VO^O@547'
M+(>+D,]K6.&B$A%P<R63R]UC6"Y0<)>NR IBLT:FM56*6C8UH0:-U'39!)VN
M$V<""*7\?K'V'\?B_J[O?%XO']3VJZI\7C\?ZOZ_B][@3OP' <#2K!K=G=?=
M\)Q3$49VB#ATVOC$J+UMMF&O-2NLQ'37$WM%LT=4F^+!JX7?Q*,RY1V-LP4.
M692!XJ\D/MCG4HH1#9;V(@-V3V',T:#O0G1L\!%,&6[M.)U]+(U-VZ;-RAM#
M)HE.(--2 8&^463<)R&%Z#9$'(MFCW?0^+2?1LJ%=NC:UXD>G,.FCNS];CL*
MQ#$UGX4O9T@5)Q\?%9=94H.1X(QD8*IZVE3Q@-B#X:@S3.PMFNP=I>B1[ ''
M&8T./#W:EN6&412%D63VDL^EJ2C SL%=;*0SF86"*@M:C"Y:Y92P8,E)?8CF
M-CVVY)ZLT9"T7KA!R]>+8;()J*[)Z[!/]9]D^NMU!XY(:;OVE;: 3 H=!Q(Y
M6=IP:>!Y2:B['TG)0\<)Q8Z59&RD=&_[X'1XQ=T[$L?]UOT6Z'^V<":N X'A
MQJ31N:1X)+H=( <LB<F%,3L;D\:+,#L>D 0HV3>## 0T+<.AI841:+).F)!@
MY<-';95-=NLHEOKMD/<X#@. X$*&NQU&1TY<49-6?%1\CZ_P$1:=S 5GNV3%
M?5T?'2(J&F)T:FEN[U D6,2DJS5\T1=)J;!GK?WG*>$=@F >_9E6#(F/7T=,
M"31L_8ND_'YMRS>(Z.&RZ?E8UV\A9%3137RM<9\G;'CQC/O<"")#VKZZ1>*W
M9-C%OPW2+=<9"G$;Q+CW^YM*M98J'C1Y.*R) (B1=I2785,HLY] M6[DKC<Z
M.:[-,/%\-\!F%.736M_P5A952R)250HF\),&1A0%(XYLL[$.U&)!+T7*A ,P
MEA!TENEA18>FDMY/G$-U4\XWR$I<!P' <!P(\M6V:VHZ"F+.MV9@Z^KZ/N0+
M0[,)*[PP!!U9-(A,3![$WVVNR3)N]D)P4-]EN,IM&RCS19XNW:Z++IAZ RPX
M49FTBK@5(A[Z;Q*,Q&8R*/-]E=W@J,3UY*1\/-+[^:PUW9GWD)E2#'9!=7?.
MP5WE71/3*.RH=&PK7K6IT(JXLJ<QF$ISJ<1>LX5K(BK4<O+; FA#49%X=&VJ
MV^')J0&'6V^S<:.1<.=&;9\2<:(C1[YVW#^C5J5Q';!A%3FYI'QMEV2-E1J"
M0=R02UDLH#P= >YEQ<4*USLY6%QY,L+P4(;::-&RQ)BVV6]D.T$E S_@. X#
M@. X$$M>SE OA<N,LK5B;P= ;B9=?9JLT>*.5(M=!*4@X6/KLXU10W=CY"]D
MTE #&R+A#1!;)=B\37V8+Z.LA.FVVNFNV^^VNFFFN=MMMLXUUUUUQX]MMML^
M+&NNN,9SG.<XQC&/'G@56F/>+J1 JC$7Q)K\KY"H9%+#$&C,Z%DUI*'E4KCY
M ^,.!HGK&6Q=[*%Q+B*R59^L :$6K4:"*F%5]1#%P^T"R4=D0"7Q\%+(H;%2
M6+R@.,D,;D8$@U+ SX TR0)!S08HQ579$A10>Y;OA[]FLLU>-%T7#=51)33?
M(0U=/LCUPZU>1A'V/[>V_G\[YWPMC;VF;A\SYG&-<Z;:YSYSSOE[:YQCR/(\
M?CV\03]P*H=Y)6[A/5"Z)(S*B NS2-LVCHC('$=81Y(49D <*:1D1J6B9%&X
MS'G@@B]9'9@9C,K90X4X>2A6)2GT1B/D0\;HPW@;"DMQ%:KU/M$ \O,L1S*E
M[-@-IP<5OLR$/7(]L:K>O*QC0E]YYYL]> -(WL\;>S$B+@BYU*))-@ML_#B"
MJPMR3%#23@&1]+A%W[%J\6#EO83T;Z4%JN$E-QY'T<2(C_9K39%S["?O6OG?
M,.ETU AJQ/ZL_7C^V=G?]0'G PCMOU(KSN/%JP@%KCXY(J\@]T16V)3!I=$V
MTPCEA,8N EHE&(E![P@Q:M$5WTE:&-"BR!;5LN&22P+6V<:N&H5MO/P8==2Z
MNXQ6O64W'>G,=A\'NB,@QM1U\H(&:F;@?5V1?FG.D&F=:'$&2^T R(ER "1
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MUA423*%Z4LU8/'HC,!%@5>],.RK[$8D,:FX3?9GF02IJ.,MRS(9+90*08G2
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MD%A1Z[\23EX%:-]<Y4=2\,S(22#(:J3*,#"<A!#![D/(Z5JJKU=(5TK,B]B
M5; *YB8^(VW++Z$5G'DH]%FZ5=:W'/1PB<3Y5N21)R[V?)Q;%Z'0EZ$58I*
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M*84<U<D".%PGF6]L:&@%K0^B9U;=/PR[K"217@-.RNY:OCUI39!PHZ2;K1*
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M^!\!ZQ-?@\_][QC\#_4_=X#UB:_!Y_[WC'X'P'K$U^#S_P![QC\#X#UB:_M
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M+*CQAE JF(/ZR[ 8-7)'Y?*HMB%FB3U/0/MW!T-3]]X6:[QDTJ.OJ=B78#J
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MWX'F3#LM6$0JJX;#M"!W?3<?JJ#$9-(W=H!3H(<[1VPX8,Q<<D8^2F8G(SA
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M_#^ \@M^V1WVDY_#^ \@M^V1WVDY_#^ \@M^V1WVDY_#^ \@M^V1WVDY_#^
M\@M^V1WVDY_#^ \@M^V1WVDY_#^!U'[QR*8O29(F'8CAS1R_?OG3=9!JS9,T
M=W#ITY64(832;MT$U%5E=]M=$T]-M]LXUUSP*$]<_".U)V8L&+P*)Q:WH4C9
M\%D-GT'/+4JE[#*\[&UW%B ID;EE-G]I.1=%&K=H>!2-J(E0N(2<M#R[27"
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MO%(/?_\ J2'^7_=?O?G^KP'I[?X!D'VDAG_,\X#T_O[W^\,@]_\ ^HH?Y?\
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MA.T"C]L"-0&9W8,=DZ32&AA1QB,A:PMP0F+-HT1*R=N?4D:_D,";A%TY]"J
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MVGE:X>A#C$>59[;8U=,TMLXQP,5ZO?U *N_]W,?_ #[W@3WP' <!P' <!P'
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MTG_L4<_H]P'H9_\ &D_]BC?]'N ]#/\ XTG_ +%'/Z/<!Z&?_&D_]BCG]'N
M]#/_ (TG_L4<_H]P/BO'G#E/9%S(S3A+;Q>4DNUC"J>WB^IX]%([MKG^[C/[
MG \(O6H"0.PS\]YLV^CCC5W'GI>/0DD[!.]-T5-7(9P]BJZPMQJHV;[ZK,=T
M%<;H([8VQLEIG4(:O7KO#I_"+$7*&),+)' S$C(34>Q$QI>0IP;7)F/"3CI2
M)N]"85N]8M<K#7:"K=PBCJW5QLAG=/8,WI>I6M75G%85'II-W@86PRNP]-N(
MP_=M4BBJA3=@@JE%FB2(UFN\50&,44$T![+5%DWUT;H)::A*/H9_\:3_ -BC
MG]'N ]#/_C2?^Q1S^CW B"CD5&YSL&DHZ</-]+V?>4X<X;X64\=6U5G&=\-&
M[5#'BQG&N/(0T][&/'X\^/.0G[@?SMMKIKMOOMC7777.VVVV<8UUUUQX\[9S
MGWL8QC&<YSGWL8X'Y5X;<W33LOX2]L?K"]^@R#".]PF!Z-QY#OW)G]O7_,BE
M>4TD_F40IB%MRE>2UHO(H1%5(E"'![;5G8%>O"S])@]?DV;L/U5<"IW;2$=C
MI?$A2_6Z9LXY*@K6=^4(>R!:)-BQPY!#@&"'G!U&.RC1XU@<N?L),O$"8K(&
M2^8T5*JN,!VP8N'%1";3IZ$S8C+P$YE0]U(Q+N"U<.LXQ?$]BXI4(&'GT'-I
M6T6CQB2H/Y0F9D2#$P<>X #'.&HQ][%4:QT('\=79>^*0::DEH)-@RKZ][^<
M*"2[>.Z%1VVUMRS7+9_HPDA!EJXUQKC?;#9ZZ2\G?3Q*YV\>NH61]8'/Q7DG
MV$1],<!ZP.OBO)/L(CZ8X''K"Y^*\E^PB/IC@<^L#KXKR3[$(^F.!QZPN?BO
M)?L(CZ8_R\!ZPN?BO)?L(GZ8X#UA<_%>2_81/TQP'K"Y^*\E^PB/IC@/6%S\
M5Y+]A$?3' Y]8'/Q7DGO?_P1'TQ[_P#<X#U@=?%>2?81'TQP'K Z^*\D^PB/
MIC@/6!S\5Y)]A$?3' >L#KXKR3[$(^F.!QZPN?BO)?L(CZ8X#UA<_%>2_81/
MTQP.?6!U\5Y)]A$?3'Y_W<<!ZP.OBO)/L(CZ8X%%.P?6!K(34]O"AX0[@G9^
M70O>#+V$]DTBC@)P!<,G IX_.@HE(%14@D# *X6:QX@:"$-A+O5D2;[)NQS;
M?@0MTNCW?*)]2*)B6]@5"9,B7!30M,);6<OFS]Y7FSQYL!8I:#[;KK+Z6,5=
M]TGA4ANFV=,4FR2B:S["Y!P%H!1KO.G,"88TTI9U#$1B;D-.6%:R1F\(D\M6
MGGA9.&+=@GCL1C5ZJ[RB_:F3+=9FTTV5U:N'.J"88[FU.XB8V9F'L6@P9E"]
MG:CC4[3D]36-L6GLA3<A'$HQ=$P=F4-V[;91-%DP5(;[JMTO8.JBN-<!C*/9
M3LVA"6MB$ _5UG#'CGT:WD$OFEGU2WW+ZN'#+T<LUET/>N6+I5ZALDBW<_[;
MOY"GFL+:^2IL&7L[;[WN=63UGURZZ'PS]!%XS("NR,R;:OF2^$5473+=2AWZ
M"R*[=3*B*NBJB6V,I;Z[[:*>/ =M>\N[K/=+3?HS&2NN<8\\L"[5QG.-<^)7
MQY31D-7QW??7QZ)^]MOKGQ+8S[^=-]<!W,]C>SS31/!'H1:"RV?_ #N(]<]
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MO$WK5LH@R*C(J.9V WX&_/@. X%?^NGZ6K%_Z0'8#^-F5<"P' <!P' <!P'
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MG >M<<^%VG^%O_,X#UKCGPNT_P +;^9P'K7'/A=I_A;?S> ]:XY\+M/\+?\
MF<!ZUQSX7:?X6W\S@/6N.?"[3_"V_F<!ZUQSX7:?X6W\W@/6N.?"[3_"V_F<
M!ZUQSX7:?X6W\S@/6N.?"[3_  MOYG >M<<^%VG^%M_,X#UKCGPNT_PMOYG
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M1C<@[<+:>QT%<;8\881;O>BO:.OFM.N]B,;4&2^WC@V,P"7#^L=YG*;.20D
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M\(1_[CD?IS@<>9E?PA'ON.2_N_\ KW\_W>!SYF5?"$?^XY'Z<X#S,J^$(_\
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M18-0HR%LAK15N/T<J!L?]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
M]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
M]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
M]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
M]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
M]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
M]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^ ]V!0/QID_P T]O\ ] ^
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M/N:S_P!3P'J^!^!!'W-9_P"IX#U? _ @C[FL_P#4\!ZO@?@01]S6?^IX#U?
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M:Q]<<<W;M6M@&I%&J_R;D3<6M&(VXGTDB4FCL%92$T+>3(^#)!8TW)DVV[7
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M+Z;"WZ[AD'4@M?ENOM<NP$6=3>YTV9+9T"C*HCK]7K@6W)._/$F0%G7T$HV
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M;4D2B'K;35TSNM $6?S?2+5LZ*V7-XY7=81J*DWM"KRQEHM4WI<4M8<L%H2
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MIMG775/3;?;;;;&FN-=<9VSG;?;.-==<8QX\[;9QC7'OYSXL<#2#'NQ78<?
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MVV":QD1IGV:HY5#-=X/"MO4S*D0BVWM;N/9E>YWCXG/J$Z]6RD-RZAF<M/\
MQ6<>IYLU%?/A/8*GJV7* _*]%OW;54*V; .A49D%52_<+U#C\IE,@,/Z0E&P
MVF1,@D4JD<H=&C[RJC>46Y$O(#TTE3TL8<1%RX(E)1(W3][NN6,*JN ^)BDN
M@4'*BJND%1]/8><M8XP/A*Z,0*EH^5LF2Q)(JU%FA41>B6CR8G(RA*#C9@1:
M#R+\,E(BJ+=9MH7>:N ]R,P/I-+%7;J'0SJS)5S0@OUO?N8S':E,JE@,<B^P
MX]0KM86S<[OQ &%@=V!>K5ME60N+A=FKT$@*'9T1#/?<V]=<.XH_]H.EO9T#
M*OSL'>>U9!O9<,.%"34R3,Q1QZ"\]'2I$NQ9%7Y$1NS>.R3-J^<+*.FZ2N@9
MO'*ZKZ'N4GD2@L-BSQ$&WC*+N.1@($<I1MH4*'&D>27&,6JJ8-J;-FC#<3KM
MA@B4+E"";?5V_=K*A7KKO6O46C)3/*KI!Q4+6WUR<BFEKCPK^OE;N(;S"8FK
M 5?V4F 093%X-9F+!<>KZTF:[IL!I8>@@NI[*U7<A[!*$],+=EL]K<O$>L%G
MSIE)&%B6A B0&J9K+6DO91UM#A<ZGL6=-"1A"2-(FY9Q5A)Y"QT*(1UPV!MW
MV@U5)KL'09TCT<D VO5V%1=438<V^V:52LS@-0DAI<D$B8T=NUKU1$2LU(/A
M$%JP.PV1CF57#")UR-:YU2#Q!KH.#$.SM0U- : [)RZ"U?7<+EDZB;AU-I/$
MH5&HY(9BZU+>S]7,J-!QC,E(5]7Q!^\U6+N7:F';YXXQMYYRMON%W> X#@.!
M ]S?IJZX?O\ &O\ $S<G GC@. X&DCM$>.%.P[@%#O"> XO%@MS5&3MFD7UC
MT]!)G0+6-$HQ*SHB,NQ-22,Y*QTSB[9-RE75J.&+_#N2J&W$X/PY9G!T0M5V
MJ8V!-[ ZX16$PI>0:A9Y%;'#S U*HN(CTLQ7<CA%BE0N%&:SX\P*$ L8?:-B
M"D3T"J/UV^NJJ393.Z86-VG/8#;&==NOT=VUVQG7;7:ZAF<;8SCQ9QG&8/XL
MXSCWLXS[V<<".XY&I/#FZ;2(]+:9BK5&0O9<DVCDU@X-NE*R0]V)(R=-$96C
M5/20OQ;]^->FM=<$G0]Z[9KN5&[E9/<.M&8<<A;),;#ND=(1,<C*]9VD/C,N
M@8%DE.-&F6&DR3:BZR:H:2O1CMLRUD6J>"^K3;+;#S".<Z<"3O7OL%];_'OG
MK&_T'X#U[[!?6_Q[YZQO]!^ ]>^P7UO\>^>L;_0?@=$I)[O-C"(4UUNB!<.7
M8NQ9824N *0&%!A!NHT?CB+!W U6KUB]:JJMG;1RDJW<MU5$5D]T]]M<A&,)
MKMU6B.C:N.B=!5^W2()EDV\)D==Q1%,JB*?@DB>B0*KF">A!((5*!DWNNN'.
M@HD_'ZJ8:/'"*@8LYH*)O18\&\\''U9=A1)$H8%!W.]2KBQA8VBP;FB@\>K4
M>[1F1+H"QB!1ZV13<D$1S!-VJKHT;ZIA/C.7WN/:-6##KK%6+!BW09LF3.Y!
M#9HS:-DM46S5JV1@NB+=NW1TT2002TT222TU33UUUUQC =GU[[!?6_Q[YZQO
M]!^!'BT<E3B1R68+],*;7ELS#>KDPE*TVA"DCED>QH@EZ"DIO>M=B9T-YMJV
M3]%E'3ICY#=#3S'DHIXU#X.XG(2!F72)_P!)Z4>R"?@<1:>'7<Q@KDS-HQJU
M08ZQR7$UJSW>R0#ABV;,\"#*[T?AJW0;X;^923TU#^3$5F!NK"E)K]1:[854
M6CKJ*K0:/VP#C0!F#=I[:9:!V(&!CD@>S;?;#D>Y$89.1KU-%\Q5;NT4EM Q
M@%4. !4I)6G12AEII(F9!I,)\XD%9:SB<;FT]-9(^F<D:5,T?R%]*5==G<E5
M?;[IF':BBKM'?RL:X"27/MEO&4M&N^IM:.AT_4W6G;!S9467935;<&.C.ZLM
M:JUYLA)%-XV'$1_?<SH]VV!BQPG.<L&+9ND&) X9-8Q*(E*8WU4A,>4K^$G*
M^@0 !;D>!Q*%QR4%PYF3I1J,B*]9"QKH^ZCD=2?NDT<[:,PK9JPU9).RV"(2
MOZ]]@OK?X]\]8W^@_ @HI3 @V+< S7@]NM)<([E2\Z=!RC^KGXMS-G+-T.<S
M%P/=U.JT6E3@>]>,%Y"HCL659NW351WL@NKIN&1$H.5,Q7>"F.CM%EH0JE'4
M%(<2E4 ?151"(-&[")H[QYU6"HC=*+L&;1E'4]F>= K1JW;#<-D4$M-0R0TC
M8LD$$X_(>I%7G@)J/MXF9"&K&BA006BS7*^S6-$QKZNEV3^/MMG3K9N&=(JC
MD<N5\IMM<K*>4&1#93>(<>Q$".N$1%"A;-L/&#!MPAF(\<P9HZ-V;%BR:P1)
MLT9M&Z::#9LW331013T22TUTUUUP'=]>^P7UO\>^>L;_ $'X&%2AA/9P5BQV
M:=0*IEYN#DO3,*,RBP8A("L/,><;*^EHL0+5R[=Q\EYUFT4]G"5FCKSC5MOY
MWRD$LZAAI:JTCTF%S0YT&Z[F9B#537"RPL:K4C)A"Z)M])4EA9YY5:Q0>JE(
MR9*0)J-'2.^AL@^*ZYP_=KKJ!]5JRV<#9@&7Z&=?%P]AED#T_%+'JX4&SDXV
M>;D6QF8,=ZLV:R8LW(*J/D")I)Z\2>*;NDUM5]]M\A*0F2W:!%C@8+K9#@H4
M.Q:C!(@3;P0<+%C6*.C9D/'#V<#1:,F+-NFF@U:-D4D&Z*>B22>FFNNN [M(
MA[ AL0,-IC#6[,[(;)M:<+#@,F&'&(QE-[%DLF$,=RKQ(#N[>HB23++_ "D.
MT;HN]U6Z"SG1'S^X3!Z7,_%4E]T0/TGP'I<S\527W1 _2? >ES/Q5)?=$#])
M\"(Z.567-]@E5VJC)7:]GWE-EE&ZJB?BJVJL8\K=LJLCMY6,8VQY*F?%C/BS
MXL\"?N X#@.!2GO!(, (#$-V'<D9TWEKZ9)-H8=D&];;Q>TC*8I^[7K,^SGP
M N3=-B MN^*-EX 0"2L0\&HFM\GP@\K&2X>-X.[!Y'K_ (:S&^D+\G&LZL,I
M*2X^Q@UJAHEO)IS(Y/'X>'F@R 5N\*-!<5,!-=\EHTQW0<Y6;"F0L$B-%M \
M_K;_ ,H&V/[-Q?\ _3UF<#.>Z=.3&X835>D/TEI'VMKX@-I2F*0&9-*_F\WA
M\>8242:C,2EY O&V0.09VD+0X+?*RJ'N4G01/8/,HF>P+D(X(R:5;V'8='Y#
M0(@0^!VD>C16*"9.++PT8K$8C;5H'QCC?4VSDJJQ6VJ:IXZF>F4K53W;3JP!
MJIH!(Y>;,/5L!Y^W7&6UYV%B).@J]E-< &A&F <@GC"V&SBE"/7NL8:4CCRI
MWE&>GPR@J<(K.=T(@195[+&(W5[B4(66 </#$,X&R/@. X%+NZU,3&X8[1[J
M)-YD70J3L#'+6F$0KJ<-JYGTXAS*OK-@[^.P^8O3\18AC:1.=B)&DX<3*&K>
MQ@#G F5 SOHI\D$(ZTM>X&I.FZ#J!/YC).K]J#[-E4'CA.LQ&\YC1N%W5 1T
M5!O3,O!1DC8E7M)_$I))S$F(QF/RX\#(&04E*%GWC2")^J?4F^:#D-2(,8O,
M(I(]S\8.798"5XH2RE3E4M(%)F:U--:BR:#>BYS$965CX6+'!E='!R0".JR=
MM;C+TV2KI4-R_ <#59U4H"ZZHLJKRLRKLFR%4905A]>'\B826O7^]VFK-ON#
M3=K;8YDVDZ1%G'XQ'H62DTD3F:<>F7INP)(.C<4DCAOEX4#MGNNENZRYYV->
MP=S-+(T[L>VR5K<<>A&ALW05<UY-^O\ 3\7B1J2GPT2;["@YAMV$91J12@ T
M:3>5S/55P+DC]338/-3I>T*@ZP=*(U)F?ELZG[+Q&P+UC )]DJQ"P60F[0)"
M ^%AS7")B.U!8$ZK,L04:M_1Z 2 .#*>ZC$=C94)1I:O+;C'86Q+1=4P]KN&
MEZJKJH64,2D54R$0),Q.=2APT,4]K%"T5]@4<+#R@K*#[:<"XQ9YXJ0QJ+A+
M50:W$+A5*.=&[?A<YO&66O%R?89K.;AHZY%C]$SQSURM683R*PBR(^=F+,@_
MN <IC6(K2.,1H%$GMF5TFQAPD9@))2NL391TT%G.MD.NL??<=?V:1V*RV%=/
M('7_ &*F#5%30#85N$)L]DE?LQ[[1@R9'3=9Q5.=K24FWU1\:=I@5M6J&A+S
M" ; I  #2L"9C$C'-C$?D0M^$."7NGG&9024:JLB(]VEX\>=:O&BRK=PEG/B
M414WTV][;..!HX:=(.P,:I".U2(KILJM.>DD8ZE9R"D\ 8">N,GC]M2Z5ZV"
MXT?FF>SZ.I1Z8BR+%.MV4K.I'*U #_0*:#AJ28!=3M=6UI7&0A J#TJ0&O=;
M'HZ6N;*6E-4-1^S6EKS1F:L:NX,H^4FI6N&P=HI/:O95J;E!DA-BFK*7 J]1
M:$5S057(](>QM!S@,8ZE2&5: &4_BT>'(2<Y4A1TPA0VNZ]B*!N2IFXV(9;U
M>-%0X/ 3PJ,LE^P+P%#DS@^7FB4W/II!NSX#@:MJZH:Z83? (X2KPJ_C556S
MW'MW6P1,DKO9S;XSLB8;%(9 0PI_)QQ]F3C+<I[#E&TU;Q( V4K2)[@SLA;O
MTTA@02%Z4=GWUR6:0&/$ZFUDY7MTV?6.3=1V8UGM >Q5_P!7V+D724*B<VC=
MK1N>3^"0/#&UY18[UNQB$S]F%*U;$VI!/*02M072V:UY$?!IXD]?0-O.>J,U
MMUE)R4;3%L&D"K&75'V#B00/$T5SIM7V"]*RVN1Y >"(O%E-$DG+E)%@*439
MA=#N3_R7KJ_]S'/_ ,VSX%F> X#@.! ]S?IJZX?O\:_Q,W)P)XX$%]EY9)8+
M1-E2Z(RB/PN0 0'LYE)I)LQPQ%IZOF>C_9C@JU?"%),Y&[NV4,1-," 1>7N0
M:)D>^&*.VBP0EX/RP[SLZ@F\F[!F&IB?8,CQ;C;04%$$F2@ZOX*E)T#"$8$!
MXNKN]L3,U.1]4"DY;Z0HO%VA%PD?:EQ[$+BM8Q'&,@,2QD!#M)1(6 <6>D38
M:T0-FAL>W)* 6!4FDCJ\(,PVYDMN+;NEE4F&Q-_EKJE[+7\L(DL3^K/UX_MG
M9W_4!WP)WX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X
M$$TQ^F/L-^_L\_BKJG@3MP' <#3#$J[N&:=[Y;8<+F4]E5-1ZZDA\KG+915A
MD)(Z_:S-N=J%,.7G85H0A(7,[3A)*0#8F89;#PSA!B!(2C.TT'!N"D$8C<L9
MM!\H AY$Q8&@4C8LS8UH3;,Y!&"[,_&S;5%XDLFW+ 3@]@8#D$M='8XDS;/6
MBJ3A!-34.O+ #J3A'(=G)Y)#UW&[??0]$U1")MKA!;1;9-LH=#GAN-'.NF4'
M&%AB^V45-\);)*>2IJ%%:4Z^ERK63R<%V$O"#2@3:78&%DY!'FM%&'\N$:7A
M+S;3>1(V%2$W&)/6#UPZ]C.(V/CN%47*B;]-[E-ML@$Z^T/:?UZG9G[U>F_Y
M)? >T/:?UZG9G[U>F_Y)? >T/:?UZG9G[U>F_P"27P'M#VG]>IV9^]7IO^27
MP'M#VG]>IV9^]7IO^27P'M#VG]>IV9^]7IO^27P'M#VG]>IV9^]7IO\ DE\!
M[0]I_7J=F?O5Z;_DE\![0]I_7J=F?O5Z;_DE\![0]I_7J=F?O5Z;_DE\![0]
MI_7J=F?O5Z;_ ))? >T/:?UZG9G[U>F_Y)? >T/:?UZG9G[U>F_Y)? >T/:?
MUZG9G[U>F_Y)? >T/:?UZG9G[U>F_P"27P'M#VG]>IV9^]7IO^27P'M#VG]>
MIV9^]7IO^27P'M#VG]>IV9^]7IO^27P'M#VG]>IV9^]7IO\ DE\![0]I_7J=
MF?O5Z;_DE\![0]I_7J=F?O5Z;_DE\![0]I_7J=F?O5Z;_DE\![0]I_7J=F?O
M5Z;_ ))? >T/:?UZG9G[U>F_Y)? >T/:?UZG9G[U>F_Y)? >T/:?UZG9G[U>
MF_Y)? Q^5=6I9.H^2B4T[==DY'%#B234\ <@^IXQL9':N$7"PUR0CW5T,=9M
MW?F<(KKB"PTCHEOOEH^:K>0MH%F/03GXRR'[()^B. ]!.?C+(?L@CZ'X''H)
MS\9I%]D$?0_ >@G/QFD7V01]#_W?^SWN!"=M"UFDPZX*[F2S[7V]O)\P\W8;
M(^/-,W'^B\3<>V4\K7_F_P"V>+ZOCQG@6.X%.N\^3BE 2=@R!!SD?(ZI(2G)
M0F<"KBM$5T'D7*A"D3MFFYFE(&\R; 4P+6$2]I,2)I8<RC:K4JJV7P']]*WT
MV6KF9A[%((NYK$[1/QH^P]/6">? 734!%7R8DKO9EY]@9,P=;M2+<NT:^NC$
M4\#%19P2 29&$S)L._(^XU< 3TNC[.+V-*7,$S8#R6.H^& )L1,8J=*+XL^9
M:[R.4QYR3 PDC, H1XS#-2,J.E=GR<-C<F:#'[QN$,=TY/)UY)TK<UG8QV ;
M3^] D<VF42&0PH9WB$X$),B.@Q"P8G,X\AN1&/=<Z.W4==.6^N?*;^85SYS4
M+!>T)97UY79C[A=3?R7. ]H2ROKRNS'W"ZF_DN<#%P%;R24$)&+!=X.R)!]%
M">!!Q!(#U2URU>93\O/FMU.K&B;UKJOH[&[OF6SADF9%F@NZ^I4*4:- RCVA
M+*^O*[,?<+J;^2YP'M"65]>5V8^X74W\ES@0/V"D42ZK16/S6_\ PAW82N(U
M*Y>Q@,:($HGUI**')D2$&S[&.C!T=ZD&"CPBX#1LZ2T219;:X:BW:F^^N-,>
M,/+H^?UIV47U:T1X2VYK0<YAH^?J(1<=U5=+-8F3EDM@C<D^36ZIH;CUTII
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ML0+Z?X#W3?6WZX2C_G8@7T_P'NF^MOUPE'_.Q OI_@/=-];?KA*/^=B!?3_
M>Z;ZV_7"4?\ .Q OI_@/=-];?KA*/^=B!?3_  'NF^MOUPE'_.Q OI_@/=-]
M;?KA*/\ G8@7T_P'NF^MOUPE'_.Q OI_@/=-];?KA*/^=B!?3_ >Z;ZV_7"4
M?\[$"^G^ ]TWUM^N$H_YV(%]/\![IOK;]<)1_P [$"^G^ ]TWUM^N$H_YV(%
M]/\  >Z;ZV_7"4?\[$"^G^ ]TWUM^N$H_P"=B!?3_ >Z;ZV_7"4?\[$"^G^
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MRC+^XHKKJ)8O'_G6V$\I<"4Z>\+=TEEX3K6A<4/;4E/^R@LV0CP=Q!#,NKH
MZ&&+%9,0Q:X$H*!C/I8N*K8V:39Y:MU6"6[=$CJWU<,G+P/<E'A>_!IP>I1-
MTS;UKAL*E$A8!8+F6];)_&3-D"2D-WL0?8%=BC<-8K3&MG4%26E*<S#;.1?H
MS337;;5ZZ9-'0>= _"Q=*#-O6W6EB14=6D7AEG/H16]WN82:.TE9X-AU>@7:
MG8TYLU*!#87#)0[@,HDY =7SH\9,/ ,*7D&KO7)AH+0"Y/5SLWU:[>MY=[4\
M9(CS$'0AY.11&SJ9.U7,VT8L4*I(JZFS>,3B.ARKV$ST,W>O8G)6B"HXKJ.)
M(:*Z.F#E!,+8^I$+^*$7^X G\$X#U(A?Q0B_W $_@G >I$+^*$7^X G\$X%;
M]^Q72?3;;3>RZ(UWTVSKMKEW&,9UVUSG&VN<>9\?CQG&<9Q^OP/Y]T;TE^4V
MA_U__2XQ_J>!6+LKX0#JI2S2O]X2G5]I/9)-Q#"3LHRV"$E8Y!$UM=I(>WU9
MH9\1#5OMA$(V6SA-XZPOG;RM&RF.!9=OV4Z0.D$7*%GT/NBX2362V]EQC'E)
MJZXWUSG&4?'C/BSCQZY]_7/O9QC/ [S/L#TO(.VK!E8U&.GCYP@T:-D',846
M<N7*FJ+=!+35'.=U%E=]$T]<>_MOMC7'OYQP/&[?V_ ^JM0(6"WIZ/V+,958
MM7TS5E?(Z1^+)32V+GG(6NZ_ E)6]#DVT6 K'SK9U(I'N*+J!@;0@^:ARSM%
M <Y"N6.YPVG!<# =V.HJU*W9:=HS:M:LK>@V+WMV*M%"$Q)A."$SA4@AU7PJ
M5(1M&..2+@EM.JYA#P4K'3FZS=4<BU(.PCV.>&)\&!-4)!M BY&P"(.SH74S
M*-P6A97*Y9,9/8^9PA ',#C(6,.S,LC\O(UU+!(<R,:*-\D6"2;S5H@]9N%@
M]^+^%I\&),)W0M:!9<,VFG8L2%(P0&_J0R+=#'\GDTMA,7BDZ3(1]OO#)E(Y
MK!);$1$;,:I$%CP?=JMH@F]&KO0S6K/"*=+;7E0^%#Z]LJ&2<G>K_K:V$VCU
MNE5=.=;C$TO.+_-1%?22@&>4'(2LJ_-&#*RF,(C7CH&(=[)$3+-ON$,8\,OX
M-!=Q%6HL59,C6FPJ&$(UZJ=5;)E29(A9$(D=@UY$]%X_#"*"<RFT;B,G<1^-
MJJ:/U]P1/+G1JV:*N=0]2QO"U] HH-%M8>+]=IK8'6"4]GJ1$NZJD<1AEK P
M-$'.Q ^)L;((PIV%$R,G7 3<R_;9:$EX\V<))D6F2NR(I<+-],.V?6_NM&2[
MN#P!U#YY"X_61NR*UL"K34,D$72M:%,YO$"@O28Q.-.Y5"I&,7=*16:CQJ(V
M0MF"[E)!IMC+?0)>[&1:*#(#&7[..QX>X;7_ -4=TWK80-:+-_'VCIW3??1P
MDW3W2\>FVVNVVN^OCTVVUSGQ9SC@64](#_V\S^V4?Y_ >D&'[>9_;*/\_@/2
M##]O,_ME'^Q_7_K\!Z0'_MYG]LH_S^!!=Q.VJ\LZX:(N6ZVWM[XSY*2R:FWB
M]IFY/?\ %IMG/B_=\7 L!P*R]AJEG=CFJ:DD&5@#QQ5TPDDE>QFRDCJD;.Z'
MZ^D\';KZ* 4G+AJ7"YDB[T>Y49K8TQNYU24;+;ZJX#O]=ZLF5:)V\0G"D'1+
M6G;KVS= M=IFDXP!T?0&OHF^;(9.)MW2Y P;B!:6%W.C5LDY)R)TMOHL[W=.
MW(6+X$%WMURK#L:(C(>RT)CKK#9(UET6+P*RK#JF4@9"RQXFI,7+JRDT3D[)
M9'.-=]<-RR>GEZ:;9USG7' KI)_!Z5Z1%:-HW=_=H$3U,1MWN_5\('WC>Z;"
M1\C%$)"-\QOV"QC&YL U)A4W&/T3-0AH[T_1H:\#(?<!U!\J_=[_ !AW>;\H
M'@/<!U!\J_=[_&'=YOR@> ]P'4'RK]WO\8=WF_*!X#W =0?*OW>_QAW>;\H'
M@/<!U!\J_=[_ !AW>;\H'@/<!U!\J_=[_&'=YOR@> ]P'4'RK]WO\8=WF_*!
MX#W =0?*OW>_QAW>;\H'@8K.O!ZP@G")B-@]U]T@<U(160LH>:(>$+[SJ, \
MI=B'B$?*/D\7N^SNS'EE&CMSIAD\SLBCOKAJX\?FMPR-KT!J?1LWT=6UW<5<
MZ((ZN%-/"&]YL:*+ZIZX5WUQ[H#7Q:[J8VVUQY.OO9Q^AQ]3@??W =0?*OW>
M_P 8=WF_*!X#W =0?*OW>_QAW>;\H'@/<!U!\J_=[_&'=YOR@> ]P'4'RK]W
MO\8=WF_*!X#W =0?*OW>_P 8=WF_*!X#W =0?*OW>_QAW>;\H'@/<!U!\J_=
M[_&'=YOR@>!_._0*HLZ;XTMCN]KOG7;&FV?"&]YLXUVSC/D[9Q[H'W_%GQ9\
M7ZO \"(^#TKT5%(P,E-X=VI%)QT>"L)'($?"!]XV"1T\S&MFY<RDQ3[ ^;9)
MDR";A[HT3_0-M5\(Z_H=,<#(?<!U!\J_=[_&'=YOR@> ]P'4'RK]WO\ &'=Y
MOR@> ]P'4'RK]WO\8=WF_*!X#W =0?*OW>_QAW>;\H'@/<!U!\J_=[_&'=YO
MR@> ]P'4'RK]WO\ &'=YOR@> ]P'4'RK]WO\8=WF_*!X&>0[J+6,! (1F)RN
M_!@9!^<*^84[)7J3=.B\F.DI/(S!(H6GSXJ5,'Y&8*G#14F]=D"94B\?/7*[
MEPJIL'1@'7-=( [UG5@7LL<S,+$4:[H]AK:VTQ$UK!DZT 2SEG,=$?.(012-
MHK8VQEUJLGOJ^W4>X<*;!FON=XK\?+[_ (0MR_TTX#W.\5^/=]_PA+E_IIP,
M_KZN(W6@TL-CFY]SJ=/.9*9(2>42&7FB9IVQ'#57;PW)B10FKY(\2.:(H9=>
MQT$&J>B*6GZ+R@SS@.!YIK)# <MD1KY1; U_D9KG*6,;$,-5?86N<K;:HX\;
MGS6/&KMJEC_]YMC3QYX&H2GJVN2.A.I10=U.NBO>Q P]4GNI;PDLXH)[F?#7
MD;R/OA2SI%&>PLJE]J#7Y9V],QH80 2!,2>8QLI&QH?(0=[##<;P/X4335US
MHJGHIIGQ9SHIKKOKGQ9\>/'KMC.,^+/OX][WL\#3_4/8"I*)[/=GMK*.DXZT
MD8\*/!N1\'G4H'NG\<[1]WWQP9[,AT9/,F9(6RE<;?.QSQ9L]39'A3SS&6SY
M!7<+:_[(+U,^K[9!SQ9__E%=/XO.!B4@[F]*I.0&EBEB3),F(:OV0]^&A/8^
M-.V[,HHR6(-O/QR)B5%D7:HUANJFOLKKG9JCG&,>3P/I&^Z?2V)J%EPUAR[#
MDZY;.RSLK NQ,B>/G+1HFQ;*JO)##RCK&R+-%%MKC1737S***><9U23QJ&4_
M[(+U+^4@Y\T=T_B\X#_9!>I?RD'/FCNG\7G A.#]B.A]?7%>%Y1^R)MZ\=@L
M5OB?^SJTN5R'\561IU%(MZ$'ZUBEN-_WJ=K>D?+<N_9;GR5M?,8U\C(:U1?2
MKP+HN<UW/=9[?#]_6R$30$AR@2XWT>*YACFQM@^YY@I3>%W*>PRUYR#?#V#T
M:(=,R^A+([23L&$@;!D1KK#X*.15K!JP.]CNXYD/4QAJYI<J9DO8PT:I6),X
M [JY&L:LU+U<^ Q2"Y@CO(1QA $M+WJK,,=>2UQ(X^!,#0R EUX\$3(+'D\Z
ME=F=@I?&Y9(2LQ*TC)$^PK^CLS8MU\9=7%ILE"DZU;N]I8WI9LYBS8V[.NG>
M%BCXROLN62&/!P62ZI2GP>?43>:$8-=5Y6!+9Z-@,;/3VZ %[6+-?4>J0CN/
MUG7X\NZK%@DQA\('$B^PEBBS]FNB!HP8.$2Y8@N]V"X7^R"]2_E(.?-'=/XO
M. _V07J7\I!SYH[I_%YP'^R"]2_E(.?-'=/XO. _V07J7\I!SYH[I_%YP'^R
M"]2_E(.?-'=/XO.!7NT[9\&+=LA;RRUVB,YD+0:@':E#=2WXJLV%MEG#A%BW
MT0A:""+?1P[=+^0FEKY2RZJF^=M]]LY"5H%WCZ-1&'Q^,5]/G;"%@F&HR.L1
M-6W6]&LAS511/1HR<[P1UMLW;;X413T]D*:H8T\QKY&J>--0R[_9!>I?RD'/
MFCNG\7G A3L'V%Z"]FJQ*519\^FNX!Z7C$G%%XQ +YBTPA\T@\A&RZ#SF%R@
M3 424=ET.E(<6? %FN^<MW[)/5PBZ9J.&JP5ZKE'P=E?RRMY^3[$=G+8GU:V
M!9UF#YC<^+_L(L;DULURSJF2ZEVI&L$ 8X"WA X>-"QN&"(F#8KM-22K%V0<
M/7+H(DJ&A/!(TB_CCN#V9>VC2$W7 KP@8$N&N\G'H.7K/,\S#HA'!.]3IH(P
MH?FQY'JY3?\ I"6%F^@-B6EKT?'@S5F'2@G7;P1M:6;7MM0>T+\CLKKU/?R/
M1H:Z6HV8O&MA6?:$8(SEHA4*:AES#);;LO< T&KD8-(#\!!$P82D:"'-D0\,
M#UP\&@!A$9@R?<?O,^;P:XR5]P&2.B=L-9K";2E NS@EBRD+)PM!"2#DG:HB
MX9^RL4C(,FRI[)G+U(@P)()/<!D%8]>O!%U(/@ V*65>6[>MI13,OCFQB/7&
M3<;&*)JZP:A@VQ-PI3R:K]',1LR2Y.:[[:*E"V6!#SS?V-NBN$4B^B_@7 IV
M+2$=9?8A%]$*G$4V*35%W [;;101UADW475=RF\I5QOL8>4Y*'3-=P@JW8M)
M S:G0PX6N[.)& N]U(/>#MZ;9G3RO;JO2=26Q&5> Y#-;H"7O8TNQ$*EC&8?
M64''%7E9,=&46A8%1TW&M=6V[]X[?ORIPD6*NUGFP3W;?<GKI98*&PR&38P6
MD!*]NLSQNT7K2TP[71B [&57(CC]\6.PD:&&#A((22*D7Y-^T9M&+)PNNOIH
MGG/ O/[8M;?'N#_?.!_#N ]L6MOCW!_OG _AW >V-6WQ[@_WS@?P[@/;%K;X
M]P?[YP/X=P(9M*80TU->M[$)*(R6?;7IE7#,4;%OW>4DZ9N/*BF&[1RJME-/
MQX\O?R/)U\>/*SCQXX%GN X#@. X%5>[=DVO3W5JYK1I;>%H3R!PLM*6+R>,
MBA0&R8AFJKXFY3#"5F:Q@M[%1W1$L71(8-P\63>$'"[9IN-?!:C3.<Z:YS]7
M.NN<_P!G.,9X']<!P' <!P' <"EO;3L%;=";P\O"8)#91&2)$&)79'#S[2<6
M7-I', ,>!4W448"X5?[S4J#>2*5[RDPT?1<(QC_B+LTA2AD_'@_CKAV/G%I6
M#.89:<>TJXXFXG)BMZUD-=SF&S0Q7,-L<I!]9WB0RHON*F@YZSWB!4CZOQL'
MK'U9B$35V(,"8LB]"ZO <!P' <!P' IKWO['&.LW7F73.'*QQO91<>>!UJ^F
MN%M(*&E+6*2"3^L,U<I+-=4P($3'B1'4?L]9+R<RD(AXYTD4D++?4*CUGV^[
M$&+\Z\").-//J_OF60R)QM(35CO%5G*L.])"O81U=PFY41WHIS8GMVQ:1P)U
M!&LL4;#J]0V=;5MJZT1L)0-P7 <!P' <!P' \&3OCHP 4?QD$A)CS5KLJ, N
M3*4?;DW.-M<8;*FEVC]$=IG3.^^7"C-QKCR/)\W^B\> U]QWPA2I& U=9\@H
M.61R#6E9&E>Q\_I.H*61D635FMJO@9BMANKUB?LO6=N]B$[#"0@9J2Q50M6:
M>;6R\'"G0;(N X#@. X#@. X#@8$2JNL#+]T5,5Q BI1\KE=Z2)0^//G[Q;.
MNNN5G3QT.5<.%<ZZ::Y454WWSKKKCQ^+7'B#&D.O5%-CQ22HU!7.IDR+"AB+
MG,1"*(K#H\Z./1**;!1GN.:J-W,D,;JNVC1!X]U<HI/UW*3 ?HU#V/:8I[Y*
M*U^\6+_17 X]I>G?DGK3[Q(O]%<#GVF*>^2>M?O$B_T5P'M,4]\E%:_>+%_H
MO@<>TO3OR3UI]XD7^BN!S[3%/?)16OZ_Z18O]%<![3%/?)16OWBQ?Z+X#VF*
M>^2>M?O$B_T5P/&.]>:)DK!,:9J"N7+-(J!-III1$(PWP2C)T;)0J^5Q[-JX
MV3;&1#!RLTV5V9OT4=V!%N['N7358/9]IBGODHK7[Q8O]%\![3%/?)16OWBQ
M?Z*X#VF*>^2>M?O$B_T5P'M,4]\E%:_>+%_HO@/:8I[Y**U^\6+_ $7P'M,4
M]\E%:_>+%_HO@<8I>G=<>+%3UIC&/J8Q!(MC&/?\?U,"O%]7W_[/ >TO3OR3
MUI]XD7^BN!S[3%/?)16OWBQ?Z+X'E!^OU& 6KAF+J&N4&[HJ;-+Z*P\$\VW)
M2(N].EUL*O63E5--P4(O%TFB>^C-DFIHS8(-F2"#=(/5]IBGODHK7[Q8O]%\
M![3%/?4]JBM?%_[BQ?Z*X#VF*>^2>M?O$B_T5P'M,4]\E%:_>+%_HK@/:8I[
MY**U^\6+_1? >TQ3WR45K^O^D6+_ $5P'M,4]\D]:_>)%_HK@/:8I[Y**U^\
M6+_1? \9WUYHE\9#R!S4%<[E@"!5L*<:Q$(BDW1-:-$R.JK)%FFQ>96T8M<)
M[OFSE1IYO;+/9#99;*@>S[3%/?)16OWBQ?Z+X#VF*>^2BM?O%B_T7P/2$5C6
MT?(MRX&O8.$+-/.^Q28B)@1I%MYY+=!;V.]9,$7*/G4%5$5?-JZ^<24W3V\>
MF^V,AG' <!P' <#Q)+&H],@!B*2T&*DL9D(]R).Q\ZP;% Q@6]2V1>#B8YXF
MLT>LG2.VR2[9PDHBJGMG3?3;7.<<#V\8\7O8][&/>QC'ZG <!P' <!P' <"O
M5C]:*^LZTX-<QLK80F?5U'S$8B9&*3V0QUB-$2$@Q(R!/0,R=>B\/#FPP>R+
M%$VJ9-^(:(B'#O<=K[&X'JP#KS6M;S$E.P+60/I*]&E@0U]*)4?E?JE&CQ[2
M4'8O"]#[]]ZL1TS(4&10B+&;)(.5A89'?'L0,+;- G#@.!%AB\Z3CN#N9!<5
M6 L1>7@:^DN3%@Q(9B.SV4HL7$8A!W+TNA@1+Y&W)C5P,:(>QS)=$@Q5'LG&
MCM#90,Q!R^)R=W(Q\:E$=D+^'F]XU+60,V-+.XM(TV+(GN D;9@Y<+!#>@TD
M.(;BB>C5]JQ?LG>4,(.D%-PR+@8S#II#K#C8N9P"61F<P\XDLN$E<..BY-&S
M"#=RNR76%G0KIZ+()(/&SEHLHT=+:)N6ZZ&^=54E--0R;@= J+&G!9((98,R
MH<PP>"RPL@W2=L"0T@W4:/F#YHOKN@Z9O&JRK=RW6TW2614W34UVTVSC(1P$
MHJEXU-\65'JIKX)8.H5I'=9H+B81C)= ; 2. ,A>AANS3>Z,VH$.*"():K8P
MF'&L1FOB9-4$- E;@. X#@. X#@8Q-HYO,89+HBF7?Q]24Q@_'$SPKS7I0)N
M<%.QFI<;[(T40]GC=G6'K/SVFZ7LA%/SFFVGE8R%8+#Z=@9W5\+HU&?RB-TO
M'(- *Z-5^,'@5FIN.5J6CQ:-N@Y5RRR4ALF_\7FPIY(1*Z[C42KC84@*.,AI
MQH%QN X#@. X#@. X#@.!2M.)30;X01O+<R.SC,!D?567-5 I-XX6JF'R839
MU7HCF4;'L1K(./DQT?N<+$G99T5E!9!-5--]J #CQPT+J<!P' <!P' <#RCK
MA!H$,.G+A^T;-A1!PX=BFZKLFU01:+**N!S5!J]7<OT4]=E&;=%D[56<:III
MM7&^V$MP_/# Z_CLS@C*=IR"VZ_J=:QH";%T?9M,7%=Q<QO%*)NR*BIIVA&.
MW$;33MJ[Y#*Q<VL#T*TE,=$S> 5P(,/EIN^V/,@WQTB3E9JF:F+SN%M:XFI2
MMH00EM?,E,*LX/)'<:&KFHDUWQLIC+>.D5' E''G%,ZIM-=<J*9USOL$H<!P
M' <!P' <"*;O(V@,JV7.*9 :R.RUF3<?%V>S@"CE@X*/VHYY(TT).8CH$LXB
MHUT\DC2.E) !:25V*0 +&P^A'8DU#\_L1A'9X;!>K[=DA;;RU,C:WB,)'W41
MMU2U:O>P7N3*"MFV9DY!XC.ZGE;VYJ6?I +2WG5HU\1'02*M%=F4F 2IL"5#
M]+' <!P' <!P' @;M#LP0Z\W&2?UXA;&P&OI-)!-<. BLCTF,DCPQP9BX/4*
M@@Y7?*OI"R&)):)(*J:*9U6UU\:?CP&L@U0Z77ACTUKVNV-E2&Z(#+>N2LE?
MMA%FO64LB\KNQT4[ .:^G*!MY6U5(,]Y/.9A<$>. 7^LKI<> J4<N 8YAQZ,
MANPX#@. X#@. X#@. X#@. X#@. X#@. X#@.!^5#PCG0:\^Q??F]Z8A]9S=
MSUX[ T'%NYRUHCHZ>U@@+N%ULJ&_J!KN'.9>DEI'TIO("L\HNP <<6?:DE?:
MX=2%)CLF.W<[!4:8UIX20E35%6L@#[;==1_;>=]^.RUS1NJJ2[=2RY:V[&VE
M9X;;JP$LRMNK=L439H5S%:7")"HPXNDH_P"M8R3L]FETQ3(DD)=C@M_%8=X4
M-;PF4&]M:V>S#!B#L#JVYC1.,T!V0,4'8/7UA0422[ L)P:AW8T5T.JPA)K6
M:VIZXB['@EB=BHQ*WT3(U-(9+#U0(]J&3_\ @]];]S:-%@*[[?U]><6!E>L[
M%[UM'OP%LQ*J:IB@&\+%TLNL+7@)L6-C$6[('SIN*6,-E4R;XDTSK4RF$@>[
M:.PR1HO@_4%P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <
M!P' <!P-4/A'?" 3_HG+JQ=HQ.&2"L;#HON,>;.3#<UK)'78"B:A2MNGJZ%O
MFDA'BO1]GL0TT#JCEQ:A5Z0&L]!9@>IG9!T%%(9X=21P "M(>W$'K:'ITW08
MW?LX(@#WT*N,[>3?MG/^LU95A#)/:EC X+#X#($Z<LZ8$3UH21JS$@F[$^6F
M0<2+(ZO0D63_ /A'O1".517UDZ:E"I6:'+N"E(0E;W50/ZL8Z\/ S*RWK&T9
M+V!"T;:GG5))'EJX%4M9MB';8:%DG$ %F\-7VK8)#H/PRD+N?O+/.H@8(/G*
MLG*4'(>MK: H)#9>ZHBRNLT4OV?7;;^TPF+5@TBT06E8L..0C8IL?(N";(&/
MCQXFV)O6H;P> X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#
M@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#
M@. X#@. X#@5 [A](:2[Q *>C5W)R?872=\5YV"BND5*#A2I&4UVY=J-XU(U
M"(4U[/@LJ8$'X&:!&6HU\9!/'+%N8'95RMP*\2+P1/5*1N^WY95[:XJ1=RK=
MJJ]IA)PDO#LCM6VG2KI8U7,HI-SO%7#>+J I>^-3?8?)VLU%D9+(C^Q%FZ#$
MU@V ^TL\%;6,M8U617[(=P1-O58E:@Q'L6(M6(XNB7Q*ZGHTE8\"D;TK616
M!H65( HZ^CPBM:_K]2N'D>#N:Q=PQ9MONL'?V\%'UDTO\AV@8%K6&7BZM>CK
M:'6"A*0#Z2@'U&U4E2K.',#QR(%CI*!657?LT-;065%)&^E3@J_+L"X(MAD\
99ALQX#@. X#@. X#@. X#@. X#@. X'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g16439g47g88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g47g88.jpg
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M 0$! 0$! 0'_P  1" #: ?X# 1$  A$! Q$!_\0 '@ !  $$ P$!
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MM3L=T+)4@$.YE%8LS>8K&*Z4Q:1QFIF,.I&+.XI!HZD'ZS@27CHO+!EEH0:
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : : : : : : XEET&R8JN%DD$B]S*+*$23+]ISB4H?O'0%B/\
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M2?%'VAWVY5>C1$OEJ/F+=;L<TN*=V? &::K74)7,T,E-X7<3%EGZ2PA(2)S
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MM4A;0F\MFX:LX/RE!9<K5TP;=,-P]MP?EK.5?R1-T_(%/8R\E7YRNXM6-"+
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MR8UB;9+^E+:NHL\PG&[1E &[+:HK9,I4XNXS"/TIPC$2T_F" -DRGDD\:0D
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MY"M?H\DF-H/)RLW&K-VSMLP>,F\RY;QJJ?B-<3[%_3JS-,1/%-LQYRFL=+%
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M#D2()  JN5N.$D2B/[0E ;2I<>?0S4X7L8LII/Y5\ZFIA<7<H_."CEP8! I
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MBWQ.RY(JK9J  7MV[<!]@?/]WV=_GIS>%=+;KS]M"3%EXO?IR]_0N!D@4#%
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M=9+86;0ZJ:QBJ)*)&4<+M.Z6FHXE':GS.M<]XV.*Q*5:JQ9%;+=YN[8JIDS
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MXE9-\S:W[)=LHF#:6_R=D7&>%&-#JF2(+$33*^6Y?%*);A<[YF+)L[%1&'Z
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MQ#$ZYC#R(N"H$3<"(B8XCRL0X\F,)A >3#SSJ/+ZLZ4W2Z%R:A1H!H!H#YR
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M6[S7I:I7"$CK'69UJ9C,P<LW([C9-F<Q3';/&R@"FN@<Q"B9,X"4W' @(=M
M6O;<08RO437:_;:5 SE<JDHA,PE:>LB&K3=^U:.F351Q7R=$/(HM47BQVK21
M9.FC=T"+U% CMNW63 D8A")D*FF4I$R%*0A" !2D(4 *4I2AP!2E
M  #0'ZT T T!^BE$P\!^_P"6@/P\(!$#<=^2FY_<(?GH"#7:JB%FZT3&(<8Y
MZ41((@(E%U'"(=N_')2\_8'RT!L.@D1CK%/QY@$HM;!,)=(\<@49%R9/V![T
MSD']_'VY<NGPG$S;!59^*]^\DPHCRF7[.^N3SUOYJ0\M<_D_? #[0#4(. ^
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M-QB6CV=0AHUV_:1:;U?-3F$G*6N_?J1QIUZ<O;\71FUP'P#[@U@@X#X!]P:
M<!\ ^X- . ^ ?<&@/O ![ XT!Q+#PF8?E_@/\/;JK/2_DI*LKJB'I5(9&U5Q
MD4#&,M/QA@ /@V=INS^T.P FW.(A\ X#N.NO]>E/LN8>?'D\]+&:VN)W-"GC
M'_\ SG@[_LQ<O_%837I^ABKJO8Y5Y\/NS3%KN8&@&@)8PMFF^8$OL5D/'LH+
M"6CS>2]9+>8I$V")5.0SV"G&9%$P>QCT$R]9.M-=LNF@_8KM7[5JZ1S52JE#
M7RNA4VL'K@PMDA;+N+J7D=>K3=+5MD,A*'KD^D";]B90QTQ.F;@AG48\\OTV
M&?G0:J2,2X9/CM&HN/()XZEPU-3,:KOSV9V3E)EHY8 27"DJ" ])HNQ)@/';
MJ([@3<?#V' >/\.=6G%73Y,5YI[U):K0@+%+_J?E_ASK!M.?3V3*ZHESW+^\
M-"G!T&^'XA^>@'0;X?B'YZ =!OA^(?GH!T&^'XA^>@'0;X?B'YZ =!OA^(?G
MH#SZ^+\ AF7%W/\ T9*?_P!JF]>GZ&*NJ]CE7GP^[*OX/8".1\Q\?\R8#_QU
M73Z^*>K]A1GP^Z-^?0;X?B'YZ\QU'0;X?B'YZ ^@0PB <?PT!VB$ @?/WCH"
M-;Z< 9J?,JGX\#^7WZM.5WWW@Q6K.^WNU]V=3"R9B4@IC (>;/610O//<OKE
MVF AS[A%,>..WPU:_P"3\/8M'\26-9-'DDWQ_P#UM,Z?]M5O_#H_7M^G_"GH
M<'E]7[F*6MD&@&@,^-B6Z_(6"<B15)CXR;O=!OLVSCY.@129WTLG+OU$FB$]
M3FHFZ23B8>65XQ R+2<9I%;/5$%V["1C^7U*%4F\-+/3<U34T]T]/@]1X#R
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M7VA>IMCH^D0["S2PJ3\E#D=*12$TZ?O(MG'@_=)J5N>V5MO)*VH0: : : :
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MDWWT[6IP:;:6ONYN^\1IA9+(HIMT4D$2%3113(BDF4."D33*!"$* =@*4I0
M ]P!KF=CDT T T T! U?V\4&$SE?MP;AKZXR%=$82.8OGR*9DJC#0]7AZXLS
M@B#U^6\F!C%',G*FZ71VK@D4W*@U*]-(ZXGPJG3/5DA2WK[$\ZR4U,^)3O&<
MXLA#8+QK*F:Y!M<:"UQG&"PE=TZJOTQ*E'M%DC 9I8K(B)Q(L!BNHJ#$7B)$
MG,K%/F_;Z5'$^)X6%N_A>_B8KJBR\3&39AX:KF^-(G*6X-K(1%1=E1D*YCDI
MUXZ:LK4X%50D;,X3%)["0CD@E,UC6QF\U))'!RJXBV@(!);^I]6)IISJ]NGR
M9IHF[Q[F3NXO%T+B#(L,YJ$'&URE6F(;$C8J'9(QT5&2L$B@P?,FK5L5-%+S
MV96#XP%* JJJN5#=1@4,.*7*<NZ=^<]_YK*E#Y:$?U"JUZ(F[1:HYJ4DS=%H
MM:9<B)?KA$QZ4>T21*!0\M(0*JY6X$3+.W*JJAC?JP+N;);&21-0&F;(LQ9\
MR[KK%<7M-GK=3,"2+FHT>LM(UY*1R$JRFV=?E[>_9LVRQ"O;'=GS&K1+IZ4X
ME11C6#%0BLVL@OJF+M]-,^/C'1C3'>G3\EA77?'NUD; ,?2FAH>/;."LF46@
MU#S@,10J!&X(>4!P4%02I%)T=768" 7J$ U7PKX4OFKO3&+@J5LSU=\YX[GL
M=YYIX'L$:#A%NY=-#-I!A*-#J(.$1$R2;AHZ1<H&15 !(J@LD8! BJ7U4;3C
MDYT]IC=XQ<9][(,A6FXXB/7+N99Q9,:RWT.+*.E/,>SU<18-'=9F'O( <78Q
MZYHIRL8#&=N(E1V<YUEU1#+4=]]\K@N7<?@=SD^'6FJH]<L;@Q:]!H\'JR$5
M:62(=18Y\B*I6J4BF <1S]0H$/P5D_-Z/Z.Y86FJ,KY0-8=#Q==;S=24N%C7
M3.;9NCEEE7B:[0E<(T7!-T\E3B0%6?H:H= )]/I*KGH;MTSN#D(/1U*)RGZ@
MW0XVQ[%XUK+6OQ[M]*. X7E9J375</Y9^8@%5<JF545]'0+QT-&21Q1:H@!>
M55C+N%N3<O$<@7_J : : _)S 0HB/[OMT!%EUEBMFRH ;V%'D Y$1'N   !W
M,81XX .1$W8.^@-I&WB@J8ZQ/681XEY,P^15L,\40X,66FS \61/W'Z[- S9
MB;N(<M?J@4O!2\:WQ5-^"\+':E12N=_/OM$N2T6SFXQ_$/T@69R+59HX3$.>
M4UB"01#X'((@<AO:4Y2F#N :SBZ*U*@P\CBOJI.OZU*"8KB-7%--4W8KQF<>
M6CQ,1["1PATF$0_95!1,>#$'7;*MKWZ>N-3C$.^GEOZE@[L:,7*6 [37/)]*
M*F^JTXJB =76V@;+%2KM3I >?ZLU;+.OB7R0,' @ A*/VUIM9E.;7CEH]-[Y
MBY\L/'QU,!F#24B*?#T-S7JO.5B&:^AL4))&3])3:*UZ]5YTU*\;O4%TV[E*
M_2,@")# DTDVB3MD5 [Z7!_TM+:;6T=4[J8TCH$XT3Z](SG\E>1L=D;S:<XA
M6ZJ@Z33D4R($]=J1[+UDV,U47A(MS)N(N">)<C*E=1S%)5Q9%7%@D/37:P%3
M13$.?)+SW^+8(?6:DNZ3ED$Z92B/;/#V&NRAF3*1:>LT[2TKT6HD1LV>%1CD
M$FM:BD$FT61F)OZUPJ0CGRTXTGONK+G^/LM1+[\/C:YM3H]?"ITNHU8H]1:W
M68*! W48_(1,6U8<]1OK&Y\CGD>X^_7!Y<;@NG4 T T T T T!U';@J"1A$>
M!X$>?A^[^?;\]5+\=?QKX38JYX7KR\?R1&]2>7"P,*S' <QWZW]:5((_U2/2
M,7TQR<W?IZ"&!-,W?]>JER EZA+U_BI[G,9<WG7Y%V]_;;E&AF1%QK6'CF46
MR3*DU8MTFR"90Z2E(D4"AP =@YX$1^8ZXG9*$D=_0HT T T T T T T!C-Z.
M>E7-_$<"FP<+>LX<P]729B[4$QD2F'GDS)R*K8P<B()E1.( "A==/Y4YNL]\
M\G+^-4:/V??(R#BGJ;IN0Q3<\E ?L'CN'Y!KF=%,7_WGEEL90GW]8H5EF8H2
MEE&T>*4<<Y>LJ;QXLDS06Z1X PH'7\XI3?5$4P P"'(#:5+28J<)M& +&K7*
M&JA'\1Y8MY)%=XHX1<=;PY&WK,[P7 J%*(.$DHQT^< 8YC*(+(J)BJHH<B?:
M5+6J^YQCOS^&49M0\GB\6Z3NB/T.M4S120:^D#Y+E-!83IE7,#8J76#@RCPS
M9$[,IW22BB =8I7?VW[0A]]VSJ5MY7,B/E6[I6/=(35;,:0(]%5LBNR6BED%
MR+&,=8/UB#@R0>7W,<QP3 AA$0TE>?W^1#\K](+OW.;.D-]A=J<Y<<PY!QS1
M,,6J5S%*57%KR1I]PMV3UZ0ZJF/[!'9-B)UC*4@F.59^WR1&L?"RKB?<3#5(
M7\,E&J>L.+LWU/115"G+:B^.=NOE!ILW(^%+NCP;B5KAO:"^R!G%C8-J.[O9
MJPF'=>P0JRJ^"<Y9*5R/C#%5[=9@SSCV<@C4-Y,R$*\SUC]CD65>U2+18)8.
MC9EI7)!"=]W.BK3<NW[J:M;M*'$+7,/S@ND/#EW=L=S&/,95VO3K#;-%[NZ/
MNWN]YFFF#Y.E)6Z,VE*X4NL]5+JVRVAGR07EYU!C$U[$TKM\AXN)\^0FWF7'
M,&BPC0$XDTYSPNE+K5.T6WGP,D;[X(D5::!M@I$/GM@Q'".T""V5Y'6L6*[-
M+U[+&,(J5A9UW8(NHU/.6/V55N$G)LIL736\OLR4-XVL !-TN;?0K!^8..[<
M9JXE>Z?5I^D/F8TN/#5W=3V[!7'=2/?<.[6*WG#?[F:J9?D&.!Y1]3)C>'MV
MROC-"T8^M=>S#*9>ODXUR+DXMEA*7>,-XL:T6$B'[&8R#?')*F\83Q[[\>8X
MEPN8;BE1>_"T[VC"C+DRKQ%X.MRQ;9ZGD#^E% R]YK6Z#;YN37<'PI>7T#**
MX7P'D?;O8:HZ^G.YB^WUV[O]1R*[G4K?,Y#F%ZM;6(N"P<[7G#6M15(Z\VRF
ML[M/;=7M>^'<M5CX($K 8L5PI6=UX1^.<GX#Q%MTW0-Y#!3*7LN2:1AC)5^R
M!69/$D^OE%(F#[/(-,CV"K3;M_'94BU$/0+#&Q,=8&"+L17]27,7XFU>RE)0
MU%\<KF2=4\/>/Q-E+%^5D\NGEUL9[H]]NY<(7Z!)QPSBF]E:S*+T]24"X/3L
M2XV)8B()6$6+\]O+'$ZX:M J!4&;(Q579J,4TKQIQIKZ6S)G/C6./.V>1M*Y
M1%G#@K'1IAYX4DG1/ZZJ3W"5JR.#?GN4QWAP 0,B.MU6I5.]WWU]CE2I<[0E
ML[03]K!T&@&@&@&@&@(OS3E.#PIBR[90L'!X^HPCB039^8"1Y244,1I"PR*@
M@($7F)=PRC4E!*)4CN05.'ED.(6E<32W<$;A-FF[8;MJE]Q>09[=UGM#UY&O
M+3(2U6BI%$3,K9:TW9A<S*[5?K3-5:HN0D;"QI>MFXD&8,S=+&"59ON_U*U0
MOTZ;6OR7R]7\F*5+E_[_ (;X=><Z$*9^Q>7*V.I.$:D3"PQA@G*LX/P44YIB
MFH*;85![D1DT#K1ZW<" #@BI^?*#6J*N%\G9Y^QFI2N>AJQJ<NJ7K9/4U6CQ
MLJJU=M'!137:NVZID7#9=,>!(L@L0Z2A1]ABC[> UVP<25$5 4( @/\ G\_Y
M]^@(,H]!FL=V>U7"J-(]9[-3C]613DV:SQL]:*6M*S&:N4T7+0RJ,F*"*3WJ
M-YAFSA8[91J\!N[1KAI)X72;J'#?B_E KIDK-ZM4BTH*NM$EX])@Z7CS6R/=
MO!1K\+606>.&%H;BX15BH&.(\A3A]')%9!-61AW7E(D3D4[O,_Q3W>K>Y9]H
M](*R\=W.P BUD*]4G*:,>Z8-RIQLT@5J=TP)%B^2*VGD!,Z38E5*4JXK-E72
MZ[YTW<.5/,!"W>FV+VUWL0KL<TDW%HM-KFF\>UE; WK[%TG'(ND43! )21$5
MA!V[>JBJH63%-4XK"97R$U%>M85%E7*9SGF"Y1'CN/8 [B(^[0&OR_[X<<TN
M4GB8JPMEG,UGFEWC2+F\;X_7/5<B3-6;."2[>&NYB %L:U%FS=EF92O,K$UC
M0;+,&PN9 4V2KOOOU*E,72DQWE]\.Y>P4IYE6$J^)J%@ZJVIE6+WEAB,_E9]
M$2*B4<69;,J#).\5R[MC3Y67;0%RDRJFD(B7CYY%K7I!.'<',+"EJ\Z:3M>^
M=-[7N9B8.W"V.Q95G\!7]6GW&XUZFH7A')>)5%G-&?PRL@VC!B+C".7LC)8R
MOQE7:$BTJDA)3325@U?6,;-K*M9!BR$BTKI#S^?MY3F/H0: HLJ^(W1,83<
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MX)\UDT- - - - 1Y=,;05Q+Z2H!HN;3+PWFF1"%<=@$"IO$QX(^;_%)80.4
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MLNIO4TJ4M)ZW+\      X .P '8  /8 !K)H: : : : : : : : : : : :
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M8*&L\/)UZQ1;";@IEFO'RL1*-47L?(,7)!37:NVJY3I+(JD$0,0Y1#V"' @
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M.40J4J[A3M+GO"GHC+:3F+KT\/O9<S3]!6S*N8LK4JX[LLILO#WQ?M]LTB.
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MYHRLT(- - - - - - - - - - - - - - - - - - - - - - - - - - -
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MQ;NMU5]7VC5HSI*DLT3E6326GUG$@*Y>5"6(4*\OUOVC-/0R- - - - - -
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6I R:Z*9R@5G0#0#0#0#0#0#0#0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g16439g50q80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g50q80.jpg
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M=I?2(C$V-[6VMR0U05$C,CA"=7?5&3-A<9*T)BAD<H&BX?_$ !<! 0$! 0
M               ! @/_Q  V$0 " 0,#! $# P0" 00# 0   1$"$E$AH=$Q
M06&1<8&Q\ ,BP1-"X?$R4F)R@J+"0Y*RD__:  P# 0 "$0,1 #\ _P!_% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * TH" (
M+*Q,Q(2@6)R3]UL':V;E\_'(=X\<9VV@886S7<N&:BRN5L,<<+9*9Y7MCCCC
MT]%K6JR\OV926%U?;RR9^K'6WV>@_P"4X'W"DO+]LL+"](>K'6WV>@_Y3@?<
M*2\OVQ"PO2()M+6^NV^LMBKH 06@N@"%RR*R(M!IJHJIC\AFFJDI@QQS343S
MQMGAGA>V6&5K98WM>UKTEY?MD:4/1='V-YU#0H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0'^;+PMVR\ASGKQY#"O>H+J;64GQ&VZ3KQ>X^<_)#@UJN9.HW<>KX
MJ'?I&?')^A.E.P&L!)3[>'&)IJI%.1U0DE5'";N"CTU!UI7[&TI=R_L53B'G
MHO)/O;VY&C&UH41U66:!(N->O]Y>"^XZQ-[1VR=PE.R0SFYKH!1<G\-R"G=L
M,79(W%7I*V*!0JGP^<FMC1JR3DHD$'JKE[(OSG8EJ:?68K?9+]O:(T[Z241"
M?"U<U=1:AU(,NMBZ9W(?R$]R]F"8KV%$BPXN4;.UQRKP ('B*^?&_*0!R#S/
M$4(VYLT;B$;LK9@[K\XU%&#FBIT7%YPK)!;*6WUC]NBZPUUZ.5Y<)YU+H[B\
M)#S1  _=&T[/-(PVN8GPCA%P8'E7&M65E]+ XIUDF'FZ]HG&R.3NI-6S3^><
MLH'5D=&$)5J4(AR28BR)X72B\HT$%A%32]-9MNZ[1:WIJWUT70JCRJ\)_P J
M-@<?\8,CV)IOBP03_&GB?MT>AA^Q*IL?E$0[1Y(S(F>2O&;80OM])N,B8$&
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M .G5"D_H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M!N^31R822"2<A&.7D<Y:NUK5U?R2GHO@LS4** 4 H!0"@% * 4 H!0"@% *
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M(\H^2FF3LUY::+T 6BN[=&\"Y V<#&]M[AFK\R-\WU*-[+UTR=#L%,/I4/M
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MY?\ KIZ[&S=K_P!UNROW ,?\NR-#+Z/X?V)_0HH!0"@% * 4 H!0"@% * 4
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M4=8Z].NA_-[<MP_5/'(;Y%A$4\W*/[$F](C^KD!!N5/XTO=;_.@X& )=S)B
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MSCB(.9E$QVD@V=EIBK!KPC >&O1N0:R<C^-EM@,-@%C2)*8P1N?]Z?1=O/\
M!%Y?P?\ )7DMDR AON;$,MI+<CX AO;7XY/.&VL>3QPVV:;#D4K(R&+= T%3
MM<HD->'3ED[B8V'*%X4O C?.*BI)N+/C'M=-NJ.@HV/Q@F.P(M"(YMX8:A8L
M?B&ZBJBZB$9#,4(Y@CFNKEDJMFDU;)89*J99**98WSSROE>]Z&3-4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M"C9XS=(*:XR36;N6ZJB*R6=KX*)YY896O:][4GPM^1'E[<$6UOHIKJ4$%=;
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M:UK6M:UNBUK6^2UK6M\EK6M_5:@/[0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MZW::3I3*:^>FI8O9'A!.90OPTG^60,QXC[!9 ^U(@"+XYT&\M-9IKM#8OTN
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M9"W(X---:ASR$'Q?D1R+TWNCDF1ETD3R!<RB-2!>O]8.(W2C>!]'L(>:/-3
MCC5Y$H1/58M*#,BB3LW?.'.,=D%-4-/":7UEZ_5SZ+#;.\'5QZV>8%VQEUMB
M ^QB0RTWL&$.];&:H@1ZU,=%@93K %F-<JM6"\?#)W 38J%B"&E(^<'Y^)F7
M+=]$Y8X-_(@JFOC51X9 '/@F.'[@02#L(?8;1NAJW#6;>?:[$G+&*+U/D WY
M36VOB5K>7F5-PY;^;X;)5,EW*J2\MFLS7B5(97.-N%[F=.L]/$1'2(T-N!G
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MXJ_]F#CC_P"1&H_\@#]5]7\O[D71?"^QONH44 H!0"@% * 4 H!0"@% * 4
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MVFUS$>(,D=><?H]@9YO=O*Z':L+!0U'!4M(I&ZNW)_E%,#>.(^^02E,Y>:T
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M&J.\6S><C&TC@U?.QR8A)C)HBVE&WC$T]4*J72XJ4/\ /MT?E,WE5,B@% *
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M>KP:^@==[5I?5G9<"Q>=N!ZO!KZ!UWM6E]6=EP+%YVX'J\&OH'7>U:7U9V7
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M60XV:96(I61?:A&Q,\QP61D!U!$T:ZWD( @2>19MLQV4PXZ12JOT]*6FDO\
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M;LX,ZT9K.)8G#R,0?P[^8,Q"ZUGDU(WDQ&HE==$_*U7/3X.H5#(H!0"@% *
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M279J2^$A-LV,$/M):2FHM%P;A++[3'W"IEM)RE.J3<J8T777MN:Q7\("%1Q
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M[IT4,"M_M:$Q@AW39R9Q$*.:P9!_'_6?'_DIK>#06BKE1%-$&U34CY!NE'Q
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MUG91RHP'XMK$L\W&=K6MFOFW:)Y+9VM:V2E\KVM;IZ*VM$E@YO5MY)+0"@%
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MF-IV329R(DUQNXZ"3)HQ0U&);Q\)?G =2=SUEI4J=7":;;<*7I"_P7EK1@4
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M1T?9DS2FIO.8%1F"G).:(7\@K(R;QR]B<8Z(=-8] 9<:1A>XDM;0@H!0"@%
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B"Q_XHI8_&_ O7G;DXM^NL5[/(.ZQW_JM+'XWX%Z\[<G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g16439g56h33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g56h33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1[\4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #Q    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #P     $  0/      0 !.$))300F       .             #^    X
M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/T       2 #4
M   ! "T    &       !.$))30/W       <  #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             "B0   L8
M     0                         !              +&   "B0
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "B0    !2
M9VAT;&]N9P   L8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   HD     4F=H=&QO;F<   +&
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "2 * # 2(  A$! Q$!_]T
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M_P#V)C58<MEWJ.]-M;F&J&[=Q<QPLW1ZN[V[?I^FC)*1>A_PEGW_ .Q+T/\
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M=B_Z3\#_ ')*;"HY#+#5EV4U^MD,)]%A.A=L9L;].O\ ._EL1OMV+_I/P/\
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M+NKO-4X=8:7?IGNW,(;+=U=57J6>]GZ1OK/=Z5O\XF%_4?4,X8]("QP>&/U
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MRJDDI__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      $N34T *@    @ !P$2  ,    !
M  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (
M   >    <@$R  (    4    D(=I  0    !    I    -  (R+L   G$  C
M(NP  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HR
M-2 Q-CHR,3HP-P   Z !  ,    !__\  * "  0    !   "QJ #  0    !
M   "B0         & 0,  P    $ !@   1H !0    $   $> 1L !0    $
M  $F 2@  P    $  @   @$ !     $   $N @( !     $
M $@    !    2     $X0DE- _T       @          /_A 3!-30 J
M"  ' 1(  P    $      1H !0    $   !B 1L !0    $   !J 2@  P
M  $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
MT    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$U.C X.C(U(#$V.C(Q.C W   #H $  P    '__P  H ( !     $
M  +&H , !     $   *)          8! P #     0 &   !&@ %     0
M 1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
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MDI6QT=<C)S,T-D)'EJ'!&$-&4E6VUN$9)#A$5F)C9W*8U/%896:'LK72_\0
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MA[QXSRZ[7VWVWV[ ?'AX;T#TKU%[7OV2P[M;G>T].J]N^_']X'APMO\ ^V]
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MP_9%<'+C@!ZAVTVVZSF\AM1H(**UFJW$H@B-UMMQ+((: @HJ:6#*)J2C(R6
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M[VC%X?\ TLB_^C_100O/,61JC,A#4TE@L]-42<PZ?1BAXBW4DJ;*C83O'66
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MEI2D.15J*VC*\VJ+O1/2FU[F9<U;HK3< C$6RS9?H##D5=<R;'DDFF$XSA5
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MU'4PL+@$L_\ !IWEO4NQ9A<>LV-7S+L%2JWW[*;08,8&DG!O*)<ZP5I*(--
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M% X&X#0Z*_7F66S"Y90%<HSF5U!QYJJB;$-W".;^3AT>X8-NY&-G0AJ#1/.
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<@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g16439g57t30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g57t30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C04&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #Q    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B
M:F,    !        4D="0P    ,     4F0@(&1O=6) ;^            !'
M<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%5N
M=$8C4FQT                0FQD(%5N=$8C4FQT                4G-L
M=%5N=$8C4'AL0&8T.6         *=F5C=&]R1&%T86)O;VP!     %!G4'-E
M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #P     $  0/      0 !.$))300F       .             #^    X
M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/T       2 #4
M   ! "T    &       !.$))30/W       <  #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             !P   !&4
M     0                         !              1E   !P
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !P     !2
M9VAT;&]N9P  !&4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   <      4F=H=&QO;F<   1E
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !  * # 2(  A$! Q$!_]T
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M%,3_ ,]+T/\ Q4?^))O_ (9O_P"J7GW^,"M]7UGLJL$/KQ<5KAS!%4.7H/\
MBH_\23?_  S?_P!4DIZCJ?\ R??_ %"LAA/KU?\ &U_^?&+7ZI_R??\ U"LA
MG\_5_P ;7_Y\8DI\9^L/_+W5O_#N5_Y^M7MOU<_\1W2O_3=C?^>:UXC]8O\
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M765[7^_^9MLL9Z2);DY&:]V-@.-36DLOS(!]-PT?5C-=OKNR6.]K_IX^._\
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MZT%VK3^ZMS"L?;A]/LL<7V/K8Y[CR2:I<[1<Y]:O^5S_ .%Z_P#JKET73O\
MD_IO_%,_\])*?__2[[$IJNZUU7U?3M'ZJ!4YIENQKKJWN]2IC'_I7;Z;*K+_
M '_Z.RO8KN1D9M=KFTXGK,#"X/\ 4:V7@.(KVN_>=L;O4J<:RO+R<A[VN;=L
M%;&L:TM# ?IV_P Y<][WO^E[*V?S=?\ .OMAD7]19:YM&,VRH,):\V $OAT5
M[/W=WI^])2!S\K[7:VMSPUUS6D-V:#9CZ^ZM[O\ "/=_UM5_M76A,X>5(+@(
MLQ""&O+&.U:UWZ2EOK?0_P""4.I_5JCJ?4<?/RJF66X%XR,)WJ6-V/BB?4;7
M[;?TF)6G/U=J))^ST"3N,67CW NL#_:_Z>][G;DE-RBO*RL0/RC?C/DDT/-+
MB"QWZ-V_'8]GNVML^G_QJN8[W68]3W?2>QKC\2)69A=(?@.L?ATT5.M:&O.Z
MUTAL[?IN=^\K]3<FJIE88PAC0V=YU@1_HTE-A KW?:;IKL:TAL6.+-CM.*PU
MWK>W\_U:U+=D_P"C9_GG_P!)I;LG_1L_SS_Z324IY_6:O-K_ /OB63_1[/@5
M%PR7/:_:!LG06. ,_O-]/W)6#)L8YFQ@W")WG_TFDI'U6WT>F95@(:6TOVD[
M8W;2&?SFZOZ?^D]BS*74&M[>J&U^*S%Q'DVUAN.'$_X+T:VU^NVYC;+=C_T/
MZ'^:K6Z0"((D>!2(!$$2/ I*:++,8,L;6YH:+*B .S=M$'][Z*,Z^G[36?4;
M 8^3(CFM/EX3,IK ;+*?3)+32[8=6NK_ ._H%/2&4VLL&5E/V.W[7WO<TZ;-
MKVN_,_.V?OI*1]5MJMHJ])PL_2@^SW:;;/W)4.DV5UNO=8X,!#(+O:--\_2A
M7,W ;F.K<ZZZGTI@4O+&NW1_.L^A;]'V[T^+@LQGN>VVZTOT(ML<\"/W6O.U
MJ2GS_P#QN8N5GNZ.[!HMRQ4<DV''8ZW:'#'V[_1:_;N70_XNP[#^IW3Z,L''
MN:;]U5H-;QNR+W,W5V;7^]KV;5N9736Y5XN.1D50S9Z=5I8PB=VXUCV^I_PO
M\XDWIC!5D5&_(<,J=[C:X.;,_P!'>S;]G^E_@=B2GF_K.'V]5+ZF/L9Z#!N8
MQSVSNN]NYC7-70=.<W[%TYDPYM3 YIT((J_.;^:A'ZOL(,9^>';2UKOM#CM,
M1OVGV/=^=^E;8K6/TZG'R'Y LNLLL+S^EL<]K0_T]S*V/.VMC?2]G_7/](DI
M_]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     !+DU- "H    (  <!$@ #     0 !   !
M&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@
M '(!,@ "    %    )"':0 $     0   *0   #0 !L:P   )Q  &QK    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,C4@,3DZ
M,S,Z,#<   .@ 0 #     ?__  "@ @ $     0  !&6@ P $     0   <
M        !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H
M  ,    !  (   (!  0    !   !+@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0$P34T *@    @ !P$2
M  ,    !      $:  4    !    8@$;  4    !    :@$H  ,    !  (
M  $Q  (    >    <@$R  (    4    D(=I  0    !    I    -    /
M     0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M-3HP.#HR-2 Q.3HS,SHP-P   Z !  ,    !__\  * "  0    !   $9: #
M  0    !   !P          & 0,  P    $ !@   1H !0    $   $> 1L
M!0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
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M1TA256>$J+G4*4-$8F9H@X:'E:?_Q  4 0$                     _\0
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M9 F%#&6,/U4UHNQ& 60C#UA@N0YZA8SCKQG.,^]GJX'X[^W(_)K9/.BO]!.
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MJSG.<Y\8?%^/[O X]??_ +/R\#G@. X#@. X#@/B]?7^3/ V(>@@_P ';/\
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M,1TA:%+65)F-))&$:G)74YL:_(\(W$CM1AG40?DL?8X,P69CL<]D7C@4YP'
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MG';3$R(:]V3HLF9S@(<G!#X>SSD(%\!P'[G >OW?7]WXN X$DM-_KM=9OO\
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M\#GV[% _JNW/VM6R?]$O XQNQ0.?$KMS]K5LG_1+P'MV*!_5=M_M:MD_Z)>
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M_1+P./;L4#^J[;_:U;)_T2\![=B@?U7;?[6K9/\ HEX#V[% _JNW/VM6R?\
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M %$D-85AR)X1MZIF< ^CT-L>JYDH:R#JET>H_1F-N%I",4PBA]DJVV:C$T=
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M\MRI_K^R8VTRV'/)S"Y)'YG-=&)\2+FU4)L>&Y"Z(C#TQF4BY&G5D]B<2 6
MT/NC<W-Z/77S:S5'9J6W=T5T5^K,&\?JHU+5VFE84/+NCX$F@,T01Y-!MCXN
MFS*[.%)7HYLJ)V"^#6CFT?F3I+(OD^*HE[B6&RITW%L:].^H\BJ6<7WK_"Y
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ME*' I(0M?7]S;\'+G)24@3I$99R@S]$,*9,05C/^Y+#CP<">' <!P' <!P'
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M.O\ =\7C\?X<?<X#WO>\/[/@]??X#U_!X_#U?EX':B_0WOV''4W_ !UV_/\
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M%9W'6B80B2L,PB;^D"O8I/%W= _1]Y0C$, %C4\-:A4WN"40P# %0D4&E9$
M0<#ZPYQ@*AX$2M6_TR;>?*UEOS3TUP):\# OTZ%OP)#3L*K@#E76+6JRX=>=
MHT+)>NOFU5U4DZQB*V$^-:5ND:+7*F;7.D"M_=&MQ8SXR-(:M9VY5F3+2F?
M6%W$%XNAHV"<-AZ/M*2N,3U5B)K):6&0"+4W7O9W7:'*0?2HQ+NZI)&MI*FJ
M*6ODDZU.2O9R/,KE'L-A:)![)^R*56E("I=\-\=>*"M*+UK.-1[HW!FE=PI/
ML#.S::HV+W!C5RK%#TZ-+5<$S5RES:CF$+POADM.8&^#X>YLZ$P)_5I&81;:
M0,T,FL!G,4L^"PNRH(\I9%!["B<=G$-D"+L^XWR*RMH1OT>>$F#0%FX3.32O
M2+",&%EF8*.#@8 BZPX"K. X#@.!$_6KW0]V/E8%?FN:Q<"6' <!P/DOJIU0
MLKLM8FDM^>DK>K4-+(:XE-!3LX%$#&D;C'4XA22W 5GX 0)::G/ FP/)HBC,
M R'(1:TKBEP5W2[16]OP%DA;K$E+UE L8ITDFJ-_*D,ID<D--QW.RLYC6)N
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M*G0H$*<E(B1)"2TZ5(E3EA*(3)DY(0%$$$E "6446 ("P!"$(<!QC' ]G@.
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M %.?TP?DF*/.K3?I]P*9B_0 ]+#,RGPZ.:N'N)<<E#[#7@6+-J0CN211E9E
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M>['RL2OS7-8N!+'@. X#@. X#@.!$C>3ZVZ2_K^H7Y_ZPX$M^ X#@. X#@.
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M'CSX,^/PXQG&,YZNK@?GP?AZOA^/X.K'W??\'[. VANC1^L:U[_6T_?PWE'
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MG=$!18"P8V%B^<  $( 8Z]:*#SGJ"'&,8Z\^'/@\.>O@2NX$7*8]W[</]?\
M4_S$P'Q\"4? <")NBGUH.OWWNVO_ +U3P)9<!P' PBVE]>;M5_ZM&?@S]2Q#
MZY_!P/UP' E]T:_UM"WY0&TWYQ5E\"?7 <!P.M ^BL<__I55/R<Z>_\ %3'K
M_B^/@:UW Y]?'^7\OKX>!V[_ $-7V*[0OY-==?O7C@9,. X#@:MG29]6-\K$
MZ_#_ +#-'^#_ .UV7_)^7JZO#UX"$G7[^?AZNOQ_DSX?!X_#U^'J^'/6''C_
M "8]_KS_ "Y\'O\ C][P\#:&Z-'ZQK7S];3]_#>4<"=/ B7JW^F3;OY6DM^:
MBF\\"6G P'=,7>VYM0RFMT%&:O11UHN0Q%8"V=VU&MBW=2:4(X^RK@ EI:=:
M8G)HO,E+>C;"PR 4U6%3&)EJG#+4JC'=6,J3 JGZ'\D<>L?1%CN<_8]XV'NJ
MWWA++MD"G-PKA(EIVW!,#6D<*E9:WK&(PEDJ1L9&DMM= 0=Q9AOJ4]X.4K5Y
MZ<U&0E#.1P' LYL-<[%KI15NWQ)FY>\L515[*K <61J-1DNKX3&&A4Z 8VHU
MP.3H0.CR<G+;&[*P\E-W8J(P<: O(A8""Q'23O[A6U>26,ZKRZR+,M-YLPR%
MU%45[ZU6<)SKNGF1I=["LGZJ<9LX^J (&=:^-$631D$J-E;C*G=K;"VPHA2<
MM2A?ZR=S&*/TU0=I5#6TRO\ ?=I7*,-="5K$G&)1)]F9LBK647(I5N;]/WV/
MQ:)ML>K"$2V2.RMY= =:MK3L"(I4[NJ @T+VT/=<6V"IN"75%4CLS1^<,@G3
M#/)B4J)^C;@B6*VF01R0DI%:U"0\QI^;G-C=L(UZQ#A<WJ,I%BE-DL\80[T)
M.)/O3I:32#2SBA])"TY :2,)A8^KHX.CO"+L1@SD(NH6,XSU9SU"QG&?#C/
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M:LCC SR23/2EPLBKHSB86/"!GM3^L1()-"H[V2^2M#BI2*VH8#4"HLMR)-2
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M4ITXV&'L%=-B64KD+.G=3)LOD"AGET><5,I?&CV)4I5"-D:G<P+/[&-X96>
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MQ\U>!E?FX2S#2].:,I0,PDM6=DL0N!(_@. X#@. X#@. X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X'I@;F\M<<Z 0(P.:A.6D/<0)2 KCTI(Q&$
MICE> 84&)RAB$,LD9@BP#$(00XSG.>![G <!P' <!P' <"FYA#HI845D$&G4
M;9)A#98TKF&31>2-J1X87YE<B!IE[6[-:\H]&N0JR#!E'IU!0RQA%X<=?5G
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g16439g58k30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g58k30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1+H4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   )PDQP"4  (<G(Q.34V-S8< @4
M-$UI8W)O<V]F="!7;W)D("T@7S@W-#(Y-S R=C$R("T@7T%#($EM;75N92!&
M+3%?+F1O8W@ .$))300E       0VT6W+Y2H-K$1>82F ;2A,SA"24T$.@
M    Y0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L
M 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O
M;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R
M;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP
M<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U
M=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S
M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!X"$&0        "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  (#P     $  CA"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    '@X0DE-
M!!D       0    >.$))30/S       )           ! #A"24T$"@
M 0  .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              (L   +I
M  $                          0             "Z0   (L
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   (L     4F=H
M=&QO;F<   +I    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   "+     %)G:'1L;VYG   "Z0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ '@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8
M   ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    "0   +"':0 $     0   +P   #H #JL*   )Q
M.JPH   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z
M,C0@,#<Z,3<Z-#@ <G(Q.34V-S8       .@ 0 #     ?__  "@ @ $
M 0   NF@ P $     0   (L         !@$#  ,    !  8   $:  4    !
M   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    )    L(=I  0    !    O    .@   /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HR-" P-SHQ-SHT
M. !R<C$Y-38W-@       Z !  ,    !__\  * "  0    !   "Z: #  0
M   !    BP         & 0,  P    $ !@   1H !0    $   $V 1L !0
M  $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M01<D83(S.5%XM__$ !X! 0 !! ,! 0             ! @<("0,%!@0*_\0
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M(B*+T1/H4L6RT$"X)^T9P )B,K C1\]0E]T=7'0/:0 4)S@I5T56EWVF[.0
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M,>YR[:^R4S;8M=A!*#%L@(6EUY@0(DZ-*/:U,7!.TT9G.0 0W?TQM<K"O?\
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M'R"%42?A.Z"\$7_/?K;+P3X6\/\ 2E@MU^L.F($*]7"+_P 3<UKESIB@EQ0
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22E'2E'2E'2E'2E'2E'2E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g16439g59n65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g59n65.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( .0"6 ,!$0 "$0$#$0'_Q  >  $  00# 0$
M            !P4&" D" P0!"O_$ %\0   & 0," @8%!0D)# @' 0$" P0%
M!@< "!$2(1,Q"10B05%A%7&AT? 6,H&1L1<8(R17E\'7X3="4E5BE=/5\24S
M0U9WDIBBMK>XUB<X<G1U=GBU&30V9&>"AY;_Q  8 0$! 0$!
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M05[O;1C9<D*9JG<;2%:PW9TY#+ZU3:5-Q:SYCM6,9K<,E$/%&#2YR%,1RLG
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MP2<:+MO"%$RL5'"&M,YG%WDG>@>C2P]CK.51SQ"7+(:M@INYO<_NDBX%RO6
MKAK?NIQ=&XGN-:60;5QN_"IUN"BT'M300?HRJ$D8XRTI*-.AJ43:<-6NDNCD
MV,Z&1H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H#@HHFB0RBJA$DR!U'44,4A"@'F)CF$"E /B(@&
M@(NF\Q4N'54;(.UYMXGV,A#(BZ3(;L/"CP1(T+[(]798XB7\TIA$H#I45/=Q
M\DRZTM_ C=]F^SNS'+#5N.8ICR!%I-RN^6 ?<86[4&B7 ^8 +CJ$![@40$-:
MV%F_;Y,.MY+W+:<9$R8\$QOIEJS*?_@F<8V(5/R[I'5\1< \_P#?55^PAWY#
MD=;%.G=DVZM>R^#P_E5D,WM#;I(!^ %9% ?_ .H-N _7]>FS3IZDVGJST(WK
M);;\RR"N #R/K4>Q7,/RY%("@'/F()B(AY&+YZ;%.G=_)=JK4K[3,MY9B 2$
M3!RB8" &,D#R-7Z0#@1$P*/$3*#Y\@BD3GL!"AP.IL+>55OB7]$YRK#H2)3;
M21KZQN ,HND+QB41^+MJ4PD  X$140(7VN"F/P80RZ'E?SS,TJUG;SS(ER/D
MXZ5;D=QCYJ_;'_-6:+IKICP(@("9,QNDP" @8IN#%$! 0 0$-8B,3<S@>[0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'E7?,FI1.Y=M6Y '@3+
MN$DB@/P$RAR@ ]O+GG0%._*6N / V"$Y^'TJPY[>?;Q_=JP]'T)*U74]Z$A'
MNB]35\S<EY .I!RBL7D?(.4SF#D>!X^/&H4]F@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@*'8+/7:JQ/)V2:C(-@0!Y<R;Q%H0PAQ["0*G*9=0
M>0 J2)5%#"( 4@B(!HDW@1M+%F*-KWJXZC!6;T^(G+JY()BD<I)?0L,H(=@%
M-\_3,Z5*/M" DCN@W3QXA>H#:Z+Z;SMW?F>.!EUK*_GFA LQO&R_*&.6%@ZC
M6T!$03,9!]-/0*(=N57+ALT\4O(" ^HG)SV%,P!R.MBG>^/Z,;=6Y>;R/7F?
M\^2'(K9!<M@$>0!A%0K 0YX'I_BS @< /( /0 \=CF,/?5V:=.MR;56K]/0I
MH9DSB00.&3[()NX\&59G)_S1:" _5P/Q[#QJQ3_'AA\? EZOJROQ^X[/\68I
M@NC>22)_P$G P[DBOG_OZI&R;OCR_P!X<-QXY 1Y]H,[-.G=EVJM238'>KD*
M/.F2U4FNSC<H%!5Q".WT*\/[C&!)V,HU^)ND!+V >.H1#B.A9-E5;SN9&TS=
MQB*U*HLI*0?4R25]D$+.V!JR,IW]E*70.O']/2'5XCI1H !V,!3>SK+^G4MZ
MW::P[WR-*M<#)=J[:OFZ3MDY;O&JY0.@Y:K)N&ZQ!\CI+)&.FH4?<8AA ?CK
M!L]&@&@&@&@&@&@&@&@&@(/O6>*94IIK3V<G%RUXDTGJD97ADVC59<L>FFJ_
M5("A_'>$CTU4E7Z4<BZ6:I*$.N1(IBB.E2WNG#5\$8=487UT6A *ULDLDE4D
M'EG9S4:@]?,19P3UNI",W[!PHRD&*I6*RH+/F+M%5H]1?*J+-G"2B2B*"Q3E
M#HDEAU.;;>/&..';#]GK;1S= A2)(E "AP  4 *'?GL'8/,=:(>XJ)O<4"_J
M#0'ED'3.)8/925>LHR,C6KA](R,@Z09,&#%HD==T\>O')TV[5JV03.LX<+J)
MHHI$.HH<I"B( >:-F8.97?-8B<B)1U&%8&D6T=(LWR[ LJR2DHLSU%JNJ=H6
M2CET7[ 5RI@\9*I.F_B(*$4%(@]CYPTC&3N2DGC6/CH]LN]?OWSA%HR9,FJ1
MUW3MVZ7.1!LV;(D.LNNL<B2*1#J*'*0HB '3&/H^;C6$S#2#"8AY5FVD8N5C
M'C>0C9*/>(D<,WT>^:J*M7C-VW437;.FZJB"Z*A%$CF(8IA"(L[,I[>2K\JS
M>/V,I$R#"/=2#&0>LI!FZ:,7L0JHWE6;QPW641;.8Q=%5&0;KG(JR6243<D3
M.0Q02(.J#=B1)C9:/8" W?MT'K"4A'R+R+DV+@A%4%TSH*+1\BS<I"0Z:Q/$
M(HD8#)*]!N1C2:U19:W$Q06X&)BWD3!9'=1L)(S3I2/A)('*"",R[1;*NU6Z
M3!50'7K2;1NX=N"LR.44&J*CA0R:13F)S=$87W9_LW37KEG_ $C)!!=%RBFX
M;JIKH+$!1)9(Y5$E"&#DIR'((E,40\A 1#6#H=N@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@+0L%ZK=;4]6?OP4D!*!R1C(AG;\Q1$  QD4@$$"#SSXCDR)!
M#\TPCP U4MX$=26)AS<=\N-H;/=$VPK6ZOU'->4*U+V['U#FFLP_L=IKD&A/
M.Y658+M6'Y,-/4F57L#D[)W,*/13BW2J;=5),OB[5*F&[Z+Y_HS-;I=2I^U6
M;QQP]?+D+XQWMX#W&N()/'.>W61RVO(][Q'#GKT+=VL$OD'&=/;7^ZUUPZ;U
MJ.A8P8FIN6LNE*3"[6&EO648^!DY"27(Q-5LY)<7NQQTY+>2JFM7JM]LY8-P
MN_%J+HD_,5^Q+@''5FS!F:SLZ=C^J%C#V&SR;64DBH+3<U'UZ&;%91324F96
M2F)^8C(>,CXY@^DI&3D6S1HW6<+E(:[2U7K_ &8I3J:24O3A=\+$BQ3&"FHJ
M-F(Y$58^68,Y-BJNP<LEE&3]LFZ:G69/D&SUFJ=!4AE&SQNW=-S"*+A%)4AR
M%3_V6O+2)_8LGANQSUP(7A,U8!LV!GNZ& O$:]P5%4^WY#>Y&0C9Q&-:U"@D
MFE;;/?1ZL8C/BE!DKTT95)**,^5!DJ#-NX\1$%6THG:7IV*Z6JMF(=E$K%JU
M\/,B8JG.+3$# 6^BW&57@+)$1ED@'R+IXHQDX>;9-I.-??1\J0W";UDLW7*5
MPT2<D(H)% 2,*A-+/)-:J-,\UY@+TRIAIW6_E*>^>YS>[HXVD9*Q_A^XR\._
MOV38.YV&D5LK61CYNPPF.25S\MI1J[:L7<"4L"%H@U'+=\M%J.AE$2L 5!%?
MP\NE8)PW>'Y[LTG5#JB:4X;XX:>ADI 9"K-@5(S1=F829R@/T9)$%JY,;I$Q
MRMSG_B[SPQ P&%JLKQT\B %$HCETM?)I5)_LOC630T T T T T T T T T T
M T T T T T T!XY"08Q3)S)2;QM'L&:1EW;UXLFW;-T2!R91994Q4TR!\3&#
MOP =Q - 8%Y1WD"J9Q"8>8IO1 QT5;K+H'*P3$H])CPL6L4BKX0'_>W3PJ;4
MX=0@D;I*)^J^G_+I\O=Z\SFZ].NIA9,.9^W2*DU<9N2LDHJ;DSF4<&6(D'(B
M5)JV]EJT13\B)H)$  XY,8>^MX0E:+',YILR$  *0 X^7W\?L'0'>"/'N^WC
M]F@.8)!\OV_MT!]\(/E_S0T!\%(/\G]7&@. H /N ?EV_I#0'C7CD5BB51,I
M@$/(0[>?/S#S^/R'0%PTR]Y!Q>Z]:I%B=,FIC@HX@WAC/X-YP)>H%6"YCD1.
M8H>&"[;PU$P,)B!U<\FD\5YYU[E3:P9L#Q%NNJ=[7:5ZWH$I5O7 J2*3E830
M,NN <&",DU  B"IS=7ALGQDUA*!>A10YP)KE50UA==^AT5:>-GV,L=8-C0#0
M#0#0#0'6JJF@FHLLH1))(AE%%%# 0B9" )C'.8P@!2E !$1$0  #D= 8PWG)
MS^RK+P=3<*,8,IC(O)Q$3)NY+I['2C5 X%!F(^R=T >*L'4"(D*(*:Z4T9OH
M<JJYLK+,T!^D3V]Y9RCO2V4SF"C2L%E'#V&-UN4L66PJ#\E0)E2K3&!Y"N4:
M^2:0%8I5G+,0G9\>V%M(N2*.*_89M^U36<1W)%4[2C&+=SI]-I?3KVKIU4IK
M=#NMZ</BD8"X9ROG: Q#C)WDF>W4;+\!Y,O'I#LL3,QB;%\K8,H-]PTSN <S
M^(\37L QE?I&'AU:S/V>4A698.'B\B3T:>+4DG+=NDDWRG;%I7PS<+]'2I4N
MIPJ:ZH^FDGAL[-VKJ]M;8XF0,7D/TC]RHNXW).2<B9SQ?D'"/HP<:Y=KV)ZC
M2X"*@+?N9O>%MP$7*.I>/<TJ1ESV>O2C&LW!YCFK/XHD3D4*XG*1P,X1" =U
M-N;NRFV'GOP,[-"=*5*:J^JZ9<SLS3$8;[O%=3P+S^_&C7:]3K7<9NIN$?B_
M*/HRYVO5BR5>COJY=FFZ=W#1VYR"LR,3B>+?2M0J;-%<\5"P,A#M<9G=OGKE
M0'YTWR$EK-VV<]5)4J&DMBF73]2<;;/XQ>SUM<@'*.?=WV597=O47,MGB;QU
ME/;?Z4^G63$]TA)F4-59G'M/L#3", VJK';_ $BL8QL$G&MG9JG7*AES-%CN
M]8=-)NWR4?)R3-N_2W-[.;>G7<]Q:::5L.%*J^FYMF[YRXS;5,-.Q,2%KS=M
M8>;L-U$ C?*Y3,)9+]%Y>,QUIM!*(DRKM\0V<8PQKFJ!C4I=@5&1?TE2>):S
M*L'39:*EJ4Z8/'")CN6XW"7IL9XJ"?;7L4VFI?52_P"M6VW3UPYSH9;[FJ5N
M%O/H,LEERQ8\@67<)>\!.\FVUA7FJ:MC/+WV=+>D\1%BHZ&74<P55@IUGCEW
M&1S%-Z]C($XB],Y77>JUSL7;U[^,Q2Z5]=;*4*I+I9O<\[6T,<LB9 W2X4R[
M/8BQ]D;<=#Y$Q)>MG.,]DNW> Q,PD,#9VV].8?&,3F&V9,L<%B0*RLX:LG.4
M%+C/%M]"2Q:O5HM"$91B(-TU)=-J;J(63Y;\?V:2IJ2;2AJIUU3]U-5VE=S&
M"5G.^+0D%ASC04;'CZTW7<?M^P!=<W^E5L[2P86Q/)6^P9*SXIG]U^X[CFV-
M#XVR"["F6RGRUCG*U&%C8F+R&Z*LR++KE:MUX_,O5PYYN/ZDTU2[Q2VE])7<
M13"EJZP:5[P61B;*'I *.AM'Q75[-<,11E7VY>C]8X%H\Q!Y31J.2RS->@TM
MP,9=*52=I>9CWJ3;.TI6H6,+1E["2V'(EM#W- CU%P^>$LO)QA"O?YO\%=/T
MYK;^Z:OJ;6$J\TN76H6$12YP)OQW8<T96WQ[2GF9KQN)L.8:;O@W9M\JX4L&
M*W\9@G!-!B\9YTK.$Y2C7!#'$7'IQ=IHJE>6C)0^0+$E?C3+V3<)JOH=-ZK9
MEJ9F;K3#Q^,RTJ?IUPJ4G].F*IFJIMIU3?6V%K:GZ@:M;9S'S@H-?$DZVH?J
M>0AS"8[8H]S+PYC"!6RH<B8[0P^KK]NCPC]S[JI3XZGG537P9:04]%V2-;RT
M0Z(Z9N"\@8O91)0/ST%TQ]I%=(WLJI' #%,''EP.N+36)U3FZ*QH4: : : :
M : : : : : : : : : ITK+1T(Q6D95VBR9H%Y466-T@(C^:FF7N=590?921
M3*=50X@4A3&$ TQL@VEB0%/W^P6@RC2"!Q7H,WL^N&#PIY^0!#VBF 3EBFYQ
M >"I@=^H02\K,S"=$>BI2QN^RSOYR.;KG"WKR\YENQ\$W:!["0"<QA.=0XBH
MJH<>!%150_*BAS#^>HH8QS#W$P^>JZTM[[=8]C"3>%^QHB])5M1W=W3=S [J
M=KN,%[K;\%[9*43$[@EFJ%?+-98#<.YC+C2T%YZ?C%HUVI@;(&0)DLJ]11A%
MB(_1@/U9%PDQ4PVZG,8:'H^GLTT[-=22JJ<YV=/2S2_9!^W?T<VZG;_-8RI%
M7H%HCJ)CK=9O:FDINLY(J=2<2.-;;Z.&LX)PW=6\J65E'48\M.6H0(^'?/:Y
M+S57G2)6J<KR3! '2K9JT-5?4H:;;4NFC+-?4=37SN,?*1Z-C=C/[9<\X=LN
MV2PN8Y[9=CEAJ2^1)*ETK(EEOF.LZQ9<V.9& I6Y/)V'[L2O8;DK4K+9Z)#8
MHO&63RSQN]K,R^9Q*<7F//T7_)1M)[2_YJTM0TXO":RBFZ66AE\GLQW0Q6\5
MO,Q&%,C(W^.W_5O+E<WFM\MP1,3P?H](AA%-5-M/Y**9'+=/7TJDT>XQ'&@8
MM4@Y"6=!>U;/ZN 2!+'DJ.N!G;^GLXJ-EK9B^T_^6&>,S,62@P]F/1U[O&VW
MF@8^R/M1REF=R3T>6<,(XFI])S)0*RRVZ[J;5F#,UC6O5S:O,M5*!?15WQW:
MJ0U5L4*O=5'[&!<X_EJ\=G,+)JH;RGOU_9K_ "?3VFU4E]Z;LXJIA)*-S6Y9
MS),E,V%;Y&.[S&EOL,#E*,?P-SVN6&C9JK4GCQ_3,;87QYA6DUG(N'++)2&<
M8VQ1,0%CC+?7[-C*L87M,5DMQ/C;D[8FJ87S)LU:,CK^GLN]/_)-7NZJG?"+
M*'+?(OST?NRO<%C'=!M'N^1ML.3Z#:<3XJW6U3==G^[9?J&0*YG',F0I:B.*
MWD&H,$,GV>T.&=H8P[]RO8GM/JKY=)>.K,HQ%M3(Y;132YB.)*VJJ:U34FG5
M3LJ/QI4N&XWVSF<C]'#^$;.R"15$I@'R'I#D!Y[& ?,#%'N!B]P$>0$/=T5:
MSMYU/,Z6LO/0JL)=+-4CH-W9EK# E4*"R;DYEIADW$XB<S%X=0HNP3*83$:/
MA.<W2"*3M$O24ITISD^S\B_',TJHC-=UY/;(G^#GHJQL"2,0[3=-S#T' /97
M;+  "=N[0-PJV<)\AUHK%*< $#<"4Q3#S::Q.B:>#*QJ%&@&@&@&@&@&@&@&
M@&@&@&@&@&@+0O%ZK6.ZZ]L]ID$V$:T+P4.QG+UR8!%!BP;\@=R\<&#I22)V
M\SJ&(D0YRU)MPB-PI9J@RMF"X9KDC!)&6A*8V6%2(J3=4X)J% ?X-Y/G*(!(
M/A+P()"'JK;J,5-(1,/'94JG"[S?QN9R=3?#0L1LQ*0"D(3C@.P!V#M^CCMY
M>_5,E3*S,'P#Z@'[A^KW: [ ; 'GY_CW<: Y W)[P#]7^S]F@/O@$^7ZO[=
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M9F)&R+*78-)./7(Y9/4$W#=8@\E.DH4#%'Y#P/!BCW >0'7$[XGNT T T T
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MUP3L566>% IW"YB@9,!*@F!"$Z ]"6S98YO?\91)Q;E^Q1&S(  .0X#X??\
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M 5XEM_)HKY 9K\F%)$T02?\ H\#^L_1)Y0AV!7W1X NRB@!_$#C0%PZ : :
M\<C(,XIB[DGZY&S-D@HX<K''@I$DR]1A^)C#V*0A>3'.)2$ 3& !$;B[,9W3
M^0N<N,Y(D51:IB<D+%J=BQS0W >(J3D2C(.P JKM3N*?)6I!\-+J/U_%)*[S
MZ<,%YF<_R<NRCI^WOQZ%U-68$   O(_X/'8.?C\??^C].N;;G'G\>8%2VE$0
MK<7YZEV1D3XP@8X (!\O@'D =_+WCQ\N.=0UA9*_;B^A>A(I,J?'AI\\#V$
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M#YX)?C^W[] ="B \#R &#\?CYC[M 6O,1:;E!1,Q.I,Y3 /RY#W"'<!#L)1
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MP /?W\Q'^C0%,.41'D._X'0&%>3,>'I<O9I2087>4Q79K6VR0RLN.6R3W).
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M@(?9W_8/?W<_IUU54WS5GO798XG*&OM?+2>E^&IUX@E_H2[2$"J82-K$V%=
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M,$\3)?;U3<A4+"V.:CE:RQMQR%!UF/9VJP0]?BZU&.Y,J?4HBRAH5!K%M6[
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MWU@/XX#56*Y7P.D[5+>:3]/<M7%<@:,M<[7#]D)1J$PU#@0 ';(R;1X''/2
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M>XAY>>@-'82BULN=JL[D145G+%+/A.(B/)3O%2I<#[R@F0I2F*(D, >(7L<
MUZ(A):?'Q!Y\21T4NDH%#X!^S0'J @?7H!T%^'VC]^@'07X?:/WZ =!?A]H_
M?H!TE^&@'07X?:/WZ UIYTW!Y9I>5K=6:Y9DF$+%KQA&+0T%7W8HE<0<8\6
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M[M-M[N_R!T!\_L^[3;>[O\@= ?/[/NTVWN[_ "#Z"8"/O'](:;;W><P=AR%
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MN- =7EV'0#0#0#0#0#0&F/=!_=VO_P#[U"_]F877:C\5S]6#+3T97]VZG?\
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MS<-[/0&XK-5U&ZO3ZM)@8H*(F(?I-P B'/!N YYT^G?ZC_\ 8K_!<?D_._\
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MA<CU<2K(B=NZ42%-0R6I4OKS6O9AV;OKOQ)\^ <<<=NVLDF?G,: : : : :
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M0 >0*8ASB)^_3T ';J =*K4-ZV_:]_(JQ7%&?V=HI1I+UVRI$_@52J13TX<
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MBZ(?O>\!_P A^(/YM*9_J73;K_E5_L_D0M%T0_>]X#_D/Q!_-I3/]2Z;=?\
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M0^Y1VV+'>#C^NIQMY00,!U&RJ;PQ@B84!5%3K1">:2!3)*F4*M&1#E)0W6J
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MP$FZG?N)1Y^ON/;]8_JT!,VR>K*RETM]Z71_BD.R)"QRH\")GKXPF<J$$0Y
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M3<EZS%(4Q_9ZC$*)C$*(AW$I1.<2ASP43"(<<CK9S)&2/UE ?,0\_P"C]8:
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M[:,<D<0/T) 8.?%'@OB*#[1C%Y#I(!2ZYU5398>OZ-TT9ODODG'6#H- - -
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M^C0%#M=:K]XK<W4+.S^D:_88]Q%S# 5W30'C!T7H70]89K-W2(*%]D3H+I*
M ^R<- >FO04%58&%K%?8MXR"KL6PAH6.;@;P&$;&-4F3%JB)Q.<2H-D4T@,<
MYE# 7J.<QA$1 JXK$#W_ *>.WV\: Z3NTR@/< ^L?N'^GRT!2G4PBF41,H7@
M/=[OQW^(_,- 6/,6YNV(H(K$(4 'D3& "AV#SYX[?+Y>_0%5Q_B?(F9)$J42
MP<14"50OKL]()&0132,(#PD"I>H#G(/*8F2.H8O)D&RY0,8IM4PYEXQ?'3#7
M/T*DVX1M&Q-ABHXDB2LX1L5Q*+)@$C-N$R^N.SCP*@$$1,*")S@!C$ YE%!
MOC*'!-(J?&JIU8G6FE+>]27=9-#0#0#0#0#0#0'6JDDNF9)9,BJ9PX,FH4#D
M,'S*("'W>8: ANTX6@)E51]#JJP,B83'$S3I*V64'C@7" E,14H\!U")?',
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MNF4I"IHIE( %*' !V .P>X/(/(H ';6#:26"*AH4: : : : : : : : : :
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MB)N NU2\5YG$?HSLU+"'YO*:LZOD:)@=U2>X3,)#*-6H/4P, C^89DHN*I.
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M,Z9E<5MQE%5XEXO./=W+2KWF9MAEWZ:;K?HXUR.HT T T T T T T T T T
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M26E9F36<2$F_4*7K<O'BRBZZHF.H81'7!N7)U2A077H4: : : : : : : :
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MT;;F7CCO$*UL,"_-0HT T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T!THMT&Q#)MT$6Y#K+N#D13(
MD0R[I91RY7,5,I0,LX<*JKKJ" G664454,8YS&$#NT T T T T T T T T T
C T T T T T T T T T T T T T T T T T T T T T!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g16439g62k44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g62k44.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2AF4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&4D
MY6         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -/    !@             "&@   @T    - $< <@!A '  :  @
M #, 7P!P &$ <@!T #(    !                          $
M     @T   (:                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   (:     %)G:'1L;VYG   "#0    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "&@    !2
M9VAT;&]N9P   @T    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "@ )P# 2(  A$! Q$!_]T
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M1U=G=X>7I[?'_]H # ,!  (1 Q$ /P"SU5SG9C7.)+CCXQ).I)--:J*WU/\
MI3/_  MC?^>:U4@I*;%&!DY&+=E4AKF8[ZZWLD[R;7"MGIMV[?SO?[D;(Z/E
MX[\EECJR<1MC[2TO((JJJS'^F[T_<[TLBO8W]]1P.IY. "*6M<'6"QP=,$BN
MRAK3'YOZ7U?^,K4OVQE@6PUH=:US=^I(+J:,+>V?SFLQ*[??_A$E([.F9]1Q
MVVU&NS+L-5-3C#BX>G]+\UC'>LW\[]_U%&[I^=0+G64N]/'>ZJRT:LW-.QSF
MGZ3J_P#A-OL_POIV*61G&YU;V8]=!KO?EG87N#[K7,NNL>+G/]K[:MWIL3V]
M1=8;7C'K9;:V^H6@O+F593_M.90T.=Z;O5OW/;:YF^G^;K24QIZ9U*^MMM&+
M997888]L0=2WN[]YFW_5B@,/,- R!CV&ESQ4'AI,O+O2:S;_ #GNN_0_0_GO
MT7\XB59]E3*V"ICO2%(:3,GT,G]IU_YU_L?_ "$4=8R6W#)956,MH;6,@[R?
M19<<VO$->_TMC;CL];^??3_PGZ5)2-_2>I,<UAQW&US#8:FP7,:'FC])^9OL
M>W]"RM]GK?X-1KZ;U&QC'UXUCVV,%K"-ON88V6-&[=[]WZ/\^W_!H^/UBS%K
M%&-C,IQ@P,;2RRT1MLLR&/%X?Z_\Y?;N]_O38O5[\;(&3Z%5MS::*&V/G<!C
MSL>VQON_3;OT[$E(CTKJ,5EM#K/5I;D-].'16_=Z>[_A7;/YEOZ1_P#@]_Z1
M1PL&[.LK92YC?5?Z5;GDAI?Z;\DMEK7_ $:JO_!*?](CXW6+\>MM;*6PRFN@
M.:^QCHH]3[,_=2]GT&WV>HS_  R!CY)HQPQH/J5V/?6[M%U+L._='T7L_174
MI*7JZ=EVXPRFAK6&JZ_8XD/VX[F5W-V1_.;K?T3?^#L4QTK)AKGNKK8ZJFXO
M=ZA:P9!L]%M_HU6^A_,/]:VW]7I_TRF>L91L-GIUB73L .V"[%LLKV_N6NP?
MTG_AG(41U2SUVWNI:;&?S;F/MI>V++;]OK8UE=CL?]8].S$L_0VLJI24B?@V
MLQ693G#98QMC0UEKA#G&MOZRRDX.[V_]RU!F+=93Z[=@9ZM= W. )?:2UGM_
M,J;M]]UFQG]?])L+=F^O2&6TS:&A@M;;:UNCG6[OL+'?8_I6._P:'1DVXX/I
MM:7&RFX%PGW4%[ZQM_.8[U?>DI>_#MQ\IF+:YC7V00YY=6T!Q<S=;]H93;2U
MNQW\Y5_-_I*]Z(.EY)I=D,=6_'%8M9<WU"U[2U]G^AW4>VE^Y^9]FJ_FOTGZ
M9-9G/L<QIJ;]G8 TX[W.M+VA[[]MN9D^MF>ZRQWT;OYK]"B?M6UMC[:J&M<7
M^O6#9:[9?L=B^L)?^D9]F?Z/V2S]5J].OTJTE-2VMU3@UT$.8VQCAPYCVBQC
MVS'C_GJ")<]K_196#Z>/37167<D,!+GNY^G;9;_80X24_P#_T/0G?5SHC@TV
MXE=KF,97ZEFKBVMHK9N<?W6-0<?H?U7RF%^-BX]K! +F"1) ?R/Y+ELK(Z19
MF# !K:RYKK2*C):!3$L>]SO4N<[\WW^I;_I$E,G?5OZO-$NPJ6CS$)O^;_U:
M_P"XF/\ A_>A]1MS[&8]K<3;D.J$T';=8PV6XC,ENV6X^^BI]GZ7[1Z/_6E3
MLZEU/$+J;ND-R;&UE[KJZ[!6" PM;^AHRW6?X3U?0]6_U/T=&-?_ #J2G0_Y
MO_5K_N)C_A_>E_S?^K7_ '$Q_P /[U2LZGG-RBQO17&IEUE(&PEU@:6^C;58
M*_0J]1N^S]9?5B>_])G4WLLI6GTIS<W#;D7X3<9[B1Z98X: QN:W*HP\EO\
MU_%I_P"VO3ML2D/_ #?^K7_<3'_#^]+_ )O_ %:_[B8_X?WK1^RXW^A9_FC^
MY974+,W'SVUXV"S(QGMJ +:M6V.=<ZSU+?YOT'54-JW[?U6^VBRSU:;OT*4D
M_P";_P!6O^XF/^']Z7_-_P"K7_<3'_#^]4'W]9MNOH^P,P[/18:#Z/KL;:YU
M5;?4O9Z=+ZM]UOK,KL]6NC'?=^A_1^OOC%QX$U5D]SM"2G/_ .;_ -6O^XF/
M^']Z7_-_ZM?]Q,?\/[UH_9<;_0L_S1_<E]EQO]"S_-']R2G._P";_P!6O^XF
M/^']Z7_-_P"K7_<3'_#^]#ZE9FX^<QF+@LR,9XJ:2*I<VQ[W[G.LG9Z'HU>E
M8[9^JW78]UGJ8_J^E0SLSK58M-?3F56BECF5^B^]C'EY%CK;<6E_K[Z]K*JL
M+U[Z_P"<R:*\?]824Z?_ #?^K7_<3'_#^]+_ )O_ %:_[B8_X?WJ^S'QW,:Y
MU#&N(!+2UL@^!V[F_P#24OLN-_H6?YH_N24YW_-_ZM?]Q,?\/[TO^;_U:_[B
M8_X?WK1^RXW^A9_FC^Y9/4+<W'SVU8O3V9-#PT-BN(LV9=SQ;>?T55-GH8U5
M=O\ @K_T=G]*J])*2_\ -_ZM?]Q,?\/[TO\ F]]6XG['1'$P.?O6=GYW6J@_
MTND"MS6T%OZ(7M+G;SDM;9BV/>YN[T:*]V/3Z?Z6W(NIQ[69%&G]GQ_V[M])
MFW[+,;1SZGP24__1]563]77..->'/W?IG%HD&&.#+*_8RNMM6YCV_H]UO_HB
MK661T?*=7AA^0\&JUX;BENYSG2W=LVN;N_->^OWV_H_YVU_\XDI+U=N4XM&)
MN-WIO,5EK7N8+,8WUTOM_1LNLH]1E.]U?Z3_  M/\ZJ6[ZV5^DVBJMU!WZ9!
M:ZYH%=;J!D656MJML=<Z]EOH_P"BHK_2U^KG+39DTW9F.^HES'X[WM=M=!:Y
MU&WW%JA1USI5YVC(;6_?96UEWZ)SC4[TK'5MMV>I7N<S](SV>])3GV7?6]EE
MC/2ILK&QM5U;6DF+ +;K*;LFC;NQQ;^B];]&_P"R^F^W]9KJ*V[ZT6P_T:<<
M-V@TN >7D-)MBUF1MK99=7LI_1[_ $,CU+:O5K]);&]O:2/$ I;V^?W'^Y)3
MB],M^L[LUAZA2QF.YKO5C8&MVNN],LV7WV_:+&NQO;M^S^DRRWU<>[]61NH5
M]<^WA^ \?9G-J8YCRT-:X.NLLO;[?4=QCTWU;OTE-OZ']-1^EU-[?/[C_<EO
M;Y_<?[DE.+F5?6 8KC+[[G5UL+,5U=8;9ZI]2^HY'H/=MQW-?;59?^F]'T:?
M1]6UZM='KZI79FC/<Y[#>3C%Y9.R/S&TN?\ H_H^Y_H/]3U?U2K9ZV3H;V^?
MW'^Y+>WS^X_W)*9)*.]OG]Q_N2WM\_N/]R2G,ZE7UPYS+,!X^S$5,LK<6@ [
MWV67L]CK/8UE55U6_P#2X]]GI?IZ/T@<JCK_ -FE]C[;34UME>&ZNOWBPNWX
MS\IK=MCZ7,];UW^EZ=7Z']+9[]G>WS^X_P!R6]OG]Q_N24Y_2&=4;9E_;P2#
M9-3R1K/TFU5MLN:S&K]GI/?Z%]GZ7UL;_#9&DH[V^?W'^Y+>WS^X_P!R2F2R
M>H5]=.>UV X?9W-:TAY;L8X,RW>L1'JV-?<[$IMJ_P"*NJ_FK_5U-[?/[C_<
MEO;Y_<?[DE.&VCZR_:;B^V&;:3O86!CGAU!LKQV/]395L9F^N^VNJZS[37Z7
M\S7Z-[_O>_\ 03_T8KV]OG]Q_N5#</V[.L?9/ _Z1)3_ /_2]3L<QK"7N#6]
MW$QSI])#JQ<>JMU3&>QQW.:XETG^WN_=69];<;[5T2VDTC(:7UEU3F%[2&O:
M[W-J<R_M]+'_ $S%IUV5U8U1LVT-VL:&':T-)AK:O:Y]?TO9M98])3%_]/I_
MXJW_ *JA%MJJNK=5<QME;P6O8\!S7 \M<UWM<U"<0[.I(,@U6ZC^M0K"2FD>
MD8(<74L..7$%QI<ZN8$;?T3F;6_U%$XW4*035DO?M:2&/#7B1]%@:[TKG;V_
MG/S5?224T/M6?6XM>RF[:0"0YU+B7"6MKJM;;6]W_H2INZCL:XW8]U):USAO
M:'-]H+_=;CNOKK^C_A5;(!Y$]_N57-QR,.X4/-#O3LVD:@%_N+_3^CN:[Z"2
MF73<NO,Z?C9=;_59?4RP/B)#VMLW;2&[-V[Z.U65FC # PN>ZC+# TY=/#Q6
MUK=V4Q[74^[\RN_U?2_P%R)]LR,73J%8],?]JZ037\;JO=;B_P#@V.S_  F2
MDIO)*+'L>QKV.#F. +7 R"#PYI4DE*22224I)),2 ).@')24BRLO&PZO6R7B
MNLO96'$$R^QS::F -EWOML8Q5OV[TCU'UC*8756OHLB2&V5BM]K'OC8WT_7I
M8]_T/6L^S_S_ .C0^LXG3<[$;;EWV554#UF78]KZR ?;N;Z#OTOJ,/I,]EG\
MY^A^FA78W1\FOU+,B6=4R&V4R6AQL%+,?T<:6^K6[TL7U+/\-_/_ .#24Z[7
M!S0X3#A(D$'7Q:[W-5#_ +WO_03_ -&(/3>J]'JQL;'JS?7%CC758^9<98YO
MYK6UTO\ M.-]D=_,6LR<+[-ZGVG&]0W_ 'O?^@G_ *,24__3[WZSXUF1TYK/
M7HQJ \>O9DD-: 0YE7IV6-L97=]I=3Z?M_S_ .8NO_9&685=,LW,8!7;6P!K
M7;/3]2FIWJ,:W:[^;][/3_1JA]:V5V=&L9:T/K=94'M<T.9'J,_G=P=Z=?[U
MK?YM:'3Z[ZL''JR+OM-S*VBR_:*][@-;/2K]E>[]QB2D5>)CX^5C4T5BNJK'
M?56QNC6L8<=K&,;^:UJM^FWP_$H+_P"GT_\ %6_]50K"2F/IM\/Q*7IM\/Q*
MDDDICZ;?#\2F=56YI:X2UP((D\'0J:22F#JJW-+7-W-(@M.H(/8A0-3JW;J_
M<V27,)U VP&TZMV^YOT7(R22G/&#47.LP+/LEQAUM0&ZO<[W_K&)N:UMCMW\
MY2ZB]_\ I4[<UM)#.H5_97$PVW<74.)_=O\ ;Z;OY&0VGW_S/K*ZZMKB"9!:
M0002.)T=M^FWW?1<A[]K?3R8((:TV0 QSGG9LV.<]S?[?^D24RL].JMUCIVL
M!<8G@*7IM\/Q*R^H8EN%@9#^FD"6%K,2UQ% <XAC7-VMMMQVL_T5'Z'_ ('_
M  BNOMZ@U[MN/4^L'VD6D.(\V.HVM_[=24G]-OA^)53JV [-Z5FX51#;,K'M
MI8Y^K0;&.K:7Z/\ ;[OW%+[9E#Z6#<3XM=21_P!*YCO^BE^T6-_G*+V?]:<_
M_P!MQ<DIHL^K&&RJ6N+<P$O9D 0UKS<<YNS&#O2]&O(_P7^C^G;ZGZ56*ND!
MF/52^XN-5WV@O#8+GN<^_(W:N]MUUMCO9_-_01OVIA#Z;G5?\;6^O_SZQBA=
MU'IU@K+<JEP%U;-+&GWO.VJOZ7\Y:[VUL_/24Y]'U4;4:B[+>_8ZH6DM:"^O
M&-#\*O3^;?6[#J]>QO\ /^ME_HZ?U;['=@?MZ/\ NI_Z,6BL_P#[WO\ T$_]
M&)*?_]3N/K@^D]+;C7MJ>S(LAPNT;MJ99FV;'/JR*FW>GC/]'U*_IK0O;D6]
M+GI]AIN](.H(:TR0V65N9>UGT_Y7H_V%2^LV?;A48SV65L;9:6EEM/KBPMKL
MNJK95ZN+^E]2IMC7?::_YO\ MUZ]-@LJ98#(>T.!@MF1/T'^]G]1R2FL&7-S
M: ZP/BBP2YON+@ZC<]Y86L]W\BMBM0_Q'W?^9(+_ .GT_P#%6_\ 54*PDIC#
M_$?=_P"9)0_Q'W?^9*222F,/\1]W_F24/\1]W_F2DDDIC#_$?=_YDE#_ !'W
M?^9*222F,/\ $?=_YDE#_$?=_P"9*222G.ZC1D-Q"R@"QKG,;Z1.V-UC2][;
M'EWYI]K/ZBMLM+G!A(9807>FX>Z =N[1RE>QSV -U(>P_)KFN=_T0I65LL8:
M[&A['"'-<)!"2E0_Q'W?^9)0_P 1]W_F2CLL:Z6/T<[<YKA.D;=M>K=GN]_^
M$3"\- ]8>D[:TNGZ +CLV"WVL<[>DIG#_$?=_P"9(&56'BGU Q^VUCF[F@PX
M<.;NG:_^6K*'8\M?4T</<6G_ #7O_P"^)*90_P 1]W_F2H0[]N\B?LG,?\)\
M5HK/_P"][_T$_P#1B2G_U>Y^M@O=B4-I&09L<'C']0@M]*[V7_9,?,R/3?\
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M>FK:22D.&[(=B4NRFAF06-]5HX#X]\?VD9)))3__V0 X0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0 !G/B@  )Q  &<^*   G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,C4@,38Z,C,Z-3<   .@ 0 #
M ?__  "@ @ $     0   @V@ P $     0   AH         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
M   !   !+@("  0    !              !(     0   $@    !.$))30/]
M       (          #_X0$P34T *@    @ !P$2  ,    !      $:  4
M   !    8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R
M  (    4    D(=I  0    !    I    -    /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HR-2 Q-CHR,SHU
M-P   Z !  ,    !__\  * "  0    !   "#: #  0    !   "&@
M   & 0,  P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P
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M=R'R"W_]48S]]> ^'<A\@M__ %1C/WUX#X=R'R"W_P#5&,_?7@/AW(?(+?\
M]48S]]> ^'<A\@M__5&,_?7@/AW(?(+?_P!48S]]> ^'<A\@M_\ U1C/WUX#
MX=R'R"W_ /5&,_?;@/AW(?(+?_U1C/WUX#X=R'R"W_\ 5&,_?7@/AW(?(+?_
M -48S]]> ^'<A\@M_P#U1C/WUX#X=R'R"W_]48S]]> ^'<A\@M__ %1C/WUX
M#X=R'R"W_P#5&,_?7@/AW(?(+?\ ]48S]]> ^'<A\@M__5&,_?7@/AW(?(+?
M_P!48S]]> ^'<A\@M_\ U1C/WUX#X=R'R"W_ /5&,_?7@/AW(?(+?_U1C/WU
MX#X=R'R"W_\ 5&,_?7@/AW(?(+?_ -48S]]> ^'<A\@M_P#U1C/WUX#X=R'R
M"W_]48S]]> ^'<A\@M__ %1C/WUX#X=R'R"W_P#5&,_?7@/AW(?(+?\ ]48S
M]]> ^'<A\@M__5&,_?7@=2;[+,(N-5-RBG[RCH!HLR3)'"4/";#Q:3Y\V'Z/
M'V&$L>O,-$5W26SC=NT<*II>=OJCOYOAP+*\!P*K=UXR\E_6>Q0+" $;+=.5
MH4Z2C(A_/&!9M@58$5+*3 7K5LDA]D%B5=),M[ 8QJ"R<)*I6ZC*4:!OTB!5
M#Q"%/)[2ZQWU''Y7<$-LR"[)LX0><N+7<=E6Y]8FO4$*-VBT;1#M).I_:,9"
MPVQEYA&!OFO684\S%)$Q;8EG94Z7#/PO>^H"*T 9&X]94%+VR^KG:JP\QCX1
MJ[L2(VF:#@8I8<5=AY.;#/8RD]/A=I6'7*-;$@:!</O-H* W-A4R 9!:DX8O
M+TZQQC0%-47(^YYCZ4H[ADC:1IQYO7.[T_\ J$C7'Z!WWCE?7;7W,[4\Y--=
M3'[E!3.H:?JE\JK>,KM$&%U[-^3RNTG([5[ P YT]IF%S8=VMI".5?\ #'L*
MGME&$^S]FLE1461K<$[L#$@J&L&!)I(_1!"XDRL##E@N#"?*_P#7UA)^N=0W
MBC*H):=UU#!9HO*]XRR!5,XF!RC!UX24)$4#LO6LP\#$QMRX<;RV/PZ55^(=
MYTBIBP-96R)CFP261\J11X"EE[PF%5]EH%'RLNAL1JL!/JE3ATEO=2Q!3P]!
MCE3JGI*RB#D(= BS!M_B;RR#FX.)%+OK)"PQ!X(V)!#I#RML16GU=EH+5EN6
MK2DMZZ6S:TI%UG5SF67)7,JJ&W(S7LX3F3)O,VT99QR$M'QWW['@U),>DQ%
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MQ5SMC3&=L!9+@.!33R@08V>ZE6BR !O?YX@ZKPR]'[L]"K36/1VSX9()60*
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M;3J*]))A#-EMJ[/J[>9J N)K.J7,;*^/FY319VJ/B&SS&-_W&JS#+ILMM_\
M=UU=<Z[9"S8P?$#;1(@&=-2[!?77=%Z+/.7[-;3?7&VFZ3EH0514UVUSC;7;
M3?.-M<XSC.<9X'8>K 7]&7^D27MG >K 7]&7^D27MG >K 7]&7^D27MG >K
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M #^ \)3^< ?V)'_/X#PE/YP!_8D?\_@/"4_G ']B1_S^ \)3^< ?V)'_ #^
M\)3^< ?V)'_/X#PE/YP!_8D?\_@/"4_G ']B1_S^ \)3^< ?V)'_ #^!\N'7
M6^[R)RJH9=#^[]J7;?%K]R>\/72==5_A&A)QG$*<@1SL21!%XY 9,,7:0B55
M6M%JS)1JS)JJY&KLYF'BLIW*0MS'0@X.XMZ.^5*QU<[JISQGY1O1FOTT[%(
ML7S:ODJIC#E),I "&!J0P-TPK*)W=M,%4,/=8XY8%L $7&5<&&R^=V?FA=&A
M9A0Z_?Z.2GJE*:)TI".>3?$I6W(*L)A4JV##%;3B:_61O,B()YJ&8F&L,:W
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M?'&-TU45$U45-=%4=]%--=L!2(Q35P">W55/HI-TVE81VN3@L3&BDVG! EF
MB7<"&3-B4</T"3\G(B9HT!*"22\C\/-BPG0AOG&C],F%]?5QI^GR#ZQ&O;>
M]7&GZ?(/K$:]MX%>NU@)LWZ_6.OH]-J;), ^^-%SA9=';.)*%^)1!5WNDKI_
M[6BFNVNW_P"+&>!:7@. X#@.!7ZW_P!]#JI_7/+_ /AOO;@?/XMY*;M(K<21
M9&+1IO"M^WSBL%"6TSCVNC;R= 7LHOWMBRWO,V>INW"^]T;:TVY@.4\%L1;?
M<OLR1&ZY<*A"37J;_P#2--.O/9 ,6[$ER-FR&[JT)@13&9,6I62P4:2GN+(,
M4S/VW:P&6@X:1:$:Y=I0=*3=6!S45%'[4+%PSTL<8R0+X]/>J7E)*P[CP*YK
M^ECB?5Y)*CIN*7DY"R<#!SDJMZ*]?'\:5M>=Q^/V$?&34%$9"@\A+J 94*M5
MI;,VUI@W\A;1QNH-"/\ L=Y,^<26D^]A.)=*Z/G-H]H.QAH;'X>!^ >NI!"^
MOD3@,AK^G+)K<Y)0!^KDK0'RR32ZW#;B>C])+NE9DU0;.&4I%QM'4-]U'1F3
M0NEJCATT3!I2^)UE!(U*$HRL0<1Q*0 HN+%ET@+@LHL47#IOVJ^@Y8BJJ^5:
M:I;NE-UMM]LA*7 <!P' <!P' <!P' <!P' <!P' <!P' <!P' <")2O[^T#_
M *I;9_QC2W EK@.!73MI_!XLO_9HC_=ZRA?'^[@6+X#@. X#@48[VR(Y$(3#
M9;&"2P:2Q?\ " D4>,-DVRKD4<"=-^R1(22;I/$'+11=B_;-W22;ILX;[[I:
MZKH*I9WTV"9?@(=>/F_#S?WG?^SZ[ ?'^7\GJCX_DX'Z^ 9Y\N_8#ZZ@ONCP
M'P#//EW[ ?74%]T. ^ 9WG\E[]@/Y/\ ^-07W1X#X!GGR[]@/KJ"^Z' X^ =
MWX^;\/%_^/Y?#UV!>/A_+X>J/CP.?@&>?+OV ^NH+[H<!\ SSY=^P'UU!?=#
M@/@&>?+OV ^NH+[H<!\ SSY=^P'UU!?=#@/@&>?+OV ^NH+[H<!\ SSY=^P'
MUU!?='@?GX"'6,^;F^+^QG/Y,>NP'Q_W>J/CP&:(=8_+?%_8_+^6; <?D_+_
M .J/\7\?\G Y^ =W\7_[=[_^/\G_ ):@OC^+Q^+_ ,D?C^+X_P#5P./@)<^'
MC\/-_>'CX>/KL!\/'^3Q]4?#QX'.*'=;?DOB_P#/^J; L_\ =$> S0[O'AC-
M\7_C.?R8S-07Q_ZO_)'X^!S\ SO\OP[]@/#'C\?KJ"_B_+_ZH_Q?Q\#C%#NM
MO_-OB_\ ;_5-@6?^Z(\#GX!GGR[]@/KJ"^Z/ ? ,\^7?L!]=07W0X#X!G?Y/
MAW[ >/\ )ZZ@ONCP'P#//EW[ ?74%]T. ^ 9Y\N_8#ZZ@ONAP'P#//EW[ ?7
M4%]T. ^ 9Y\N_8#ZZ@ONCP'P#//EW[ ?74%]T.!"W7@M(R%C^]TFE)R8.8D4
M[>0L6;DBC!<VI'HS=%4#@C1^Y',!J#M1@PT2::NMFFJZJ22>7"BJOG*;!>G@
M.!73MI_!XLS_ &:)_P!/_K(%_P!?_=G@6+X#@. X#@:_O*(?O3B_]C=E/^"G
MLUP*R&>C$JN?M!W,L ZPKV! WO:?K;8D*L!_0"Y:^Y&%J#KOU-,.$*AOU:P@
MJ42AQJ:0(Y7<A;LX#)]==<6 *]U^ZBJJ8P*54U(O*8U]#JCKR"5_=D5=0NB7
MU<MX3(:VD9:,II@.@[Z2P"2HGRD-B55PLFV[+"0L.;@2DLLB<F98\>BI>[@,
M5U9@W86NN":]QA\0A^*3SVT/PE4?=^X:4SB E8[;^]K,PM;.:A''8@*IR82L
MI6FTA>V:U'8N",T]&#9 5AC-IT#@"<,E,C#"@+7N-7NUCBZR9=DF2YJX^R,O
MO,:YK3=.-QB RKM%%B@J4]97!B+;#9?81>K2]HR:-"XJ:GSYXKYVQP5N2Q V
MCT-JW4@G996MI O8V9VNR1L^P&E6DK3".(W9AFH&YCS805G((@* FAIA=++Y
M-FE(P(63JQ] *YD8Y(TN]W4#7?#X&5@T9*:J]9[)D_?$)+.RYL[V(%0(]'LK
MMS+.U7D*GN;RR';1>W(B7!DZ]C4/H=K(Y.1&E,QIF^@(=.NE2((/3T?]_HA:
MM719-U=4C!+1GK64'2<FS('QQM61:&'O:AM:+$95>L(#EPGGZMP3>56?6;^+
MHHQK:L(M.B&IV-OPP'W]\HO%(73K4LIV"E<>DE>=29C?IYP*,L;%C4XF=(=@
MW-T!8QBNZ3LF8#6 JY([2+:5Q&'5H?(1#8RDV72 Q@W(2;,/=4L7NB;4EA%9
M?MU$;1@'5B+,E(CI2%@NH)='9 M7,0EDXDL6(L(#(ZAB(2O!XXW'1H!A/57<
M]N"0R$0&1RTC<8;S$.]F\A[W65*;/D,(+]G()"F4RT>52Q:UQK$G9*-E>Q5$
MQOTQ"/3*!J2#W*RIDI:95J'D#-D]'CMR!XP-1+1YFL*#'I).?*#@957$6&#^
MP;Q&,7>R$('GT$DTQ86)4&_?VSH%(TI9I&H +B89<3U+80F8*V)9=B-52$4W
M:%*^KF42LXYE# +,^3/#7+#8Q'J_D[>\6U?1+KW4[$R/O.%O8<YB]YIE)6A*
MXG7&"D:C3HO#1<11C&'3L7F015)?WIU&G5I"M+D$@@GMA3B,FN;R@"[?KS+Y
ME>MG]?:9C'3NUQ=$2V08C%P"X9:8Z.2".]@F</=Q2GW%>V(6B4F*G2L[BJH'
M#5(QIZ91)'14(-[#]3;XN\C99">1&US1,!3/?^(PW:.QU(>)?$IG;%)#(QN(
M;,X[Z)Z6M& ;31GN4TQDQ-XD.>-GCMZQ;O=50OMV8@BRD_C=.-XM*24$9]'K
M_!T9%*W, (1+7MIH-HC"SS2!R$G[BCD5M 94Y;=G6Q-PF.:,&1J>9T50%>^^
M$@U\2^BSI".P^/!:";KTJ$[1];)\5FX3R>MH0/4R@RJCLA')>WGW1]4:1];7
MU<X7K!$Q<D.@<8 3!:>@HWL-7VJ71TD&PR(#!T:N'HL/IH-H"4<(]C15HCA]
M G.LK!W23"+Y*OB9&H9,$C)8'J,O![3Z$;<K"U</%Y))B A;+0T<54#.^Z_6
M:96]-J*M6NY3[T3JL"RH",LUH,O*]1;Z43FM):I.QTA3DH9"N58ZSK9R+E1I
MR)D6)A7\@E%:-T1KV7-GV ABI&W8N:^3Z[.UG8]5/HY*V%*V!!8'%FT!D47/
M&I(?H[*\MB^@HR0*/K%>"+5,R*+L[7%.5!5RN4MY@)W=Z%/=SL*<B*<[7=9Y
M2ZU@-5-XP+ED!ZH"ID0ZKTO*J;A3VH8T.LE2PB943$ O867(=G 5HR&'QJ6[
MA(K*I(8I!=$U#Q**[.7[PL.]+LN\5DN*C;V\+[#.9Y&+:HB:4Z/ 5PHA72\"
M'125Y.36[SS*+;QN.6F'EKQ)(RTDI."G<)H14BV@$?&E):&'A((NT^[$J1KY
M66M>VT1K%O!Z-#V^=AU(%F]M-;,:]<;7WFKB)1<G"%I"6%.NQ+."CI4:"1TA
M%%W6H9PL0:5.7-2+<,4*1CN)![HOB10&/W]G27VE)YE(SCZ"#SYH37QZI>A8
M60E*G(K"ST2Q/&4>#=@&49A\&/R!F]G$+9!MAIUP/!HO SM\5[XD<30W#S'9
M/2&01B5D-#(R*$)"YA9#%G?-=,0[>VX^;A+&3.7RT)=62S0BYL9&)"\KQ(/(
M9 -T/MTS&@3#VZM&]1W:GX-J;D]Q9D[?KI IY5U?P6(;'*U/68^O(]'2;RZC
MZ,5+I1>&+1%A[@?.Y)(8O'=AFA5PT>YE;./XR&:]BSO?-C8M8#*XB3=O%+@<
M+UO,WM=2?$['4TWB\IC$Z;6RL1E5>014(2F];H6W7"[1V@; -)IM4ZB;_P ]
M=]A4-3!HSY3FQF2<AQ!^P*\G@(V$6U6NIRLI0B=KZZ)+U$[XQ>U8ZPE,V@E?
MC9FZ$3+--"_/ 5Y&ZS92&9! ,#UD+(EH;*A;:W;<\H&?G4Y+UC&+X'U62E5P
MJ4D[VKF91>0XEC*+=><4^RE$$>U =D>]=$B;RW7*3&TUZB@[YWH>93^S(>Y8
MQW*0;0NK"/G K9<NT&_OBGV.O]%1;1/7SDO3V$]4=H(*9RHIHW57;I;;)X5V
MUWR@CMOG?9+3; 6DX#@5T[:>/X/%E^'\VB/]'_K*%X%B^ X#@>@4T(*#"*8A
M9NW*[L'>@QP[TRJU0(;-U-62SE/7&=E&Z3G*6ZVFN,YW3UVUQCQSP-3E-!>V
M@F\@<7G\RL-.3JYKJ:X$RBYJWDD2Q6P80- =C2#ZN@CW$E<MYI:+U^XJ1^B/
M,MXL*,19LX<U@@.=U_D,V[^DK*6BV&)>(PYA!40?9K(B2,)V6)2=]OKTJ[*>
MY]7\07@(T:-U5QLOZ;9&8D<H>B3\S5?TVV$@O=<=N0RBJXD-I3]VX:1B.;!6
MJ_N31!1Z^*R:0"HG& K#5VY8L<$)!)SH<&P4(/QXU)X115(D&#'1P[1"(QG;
MZM"/7PSV04$RQE"Q)9W'VHO3,,D)J4'?6MM"  Z%%X9,Y/7<NTF<G("Q$6,@
MIX\CKEZ22;%# ERS+HC0A>2>4NI.'NR8F3P2X@TBB1N0A+.C3H17NQ:KMHW(
M:S NWDAW;V4N*EFKQ"WZ_D8D141.RI22CA]L[;Q_+W;4?N&Q+&?'&,X_C^/^
M3^[/Q\!P' KM</9"/4I)(D%E$%LHB%E)N#1M6? 1$<WA4?/61.!U?0T,0<FY
M6#/GRY20$D=W0BOH]-2@$-IL<D3,2+69N708S:_<:J*CMR-4B7;2&0V!(F\(
M?*!XTM#/=8<98DI+Q&*$-Q$EF,:DDKR](1R4/W0>M@<YD8H!&C!XH%9C$FSA
MT'OTSVKB=SSDM7S6O[7KT\TA3:R@"=GQT#'=IG7;V7GX4PF 44-E1V2@F3XH
M W=-0]B H/*]Q1,6\WC^F=WR+ +0<!P*:]M>S$VZ^PAS/X!7$2LF,Q>/S23V
M"=D5H-80+"XBS07B.U['D1D=FL@E-LVJ=+(QRNXNV!-1CPDU=MRAX>^<@QQ@
M//VL[<#^LM1@+ Q!#4VF,M?QIK'ZS;O$ YC1@0(A=)A(9 _61>(! -=@RBI6
M1/E$%_3/TQ<9&INCTA#-'08'1'>5E>]Y&JW"1)@,A*)F\8K'904(S 7)34GH
M"?-Z[F;=H,-5\+@$D9+&$RS_  E7]G3"1Q<.D#=S>.Q]0_JB/#UKD[GZPVNK
MDMV-TB\MB.T3=3"HQ;UB> #%TY<P<LHK9LU?N) @CB.Q6#/Y*^A>KZ-YE,M/
MFFAX0C'6@Q;5^L$K]T^TX[I_0$YN/,0(63)@  ^2B-:B"" HE+W\> DI,6PJ
M4<(.] L>CT=#EI)*C^S)][T A;M5LP)$U1XM\%>7/>YS^$"8JP34\+5D!N<7
M315:*DK%3%V-*[#HFKD+C<M9;&M88Z5BM8R<4\,>JTC;G)$[14< C#J-),Y:
MFHQ"]]/6E%[OJFN;BA6[O:)V="XY.8_@@CJV(HBY**;%6K4DVU45U;$6FCG#
M4@VPJIAN\161\_?S/.R$D<#68^\H>H9M:P:BKBJTS14?;%/4W44LE<OVCD,M
M*0V",N(Q,I-[J%QV2%PL%@B%'3X:.,-A1IY.#(C.1 ]K''PN2/0S(MW2E*O5
MZ#WC#J9*2>=2JW75*&:]$ZS^9C8I*87:\LJNVS2Y"KJTGLY-1"'O:]FI,(1%
MUOL1D:3< T>"X^X,K>]P1)(/*=A(I+] )2+0DB 5J5A-&\L$6*]:-E9(_$KO
M-2+T9)H6"(1ZDF!]!: R&T9#H.*1:;#)&*D$)8^KI3=$-F$&FL9L6*!IE#CX
M631XT@MNS-1Y_J2$N5V3MP-)H-GFNB>V^XXJS>C7:2R*#IJ]9N&KQLW=(+()
MAEG H#V=[<[=?YW,\A*LC\P1IWKVV[!WG*BDF]6)"'IG>;FP+45!$&T5/[RZ
M1XQ%;"D:8(X7B(!-0(R:^_.'4@W<C0FJ[.P)&I)IUPBK&M#\O%WY:Z%:D)LV
M+ 14:KG1S%3\D9/C*+Q]O(3!4WN$W9 Q ,&Z9;IHEGAHX$PR8-S 4HV\I=*,
M&:4!8IB,ZN^WB;]_U*6VL\ALVD08+:$2@9I[<?F5]E6OG#:/3^'SQHSB&EDX
M=MG)@ HX:OA;=V3"^/7FYW=ZU5K.5HTVC,G%3&T:UED82-[F!(V?4]8\KJN9
M-1,B]ZA[@I'59/#R;@$7<@AC]X%79.7H8>\W68HA@76%S)<!+B\P0&V_^TO?
MN=L['G>OAOFPBGGZXQ@!OYVN,_%KMG.N=L?'G77Q\.!9;W5*?YF"?6!Y]WN
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M!J QX<81 S$*T-L&Q9C[A5PT)-47>&SY#19=)-TDKA%=9+S%=PF?X**M^36
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M<T"OV$T8CX=$UUP$+C+>0)Q:'CEE4(R%%84WSD/>?59Y$HI/=;/+PV9&9UC
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MM$]UBKYHW$MT_3ZJ*KODTT=%EMDT5 DCU7C/]'07T0/]GX#U7C/]'07T0/\
M9^ ]5XS_ $=!?1 _V?@/5>,_T=!?1 _V?@/5>,_T=!?1 _V?@/5>,_T=!?1
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M)C=]1!YE.HR_(%M)'K))#I"1NA</KLX#@. X#@. X#@. X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g16439g64u74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g64u74.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5 J:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B"B @("!X;6QN<SIX;7!44&<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @>&UL;G,Z17AT96YS:7-&
M;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E
M;G-E+R(*(" @9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@
M("!X;7 Z365T861A=&%$871E/2(R,#$U+3 X+3(U5# X.C W.C(S+3 W.C P
M(@H@("!X;7 Z36]D:69Y1&%T93TB,C Q-2TP."TR-50P.#HP-SHR,RTP-SHP
M,"(*(" @>&UP.D-R96%T941A=&4](C(P,34M,#@M,C54,#@Z,#<Z,C,M,#<Z
M,# B"B @('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*2(*(" @>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HW13$Q
M-T0W0S)%-$)%-3$Q.3%#0D0Q,#)$-T)&,3(U-2(*(" @>&UP34TZ1&]C=6UE
M;G1)1#TB>&UP+F1I9#HW13$Q-T0W0S)%-$)%-3$Q.3%#0D0Q,#)$-T)&,3(U
M-2(*(" @>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@("!X;7!-33I296YD:71I;VY#
M;&%S<STB9&5F875L="(*(" @:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4]
M(E!R:6YT(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#TB5')U92(*
M(" @>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD](D9A;'-E(@H@("!X
M;7!44&<Z3E!A9V5S/2(Q(@H@("!P9&8Z4')O9'5C97(](D%D;V)E(%!$1B!L
M:6)R87)Y(#$P+C Q(CX*(" @/&1C.G1I=&QE/@H@(" @/')D9CI!;'0^"B @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY5;G1I=&QE9"TR/"]R
M9&8Z;&D^"B @(" \+W)D9CI!;'0^"B @(#PO9&,Z=&ET;&4^"B @(#QX;7 Z
M5&AU;6)N86EL<SX*(" @(#QR9&8Z06QT/@H@(" @(#QR9&8Z;&D*(" @(" @
M>&UP1TEM9SIW:61T:#TB,C4V(@H@(" @("!X;7!'26UG.FAE:6=H=#TB.# B
M"B @(" @('AM<$=);6<Z9F]R;6%T/2)*4$5'(@H@(" @("!X;7!'26UG.FEM
M86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ
M84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))
M04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"
M9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$
M031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!
M,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G
M055!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!
M04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!
M)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"
M06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH
M37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*
M;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X
M9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+
M:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S
M<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).
M:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7
M:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P
M)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)'
M,75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*
M5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%
M44U2040X03E5-'%P6%8S83)D=DIC,V,P9'9B)B-X03M21&Q,3DMW4D9(:7I-
M44)I<5A396)V2W-4.$ID67-O>5DT-6=8;FI65$A-<G1'-G-7;U%Y>$UW<#)&
M96U+<6QX-6XX=%<V3$IC871:)B-X03MW>'-70W9*8U)+0U9:;%E!;&@P84YG
M9F-(=WA6:'8U:&%666%P<FQU.'9N1U!Y*SEN6E-*1F(X,%%L8CE*66YM3%!*
M2%5L52]D,#-5)B-X03MO5&A62E X04)L:F$V6&,R5GHU,W,W5DPR-D8W2$)%
M=VAG9T5!5TM1,C-/-65D5VEE2G=#6E-G3F%R>491<3-,<$9H8BM88E143&(X
M)B-X03MX57-:3DMH=51D5%<P<#1U2C5*5VI!5EHK6F%&6356*S!Z:W)5.4U6
M54Y7.'58<VYL;' U+W=!>F\P:6EK64YQ9G%-44HT,E-E9T,S)B-X03M)5#%6
M5E!S<74S-TMR=E961&IY,60V<E!!.6XK86IF=DAK:7-O1$LV5$LW=DY(16=2
M-VIM6DMC;WE3=DDP4#=1<FEQ2W0Y3G0S=#5*)B-X03M&+TU9>'EA;F5M9415
M2D=K9V%73WI%,$Q7-%IP:U9G<VQZ2'-H05!$-THS3TMT85@U9&YT3%-+,FLO
M3D]/4V5/65A.>$MK-F]85510)B-X03M02W),.5I+:%-K9TQ(:E4Y>G@R>%8V
M56YN9GEC.'I23')L:5A107-28U)C9FDU8F-U6$5T*S=9:U9Q04U#<61V-2LX
M:S-$>7!$<G1I)B-X03LS;S=34#E9:D-6;W@R8VYI,4)'>$Y$=%1F1E5Y,"]7
M.4<Q2FY85'(K,G9':E97:T9V2VMP5EAR>$HT13!$53)X5D=9<3=&6%EQ-T98
M)B-X03M9<6PQ-35K.'8R8EA3,U=P5S!-;&EQ3F52=$MN3TI:0V]1>4I8:W9)
M=71+:F5O>%9P4$TO;'0Q9&LQ87I:67<W4TU,:4EH5FIR-FA.)B-X03M',D-C
M5'DX3591;7-A.6\Y>#5F,653,#%U,'1V<3EU-GDV9W-I4W)A=DI'9E1K:T-S
M3VQ1=T926'1I<GIZ4R]*5VTR:VM":C@Y,G,X)B-X03ME;6]$2&--,&(S14-7
M.#=Y8U9:<#)H0TMI3GDU>$@T;$I*<%595E8Y3#!J>6YP=7!A<'%L.34Q<UHU
M8GA,9U=S:TUY4GI13F5X>'(V)B-X03MQ=4HS6FU+<GI8:4%/5'-Y,')I<4AS
M=$1V-VI52G)'3#@P5$QD,T%J4T="2$I);E=&,&QA1"]34&I0<69%67A65B]A
M1F%55E%,5T9Q)B-X03ML>&9A6&$O;6Q(86%J36AD>$9,25DT5#9O9#(U4&-S
M=DPY,E%X6BME.4=/*S9Q=F)E5UIB8CE(5S!V-6M09G=E<$1D>%<V97!+:G<V
M)B-X03M31FMU84=+6BMV1#1G>'!5.4-W1TMU;C!"<$Y13C)F>E5H0VE:>D9B
M4WI$:VI.>"]D8VID3$Q'9'!&64E686IF-4EX5FUN;#-7=$0P)B-X03M'0SAH
M,5!Z:D)R13DQ8WI8;'-*2F\R;5-":GA%56-A3S=S<UIJ669#2V)(655/0E4R
M;C@O95-95VA2=&1S6&MU1S114GA4>'EU-7%2)B-X03MS<UI:<595:71+67%I
M4#A!1C-L4&8O8S%99D-V3G8X05-O9&PU*VYY4'AD3V9W+U!B1E4R>%8R2W!F
M<BMI5W5U85!D859D4$I(8C-A)B-X03LX2DAI259W05$S=VMG,#99<7AI9CAL
M9GEZ;FDY2CE&:E=-*VE:5FIK;&HY5F]/6E8U941,>F,K<3-*,BM*=35X5E9V
M4'DR+TQY-7-))B-X03MT3G4W6EI)3%)B:$56-VE4;6]U2C%U6FEZ."M24'%S
M<E9*,C551WI9<7%A,2M72&M8>D9B>'AA<&%09E%X2DAB,6$V=5-75S)A54ER
M)B-X03MU<VY*:6I4>41C,3-P:7%M9GEL.&QV8U=K:VQV3DI&64LS,5<S9655
M;W-J>E-Z=$M4>35S-64T9C=454%/,DMO9"]Y4B],3GA-1S!I)B-X03MV<FA6
M:R]F>B]:4D=J440T.75#4'A7;EE$=WA653%(.'%0>31U9$YB4V)Y>$@Q3U=:
M8F]W3F-Z2U1):U-7>718,4$S,E%Q,#96*V5+)B-X03MO<E)V>34X:#9F<E-A
M>'!T;V\Q3THR;E=D6G!*1T)L5U=)<U%886]+>4]G<C1$*UA&5D]F.'!026,U
M=%1.<#=Y1WIE9#1'831U0W=A)B-X03LU05=3<D=3<F9#:6=6-D%9<6AF*U9)
M+VQR-DAO:E-M0RMK<T%B-GAC8V=I.&@X3$8V9VQ:1U5K9%%335965B]*=CAV
M,'5*<FE/=VQ2)B-X03LW;%538TQD6$E6;&IG93-7<2MP5&%+5C%R,3-X5D12
M+VM6*U=%8TUK2V%34D9):&I:1&-80DA!<WIL4E=1-V5O+U X03%G1#)'2W-G
M)B-X03LX=6529DQ(;'DX=G)Z4C=1,C%X<4QC-W1J2DI)1U!.;C9/>D%F134V
M67%N,DMU>%8R2W5X5C)+<U1V=GEV.&XV;').+W$K<#)P=F)Y)B-X03LK:VIL
M5G!73DQD;S1O;V=93U!(9W@K<F]3,U@S<'1I<6YP9C53*U%T3'4W<39S.4]:
M2'95;&IU5F$T=4A2;&Y4,#50:&52:%9K,G)I)B-X03MQ=&$O;&HU3W1,93ET
M<F$Q;&AT.5%I5T<W:5<U=4%J<D=I26A+.#9C:T59-'0Q1R]J:7%!;"]*:GE(
M-D8V;')A>3)K=#E"3&)Y5'AZ)B-X03MY<W=76DA2;4-Y=$EH64-6-D9G975+
M<7IF:R\K6#=+;V)4;5ER3#8O4#9X8U9-,T-.4DDQ2"M*:#9+<TLO=&(Y4V-6
M5DY-+TMB>41P)B-X03MD.41F5T]M96AC,C4U47-S,#-&4TI6;49&3#AD;6I8
M=#!'2V]C9FMT*U<T4S5J1VQ(:&1Y97)/<'5,9SAN049$=DEE-DMF;4U65%)V
M)B-X03MY.#AO=&(V9F)'>5 Q9E,T6G)E>6A%<W9"16YJ84HO:#4P2C1334%4
M=71D<5EQ;&IF:W@K6$Q88TXR,FQS6C1*2G!9,BMS6$9!,7<S)B-X03M+5&(Q
M3S5X5E%J+TEZ.'-O,D)84VTK1TM/0D8K<S-.06M5=W5&04AQ9C<Y6&UF13%X
M5E=B.&UF>3AE.71R,EA4<$IB<3 U96Q+.7IC)B-X03M&:C9J=$DS23@O:35-
M-7)8<FER8F9K>"M81%=X="\P5%-*=4E)13@T2C1%1DMT-FQF:$-+;SA&04AB
M1E=B055&3595;V)U,6UE4T]')B-X03M:2DI)5'AM4D=$1D<X1T%/>"ME2W-+
M;7103E=J*V5B2S=M,34W=E-V34]Q1S-84VI%06M%15=L,V-W4D=:;G K.70P
M66Q/4$QV6$97)B-X03MD67%W>50X=G9+,G!I5SEU+TQL:DI,<4A+939,>7E%
M=3@U:F1Y,S=V<5=H5#=S2W!V-65T3%13-W4X,&5Y<TEB1S)J5DPT<D$W34=L
M)B-X03MV2EIV54I$2W1.-'$O5&=64$U69&ER14I03'5G*V)43'%6-T)96#AI
M=$Y9<DPV8E,P:&=U+U5J47-S,4LX-&MC*RM&5S=8>7!P6&Q2)B-X03M%=3E&
M<S=/>FML:W1,2U5X475P345T-&]+,4UR9#4R4%1R:7),<T-P3C5Y=4Y8='9+
M;7(S1VIY>'<V<D9A>79:4WI.1W-A>6A355HR)B-X03MM<$=!1"].=#0T<3AV
M+TMV>DPK8C$U96%Y9DY7<#9B95<Q=G X:W1M='1C861)5G566F5$4#E687%P
M4W13+W<T<6XX*V]F;7,W,C%X)B-X03MA86QO:'-L:5$S665516QL9#%B-&Q3
M:7,S3TY724I8:TYH=FA69&8V="M9:VLY-DQ45TY'=&]L.5%7-E-325IA2TXU
M3F<T-'(X2D%9)B-X03M6,V)L*WI246YF;$YF4#<S9W5D8G9B0S8P>5-.:6=T
M2VML:34T<W)"44]004PS.&9B1DQ,8T-U>%94:W5R84]A3T-36D5M;7(V351-
M)B-X03M!>CAD>GA5-VUN=&ER>DQ8+THS-6@V9$YR1W4R,VY36F109W5,;E8T
M3E!A2FXT;W1S+W R,5=K2RMM:D@W4$AI84)I=DQ&5V,K5$Y2)B-X03MU.50X
M;C9&<58T-&4X=G10=$QM-6-!2T=K;&=2,U!%54%Q>F1":7%C67$W1EA9<3=&
M6%EQ-T9867$W1EAG,G!E85!Z=50X>7!,1S,Q)B-X03MB4S X=6I65FE3,6$T
M,'-4+U9$3T)W2TTS<C@O5#=5-58Y.%9E:&%Z9BME2DY5,6$Q,&TK,#9'3T]2
M13 V3U=337HQ1G%J34A3:C=E)B-X03MT3%5H<4=L2V)(8W%G>G%N-6EH3$M/
M6%5T1VEL95-28GE:6E9-655T1$9#1D1$:UAD>%!153=!13%X5E%S-5!Z979:
M,TYP<D=J5#(X)B-X03M:1&M+9E5F9%=#<7AJ4VY%:V(W8C=L5%-G>%9R.&YR
M,3=R5G9/<FY46G1.:2]3.&IX<D]S>49Z23AJ=7=34U-65BM);FPV64-L<70S
M)B-X03LT<492;7$K8F1,,5!Z,6]/:7=,26PW<$=U4TI/2#1C6#5A2F90>6I+
M3S5O=DU!.&=P.7-66G)Q>4LK;%AI=#!-36QA16HY:SEX:7)T)B-X03M*4E4P
M<7I696=H:G!5:R]S:G5C5E%T=B]!37!2<4@O349:9CAN8G9&53!X5C)+<&1O
M2"LX378X07I'6'8O55I,:7%Z>DHO>'HT9CA!)B-X03MM3G-0*V\R2$95,'A6
M0V%T<'-/<#9B8U=%>G9(1F-O55HT-D(Q<C-8:T=&4C=J1E5"1C595G)L<#<O
M56)V56UA,FUS,5<T1G5I<D9C)B-X03ML1$Q4-G9$06%T-E,W:VUN8D95;U0X
M<'9*56$S9VAT<%EM=C-6-W0Q;6MQ-44X9'=A,4I&5V5"07A!<E%5<FEQ>38O
M2GHX=DQQ4DAN)B-X03LP=W554EDQ2')48DI'=D9".79T56XU;D975394<$YH
M<$YH2%E7169O,FM29&\T-FQQ1U)Z23(W16YD;4]+;W9&6%EQ.'HX,5AS;R]/
M)B-X03MV>6IA>#9B8T]"8EA,5&%K<7I#0E9D2&]J36MQ>$UA<#!D1'AQ3W1D
M;%8S;DPX,79,43 O5SE%2UA!=2\Y3C!T;4MX0E)+;&\X:&-G)B-X03MY8R]4
M,G!53%=V8FE14U9:4BM82"]K=E!++SA!,GE,1"]Q1VIW2WE,1EA9<3=&6%EQ
M;#,V6% X06E$.40K9V8Y-69R9C%J:T].4%4Y)B-X03M0:G@V,7)I<5DT<3=&
M6%EQ>"M4>6-R<DI#3E9V57-*8FQR=#="4F$K;'IE-$YY=S5'07IC5$M39C=Y
M=G9I<48Q3#AS9DIU<&5:0C5K)B-X03MV3%(U3EA6,&M78U13<4%Y4G)%2TER
M0F0P6&E25&9&54XO>7%,>4MY34IR3U-A4U)U53!Z5%-"-40X22M,9U9(4D9'
M=TA41&%P>#5D)B-X03LX;6589DQP:V)38EEW4$MQ2DEX:V1Y5FI52W8R>65Y
M:D%R1%!Y63 Q-U,O.#)3>5AB6#!K,2M&3GDQ.&PY>D-'46AL-"]&1W U,6\T
M)B-X03MR5V\V045K<7EJ>E5Q:E@O04-A44%#,G-Y;&E/-2]1,F]$9C9"9U9+
M4'I,+T%$8CAO*U-Y;6TV,C%W3&Y53&%2-V-1>&5O=DAD4&E.)B-X03M25&9&
M6&9L<"MB9FQ(>F]8,#-21W5$8S9F8E)V8T-A3# Q-#=*.$IQ83<T<7EM,R]!
M3U5O,40O;4-S=BM4=#-I<6%9<3=&574P1"]E)B-X03M'6"]M379F*V]Y6$96
M;FU4+VIN=R]W1$UB668Y4G-/2W!P:7)S5F1I<G-69&ER<U9D:7)S5F5995HY
M34TO=T-D;FQI-TXV>DI"03=F)B-X03M59G(P8V-A34DU=TAA>F(T,UHK4C1L
M4#546%E95EIR-7AI:2]W;G)J.$8U+U5,;SAQ0W1F45E6<CAT<T-O9CA!3&HO
M>5AN;&8O=&M7)B-X03M(+U5.2&ER27-69&ER<U9D:7%19CE..2\R-G8K>&Y#
M<68T1F1I<G-64W)78GDY9S%(4DER955*1F58:G=82VQ1>%I&=%HU.6EF<VYL
M)B-X03M!0CE/2W!R:7)S5F1I<GI(.&ML,&=*-6E/;FE65RMV1EHT-6Y,<T]*
M8TM25T,S1D<V9V=T6#)/17%R6&5G95ED4"]-2%-.479T5TXW)B-X03MP=7!A
M-C<R3F<S<70Y5T-A3'%!05%V27E)1'9Y0W X5W@R;V%H6&IV+T]94"]+5F%$
M+WI!=B]Y94]+43<O;D0W+VQ+=&4O-6=5+S50)B-X03M$1E,K;')F+T%*4VI5
M4#A!;4-S=BM4=#-I:$Y-5F5+9C@U86MJ.'1B16<P23%E0VA(6"]E931X4TAI
M4"]!1&ID2DDS-7@V14=9<T].)B-X03LT845K+W=$2&Y.:7!F679M5"]J;G<O
M.$%-8EEF.5)S3TM%,'A6,DMU>%8R2W5X5C)+=7A6,DMV2V9-1VXK6'!0>C@P
M0SAU16Q'<U)7)B-X03M.3&%54T])=5!'-$A$9TE(6&Q2,E!X4T0R-DA&5DAZ
M;"M8,VYT53%V5E4X-%10<&9Q6'5O9F\V5#$K2S(W5WI"8E=I>D)'4E1T>$EP
M)B-X03MT5VQ38TMS-B],:B]!36PU-5@O-UI&:"\Q1%(T1E1E>C%!6%9Z95%#
M0U-,-FQ)26UK9FAX9&U26E!G-'-Z531U=C)G3W5+;W9&6%EQ)B-X03LW1E5G
M+W=#;2LO-V18+UEZ:%906E)+66Y%5$MK<%4K;7I!<V]A;7A+9W%32SEQ:D%Q
M6&56-RLY,4AY-7!M;UAP:DXQ93(P5GI,-DM.)B-X03M(1T1-9V9I<7,X:F9#
M1W Y<D95>GA6-&HU>"\U>4\X:39F-6]G,#8T=$Y33G@U93%3-%,Y2WA1;%=-
M549X84@P:C9W<E8U45)51&(S)B-X03LR>%14,51Y6C5S,#-Z9#5A<R]-3VUX
M>E)75CDV:&A3-%96;$%I;&%).&=J4TQU,%I)*TQP:6A/<U9D:7)$+TE8*TLT
M=%(X=S)E=3)T)B-X03MH87=16&).<$ES1FIJ85<R;&ML6EHU;S!K:UI79B]+
M<%AF=E4T<7,X>#8U<$9Z-7@X<3960F1)*V\R97-31S1T<3!D461&=FUR42]A
M)B-X03M!1')7;E-O<C%X5C12+WIM1"]Y;%=G+SAW3"\X;FII:T\O-7<K+S53
M<EAV*UE&4"M4=WA5=G!A,R]W0U5O,40O04IG<DPO:S=D-&]4)B-X03M41EAI
M9B]/5R]W1#5,4W@O-V$X2"]54&-9<$1X1"]N1WHO>6-M:&8V=#4O,4)Z67%8
M,F1R1FY.9#)K8U563U,S3G)-86UG-'<S36-R)B-X03LO=T1#;V%9;U)U2W5X
M5C)+=7A6,DMU>%8R2W5X5FAU=6YZ9$(K65=G>3).<EE0-61U565$57(R55)R
M95)Y2VMR;VM4=$E(9%<O;%9$)B-X03M48RM/2W)F3TAN:GEO9DQU=C)8-E)J
M5S5J:74Y4&1'5C%P8W)A>5-&2VQ1=7EQ9FER>')T5W4R2W!&<6YM6%903% X
M07IJ>' K=395)B-X03LV2G%&;F]U;'1!-W%(548Q9VI.5D]X*T9Z:7)X1'EF
M+T%--44O;5ID96$Y4'1*<G$R84163E)T:W9&1G5G3$-2;S1';U(P*T)2,'A4
M)B-X03M4-FLQ,WIH<&5K<F-P.&1Z93)Y0C)T26\U1UDQ2$E$:W%-;TI88U9X
M46I.2S$S5&15.5)B4U%T3$-Q3E!%>5!'>4-3=D4P9%5.0U59)B-X03M!*S)+
M<69M<#-4>79R1&]X5C%S8FMQ=TY#0TE724E)>%8K9D@V9#%V;GHO4T9Z>G!X
M-65T2E=N5VQA-'-N,VIP970V:$)P2&QY>71,)B-X03M0-CED,VUM3&-U,&MW
M:4%70DQD5TI9<35*6G)G67-6,VQ/-C%F5#1T23AT-G!92F)Z439B5DQI3V-3
M<7AS:$)#-#0X14EQ6F=2:7)+)B-X03M-5F9N+W=$;6XO-4UV>E@O04YT93DO
M-FE(>%I".54O:VAQ-V%B*U-V;%9O-UHW=6$V;'5,94=&1U)#5V$V=4=Q5V-Q
M;T9%3TQ%<WAT)B-X03LO35!M2S)M4F1:,&MW=S-.,&QV8GI24$921FQ93$@V
M:6E74FU.97!(,UE66DYG5C5Z*U5/:UA/;GIA.%I,3SAS-%IP-'944SE12WI-
M)B-X03MV<6,R3$QB5U%K8SAH>F9J2EAB.38O-TMQ92MA3%<R:CAY*U5:-#1L
M5V%F5UI05VM!05HK1VIA9T8U2'919$U69E S+T%$;40O=T%P)B-X03M6;U O
M041!=B]W06YJ:6M/+W=#8U!V.$%L2W1E+W=#6490.$%K.$U63#9953)S4&U+
M679D4DQC6&QR0VM.;UA!;4ET,VU:,T-%,4LO)B-X03MV:#!X46U72W9%+RMC
M="\O04-7;&HO,C$T4#A!<4AU355H-&@O=T$T,F8X06LU3D,O=T)7."\V9S5S
M5DPV=C%Z5SE0=EHT26\Y3W5R)B-X03LW.4@S-BMP26QO.'%+,$I)9FDQ0TMG
M*T=&0V8V5'$Y<G%K16MT=7-I96I),$US8S!B4D]R<4%30W)54%)H9U9'-'$W
M1EA9<3=&6%EQ)B-X03LW1EA9<3@V,3=2-W%8.#,Y13%#2S%V4VM523E7.%96
M83-#0T\U0E%39E9M35DU3U!553-A8VE6<$4Y2VA64&9.=FQZ44DO3#)V,S!E
M)B-X03MN5S98:VQR9%A$,T-X24AA8C9S-F5O5T%R>30W5GA69U!N,R]!3EIB
M:2\W66UK+W)T<U9F3$AK6"]L3B],,R]B5',O*V]H35=29F57)B-X03MJ9CA!
M2U%E65 K33%T+S%$2FEX8G10.$%L33E5+W=#,F1P,R]!0V9V<U969DYV.$%Y
M:75S+W=$341C+SAM5WA6*V1E3$HY.6589CA!)B-X03ME:GEJ+W=#02]0.$%R
M,"]&:6UT,R]W07!N<&8O04=Z=%(O-5 R3TMP,6ER."]W1#@P+SA!>5IF;78O
M='(S=CA!,450:7E$-F4O2G8O)B-X03M!36Q&-4,O-V%%=B]!0V9U.%=*96HK
M878W:E1F*S)L6B]W1$HT67%N94MU>%8U,65E6%!Z674O3D18>C9L<&)A6' R
M<$<Y,$\S;FEK)B-X03M:,6EA>6YT4W)M25)(<&1%;FMX4$EB1VTR2W-3+TY,
M.&IV4%@U9S9L6E@Y+W$R;#)R,E5*9U))26)G06=U6'%E8E T-'%#<&9L="M3
M)B-X03M8-6<O;#%E,VUO851Q3VPV:%!E<D1B4U)816,T5EEV5U5Y3T-R4C=Q
M=%=P,W!41E=6,E@U9"MA3&$P=#1(:#!#-&MT-&QI3GI,0F5')B-X03M6*TE!
M3$TS<F17-#%B,W<R:$]D3#!Z.'HY3S!Y>C Y3'I2<%5S-$DW9%I:26)S=7=I
M44E'62MR,4Y..$-73F9M9"M7,S5H969V3#A/)B-X03MI,S)O-E)A=W<S4UA9
M:V=H=5%X6D5D05!I9'A4.34T67$X-3AU9FMV<E U8V5:13AX4BMA9$-B5DY-
M:6Q-3FIF4TY#<G9C=U-X>'$O)B-X03M*-'EV3VIC5%@Y:RM">%1B,7)1-W9Z
M8W0Y9F%6<"MU*U=R=E5&;FYU8GEZ:CEA4V5*;FLK35!':R]*47).>"M)655*
M:%EA5BM:=&LY)B-X03LR,&0Q;W)'.&YA-69L1&0W37EQ=$)36' X1TMO9GI*
M;VXU=&%V;VPQ<'1V<2ML-EI.8T)1;#EA4C-C8SAF1G<Q568Q5%-T2V1/:'=+
M)B-X03LX,FDO2V(X,'9,3C$K;F11+TUE0S!T;'5)6G(V5S=N;FAH;4MU07%4
M=7I)1T1F6F]4,W!I<DQ,3S<X+RM:-4]6:C5X,$]+-6MJ67!:)B-X03MA6$M*
M=4M24TUH;$9(;356,D1%,4%/,D9746%8;R\U<U=,4RMP<D=M6'E30D%Q,U5-
M-T9#=DMP56\P9C)Q:71F1&)&5U@V64Y51FI%)B-X03M.56%"-R]F,6UT5F1)
M9G1(:GA6,F1V<S!R53EC0V]R1EA9<3=&6&QU=658=GIX,4A59%%T2719,#%0
M3#DU8S-584DX65IX65111EEK)B-X03M93$5R5E%N96HX=5<O3&IT:7%Z5V9Y
M-B]-5%9F>318>5!,<4=K2EIR6C)T;#E:4T<U.5AJ82MN>&%P8W)5*VM++T1I
M<GIJ4G8K8U0O)B-X03M!1%AP97-73W!X-C=94$I9,T56>6E.1DY1;49W-$)P
M5&(T8U4R.6@P:E1V>E=J931V-VE84EEB=E5$1SEX8FU+-F19,FI14F=+>7DW
M)B-X03LW3%A#:%AJ,'(X>EDY5G5.4D8Q;W!L=5E)3&1K.4,W-&AB9#5N56HY
M-U=P3G=A+TQ!<3=5.4XO338O,#(W<TI,<E)%:G4T6DE(6EE,)B-X03MU;T5I
M;$-25UAR=FER=T<X+W=#8U1D6G-K4U,X.#!A8F)*23-"1VU$>&AM;U<T9W13
M<&]P3E!B1DYV53E,,698<E-45'!:4$TO;%)))B-X03MR0S%/;F%823!Z15A-
M17%7:D=8830K,39I2V]P-&HK65E537!K,'(X>EI.5G0Y4DXQ;V]L=&]*-V1%
M148S>$LS1'A/>% W,G118F-5)B-X03MW2VDO5"].3"]L;S!0+VM29"\X0598
M1EAI4&U0+VY&9GIB<FYM1%5T86TQ>7=J;3%+-FUU-4DP:6U#<3!Z;'E&<GE.
M0GDX8U4R>4QY)B-X03ME;7 V0G!':RM665!.=FQ75S$P4C%U8D]D<F=T3$Q.
M3&-80U!'>4Q/1%)8;%9A.%)6:E1Q1&A1.4(Q2%-V>DYV:V=74S8P5E)B>GA8
M)B-X03M+.%E,=F1O5S5!1W-V431Q;FUI2C5W13AH,7E85#-G-"]U:%I2>F\O
M3W8W4FQD>%-N9TU#<'AI<G-69&ER=R]Z+TAP="]W0V9P,#%Y)B-X03MY,5E8
M25,U:#!U0W=A3S5G=6].3W-2<410.5AN:%)E6BMS3DA%45AP3C!91D9/1E50
M-4$O471P-7IT.65J.'9E6C1B>3EK5WA2<C8Q)B-X03MJ16-A6$-P1C9S-59%
M6D%N;V)N:V9H-"],1EAV1T)867$X6C@U+S12=DYC,39B52]*6&U#.'5%:%IB
M>3=S>$U"95)R2D9:3$9!27!6)B-X03M$;UDS.5-M,C-),')80W%.+TQM-3AR
M4BMA4F0V9C5/,6Y2=%0Q;$IO-3<R.%-:;T521E=90U)P6$E1<T564CA/>$A%
M8EEQ.5IW2S=&)B-X03M702]M1C5I,#9#+W1T1CAX-D4Q+V].-6-70U<Y>D<U
M9FYE5'IT-F-C:TQ):6-5.4%S,S<Q<3%!-#<W2W-&.&YA>C5/.')A;&1896DO
M)B-X03ML-S5L<S-S-V,R<5A"9VUK.5=.;F%2,59'8W%W<D=P1&146'0S2W9D
M,&)K:711:6]";V1I2RM/0E<X5F1I<G-69&ER<U9D:7)Z,S@U)B-X03LU5E11
M-TDS8T8P,FHR.#<S,F]85FI.-DTP4#%/1C5O5%%X4TMW.5)1848P*TE,=5)5
M67$X=V)1=DLQ>E!B5S!V;#=Z3F4R3FY,1E O)B-X03M!3'@R=W0U5G9);S!P
M1DA(145E:6UJ,$LW-S=M;498,$9O1W%,<3)I,E=P3&%Z,DLS8TM3:7IU:SE/
M84E-2SA(5&5H1T)59FER>C,X)B-X03LR;3!#-&HP+U1T83AR-FPU:FAF,6)I
M05=3=5E),VE50B]784XQ2VMO>$,Q0G%#44\K2W-/+U-(;$<S,4]855<X:65:
M2C4Y4'5(4#%M)B-X03M28FE74U=E,C1Y<DYW95%R27(O5FPK36YQ96U&6'5%
M179Q=WAY.$=J.5)1,T)X>&1E47)2:#))-S1&6#1Q;%AM8E9T4C!R5$9U-T-W
M)B-X03LO4TUP=4QA0C=F,4=J2W@S1391=$Q6235J4TPQ3V)B9EI"3F1S5F5(
M4GIF;&9F='!M<C9D-4$Q=3574S%74S-U65DU0D9W9W981$)N)B-X03MJ:V)L
M2U=J3&EV,F=2=4]X5C=F-5@X>$18.4YA*T=N,VUM8UIP641B6#A8;WEN,&TT
M.'=T5#A,9%%C0W!V:7(O05 O6B(O/@H@(" @/"]R9&8Z06QT/@H@(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" \>&UP34TZ1&5R:79E9$9R;VT*(" @('-T4F5F
M.FEN<W1A;F-E240](G5U:60Z83EA.#DU,F$M.64R82TT,3(X+3@T,6(M,#@Y
M-64X9&0S,38Y(@H@(" @<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HW0S$Q
M-T0W0S)%-$)%-3$Q.3%#0D0Q,#)$-T)&,3(U-2(*(" @('-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#TB=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$
M,S$U,#A#."(*(" @('-T4F5F.G)E;F1I=&EO;D-L87-S/2)D969A=6QT(B\^
M"B @(#QX;7!-33I(:7-T;W)Y/@H@(" @/')D9CI397$^"B @(" @/')D9CIL
M:0H@(" @("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@(" @("!S=$5V=#II;G-T
M86YC94E$/2)X;7 N:6ED.C=",3$W1#=#,D4T0D4U,3$Y,4-"1#$P,D0W0D8Q
M,C4U(@H@(" @("!S=$5V=#IW:&5N/2(R,#$U+3 X+3(U5# X.C Q.C0Y+3 W
M.C P(@H@(" @("!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC:&%N9V5D/2(O(B\^
M"B @(" @/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@(" @
M("!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C=%,3$W1#=#,D4T0D4U,3$Y
M,4-"1#$P,D0W0D8Q,C4U(@H@(" @("!S=$5V=#IW:&5N/2(R,#$U+3 X+3(U
M5# X.C W.C(S+3 W.C P(@H@(" @("!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC
M:&%N9V5D/2(O(B\^"B @(" \+W)D9CI397$^"B @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @/'AM<%109SI-87A086=E4VEZ90H@(" @<W1$:6TZ=STB-C$R+C P
M,# P,"(*(" @('-T1&EM.F@](C<Y,BXP,# P,# B"B @("!S=$1I;3IU;FET
M/2)0;VEN=',B+SX*(" @/'AM<%109SI&;VYT<SX*(" @(#QR9&8Z0F%G/@H@
M(" @(#QR9&8Z;&D*(" @(" @<W1&;G0Z9F]N=$YA;64](D%R:6%L350B"B @
M(" @('-T1FYT.F9O;G1&86UI;'D](D%R:6%L(@H@(" @("!S=$9N=#IF;VYT
M1F%C93TB4F5G=6QA<B(*(" @(" @<W1&;G0Z9F]N=%1Y<&4](D]P96X@5'EP
M92(*(" @(" @<W1&;G0Z=F5R<VEO;E-T<FEN9STB5F5R<VEO;B U+C$P(@H@
M(" @("!S=$9N=#IC;VUP;W-I=&4](D9A;'-E(@H@(" @("!S=$9N=#IF;VYT
M1FEL94YA;64](F%R:6%L+G1T9B(O/@H@(" @(#QR9&8Z;&D*(" @(" @<W1&
M;G0Z9F]N=$YA;64](D%R:6%L+4)O;&1-5"(*(" @(" @<W1&;G0Z9F]N=$9A
M;6EL>3TB07)I86PB"B @(" @('-T1FYT.F9O;G1&86-E/2)";VQD(@H@(" @
M("!S=$9N=#IF;VYT5'EP93TB3W!E;B!4>7!E(@H@(" @("!S=$9N=#IV97)S
M:6]N4W1R:6YG/2)697)S:6]N(#4N,#@B"B @(" @('-T1FYT.F-O;7!O<VET
M93TB1F%L<V4B"B @(" @('-T1FYT.F9O;G1&:6QE3F%M93TB87)I86QB9"YT
M=&8B+SX*(" @(#PO<F1F.D)A9SX*(" @/"]X;7!44&<Z1F]N=',^"B @(#QX
M;7!44&<Z4&QA=&5.86UE<SX*(" @(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D^
M0FQA8VL\+W)D9CIL:3X*(" @(#PO<F1F.E-E<3X*(" @/"]X;7!44&<Z4&QA
M=&5.86UE<SX*(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" \<F1F.E-E
M<3X*(" @(" \<F1F.FQI"B @(" @('AM<$<Z9W)O=7!.86UE/2)$969A=6QT
M(%-W871C:"!'<F]U<"(*(" @(" @>&UP1SIG<F]U<%1Y<&4](C B+SX*(" @
M(#PO<F1F.E-E<3X*(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" \17AT
M96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @(#QR9&8Z0F%G/@H@(" @(#QR9&8Z
M;&D*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E
M("T@5%0B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3TB07)I86PB
M"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,"(*
M(" @(" @17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3TB36]N;W1Y<&4@5'EP
M;V=R87!H>2(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB-2XP
M."(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P
M(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K
M<W5M/2(Q-3DX-S Q-#4Q(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I#:&5C
M:W-U;3TB,34Y.#<P,30U,2(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z4&]S
M=%-C<FEP=$YA;64](D%R:6%L+4)O;&1-5"(O/@H@(" @(#QR9&8Z;&D*(" @
M(" @17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@5%0B
M"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3TB07)I86PB"B @(" @
M($5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,"(*(" @(" @
M17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3TB36]N;W1Y<&4@5'EP;V=R87!H
M>2(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB-2XQ,"(*(" @
M(" @17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P(@H@(" @
M("!%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/2(R
M-3DP.30U.#4P(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3TB
M,C4Y,#DT-3@U,"(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP
M=$YA;64](D%R:6%L350B+SX*(" @(#PO<F1F.D)A9SX*(" @/"]%>'1E;G-I
M<T9O;G1396YS93IS;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ K (C P$1  (1 0,1
M ?_$ !\  0 " @(# 0$            ("0<*!@L#! 4" ?_$ $L0   & P !
M  4(!P4' 08'  (#! 4&!P !" D1$A,4%0H6(3EW>+>X%QDX6)>VUR(Q-C>T
M&!HC<79YM4$S5W.6T]0D,E%269&Q_\0 & $! 0$! 0                $"
M P3_Q  X$0 " 0(#!08$!00# 0$      1$"(3%!41)A<9'1 S*!H;'P(G*R
MP1-"4H+A,V*2\4.BPM(C_]H # ,!  (1 Q$ /P#?XP!@# & , 8 P!@# *8_
M,ET);T)KVGN:^;91;\/OCI&7/S@"8T+7<PM2T*\J*FV8N6S28M,0@3+(I*8E
M=9NNJVM7%84TC2%,\]>3E"@DM*;@U2L6X:63LFWEZO+ AJ'N;77C_P RBOCJ
MNP^!Z:D'!L]MR6.L-GC10CZY]HUA:OZ)[WK1ZELH;3%ZLSGTQC<7TFHRO<E4
M@)DB=ZDS([M+86A*&]G9VH6VU4EA/PM.'"UM?EB2+YP[2G+)>G0JDUTZ9[8K
M-'SUXREM;CK>JRR94M-N6ONCGR57DYU0]J:^+@#=81<,C3O- $H6X:)S4L*0
MA@(3[ 4E$=-EA2YK3EZ-6G.)(E3CIJUFV?=RUY3/D!3R:/S+FJ/3VJ[CL^XH
MU\Q*QL-?UDAIZRG21O<9K4M5R,Y0O<Z25-75;?,Z:M$V^9QMA.+FVO;<]-P7
MOW[R+'=FG!W2Q:B?U?%A.*C GCS5TO=#7XX.@+8@J!]O>Y>:+"OF.K-6!;9E
MXLMS&47,/:34RI[88X35"J61V21)O>VVM#5$.:3VJ;%ZCKRG=2VI6:M&6EMI
M8)QELQ.ND9\R+5[>;.S(O10^A:BBE+K8=,5?5=E40P3Y#/B)9;/,O+XX3$QV
M$$PV10J*QHZPK"<Y0)K5N,B,D:>**H!N&5-:+N]/(&<547AS^68R=67AUNH@
MRPZ^7*Q&YRZ6FFH_SB5"J(*OYG8N;W6?S!#V!8KS2/-"'H!/+XNVH6=XC;G"
MI?M2<6%*HC3(!GKP@Z?IIA(7,HF#KA-B8QO%_P MZHXZ>-HS.*RWR-7(EU0D
MB<I_S'9SZDL*YE[H5RM9E@JX"K:F?QR7/TQ&8A;T:=/?@&KTLBCJ'25$EFSZ
MD=6OX#-](X>]@+8$XJIW-*$[_.J;>#^V\\*;RT]&,\3>45BQKFZ+61+Z\X%L
MNE36U+:KW&51/:S;;+J;7+VT'O#2.03F')*??CVIZ<9S4<!>2%GM'R0Q?;86
M%Z#964M34GA^6/6='P9&]L\S?4FD3UT<[-50GP87CVJJWX]S^C5G%IA6S-.S
M+#Y@D%A$2LET4N#E$8VHBI,UF:,+RZ-##6R!(E;7E ZJ7R8NKW_/OU&PL$_S
M-3N5*:\7>#(5J>7+I!]IF5Q)(EYRI.>ETOWO)W.YY)86TD2EAO,B"!,S!'J-
M31.>RXV&7D_*;33NRJ(3"7S!V@*Z$.0S&63I')O4$AL*<W>FT:SCKAEK$HL,
MEG4M]U_S=XQR*W)@<NMCKYVINJ'V6W(.4+V=K7R'E&Q;B=YVXD15>VN[TZ[?
M*[),4M_OJ0#P6X+DFW!I/4DNZ"+!:P9A35I3?_LE'F5W,_E?Z3M>NJA6SV%0
M""CN**>.R_H@HIF6SUE=V*.WEW4Q<X3J$RYV=C3MOR9R(;CI$!.V)&E#\!>E
ML#>M2$))DG<*:V$IASWUQBC:7OQW&17;S)6\U4Y9-T!9N4W(U2[.S#7E#H9W
M--W[31Z#L2-<H?.?I2/G!+8!PUJU)")A*UZ5XJY4S/QC' TA+J@?5<_CH;"F
M+Y7:L_AVK<8A8SCN+8>$NC9GU%09-DV#&XE')8W6%9M>.FX')&:21!_W7DT=
M8N1)F?X/*)D*-B=TZ H;S"'B2N[]"I"4[QIS<7 QM X*AFI;+A;O-23)P9&
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M.91#J5F:7EBZHA50837BV&R*PCV";2ILEQ<K?#D<EN0B(MZ )[,S3Y,Y$C3
MZ$M7W;)2_B4[OLWN@Y/<WD\M=\KGO94@?N=(,SU##^\X7 ZP:;/GT:[')D7*
M<4--1V@@TB;530*-S80396V; U0=?$(D[PV0H)',%[@:TD@J;TXW=-X^'XLO
M#QERK',VKRB7I'[#3GS*'4NCYX:.N+ X]=GE2X6**T"'"$\6J>KTMHNSFE+>
MV8+$G+:E<<D36@B[T^N)1PG5J*(4I0-SD)LJ+-SLJK=>I*/,BBQ>7'K:ZW.M
MV)C>^?*T2H.ON$X[*)XUM;RGB<WI[JBO+AGB:..#?)9E(Y%%41*NLDH#']U4
MP";25J=V7WN#P(*IQ9G(792U;BJV:::6*QS4:ZHYG&/.'>\AAEJS(^DJ;84'
MNL?/KHV13LIJ#39DC[$B?*03>D&<F9N<V<8W&TTO^?\ +)FQ1"N65E<XE)*[
M7!2*U3/*#Q7V:6?EC\+JLK:1XIDJ.6^P;E1\<^5/HR:32#W5,.9+X[%<8&;&
MGIW>*D5-=(T1!IDPQ2(J#'%4[ML!4R%.YF[9R7IP5LHW=T0$OKD<1IT4".E3
MV:5MI4SK=NYCZ$>3CKT5P1N%V/7'./S.,Z&X_IF4*80JLPJ3#;^U:,_2W$54
M?-?' ]K3+ZF7 TT21Q<$JM/8Z59I0U,E>FMV].4X[O/^2.E1GA4_\7'GY;S@
M7'WE%MZ:1WF:'.;YS]#F\%#<83B=J^G+/GGZ8[]7]3S6;0XQ!0KNA1N!LDD4
M+,B)* )KW'),&93E\;HJZ+("W:.E0"ND]Q70KN_YL$H4).^F/*]\"4/C"\E=
MJ]U2J2H9[6->PF/KZH9KDAQ<5EK8HE\,0N\_D\,W7-D197,7N4.3VD(9DZGY
M_$Q:!L![^WR^)FQA"N84ZERI*Z=G?Z/1KC>TNT%S&# P!@# & , 8 P!@# &
M >LM6HVU&K<7%6F0-Z!,>M7+EIY25&B1I2AGJ5:M2>,!*=,G) ,X\\X8"B2@
M#,,&$ =[T!PR#VI6%G:>-UM8\#L+4=5)4,@W!Y?'I9IB6KDH5R)(\;87%?\
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M4%*T2Y$K* >E6(U1 S"%*52086<G4$F#*.*& PL8@"UO8'M8 P!@# & 8CZ
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MW8(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M4DZ]Y]<V%VK)$?EE<^8HO3O>'3/.L!J=OYNY-EZ=J@53RA$ABZGX_/8J7*7
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MY!N-\&JL*/E?UU$Y<&1@& [H_P 8<S_;X9^!EWX*L'P^Z,^8(, 8 P!@# &
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MV>#<SEICP+U,&!@%.?=7UH?A)^TKNG\HKY@W3W>TX4_4BXS!@8 P!@# & ,
M8 P!@# ((<S?M;>2+[9>?_RC4O@KP7#[LG?@@P!@# & , 8 P""'%'^-^_\
M[]\Q_+WS;@KP7#[LG?@@P!@# & , 8!J[VDW1*0=Y6(C;NP74$S9>G8^-UE*
M.H_)VZW)3(@R&+/Y%%L?S"GR;D3<3''QIXXQ/+S" 05Q@4D3R67QB;"5KWI^
M'1.*;K%.WPP]^&UR<S@U)M$8.9 7R3SB:0#F!X>:[WT<;-5DLC3'&F[F.(2.
M539R=W42TA"&6*X?6MK2V&U.SJ=%2>QY=%8BMDR=A8C&./)WEY?D,7?QJG'+
MQB/-I3I?J5/NDWZND_E7\,31T56\;:XQ'(9V:76MWH96Y$R_H,]9R'&_GA.I
MU1SY7D!D'/STN5IFQ[/KI\*6N; MD#A&UA:11'3=J1I1L5P])6BVEGGY:FRU
M@YG4R^<OZVCN/[8-?RE&<'L[+^G3X_4RJ'!T-KSY(9^WWT+]S^2?C12N#CV_
M<7S+T9V'F#RD?)G^TI0WV<7_ /Z^EL%R?%>C)!X(, 8 P#I[O)]]9-Y ?OI]
M0?C7-<'NH[E/RT^B(,8-&YS\CI_S8[G^SRD/YDL3!Y^W_)^[[&]_@\Y@.Z/\
M8<S_ &^&?@9=^"K!\/NC/F"# & , 8 P!@# & , 8 P!@# & , 8 P#5WO\
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MK@[ V\'0.1)QN["K=%,?7H&]4T&EB!1L5P[PI48?$LYN;-V#F, 8 P!@# &
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M@RBC5#5=8#S2RQ"V !AX$R<!PPZT(P)!(1[%HH&@CS]O^7]WV-U+!YQ@# &
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M_P!GE(?S)8F#S]O^3]WV-[_!YS =T?XPYG^WPS\#+OP58/A]T9\P08 P!@#
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M .B"WXBPI;'X8M^ --?60SER8M#$G*0_'6=[;8TR/I@T.C!K94I3CG&%VL/
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M]Q?,O1G8>8/*1;O?I7E#GR80A=?]JP*MIDK:WI'!#9<XGH5ZELD*YJ3/*=J
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MHVZM?)=#XJKY/KX?UR@Q4MXV9EBH[8=FJ55O]"*%!NPA" .S#C;:&8/80!"
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M?[:P)9*U"#W5.O5E^R;349)_M?74%G#+*$"^\9]2-MXDKL$& , 8 P!@# &
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M1ATFBK'.=.8I?4<C$0Z(IM 4NGYR)BRU:@9E E5.RD]=UN=U.$K(M!P9& ,
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MMZ^G6  @ $0QA $(S-ZV8((=:$/80Z"'8Q:UZ1;"'6@ZV+>_0'6M:^C6 ?K
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M@<7<@EJ&%4'EWG[V\6;Y:TQT>ZA@0O@S7/%DC<)HW-X!,.P)T,I7S&7K'Q*
M.B7%3+)0>I 89('<2P7:>KYOWDC+M;U=6].Q1)!JH@<2KB&H52]<DB\)8&R-
M,9*YU5FKW1>%M:4R5*)<Y+CSEC@L&6)2L5&C/4FF&BV+8DSC<YW@# & , 8!
M^0@ #6] "$&MB$/>@AT'6QC%L0Q;UK6O2(8M[$(6_I$+>][WO>]X!_!E@- (
MLP # "UZ! &'0P"U_?Z!!%K>MZ]/T_3K /[H  B&,( Z&9ZOKCT'6A#]36]
M]<6M>D7JZWO0?3O?JZWO6O1@'ZP!@# & , ])R;D#PWKVET1IW!L=$2IN<4"
MLH!Z1<@6D#3+$:H@S0@')U*<TPDXH>M@,+&( M;UO>L QA3M$5-03(\1ZI(>
MEB3;(7HJ0OX@N+V^.;V\IV)EBR):[/LD<GA\<1-D7C<?C302L<3D[/'F-I9&
MLE(V-Z5*4*VWB9;WK6];UO6MZWKT;UOZ=;UO^_6]?^NMX(?@))(-@V HL&RB
J_8E["6$.RR?[._9 WK6M@+]( ?\ ##Z _P!@/T?V=>@#R8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g16439g80t23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g80t23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1*X4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -9    !@              K0   YT    2 $$ 0P @ $D
M;0!M '4 ;@!E "T 3 !O &< ;P M %( 1P!"     0
M       !              .=    K0                     !
M                 !     !        ;G5L;     (    &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    K0    !29VAT;&]N9P   YT    &<VQI
M8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$
M;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,
M15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *
M15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   *T     4F=H=&QO;F<   .=     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]3LL;6V3K.@
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MSS[#]F].OZ>_U5U:22G_V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !+DU- "H    (
M  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!*  #
M 0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0
M "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,34Z,#@Z,C0@,3@Z-#(Z-38   .@ 0 #     ?__  "@ @ $     0
M YV@ P $     0   *T         !@$#  ,    !  8   $:  4    !   !
M'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0$P34T *@    @ !P$2  ,    !      $:  4    !    8@$;  4    !
M    :@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0
M   !    I    -    /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-3HP.#HR-" Q.#HT,CHU-@   Z !  ,    !__\
M * "  0    !   #G: #  0    !    K0         & 0,  P    $ !@
M 1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !     $
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M"?/ JCD7\AB(KXL9ZI]V&B.17JJ.8YJM(1KW/$,7C6_R6>]*'4&2T]IW(WV
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M\L,B1>_PR:T/>FOP[L] <<LO-BX$ML5K7'VNL[:WAC6.&VN\C/=V>9BC50%
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M<,]5S<^N8>L,%L,'L-%P]E46,W.*TMO4X=DLBTP84PV+0[*')!2@,:PN#C!
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M2>YZ?#V=_*H<  $#;K[!3>X.G-15E2M#6ZLUS HU"L=U/#PC&8U6X"IV4+H
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M;^^20(B_-A4+Y?M\DL1:_%V&BB(U1EM3I[<IS514<D(**JQ^Z?FR".]]$5?
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M<4I!?4-4)ZF_7EAO3_C[GVO2UT?3R9%OC(XZJZBRK8LN0,<G *^:#R%-EJ*
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M0<6!50I6?ADV,R0]?$46(,Q7_/BQ41>U?%D]OW#]*GE7V?>?UJ7M@T!:#)[
M7MJV'.,2P@/1%]MT>41Q'"8O\\8RD K>_=$8QW;Q>Q5T@>D;P\NN'7%;4MD;
M9H</G;VYU+IZ55V@DQN6N)+B2VA(Z+_A=Z]SCFB)YTCMX)641W$);N# 7RWV
M-MVYN::!%MYP3ZP>-0H8_P#VH%DW&_5B/Y3MI/.BJ^S^_P!^SR]OYT<5/[_W
MHXJ/WY^7]_M%0GU X+*SW6]G!K(Y)=S3G!?U,4+%(>7(@L,.3$"-J*\II-=)
MF#C!8BN-+^G&B*JIRK6<^0Y+.T@FN;N>6..TMK>)YI[BX=Q'%!##&K22RS,_
MAQ11HSR2,B*I8BNS>$FJ(-*ZTL;J]E2#&Y&*7$9">1@D=O%=O$\%Q(Q]5(H;
MR"V>>1B%CM_&<D 5RT]274DS+V3,!P*41N,(]07]\/S"_(7"?]ZO@=_$C*-K
MV-<:0J#);.;[;6MK$=]H^SN!? IM-/;:QUE;(<_RB7#X>3ED7"AU]6]O=B4;
M+%&(B@',N-!YV8WY LMOF@]!G%F+-9F-3D.4-969V86(9?XTW=3>$$A$&XMA
MZVYG(\"X_HM]8^'=-&\LKU]M&\C8WKG>5?1UC<FLCCC4N-9WCLJ:N,S+R69S
M UM+;0[FXJ)UJ5Z1X,TM.>>^/6CFS8GNC0.>@Q&1FMKR00VF01$\9SM'#<1,
MQA:0GHL;J\D;.>BDH6(0,P\]>G#P4S7%'06(U'I.PERFI=!7-_='%VL;2WV3
MT_DH8/\ %8;"% SW5]:36-C>06B*9)X$O8[<273002]FXBB.(9P$&8)AL*$P
MGM((HB-1XR#(Q58\;V*CF/:JM<U4<U5147G?@((!!W!Z@CJ"#V(-:1G1XW:.
M161T9D='4JZ.I*LK*P!5E((92 0001O6/NKREQJIGWV16]704=5&),M+FZL(
ME54UL,2=RRI]C.*"'#C"3Y(>088F)\N<G*22QPHTLTB11(.9Y)'5$11YL[$*
MH]Y(%?HL;&^R=W;X_&V=UD+^[E6"TLK&WFN[NZF<[)#;VT"2332N>BQQHSL>
MP-)_VSUE[(ZRLHN>F'T[I$@\-[EJMR=8!(TL&O\ 5U!)7V+*)KVP\ $R/,["
M*XPZ:QK3"(J=YN+D>'W,PQO@E]G[O/S/A]+%BI/AW^<V9;:SB8$.+9NC23L-
MQ&Z$$]X.G_<1>S=(<$],\$\59<5/22B2*8 7>BN#*R0OJ/5F0B_ZEM-J.WYG
M7&82VE"-?6UU&Z@_]#*HK\N%RC$.F+IHUGTGZEHM2:PKG"KJ_P I]_D$YH7Y
M#FN42QB;;97DLP;&++M+%XAL8S_)ZVO!"J:\8*^!% /E6'Q%IA+&.QLU]5?6
MEE;K+<3,!SS2MYLQ'0?510J( J@5YNXJ<4=4\7M89#6.JKD/<W.UOCL= 7&-
MP>*A9S9XC%P.S>#:6P=F8_Q+FYDGO+AI+FXED:PG/J5US4!_XMVLR=0?^,W-
M!=6>T08C_ BHD6-JZ31X]1*SVR,H:?V&#@2S--9>[+0Q"/\ MNX3X;-<C+<Q
MY>7RWW^?OJ-NN_G^^U3YRM36,NZ:KR.FM\>NX0;*EOJR?36]=);YQY]7:12P
M;"%(9\>0940Y0%;W3R&1R?KXI45Z$T3A/3AKJ#JS71\B?B%78VEC5Q<DN7W<
MJM=<2?KIT.'*($#A0"6!)5@V,K7(R7.F$1W8J-;9F+'<]_=4 ;#;\:KQO#TW
M^E'?&0RLRR#!YN'YM/,Z389=K6X-B%G8RGN<\DZP@"#,QN;9F(Y22+>31%MI
M3NWU,TS41J2LC+TWW'L/45!4'^U1%0^D)TJ5]Q!M\FM]T;%^SCC/%KLRV05L
M$;PO0@? V*5&+W E&YK51T>U"OPGRGSRWBMML H^ _7<?=4<B^\_OW4TIK4:
MUK4[JC41J>3G/=V1.R>3G*KG+_.YRJY5^5557OS%5Z@OJ&Z==;]3N"1M<[2!
M<R,:BY%6Y0(=':OIYOVK51;&)$<Z6,)G. @;25[@?#L]RC<KD\.RV5BIW'>H
M(WZ&O._^G?7'4MB5)A>S@7$BDQ_,*G.*YE):OJ)+;VFA6L"$\TA@C*6*D>XF
MH6,K40CU&Y7)[?92L5.X\QM0C?H:G3E:FH-A=/.N:_?]QU+1P7";.O,&%KR?
M(?:/=2.QP,FKEL&*H]I&#F>]3PU64AE<K4(WP_*+VMS'EY?+??YU&W7?W;5-
M<F..7&D13>2BD@+'*C5\7>V8;AO\7)^:[Q<O9?U+\\K4U!&E.FO66@=32]+Z
M]CW0,(FFOSG%;VS[.S4F2A0%GXV#PB<U'#3\@GMK[2_*>7+,Q8[GO4 !1L*S
MFB-&8'TY:UJ-4:V#:@Q*DEV\V".YL7VM@A[NRDVLY2S7B"XC5ERBJ)JC3VQ^
M+$[^/?D,2Q)/<_[4 V&U8W??3OKCJ1QS&\6V8"XD56*9G59Y4MI;5]2=M_30
M[*#"?(,P)E-$0%K+0L96M0CE&[S3P[+*L5W(\QM\J$;]#4Z<K4U!=7T[ZXJ-
M_P"1]2T,%PFSLIPF/@%M():O)2.QZ,6C,)@*A1(P,M'X]7>4I#.54:9/#\JO
M:W,>4+Y [_.HVZD^9K]M[].FG>I3$F89N+#8>4U460Z;4RO?E5MY0SW,0;IU
M'>5IHUE6F(U&-DB#(^CGC8P%C%EQV^UPK%3NIVH0#WJF%;Z272L&=!+D=GN?
M/:2N,PT/#\QV=-DXN%!*BC"R-2UU'9M U$1G@RU:KV=V$<]KG(MO%;RY0?:!
MU^_>J\@]],GH:"CQ:EJL;QJHK:#'Z.#&K*:DIX4>NJJNNAB:&+!KX$08HT2+
M'$QHP@"-@V-1$:U.8ZO40:'Z==;].51F%)K8%R"#G&;6FP+U+FU?:E?D-Q%@
MQ)CXI'A"L:(X-?']N*B.0;D>Y'+Y=DLS%MM_(;?(5  ';XUO6SM=8WMS7V7:
MSS <PN+YO1S,?O!U\IT&<^NGL]N0V+,:PCHYE;^85&.5J_/9>0#L01W!W^RI
M/7I1K'76-ZCU]B.L\/',%B^$4D/'Z,=C+6=.9706*P#94QS!ND&1J_>*K&JY
M?U)P2223W-0!L-JI+MKTMNDO;.6V.<KCV4ZWR>XDEG7,_5F2_P &(UE.D.5\
MB:^FF0+FC@R91%4TM]36UR3)*OERFFEF.<EQ*X&V^X]A&_\ ?]]*@HI]WPK[
M]-^F1TKZ6S:BV/3T^:Y9F^+SA6>.Y!G.:V=H:IL@*[V9H8%2RBJ)9A>2^TEE
M7SA"=V*,3#-81HR,1MT ]@ H% ^-7BRC%JS*Z]8-@Q6O&JOB3!(GU$0RIV\Q
MJOP\;T[(4+_R941%5$>P9&=5<6.$FE>+^G#@M1Q/#<6S27&&S5H$&1PUZZ<A
MF@+>K-;S *MY8S;P72*A/AW$-M<P?3QN3N<7/XUN058<LL3=8Y4]C#R8=T<=
M5/M4LK5GR'6624"%/X1["O8[LDV.<(E1JJOA[L:009F$7M\M%[[&K\(5R?/-
M6G$CT5^)W#SZ5?\ @8W46G(9"L><QV0L[-A&S$0_3,7DKFVO(+AP/7AM/\1@
MC)V%W(/6KL:PU'CK[DCWD@N"-_!D1W&_GRR1AE8;^;^&2#]4=16B#AR"D0(Q
M^1%541OFQ/E/Q^7.1O\ [\\_VN&R5[=BQMK;Q+HL4$7C0)ZP[CGDE2/Y\^WO
MK[1FC1>=F]7OS<K'ITWZ=3]@^ J2*74N3VGM%E_2540G9WO&..49PU_UA B$
M*UR_^4QX_P#O5.>G-#>ASQ7U9]%N\N,/I##W 60WM_D+7+7KV[C<2V>.PMQ=
M1S.1L1%>9#&]#U<'I7'[S5>-M@RP^+=2CH%2-HD!]C/*JD?%4?X&IVQ77]#B
MWB< EG67CV=92VM<5O?\Y(HD[CBM5%5.X^YE:JL(9[?CFP/A+Z.7#WA*(K^P
MM'SNJ1&5DU/F4CENXBX(D7%6J@VN)B8,R<UNK7LD3&*XOKB/91PC)YZ^R>Z.
MPAM]]Q;PDA3VV\1CZTIZ#HVR C=44TC+K]]%&IW/DU_N/I<M,?P3.K^3(MLK
MUG>H6NPC)KB21QY]QCEI"!*7$[BQ*YYIE86 ;'[&>5TEIZ%SY19/+]3</TOY
MI+_#/%;W$A+S6<FZ6\KDDM)"ZAO!D<]2A7PF;J&BZ[^^_1W].:\T1B\=HKBO
M:9'4&G\?%'9XC5&/Y+G.XJRB58[>RR5I/)$,Q96R )#=)<QY&VMT$1CR 6)(
MN:K=/2_O'IZR.5BFV\+;BUU$(K'QQY)B=Z,C>WDPHY&.WML%1E8K2,1[QE1'
M(A!C>CF)U-D,5?XJ5H;Z#P9%;E($L,O4[D=8I''4*3^-;/\ 0_%;07$?&0Y?
M1V<.6L9E#+(V+S&/93U#(T>2L+-^9""K%59"1NCLI!-N.D&1ZF^6)$P/I5V-
MM =.$:CC4 ]M8_68Q2PQ-:I20:;,\G%75L<+'(1XZ: AW_[,!7_=Y]K!MJR<
M);X6[O!'_)$M]'%"@WZD1SS*BCH=^5=SY FNG>,T7HL8@S:AXMZ:THUZ[<TF
M1;1^1NLK?3.6"+/>X/%M<W4CLI56OK@QK_,ZKUIS&L?2*Z@=T3JS)?4.ZJL]
MV96Q90Y[-/XUG.47E.Y[/OL'89+=DB5U/W57"FP\0QD1G-570<H"[L].>V>A
M\I?NDVJ,S<72*0WT&*YFF!V[!YY=DC'^98(MR.JS*3T\2ZJ],CAUH>WNL7Z-
MW"33VE[J6)K<ZTRF Q-A>A6]5FML78+-<WO8/!-F<J\>_2XQ+C=2\O6.J]<Z
M7PRIU[JO#:'!<-I!>W7T./PF0XK7JUK33)9/ORK*SEJQ"S[:R/+L[$_E(G2Y
M!WN(O8UG96F/MX[6RMX[:WC&R11+L/(%F/5G=MAS.Y9V/5F)ZUX)U3JW4NM\
MW>:CU;F\AG\W?OS7.0R,[33$ DI#$O2*VM8>8K;V=K'#:VT>T=O#'& HD#GZ
MJX[1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE
/'%*.*4<4HXI1Q2CBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g16439g81p33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g81p33.jpg
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M05%AH=$#$G&!D;'P$S+!(N$S0E)R\00C8H*2HD.RPM+B_]H # ,!  (1 Q$
M/P"56RK!-V385VG)Z5/EI>2M,Z0;('E/$DD.KDR?FMUU:E>5"<80TWC.&VFD
MH:;2AM"4X]\(8!KAV7G5$>HY_2+_ +2O[^5$]1S^D7_:5_?PBJVA58Z^7.LT
MX,K CMAF0HUR0?4K(L6&\\G,C,&YPK'D AX]),F>YG.,-!B/N*SC",YY"6!-
MR*ZUBT3),W&>CZM8HUZAAQ50LT+?;E(!5*--KNPX\22IB#5/DOLLSQZ27X\V
M+$65D"0AY]12V (61+%F](.)EPPG,51=WGIEMJ@JVR!* 3-EM5<CI46& E8=
M#,/-'[4G=7L5Z3,<DUH,>.DX7#$<7&X6V_,E.1F6_0 <D'\^I64@3>7  +C@
M\P;%6ICJRH. TC?9Z+C9S+L#!PLL#&FARMELD?"!Y7.3MEKM?CWUE/86-)3T
MC3K.Y&BD(;[Q4,9.%N"0J$GJUOB=K7=<G$\>+3'SR17%J>L)6>7MB,DG3(>Q
M:TK8\CF'>0C"R)]S:^O=9D0D@XXZG 6!7;H42Z^CU,I)CFV,I]-U;B!B;=N)
MRW2?A+\-0/E55+]-VR8823)(D*44Y%-WI+X$;>8*0D7I#6$8N<V)#!"#%+67
M)TZ!2B:ETLY4&H)]A$>8<:[@3DWQC-K+(BP/ E&\X57*<Z8=HM+]V4=2,R&)
M7-=^%(OD Y)YM+T6B;BZLD1!:E+FYJ*4HN.81E0R%M. 21<?*82"IOC$<1)G
M9W14E"Z0V38)MBO1@ CLH2QK$AEER9 ':4UM^)BIJC940^0VPW[^!- .%^HX
MG$8MQ;9N65-.>6F( .<?^I8IYU78$Z3L4=$$2QTM!/QSP,!(Q%EBK-#G5)0T
MM:).I%KDI1).'A\Q\Q$'A/X8%=\BV$FY\\64$<2W@[,;7%H8/3$(N;CIUV#F
MQA57,K2D3$H!4C(IA=SB\*DGKW@YVHQ@S'J9,1(3(@"Y)'O8HP($67%24J:
M%,1;Y<WX6>;3>5&9^]B+M,=.EJ>K]3/B3$V&?N=8C)L* C"XQAV#DI';DWJE
MJ(G'#I)KLVX;#Y>^)-)9'#-7(!GH8$A2Y)UOAS8 3.\;KN-)NX95J8ZD+H&]
M"7=YLF1:FJ2Y5Q(54\_=4W*,^B: &K$#5"T8DLKP\N1"GY./!?B6PU2:FS@9
M 80B+."-(N\+C5F:;L_:=RGGPK5VBOS=.L<[4Y]OW6;KDL?"RH[1;)C+1\:2
MX(2E@L1UX4MCU6E98*%>='(:RAYAQQI:59H+@$4(?JBZ+U'/Z1?]I7]_*B>H
MY_2+_M*_OX12XZ$Y^;A>J_2_PJ5/ 3*VMJ&DT"DNM-R$5(B%L& &M)5ALH5Y
M"L*RR\E:$NH:?1A+S+3B,;0?1%P5AJ.(5+]7\_-SO4_O=^8E3Y)T#:5UA 5F
M$NOY#B(2P'Q<3'#86K.&0P !6!AF&\);;;;QV3WSG.4  @A85A'9TBJ>)4;_
M %'/Z1?]I7]_-J)ZCG](O^TK^_A%+_5/3>'L.GT*P$YVBA%XL=@@#[57*B--
M4#78\.9&!IGKU,$2$>W&Q Z)%<K+/O&A8$B 2R6UNJ;PA7.*-B1],@)$S/#P
MJ@/\EI!6GAM%;!LD=%G5M<#8'I:5J\2U$Q=DCGI41ZZS*("JOR;*WFAX]F8E
M'A1T-DE(- 08&1+!QXY#;N=;P%7$B9B4IGSHHN2-H6[%DRB!YNDKC8EJ%]\L
M*[E&CP+!]BD)J*AH<XPE;+L)*%R%<FV5LV$:(8!9!Q(R)(D4;&G&M\7&VR<F
M/.MCIYY<OQ>C;N8U2GH,-1+=P)J4,VHN5B6TB3MO#E9"+66M@UUN-@B@H68*
M8E9-8S;8\-+O%^@V$XKC>$WL<T- TIVSS"+HI[45UKM7Q:Y!42H5H.N2<G%"
M3@95A@HBX"H.JDM-0[3F200)X1\-\5S/J."XD8IJ5:CWY2/:);P=IVS:4JSP
M15@+H2>FX.CSD#.1#(EAH,?<K ;:)D"O1T$3,;2OFM(B.'?)?4](X-*J(;B?
M=V'"&GY)W+S+8(KI:)OUD91&$-.@!?-5J<'S9>!/3ALH)XY!AE/&%AA;(_8I
M5=V@W(BMDTV<JM>ML1+R Y3S&)F D;M5TDQX&3W#$2XWP?,D[G+.&^)5FS2J
MX)'5BHN+8.GG9E<=-8+S737XKZ9(FFH:V0\OF%?H]5*NTP+(N E.LMD/58-^
M6C$,N/I-2VX#A;<FP2$P$8-XI4-4[O=%^P'3QLNQ,0Y F:Z'BQ$56/KC,K:X
MF.)GIJ[Q"9JJ046,03AY^4F@U82RA:&Q!2<H'D"PW'6<.4Q@/4M5A=7I_"+P
MC-&V:Q&! 0<E#"&/T6,O+XEFL45$/YB"*\]8Y*685@AT=J%CX\=\EXH]\1P5
MI.$FML.JPCDWP'<&K2#\.9N1=I1NG6W7,^F-YL57CXBU6*J5P^58G I9RJ&7
M:&DK!6FYL(8IIO!DI%1)ZVH\<YP@&093#3?PB5=;$4,8#R+S8,0[5;R=B+A-
MZ$M\AB)<C"X<0.4!J[04C8K/!Q,?/62V9E<PT)6RUFY;,5)-Q)3X[Q?N; +&
M&7IPB+0:!DEOB;XR +@"_P X6HNEEM)7^#JI5JD_@PS0-?"MAT#FP *M058.
ML[%+;G#(##V3!A6K44+"D,/81(LOD-DJ"S'^<Q%W@[3JSM)V>O!//A6?]1S^
MD7_:5_?S2)ZCG](O^TK^_A%=[0%@FZ[N_4DK!RI\7(-;&IK*2@BGAW5#E6&.
M&+%<RVM/JBF"NNBF"NX6P4,ZZ.0VXRXM"LQ^V*WZ3V*HJ.(7ELC4^SH"_P!S
MB):@7 0\*SSC3S2JY+K1G_G(E3;S#S8BF212&E(?%*86X.4.XV0.XXRXA:D,
M4)A$Q06J*BOJ_OGX)MWY;F?\%RN+QU")]7]\_!-N_+<S_@N'%XZA%7% SMS6
MLN=8JK3K8!8GX&8@HN?9@;,++5I4Z-\./F:\: D1X";^%/'Q@QV5.^ZL213S
M#:#$C$CP[L08D,X+.)M?@BNHYM7=D[#B0>Q]92VUA& H\,PR]1NR#9V9S!6"
M>L58?F+ !,@2YJZ\_:K1$A(44EMRO3YD6^E>1(<F+SNP6$0UH0&<,6E:PYCB
MJ]\^+KI2[WN5^ #A ]8DPCX,6S$BS,'4+1&FBB!;3E=NQ/N ;+WP2-5#V:;D
M!H_ $6.RW#K'$6TX\*P4F@0@N]I+.&F #C9>HJP%W?OABQW.<7K*49C[H13B
MR:Q Q^SZ=#1+U"C9")K3$0149^%G&HML&7EF92)+ERPY=<B^>2G$NR#)!S=A
MDT0D\_I)+UJ&X2E2DD5J8&4V] 2E_F&J#-G';'":#GG#JM8U8;]/8E1V8H@'
M#&&,MOO3M-CQG,D*);S&E'M)0DI8Y8^CND /3$7&'L4OQ_E5 N[;E60^3G6I
MWG?DM[RB\8J=J\F'^H*FM4FVH3C+V<^E$QC22:YC*LK'.SE<FN4'[#XC0_J'
MY+1^0N.J??.2YJ-B[K19&[1C6963F]FQNU,,9J5L]TS.Q<8J*8!RCWCUOA*V
M%96ZUA[!F7OF@U"/L<-"S;TC"8:BU%W<3MG;D(F')C]*#HG8YK50Y]A=K.P'
MCIL?34:!"TH<L7,QB*":1#Q@(DO\* !<E'&,%K<9(SYL9,,)<&.1WI2EO%S-
M5Z&YK[.?EBIVJW?:M9@Z]6B-.-6B!K_PS&(JR4^XDAR[45=92]CCS+(1H"2Q
M79>5='+&3Z+!4:RT(^VO"B%OZ.Z?S,9S!$G#?"BK*#W1N&NSMAL<5IDP:3LU
MCKMPEWTHW-AZ3LM<,G"V"Y@Q-P3)3,4>J=6J1K4@:]7WGXV*?;CV<M&H/R88
M2 #$) @-NR!9VD9RKQXJN>L[;.?.=JZL3;6ZXOX4N&U.J-)ADY%")Q5+H:I4
M2WMF7W"'#EL''OB$ABV&?FHQ;BATE'0!Z@SGR"F1SFKNP_JS'Z1#V YJ/3#5
MU2\W:=FR%5D:+"Z>?JE..B,QB(2)KU[-]T?(MD);Y&8:D)Z1EI!Z2D3:[#QK
MN2R"!&86/%%'%;+2Z>_6A=S$Y=W<7$ 2XD\3R5?SF_P%;ZZQ6R[U;;#<92A6
M(61LDL9,&CQ]8GVPF2#7<NN-BH(9)?2RE2LX0ETAY>,?RG%9^?*-V$  AAB%
M#.:ICZO[Y^";=^6YG_!<KB\=0B?5_?/P3;ORW,_X+AQ>.H12PZ'=8;%*ZI].
MF-TBU-@P=H;G)@\F!DQ (R*CQ"G23#C21FAAFL?89:R\ZC)!3S C&'"'VFUX
MVD0W(IBEZL,R.*IKJXU;L>.ZF-X.$T6V>A,;-N-ABBF8"4)$D8:?G3I:*D B
MV!7!R1R@BV5X6RXO#;OJ#N^1]EUM%@B&Y#,>T"HL#)%4\2HZ?5_?/P3;ORW,
M_P""YIQ>.H43ZO[Y^";=^6YG_!<.+QU"*K)6/V;+U2I5 B@V%N.IQ%C)CB&:
MQ8$FD+LY(!1V#5K:<86EER/92+A@<?*$+<P]E[.4J1'A<EQ-K18BO>+N'<0]
M6C*F_II<G&QT-1H7W>2B-H/Q3K% E863B76:XS8AZ[%D2V85*;43#Q@!<Z:?
M(S*R1I<E9?,[L+GZF=Z,\P7F7?"X!D7:#;VW8+80+$C4LRZ;#1$/$1!A#VYU
MS[0T++3\PR+*VY%L:M%AACG;"2!)UR8E28(B'CX0 <$146V0XW86;>$RY]MH
M +!F%'MFJ],)<O)<%1;&R=YC-S[;.NBFTV#7S.OG4MTNQ--1K##4P$U9(<=E
M38X%E9A;)9X$4E#2H\*,L,DD.-8*]U)&$0EI_F>HZ=0#R4=NR\+GL/=UYHX=
M*F:':<M,1M3ARY)(^RG\&1M)C1HJ"9:KATP73HHA8H4>N6.B*\$7)% ,E9=8
M>*EE2= A!=Q;*4GKCP>CG!GGGGRNGQ:-PXJL+4?JXDOA\'7J]6Q2/HI:/?'0
MJWL2V[*">(7ZGH**>FKC(AE*;8;:5%CA--,LEH?,(-#/ZJDFHM ![)=A_*Y\
MI>=S2T!=JZ1K4YL.]S-_FY5YFIVK!(I6Q;5JRW3#<>I;RVFV!)#4E?'C$DM$
MN-AGS""G"WW@GP#0N"]&M%@B'_R.2KR;RS1=J/LS<B9B?DS=3NR(UIGK5-3T
M2]5[HP(8U<J)+:\G(IE\0UD\,1<#,ENAOLE8/%DDCD^].LMJ%<C0_JN:8LBW
MAGDHO83M#<:Y>C28&H4Q#&O+;KRW5R)"JEX< 01K.+"B*_&F.'R9D@6 ^( S
MF5<6=B2,(RZ^D]A;F>-V&?U/O @N0\ZX<)25>;\,EQQ+_LENL2%7D]$CS(\K
M7Z;5I"2?@]G1LN77J.&EB(AGC8&Q1/FBWS6QYN5C\-I$DYD*,+*:6F)BV@S!
MP=X2)-EK9RD4>N*JQK>N[F1*Z*G3[SN*Y,ZSGA$DQ>T20DGZN"?BX9D&&=L2
MH2 BI.-,D&IN-KD?%-DE2#YP[@K@\:@";L+N8K[1:7YLH_QDJ8"V-M!D>(CY
M+1X\[#UERKFU:)DJWL)(T%+T],FS$2*'@)D,V02\+)>ZS$=)DEQ\HT!'*6PT
M^PXZ]2!9&SN_MF#Q$DY*EYJT[GL#4\F5H4R219->A:ZE3LU2QI)>C@[]$[%S
M+)\N,,)F2IR'89)<]'W#(#Y#;(#3ZFB6JT(:="]1<1V*/7'5U:+ZO[Y^";=^
M6YG_  7-.+QU")]7]\_!-N_+<S_@N'%XZA%=K0NJMES6Z]4A1U"MSSV-A4\M
MU2J]*LL"A S\>6<<82\(A@0($1EXHLHAQM@=AI;KBTI3G/,QQ#<BF/:;;PRL
M-1Q"VUD6ILKS.1<)/3 >%K;1(!#!,!$9;5E"EAN2DA'.&#9SCNR<*T\ 4WE+
MHA3[2L+SXEW=_/-%Y_2$[\(V?^JO?Y@X1/I"=^$;/_57O\P<(GTA._"-G_JK
MW^8.$3Z0G?A&S_U5[_,'")](3OPC9_ZJ]_F#A%[P[$P0:S'&1\I#&E)=4$U*
M#-):-]!&7'FQC0B#H]93;27'_<%EH/6,R06V*L48AYHCS;^.JJ#A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1<*1D0XH-X\YU30S/II5E#3Q
M#SCK[K8XXXPPS;Q)991+K0P@8K+Q193S0PS+K[K;:B+I,6,Q6,934K0I.?FE
M66X)O.4Y^[.6WIUMU'?'S\CK:'$_<M"58SC!%^_2$[\(V?\ JKW^8.$3Z0G?
MA&S_ -5>_P P<(GTA._"-G_JKW^8.$7'9MJR'2F&*U/OOA.H9,9:=K3CHCSC
M+9#;1+:+%E;#BQWFGT(=PE2F76W$XRA:59(@]L67AU0E:GRDL$/"/Y'=K3^&
M2AEY;(&=RW8E8;(8<QE#S*^SC2\92M*58[<(NXBYH6544RVT6&<#EK!T=(#K
M%-&P1A>1W<HSE3)(A'I/('/!>* ?>'*':)60(4TR1=OPB<(G"*$'4GU)273-
MTXZUL%4JF+UL_9<]JK2>G*:Z2@$*Q[3V(#@:LQ\D<XZP@..2W'R!A3[CS#7E
M%PV\2&PXX8/IOJ+T!)/59?Z1:2!V?RU8UHWPK>I_4:*EOVG=0U;O^_\ 6FT[
M[U!XUN37;S'4*\V2Y/;!EYG68TW)[--C1HSS[!F(F#FU:\K_ +[D*%RZ)4<N
M%R UW@0!NL)\9CXKQ0BIM8"ES387M]B)*?,'M+8W6CTL:4WKT[2<EK^7OSDS
M 6V+<L#T:Y78>P-6S4&PI0)Q3.!)*PZ:NR&-F5)P@020FOH"Y7PGHMVU$HSD
MABRU"=>8[@TNFZZ@A7B(8E[JQ&!AC1*2[\1K?$B;J,X,>0R=$#:_A[?*96JP
MRNKAX,*RGER(D8!ME^Q2]2'E27XL>R.BQ:^EJW.S\ZR>RZW!<LZ$Z_41ERE:
M9/,C2J";$=0X/9S^LI!V=R5'ZP@ZL/LGZ'A/PD+\'$;V+.G@ZM,KL858A8XA
M]R58.+'ER?3;U'.C\A/%3#T@C9[>LJ^C<A+A>P<$V/,J^2%68\]48JT32JHB
M6%IITE5$S;-2S!,S;M>*S$DRS9A(; C3V!&"R?/"JNL/_2]%_P!JC/\ @BX\
MHH>'R%#4<?@JJN158+>OGQS-*]%>QQ-6!4J:V18V);$183 EOC1,4>V[AHJ/
M:=:&=]X('7YFG7E.MH0^A:&V2$X\^=B!@#%+>9@,:%9<DD0AVJ_GF:R-=+G6
M5JGJAU&[MF",34@8<-DNW@6@M@!%7:<'63[T=*%X#$Q&Y;9?7[^]@9#?H/8?
M0UA&%*D4!A+7TE/H@B!%S55YM1[JU;OFM'7/4%RB;]4 ;%,57Z40"W28$^9@
M%LLR[<-**:0)-!!DO>Z9E(MPJ,?)9(;%+?\ 07G$((JJ"#172Y%4X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X18>_$=\8/3WA^%#UD^KR^PKPOW-4C%QF7F@(-LY
MM#PN#B6AWLND/,.-/992L=#3;K>5/J<\[2=PP.')8.P:;T'*OE5ER3NPASC1
M2-Z$NOW6O7-1L6*K1<C5+(*"S(2=6E%*=<2$ZIMO!X)66!\OCI>=:;=;6TEU
MC+K/=3J5^IQ%!NL07!I>'F''!(8GD9$?%<U,^W_]$B?[44?_ (T@.9%>1[%4
MTYCN% "G4CQ  9638G[M$B0UIM7UH/OQLU7K&15&[Q>M5!3FC0W+C RI#-=U
M?0@]N3<%,P+3#4E,RU7##,<8C"8V1BVXNPXX\[<'FZHVA5+Q$:T%!JEIRSR9
MQ$12F;HF3L>H;#CX$'<KZ]?"*CB8>)9"W\;6)&E+J^2O=]"KR/-ASC#'N->8
M')]/)Y5PKAG<O;)5[Q)BI"L3J)49N>BXP$>VAAS&OAZ*MHVL2S,N5KFOM%@N
MS=T%RZ#AM.W4O4UK9/\ RF)]#7C3+P9/ITOY_P#YFRE'T_8ZJ&K59&M].BR%
M:72]>N01S M%AFA;8U5X9FWA"1E4.GI60+,G_CLE9)28E8R! D%@PM$ACX%A
M<\64+68W_.6:@EO].W^BG;]VV/K>?CSM<;NJ=_\ <8*03(2\W 7J%J,[:A91
M\1["(\B.K$F/[U&2)!1#OP27D8@^.*]S^(O] =]@:B;WT&?WM7(_0Y%#9U[*
M=/2#T^V'0U$E6[[8&+1LJXS#TO<)< Z2-B59&(,1%L@NR:!R2'7622)23D"0
MV#2I&3?&?60. $[G,1=FD M0AGO*D<)_IG/_ .S%1_\ 5;MR6#B>P5M/ =RJ
MGY%4X1.$4">IW2D'U$]/U.U^)LV'U=MO55EUWL[65EDC TN4O;^KD9Q#OS,2
M0\T4[&N^O*Q!;K+:W6@Y+$S&8,4P(@C8=R0'!)L+$.LR8 EB!?,%O.(P5K+%
MNKKNM=(>US$ZYT+0-C2X#\%)[Q>WC5Y'6,%[VRL0JU5BO1TD1LDD\-IQ1T(#
M)54-))[3#)V8AAU9 C=%?J.#,7Q-SW*;Q_Q&+C(.6S7=16DR]!=.FA="].>T
MJN0;K1F^CE6JQ6N,AAS+C;M?[.*<V!86@')-[$63LJV%R*:]'@RN(Z2G(0QK
M'N]<R<S"(B22#/!;A,(J0WW&-SS5O)W576'9Z.8!-=66L,VIUF6$' C]D*CZ
MBE T)JJ)J#Q;[.LLS,DRV<#N6:M<=,-RS5D39*S%2Q$HRR@BM1C<>A5WH+Y8
MD8O:,/*]3A'7=;[58G:[ONA4*M0E@L48G-[MU==>LYZIX,@&VU$6'H)?P6J8
MK:)>%;J$TFUQPS\T&?$6B6DH<.=A#&X]"IO0>' XWM/(6W,DJSU-@68?#G4)
M1;C0&%5H8%DB^1N;>/,L[V M@%G/%$J-5AR8ZN4_(K%E$=EC'YR#@WZ_'CI0
M26Q8S&X]"F]#>'RIQJ^N"G\7-PT_.5!B"E8Z9=CYLV4/Q%&CR"00,5:QQN"2
MUBN.MCH<.D@AF</*0M]Q[/HI<2R^II1WDX^0I5FG.S@55TL0:'%21<<'\1D!
M0"R 8_U?0]_,9'<<&#]?TW?1]Z>2ACU?2<]/S^?R+\OES%2OG!]=90&T>M,^
MS;\H5@C*C<Z_6)J+ID+-GLR]/O\ .2E1,M<5(.@.9;P14W[//M*;=$>8L4LD
M!$P<S"882UZ&)(=VD!7A1YL&%'-ZQ 2(8C#[@3O. Q#$VBT@XW+*7T =+EYZ
MP^B><Z6K.U(-2UKK-BV)7MM-3)@D;3[%2W*T;JZ.M4: Z^S,Q&POIS.CFPCV
M31H>,",DXIY!,7"-KD43 .7H#T)\YBQ98111-*X8],RQIP5^.G#PNO%WZ9M8
MTVV]-_5A"4F6-C,3EAZ=KK(S+-;@9PIYY^2@\0TK%WG7<H8\_A67YA <#DIQ
M_+R3&\*]XSDQ0F1ZM\U00Q 2.+/X%-NF>*AU.=,TC'4_Q1.DVT:IB'B6(UKJ
M1U)&$6_5#K[B\-,D6(2%.L@<?ZW;+[RX*QG2.<9_<T]AO&?+#"#[2_G7JJ(B
M/<.?GPLW.O-CT+;5.A-@ZRM]?O5)L@B382S5F2&E8B085\E>D4*M:4O,.84R
M4*]Z909"'!BF67VW&T\R"*KH"#15KPB<(G")PB<(G")PB<(G")PB<(OS/W9[
M??VX1?/Q\9>P2FQ^KN-G]S:YE(/7RE[&AK=10+!(-2WTHK$C<8:KD*.B<L%L
M V!FKUJ?<FF0RY >$*S'Q8@Z\R"7.TVA!F+0YG(FPMAPQ<K,!8Q,?J<,6E4O
M48T,I3=ED<\!61N]!OLE78.N2-LI=NV3;JS7SSS$,R%&U4+'70Y-@F&V/>&L
M?#YBB5VF>Y,J\ALI)H,4P$^\>XTC'T3-"X$J.P;.0N!(6008P0 ' >5K.6XS
MK><%MDW+/IP:7\I7EH.<JD@4M"%+] &.M4*<>6YA&,JPP&$.^60OMG#0[+CB
MOLHSSD/@]BMGY'<+J;!;:S(P$V#%7:HCR1T/)"1I)%@BLCL'$A/,AOO=G2,Y
M9:(6VXYV8?\ L)5V9=_D*,;CT1Q>.JQE2M-ZQXTJ(B('J3UM)GGU66>=G)&R
M0F*Q6C([=XIQ5<"-CZG!V*!;L^A"JS4(-V'"D'FK%5[3*$OQ,B\/<98QN/0K
M6]!?GAQOFNVDZ)UDFAA2".J/6.;K&H?$(DGMK>A3[ #)W&,/E%XHU>U+6D04
MBG7$6BAB&,V U3-@.)V!!8J<QB13/&-QZ%-Z"<QE=QE.>JOCT]0VX*I=Y&S[
M[WGKZ]Y>UU#5K!4-L$)X(VRLR[LB=)ATMJB4R*JXX\9D&%?,9F)MZS' D6/X
M54\RI$,V8W'H5#%#80.?W\Q70];5"(WA"4@&BV6G$OPC.SFC_>;3 #81FUZX
MF:S&>7)$DSYL*D3FO4RCS>1O"LJ\O?'?4+@NQLL+5FN<<V8BVT<K5.3Z;TO\
M7U?_ /OQ/^+YEC<>A6W%XZA<2#/"E[-/R<62Q(QGP6LQR)$)U!(+IP9UI*,%
M8+:RMA]T5B1!61AE:\-9)0VO.'<+0A8V)S9!4D8#OJJSY%4X1.$3A$X1.$4?
MNK)R_-=*_4N[JF0D8C:+73]N5S6TM#N.-2T9?D:YL:J=(1;K.4O-R(5BQ'$A
M.-9PX@EII3><*QC/"H9P]'#\'FN\Z=MTU?J.T-IW?=+)9)K&X-;4[8<1Z#J7
M?=6;3!!2SL81G&<Y:.ARB7XJ2&=\KX<@&2(0AM]EQ"2$,2#865Y>%$X1==+R
M\5 1ILS.20$/$1S"RI"4DS!P(\$5KMEP@LPIQH<=AO'S6XZXA&,??GY]N$6A
M1XW6Z>EN[]2KDLJLUG9\#8-BU,FN7: L=BK)!988%?JUY#=/C0CVCFX<T>&)
M]W7'#M3XAL>1B16 +Z[O:0AA$=0:$TGP-!92<VHLP;Q,9@INEY"XFAO8SLXK
M9"\(C>>C3=2NT6&F:=3K58I@>?K%%06Z"=(TW,)%1-6/#Q*O*685)1T;B0;B
MFB73PH\@3&1$,90XMM(3(@29[R,2+..9DLP%G!KT\X+--SBNBZ^6B8J>C#H6
M<C(^9AY05X*3B98(:1C)$(A&6WQ#@#&WA2Q7V\Y0\.0TXTXC.4K0K&<XX18I
MK/T<W'HONDOU#= 4<2W4I$S,QO/HK;.6W0-F12.RI.Q:7'+<4-KW;$<(EQZ'
MC!<MUJR898@?0C6<MC%[WMZ47(W<?-1S(W9PXN]WG-9*]6[,J&X]?579M#D5
M2=5N$4U*1C[S#H9H^<K6.=%2T>_A),7.0LBP7$3D06ALR*EP38XMMLD9U"<D
M,2#4+H"X=5]R(G")PB<(G")PB<(G")PB<(O20^P*P\22\T...TX\^^\XAEEE
MEI&7'7777%)0VVVA*EK<6I*4)QE2E8QC.>$6E3[0KO?IBMMG,-S'T_<40/7*
M]739J!L<S#FQ-_K<G*R+,&/9X$<]O+1M9D)$EF2%CY-E28R5BARL//92QVD-
MG]0M-]S@%J.7Z+$+G:?17[-:1W61_P $G>G3Q TPJLA2%/UJJSP=3A=>Q)TD
M4P39QJTJ7:GG\RDPI#3A/TFDCHX5I:PLS189IP(CBW74-MH)#=!85XRZMK>I
M"6B.]4VG5;'O?O\ _P"\XKHG")PB@SXCF[I;1?25L"4J$R7"[1V;*4GI^TR]
M%$K&L*]L[\N,+JNG$5E3*DD9G( FS/VT=0^?6%'KI1R<9P(KA:A#G .3P =3
MFX64X1>#N%9;<PA7E7E"\(5C&,Y2K*<X2K&,XSC/;/;/;.,X_P!>.$6F9T:>
M,CUR;&ZK]=:#VOO;4L+2[7L5RGR5PV!JF'RX(T@PH<.)%?IBJBVB;GRF!X"'
M/EWFXP:5D1291Y0S;C;G8PP@4?F=5Q$45^06YMC^O_Q_U\XKLG")PB<(G")P
MB_,XQG&<9QC.,X[9QGYXSC/WXSC^?&>$6N+TU;R%\(KK)L_AR=0YR:IT=]1%
MXM6V?#KW-,N^YTJE$7J>5,WOI:LDN_E,=!-5NZ39#E*?,(1Z7QH!V7)PF]08
M\470C?A$0G$&$0['I+^"MCOA<U&OJZZDZSTDZ O^];2+F1#I\;EP"(2\D=<Q
M+D84D".0\K&<(]127'W<XQE>6&'<-8R[E&.6$.;A4E0EAC0<5H\X\8[JCZX*
MU>[KLDJN5[7;%P+@*K28J'%?BA"1@0I-;3(DLV?&ONQ(,K&+S(SHM@D27RTY
M;6$C"DI[;-J@-8Y+W6L/C@:'.U@,! )<D/@')IT;DH*;:V9JJX!"-;GUW#;%
MCXR2]^BV4N0U7= +)PTPH_)%(:KTJ7C"$LH>9/?( =:1A) ZTXQY=1$1,X=J
M"Z@LGT(%K!2#?!.Z6)D?X\GS4J]0=1IK4C'R4&1%!AM,B-1C6(6B$^ZM!LMB
MA=B08/!BU!,,,-,K28*6A#3>$F-YQC.*""S3N=N<^4C91F7.BRK= WC8;QA>
MM&8Z/.HDJ+N=%PU7U0]MR&X#+5IJPQ,5.0[PQCKKQAT>]$3 ;K\?*$3+Z7\)
M& D6$Y4E7**$&(PAG =[^-DP?"NS10P0QDO#$2&MDXETHMP3G):74RLT%$)'
MP1Z[Q1CBF@(\(=TP\YU"?,M(XS*5*PVWC*<D%O99!"0I+II0S/=S!'_B]6<I
M=9+H%LO9M;H=C"JNP9/%TD(-HRE-C1-_(2@2SRT<-BW>FP/<V&HV6E!A\-,X
MLH,U.O)?D+.<]G18@3#B5M+++,^4\AP3(L9V5ZVJZ/Q^6_!%H_WNE_YOY&%X
MST5<W'+5/C\M^"+1_O=+_P W\,+QGHCFXY:I\?EOP1:/][I?^;^&%XST1S<<
MM5[PK$P0:W&' 24')$)<6('+-#8P:AI&7'/<CXXN1B2GVVTN.N@LR"Y%EAIP
ME\-L;&'<SF_F*O)O,%4/")PB<(G")PBMUMS9E?TWK.[[2M*_) T>OG3Q^,+2
MTI](K?8<-MU?=#;IQ:V VG%XRA#CZ5+QY<9Y0'(%ZA+!UHO6CQQ>IKK3V!O.
M,].O471-"E6(6.J0,?[TDUJ1.G!()N746M;<R?(L5Z0/-(F5G1C"QU-!0+:%
M(SSK P) %&F3.1PD!(\)*;2$PPP&(SC<M)A34+'_ +:VU1KA#2<9MNF0^P:L
MX0U(NPGHUBLO.DA9?]%Y$G3X^O6-MP7#S^6D FCH3AQ:,M>12D9V2"&CF+)V
MV3ZTK:X6(-X%X"QUY&OEBNOIG?D8$-6AJ,%#P-4@P1(N#@?AM)E41T>)W4+&
MY--@Y*6?:&]1S.,R!!!F5K<=<(P^IQW-A(:5#_UE4?-S":S$"Y>M7G/LLF'3
M]XV'4-T]=7&LNG[99,7L+2^Q:K&3H(Y 2@C:Y$G'2D0.7$2;SY!(CPDE"2 9
M SAQ\*MEE3K,8"I2,MXCA!CW6 )H0>3'@W'DM@1" QCVB+=;D\NJW38:6!GH
M>*G(Q[!$;,QH,M'D8QVP^%(BM&"O8QGYX]1AYM?;/SQW[9YP71)F9B*[$2E@
ML$K&P4#!QQLO-3<P<+&1$/$QHSADC*2DD:ZP''QX C+Q1II;S0PH[3C[[B&D
M*5@BUY]*;8,\8OQ"JQNFC,'N>&_X<=MEY'6%G-%(&B^I[K))B'X8*\Q(Q+;*
MGJ;I> EBI>I%]FSAI61B)9]+H]T?BZ\70C<A8^Z.O^,+_)KP6Q5PN:<(G"+!
M/XAW@TZ:W'TX B]-%(A]?;RTU&RTMK\Z*2@0K8Z7S2[!.5.Y2F<H>E)BP2I)
MLG V$]W+\38BO1P\+"G&--[$9>=#E]OY6# &E49^>87U\'KK,F>K/I?:A-DO
ME)WSH"4;U5MH652XS-GO1K+C5:M<H*_A)+1TW'A$Q\THA*'7+3 V%:FVTJ0C
M$C#' JP%QB%ECYE:3A$X1.$3A$X11'ZVNB;0W7[H2R]/G4#6\R]9F,IDJ]88
MW+ MOU[<!&"&8>[TF7>8)^%S\5[R^UG#C)$=+QI)\'. R,+)'@$%88C"014+
M3EW!X@?BG> GL*F]$NZ]F4/J3T<3-:\N>F-L3C;$_M1OI[K6R(I%IJ PITL5
M-P;5CJL-8-=KB;V!8'JJZ4^O5%X4!7H\@4NXA@V@,0!!FXQL6P+[0:U)W7PC
M]W677Z7)MH?&M+J%(QSBD836G[+$^M--*SEI>1<Q<KAU65>7RL/Y<<3Y4*3S
M4-O[3E/LO. -Z#>IO!Y<?F2T>JIK84SPQ*;=*,?.0=H'O.RI*76O#3[<P<AZ
M*CG7FL,)%<#';0"&(PKO*8R,TEY]UE]Q0C70#^W(LTWM-^,F%)AUJ,CU_JF)
M0R>E>+WTZ36+2&V-91&I5,I.MO>^BOM(42\Z^^T6RXAUA:4"H=2G"7$=VUJ3
MC[792%XSC&<<G-_GW_E>@[.$MN@V&DCU9^'::D_TB0FR;7M:M1B;!Z<%)%#E
M%Y&)]]6\.0M2<J880[A:5)4CRN)>RWZ><?;\JL<WLWW@'E<]FN%5PVWILPA:
M(2F /.5RRJ;0I1\1XN72A3=:"FR4M;ZOH7-H9=+%;S*M,SQD6E7IJ;:4E> H
MI*2,,F'MK#6-Z>>[+V%:B)]24B:W&>,W'DESAG_3G>LC(A%KL#9+AQFOI58^
M6,8_U<XJJDQ<8<O$VI>/.H6JUA(V5?:R/@Z7MV3<,=^_H^^9CP/>O3\OO'N(
M?J^?W9GR6P<3V"EIX#N5#W9)G7&!?MAHU-'U,FDD6XPVID6Z)AI]?P%&JM&@
M1P$2VQL:F%1@&;\K<<@6W+BF'D28H[V'A(-P!B8BW],GY]3.AL9=8U=.OJ,L
M+<O*ZXI$]3WKA%H,J\!%P8EEBJ,3MV]1TR2#,R.X\AS4U%:;K5$G 6W 0,2%
MEV#)YR+G,0FM0Q/IO\887OR'-4@J_P#B7LUFHRF=/ZP*L$\_7U6>NY5#A.4=
M+<3=52HBC&-KS -C1)V(6BL$DA&BMP\1)2C8Y3JLNV.!)]-CZTPE;8=<F'"R
MJ4N:4XAFB.W[T*<K)@Z\?);;K5BC,9\B\?:0EYE;PK_DRG+HI! ZLY;>6G-'
MP>Q4/R.X55\BJ<(G")PB<(H%>*/!3MD\._K$B:R"_)3[FB+N;%!C*RDAPJ(C
M\RZ7&<IRE7J#I!42G"58RK+7EQG&<]^:AKU[%0M;1P_!PZ^<UT@:XC[?T*]0
ME@C39V'OXVV LGRZ?2*9-^%U=\L4-D=M([V6QDR9CV7_ 'XIY1917<-D=#3S
MVX \,32-]LKIBPD\N2WMS_<@! ,(A# .)&5O@E-UC#C;];8J:-Q.SJ2$H4=&
MFM&ON/*[K9>85E#(Z'%Y1ZG;S^HWG&,_)>,9[XYS!+N_7I_/\+OZ<$0&["12
M(-(7LY:EC8*Z>B&]E678=<3$V!* 9B3:]X=:+4^I;+1+;;[:0\JP1@E+:LY2
MVXVCOA7=7=*L<U"YBK7AX*868+GM?3AA(8@C!G?A?T;%95NOZF/479G08Q2%
M'GWZ>J\[7R7W"!AU&@#W !W OHNISY7/>)@KW7+<FMS/D+;=8:=6WSI&^_"U
MG'B_&;G&]<MF'V6U?VAC1_J8@-/K*Y?0>WGNQOI!Z!M@;TG!&VS=$],Y=I9B
M'<>JV7:ZS06VZ]7<^7Y*S+6I$;")5G*6L++2I:T-X4O'$U/$I 'W1:6"U'.E
M"X>)-[26/'T+=^Z*UHGH8T@BC5WJ.$T\Y'0%[WU=1(@.2(3+5]DLTUT^X$BO
MS;2I&.A--U!:\$P-3MEEK7N28O1%N[*@>(S#B0'G-;KFC](:KZ;]44?2&E*;
M$T#6&NX1B!JE7AFUI&"#:4MY\DDAY;IDG+RAKQ,K.3<D05+3<P8;+2IA<@80
M0X7 DDDFI5UN%$X1.$3A%@I=H:.CCQH*C9JNQB*U/XBFM;M$V.-83Z,6+O'7
M(B+69(I91V925,LB"&-+5^]?E;I9G$?)Q2>=*P8P^=CDN;-'<#XW59UN<UT3
MA$X1.$3A$X1.$5,DTJG&V-FXF5*LEVX8%B+'M),#%OV,>-&?**&CF9MT54FT
M".2::0P(@I([3Y93S;:7"'5+(M?CVG+<,CK[PWY^BP!R&YK;5SJ];=C67T>_
MGP+<R W)>0/OEYX-!9T<VXXE&4H.=CT95A:T8SH4B. '4JPL=I #1S$?]825
M@LV)TQR>D?!BZ=2CA/=IJSO7V/E6<MH2G,E)2*#7T.^JG&%N96Z<$OYI6C()
M&<8PII7D["0,-P!YF[C7HN446]'OWQ=FZ?"U/=@TPV@V8FLR25MGAB1[I;+B
MDJ6R^6&R0XVI2/LY[9<\V/+E6,)4E/F5G&<YX1!B1<OH[./?AWL3DLGOA[4$
ME&:/LX-Q;C0ENDX*14IS&4"K)6,X*VVTM6$X4MH8E?GQC.4Y<6I&&\X4M779
M"1-QZ2!MO^)BB\?]1%]<4/[6EW^&65?Q>];6KIDZR/#TZHZTR4T*;KW4*)<P
M5"FO06NYRIX?J.-IQZ:B!)4T)MY6>S;HHK?;&<MI6B]PBNB(BZ]ID.ILY[/:
M;,U,/J0S9V'V$J]);^^M;8)>M?4NX!'"23%CK4/+9,">;?%=(+"969AIQK*F
M\^D9Z[*TIS^[<;6VK&%(SC'(R)&*@F <%S _]-[%_LM3?_5;SQ8.)[!+3P'<
MJ,W4A(=4$!8XZT:861(TBO46US$W5 (.LRI%CMT-#6.6KT*1DH&8NQ'THG@Z
M?3AHZH18J!XR?L]ID[/#D5F*BK)%H-V_GS[BPD]5/$@>D4/!7\5:XN0I1&7X
MH#4P=?>$)UE;8W9+,# FA-2EH(8LSL7+TQ=[G*M&L7TFMQ\C$$T*%G[2<5^G
MO??)^4I3ZJZ-#JW7$-=*E,WG9D=*U5ARHM6>KMP6M(J/.":HNJXZSE/-QE:/
ML8DR5;B=NSQ+$1>78I$F!5V(7+-74[$'E'#4G]SCPLO44MJ;7WGT+[BVA+R^
M"MA:DVC4[S:*)-V:P.R3[5WJM6.G8F,.!P^]+LO1*1F*_)*9;#C9J"=B"<R4
M<[&CA@=)1,&8BK7./Y'/!<YPF]V <VM+[X-<I3],NL=QT755HG][3LR3L"\7
M2.E3ZP7/-S$774LVYA+AHZ ""85N5LQ3KTL:[%N+&Q&YA1$I&?&+83"03*@A
M(R. IW<VH PG4F'N//'4].86TX1.$3A$X18F_&\W,7I/PTNIF>B9%D">L%(D
M*A#)R0VT64[,C/8-:#:5GSD^2.9*<-;;2KM'I*4ORH[JQJ&I-P)RY( \4 L,
M<(/!W^%JE]'G3-+Z[\%J];8F G IBP[8=EW<.M80]@6PU4=,8DC#R<IRXT*W
M'.8:7C'?XBUCMG+F,+ZP?2-V8)!B([/633H+7DL[6+?VA(H"(0>%WF,G6KEM
MFBGT:?&9DF\L$3PK\^AG*D*PD4Z1-R&XCR9RE+;HR6E(3YE9QG"LYSCOA..4
M08W/-KG);)>W91[X/^+"7 *7W0UKXBP/%74%:UD4NYPKY367,8:'")%4/A[+
M;F<-K4LHEG'S[XRI#?="\X1E&]G"[F[YM:UN-O->?^I+$!JPYO\ ;P+-YXTN
MDK+6.F#H!ZJ:N.^HZM%WDT\EEOS*' 7-UK+1+F6T]U,BGQ8ZG,Y5V0U)NNJS
MY?.K&MH023#^4CMVE9=S.-@SQ014VD) G4B@S-;96K>$Z)]HL[GZ4]&W_)X\
MD5.:\KR9939#93C,D+',"E"'*3E7E.:PAOWMMWLYZCF5K3CSX[\H_<<9]5F&
MG!QT4@H.F4^L'3$G6JG6J])6%0BY^0@X*+B3IQ<?[U[@J8+ %'?DU!>^F^Z*
M-<?R-[V5Z.4>\.^?*TJEX1.$3A$X1.$6.'Q!Z=\5L?07>0FO^>Z!UYZ00T2C
M'[YN NK5BJMD%PO'VL,%-% .$([^1>!4*7C/IIYJ'\W[2LQ?E_<%D>YE:3A$
MX1.$3A$X1.$3A%\^+VA?;&P]U>*Y6M%PLS+)@-+":8K,7 @..Y$?.NHP^P9
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M&ZD*&H&+]!JRO3R*IPB<(G")PB<(G")PBU ]']* /5]X^O6ANJ:$S*:]Z?\
M<%.'+>?1AT(F:H.LXJ):B$J5C+2U?2*2:;=9RK*_<VC,XPGT>W.KM"3;]('1
MYWUX9*&<,,-A,<47#>^=T=.*@#[6)OV;E^H+7^B&6G&8"J56+/>=2MQ*'C#&
M<3&/-A*O*K*\2ZFLI7C*5I%2K^4UCMDR@ _423.YQ/SI;UV$+[2(O[0  UXK
MUY\EJ#K?><:98<=<6T/ZF&&U*SE#.'5>HYAO&<]D86ONM6,=L95G*OOSGF%Z
MVF3>RKS-F<#D:88U+'/E5\.+%P\E3@S<:,Q(.2"QH]YO*'ODHE]+CS?EQYU.
M+:6YE25IKTPNE>?E<]QQ'(,3$95+AIX\0]]J^EOX;\;&>(;X0TYI;90+*1;5
M6K+0L9(0IU$:2=&C2L))(PO'GPN)L!"BTX3V5EMGT^^,+SS<1G#%?"'[862G
MV8GP@>X SABD>!EVN4;_ &;37LYT\2GB$]+UN8?C[/J[=].+?CR>Z7,#RU8,
M]0EMM6?FVI]*6_51CR*3AOO]KDB#4F 2QP(!'G5;,6\0;X _$1$'O=;UV.+G
M#3-AQM"N5V;^C%DLVJ6(>LV'.9!.8:9)Q? !9MGX5(1$JY\!/E(PXCX3*QL@
MQZ@ON\B 20*2G-@XGL%![N0[E0J!Z*-SDP( ENZF[Y:),&\0MA2W*779Q<2[
M6*WMZ&VG 5@H5BWQ<:1*QK,''UK-S8@ )0L(?*,BL0Y)$ J+>]@!*P7AEUFN
MNA_>NOH9N#!ZF9]D%J<D))#$;.;2$$:E)K8&Q+X?L0>-<V \ FS#-7D"N+U^
M8R?J2U8K#5CN%;E#9$>-@R&)[!]I2I][BNI@.@[?L(7.28_5?<HF3LMLUA.S
MY=?G;]\3FLT+5AFMI*6FK#9[39YJ6(L4M\*V$34R'T5C!,>-2W''(^.BK$(3
M>%PRO>[ES=3=Z>-9WS5%&-K.P]CRVT)EZRGRHEBG).>F)-F,(CXD5$>_(3YY
MI#C>9 &1E1!!F@QX@.4'AGW;#*QTE<K*4)<T97-N><9A4,=_WA<Y6!&$_P#>
M6Z_8XI..R?Y2DMHPM][*<9RV.T\]G'D;5G%'P>RR?D=PJKY%4X1.$3A$X1:A
MW63TO-]<_M 0%%=;=,J&EM$Z,+O#V,96/'C9LLM?#!E*[9;:?) #'0.ES.,9
M-)83Y>[O?G2&CF@ASWY=M9+,1^EA6*-N0AA>7.NDK<^UA[PD*3KC1'3U70\
MP$K$DRQ.!<K89&#47\-$$0EI2<):&8KC#+*<X\F$$K9SC*'.W([0$VQ1,;V
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M #AH[]5.&%XST1S<<M4^L_9G\-VR_P X:._53AA>,]$<W'+5/K/V9_#=LO\
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MKME3%Z*J$JBMU?:\HEV.WY&.AV@_6],V=<0;'37GZ$-*6;3MI<UX/4@MCQ$
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g16439g82l25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g82l25.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1I84&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&3P
MU0         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -#    !@             "%P  !"4    ' $< <@!A '  :  @
M #,    !                          $             !"4   (7
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (7
M %)G:'1L;VYG   $)0    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "%P    !29VAT;&]N9P  !"4
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!0       0    &.$))300,     !#7
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M:S8U]BZ^IG1;KJZ:^G5;K6E["['+&P/WG64MV?R-WTU:_9/3_P#ROQ?\QO\
MZ224\!5^SH?ZKFSO=L =:#LVGT_HUO;]/Z'J?]>]B>L=*-#0^P^O#9<-P'YV
M^6.&QMO\AMEE7^#J_?7;9%'2,>STK.G5%Y87C91O:0.?TC:?3:[_ (QS$6C
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M $<OG%))3]/=)_H+/ZUG_GQZN+Y5224_522^54DE/__9 #A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      $N34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;
M  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
MD(=I  0    !    I    -  &8_\   G$  9C_P  "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HR-2 Q-CHR,3HS-0   Z !  ,
M   !__\  * "  0    !   $): #  0    !   "%P         & 0,  P
M  $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$
M!     $   $N @( !     $              $@    !    2     $X0DE-
M _T       @          /_A 3!-30 J    "  ' 1(  P    $      1H
M!0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R
M 3(  @   !0   "0AVD !     $   "D    T    \     !   #P     %!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C X.C(U(#$V.C(Q
M.C,U   #H $  P    '__P  H ( !     $   0EH , !     $   (7
M      8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M     0 "   " 0 $     0   2X" @ $     0             #P     $
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M-D9'4V=TB)+20T1%9FB%I:=(8W6$A[/$_\0 % $!
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M;+:OQ*FH*5&(1++0=ZVM9I1/$@7IP'QI)$YRK4G+'AS7K40G"$/;ED7=E9(
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M'TZ. X#@. X$H4A]FBH?W4(!_G6T\!=_V:;>_=0G_P#%+';@1?\ 3Z8X#@.
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MMAZ*^T$U?#.ROEGP'UL+13V@6KX9V7\L^ ^MAZ*>T$U?#.R_EGP-/K86BGM
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M1$8\WH&IK(4K5:AQD#XV(0=F5DLCO&5"DPE*2<<6$?\ J[M?M:7E^2*7_F7
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MZ_1]B&8?F/K?K\!ZN[7[6EY?DAF'YC_BX#U=VOVM+R_)#,/Z4/3P&+W:\_\
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MSXGCRLA.T)B$TSE;:N1.#4M1H&\,L=M =?F&&.,;UAC[=HC)7"41>8&65IE
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M1%CQ7%<UP7(USP\HFI?*K(LD$YMR9G,C+F63YYPV)\!"7==?TJ[_ -\7:O\
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M+N<\:JMG(*0)E4H?9&CA478#I[?#M<<^0,[4'+3)D#HL<7-8%D-3=:G35>N
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M>8PY/DXV(=]A*EKYLFL7I!>IGB)Y82XUX[7+F0Z-QF9Y;7;LUME*$,<&E4J
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M X#@. X#@;<21(-42N&E3C6IR%"9.L$26)40F5C3F*DY*C(<FE$*3$B4Q04
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M[))+^.(?1O >3IWLEDOXVA]&\#7R=.]DDD_'$/\ #_Q=P'DZ=[)))^.(O1W
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MR!Z1@*-4M2\UN/.$A<"B3R#\I%8"3A)SR%  "(.+,$&.6#MUJ[4]IQ"D+,V
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M!N3]@:=*P3ULF]>T:^#V?4QG(^OTR;S=7HSC.,^?&>!PRG?G35&#!BK96D2
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M/'ZGV,2/_!-/IC@/'ZGV,2/_  33Z7X&GE I\_\ O8DGF_\ Y+3_ !?V7\_
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M!QCHP'&,8Q]S&,=&,?P<#7@0#:'V8=9_VY6+_-#,^!/W <!P' <!P' <!P'
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M[ RH.Z&IP)&M$0$!  L+P(#V4^QHU^O]FG6CUO7_ +9&J.!/G <!P' <!P'
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MN)2Y"A3*%+<M*(#)K0^S#K/^W*Q?YH9GP)^X#@. X#@. X#@. X#@. X#@.
MSCIQG'W?-YO-G^]G[7 B)L<$51-S2QSZPW![)DTU5,<-?)0FZBI/XXP<M88B
M]2 @&42Q84,E4ULKP[Y0*WH0FUK,RN>AX/7A+O <#;!6HQ+#6X*M,)P)3$+3
MD(3RLK"D:DU00F5FIL#[<M,H/2*B2#Q P4::F4%EC$,DS 0W/ <!P' <!P'
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M<A22XU&0CDJH>5A[6XQ5U).,0/S6ZH%*8X)J883V]9E2TNB=&X(SR<!;7@.
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M0Y1Q@<4SD!Y3+V1J6IW@M.!&6ZD*D)!Y3D6D*P$M*!<68%4%.7C " FX*!C
M0XQP*E[=ZWM=QM\#DL=KUJ?[.CEM4,:HD1$B=X0]@JQANZ#R>PT#F]QZ2111
M*V!HC#>]29! I,K?XPXR-N;U08LZNQ2(H0<_M57T:?8[%)@X^4/CMEMW6U @
M[A-)FSL_=SMCZTP/OL9:']#&G4_H7*.JK=6A:K+_ *AV9X>Z).Q"Q_DNT?<<
M_?\ ?O2? >2[1]QS]_W[TGP-?)AI_NI[_O\ Z3X&GDNT9]?#G[_OWI/@/)=H
M^XY^_P"_>D^!KY,-/]U/?]_])\!Y+M']U/?]^])\!Y+M']U/?]^])\#3R7:/
MN.?O^_>D^!KY,-/K_P!E.G_^OO\ Z3X&GDNT?<<_N?\ '[]Z3X&ODNT?W4]_
MW[TGP'DPTY]?QI[_ +_Z3X&GDNT?<<_?]^])\!Y+M'W'/W_?O2? U\EVC^ZG
MO^_>D^ \EVC^ZGO^_>D^!IY+M'W'/[O_ !^_>D^!KY,-/]U/?]_])\"G&V.M
M%>VTHJ95)7*<I<IIZTQ4LEFF#FE3X;Y2;G+HI"4M\88)=,8;$H$KBFR0H( $
M0,"%C(>J%@6&N7R*GR4]1+9#.V,:,M1%8ZZ+#T4A:U:4@W VK$J2NS:D=4*W
M($Y2,U[;?&*0\1IS@^K2A_U(-TPND<7QMO?Y2UR*MCUKB)G&R3J3GM:\EXPI
M,2%(B5*>2K&IR[^84(QI/;5ZH#DG$ U/C.1"+ &>>2[1_=3W_?O2? >2[1_=
M3W_?O2? >3#3_=3S^O\ V??_ $GP'DPT_P!U/?\ ?_2? >3#3_=3W_?_ $GP
M-/)=H^XY^_[]Z3X#R7:/N.?F];^S[]Z3X&ODNT?W4]_W[TGP'DPT_P!U/?\
M?_M>M_\ :? T\EVC[CG[_OWI/@1.\M*)NOFI1I<*^L9 +E +O+DY+0]7#E4V
M<=4"U6H+ +IQC]& (1]&.KUNKG.,A(=ER*&1"N9_++'&F!7D8A4ID,\&L;%+
MTD!#&5C7.,G$J9T:5<K=DP61,NR>VI42Q0N*ZR4E*H,-"4,*.:VZ'ZHQ973-
MZ5@\7+-XA%(TGE6L<3LFY+6F=84K&YW$Q(4*JIJVF[P8DB S(*]CCK6%X0K'
M>.1]6>S-^6K!JLH8=C/ <" ;0^S#K/\ MRL7^:&9\"?N X#@. X#@. X#@.
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M@. X#@. X#@. X#@. X#@. X#@.!@,^B[A*,0S" Q,7Y/3Z-RA;WD9@.NWM
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MPV!97=8RM2IU9@#"8%I<E"$@U<V!&'(@C"@4C-2X&'.0BP5C.,YQGIX'-<"
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M/H/?_/HC@._23\ (/?\ SZ(X#OTD_ "#W_SZ(X#OTD_ "#W_ ,^B. [])/P
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MORF_-N \8/\ ['2_?E-^;<!XP?\ V.E^_*;\VX#Q@_\ L=+]^4WYMP'C!_\
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M'*:_5RD\$G-:907IMH[.)-KK5TFCSZ2TLX:P?+&L"Q'YX?V%V0SPV3J\P9:
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M8"$(9,*,7\,YZ4CA^L E$D)"FD1XD\T$<_)P%Y* 0]&Y8\C="0%9R4$I<(\
M2\Y!@. YSC@:$1>_DQ28A-#]7TY*-.D1HR2$\T**2I&]7XP0)4Q9;&$!"=$O
M_KU(05@)297_ %R2$!WZ/@;PYGV-4%.I"B.:UGDON.J]DG9G1I3R'NP$70ZE
MC9A <,=S++2="O!V.[%@(_2@!!@-XD(V=0)4Z%"UZ[HD2,@I,D1I%5@IDJ5,
M0 )9*=.G):0%$$$EA"6444 )98 A" . XQC@;CM-I_O37_WPL7T9P':;3_>F
MO_OA8OHS@.TVG^]-?_?"Q?1G =IM/]Z:_P#OA8OHS@.TVG^]-?\ WPL7T9P'
M:;3_ 'IK_P"^%B^C. [3:?[TU_\ ?"Q?1G =IM/]Z:_^^%B^C. [3:?[TU_]
M\+%]&<!VFT_WIK_[X6+Z,X#M-I_O37_WPL7T9P':;3_>FO\ [X6+Z,X#M-I_
MO37_ -\+%]&<!VFT_P!Z:_\ OA8OHS@.TVG^]-?_ 'PL7T9P':;3_>FO_OA8
MOHS@.TVG^]-?_?"Q?1G =IM/]Z:_^^%B^C. [3:?[TU_]\+%]&<!VFT_WIK_
M .^%B^C. [3:?[TU_P#?"Q?1G =IM/\ >FO_ +X6+Z,X#M-I_O37_P!\+%]&
M<#(:,L5XM&OQR60M+8ROK;/[AKMX1,RU4X-)CC4-OSJIECHVJ5R5&LPB?#X4
M-[3)E1&#T)3@%$::I&GRI-#<5#_Q-+OW5[7_ ,_7WZ?Z/6X$K\!P(8D_V=ZA
M_:%<W\HU-P)GX#@. X%)]TO^*Z4_?&:O?]+S6_@=;LFD^V,B9=P;-K:27%'5
MU,[";;$K+-?[?2KJE(IVM(;,"T5>16EARIW$GE:-PRQACDB!7\?-:G9#A^-E
M:E.G.;WD-@+PLUP,4C*C!$0KN1,#S%9VTQ.7.Q9[67&Y15]JU-34HFUBGXLP
M^>/T+BZN>ND_LLU92U-LS2RLYB6%SZ=M6#YD )OM3PA5\5U(XK#X_'*4MI:U
M0R03B8S:!.#>W5]9^62]7"I?(&NG*R;L@(H#-$R!M*,E.2U5^IHS.)%'HF4C
M?$*D$A5!%\'\(%?T+98Q$WJ2TO92^RIU.VIFGBI/)#R]>$(MX$6O;3C88U'-
M2TTH+PQ3(!D60,YE4B$]01R@ZEP4)@&S<D+,2[9VQ9[J_5,U52)!63?,-LCM
M>KEM^!=LU,;?6D8N*>52ZV5 '20'/AL+8+:=8A'6=CDJEV=5D&06'A>R2Y0[
MM33*^!PC[LQ)ZGFK956OMF_5 QII6[,2V<*K+9I?9$LCZ2CJVJNP\435L^1O
M,.!8;V\J)RI;@3>3R6RUD+=7H$<>ANZV)'10L(8@?A&MJ["5P&)((=1K"]V
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M@*R/*<TH 0ZR2C5")%3J)QN1:\QDB&'>/+,C3([ULS%110QKT*?QQ.F9 H3
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M!]229IB48:Y&[;&:R^-9 W,+4B>W/O.X.MJA3XP=4R0I>M[P>6 \_O)YG:G
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MV)3)379M*#NEK^"1:KX+#ZW@[0D8(=!(TRQ*,,J DM.D;&*/MZ=L;$9)100
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M. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X%=-=?TJ[_ -\7:O\
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M*'Q:_LBA0M2DN*+MBE'8&*&Y2C6E![8@H?63*23.D&,=?JYSC(9CP' <!P'
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M:I4:R1LR1M[:M&<C2/@X\R"=""0+<M2#MN[%AD7 <!P' <!P' <!P' <!P'
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M[;;"5CKQ>Y*\0=ZD#PS-#4TM,HD$=+0O$AAR$QZQ"G-8?&%;^Z.+8L-"%H^
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g16439g82t66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g82t66.jpg
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MR==L<6^A)Z%>+QTM$2;95G(1S]L<4W#1XU6*15NX14 2*)*%*<A@$! !P*G
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M*_6$\N?&E.'TZHX:]C:4IU-@$=@&JYK!'[+VA..&\_3U+(52"D.'JQUZI ]
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M_,Q>_&UH7?RLZM/L64W^,/JSS?/_ #,7OQM:%W\K.K;'U+>7#M#Q%:JY0_\
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M"FP& P& P./.?W0KY8X&Q@:%/!J>0;T1P*K 8$5UWA?*_4.7L8]OW"EO#O\
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MMFU':VZ-71VHHAK?%*;*24I1JU%NU8VYQ+"L@TLZCADG*BXKR[Y=N0KU<9!
MAWQ05*B*I0R2I\2O#FMX+?VE%>7N='M2BGY?]V>' GI\0&AUO [LU&K_ +/9
M%-/W?)F1P)Z6Z]-K>!VUK)7E_DKY55/1E1P)Z>U=7+<G0[(H*O+W.CN%>/R\
MO<Y.;(CW<"P3V!0UN3H;M45>7N='9(8_+]_M<UZ/+VNW@3T[75EO V2 5Y?Y
M.8CC^BY' GIRL6MX&2CU?]F\;G]%0?XPP)Q3D.'*0Y3A_&4P&#_O 1# U8#
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MK'/62S-N9JU54;-Q21(**"AT4Q*F<Q1#- KPZ</JWAM%:;5Y?Y76-)4]*#'
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M!S5D8%0[\.;Q%]$,QM_*>WB&UCXQW\RC958P*?.ASHBW?_ &!%6[SX0P(F!
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MD&!#P*D_?F\HWRC@0'?=)XA^4,"O7\$?Q?K# K,"J4\(IY9O2' @._X/\O\
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M@5>!E3TA^]12O[*/_?7>8V_E/;Q#:Q\8[^9>%,V8F P& P& P& P& P& P&
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M+66\>T-QK"]'. E@C"'- /NA$AV^41^^_#^/%^SGM/HN6LMX]HJFJ[Z8@@$
M81'D_P#M&(_C#_YAB_9SVGT7+66\>T;UJ-@?@^;SE#_6&+]G/:?1<M9;Q[5Y
MM0[%$QA"N&Y!,(A_K2%^^/\ :6+]G/:?2+LY3HAN-.[(.)>;6SCR /+_ *TA
M/K+%^SGM/I-VUE^O*O<Z4V.X;JH*57IDU2"F=)22@3IJ$-VC$.0\D)#%,7E
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MT^FP'7V$]V8KS@T^FP'7V$]V8KS@T^FP/H3D*80*68BQ$1   )!H(B(]H
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M5F8H\NLW82Q#<UQ+M&:K!86ZJ)&PD<'*"QUDS)@'#X;B2.N^B59F!.C6!U]
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MG^49_P#:./'A'&-<_P#Q5T"?XG[/'5.)=7/:3>$G]QZ[A)BPEJ$HWM\# O\
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M]\J__'&Q?6.*1E&D%9SG63UU]I>^5?\ XXV+ZQQ2,HT@K.<ZR>NOM+WRK_\
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..S&$<QG&?N6T81]0__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g16439g83h98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g83h98.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C&4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #Q    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #P     $  0/      0 !.$))300F       .             #^    X
M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/T       2 #4
M   ! "T    &       !.$))30/W       <  #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             "GP  !2\
M     0                         !              4O   "GP
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "GP    !2
M9VAT;&]N9P  !2\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   I\     4F=H=&QO;F<   4O
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !1 * # 2(  A$! Q$!_]T
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MI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      $N34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  '_B<   G$  ?^)P  "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HR-2 Q-CHQ,SHS,P   Z !
M  ,    !__\  * "  0    !   %+Z #  0    !   "GP         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 3!-30 J    "  ' 1(  P    $
M 1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X
M  !R 3(  @   !0   "0AVD !     $   "D    T    \     !   #P
M  %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C X.C(U(#$V
M.C$S.C,S   #H $  P    '__P  H ( !     $   4OH , !     $   *?
M          8! P #     0 &   !&@ %     0   1X!&P %     0   28!
M*  #     0 "   " 0 $     0   2X" @ $     0             #P
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M 0$! 0$! 0$! 0$!_\  $0@!,P)@ P$1  (1 0,1 ?_$ !X  0 " 04! 0
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MCFWLS->$F=79V6IFYL;&^&0)6N<'!:<!.C1(TI$.&<H4J3S $D$% $8:8,(
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MTA7#ODC.[VLJ[(I6:QVJTB#P9Z-EP)!$4R8MKB=51DB0J]MZQ_3O.P-AK2X
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M: )H ;$4/JWV# ZV$75OJWOJW@;; T_OO^_[F!K@,!@=@'"&7-K#&^2+%'+
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M574=?+)6/EE6LKEK(PO4W6J94N6R!P<(:OWWC;*280T2=IBA;8E>],1_@$X
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M=<.DI)_"1RA,."]W.VL3C"N38Q(_*%TDKB<8[N-3/\@CA)C 18[TS%Z,/\"
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M/T;@/<<>9WO96WMX3]&X#W''F=[VUM[>$?1N ]QQYG>]E;>WA/T;@>M7 8#
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MS+ U\_\ S5_>_57RIJ<_V?\ L7]_X<!Y_P#FK^]_*?E34[\R_P#+^3 T\_\
MS5_>_5/RIJ=^9?W_  8#S_\ -;][]4_*FIWYE@:^?_FK^]^JOE34Y\RP'G_Y
MJ_O?JKY4U.?,OP_\?X,#3S_\U?WOU3\J:G?F6 \__-7][]4_*FIWYE@:^?\
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MDC<JECH6"8J#[CMYSFUBHC)"9W04H5LZ.)QQ:X"1$JCI4N$0&3,OWS&P]_\
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MM["WHTB4&RS0@VG3D ZMA+!U!D> P*O<P(AQYDU-;?\ E),&JOZ>IVPZHO\
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MUF/173.YPR(Z(]X(W)VE\7Z-N&7JNL25L$2<IH4R1FZ(G/2D!Q1L<6,;(<Q
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M?I)95V7*QRI# I W1*GY>G$P5R4"763#U2)W&_=^UVSA<SF=Z(Q0OXX7%O\
M2RQ8%Q,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4X<?O@D/_
M !.+(_3956!<? 8'0?T^DLJ:*TWQZ%/4%R)YVZVU*VVEI?2%NPFFIBUV IJN
M6IF2$)WZQZPN:&/P;@D2B,UV='G"N'Y<VMKLYV*TZ"JK_:1<'8/T9KI"WK@=
MQF=J^CCS%8LOKP"E,U2";EV8ZG.9CV[[DC\=9!++&DU@IY7)>]Y0WS=%&XZ@
ME;<\)'U P,J->0V)0O3@,"B#+U^Z96'^#]1%5?\ +Y\;6P+WX# 8# 8# 8#
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M6N+:RO+<XIT!D>E3.[1%Y?FU4%,NBR<X_()C;;] H>RT97JB%P8MGI:.V!S
MG<9FJ@YZE:TKD/"5G*^@..C:ZPF4,YS?&F&PZ+BLKA-AD-NS7F?/(8]$D;<%
MKV7[YE8>_P#W(JK_ -]XVK_PP+WX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M?F> \Z< ]8T_\U<?F> \Z<!]8T_\T<?F> \Z<!]8T_\ -7'YG@/.G /6-/\
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M G C;G%W7+%ZT?@TB)"V-"1<XKE1X];[!*5*:/LA&8+02P#$$/B,<P-E*7P
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MU_)K =6OP:_DU@.K7X-?R:P'5K\&OY-8#JU^#7\FL!U:_!K^36 ZM?@U_)K
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M@$"H9P];  E*K..[6MZ$6'JW@<8BFRY[BJJ1,,,E)BT Q$HH[(D.HD[*S=;
M'8S"G@1>TJ4(Q[[2@81[&668-.4?_@]&!R#EN<J!1\;+N,MA0AEFR<EY(<G8
M\).]%;,1,QJ!:U%!4:ZSM!7*P'$ZV '6B%H>]@#Z%,TB!+U+X;,59\9-:"T2
M>%"9F8"1(Z!4;,,>@/A:8+V<,Q/H"?2 ]0-(7OPAP=;$, "@I/1%-((YRCY3
MJ'"1O,L(7I*L<')ND*=N4-[BXOJ:0/Q+@K3A3:+-6LHRPM[4HT  T[8$A)OM
MA3E;"'8"$(0AT$.M!"'6@A"'6M!"'6NK6M:UZ-:UKT:UKT:UZ-8&N P&!\3U
M*=*6(Y4>2F*#K>Q&GF@)+#K6NO>Q#,$$.M:UZ=[WOT:P(5>>2-(,QY205B,+
MRN4+SFHE!%3#I:J$[$E&G#:S@QLES+1+]@),T%.X&I!"&'L:^[WK6!P">])?
M)1(PP*@K1<R%AK@E,=YL0TUHTM*E$(P!!KF1)%WE*>VKQE]:5?'XX^]98RS1
M$: /KT%79*KY&'](MQ?4/;%5;77I_&N["W5M0RJ0/<B0O9CQ4*B=G-BTZ',J
M58G0O)D+;8^)0!'MW:B7UP6)V=5XLA-#LQP& P/R/]@+^*+^C>!2+HT_O?O#
MG\7BK_ZL(,"[^ P/+X[V#%%72\3J)\BE_-O<Z=>0D3KBGVV+;X2,W%9XH=]A
M$ +C41L1CESP9R*?HN^2]=,-25.@3+%<J3K4*QH;BMK--Z</4'@1Y;L9EDUJ
MBSH= Y6= YQ+*^F4:ALX3[4:40Z5/D=<6R/RD@2,92L)S [*DCJ6)(86I"-)
MH2<8#M %H.L_CCP^N"N+SKJ>AI:MJ!9XR[2-=:DLA7.?D[R+D-]-+G7DWC22
M/2Z"VC54%CZPPV?/\8LXZ72N1RB1MKI%QDH1'+7IQ<1!;#F;^UBA?QP>+?[G
M7_\ O98O[]?[F!</ 8# 8# 8# 8# 8# 8# 8' /TJC,7"@%(W]H8^]%A;<V!
M='!*B,<EYNPA+1H"SS &+%(NT'?@$P3#-!WVQ!T#6]Z#X%OZ\V4J8\&+/I;>
ME;BUHY:?MJ*CYZD_>O!MB$.G(3PJ6%AT,2L>VLE(GZ@!TI,&9U!#BB(])7F/
MO#1-G\OP[HK.T2J@FW>)*&YJ\* 29(G<P.JIV"MV6#J5N*94C&9LTP*<E*#L
MZT%3N;ZFNJTJ:%V1,X8FF+%54S9'=6B5H&]^?%L88F-^='9F2JY",?C)CJ0U
M%!/ O6A(7*2R3%QHM@\($+TEEEDEEE% "644 )998 Z  LL =!   0ZT$(0A
MUH(0ZUK6M:UK6NK6!\5BU&W)3UK@K3(424L9RE6L/*2I4Y)8=C,-/4'C 446
M &MB&88,(0AUL0MZUK>\"O:GDY!'5>H9*K:Y7>#ZG$,HX%8,PG.*(5 #"BAD
M.]FNAS36K8H)V>2<<VF2LU]\3'XZF:%2<(AZ#X&-7)B?#")QD<.HB/&ZWH;;
M%$A=E6(84(S?I-DS^D;X6PK!)Q]@:=%%I:2D5E:-)=W @>R]!S\>XYU>SNQ$
MF>VQQL>9)Q[.*F-HNRR=OB4\0NWLUH"^#/:(T$(]CV0FB[4RHT8#!D(DZ=.+
MP6!.@0A '00AT$(=:"$(=:T$.M:ZM:UK75K6M:]&M:]&M8&N!L71L;WML<69
MV1D.#4[H5;8YH%0-&IES>O3F)5J-06+T&$*4QIA)P-^@98Q!WZ-X&C6UM[(V
M-S*T(T[<TM"!&UMC>E+T4E0MZ!.6D1(TQ0?N2TZ9,44026'T + $.O1K W^
MP&!3AQ^^"0_\3BR/TV55@7'P&!TC]-U*ET<J[CNEDQW(@OCZ^7.[I+[*XSI.
M.P;$5MJ.LY>X5R0!ZY,.". H&X%D$,"M8W$$F/#JF2GGI%2;NK9"X+[<"7&#
M/_$ZGY57QMFKF"4Q\;IWU=:BL%]R/BM(M4L(UUG.U.'JZZ=I2F3LR5F$KCBQ
M6E):6MK;A&A&A$24&TY[2Z80+CD^32+S99 &B-RN"N5FR%DG]055+_-1J4-Z
M>;M<&L:_'5@J"'RQW0'E-R%VFDEBI&TBA>B8I9%I4K8G]N"K?1HWB5>DEM=Z
MK6TK(GM&L<<AS=MJN3E#P_Y2S=GM)6[2@]Q7,DFXEW%?!,9B[A%B&HA:TV%8
M83E[HC3*(C%64".4.4@"P3+]\RL/\2*J_P!.-K?W_EP+WX# 8# 8# VIJY$0
MH(2'+$I*M5VO%DIJ@HM0H[&NL?@"1CT8=V=:WL7@PB[.M=>^K QHB>116LDK
M8WNQ;FZQ!*!9(&IM(5+G)"4:6H,(#I&G)&<I.4Z2GA3D)0G''&%[++!L>]!V
M&P(G![M%6V3QF(2UV[U,*"0RNK2;"GQ&68(01J79KFG<;@W$D=GK,+,2#5BT
M(&R$IH1=K0<PI-E@W9CTA2,I+$,@PZ0C7'JC'0H[80>!2-@$VM)1;T,0]G*5
M ME[T7V0%]8]#"&U3,TKVZR ]QE^CF1R2#2LS2@8T:%:P&B&?KQ\MY&<J&O4
M:(,)" M4BV06>1X;01A,V3H-BGK](9$B8C(Y#*I>06<4>>\/3OI$^KA$G!.*
M L6QA-'RAD:[(2C$Y28HE23VBU0#M&&=H,I$QLXS4)YC8A-/;"P%-QYR8HXY
M$ OL[!I,::$0R=AV .PB +0M;UK>M]>!RO5K7[GZ_P"O_#@,!@,"B<.:I0R]
M(M=*A4YF[B,TXQ52^M3.0M4C2 =H]-Y5'%SBN;]A D*<AE; F3*0>&.-0@V6
M(P 0^#P+?R.?0>(;(!*IA&8Z:KT9M&0\OC:W*5NR@#,,"A2JE)2A:8 LLP>R
MTI1IG9 /?9^YWU!$(.3]<O'@@5^@G5IG*A+B$9E?062O3*8X-YVTZAM7RLU
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MTW_"&",,%L9GW8M[%Z<#(TM252B['B595ZD\$'8"_%87&T_@P[]&P@\$V@[
M=Z_7T'JU_!@<T7"(627HHJ(1<HH/7U%EL#2 O77Z=]0 I-!UU[_7ZM>G _7D
M7#O5.,_D)K^:_P .\#7<+AV_UXG&M_Z6)K^:X'Y\B(9O]>(QC\@-7S3 T\B(
M7ZH1?\@-/S3 >1$+]4(O^0&GYI@/(B%^J$7_ " T_-,!Y$0OU0B_Y :?FF \
MB(7ZH1?\@-/S3 >1$+]4(O\ D!I^:8#R(A?JA%_R T_-,!Y$0OU0B_Y :?FF
M \B(7ZH1?\@-/S3 >1$+]4(O^0&GYI@1^"@ZX!:JBVM,3=MZ45ZCK@33MG8M
ML(6E')5TG+< )NZ_&@NHUJ\Q.:=XYXN)(62#Q;1H/"["0/(B%^J$7_(#3\TP
M'D1"_5"+_D!I^:8#R(A?JA%_R T_-,!Y$0OU0B_Y :?FF \B(7ZH1?\ (#3\
MTP'D1"_5"+_D!I^:8#R(A?JA%_R T_-,!Y$0OU0B_P"0&GYI@/(B%^J$7_(#
M3\TP'D1"_5"+_D!I^:8#R(A?JA%_R T_-,#04)A@=;%J(Q?6]:WO6],#3Z-Z
MUUZW_P#5/W-X%2NC4WU]']PX_@X[U=K6OUM:UJ+H-:UK6NK6@ZUK6@AUK6@Z
MUK6O1K N]@<:\NR-A9W5\<!# @9FU<[+AE@V88%&W)35BD19>MZV8,))(]A!
MK>MB%K0=;].!TY<8NEXD'*R=0*M(!P+Y--,IF)57V8]NTE>*G!6U<\5;C;1O
MU<W_ #>Q&2:/+2C>I>Q(GT3#12!,X6>I>(\[H5:) UIN_AAW/X'#2+<@U'WW
M<2"S#E6F=SW&@2(:TN/C?](CMLX'TQL :XELXG'Q<+F8@*-6@1;.$E*,/T
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M^-C"Z#\-8=B6]9YHMHC#4TEGB]D8A*481!\.&,P J',  *]BWM:B$@,;U7H
M:DV7K0<"38A5%8U_H.H17\/BH@>%ZCF*/-;<J_PYFSC^TK3I@*1>'.WLT[8C
M=[--WLP?:'O>\"0,!@,!@,!@,!@,!@,!@,!@,!@,"G#C]\$A_P")Q9'Z;*JP
M+CX# ZK.6'2FQKBA?)M/.7&J_P"W8]'H]4:NP+#IU%#),IC<UY%/MC1/CS6<
M>K)9*6JP;#E%HRZLGJ.:/B[2:S1-8[1M5(W!*V+UZYJ#L I.;SBR:KADZL>I
MGVBYG)VPQT>*FE,@CDGDT)"<N5A;6N0O,16.,:.>S6D"!>ZHV=Q<4C2N6'M.
MG!<-"-4:$:<N9';\6J 3G36I4F=A3*%HIG(:^@K?:%DPVKUKZF)GLOKBMW0A
MP0S:9,C+L9S8S#8)BH*),5NK= ; <VU'"GX*]\,W:QI+:-@O3X\W_:D&(KR*
MMC5<W+#BY%.,USDRG<GDZEUK5@2,U/4 \RZN437W7)AF.54HVQCD+F+NN;S!
M4].S/!PS-E^^96'^)%57Z<;6P+WX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M-_:S0OXX/%O]++%@7#P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M P& P& P& P& P& P*<./WP2'_B<61^FRJL"X^ P//ETV]K-DT4T9PN>*QY
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M $ 0AT&[[IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\
MS0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\
MS0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\
MS0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\
MS0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\ S0V+]M^ [IY3^O\ Q_\
MS0V+]M^!A]AO'*2OX!.9X;+Z!=BX3#Y-+C&H%5V(A&Y@C;*M>1MX%HKF6!1B
M6!1;3!5"2*M)]F:.VG/T#P0@MA@,!@,!@,!@,#\C_8"_BB_HW@4BZ-/[W[PY
M_%XJ_P#JN@P+OX&+3EQ&SPF8NY0E0#&J+2%Q+&B4%)%H!H6E6I )(J/2KB$R
MH(BM;3J#D*PHDW0##$J@ =DC#R<=&=9_#WD;RLKVT7?I1[R=>1L?K;BT_1Z*
M6KREZ/:<NUR.=X1!XFLIXRH%,7XC5K<DF1U=($HXE.8C%).TO1CNZDZ4MD9<
M#]I#0]>& P&!3OF=^UBA?QPN+?Z66+ D61_Y4U-_Z@.2OZ1>)^!U3ZXS<W:V
MKNDK3ASN_.ULL:N6D3*KX,>VQ%<I3.%=WUIOF5HR"=6%9D*MFP&.1OT(;X:X
M:B;<TIUCDJ'((S($0T/DJ$E0=YZ48V"2\V4$2Q39::K[E)JPD^+<>&"&R"6-
M\TY&I:Y>[23D.+P[Q^8N,11<=5D6:XR\[AHS7=PU.68)NI5W$&'H6SI-D\XD
M\R8CK44R-\J=BC\123A/QY+K56=&9ERU<3#;+;FDE"XM5AIV624[J*.L#9H,
MSR4Q1$$]BM:Y(R3!,V!V:<:%%QJ(3(!7(*5&J@3IY+@2NPD=?MUF+J_TVL@D
MBBPD%5I&ZODKWJ5#EJ9F+CC<AT.#)XB<]DF28UZ5* AODW#+!>;/8GTVO[&N
M.J-4Q/HRT0&M)X1 '1@N]Q?HZLCTT7O I;#%C*L51I*XL<6LIL<E;M5BHMZ5
M-I*$R5G*3@A9>5TC+=-J]4HWJ3K(P_7!;ILH9P(:*=6:)01!R<1M5:,#H<?$
MV.5.,&6\84ZE[0OR.3%6*;)#UKA)'0QZ[EAJD(W8#NE79BZF2/SI+9*G4M,$
M=)X]#8^-O?A4[<H'QG72N+2!K:8W'V8=6MDN4<D42TZ+&L$R*&C1%-LY4E!B
M0'$.?C<KZ1325C7[:KK7'S27K%+C'YM&>,B<ZI&-3>/'0#-'%;Q&D$?2R) W
M<?6J]5TED*0AZ5'3N4/3:P'*2FZM3D(88SE]*[&88WJ7>36/.Y"YQF%M[Z!4
MR\4T+A%7A='.&#A,)2Q)&"O&E"\.#'*9%RY;O)]9I8VNS#$TK<U[0NNXG*EP
M2GPJ0\ZTEF.+MR(*LA(CFFF626&VRPBF 5HF5I.,W'**!6P B$.+]-([-U]Q
M1JQMO\53R$^L4J$,H=V]J"L=XV]N@=K^!TOQZK>6+>ZL"F"0B=PB1L]HWNJN
M*32-SA+HU6E"IQS(CDAK(+0W/$@DK?(W&*TR!^?F.0/#(B<Z^CA"F*,2A(YR
M';.(.2JND^4%/<=KU>9'(;8D-DN?&^DVY*<\.4.>9BW/B"//[S?VH ; &1 X
MJ+%&Y/TA7,R]48Z*'^<]QK2U3H=X52:&*VQ4O)!P56L"JZ\FTA9)'( N;=(W
M60:5*C8"9;U/2EM;(H]LUW1UCMJ N-?,"]LCE6S6M(7*:Y8"YE&$-HJD[V(F
M<!="LT\R;[9I!O9(ROAS&76UW;M9@+AI\ C($VY5!C:U7ZB9,TL!L;) H=3Y
M.!G/\IUK@YM@9FK&6E3>"1I@O1@4(Y<2WD>UVC242H!7/BC)%"[A?%Z**QRK
MW.(N,NB\LH9%"B+:?K&9E[C'JZ"URF==_AKYS9YNX(1JCF,Q0XM:+:<,&Y!N
M/2'()BJ2U0W)3X4LCK3,372#+:X7+65P:'9? I)6;-JQX:8M/<I"SS6-WDS.
MS@POQ!:^GY?!>\4::7LB$\*WTZIZ4AA4O#C-8W,'%ZGUC,!*A<N1TR0V)FF/
MRGB!&!2V0L":5/J.$MD@IZ.<@E+XRP-0J)!)G!X7MC87)5427X%\.$:SE6MK
MIZ.Y9@=2IQMQCNDR=Z15TF4)5FX/&Q39,RJ:T3-K0OAA$Y$_%18]V:@2 "8"
MH"EYD37W0ZFA*/%K_J K3_\ !E?_ (TYX$_X# 8# 8# 8# IPX_?!(?^)Q9'
MZ;*JP+CX# \N?2TW/QZ=N72_CMR9YIW5QW@BXCA9'2JR9K]X;PVJ)$UWE/KN
M126Z7JL^2_%^UUZI#2:BN(\YS*2$2Y0Q!*>8X(TF&*F\"][#T'<644%;>/=4
MMU97JNY,0%!%R4<4O5REE=SE98S.F5*B4SP;*ZFC\5KAY"G[ FH@^(QYI:2B
M&\I*!*$T@T0@A?I$5BENXVK7$N5;842&PJQ.>HP3.;:K=RM]H',FM.HIACF-
M#1R8W*@?+"./3MC8UU[$I(ZRY06&&.C.JC$A?M!"KO1G/Y,BL.X%#+%GZBF!
M'!X&2?QXF-H<S)U)SGA3(IH,%O C/,NF*0?8:QN2)/N(IG:O(Z[-4U7M*Y-*
MG8M7"HXFP+,LOWS*P_Q(JJ_3C:V!^[T8YK)W?G)&JV X&6+(>"< 8X"6T.(&
MAU'-795S.018#8[&+&\MK<!/BA!I$XF+T($2G9:D2Q,$K9P J;8U#<U*7D,=
MD]%R-V?S)?&92VRU#4\>C<4A=3+%!-'H&9YC]2VW/;0:97)'=3$9&JE(TSLT
MIW1L4NO=BB%O*A7)7<.;8'OI-SZO6K)4AG:.U3TE/G2)M96GC>FBS&QG:J;<
M[.JI28BE#BKLD85%I;FS=-$LSB"0:!2" %(Q:AH7T,.A[;TE[$^SAQ5J+7V*
M7RBHI+/_  C?QW5-C?& 5CPWC%AN%!MBPZ1;;;/VL8.1 W6*2=8X5H!W1KG6
M,QP:YZC*MY#M:HDVS3ZB@9MQEFE62-EUN3!5@82W79FE2G389(2HIH$4*E1S
M+IM.EA45+*BY4E&ZEQT@AF"B* %9+?AED*.0KW)7&N;!MR"N5?4JV4LCAEB
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M6Q3>_K5X[0.4Q"S'>P$,DF-51&02!T<AHWJK*V6MC K?*RNZ&A7' .$!W@+
MK1%NC7/$RIB"?+QM,JEZQD-AC91R-2VJHRR,[$%?W24[26;2QC@\50KG?Q)S
M$S-*B22-J \/);6ZFM+5M8XDM3F:F A4!![ORO=V.@G.Y#ZA<7A\C5NN%/3&
M&1N9LI[6P.;'<I]/2"6$2^3(8FI>H>WJT_?R<;?$MREP2J4J$N*E*/'3$(5Y
M>>DQ2I5,H"UU6UDMS?.9K#HP\SZ?2RN&ES25Q*K?A,KDTE=76F%[.T-"^650
M3&8.;"'.T"'Z33R&1V1JX2[NR5*H#L<KB<-5G5Y [)82%R5CL*&1><,R9S)
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M@7KF%?;-Q.B1<Z>52N<*7M:8Y016J5O[I+URJ1OK^I/->9 [F^./BYP- 7L
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M5$I21Y2X+2HV\K3H7(I7&QHI<PD-TO8MH7U6=W ^MG>1+>Z>.MJ0)RP& P&
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M1Z#CC8#!3_*[1\+B9VK ) GGFC8XSF>6R<IO$TED2[MH]^4A);4(38 IY\=
M!O$)&$.DV]EX&U%6E<#3PU(.OX2-+71J8ZODPHHQ"3P0Y&G C1FPTG:#9<8-
M2I"RTJ8QD"A&0G  @K82@A#H-VC@D';EZ1U;X;%$+H@<I"\H7)''6A,O1.\N
M&$R6.J182C H3N4G,"$<A7$F 5/0PA$Y&J1:UO RO 8# 8# 8# 8# 8# 8#
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g16439g87q91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g87q91.jpg
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M>RIG1O*33A\^1 <L^*!V#8]HTO%H_%:ZK,&&CWQ3Z^Z<BL;L(D_6,6EPTS
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MGT\I>M[&/'+D S.QUAM=NY(+F]23\53Q&A2QPNZ0?LVM=*6Y'K"BVK38KO\
ML30Y>,Y&>'[93G>(MU4SWB/:V'PTKKF_0/$='V)99+][8C=K.JSG,ERDFAM+
MI91UG36DSTU411QJW26FA*OG$J72:ZZ-$URZB;5))#5-+02I0_![Y2?O^[R7
MK\(/ / / / / / / / / / / / / / / / / / / / / / 4SZO[6@',.T6@
MS".R*[.E+3U=-J0YAK'\1[9]E/4/K36+N_R=]1D K,&IKNXFEKS-8=#XL.;O
M%5') FFV#O!4IY)9>B^:)79"=&\4S^>V9'.M/B!2&.VWT)'U]RE.TU&ORW7-
MO(:+K7&=&]7 BNFF\[MS[7T:2:_)>RS(W+E--A!V$1 ,FZ3L5M*53C?5]>7+
MQEFBDRB$9L*(2J S0,SD<.G$;.1"61XCKON/.QF2C'04\&?:)[I[[LR@MZZ9
M.M=%--]D%]\:[ZYSC.!DYUU4-7D*HS11*"1DK3N\%1K%6MRPMN5B3FOVX1.-
MHQ)V((:N6[P+H"23&?B.M5M=FVFNN^=ML?5X)UUS)06S_A)\B3>%4S641KR,
M5I6]9=01KIZ7104"7.9MP]&JQGU7L@DLD)8U_)4]VPB:LU@DC_:OR47UBP9E
M'T6*2+=1F-<;O+RHVBZ=NZ)V4^'KQ7O%JDA6.<Z[0C-%+3AQ5 UHR?,OX@O9
MFF-;&6;O6;] @25GF^J;J8*&W9/:2/T6Y(OEV_;H.4Q)>[OF^3R9#\-?@^5%
M(J:D/+=4E"D)A=>5]&':X5;7<9$ZE19M:Q'_ $HNTDWCJ!L&#85%C1#1V=#A
M<+!69)(2Z=,U@XGNUG%LY)$ <8<K1:]B?3,>HJOQ%ZEWIPJ]L5F)RF6P=E Q
M +*),R:96V#"Y9* [=,5)I8,&LY)(1V561DH];.'":H2XB7!%A?X>E S.3=&
M[6C&05FUAT-:=>WXO5\C";I(U_?,0@+"LY!9\+E@XLU,ARTRBL8A6B^P9(,4
M%$QTI=_O"32:.QPT)=N4KL[QXMOOR19B/433,3IQOSU':O@XJC6T0?0#2J&T
M<&9@BL,*M73(O''<<5;J#GXPRW?/M3*+Y%QDNH^>N"6SIP\<JJB2YF;[ZE?!
M/PX.& =026AA7,M8LZJF$G"S621K08[W<%)=&=&J48DJDF5?*2Q W%VK-NQC
M!%H=0=1P;ID8%48CU%6VXKJJ=Y<KGOGQUW)X;\^4@UH_/-3:JX2A068.XK;:
MI$@++2#[09VQ4&NHYN$PGAMNQ<M5EL.-ML9<KN%57JJ^SU39QD)<S+G,Z^)#
M4$^'UQC6;D8]@W/D& /Q$ZKZSV1%'4N[)YL2J@TKCM>35Z2(E'CXI)8J F\H
M"C2Q-P\>?JRFS%PJNV:,$VH<3WY=G=^+4]>K/9)\-<CF8Z,B12AH&]C85A?(
ML6'69O,LV0_I]5VO?[1'7#W&V$K46?.U)3C;;;+G9=3\?+;YX^02]]O+'@>X
MVX_YE9I*(M:9AJ*2MNU[?:FFC5UC7>XJH&1T-7-@[?-WGYR"(BXE&V0A?_U*
M2(=GA1!7.FV=@E[Z1VV\SS(1Q)R56]UG.BX)0%;1>ZY$ZD9 E8 D"F@5U*S+
M[>9F:%-L[["@!Z9_:Q_,#H$>-,2GZUOW[TA^0O\ <"7$3;8^*\>%.0^E99F=
M7M04"LR6*1!"!.C4B9/-W!&(,RCLX+!ETF;UHU,-@)Q\]-QI0J@\<QDPZ7*Q
M]<:_5W<9"6M>?</>%./R-TE>B7W/=;NKJ.(D$RT_6#[;%GKHM&5(64.*M_O_
M *O$J(Q!56,O9AHPTE3D$JJ+6,;LU-T=@EQ$VV.(DOPR^!ICF(YDW*U3&,02
MOHM5<6U=!%\:#(#!L?3"8]NFD\33(IP]/*B46?E-7I6/HKN4!+YHDZ<:*AQ5
M7N[N7UW.R></\SM;4/=!0^G:ZB_0A)Y(I.)M#>.+%DPMER"-N8PXL[,-_:CH
MT[FK@:O^&<D[9L+ED@%[NQ;V2Z)/EU<A/SEM\]CO^8: B_+//]4\_0Y\_+A*
MPB;,!M("VJ>IB5G%55RDKF9K1+;9'0U,Y20,RDQHAG\?0F7=:M\:HXTUP#<M
MO<GCP@\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \!RLYF\2K.%RVQ9Z
M?'16#P.-&YA,),76_'%Q^,1L:Y,'#)!;&NVR;,:-9N7CC;73??[2.WT:;[_+
M7(*]EEF;-I=WRJ[9B]YQ^&JVAEX6QJT&JV5T@0<['>5^7 AYDB^9%I=)P+C+
M>U+6?"W*3Z'4C"":I%QONF6G1:+1YHXR]&HB]5EHM7^%S:Z26(Y0XKKSEW64
MS%8]([FZ+M/9L]O'INS]VI*U+1)H8UV1'_?;IZ#X170/?75M"JKAR R&1$6@
MT;M63LAH[+/1&YY+1:+YODN1X0> > > > > > > > > > > > > > > > >
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MF$-AC8HJZ1'JKY)C6&NVKE5DZTTPCLIMC*.WUXUQG7.9#65!$T\,L%X4> >
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MS1+3 [N'=8<.-I4QVP7%\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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M8OV&-W)%%3=4*6DY<VQ&9TY2LZ8,I8=17>E%*0GENZ*6O8IQY2795G6?)!7
M<OM8(PE=-=&UE,K!I^OJPD\<,5-;IBO>=.DR9T?/ J)4$Z$LR\(?/6A4""T*
M*OGSN:LY:=^%*\*ZA/>[5\_Y%9XS"NVH/1M;<FUFI?T&Z- _#X[UM!W0XBQG
MX>UFLB5^*97,[BQXNSC<E;,G5A2.I#!W2-2%!SEU*!TE?L #]TRD"B#H7[7+
M<1Q4J8_XU6]+=#3V9(]V6+(.XNK:L@76,46K/HWBWHCE>@;")R6"N;HK"MZ6
MCT,Z,I9M $Y$2%BQ5FLG$](;1%TQ_*VL;^)'#(5E*DLX:#/VRE;]+3>S;;3G
ME;M8JMU?1_Q'V_.-(PYL ZRF70$FYIOWH"3VA6]C=#'&44[$M29LY^,I9G%*
MIO*H0L$=52*?YBU:3>T"DZJL!'0+N.16HI9('ZHPF^:_.FQ:>&;M1Q)7C"UU
MSK'B3B1HWN@[:DMO=PXZ]TF@'X@/PZWU>"$+,M</ $N=RU8T&+ZT=9J1G)F5
M>E(<[(;SQK8^#<6>Z"WXLMEBF,<+F]B0?;96_35,Q,S5PWW_ $X>.4EZ_A%4
M8>YZ"=JP&4U]=4)+..Z>CI:&*6D<GDBC,ZK:5V/(S%72VN34QDTA:&T2<0<,
MG<ND(O#<L</.=7LS=EI)ERYT&:G+6/TTXY))SW\HT-?O#(\ \ \ \!1;NRZ"
M5?0 57<6>*L)=;/[@<H4;*92=@(,(29:3 JR5T_S$"K[!<7&Q*^N4E6:IMP9
M:J_D!M4]]T4R[X5^NR^;&*W"C?T,>F[=!H@BU;))H-VR2:""*6N-$T44M,)I
M))Z8^6-=---<:ZZX_IC&,8Q[J<C^EE4T$E5UM]4T44]U55-L_+71-/7.^^^V
M<_TQKKKC.V<_\L8\!K-S@!MVG*&JZ0 TEK)B$ABK.;R*N]\-D)?%7<X56F)/
M>$O]-4FYE%!<XOLZC1'YNMWB:FHU]NJZ4SKS?#4VG]K4WT>TK3:9@ZJ4D\IZ
M:KI^/Y+EP:Q(99P94C%R:!)!/.S,L+<I9;%1#K.-DUQIT.ZUU=,'.NVJB6Z3
MA+[2^--]VZBZ&<*;8=+ISVYFDT\$=75<T6YCA\=E!J 2YS5J!Y,1-Y+7D;9E
MPE,1APQ(N][#FL<%NDI'I !Y-%FQDA>(QV1;15J44E<D:"XD(/'1TF;N[*EH
MH6RQ^WS<HU7%Q .89K8E$<^QHOT_74@_07I3D#I(G%5F5$@;EW.R221:66#,
M#T3J6,U(9.Z:V320H=-C4_=Q^>2&/Q*M]JZ@L6).A6U$MP\.9O$:7?4\[B:6
M/PD&5YRL2.J5W<-,;$]7$&)E1I9Z;JDS)3#JLK("F1:FXZ5#2P!=H!F!<3E1
MN'L\-+X\[^G+9@Z(CC6L5*ZJUYJS7XW1=[PP4NM*OY!<78U'1"O[5EU0R6#\
M_P!_RR:3:!A*]D)D;#YC.*&!1B)%6-DPZ<QYLTL"1Q8P<"K;!='KA:I#>6;Y
M-)B_:O!UH4TU-J5-*ASF'>5&/<NO2W+\*IP\6GCJ33VW+</"<1\Q<%N%Q!F9
MYC6':)#,6CHR+Q^'U]7L6<$6S0D3CE:PB'B#Q1D/+2%J6*CV3U ;TA*%LODO
MN62\ \ \ \ \ \!G]).5+<KJ:2^8\J6+!@46L*2%YM,:%N"-'2\ ;SV2/52<
MLF-73.(F!TEK!S-32[J1S:./@%A1(U*7Y.3! T3-FY(^.B5)59RK2GISSVP1
M!R,-E38MU,]L]*-ZW.KTN>$V5F*KDW8-HF#K:L4:W$@W1MJR+X I54YA9Q@W
M=M&>JKR0E3>&:;DV\6<#G79I+"IM/5R_$N1X8*;Q/H&BJE[]MV/3VW*[K<A,
MN<.;!"S6;2T+%&LAF+6R^BMXL&%NS3QD/=RW4(?7V>"4W'[MR++PS_9G#5P(
M^0[T)\&-7%M(4SWQW+BO>D6AN\&M$U#%%[4.QD@VWOJ7,C"0>OJ%"NAW[)D+
MDTF_7E4SUMR!!<<YCM0 &ZQY$(^1E<X(0:,OH\4D U%I\.?[<R)IK4%_23I"
M>3"MG8RK!QV'1*#NN@YN]!V5- 4,9(ZF2D"YDIU(>G$H.D4DCE4]-[,N,E)'
MAF8#@[1W5,^A<4@RD?"T>WNW[=;H^X-PM'8&RV1J"\[\JYV2>DSDP6:R&%V
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M;34;-].FGX,KO=#F?,\;:/&CIHIC&4W39=MOC/\ PSHNELEMC/\ ^'RVS\_
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MPG\L0"(GETD@T&Z5FLW-*X:CE,9;QJ)&UFN%-7Q/4>&0(%&0K5G#7G^#^I
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M>J: LF87^&LJ%]<3&2BVH0Q$[7AZ56S,;!&*R!!6OJ%L*('UZ]K<4X)-\''
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MD%EA,7C(!R0> HZ""NRRV'!5T)$#QSDFOC.VV%B"[-NBJ]6QMOOMA1SLIO\
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MG+H00;%A+W5-3Y*-B LFS:D!Q!HH@]8O&Z3AJNDKIC;P&?W8OPE.:NH=<SF
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M1N6X<>/:(#TMSX+S4O1:\BZ4NF,3@,?>RN;R0)$HT.48(OCLA)-!(ILN5(M
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M6@SM1(?\_P"S7"MU.G^B?RVV>J[XSG8<_P"HI_3;K>/"/(YEBW"=.V4UKF_
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MPLWFB?\ PU=K52A=;AFZ=:Z_+95!&W!S997ZMD\M$ML(:"<%'_+.)6.L?$6
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M".C!XML+[67)$T^ > > > > > > > > > > > > > > > > > > > > > >
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M,&#)JFDV9LF;9))NU:MTDT&Z"::22>B>FNN /M\ \ \ \ \ \ \ \ \ \ \
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/#P#P#P#P#P#P#P#P'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g16439g87t41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g87t41.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %M EX# 1$  A$! Q$!_\0
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M:46?5LQ-KT[HAT:5M>'7S]2B>INT*+5;7+<GVBLQMJ:,8K]DGNN-.NS3X9H
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M@MC6MIU"0A)V,34IMQ.(N<H5C D=S]9W[HE(:BV/.ZM2XKVT2/<^LSV=CT[
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M@:=LT+7>PNB+.)<,+LR:K9^K>D;<)[99!J_5VSV@G21Y^ZPCDF"-KHBLSH0
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M76TVQQ;EO!4@K6')38*+"T!I*W,TQB0;V/02,E!FWVRP0AL06*+W>PD!%K=
M5![N\RU6'"J7Y2O=UN>6>7N.)Z9QR6JSYX%^;ZZA+3K@S3X%78#NK)@PUEGC
MBX>/+R7A$;.,$RX0<G(OU4GKDP!;A.7+15ZK?9@C"AQJQQ H3#.#423F?/-6
MM#5JU$16?*.?IYD -[HW:X/KLHF;IU;&'+932JB,"G'!^:Y6Q?4O5M:FQ)X@
M3NLJ+.BGJN8CD")+Q()$.+',,H95&(1Y8HDN<?-ENZ,.Q)>:]XI_=&>-_MM"
M*7U!;9"0)A.&N!<SD\%KXH-TA*C7$I>";<OI[%6@O/JI\S:RI"(%A6>&GO-9
M,18)+TY\JP5,J/'@[F*TOE32/[L:9>016G\4AMW7K//[,_;.H_8KH>TAX-^U
MA@%ZS+*0';U#U.RQJG-MZ*=#(0=2 H*-@/O,;#7,G2BT @Q8I\QJ% 17TU9Z
MTM/N\*S=1WW8QG==RYAVG6J]XOI,*]22N9N+9DRH;8KDK#80MIW4!W8I.YMQ
MC41R9(?KX6Z:3EPG'22TDV)+8VZB-F1I/E48N4ITV$H?##V/$-,25-6E]/ZC
MWYFI=5DGWL_N^XWJAO.R(D5]]A45Y^.P\]%6K"EQG7&DK<86K&,84IE:LMJ5
MC&,9RG.<8YDT=C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'EWM_1.^F-V]6-Q
MH==(EPO43IO6].JIZK6:BC)E;LU("6H++AW<5?84N/)J)19V*X16#@&2CXW$
MF-%B-2,^-;VFHLUJF[UA,RCFTY;B]1?[7^?9I@ST']:@N),B2[&4)70>D*+K
M-PJ%]#5BFC:D,T; I4H!$DJ0Q;Q@M=JBE,QJ,)J(VKK8(QR??0V>AQI.^*SX
MO/<G#:3S\]\J;$_N?0EU!##6L8NO5%!>L$:ST:G=M1KMT;(2;MLVLLW:+=BG
M<%S,0:O8)3Y$Q5"A&0<+BH9F$)D.//*F1(C+T5I5G-Q*PP4I<@[+PNI,/O&)
ME*[T*;[?I^PUVIT@1N0K5-;&]/Y UL^=/,T:X0]S;;M;BD3 V( H*]&HU@HX
MU30_!4;$0*C@(I0Q""1B4H[5G"[&E]*]7Y%!PN'2OO[:Y)_O"/HZ$-WA!H:L
MC0!Z-68&X>HFU6^%6;A6RL*ZPKX>*EM/'1@*YVL0)RJJ")T\0;<-Y#%Q90BD
MF&C6%['EJ;QV9Y+.=<"<+BYW^=,]=#O5CHUZH(-?*CKN!/7K9\PUJM=/VE.Z
M@"*8%(H5<U2$JMNJA:<PB$<-R)EGA')LH-$H:ZY;^]F9IHD-?4XAIQJE859H
M\:]R\-K*M(?7LC8?I,Z2MH=/FTM)D84:)7-=0ND6!1]R@Q5I(3!QS?0X\&=B
M'E!'W'(DMV,$9*1F3;"(RDMOKCX:\!WLQBU:37.E,([FK*AW12M=:=%\GIJ=
M_8F;_!I_G4<P6W_:^7RBK>#B. . . . . . . 3*H?V<_P#^F-_I?X-V+^7V
MB;<'4< < < < < < CUG_8M7\.S_ *5<&+=W/Z97'!R' ' ' ' ' +C8_M#/
M\$W_ *F.#T'+P!P!P!P!P"O[9^R#'^!H_GG^#E;OY?;(OP8' ' ' ' ' /CP
M,?LL4_QC-_VEWGH!Z*]*XZSG]'3P4*)-5%7LRPNUA K<U[UA..'3$#4M2+P7
MX-0IAT3/AC)9^AXQ/M9B EI5@>2)8:@1K/.:R[^5:32KSQAX/7 UASI6*TTP
MU:/-GFC)]G6D_P#H9U'_ ),:%_Z5$\X.]^[^3NKE[+X)X3#C#*(;9.&U+2/)
M0#$'+GA)<B$Q<A$J%,CNMJ0ZTZTXG*%^ O"9$9R1#DI=B29##L*9+@#@#@#@
M#@#@#@#@#@$.Q0*AX-C0L(R^FVF81ZR>52)LQ1@B.5 5!\K7*DO+4/BX&0VF
M0R%(#(C(>BX@>32I;3[SSJ(77Z)CP!P!P!P!P!P!P#^9SC&,YSG&,8QVYSGV
ML8QC[N<Y_:QC@&ND#J=H!O7L78M9%6^S02%X%:_&@!@T5&LI Y8'8+M9>8C'
M#@<6T*LP(N"MH2?-+Q42JN>$$EH9<E9BMV*Q*NG3;RAGB6\<RQ:3L\#=(EF<
M5",U$I22'=MSKMSC0Q)BLOJ%1#L=\@Y%GD@LD7,"SHQ*(;$&"89]E4AE,_RR
M 0C1#4?3*G/9WG)[+NI^Z'[![)^O.X8I;N&4;]>M;[HC'?)ES.Y7R7>?D;);
MR-IR7W<X\F9Y,VM_Q/BD*5A#NAR)6:ZF3@["H).<2%C;Q3R!,,5B@C Z#90L
MN<*-SGWXL(,2B1YKDB"5ER8TF/%'RFVI<A^.^RTRMQIQ*9#R+*S/[(V#08A,
M4$E7>H1C)V>0%!!$BRA629@F)FK&E1PJ Y-3+(3QA%IR 0AQ&GI$*:VN+);;
M?0I&$/(2LR'V+?VEZN.-$RFSJ/F/6Y]?&6!J#9PA"6#EV<Y$KH5)>)$G.OC&
MI12:TTJ1.1'889;DRGW&XT20ZVAY$E5K=>9Z-M*A..B(A"TUT"5L)RQ5ZNA3
M=DK<4O82-9L<^L3T X3)>2HHI9& KQ<6&ITA'2^Q%)PAY3$D?'1W$K/R8,L%
MOE&LA<J KMSJA\\"3A1L(%L0@J7#I4\N.E14;!F/S!Z5/H6QC,MEG&7D+;Q^
MO3E.$/(2G<T2O@I [)2G;'+(2%GIT)DA7"-8<AL-^''0/*OC79SB4+?\7B:X
MU#E1T2T--O(;G8SE2_(V,<J<88SMXS+LRVYPC>2&N:50^.2.?V%L!#2IAJ5*
M:A&DPX<U!Q3JY427"\0\U)C8<??>PF2I];KTB0N0MW"VT-7BK,+ID3@_D\9\
M^<SOD=72U@9(>!=;FZY(?A(\H)V6<XXD:B0\U*BN/(:6M]"!\MSP&\H:>(OP
M8+)&=X#DJ2HK5;ET7+S[*[-+WU?FNU#MXU<VT8F&HMLM$5Z4Q(C>0M3\I$-Q
M\OF7QS&8*/ 4XR)[VPW%8S(PPIJ&RAQK*%+3Q-(A=/+\1PPYE^7=-9,*G2,-
M YD6U>;Y&A1I4>7%B1#+<>)$=B3FR,?,9I,53J%(DH<6MYR0[*=5(<<<D9=;
MCK8<>EGH.#6UU,U-U8S,E19B;G>(<B,.B0%OPS>&Y4KR1A3"7I,Q<=V4KQV5
MJDOQ4/(ANS5*E*8R[E.4.+"%?-PX=7YK?[KL<U.H9.L6 N1F6VTV$>[ 8A"V
M#Q^01\#+LI^=.?DP_)XT-$AEQ;4,>\VE:VX"5-*SA2U9R;E7)/10$FFZMY2S
MJ;VV;6],ZAONTK@@DNLT@$X<-(#Q6YI-4)B1';7B%$>D1&GW_"=3X+:Y+*<X
M[>U>.SD2EP+?]KY?*/(#[=/T=_@.XOD2&_2[FN!Z;]CB/MT_1W^ [B^1(;]+
MN.!Z;]@/MT_1W^ [B^1(;]+N.!Z;]@/MT_1W^ [B^1(;]+N.!Z;]@/MT_1W^
M [B^1(;]+N.!Z;]@/MT_1W^ [B^1(;]+N.!Z;]@/MT_1W^ [B^1(;]+N.!Z;
M]@/MT_1W^ [B^1(;]+N.!Z;]@2$#ZMWT9#52LR(&Y\^.PSA'BZ,%5_89<\+M
M[;BGL_L\=GW?V^.!Z;]C5EPY>1(_MZ'11[G;L^0@/]-..!Z;]C?&M=NX^WH=
M%'N=NSY" _TTXX'IOV'&M=NX^WH=%'N=NSY" _TTXX'IOV'&M=NX^WH=%'N=
MNSY" _TTXX'IOV'&M=NX^WH=%'N=NSY" _TTXX'IOV'&M=NX^WH=%'N=NSY"
M _TTXX'IOV'&M=NX^WH=%'N=NSY" _TTXX'IOV'&M=NYB3/JX?1=/A9CL#]T
MX<RZVO\ JE%")3V)[>WV\7)6>WV_:]KC@>F_8S:M)J%-Y$?MT_1W^ [B^1(;
M]+N.!Z;]C ^W3]'?X#N+Y$AOTNXX'IOV ^W3]'?X#N+Y$AOTNXX'IOV ^W3]
M'?X#N+Y$AOTNXX'IOV ^W3]'?X#N+Y$AOTNXX'IOV ^W3]'?X#N+Y$AOTNXX
M'IOV!8+7JYW12AMM&1^[.U*$)SV40'V=J4XQGL_^,_\ JXX'IOV.O&M=NY^_
MMZ'11[G;L^0@/]-..!Z;]AQK7;N/MZ'11[G;L^0@/]-..!Z;]AQK7;N;[=+O
M5]I#J^J)*VZ<L$J7D%/[NL=8/1&A-NKKSBG<P'BP9$N9A$ LRRY(%$HDJ6/F
M8;DQDR4D(!&'$RTU>:33N-GN0HX!7]L_9!C_  -'\\_P<K=_+[9%^# X X X
M X X!\>!C]EBG^,9O^TN\] -].E^<J'HK;&",G;C%<EE9L*;C0R]G(O+\Z8!
M',0XUIS'_P#T:52Y/A*:0T=_^-'D9LJ(6%#,MXYEWK[CG&,[<RJY[Q.5)PB>
M9Y]<T0^SK2?_ $,ZC_R8T+_TJ)YP=[]W\G=7+V7P6=R%' ' ' ' ' ' ' '
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M < < < < TC]4B_^1?J:_P F9#_;A_-6/[ES^&9M_P!KY?*/@[YV.(X X X
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MX"%=[CE..PAVX-US-RX[T0_,<0^X(E$I 22W$4VP1;@CR&$QG,KC-INIZ?\
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M_(OU-?Y,R'^W#^:L?W+G\,S;_M?+Y1\'?.QQ' ' ' ' ' ' ' ' ' ' ' '
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M!P!P!P!P"O[9^R#'^!H_GG^#E;OY?;(OP8' ' ' ' ' /CP,?LL4_P 8S?\
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M(:6XAC:XHOI.E,9KE>8?#-56/:<(UR_T5-/TWTS.PI<F/TT6=<0R2*956:[
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MKLX932[R1*7_  =;_N.7ML<\G0?31 DP([?3A8>Y9;=7L*@(Z$>57Y!>OUY
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M!P"/6?\ 8M7\.S_I5P8MW<_IE<<'(< < < < < N-C^T,_P3?^IC@]!R\ <
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M_P"4(_Y/ FUZ=T/+"GN/_*$?\G@3:].Z'EA3W'_E"/\ D\";7IW0\L*>X_\
M*$?\G@3:].Z'EA3W'_E"/^3P)M>G=#RPI[C_ ,H1_P G@3:].Z'EA3W'_E"/
M^3P)M>G=#RPI[C_RA'_)X$VO3NAY84]Q_P"4(_Y/ FUZ=T/+"GN/_*$?\G@3
M:].Z."0J9+;PS* ,R6L/1Y&&GY<1UO#\20U+BO80XVI.'8TIEF0PYV>$T^TV
MZC*5H2K 3:].Z.?RPI[C_P H1_R>!-KT[H>6%/<?^4(_Y/ FUZ=T/+"GN/\
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MT$_*<5?[:8O3!.)DVCJVKO6S9DV-RS%;!)=7;Y<^498%I)S)MH=J2&&UR1,
M6Q@6$&U9D:.'JC.-M1,CV6LLM"HZ%2:1[;3\S)I*',S??K'8MGD*. . . .
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MN'.+DGF1PN)(4W((3G6XD1MV0M+>4/(DK-%@<%' ' ' ' ' ' ' ' ' ' '
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MFLY\3QNH=F!;DR'@L'+C;-2UK [7.QU+;\4\B97H9$E/!#H+48'6WSYCNL5
MR2F)>#B;QF=;UY>9ZS]#W0SL1D*'N?3?J<['U_<KK."1;-2\QX[5BV;:6-H7
M]B,LHQ&:M@"\78XU:+()RX;IYRT+7B;#?*C7F(@<5K-X9X7;8DM%:<Z4B<Y>
MP NM:A/+0=SWZSNEQE7*RB\+<MWA3.F?8UH>@QH:R$:<:!PB% L-B<AH"IJL
M.84>FM5V,\60\^R32^EV]W_8K<)TU] (5&F]_@=*ZMA-:ZHM,BZHO4&ED/$4
MVDZ_U\:-Z]F3V$05,A4T.A.EFZ:;ND&.5J2238().'%S,$?,1U7^O(#M35MU
MKCC5]R\L=/G3I/T:/Z:\:WHLC0<*N ($'4V8C6:<U5 Q6&= PU!LO8PL(P4'
M1);3$CPX<A4?Q,A+S.76E"RVYFKQ(WLCIPZ4.I:RGI^T]1Z[VK8A-?KNOS[]
MK ()JE5&':*YN2K@)B9:$Q#]7CW(8$M@OM00$-V =.99<Q-BF8B 5IJYQ&TK
ML_((D3]3MZ'3-(J6N2W3!J4C3*.8MIZN!9E;;D)CE-@2X\Z_O$9SCJB=@8OL
MJ' <O$"PS2H^WX&C&[%%)-#8"(X2UC?Y_K(R=OZ!^C6^V>SW.X=.>LSMGN=I
MK5UM!:6%4EXU:*E3R.O@Q:6U'D,QO'>L4N2IY=EIAN+9:U,="V1@L/REA(2\
M_+_FOO6\V-U_0:;JND5/6VNZZ-J-#HH 95J?5@[2F!-=K@6*W!$AAD=2UYCC
MQT)EJ)#CX5E#$=IMEO"6T)3@1UJ[V2_@#@#@#@#@#@%1[YJ!V_:?OU0K;<>4
M8-@UQXXN9*Q"A6!EJ3&ED*K.FJ2MN)!M@Z/+K4R4ZA;+$4JZZ\E32%IS4X:\
MY\KR6DVFD:L7(/M;95Y@DQ&K3(.GC<:J9<9ME2I-=L]<?KG4#H.UO5P$>"74
MW*LM>A *Q?[.>5B S7X;L('&KA0M(>D-\M$K\[IBJ>GLC-6YB%3!*YIYZ,AH
MH9U11K%*L.1&U8XQQ=6L-GKJ[07*.MSJWU%:M/V6N@I9[9Y4*9=F:D3L"*A-
M$IFLJ?9@[ZZZR/,R$QX8Q3YBFGMG%[?VXN+7RTM8=,DE[DUCC]W$BCIBVU[>
MJQ$\MLZ;0 =4OT:M%@)PAM>>0IR[VN%:LB7*ZJAJ I"#["S:ZB '0;$,+@,D
M)@X:04TPO6$=572:WA35OBAS$.J\U<+F8)=/ZB)[$$?&5N08;DX@0]QF96PI
MJ0IDU(WWJJ4T4U*TFURFZP$8UC'VC)<13X%7AL58B."'X$VS-QX8Q*TTIH[\
MZQ?-="_EK.-8K.#]INI=B=TG0-ZU*"8FUAS<-D<E2-] '!L_;EI*.-4Y[8%=
M]B^:,6>M$Y]DN-IZ34\87%O0KZ5AHDA7+/!)2QLJ$E/)77+1SAGRT$/"<<7%
MZ2QRK?,FP/3.-V.(K-X@;%59%^+V.2=I3MHD&I!%ZE2JM4)<5UKUS7W9MHCP
MEV%^R9CPK)="A:"KQL1V.'CLQPH]:B:;>[T7P6S,5SI.75FQ_,FAP!P!P!P!
MP!P!P!P!P#57K@_^4O?'_<.=_M43E5Z]U\F;?]KY?*/D1YW.(X X X X X X
M X X X X!??3/2=RWG<E/':(<(#]@0"#96%8H;JXL.K0XRTMS3IR;AIYF.#8
M9>RP09DLR6RC<G 9$(B^0:@28VE?=\Z%2;=#["@K):.&$QSTZ(3.,#8+)DE
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M=4O5B.&]0IK#LZN>)MZMMAU?OS-BNI4'L")KZ*HN1V9"K(,G41V:Q<=8A:S
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M*N#%N[G],KC@Y#@#@#@#@#@%QL?VAG^";_U,<'H.7@#@#@#@#@%?VS]D&/\
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MUGI0U=8,TU!J]MV!62BH5:1M>Y:<%VN?9JY+(U:+6"=SI),0\?DE6! (P['
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MXL?1< >5E?<A/G%CZ+@#RLK[D)\XL?1< >5E?<A/G%CZ+@#RLK[D)\XL?1<
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M12<3$L69ACR4=F>,G0R8V2[$3&)#I<:? >D1'FWE2XU*9,N . . . . . .
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M:4I*>>L1=4B;O<94]XO;@G-4Z@M;76 !)U^<1E0K(6J 06ZL8\SAR?=Z:B]
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MV:DU_P";,'J]6_\ FZ _Q*+_ -A8YYST&:X X X X X X X X X X X X X
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MP"XV/[0S_!-_ZF.#T'+P!P!P!P!P"O[9^R#'^!H_GG^#E;OY?;(OP8' ' '
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M5<_@^[>\]:$]-_$+-;]@5_<X\783\&3<.ES;!EV!%F#D879]+PF9H@B]$D$
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M9Z?=N87EUM7ZXSHC..Q.<]O]KW6XK]O^Y[/W<XXC5;]C-M-JF9#O7-L+X/\
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M(5NMV4>[P;CR#9CF38X X X X X X X X X X X X X X X X X X X X X
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MX["1'=.%<8)EUS9^,2,);\\Y98!)+R?DE?(4< < < < < < < < < < < <
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C . . . . . . . . . . . . . . . . . . . . . ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g16439g90m83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g90m83.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2@>4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!D]<*         "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          3A"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #3P    8              ><
M  (,    #0!' '( 80!P &@ (  R %\ < !A '( =  R     0
M               !              (,   !YP                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !YP    !29VAT;&]N9P   @P
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3004       $    !CA"24T$#      >4@    $   "@    E0   >
M 1=@   >-@ 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ E0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MGKWMWW;?2<W8RM4FVAN4S):PD,N;<UCW%YEKQ<&ON<-]GN;_ #NU)3/[%?\
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M/_2R7_-SZJ_N-_\ 8BS_ -+(K,WJE>3]FOP&O:'P<I@<*]A+-CMH;98_VO\
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MKK;<[*R!26ES["RH>G#O1VVUNJ;=O];]%M;7_724ZL/_ 'A]W^U*'_O#[O\
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MMM3V5VM):6N<TM8]KV^YNUW[J2FLXY%D.=CM,ZSM$ZC;_I/W7)P<IHVC&:!
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M_*9NQ;<W]F_M2Y]'J8]_I>G1D_I4*FJST<7[9D]5- 9D_:#E8]@I+C3C>O\
M:O4RRROT_P!.[*];U,*VS]H_9?1N_2+QU))3])?5)KF]!QPY]]@]^TY;-E^W
M<[8W(:VRYF[;_-OJ=Z7H>EZ7Z-;"^54DE/U4DOE5))3]5)+Y5224_522^54D
ME/\ _]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !+DU- "H    (  <!$@ #     0 !
M   !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M'@   '(!,@ "    %    )"':0 $     0   *0   #0 !F6    )Q  &98
M   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,C4@
M,38Z,3<Z,#4   .@ 0 #     ?__  "@ @ $     0   @R@ P $     0
M ><         !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !
M)@$H  ,    !  (   (!  0    !   !+@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0$P34T *@    @
M!P$2  ,    !      $:  4    !    8@$;  4    !    :@$H  ,    !
M  (   $Q  (    >    <@$R  (    4    D(=I  0    !    I    -
M  /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q-3HP.#HR-2 Q-CHQ-SHP-0   Z !  ,    !__\  * "  0    !   "
M#* #  0    !   !YP         & 0,  P    $ !@   1H !0    $   $>
M 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
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M$-T3STDT\G1BWTSA#&VFN==L;9#1[.ML;S67[8C3.&8VE!_/L>.7<NF$4_\
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MCN5.8$45:+:,38J4A4#P=J]\VNZ561BI9!9;R'FKT*,<!P' LEW(_A:]F?\
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MF 80-8KHNG;M19%VL&5A/"!1*35/4*.O::VNMDBK2LVL#E=<0VGP5B,IP3C
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MOW:FRSIZ\<*YV5<.7*VVZJZZNV5%5-MM]]MMMLYR'6\!P' 8_P##_'C^7@.
M_P"O@/W_ '_T<!P' <!P.W:GS;(.6CS,L_:@SS@8[-"4'2J3 LX"Y>9$K$&V
MF^J3O8=L1>[,_/:[X0W<J[Z8QOGQ\#J.!Q^_[YQ^_P#CX#.?%_%G_DQX^!]J
M\N\'ATVG<ID<UEE)"S$HEILI(Y$54E,^;*$C1EZL0)OMV[&5MF:&[IXX67V2
M:MT&Z>=\ZHHIIXUTP&/>YB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^
M0$1],+(^V7 >YB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^
MV7 >YB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >YB]%
MOD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >YB]%OD!$?3"R
M/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >YB]%OD!$?3"R/MEP'N8O
M1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >YB]%?D!$?3"R/MEP'N8O1;Y 1'TP
MLC[9<![F+T6^0$1],+(^V7 >YB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F
M+T6^0$1],+(^V7 >YB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1]
M,+(^V7 >YB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >
MYB]%OD!$?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >YB]%OD!$
M?3"R/MEP'N8O1;Y 1'TPLC[9<![F+T6^0$1],+(^V7 >YB]%OD!$?3"R/MEP
M+Y\!P' U.NI5WHEG83L#45?VG#S4)A-@5@N=,:5B"@DRKJ+R^'Q"1>RL ('K
M*F;24IKAV9 @^G<BKY8>XDTAD88(-S[.Y9"0VQ<#IH](@$M"#)-%38F21TVT
M2(!SP(@T+!RK%?'C1>#B3%5=F]:JX]]-=NLHEOCW]=L\""(U:MQS4<Y/16GX
M6XC^9!+ HQT9N)^*)O$8M*3,64>NAK:J2R##9ZN&5=:-4R;[S"2R:>SE3;7;
M/ [_ -JNPGR-5Q^G(M^QC@/:KL)\C5<?IR+?L8X#VJ["?(U7'Z<BW[&. ]JN
MPGR-5Q^G(M^QC@/:KL)\C5<?IR+?L8X#VJ["?(U7'Z<BW[&. ]JNPGR-5Q^G
M(M^QC@/:KL)\C5<?IR+?L8X#VJ["?(U7'Z<BW[&. ]JNPGR-5Q^G(M^QC@/:
MKL)\C5<?IR+?L8X#VJ["?(U7'Z<BW[&. ]JNPGR-5Q^G(M^QC@/:KL)\C5<?
MIR+?L8X#VJ["?(U7'Z<BW[&. ]JNPGR-5Q^G(M^QC@/:KL)\C5<?IR+?L8X#
MVJ["?(U7'Z<BW[&. ]JNPGR-5Q^G(M^QC@/:KL)\C5<?IR+?L8X#VJ["?(U7
M'Z<BW[&. ]JNPGR-5Q^G(M^QC@/:KL)\C5<?IR+?L8X#VJ["?(U7'Z<BW[&.
M ]JNPGR-5Q^G(M^QC@/:KL)\C5<?IR+?L8X#VJ["?(U7'Z<BW[&. ]JNPGR-
M5Q^G(M^QC@=E7=ARJ32F;PV9PL5$#D-81$K_ .A)@K,1I(?+\2'5IOJ[<1:*
M+M'31:..]'#?9DNGMHLW43<YSE1/0)?X#@. X#@:"NWZTA;=]&S5DMU?V>EF
M->: GDL?]1FYF+[XD52.H^2MH59R>>PI0B\0"7,*!;5VV--'\7,1 9'-(W(F
MCZ2,0VK]G.JM-]FP #>S8DD6E%:.RDEK*7,!P%]*X8==L,-B&P)&3@I1&B;0
M\T01'F8U*XS)HH>13:Z&(^0V:,\H!@'3>J2M(=***AE:UY'8=-$:R@)201::
MA]:X5Q+28$,I*MYRTB43T<-I<UUU48$-LQM)QN]'(,G*3-%'&K<.YJZ12F*]
M1)=+%=!#.7QL;V'D*>H]1P4#-SP:;V022\QN0:,%WK%(@VQY&'3-ONNAKC"J
M2>=]M,!K$%=Y>TT.JSKU?9LI.#]*3. =<9-=LKNFM*_JO(V<3\U'"4IC-.OM
M8]68]_""D%7F+Q_)96@0&13=C#WR%@;Z$C** 6-@OA/);84I=52"ZU9;77A]
MAZ*B\GLB65]"2D)Q5AZT/7V)I9E%0J2M##I".$ 8@>I6JD.,*N1<B9V+F(KD
M#@L,=['>$WF44C?9D?5=*2K5U6D*O:/PVU73"4F0+"Z:RZOE.P@U21XTKA:G
M<5\XV;)Q5F<;W<6,$9'HT\]"D8L792)4)$,>$5FL;<V3#"E! '-HT1&K/GET
M"6MUY1A#" 515=)6Z:)U_.'M5M',QF!:,WO$V@V('(G Q+(\//(&YH+ )A)&
M<#9K&3[*51R/R@;JOH.D@04?8:.D\(NM&1A@@1:ZN4L;;X27U0<)X63QOMC1
M3&VN-MO%X\AW? <"E7?V8V["NOC5]1<T1KZSCMY=9()'Y0[$C#@YJG8/8>LX
M478EQ95D^0<A#0<X_#&\-DVY9,4_>*A2(LMHR(M0JQ3'>6Z)J\[%F1%=[3G2
M*]C=:QU@IY"Y4'U.NHYUSZ]G)I UEZ ZP]AGA!8?:DHL#*I"8Z@_2O+U4 D2
MXO9)J*#%^V5W=A81,;1L:HK#G[#:A.D\D[16/4#EM'"U</)M.H](X33T#31E
ME91&P1P:/$899-K2;)AY$9(Z(Q:*,RS,"#*'P6@7,Z83FQ)"WN^$VB=/2.5U
M=9D=#J$"9N/3(4B+F=-5A9XMA'9]'*WJ5K+&:;::>G/O3(,P>Q\D1<QY I)
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M71*LM%@C>3FG5SJ1&1P3(F33$49AS%O4P]K$8<_3>06,D[*;GY#)/_.)6-"
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M)3S>^N_FU=<8SLGOY.<^0IKC;7.VFWBVQC.,YQ[^.!Y. X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@05#_ .$%=W]1J1_UBU>!.O <!P/SMG.N
MNVV,>5G&N<XU\>-?*SC'CQCRL^]CQY][QY]['X<^]P-*O@X^^G=_M3<,QB-^
M=7?N7U^%834HYE3:HKMK@-#';9*J]Z^A@VS+->OJ[[*NS)(_<L:,3ZC%M8DD
MI4+*6Z-&$;L:(8>!F\HIVV3':>=W&UZNZR$9.SE;-%"%RT3U>MPK$1U=LM &
MI* 3Y3P@\1D\6CQ-/TB3MQ#>M5E Y9TZ-(Q1S(B1O0L&P2TJ2UL65PB?!;$F
MM7SR B)E' LHA;* EEU(Y/5XH\DX9Z*L>%3L%LF]>PB,ND7[08T+M,CU&Z!#
M5D^?-G >"$T;F"1F;BP]G3_>6V--?N@3&S%V=<:RLG)<@XO&-W"(AM $*]'M
MU8W#@8A5NRA26%-47!#;?)=VL0V#'.M(,LC3(IMF9'W3I"4VPWV(O&<6\^Z<
M)6O.$LOW:+*.,6?GUU-?2'"3-LR:^<WWU;H-TO(TT"LM$],.S'6H-<:T%[?Y
MLZ4VY:^MMOM+JK%!_&F1LFDX;S)DQ3B\H&%A*,E;HQ]%KN/=9&1_(/51J =^
MG.-.!,N]K=C(0]U:6E0\X.!DV^%74_H"3P&R :&<;9PIZ3!I*&@EI:*:Z^2I
MHVCT7F.VVGEXPXV5UUT4#+8#V9HBR2V\;CMZZLI@DOLV5@4W8-:SL1)QKC7;
M=+>OK&B,5F>,Z8VTSOMZCSIKY:?CW_WS3R@L/@2_^,QK/^/S$>_Z@7 >J7_Q
MF-?D(]_F_P" N ]4O_C*:_(1_P"H^ ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"H
MN ]4O_C*:_(1_P"H^ ]4O_C,:_(1[ZB_?Q_Y. ]4O_C*:_(1_P"H^ ]4O_C*
M:_(1_P"H^ ]4O_C*:_(1_P"H^ ]4O_C*:_(1_P"H^ ]4O_C*:_(1_P"HN ]4
MO_C*:_(1_P"HN ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"H
M^ ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"H^ ]4O_C*:_(1
M_P"HN ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"HN ]4O_C*:_(1_P"HN ]4O_C*
M:_(1_P"HN ]4O_C,:_(1[WO_ ."_Y^!#D$;JMK]N]-9ZY?[>Q-);86=:,]%,
M8RO:F/(QADU:)9UQG&<XSE/._CVSX]\X\6,!/_ <!P/$MC79%77;.V-=DE,;
M9TT\YMC7.F<9SKIY._E[>+\&GD;^5GQ8\G;Q^+(?-;X%JUG 645%08&Y^S\A
MZ_GNL\RGW52L[1FW1^PQ(JJ8%-X7&W*]K".OO5FI+CHJQ@_MI'VT2@<ZLR8A
M'3%],(\YQK(8"L/%A]*_ <!P(*ZW_P""=C_76W?]KTZX$Z\!P,$GU7UQ:89>
M/63!8G.@KC7&J@Z5 1IMOC.N^JB:B.'[=;9LNDKIHJBX;[)+H*Z:*I*:*::[
M8"O?WH F)O6C^B;DNRA$VNN<+16,2QG/JX)8UTQH@BY@-S";&#@VB>NNFFZ4
M"VA2^Z?EYT=HN=\NL!X=37=NN]#:YV(4OV* #O.+AMJ_+F:9M$LR3TWW]%6C
M,T5E==/CV<)^0DKBP8@(?.%DD]TPZ.BCC@>-GWBJ *T%[7D)L3J\1*NM&""/
M8&&$(;&MB&_E8T9(VDQV-U(X=*[:+9;M$YUA^NBBH[U9^B9T7W"U<;E,8F(I
ML>B,C!2H&\TU4:&8X7'G!3I/?7&VN[8@,<.FB^FVNV-M=DEML9USC.,^+..!
MWW _/EZ>7YORM?+\GR_(\K'E^1X_)\KR?'X_)\?O>5XO%X_>\?CX'ZX#@. X
M#@. X#@. X#@. X#@. X#@. X$%0_P#A!7=_4:D/]8M7@3KP' <#IY"?"14"
M9DLD-AXW'P QZ7-2"0D6@@"$&#VZCIZ4,E7Z[9D.&,6Z:CAZ]=N$&[9NFHJJ
MJGIKG; :(_!EN[@^^=EH:35WUQ@,N$4JX7[M2"NG?1C<_>/8.23K6459;==C
M>K1LK>3"L2$0,3QGE;M@+A\B)Q[[F+\$!?3!:T9$6#?IP*U7?'[XDTTK(55L
MYE5=0I<9/]IK*X:*J0Z]&RY!.+.:WVE8:U!19P4KEPFC,V,C8U[HRFS@H[CF
MB!40+R1+L Q.@Y'VU9QNZRO8VO&Q.5L;A1'5=&:Z.U_L&.UDUK2JQ[F21-Z2
M.A7(\"8LC2S)"U#6@41GXALON'6W)#&L=<O0RGK*9+KTZ'77B)EDNO++5778
MN'\95<,EEK8FZBK-PJS/.F:B[53;9!51HZ<M=]]-MD%UDLZ[[!/GK0E\6RGY
MV"^M^ ]:$OBV4_.P7UOP'K0E\6RGYV"^M^ ]:$OBV4_.P7UOP'K0E\6RGYV"
M^M^!ZCU50DWV:$8:Y(-=\Z[;MGN\<=-]LZY\>N=D5RBB>V=<^_KG.N<XS[^.
M!5T_T^HHK*B<] U?+ZNG99OE)]+*6L<Y3[YVX\O51,D4&5[. $:D)%-777?9
MQ)01G5UC&4GR;I#.4LAA>T'[U57'\_<VMP'V(=,WOC;QOLI%HE$"KP+G?3&C
M%&T*:7#Z-RS5'&V-"ARMI'@CMXL/,(*[[.\!6N4=_I#$>\E 438-02V-F9#$
M3XVURT-(O9?7,1D.X<X=CK-Q*E8^ :%8[ECE@7*G7B A*,K+YP_2W:C7A# ;
M)8#?]:VELNE7LC!RUXTSMAZ*$2>**G!VVN=L9U)@%#B9H9MGR-MM="#!MMMI
MCSFN,Z9QMD)0]:$OBV4_.P7UOP'K0E\6RGYV"^M^ ]:$OBV4_.P7UOP'K0E\
M6RGYV"^M^ ]:$OBV4_.P7UOP'K0E\6RGYV"^M^ ]:$OBV4_.P7UOP'K0E\6R
MGYV"^M^ ]:$OBV4_.P7UOP'K0E\6RGYV"^M^ ]:$OBV4_.P7UOP'K0E\6RGY
MV"^M^ ]:$OBT4_.P/UOP'K0E\6RGYV"^M^ ]:$OBV4_.P7UOP'K0E\6RGYV"
M^M^ ]:$OBV4_.P7UOP'K0E\6RGYV"^M^!#D$77<7[=^Z[)=AOB$4CKA%PHT5
MWSKA>U,XWQLS<.4O)SX\XQC.^-O>SX]<8\6<A/\ P' <"KG=/KCOVWZPVUUZ
M1E>D*=V(&&-Q\C<A]9&*9DP$C#2H6VD<;W>#]9'$RA &V%2V/Y?LO7<;>E!F
M';?9SA;0*==1/!J'NOE]QKL'/+4B,SF0:M;R$GE(16BD$<SJT>S]Q!K=N"5R
MXL\E,D>DH?%]H5!H?2$,V\2D(C[>1[D"YAR82]%#;1P' <""NM_^"=C_ %UM
MW_:].N!.O <!P' <!P' <".#M;!)--!LK.H-R;<7'B() 0[1U78N=2Z9!D3P
M2:K84:D&3H817:;LW*.Z><YSMMC;'^YX$56+U4JR>J0-/V0@P\9"E=VNK+V+
M&ZE<!%<)ZZ-(K-Q"H2=P D+SIE8.1BLC9(([;;(/![Q#"&&P1J&KFV8:8ES*
MK;IM*'!HBX1RRBW9D8,N2L#@YWKOE E&[*VD#2W-&.^4LH*M)!9[TB&4TU]*
MC:.KI+=8,TUNJ\X AKM<O7DH:&([;9=SSKH=0M$"@TQ[^C]] C:,0MA#;*?^
MZ5'Q6+3_ &1\G;R7J^,IYW"2:][$TI:3GU9#+$!/)#KKY;B&F,NXG/F&/'C&
M=2E?RUJ#F@K?7;.--]"()KOIO_N-M<;>]P)IX#@. X#@. X#@. X'YVVUTUV
MWWVUUTUUSMMMMG&NNNNN/'MMMMGQ8QKC&,YSG.?%C'OYX&(F;"@$<:BWTAG$
M/!,CC?TL(\,R8*+:F&OFT%O21;A\]02(-_-.6ROGFFZR?FW"&_E>2JGG8/,T
MG<(?MPKMA,HJ]:R1XL/CKEI(1#EN>?ML[ZN&(59%YNF4>(;)J:K-F.RZR6=-
M\;Z:YUV\09"D\:+KNFJ#ILLY8[I)O6Z2Z2B[/=='5PAHZ2TVRHWW60WT72U5
MUTRHCOJIIC.FV-LA[/ @J'_P@KN_J-2'^L6KP)UX#@.!^%<^2FIMY6=?)TWS
MY6NF5-M?%KG/E8TQC;.^<?AQIC&<[9][&,^/Q<#Y*/!0]L=HWVP9!+L[[V+:
M@"Z,2UA3S26TWX3,6([ R6>OJCC8>;R AVOZ]06BJ%U$2^$2+>'0VHIJ0AKZ
M:=A"U:A7S4?'($$)A];7 K[>?:&G.N#RO&-M$YJ*7M0^[BL'WBU07!9S,G)6
MC1-[H!?$*O@DQ81PL414SK'&,F<AW$I<H.V4;3*O&3M! /9Z^=B8+V/I^,W7
M$!TVBT4D[5!RU:6A"9)6YQOY]!LXTQLPEHX9J19[:NT4D#@)<M'GKG#AJP+.
MG#-VF@'CZVO&F]2C]]'3?;3>9VWOIMJNEMKOIO;DYVUVUVQMG&VNVN<;:[8S
MG&<9QG&<XSP)V]*;?TA#\JG_ 'N ]*;?TA#\JG_>X#TIM_2$/RJ?][@/2FW]
M(0_*I_WN ]*;?TA#\JG_ 'N ]*;?TA#\JG_>X#TIM_2$/RJ?][@/2FW](0_*
MI_WN ]*;?TA#\JG_ 'N ]*;?TA#\JG_>X'7%V("0"R ,ZT$F0Q9HNP*"2B+1
M^.(LG.F4G#1ZR=:JMW+99/;;15%9/=/?7.<;:YQP,0UCI$&YA+*#R(-'H7&F
M^XDK#70E(DV(AM4$TA^!);!!L2"D!&4=-&FV^Y$:NU570=#]E-6SAN&#2:)4
M[>_M#'K7J0:3VB13#)NYL*,"5/+36RKZMD<&EJ"KS"2;Q+&5&[P&88GQ"BF&
MI1J*?[>CY#"L]?97"E$UJ,[%6%"&#;&,I0*QWJ=[5\OMK_[I1:P7CBUAC?/^
MZPFVC]J"6+7RM<),=FR"+34/SI;78V J;I6?1HJQ@J7E;;S?KK*QY)RDVTQ[
M[LM55COXQ)VN^WB\>!T,D-DO\[;:ZI)+:XW4U#-X!VDH>R2OLV L%@,F>J>5
M%:_G(\S6UAHZ:^/"F^8)8 Z-2I9NGMKG&7K44X8*:^0J@Z50525W"><NFV/'
MXW"/O>__ /6I_P"7_P#-P.HC\E$R4"%D0UQCU<>%#S+#TC.B*_H9-HD];>>1
MSOG*2OF5M/.)YSGR-O'KX\^+Q\#M_2FW](0_*I_WN ]*;?TA#\JG_>X#TIM_
M2$/RJ?\ >X#TIM_2$/RJ?][@/2FW](0_*I_WN!5'NS5^ET=;;-A>]HV%6P7,
M6DY>5*U;(F$5D$TC8V)2'9[7[^5X'NY)&XY(G"K-0V2@A2*S+=L/U'#I0.8O
MR:#P-6%AQ:E"W@8^E,@FM ]?KWNAWU-Z@TGUEUO2I*ZMAE$[F["P&HZPB9-D
MVGH _H.$#I"4#2F6MV*6N20>*;Z.&[W=NW1X'3]B?!M0OK+UZJMK4!ZMX91_
M63KIB$'BAQ$BRGD2D8J]:HOF07/3P.*QHD--W-;9^"%8V^#Z/X'EQ()%&5A9
MM5D,]FW83_T [5+KV47I^S:X7!6Q=ED]D9'.+&3ES ZF6NZC-ZM'6M7K@ B,
M17CT$K 5-X]55.GM3QM.5QNJGY0HPC:Q8$K)@W+>E-OZ0A^53_O<"#X;OHIV
M N[9/?7?7V'I''CTVUVQX\.+5][QZYS[_O\  G?@. X'C6SKA)7.^N-],)[Y
MWTSG7&-M<:YSMKG.^VNF,;8\>/'OMKKCQ_[K;&/'G@?*=X+JJZ![8V#15@OI
M-0K^'5A$AEG];^O44\)U.>R-U=8H[')U#9F"J8I02]01 5&(,#E\8K0K-5'U
MF3]P+E-4UD!&G2L7W)IEP^K7@=%)XO&9M'R\3F4>!RR+'V*PP[&Y*)8'0)D<
MYU\APP*B":#H>09KZ9\E9L[;JHJ:^]OIG' Q:.5#6$3K:.4\#@D:;5?$0HF.
MQR#.AC<K'184%HCH''I,"VKY-5$=ANAEKLX\\JFHEHKA3SFN-^!&O6>,QMI4
M EHUCX-JU:2ZUVK5JV$L$&[5LWMJ<)(-VZ"3?1)!!!+35-%%+35-)/773377
M7&,<">O4 +X%$_-S/]3P'J$'\"B?FYG^IX#U""^!1/S<S_4\!Z@!? HGYN9_
MJ> ]0@O@43\W,_U/ >H0?P*)^;F?ZG@/4(/X%$_-S/\ 4\!ZA!_ PGYN9_J>
M ]0@_@83\W,_U/ >H0?P*)^;F?ZG@/4(+X%$_-S/]3P'J$%\"B?FYG^IX'5'
M()"I*(( )!$XX8"E6V[0B,(!A[EF\;[^+.4UD5$-M=L8VUU43V\6-TE=-%4]
MM%---M0QC6OW(@M#6\5VBC"! A:@4U%2L8V+$WC5NSPB%>!Y2H3T>,G@]1%!
M%TF5:&DB3/=?;?=N]PFZX'OQLE&9'N>;[PY['G4>-+!7K>2Q9,5HZWUW\3(B
M'?[)*BC8HHALBY9/!3YWY&%M6C]-D1379)!S,JEJVQ!"H">UQ!IF%6USKN,D
M\5!FV>/'XL^6F@08N-$5M-L:[IKHXT624UT43WT4TUVP$%:=76%9AI,XZ]FC
M,9+JQ$^+B<"G<MD,VIUC)7K+9,"75#RI.7R&,CP3S"*Z8>"$P(A5OHHTW%;:
MJYWU"'NO=CNJ.H?KS$^VGL]L?*U]&V6][@8IHUIXD0<;:M(P#E!C9FW4@TM>
M MA6SQW)!06'%2JF[<-(7))Q@7H%_P!(-'ETTUD1099%5/11)5)BQ43424UQ
MMHHFIJEG7=/?3.-M-M<YUVUSC.,YQG@?OU""^!1/S<S_ %/ >H07P*)^;F?Z
MG@/4(/X%$_-S/]3P'J$%\"B?FYG^IX'HE(=%#0TB'*1P*]&%F+L:19K#6N4G
M;%^W4:O&RODI:[937;JJ);^3MKGR=\^+.,^_P*25M,O!QW9(A?5"K910-@RC
MJ*5B9$/3L9,C"1:J2E+.$8K&G; :@X\^[S6Y!)L =J(K%4 !;T5@<R@1403V
M"PUX->NP>* GM]HUZ*A^MCULD!WF>&#$4[LQ:9A]*P8MDE/-:%#BTWR%W C-
MDW6%BJ35QZ-MZ-YQ(*V369^#4ZR=F1WM_*>O%1]G+O;K8&,Y*9$!Y.>1DCJ.
MAWK]N,?.,B(NK.B$4BHPF:PV!.+!)18&T?O3KV/LM&83/+>T74"!W?%>MDSN
M"FXS?,V18+Q:K#!D$SEQ;!?TS 5%(<KC'F'AW9@\U L':C=Z<W;[Z"6[S?R=
M<AE$':-6=_7>DS;-VJ6812.^4VR*:">=\KVIC.V=$M==<[9QC&,[>+QYQC&/
M'[W GW@. X'X4QME/?&N===LZ;8UVWQY6NNV=<^+.VOCQY6N,^_G'CQX\>/'
MCQP/E6\#F9ECWNJ[$G^YU2]EB+"@)P2L!I +=%2@7K8+DS4((JV@$"B565Z)
M&Q2/2>.V%)4I&1*'AV\8M"$1((/8$HB9)DP^JS@. X$%=;_\$['^NMN_[7IU
MP)UX#@. X#@. X#@. X#@. X#@8_*HI')N (Q:6AV1Z/EDTDWXL@EYUNOYAP
MD[;*X\6=5$7+1XW;O&3M#=)RS>-T';55)PBDIJ'4X$2T:?C28,P'Q AX7829
M EV)1_)-EVJ&^HHL,E*A93=97'D-VI-H98/5'B6%'VI--YY>BX1_/+&&/:;N
M0]CU]#5(G&9R.(+R@<_B;D:0'@W>[<@R?/L-VKQBXU6:.Q9H.^=LEO/I:)NM
M'J2[=$)3'A(TYB;&/-QPI_$5@#04W%*(H$@KL!LP3;(,MD'&'#9Z.68>0EYM
M;"R*[?;&-_+TVSXPJ^I2UC41LL6ZP$69.$)J.'C_ *T3DJY0AN-5=O/+ZT],
MU421.JG>GDYU&0Y=N5J[.=L,60:&:*J&$ E>J;[A%K.24=;)F(;9,;;H*S*I
MITRT!6!$]EL^1A5T-PNY8G0BBV-DF,OB1*00\KG&,C#KOQYQ@)LX#@?+59%P
MMF':WM01!=P+JSW"K_PD%!UUULZJH7K,F\./5/.0?7M"T8XVZ\>NDXE8<%+0
MTK94CD\I+QP\E5;T!J; EX8\<DLG0N5":@[\->QNIPW#>UK*M?;R3O/6\@\(
M[6,TKU$ Y7,9$O'5)L>O8@Z1C^=%66[:%IS)!\P0V0:*&%]V>ZJP5HZ8633,
ML%^!-J*M)3#R/8GK)6T^QVZC(5^PS-J81BW6LY7G8UI=31/&24,<2+LP_C:C
MM&5Y&;2Z1M<2$;H40:;/T0N/X56MJ,N6CNO_ &:::A+*+1'L1TV6IB=BI<\D
M\'9!)_VKI/9[,(8.&F7<!?%SP3R1["P&(YT>]FB#X2+.)A2[]LZ"A_A,I(RI
MBQO"91"'6_U0(2/N5U^K-E+ZGNW[H##LT+DZ%7FZIJ\)U@KIC"W@3M**GSYB
MUP-!!IK&4Z@L98U(#CHMZ>J$T# K1D$8AO7[PC'5.S91'U?""6MV4ZJNZE@Y
M!\UQ;]G'W-7=2Q-*3JO6"VNYJ4 H5,8;-GCZ21Y!Z+A6\<E"AIZ,\ERHJ'TI
MP_\ A!7=_4:D/]8M7@3KP' <"H'?BW<41U"N^V-)C8D$>1&,LEQ$@J8!6DFL
M?:0$Y"&"1T!$ UR I)5S@O+3A(?%$EYR(7CX_0RH1>KL=6N'[8*/=*XU8'4?
ML;5W2&=7SV2EL.WZDNY[1T$G\+Z:LZE1%P&0PJ-6%$!!^AZ8KRS1\EI568PD
M4P1.$MH3)0,PV<"-':P+31F&Z#@4R[>]>+)O$< ?5?-@,<D,?CLYC. DS]IM
M8B30G:\0V=&U7$5?MR3 V,'Q9_&/2$F3IR1A$YGL99$(VO(/7K0,TIZH)]5E
M>RL*',US%Y#*)HK+@T9"1,V5J&KQ[D1&0[J%PF-(R.&$MPCA0"1DRJK=U&VV
MTLE9PGJ#214V:N =9&TNTIT/J],QQP^TE=JZ/5VL:)M&B[S6V9QARNU:*RMZ
MLU;*K8WW0:JO7BJ"6VJ2CMSOKE;<)\\Q)?A0'\Q/_P 'TA_?WO\ 'XP>8DOP
MH#Q_\"?_ &AX#S$E^% GS&^^T/ >8DOPH#^8GWVA_?\ DX'/F)+\)@_F-_\
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MR],Z^+;QZ[8\7O\ O^/7;WO_ +.?P<#Y->FH#PC*-\=>H= [7[.2)'KY)(A
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M.:%=3/9"T=%@K14'O&I=@4W)24 7E,;".YIZAS!VDBD<=CT@,@(XYDB1TTP
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M)>2-@M+V//\ 9:,#(L=Z]@('*![(B0VLX+(H^6DTYS'/0M=V!"L 2-BU='Y
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MA5#!F6.IU4)4.>GROTD4Z6*-@S!NM(41S!Z]>#$&R.RF O/P' <!P' <!P'
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84/I*X#@. X#@. X#@. X#@. X#@.!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
